PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FLOETER, MK				FLOETER, MK			CAROTID ENDARTERECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											FLOETER, MK (corresponding author), NIH,BETHESDA,MD 20892, USA.							Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					763	763						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738385				2022-12-28	WOS:A1992HH06400012
J	HICKSON, GB; CLAYTON, EW; GITHENS, PB; SLOAN, FA				HICKSON, GB; CLAYTON, EW; GITHENS, PB; SLOAN, FA			FACTORS THAT PROMPTED FAMILIES TO FILE MEDICAL MALPRACTICE CLAIMS FOLLOWING PERINATAL INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMATION; CARE	Objective. - To identify self-reported reasons that prompt families to file malpractice claims following perinatal injuries. Design. - Families were interviewed by telephone using a questionnaire that contained structured and open-ended questions. Participants. - Mothers of infants who had experienced permanent injuries or deaths and had closed malpractice claims in Florida between 1986 and August 1989 were interviewed. Questionnaires were completed by 127 (35%) of a total of 368 such families. Outcome Measures. - Reasons prompting families to file and families' descriptions of medical events, advice from acquaintances, and the quality of physician-family communication. Results. - Families volunteered numerous reasons for filing: advised by knowledgeable acquaintances (33% of respondents), recognized cover-up (24%), needed money (24%), recognized that their child would have no future (23%), needed information (20%), and decided to seek revenge or protect others from harm (19%). Over one third of all families indicated that they were told by medical personnel prior to filing that the care provided had caused their children's injuries. Families expressed dissatisfaction with physician-patient communication. Families believed that physicians would not listen (13% of sample), would not talk openly (32%), attempted to mislead them (48%), or did not warn about long-term neurodevelopmental problems (70%). Conclusion. - Families give many reasons for filing a claim. Obtaining money may not be the only goal for some families who file suit.	VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37240; VANDERBILT UNIV,SCH LAW,NASHVILLE,TN 37240; VANDERBILT UNIV,INST PUBL POLICY STUDIES,CTR HLTH POLICY,NASHVILLE,TN 37240; VANDERBILT UNIV,DEPT ECON,NASHVILLE,TN 37240	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University				Clayton, Ellen/0000-0002-0308-4110				ALDRICH J, 1975, AM J POLIT SCI, V19, P571, DOI 10.2307/2110547; [Anonymous], 1986, COSTS COMPENSATION P; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DANZON PM, 1985, MED MALPRACTICE THEO; FADEN RR, 1981, MED CARE, V19, P718, DOI 10.1097/00005650-198107000-00003; Felstiner William L. F., 1980, LAW SOC REV, V15, P631; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; KASTELER J, 1976, J HEALTH SOC BEHAV, V17, P328, DOI 10.2307/2136711; Katz J., 1984, SILENT WORLD DOCTOR; KORSCH BM, 1968, PEDIATRICS, V42, P855; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Kruse J, 1988, Fam Med, V20, P422; Kubler-Ross E., 1969, DEATH DYING; LAVERY JP, 1988, OBSTET GYNECOL, V71, P138; MARTIN CJ, 1987, STAT MED, V6, P613, DOI 10.1002/sim.4780060510; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; SLOAN FA, 1991, LAW CONTEMP PROBL, V54, P131, DOI 10.2307/1191857; SLOAN FA, 1990, LAW SOC REV, V24, P601; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; WHITCHERALAGNA S, 1989, W J MED, V150, P356; Wolf S M, 1988, Law Med Health Care, V16, P197; 1991, DHHS PHS911232 US DE; 1990, BESTS REV PROPERTY C, V91, P42; 1987, MED MALPRACTICE CHAR; 1990, COST MED PROFESSIONA; 1969, PROFESSIONAL LIABILI, P980; 1990, BESTS REV PROPERTY C, V91, P117; 1989, MED LIABILITY ITS IM, P1; 1977, MED INSURANCE FEASIB; 1990, PATIENTS DOCTORS LAW	36	323	325	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1359	1363		10.1001/jama.267.10.1359	http://dx.doi.org/10.1001/jama.267.10.1359			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG678	1740858				2022-12-28	WOS:A1992HG67800029
J	HILTON, E; ISENBERG, HD; ALPERSTEIN, P; FRANCE, K; BORENSTEIN, MT				HILTON, E; ISENBERG, HD; ALPERSTEIN, P; FRANCE, K; BORENSTEIN, MT			INGESTION OF YOGURT CONTAINING LACTOBACILLUS-ACIDOPHILUS AS PROPHYLAXIS FOR CANDIDAL VAGINITIS	ANNALS OF INTERNAL MEDICINE			English	Article							RECURRENT VULVOVAGINAL CANDIDIASIS; STRAIN DIFFERENTIATION; WOMEN; COLONIZATION; ALBICANS; THERAPY; FLORA	Objective: To assess whether daily ingestion of yogurt containing Lactobacillus acidophilus prevents vulvovaginal candidal infections. Design: Crossover trial for at least 1 year during which patients were examined for candidal infections and colonizations while receiving either a yogurt-free or a yogurt-containing diet. Patients served as their own controls. Setting: Ambulatory infectious disease center in a teaching hospital providing tertiary care. Patients: Thirty-three women with recurrent candidal vaginitis were eligible after recruitment from community practices and clinics and through advertising. Twelve patients were eliminated for protocol violations. Of the remaining 21 patients, 8 who were assigned to the yogurt arm initially refused to enter the control phase 6 months later. Thus, 13 patients completed the protocol. Interventions: Women ate yogurt for 6 months of the study period. Measurements. Colonization of lactobacilli and candida in the vagina and rectum; candidal infections of the vagina. Main Results: Thirty-three eligible patients were studied. A threefold decrease in infections was seen when patients consumed yogurt containing Lactobacillus acidophilus. The mean (+/- SD) number of infections per 6 months was 2.54 +/- 1.66 in the control arm and 0.38 +/- 0.51 per 6 months in the yogurt arm (P = 0.001). Candidal colonization decreased from a mean of 3.23 +/- 2.17 per 6 months in the control arm to 0.84 +/- 0.90 per 6 months in the yogurt arm (P = 0.001). Conclusion: Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.			HILTON, E (corresponding author), LONG ISL JEWISH MED CTR, DIV INFECT DIS, LAKEVILLE RD, ROOM B-202, NEW HYDE PK, NY 11042 USA.							BERG AO, 1984, JAMA-J AM MED ASSOC, V251, P620, DOI 10.1001/jama.251.5.620; CONN HO, 1970, AM J CLIN NUTR, V23, P1588; DAVIDSON F, 1978, BRIT J VENER DIS, V54, P176; DISMUKES WE, 1990, NEW ENGL J MED, V323, P1717, DOI 10.1056/NEJM199012203232501; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; FLEURY FJ, 1982, CHEMOTHERAPY, V28, P48, DOI 10.1159/000238152; FRIEDLANDER A, 1986, PANMINERVA MED, V28, P51; GOLDIN BR, 1984, J NATL CANCER I, V73, P689; GORBACH SL, 1967, GASTROENTEROLOGY, V53, P845; HUGHES VL, 1990, OBSTET GYNECOL, V75, P244; ISENBERG HD, 1960, ANTIMICROBIAL AGENTS, P570; JOHNSON JL, 1980, INT J SYST BACTERIOL, V30, P53, DOI 10.1099/00207713-30-1-53; Kandler O., 1986, BERGEYS MANUAL SYSTE, P1209; KLEBANOFF SJ, 1991, J INFECT DIS, V164, P94, DOI 10.1093/infdis/164.1.94; MARDH PA, 1983, SCAND J INFECT DIS, P47; MILNE JD, 1979, BRIT J VENER DIS, V55, P362; MORRIS CA, 1967, J CLIN PATHOL, V20, P636, DOI 10.1136/jcp.20.4.636; OCONNOR MI, 1986, J INFECT DIS, V154, P358, DOI 10.1093/infdis/154.2.358; ORIEL JD, 1972, BMJ-BRIT MED J, V4, P761, DOI 10.1136/bmj.4.5843.761; ORIEL JD, 1975, J CLIN PATHOL, V28, P403, DOI 10.1136/jcp.28.5.403; PAUL D, 1972, AM J CLIN NUTR, V25, P763; RETTGER LF, 1922, INTESTINAL FLORA, P118; ROHATINER JJ, 1966, BRIT J VENER DIS, V42, P197; SANDLER B, 1979, LANCET, V2, P791; SARRA PG, 1984, MICROBIOLOGICA, V7, P331; SOBEL JD, 1986, NEW ENGL J MED, V315, P1455, DOI 10.1056/NEJM198612043152305; VELUPILLAI S, 1977, PRACTITIONER, V219, P897; WARNOCK DW, 1979, BRIT J VENER DIS, V55, P357; WILL TE, 1979, LANCET, V2, P482; WILLSON JR, 1983, OBSTET GYNECOL, P608; WITKIN SS, 1988, J ALLERGY CLIN IMMUN, V81, P412, DOI 10.1016/0091-6749(88)90909-8; WOOD JR, 1985, AM J OBSTET GYNECOL, V153, P740, DOI 10.1016/0002-9378(85)90336-9; 1979, MMWR, V28, P61	33	188	200	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					353	357		10.7326/0003-4819-116-5-353	http://dx.doi.org/10.7326/0003-4819-116-5-353			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736766				2022-12-28	WOS:A1992HF26800001
J	BERMAN, EL; WIRTSCHAFTER, JD				BERMAN, EL; WIRTSCHAFTER, JD			IMPROVEMENT OF OPTIC-NERVE HEAD APPEARANCE AFTER SURGERY FOR PSEUDOTUMOR CEREBRI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV ROCHESTER,SCH MED,DEPT NEUROL,ROCHESTER,NY 14627; UNIV MINNESOTA,SCH MED,DEPT OPHTHALMOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT NEUROSURG,MINNEAPOLIS,MN 55455	University of Rochester; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	BERMAN, EL (corresponding author), UNIV ROCHESTER,SCH MED,DEPT OPHTHALMOL,ROCHESTER,NY 14627, USA.							KELTNER JL, 1977, ARCH OPHTHALMOL-CHIC, V95, P97, DOI 10.1001/archopht.1977.04450010097009; SERGOTT RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P1391; WALL M, 1991, NEUROL CLIN, V9, P75	3	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1130	1130		10.1001/jama.267.8.1130	http://dx.doi.org/10.1001/jama.267.8.1130			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735931				2022-12-28	WOS:A1992HE39100032
J	KELEHER, CA; REDD, MJ; SCHULTZ, J; CARLSON, M; JOHNSON, AD				KELEHER, CA; REDD, MJ; SCHULTZ, J; CARLSON, M; JOHNSON, AD			SSN6-TUP1 IS A GENERAL REPRESSOR OF TRANSCRIPTION IN YEAST	CELL			English	Article							UPSTREAM ACTIVATION SITE; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; CATABOLITE REPRESSION; INVERTASE SYNTHESIS; GLUCOSE REPRESSION; S-CEREVISIAE; GENETIC INTERACTIONS; ALPHA-2 PRODUCT; CYC1 GENE	The homeodomain protein alpha-2 and the SRF-like protein Mcm1 are required to establish cell type in the yeast Saccharomyces cerevisiae. Together, these regulatory proteins recognize a specific DNA operator, marking a set of genes for transcriptional repression. In this paper, we show that occupancy of the operator by alpha-2-Mcm1 is not sufficient to bring about repression. Rather, repression is effected only when Ssn6 (a TPR protein) and Tup1 (a beta-transducin repeat protein) are also present in the cell. We show that Ssn6 represses transcription when brought to a promoter by a bacterial DNA-binding domain and that Tup1 is required for this repression. Based on these and other results, we propose that Ssn6-Tup1 is a general repressor of transcription in yeast, recruited to target promoters by a variety of sequence-specific DNA-binding proteins.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	University of California System; University of California San Francisco; Columbia University; Columbia University	KELEHER, CA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Alberts B., 1989, MOL BIOL CELL; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V1, P495; AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CARLSON M, 1984, GENETICS, V107, P19; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EBINA Y, 1983, J BIOL CHEM, V258, P3258; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRIGGS DW, 1992, IN PRESS P NATL ACAD; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEMONTT JF, 1980, GENETICS, V94, P899; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; Miller J.H., 1972, EXPT MOL GENETICS; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NEIGEBORN L, 1987, GENETICS, V115, P247; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHAMHART DHJ, 1975, J BACTERIOL, V121, P747, DOI 10.1128/JB.121.3.747-752.1975; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW P E, 1990, New Biologist, V2, P111; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SILICIANO PG, 1986, P NATL ACAD SCI USA, V83, P2320, DOI 10.1073/pnas.83.8.2320; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARK HC, 1980, GENETICS, V94, P921; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; TRUMBLY RJ, 1986, J BACTERIOL, V166, P1123, DOI 10.1128/jb.166.3.1123-1127.1986; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; WILSON KL, 1984, MOL CELL BIOL, V4, P2420, DOI 10.1128/MCB.4.11.2420; WILSON KL, 1985, P NATL ACAD SCI USA, V83, P2536; WRIGHT RM, 1990, MOL CELL BIOL, V10, P1297, DOI 10.1128/MCB.10.3.1297; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F	72	587	598	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					709	719		10.1016/0092-8674(92)90146-4	http://dx.doi.org/10.1016/0092-8674(92)90146-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739976				2022-12-28	WOS:A1992HF44000011
J	TAKASU, N; YAMADA, T; TAKASU, M; KOMIYA, I; NAGASAWA, Y; ASAWA, T; SHINODA, T; AIZAWA, T; KOIZUMI, Y				TAKASU, N; YAMADA, T; TAKASU, M; KOMIYA, I; NAGASAWA, Y; ASAWA, T; SHINODA, T; AIZAWA, T; KOIZUMI, Y			DISAPPEARANCE OF THYROTROPIN-BLOCKING ANTIBODIES AND SPONTANEOUS-RECOVERY FROM HYPOTHYROIDISM IN AUTOIMMUNE-THYROIDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING INHIBITOR IMMUNOGLOBULINS; PRIMARY MYXEDEMA; HASHIMOTOS-THYROIDITIS; GOITROUS HYPOTHYROIDISM; RECEPTOR ANTIBODY; GRAVES-DISEASE; CELLS; GROWTH; FRTL-5; INVITRO	Background. Hypothyroidism may result from the production of antibodies that block the actions of thyrotropin. How often these thyrotropin-blocking antibodies are a cause of hypothyroidism and whether their production may cease, causing hypothyroidism to disappear, have not been extensively studied. Methods. We determined the frequency with which thyrotropin-blocking antibodies were present in 172 hypothyroid patients with goitrous autoimmune thyroiditis (Hashimoto's disease) and 64 hypothyroid patients with atrophic autoimmune thyroiditis (idiopathic primary hypothyroidism). For 6 to 11 years we then followed 21 of these patients who were found to have thyrotropin-blocking antibodies. They received levothyroxine therapy for 3.5 to 8 years, after which it was discontinued. At frequent intervals during this time we measured the patients' serum concentrations of thyroxine, triiodothyronine, thyrotropin, and thyrotropin-blocking antibodies (measured as immunoglobulins that inhibit thyrotropin binding and immunoglobulins that inhibit thyrotropin bioactivity). Results. Thyrotropin-blocking antibodies were detected in 9 percent of the patients with goitrous autoimmune thyroiditis and in 25 percent of those with atrophic autoimmune thyroiditis. Among the 21 patients studied serially while receiving levothyroxine, thyrotropin-blocking antibodies disappeared in 15 (group 1), 7 of whom had goiter initially, and persisted in 6 (group 2), none of whom had goiter initially. Levothyroxine therapy was subsequently discontinued in these 21 patients. Six of those in group 1 (four with goiter) remained euthyroid (mean follow-up after discontinuation of therapy, 2.1 years), and nine became hypothyroid again within 3 months. All six patients in group 2 remained hypothyroid. Conclusions. Hypothyroidism in some patients with autoimmune thyroiditis may be due to thyrotropin-blocking antibodies. The production of thyrotropin-blocking antibodies may subside, producing remissions of hypothyroidism. Chronic autoimmune thyroiditis may therefore cause transient as well as permanent hypothyroidism.			TAKASU, N (corresponding author), SHINSHU UNIV,SCH MED,DEPT GERONTOL ENDOCRINOL & METAB,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.							AMINO N, 1977, ANN INTERN MED, V87, P155, DOI 10.7326/0003-4819-87-2-155; ARIKAWA K, 1985, J CLIN ENDOCR METAB, V60, P953, DOI 10.1210/jcem-60-5-953; BASTENIE PA, 1985, AM J MED, V79, P91, DOI 10.1016/0002-9343(85)90551-0; BUCHANAN WW, 1965, ARCH INTERN MED, V115, P411, DOI 10.1001/archinte.1965.03860160037006; CARLSON HE, 1980, ARCH INTERN MED, V140, P1675, DOI 10.1001/archinte.1980.00330230122034; CHIOVATO L, 1990, J CLIN ENDOCR METAB, V71, P40, DOI 10.1210/jcem-71-1-40; CHO BY, 1989, ACTA ENDOCRINOL-COP, V120, P99, DOI 10.1530/acta.0.1200099; ENDO K, 1978, J CLIN ENDOCR METAB, V46, P734, DOI 10.1210/jcem-46-5-734; Greerspan FS, 1991, BASIC CLIN ENDOCRINO, P188; HASHIM FA, 1986, CLIN ENDOCRINOL, V25, P275, DOI 10.1111/j.1365-2265.1986.tb01692.x; HOW J, 1980, LANCET, V2, P427; IIDA Y, 1987, J CLIN ENDOCR METAB, V64, P124, DOI 10.1210/jcem-64-1-124; KONISHI J, 1985, ANN INTERN MED, V103, P26, DOI 10.7326/0003-4819-103-1-26; KONISHI J, 1983, J CLIN ENDOCR METAB, V57, P544, DOI 10.1210/jcem-57-3-544; KRAIEM Z, 1987, CLIN ENDOCRINOL, V27, P409, DOI 10.1111/j.1365-2265.1987.tb01168.x; MATSUURA N, 1980, NEW ENGL J MED, V303, P738, DOI 10.1056/NEJM198009253031306; MORI T, 1987, ENDOCRINOL JAPON, V34, P237; NIKOLAI TF, 1989, AM J MED SCI, V297, P18, DOI 10.1097/00000441-198901000-00005; OCHI Y, 1976, ENDOCRINOL JAPON, V23, P183; OKAMURA K, 1978, ACTA ENDOCRINOL-COP, V88, P703, DOI 10.1530/acta.0.0880703; OKAMURA K, 1988, J CLIN ENDOCR METAB, V67, P720, DOI 10.1210/jcem-67-4-720; OKAMURA K, 1990, ACTA ENDOCRINOL-COP, V122, P107, DOI 10.1530/acta.0.1220107; SATO K, 1990, J CLIN ENDOCR METAB, V71, P855, DOI 10.1210/jcem-71-4-855; SATO K, 1988, CLIN ENDOCRINOL, V29, P231, DOI 10.1111/j.1365-2265.1988.tb01220.x; Smith B R, 1981, Methods Enzymol, V74 Pt C, P405; STEEL NR, 1984, BRIT MED J, V288, P1559, DOI 10.1136/bmj.288.6430.1559; TAJIRI J, 1986, J CLIN ENDOCR METAB, V63, P412, DOI 10.1210/jcem-63-2-412; TAKASU N, 1990, CLIN ENDOCRINOL, V33, P687, DOI 10.1111/j.1365-2265.1990.tb03906.x; TAKASU N, 1978, EUR J BIOCHEM, V90, P131, DOI 10.1111/j.1432-1033.1978.tb12583.x; TAKASU N, 1984, J ENDOCRINOL, V101, P189, DOI 10.1677/joe.0.1010189; TAKASU N, 1987, J CLIN ENDOCR METAB, V64, P239, DOI 10.1210/jcem-64-2-239; TAKASU N, 1990, LANCET, V336, P1084, DOI 10.1016/0140-6736(90)92567-2; TAKASU N, 1984, J CLIN ENDOCR METAB, V59, P142, DOI 10.1210/jcem-59-1-142; TAMAI H, 1990, CLIN ENDOCRINOL, V33, P699, DOI 10.1111/j.1365-2265.1990.tb03907.x; TAMAKI H, 1990, J CLIN ENDOCR METAB, V71, P1382, DOI 10.1210/jcem-71-5-1382; TANAKA H, 1987, ENDOCRINOL JAPON, V34, P689; TOKUDA Y, 1988, J CLIN ENDOCR METAB, V67, P251, DOI 10.1210/jcem-67-2-251; WERNER SC, 1978, THYROID, P843; YAMAMOTO M, 1983, ACTA ENDOCRINOL-COP, V102, P531, DOI 10.1530/acta.0.1020531; YAMAMOTO T, 1978, ANN INTERN MED, V88, P808, DOI 10.7326/0003-4819-88-6-808; YOSHINARI M, 1983, BRIT MED J, V287, P720, DOI 10.1136/bmj.287.6394.720	41	102	105	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					513	518		10.1056/NEJM199202203260803	http://dx.doi.org/10.1056/NEJM199202203260803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1732791				2022-12-28	WOS:A1992HD65800003
J	FOULKES, NS; SASSONECORSI, P				FOULKES, NS; SASSONECORSI, P			MORE IS BETTER - ACTIVATORS AND REPRESSORS FROM THE SAME GENE	CELL			English	Review							TRANSCRIPTIONAL REGULATION				FOULKES, NS (corresponding author), FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,U 184,INSERM,F-67085 STRASBOURG,FRANCE.		Foulkes, Nicholas S/K-7003-2013; Sassone-Corsi, Paolo/H-6182-2011	Foulkes, Nicholas S/0000-0002-1794-9891; 				DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; JACKSON ME, 1991, J CELL SCI, V100, P1; JONES N, 1991, Current Biology, V1, P224, DOI 10.1016/0960-9822(91)90063-3; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	17	270	283	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					411	414		10.1016/0092-8674(92)90178-F	http://dx.doi.org/10.1016/0092-8674(92)90178-F			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739963				2022-12-28	WOS:A1992HD39800002
J	BONFINI, L; KARLOVICH, CA; DASGUPTA, C; BANERJEE, U				BONFINI, L; KARLOVICH, CA; DASGUPTA, C; BANERJEE, U			THE SON OF SEVENLESS GENE-PRODUCT - A PUTATIVE ACTIVATOR OF RAS	SCIENCE			English	Article							CELL-CELL-INTERACTION; DROSOPHILA RETINA; CAENORHABDITIS-ELEGANS; NUCLEOTIDE-SEQUENCE; PROTEIN; PATHWAY; SWITCH; VULVAR; EYE	The Son of sevenless (Sos) gene functions in signaling pathways initiated by the sevenless and epidermal growth factor receptor tyrosine kinases. The Sos gene has now been isolated and sequenced. Its product is a 1595 - amino acid protein similar to the CDC25 protein in Saccharomyces cerevisiae, a guanine nucleotide exchange factor that activates Ras. These results imply a role for the ras pathway in Drosophila neuronal development.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006461] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER; NCRR NIH HHS [RR6461] Funding Source: Medline; NEI NIH HHS [1 R01 EY08152-01A1] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1991, DROS INF SER, V69, P1; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; FIEG LA, 1988, MOL CELL BIOL, V8, P3235; HAN M, 1990, GENETICS, V126, P899; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KARLOVICH CA, UNPUB; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; PIGNONI F, UNPUB; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5	23	243	248	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					603	606		10.1126/science.1736363	http://dx.doi.org/10.1126/science.1736363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736363				2022-12-28	WOS:A1992HB53100045
J	BERWICK, DM; ENTHOVEN, A; BUNKER, JP				BERWICK, DM; ENTHOVEN, A; BUNKER, JP			QUALITY MANAGEMENT IN THE NHS - THE DOCTORS ROLE .1.	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE		HARVARD COMMUNITY HLTH PLAN,BOSTON,MA 02215; STANFORD UNIV,GRAD SCH BUSINESS,STANFORD,CA 94305; KINGS COLL,SCH MED & DENT,CRC,CTR CLIN TRIALS,LONDON SE5 9NU,ENGLAND	Stanford University; University of London; King's College London								Batalden PB, 1989, PROVIDING QUALITY CA, P133; Berwick D M, 1990, QRB Qual Rev Bull, V16, P246; Berwick D. M, 1990, CURING HLTH CARE NEW; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BUNKER JP, 1990, BRIT MED J, V301, P531, DOI 10.1136/bmj.301.6751.531; Deming EW., 1986, OUT CRISIS; Enthoven A.C., 1985, REFLECTIONS MANAGEME; Feigenbaum A. V., 1961, TOTAL QUALITY CONTRO; Imai M., 1986, KAIZEN KEY JAPANS CO; Juran J. M., 1979, QUALITY CONTROL HDB; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; SCHOLTES PR, 1988, TEAM HDB; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WLATON M, 1990, DEMING MANAGEMENT WO, P83; 1989, CMND555	18	79	80	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					235	239		10.1136/bmj.304.6821.235	http://dx.doi.org/10.1136/bmj.304.6821.235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739800	Green Published, Bronze			2022-12-28	WOS:A1992HA98000029
J	FELSENFELD, G				FELSENFELD, G			CHROMATIN AS AN ESSENTIAL PART OF THE TRANSCRIPTIONAL MECHANISM	NATURE			English	Review							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; RNA POLYMERASE-II; LOCUS ACTIVATION REGION; HIGHER-ORDER STRUCTURE; SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; HYPERSENSITIVE SITES; PREINITIATION COMPLEXES; POSITIONED NUCLEOSOMES	The increasingly detailed biochemical definition of the protein complexes that regulate gene transcription has led to the re-emergence of questions about the role of histones. Much recent evidence suggests that transcriptional activation requires that transcription factors successfully compete with histones for binding to promoters, and that there may be more than one mechanism by which this is achieved.			FELSENFELD, G (corresponding author), NIH, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EMERSON BM, 1984, P NATL ACAD SCI-BIOL, V81, P95, DOI 10.1073/pnas.81.1.95; ENVER T, 1988, MOL CELL BIOL, V8, P1301, DOI 10.1128/MCB.8.3.1301; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FISHER EA, 1986, BIOCHEMISTRY-US, V25, P8010, DOI 10.1021/bi00372a033; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KIMURA T, 1983, NATURE, V306, P709, DOI 10.1038/306709a0; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1980, CELL, V22, P87, DOI 10.1016/0092-8674(80)90157-9; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; van Holde KE., 1989, SPRINGER SERIES MOL; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1990, PROG CLIN BIOL RES, V322, P171; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	87	832	858	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					219	224		10.1038/355219a0	http://dx.doi.org/10.1038/355219a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731219				2022-12-28	WOS:A1992GZ69400055
J	KENNEDY, AC				KENNEDY, AC			DISCOVERY IN MEDICINE	BRITISH MEDICAL JOURNAL			English	Article											KENNEDY, AC (corresponding author), BRITISH MED ASSOC,LONDON WC1H 9JR,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1569	1572		10.1136/bmj.303.6817.1569	http://dx.doi.org/10.1136/bmj.303.6817.1569			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773174	Bronze, Green Published			2022-12-28	WOS:A1991GX95600006
J	BUTCHER, EC				BUTCHER, EC			LEUKOCYTE-ENDOTHELIAL CELL RECOGNITION - 3 (OR MORE) STEPS TO SPECIFICITY AND DIVERSITY	CELL			English	Review							ADHESION; LFA-1		VET ADM MED CTR,CTR MOLEC BIOL MED,PALO ALTO,CA 94304	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BUTCHER, EC (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.							ARFORS KE, 1987, BLOOD, V69, P338; BERG EL, 1991, VASCULAR ADHESION MO, V2, P111; BJERKNES M, 1986, SCIENCE, V231, P402, DOI 10.1126/science.3941903; HAMANN A, 1988, J IMMUNOL, V140, P693; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; JUTILA MA, 1988, LEUKOCYTE ADHESION M, P227; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, BLOOD, V77, P2553; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; SCHALL TJ, 1991, CYTOKINE, V3, P1; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538	23	2595	2665	2	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1033	1036		10.1016/0092-8674(91)90279-8	http://dx.doi.org/10.1016/0092-8674(91)90279-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760836				2022-12-28	WOS:A1991GX16400002
J	GANNON, MJ; HOLT, EM; FAIRBANK, J; FITZGERALD, M; MILNE, MA; CRYSTAL, AM; GREENHALF, JO				GANNON, MJ; HOLT, EM; FAIRBANK, J; FITZGERALD, M; MILNE, MA; CRYSTAL, AM; GREENHALF, JO			A RANDOMIZED TRIAL COMPARING ENDOMETRIAL RESECTION AND ABDOMINAL HYSTERECTOMY FOR THE TREATMENT OF MENORRHAGIA	BRITISH MEDICAL JOURNAL			English	Article							WOMEN	Objective - To determine the advantages and disadvantages of endometrial resection and abdominal hysterectomy for the surgical treatment of women with menorrhagia. Design - Randomised study of two treatment groups with a minimum follow up of nine months. Setting - Royal Berkshire Hospital, Reading. Subjects - 51 of 78 menorrhagic women without pelvic pathology who were on the waiting list for abdominal hysterectomy. Treatment - Endometrial resection or abdominal hysterectomy (according to randomisation). Endometrial resections were performed by an experienced hysteroscopic surgeon; hysterectomies were performed by two other gynaecological surgeons. Main outcome measures - Length of operating time, hospitalisation, recovery; cost of surgery; short term results of endometrial resection. Results - Operating time was shorter for endometrial resection (median 30 (range 20-47) minutes) than for hysterectomy (50 (39-74) minutes). The hospital stay for endometrial resection (median 1 (range 1-3) days) was less than for hysterectomy (7 (5-12) days). Recovery after endometrial resection (median 16 (range 5-62) days) was shorter than after hysterectomy (58 (11-125) days). The cost was Pound 407 for endometrial resection and Pound 1270 for abdominal hysterectomy. Four women (16%) who did not have an acceptable improvement in symptoms after endometrial resection had repeat resections. No woman has required hysterectomy during a mean follow up of one year. Conclusion - For women with menorrhagia who have no pelvic pathology endometrial resection is a useful alternative to abdominal hysterectomy, with many short term benefits. Larger numbers and a longer follow up are needed to estimate the incidence of complications and the long term efficacy of endometrial resection.	REG TECH COLL,GALWAY,IRELAND; ROYAL BERKSHIRE HOSP,DEPT OBSTET & GYNAECOL,READING RG1 5AN,BERKS,ENGLAND	Galway Mayo Institute of Technology; Royal Berkshire Hospital			Fairbank, Jeremy/AAA-3411-2019					AZZIZ R, 1989, FERTIL STERIL, V51, P1061; BOTO TCA, 1990, BRIT J HOSP MED, V44, P93; DECHERNEY AH, 1987, OBSTET GYNECOL, V70, P668; DERMAN SG, 1991, OBSTET GYNECOL, V77, P591; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; GARRY R, 1991, BRIT J OBSTET GYNAEC, V98, P357, DOI 10.1111/j.1471-0528.1991.tb13425.x; JOELCOHEN SJ, 1978, CLIN OBSTET GYNAECOL, V5, P525; MACDONALD R, 1990, BRIT J OBSTET GYNAEC, V97, P3, DOI 10.1111/j.1471-0528.1990.tb01709.x; MACDONALD R, IN PRESS GYNAECOLOGI; MAGOS AL, 1989, BRIT MED J, V298, P1209, DOI 10.1136/bmj.298.6682.1209; MCLUCAS B, 1991, SURG GYNECOL OBSTET, V172, P425; PARDTHAISONG T, 1984, J BIOSOC SCI, V16, P23, DOI 10.1017/S0021932000014760; RUTHERFORD AJ, 1991, BRIT J OBSTET GYNAEC, V98, P228, DOI 10.1111/j.1471-0528.1991.tb13378.x; STIRRAT GM, 1990, BRIT J OBSTET GYNAEC, V97, P459, DOI 10.1111/j.1471-0528.1990.tb01840.x	14	140	140	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1362	1364		10.1136/bmj.303.6814.1362	http://dx.doi.org/10.1136/bmj.303.6814.1362			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760601	Bronze, Green Published			2022-12-28	WOS:A1991GU38400018
J	OBRIEN, J; AUSTIN, M; SETHI, P; OBOYLE, P				OBRIEN, J; AUSTIN, M; SETHI, P; OBOYLE, P			URINARY-INCONTINENCE - PREVALENCE, NEED FOR TREATMENT, AND EFFECTIVENESS OF INTERVENTION BY NURSE	BRITISH MEDICAL JOURNAL			English	Article							DETRUSOR INSTABILITY; STRESS-INCONTINENCE; CONTROLLED TRIAL; BLADDER DRILL; WOMEN; SERVICES; HOME	Objective - To measure the unmet need of patients with regular urinary incontinence (incontinence twice or more a month) treatable by a nurse. Design - Self completed postal questionnaire and randomised controlled trial of assessment and intervention by a nurse. Setting - One urban and one rural general practice in Somerset. Subjects - 7300 adults randomly selected from 10300 aged 35 and over on the combined practice lists. 515 women and 185 men with regular incontinence were offered assessment and treatment, of whom 134 women and 49 men had no intervention for three months (historical controls). They then joined the assessment and treatment programme. Intervention - Four sessions of pelvic floor exercises and bladder retraining supervised by non-specialist nurse who had taken a three week course on assessing and treating uncomplicated incontinence. Main outcome measures - Number of patients desiring treatment; self reported cure, improvement, or deterioration in continence after three months. Results - The questionnaire achieved a 79% response. Validated responses showed a prevalence of 4.4% in men and 16.4% in women aged 35-64. 315 (45%) of the 700 patients offered assessment refused it and seven had moved away or died, 64 men and 41 women were referred to their general practitioner. 197 of 292 treated women (68%) reported cure or improvement compared with seven (5%) of controls. 22 of the 86 men desiring treatment were suitable for intervention by the nurse. Seventeen were cured or improved compared with none of the men in the control group. Conclusions - About half the people with regular urinary incontinence took up the offer of treatment (9.2% of women and 3.4% of men in the study population). This condition can be effectively managed by a nurse with limited training.	SOMERSET DIST HLTH AUTHOR,PUBL HLTH MED,TAUNTON TA2 7PQ,ENGLAND; MUSGROVE PK HOSP,TAUNTON,SOMERSET,ENGLAND	Musgrove Park Hospital								BATES CP, 1977, UROLOGY, V9, P237; BROCKLEHURST J C, 1972, Age and Ageing, V1, P41, DOI 10.1093/ageing/1.1.41; CASTLEDEN CM, 1984, AGE AGEING, V13, P235, DOI 10.1093/ageing/13.4.235; CASTLEDEN CM, 1981, BMJ, V282, P1003; FANTL JA, 1987, OBSTET GYNECOL, V70, P739; FENELEY RCL, 1979, BRIT J UROL, V51, P493, DOI 10.1111/j.1464-410X.1979.tb03585.x; FRANKEL S, 1990, EPIDEMIOLOGICALLY BA; HALL C, 1988, BRIT MED J, V297, P1181, DOI 10.1136/bmj.297.6657.1181; Harrison S M, 1983, Physiotherapy, V69, P144; HENALLA SM, 1988, BRIT J OBSTET GYNAEC, V95, P602, DOI 10.1111/j.1471-0528.1988.tb09491.x; HILTON P, 1987, BRIT MED J, V295, P426, DOI 10.1136/bmj.295.6595.426; HOLST K, 1988, NEW ZEAL MED J, V101, P756; JARVIS GJ, 1980, BRIT MED J, V281, P1322, DOI 10.1136/bmj.281.6251.1322-a; JOLLEYS JV, 1989, J ROY COLL GEN PRACT, V39, P277; MCGROTHER CW, 1986, J EPIDEMIOL COMMUN H, V40, P134, DOI 10.1136/jech.40.2.134; MOHIDE EA, 1988, CAN MED ASSOC J, V139, P953; PENGELLY AW, 1980, BRIT J UROL, V52, P463, DOI 10.1111/j.1464-410X.1980.tb03091.x; PENGELLY AW, 1980, BR J UROL, V52, P462; Smith N K, 1988, Health Trends, V20, P22; STANTON SL, 1980, SURG GYNECOL OBSTET, V150, P555; SUTHERST J, 1981, LANCET, V1, P1128; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; 43 KINGS FUND PROJ P; 1986, LANCET, V2, P1316	24	119	120	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1308	1312		10.1136/bmj.303.6813.1308	http://dx.doi.org/10.1136/bmj.303.6813.1308			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747675	Green Published, Bronze			2022-12-28	WOS:A1991GT01100024
J	PATCHETT, S; BEATTIE, S; LEEN, E; KEANE, C; OMORAIN, C				PATCHETT, S; BEATTIE, S; LEEN, E; KEANE, C; OMORAIN, C			ERADICATING HELICOBACTER-PYLORI AND SYMPTOMS OF NONULCER DYSPEPSIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLACEBO CONTROLLED TRIAL; CAMPYLOBACTER-PYLORIDIS; GASTRITIS	Objective - To examine the effect of eradication of Helicobacter pylori on symptoms of non-ulcer dyspepsia. Design - Four week prospective study. Setting - One hospital outpatient and endoscopy department. Patients - 90 adults with persistent symptoms typical of non-ulcer dyspepsia but no clinical or endoscopic evidence of other peptic, biliary, pancreatic, or malignant disease; all had histological and microbiological evidence of infection with H pylori. 83 patients completed the treatment regimen. Intervention - Colloidal bismuth subcitrate 120 mg four times a day for four weeks (27 patients); metronidazole 400 mg and amoxycillin 500 mg each three times a day for one week (27); and bismuth subcitrate 120 mg four times a day for four weeks, metronidazole 400 mg three times a day for one week, plus amoxycillin 500 mg three times a day for the first week (29). Main outcome measures - Change in symptom scores determined with questionnaire; histological evidence of gastritis and microbiological evidence of presence of H pylori in biopsy specimens. Results - Overall, H pylori was eradicated in 41 (49%) patients. Although gastritis scores improved significantly in only patients in whom H pylori had been eradicated (from 1.56 to 0.61, p < 0.01 v from 1.83 to 1.07, p = 0.52) mean symptom scores after treatment were similar in patients in whom H pylori had or had not been eradicated (3.0 v 2.3, NS). Similarly the mean symptom score improved whether or not gastritis improved (2.8 v 3.1 respectively, p = 0.72). The observations were similar for treatment groups analysed individually. Conclusion - Antral infection with the organism does not seem to have an important aetiological role in non-ulcer dyspepsia short term.	MEATH & ADELAIDE HOSP, DEPT GASTROENTEROL, DUBLIN 8, IRELAND; UNIV DUBLIN TRINITY COLL, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin								ADAMI HO, 1984, SCAND J GASTROENTERO, V19, P216, DOI 10.1080/00365521.1984.12005712; BARTHEL JS, 1988, ARCH INTERN MED, V148, P1149, DOI 10.1001/archinte.148.5.1149; BORODY T, 1987, GASTROENTEROLOGY, V92, P1324; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1988, LANCET, V1, P576; GOODWIN C, 1986, J CLIN PATHOL, V7, P206; HEATLEY RV, 1987, LANCET, V2, P779; LAMBERT JR, 1989, SCAND J GASTROENTERO, V24, P7, DOI 10.3109/00365528909091728; LOFFELD RJLF, 1989, GUT, V30, P1206, DOI 10.1136/gut.30.9.1206; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MARSHALL BJ, 1988, CAMPYLOBACTER PYLORI, P235; MORRIS A, 1986, NEW ZEAL MED J, V99, P657; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; ROKKAS T, 1988, GUT, V29, P1386, DOI 10.1136/gut.29.10.1386	16	132	132	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1991	303	6812					1238	1240		10.1136/bmj.303.6812.1238	http://dx.doi.org/10.1136/bmj.303.6812.1238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747644	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200023
J	SUNOL, R; DELGADO, R; ESTEBAN, A				SUNOL, R; DELGADO, R; ESTEBAN, A			MEDICAL AUDIT - THE SPANISH EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article									HOSP BELLVITGE PRINCEPS ESPANYA,BARCELONA,SPAIN; HOSP UNIV CETAFE,INTENS CARE UNIT,MADRID,SPAIN		SUNOL, R (corresponding author), HOSP SANTA CRUZ & SAN PABLO,E-08025 BARCELONA,SPAIN.		Sunol, Rosa/AAS-7276-2021	Sunol, Rosa/0000-0003-1902-833X				Bohigas L, 1984, World Hosp, V20, P20; Saturno P J, 1989, Aust Clin Rev, V9, P54; Saturno P J, 1989, Aust Clin Rev, V9, P81; Sunol R, 1989, Aust Clin Rev, V9, P60; 1983, WHO1983 ANN REP	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1249	1251		10.1136/bmj.303.6812.1249	http://dx.doi.org/10.1136/bmj.303.6812.1249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747650	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200031
J	LAAKSO, M; KESANIEMI, A; KERVINEN, K; JAUHIAINEN, M; PYORALA, K				LAAKSO, M; KESANIEMI, A; KERVINEN, K; JAUHIAINEN, M; PYORALA, K			RELATION OF CORONARY HEART-DISEASE AND APOLIPOPROTEIN-E PHENOTYPE IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; E POLYMORPHISM; APOPROTEIN-E; ARTERY DISEASE; INCREASED FREQUENCY; C-PEPTIDE; SERUM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ASSOCIATION	Objectives - To examine the relation between coronary heart disease and the apolipoprotein E phenotypes in patients with non-insulin dependent diabetes mellitus. Design - Cross sectional study. Setting - District around Kuopio University Central Hospital, East Finland. Subjects - 138 men with non-insulin dependent diabetes and 64 men without diabetes as controls. Main outcome measure - Apolipoprotein E phenotype, electrocardiographic abnormalities, other signs of coronary heart disease. Results - The prevalences of definite myocardial infarction and ischaemic electrocardiographic changes were highest in the diabetic men with the phenotypes E4/4 or E4/3 (25% (95% confidence interval 18% to 32%) and 50% (42% to 58%) respectively), although the difference between the phenotype groups was not significant. The prevalence of angina pectoris was 69% (61% to 77%) in men with the phenotypes E4/4 or E4/3 (p = 0.005 compared with other phenotypes), 41% (33% to 49%) in men with phenotype E3/3, and 47% (39% to 55%) in those with phenotypes E2/2 or E2/3. Similarly, the simultaneous presence of angina pectoris and ischaemic electrocardiographic changes was highest in the diabetic men with the phenotypes E4/4 or E4/3 (42% v 22% in those with E3/3 and 29% in those with E2/2, E2/3; p = 0.038). Overall, the prevalence of any evidence of coronary heart disease among the diabetic subjects with the phenotypes E4/4 or E4/3 was 81%(p = 0.01 compared with other phenotypes), 58% in those with phenotype E3/3, and 53% in those with phenotypes E2/2 or E3/3. Conclusion - Apolipoprotein E phenotypes E4/4 and E4/3 modulate the risk of coronary heart disease in men with non-insulin dependent diabetes.	UNIV OULU, DEPT MED, SF-90100 OULU 10, FINLAND; NATL PUBL HLTH INST, DEPT BIOCHEM, SF-00280 HELSINKI 28, FINLAND	University of Oulu; Finland National Institute for Health & Welfare	LAAKSO, M (corresponding author), KUOPIO UNIV, CENT HOSP, DEPT MED, SF-70210 KUOPIO, FINLAND.							ASSMANN G, 1984, CLIN CHEM, V30, P641; BASU SK, 1982, J BIOL CHEM, V257, P9788; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EHNHOLM C, 1986, J LIPID RES, V27, P227; ETO M, 1986, DIABETES, V35, P1374, DOI 10.2337/diabetes.35.12.1374; ETO M, 1987, DIABETES, V36, P1301, DOI 10.2337/diabetes.36.11.1301; ETO M, 1986, CLIN GENET, V29, P477; FRIER BM, 1977, DIABETES, V26, P369; GREGG RE, 1981, SCIENCE, V211, P584, DOI 10.1126/science.7455696; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HUI DY, 1980, J BIOL CHEM, V255, P1775; IMARI Y, 1988, METABOLISM, V37, P1134, DOI 10.1016/0026-0495(88)90189-8; JAUHIAINEN M, 1983, CLIN CHEM, V29, P1731; KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LAAKSO M, 1985, ARTERIOSCLEROSIS, V5, P653, DOI 10.1161/01.ATV.5.6.653; LAAKSO M, 1987, AM J EPIDEMIOL, V125, P611, DOI 10.1093/oxfordjournals.aje.a114574; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; LENZEN HJ, 1986, CLIN CHEM, V32, P778; LEREN TP, 1985, CLIN GENET, V27, P458; MADSBAD S, 1979, BRIT MED J, V2, P1257, DOI 10.1136/bmj.2.6200.1257; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; PENTTILA IM, 1981, SCAND J CLIN LAB INV, V41, P353, DOI 10.3109/00365518109092057; PEPE MG, 1986, J IMMUNOL, V136, P3716; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; PYORALA K, 1985, CARDIOLOGY, V72, P35, DOI 10.1159/000173839; RIEPPONEN P, 1987, SCAND J CLIN LAB INV, V47, P739; Rose G, 1982, CARDIOVASCULAR SURVE; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SING CF, 1985, AM J HUM GENET, V37, P268; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1984, HUM GENET, V65, P232, DOI 10.1007/BF00286508; WANG K, 1986, ACTA ACAD MED SINICA, V8, P198; 1980, WHO TECH REP SER, P646; WHOMNC821	39	71	72	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1991	303	6811					1159	1162		10.1136/bmj.303.6811.1159	http://dx.doi.org/10.1136/bmj.303.6811.1159			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747611	Green Published, Bronze			2022-12-28	WOS:A1991GP48800020
J	HANDEL, J; TRIPP, JH				HANDEL, J; TRIPP, JH			VITAMIN-K PROPHYLAXIS AGAINST HEMORRHAGIC-DISEASE OF THE NEWBORN IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article									POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter								Lehmann JL, 1944, LANCET, V1, P493; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; TRIPP JH, 1987, ARCH DIS CHILD, V62, P436, DOI 10.1136/adc.62.5.436	4	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1109	1109		10.1136/bmj.303.6810.1109	http://dx.doi.org/10.1136/bmj.303.6810.1109			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747579	Green Published			2022-12-28	WOS:A1991GN20900023
J	ALDERMAN, MH; MADHAVAN, S; OOI, WL; COHEN, H; SEALEY, JE; LARAGH, JH				ALDERMAN, MH; MADHAVAN, S; OOI, WL; COHEN, H; SEALEY, JE; LARAGH, JH			ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-RENIN; WORK SITE; ALDOSTERONE; ANGIOTENSIN; SECRETION; SYSTEM	Background. To test the prognostic value of plasma renin activity prospectively, we determined the pretreatment renin-sodium profile of 1717 subjects with mild-to-moderate hypertension (mean age, 53 years; 36 percent white; 67 percent men) in a systematic work-site treatment program. Methods. Renin profiles, obtained by plotting plasma renin activity against the urinary excretion of sodium, were classified as high (12 percent of the subjects), normal (56 percent), and low (32 percent), and there were expected variations according to age, sex, and race. Modified stepped-care treatment for hypertension, prescribed without reference to the renin profile, was similar in the three renin groups. Results. Mean (+/- SD) blood pressure at entry was 151 +/- 19/100 +/- 10 mm Hg in the subjects with a high renin profile, 151 +/- 19/97 +/- 10 mm Hg in those with a normal profile, and 151 +/- 20/96 +/- 11 mm Hg in those with a low profile. During 8.3 years of follow-up, there were 27 myocardial infarctions. As adjusted for age, sex, and race, the incidence of myocardial infarction per 1000 person-years was 14.7 among the subjects with a high renin profile, 5.6 among those with a normal profile, and 2.8 among those with a low profile (rate ratio for high vs. low, 5.3; 95 percent confidence interval, 3.4 to 8.3). The rate of mortality from all causes was 9.3 in the high-profile group, 5.3 in the normal-profile group, and 3.9 in the low-profile group. The independent association of a high renin profile with myocardial infarction (but not with stroke or noncardiovascular events) was affirmed by Cox analyses (rate ratio for high vs. normal plus low, 3.2; 95 percent confidence interval, 1.2 to 8.4) after adjustment for race, sex, age at entry, serum cholesterol level, smoking status, electrocardiographic evidence of left ventricular hypertrophy, blood glucose level, body-mass index, history of cardiovascular disease or treatment, blood pressure, and use of beta-blockers. Conclusions. In the study population, whose blood pressure before and during treatment was in a narrow range, and after other cardiovascular risk factors had been considered, the renin profile before treatment remained independently associated with the subsequent risk of myocardial infarction.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,CTR CARDIOVASC,NEW YORK,NY 10021	Cornell University	ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Sealey, Jean/A-9562-2009	Cohen, Hillel/0000-0002-4524-0898	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BRUNNER HR, 1973, AM J MED, V55, P295, DOI 10.1016/0002-9343(73)90131-9; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1972, NEW ENGL J MED, V287, P1209, DOI 10.1056/NEJM197212142872401; COX DR, 1972, J R STAT SOC B, V34, P187; FREIS ED, 1973, AM J MED, V255, P275; GAVRAS H, 1971, LANCET, V2, P19; GAVRAS H, 1977, ARCH INTERN MED, V137, P155; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; KAPLAN NM, 1976, ANN INTERN MED, V84, P639, DOI 10.7326/0003-4819-84-6-639; KAPLAN NM, 1975, JAMA-J AM MED ASSOC, V231, P167, DOI 10.1001/jama.231.2.167; LARAGH JH, 1972, AM J MED, V52, P633, DOI 10.1016/0002-9343(72)90054-X; LARAGH JH, 1973, AM J MED, V55, P261, DOI 10.1016/0002-9343(73)90128-9; LARAGH JH, 1960, JAMA-J AM MED ASSOC, V174, P293, DOI 10.1001/jama.1960.63030030007014; Laragh JH, 1990, HYPERTENSION PATHOPH, P1329; LEDINGHAM JM, 1990, HYPERTENSION PATHOPH, P33; MEADE TW, 1983, CLIN SCI, V64, P273, DOI 10.1042/cs0640273; MEYER P, 1990, HYPERTENSION PATHOPH, P541; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Sealey J E, 1980, Endocr Rev, V1, P365; SEALEY JE, 1988, J HYPERTENS, V6, P763, DOI 10.1097/00004872-198811000-00001; SEALEY JE, 1981, CLIN BIOCHEM, V14, P273, DOI 10.1016/S0009-9120(81)91000-6; Sealey JE, 1990, HYPERTENSION PATHOPH, P1443; SHAPIRO R, 1976, J LAB CLIN MED, V88, P222; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; Winternitz M C, 1940, Yale J Biol Med, V12, P623; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1985, BMJ, V291, P97	30	688	695	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1098	1104		10.1056/NEJM199104183241605	http://dx.doi.org/10.1056/NEJM199104183241605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1759997				2022-12-28	WOS:A1991FG91200005
J	EBNER, SA; BADONNEL, MC; ALTMAN, LK; BRAVERMAN, LE				EBNER, SA; BADONNEL, MC; ALTMAN, LK; BRAVERMAN, LE			CONJUGAL GRAVES-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Note						GRAVES DISEASE; THYROTOXICOSIS; AUTOIMMUNE DISEASES; THYROID DISEASES; CONJUGAL DISEASES	YERSINIA-ENTEROCOLITICA	We describe a family in which the parents developed Graves disease and their four children had thyroid disease (two with Graves disease, one with Hashimoto thyroiditis, and one with a nontoxic goiter). Data on the prevalence of Graves disease suggest that between 20 and 1500 married couples in the United States may be affected by the disorder. Several environmental factors have been proposed as etiologic factors in Graves disease, including Yersinia enterocolitica, a retrovirus, excess iodine ingestion, and stress. None of these factors was evident in this family, Physicians are encouraged to report cases of conjugal Graves disease in order to shed further light on the relation between genetics and the environment in the etiology of this disorder.	UNIV MASSACHUSETTS, MED CTR, DIV ENDOCRINOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester				Braverman, Lewis/0000-0003-1263-1099	NIDDK NIH HHS [DK18919] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWNLIE BEW, 1980, NEW ZEAL MED J, V91, P246; CASTANER MF, 1983, ACTA ENDOCRINOL-COP, V102, P535, DOI 10.1530/acta.0.1020535; CIAMPOLILLO A, 1989, LANCET, V1, P1096; GAITAN E, 1985, CLIN ECOL, V3, P158; HOFFENBERG R, 1974, BMJ-BRIT MED J, V3, P452, DOI 10.1136/bmj.3.5928.452; HUMPHREY M, 1991, LANCET, V337, P17, DOI 10.1016/0140-6736(91)93335-7; SHENKMAN L, 1976, ANN INTERN MED, V85, P735, DOI 10.7326/0003-4819-85-6-735; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VAGENAKIS AG, 1972, NEW ENGL J MED, V287, P523, DOI 10.1056/NEJM197209142871101; WEISS M, 1983, SCIENCE, V219, P1331, DOI 10.1126/science.6298936; WINSA B, 1991, LANCET, V338, P1475, DOI 10.1016/0140-6736(91)92298-G	11	3	3	3	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					479	481		10.7326/0003-4819-116-6-479	http://dx.doi.org/10.7326/0003-4819-116-6-479			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739238				2022-12-28	WOS:A1992HJ59800008
J	BLENDON, RJ; DONELAN, K; LUKAS, CV; THORPE, KE; FRANKEL, M; BASS, R; TAYLOR, H				BLENDON, RJ; DONELAN, K; LUKAS, CV; THORPE, KE; FRANKEL, M; BASS, R; TAYLOR, H			THE UNINSURED AND THE DEBATE OVER THE REPEAL OF THE MASSACHUSETTS UNIVERSAL HEALTH-CARE LAW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives. - The debate in Massachusetts over the repeal of the first state-based "pay or play" universal health plan is discussed using data from a survey of 1066 Massachusetts households. The survey attempted to measure the problems of the uninsured, to estimate the likelihood that they would buy insurance if offered, and to calculate the proportion of the uninsured who would be covered under an employer mandate. Design. - A survey conducted in person and by telephone in 1066 households, with an oversample of uninsured households, using stratification, clustering, disproportionate sampling, and poststatistical weighting. Participants. - Adults aged 18 years and older who were knowledgeable about the insurance status of persons in their household. Main Outcome Measures. - Insurance status, employment status, access to and use of health services, and willingness to purchase health insurance. Results. - First, the present system of hospital-based uncompensated care in Massachusetts is inadequate by itself to meet the needs of uninsured residents. Uninsured persons are less likely than insured ones to seek medical care for chronic health problems and serious symptoms requiring evaluation. Second, 83% of uninsured families and 24% of uninsured individual respondents would purchase one of several insurance options with 30% of the cost subsidized. Last, the employer mandate provisions of the legislation would cover 43% of the uninsured in Massachusetts. Conclusion. - In the current economic climate, the political viability of the universal health care plan and similar national initiatives is uncertain given the intractable conflict between perceptions of the financial stability of small businesses that do not offer insurance and the health care needs of uninsured individuals.	COMMONWEALTH MASSACHUSETTS,DEPT MED SECUR,BOSTON,MA; LOUIS HARRIS & ASSOCIATES,NEW YORK,NY; UNIV N CAROLINA,SCH PUBL HLTH,DEPT HLTH POLICY & ADM,CHAPEL HILL,NC 27514; CUNY BERNARD M BARUCH COLL,NEW YORK,NY 10010	University of North Carolina; University of North Carolina Chapel Hill; City University of New York (CUNY) System; Baruch College (CUNY)	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					Cochran W.G., 2007, SAMPLING TECHNIQUES; Davies A.R., 1981, MEASURING HLTH PERCE; FOLEY P, 1991, UNINSURED US NONELDE; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P7; GOLDBERGER SA, 1990, J HEALTH POLIT POLIC, V15, P857, DOI 10.1215/03616878-15-4-857; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; KISH L, 1965, SURVEY SAMPLING, P197; KRONICK R, 1990, J HEALTH POLIT POLIC, V15, P887, DOI 10.1215/03616878-15-4-887; LUNDBERG GD, 1991, JAMA-J AM MED ASSOC, V265, P2491; NELSON C, 1990, HLTH INSURANCE C P70, P1; ROCKEFELLER JD, 1991, JAMA-J AM MED ASSOC, V265, P2507, DOI 10.1001/jama.265.19.2507; TAYLOR H, 1990, PUBLIC CONSUMERS VOT, P57; 1990, HOUSEHOLD SURVEY HLT; 1983, SECURING ACCESS HLTH; 1990, REPORT EMPLOYMENT WA; 1990, PUBLIC ATTITUDES TOW	16	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1113	1117		10.1001/jama.267.8.1113	http://dx.doi.org/10.1001/jama.267.8.1113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE391	1735929				2022-12-28	WOS:A1992HE39100029
J	GODLEY, L; PFEIFER, J; STEINHAUER, D; ELY, B; SHAW, G; KAUFMANN, R; SUCHANEK, E; PABO, C; SKEHEL, JJ; WILEY, DC; WHARTON, S				GODLEY, L; PFEIFER, J; STEINHAUER, D; ELY, B; SHAW, G; KAUFMANN, R; SUCHANEK, E; PABO, C; SKEHEL, JJ; WILEY, DC; WHARTON, S			INTRODUCTION OF INTERSUBUNIT DISULFIDE BONDS IN THE MEMBRANE-DISTAL REGION OF THE INFLUENZA HEMAGGLUTININ ABOLISHES MEMBRANE-FUSION ACTIVITY	CELL			English	Article							MIDDLE-T ANTIGEN; VIRUS HEMAGGLUTININ; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; PH OPTIMUM; EXPRESSION; ACTIVATION; GLYCOPROTEIN; CLEAVAGE; PROTEINS	Influenza virus hemagglutinin (HA) mediates viral entry into cells by a low pH-induced membrane fusion event in endosomes. A number of structural changes occur throughout the length of HA at the pH of fusion. To probe their significance and their necessity for fusion activity, we have prepared a site-directed mutant HA containing novel intersubunit disulfide bonds designed to cross-link covalently the membrane-distal domains of the trimer. These mutations inhibited the low pH-induced conformational changes and prevented HA-mediated membrane fusion; conditions that reduced the novel disulfide bonds restored membrane fusion activity. We conclude that structural rearrangements in the membrane distal region of the HA are required for membrane fusion activity.	GENET INST,CAMBRIDGE,MA 02140; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Johns Hopkins University; Harvard University; Harvard University; Howard Hughes Medical Institute	GODLEY, L (corresponding author), NATL INST MED RES,MILL HILL,LONDON NW7 1AA,ENGLAND.				NIAID NIH HHS [AI13654] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013654] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDDELL CR, 1984, BRIT J PHARMACOL, V82, P397, DOI 10.1111/j.1476-5381.1984.tb10775.x; BELSHAM GJ, 1986, VIRUS RES, V4, P157, DOI 10.1016/0168-1702(86)90039-0; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DOMS RW, 1985, J BIOL CHEM, V260, P2973; JACKSON DC, 1985, VIROLOGY, V145, P72, DOI 10.1016/0042-6822(85)90202-8; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; PABO CO, 1986, BIOCHEMISTRY-US, V25, P5987, DOI 10.1021/bi00368a023; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEINHAUER DA, 1991, VIROLOGY, V184, P445, DOI 10.1016/0042-6822(91)90867-B; VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0; WEBSTER RG, 1983, VIROLOGY, V126, P587, DOI 10.1016/S0042-6822(83)80015-4; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P368; YEWDELL JW, 1983, J VIROL, V48, P239, DOI 10.1128/JVI.48.1.239-248.1983	38	155	159	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					635	645		10.1016/0092-8674(92)90140-8	http://dx.doi.org/10.1016/0092-8674(92)90140-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739972				2022-12-28	WOS:A1992HF44000005
J	STRUBIN, M; STRUHL, K				STRUBIN, M; STRUHL, K			YEAST AND HUMAN TFIID WITH ALTERED DNA-BINDING SPECIFICITY FOR TATA ELEMENTS	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; BOX FACTOR; SACCHAROMYCES-CEREVISIAE; ACTIVATOR PROTEINS; SIGMA-70 SUBUNIT; GENERAL CONTROL; GCN4 PROTEIN; REPRESSOR	TFIID is the highly conserved, but species-specific, component of the RNA polymerase II transcription machinery that binds specifically to the TATA element (consensus TATAAA). Using a genetic selection, we isolated an altered specificity derivative of yeast TFIID that permits transcription from promoters containing a mutated TATA element (TGTAAA). Biochemical analysis indicates that this TFIID derivative has specifically gained the ability to bind TGTAAA efficiently. The mutant protein contains three substitutions within a 12 amino acid region; two of these are necessary and primarily responsible for the altered specificity. An analogous version of human TFIID, generated by introducing the same amino acid substitutions in the corresponding region of the protein, can support basal and GCN4-activated transcription in yeast cells from a TGTAAA-containing promoter. These results define a surface of TFIID that directly interacts with the TATA element, and they indicate that human TFIID can respond to acidic activator proteins in conjunction with the other components of the yeast transcription machinery.			STRUBIN, M (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TZAMARIAS D, 1992, IN PRESS P NATL ACAD, V89; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	56	145	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					721	730		10.1016/0092-8674(92)90147-5	http://dx.doi.org/10.1016/0092-8674(92)90147-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739977				2022-12-28	WOS:A1992HF44000012
J	IBRAGHIMOVBESKROVNAYA, O; ERVASTI, JM; LEVEILLE, CJ; SLAUGHTER, CA; SERNETT, SW; CAMPBELL, KP				IBRAGHIMOVBESKROVNAYA, O; ERVASTI, JM; LEVEILLE, CJ; SLAUGHTER, CA; SERNETT, SW; CAMPBELL, KP			PRIMARY STRUCTURE OF DYSTROPHIN-ASSOCIATED GLYCOPROTEINS LINKING DYSTROPHIN TO THE EXTRACELLULAR-MATRIX	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LAMININ-BINDING-PROTEIN; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; CELL-MEMBRANES; SURFACE; SEQUENCE; CHANNEL; LOCUS	The primary sequence of two components of the dystrophin-glycoprotein complex has been established by complementary DNA cloning. The transmembrane 43K and extracellular 156K dystrophin-associated glyco proteins (DAGs) are encoded by a single messenger RNA and the extracellular 156K DAG binds laminin. Thus, the 156K DAG is a new laminin-binding glycoprotein which may provide a linkage between the sarcolemma and extracellular matrix. These results support the hypothesis that the dramatic reduction in the 156K DAG in Duchenne muscular dystrophy leads to a loss of a linkage between the sarcolemma and extracellular matrix and that this may render muscle fibres more susceptible to necrosis.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV TEXAS,SW MED CTR,BIOPOLYMER FACIL HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Ervasti, James/AAZ-4786-2020	Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BONILLA E, 1986, NEUROLOGY, V36, P171; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CLEGG DO, 1988, J CELL BIOL, V107, P699, DOI 10.1083/jcb.107.2.699; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GORKA J, 1989, PEPTIDE RES, V2, P1; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UTRNER PR, 1991, J CELL BIOL, V115, P1701; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0	36	1122	1143	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					696	702		10.1038/355696a0	http://dx.doi.org/10.1038/355696a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741056				2022-12-28	WOS:A1992HE60400053
J	KADHIM, MA; MACDONALD, DA; GOODHEAD, DT; LORIMORE, SA; MARSDEN, SJ; WRIGHT, EG				KADHIM, MA; MACDONALD, DA; GOODHEAD, DT; LORIMORE, SA; MARSDEN, SJ; WRIGHT, EG			TRANSMISSION OF CHROMOSOMAL INSTABILITY AFTER PLUTONIUM ALPHA-PARTICLE IRRADIATION	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; RADIATIONS	WHEN investigating the biological effects of ionizing radiation on the haemopoietic system, a confounding problem lies in possible differences between the biological effects of sparsely ionizing, low linear energy transfer radiation such as X-, beta- or gamma-rays, and densely ionizing, high linear energy transfer radiation such as alpha-particles. To address this problem we have developed novel techniques for studying haemopoietic cells irradiated with environmentally relevant doses of alpha-particles from a plutonium-238 source. Using a clonogenic culture system, cytogenetic aberrations in individual colonies of haemopoietic cells derived from irradiated stem cells have been studied. Exposure to alpha-particles (but not X-rays) produced a high frequency of non-clonal aberrations in the clonal descendants, compatible with alpha-emitters inducing lesions in stem cells that result in the transmission of chromosomal instability to their progeny. Such unexpected instability may have important implications for radiation leukaemogenesis.	MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND	MRC Harwell								AGHAMOHAMMADI SZ, 1988, INT J RADIAT BIOL, V53, P909, DOI 10.1080/09553008814551271; AMENOMORI T, 1985, INT J CELL CLONING, V3, P133, DOI 10.1002/stem.5530030301; BLACK D, 1984, INVESTIGATION POSSIB; BOBROW M, 1989, COMARE3RD COMM MED A; GOODHEAD DT, 1991, INT J RADIAT BIOL, V59, P195, DOI 10.1080/09553009114550181; GOODHEAD DT, 1989, INT J RADIAT BIOL, V56, P623, DOI 10.1080/09553008914551841; GOODHEAD DT, 1987, DOSIMETRY IONIZING R, V2, P1; Lloyd D.C., 1983, RAD INDUCED CHROMOSO, P23; LORIMORE SA, 1990, LEUKEMIA RES, V14, P481, DOI 10.1016/0145-2126(90)90036-9; PIPER J, 1989, CYTOGENET CELL GENET, V50, P111, DOI 10.1159/000132735; SINCLAIR WK, 1985, RADIAT PROT DOSIM, V13, P319; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VANDENENGH G, 1979, EXPT HEMATOLOGY TODA, P19; VISSER J, 1977, EXPT HEMATOLOGY TODA, P21; VISSER JWM, 1990, EXP HEMATOL, V18, P248; 1988, UNSCEAR UN SCI COMMI; 1990, NCRP106 NAT COUNC RA; 1991, ICRP PUBLICATION, V60	18	535	555	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					738	740		10.1038/355738a0	http://dx.doi.org/10.1038/355738a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741061				2022-12-28	WOS:A1992HE60400068
J	WRIGHT, JW				WRIGHT, JW			PERSISTENT TYMPANIC MEMBRANE PERFORATION FROM VENTILATION TUBES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											WRIGHT, JW (corresponding author), EAR INST INDIANA,INDIANAPOLIS,IN 46256, USA.							TOS M, 1990, OTOLARYNGOLOGY, pCH22	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					1008	1008						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734091				2022-12-28	WOS:A1992HD15500039
J	KUO, CJ; CONLEY, PB; CHEN, L; SLADEK, FM; DARNELL, JE; CRABTREE, GR				KUO, CJ; CONLEY, PB; CHEN, L; SLADEK, FM; DARNELL, JE; CRABTREE, GR			A TRANSCRIPTIONAL HIERARCHY INVOLVED IN MAMMALIAN CELL-TYPE SPECIFICATION	NATURE			English	Article							HEPATOMA HYBRID-CELLS; GENETIC-ANALYSIS; NUCLEAR FACTOR; RAT HEPATOMA; ALBUMIN GENE; PROTEINS; EXPRESSION; PROMOTER; ACTIVATION; EXTINCTION	ALTHOUGH transcriptional hierarchies have been extensively studied in invertebrates, their involvement in mammalian cell-type specification is poorly understood 1,2. Here we report a hepatocyte transcriptional cascade suggested by the expression patterns of hepatic transcription factors in dedifferentiated hepatomas and hepatocyte: fibroblast hybrids in which the liver phenotype was extinguished 3-6. These results indicated that the homeoprotein hepatocyte nuclear factor-1-alpha (HNF-1-alpha) 7-8, and HNF-4, a member of the steroid hormone receptor superfamily 9, were regulated coordinately or in a hierarchy by a higher-order locus, independently of other hepatic transactivators. HNF-4 was implicated as an essential positive regulator of HNF-1-alpha, as deletion of an HNF-4 binding site in the HNF-1-alpha promoter abolished promoter activity, and HNF-4 potently transactivated the HNF-1-alpha promoter in cotransfection assays. Moreover, genetic complementation of dedifferentiated hepatomas with HNF-4 complementary DNA rescued expression of endogenous HNF-1-alpha messenger RNA and DNA-binding activity. Our studies therefore define an HNF-4 --> HNF-1-alpha (4 --> 1-alpha) transcriptional hierarchy operative in differentiated hepatocytes but selectively inhibited by an extinguishing locus and somatic mutations which antagonize the liver phenotype.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University	KUO, CJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305, USA.			Kuo, Calvin/0000-0002-7427-5985				BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHIN AC, 1989, MOL CELL BIOL, V9, P3736, DOI 10.1128/MCB.9.9.3736; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRAIN M, 1989, CELL, V59, P1179; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERBST RS, 1991, NEW BIOL, V3, P289; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TONJES RR, IN PRESS EMBO J; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1	29	391	394	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					457	461		10.1038/355457a0	http://dx.doi.org/10.1038/355457a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734282				2022-12-28	WOS:A1992HB53000073
J	MACFARLANE, IA; GILL, GV; MASSON, E; TUCKER, NH				MACFARLANE, IA; GILL, GV; MASSON, E; TUCKER, NH			DIABETES IN PRISON - CAN GOOD DIABETIC CARE BE ACHIEVED	BRITISH MEDICAL JOURNAL			English	Article								Objective - To investigate the clinical characteristics and metabolic control of diabetic patients given structured diabetic care in prison. Design - Survey of diabetic men serving prison sentences during a 22 month period in a large British prison. Setting - HM Prison, Walton, Liverpool. Subjects - 42 male diabetic prisoners, of whom 23 had insulin dependent and 19 non-insulin dependent diabetes. Main outcome measures - Episodes of diabetic instability, glycated haemoglobin concentrations, body mass index. Results - No serious diabetic instability occurred. Between the initial assessment by the visiting consultant diabetologist and a second assessment 10 weeks later glycated haemoglobin concentrations had fallen from 10.8 (SD 2.9)% to 9.8 (2.4)% (p < 0.05) in prisoners with insulin dependent diabetes and from 8.7 (1.9)% to 7.6 (1.2)% (p < 0.05) in those with non-insulin dependent diabetes. Good glycaemic control continued, a mean glycated haemoglobin concentration of 7.6 (1.5)% being recorded in seven men remaining in prison for six to 18 months. Mean body mass index (weight (kg)/(height (m))2) did not change during the study (insulin dependent prisoners 23.3 (SD 2.1), non-insulin dependent prisoners 27.9 (3.8)). Conclusions - Good diabetic metabolic control is usual in prison, probably due to the rigid dietary regimen, no alcohol, and compliance with treatment. Many younger men had defaulted from their home diabetic clinics, and imprisonment allowed screening for diabetic complications and reassessment of treatment. Structured diabetic care should be offered in all prisons.	HM PRISON,LIVERPOOL,ENGLAND		MACFARLANE, IA (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							BLUGLASS R, 1990, BRIT MED J, V301, P249, DOI 10.1136/bmj.301.6746.249; FISKEN RA, 1990, CLIN CHIM ACTA, V191, P79, DOI 10.1016/0009-8981(90)90060-6; GARROW JS, 1979, BRIT MED J, V2, P1171, DOI 10.1136/bmj.2.6199.1171; GILL GV, 1989, BRIT MED J, V298, P221, DOI 10.1136/bmj.298.6668.221; HOME P, 1984, BRIT MED J, V289, P713, DOI 10.1136/bmj.289.6447.713; SHACKLED, 1988, LANCET, V2, P1402; SMITH R, 1991, BRIT MED J, V302, P550; SMITH R, 1988, BRIT MED J, V297, P89; SMITH R, 1991, BRIT MED J, V302, P64, DOI 10.1136/bmj.302.6768.64; Smith Richard, 1984, PRISON HLTH CARE; 1988, BALANCE, P5; 1985, PRISON MED; 1985, LANCET, V2, P755	13	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					152	155		10.1136/bmj.304.6820.152	http://dx.doi.org/10.1136/bmj.304.6820.152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737159	Green Published, Bronze			2022-12-28	WOS:A1992HA97900020
J	VUORI, H				VUORI, H			INTERNATIONAL QUALITY ASSURANCE - QUALITY ASSURANCE IN FINLAND	BRITISH MEDICAL JOURNAL			English	Article											VUORI, H (corresponding author), WHO,REG OFF EUROPE,DK-2100 COPENHAGEN,DENMARK.							GARFIELD E, 1987, JAMA-J AM MED ASSOC, V257, P52, DOI 10.1001/jama.257.1.52; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VUORI H, 1989, INT J HLTH ARE QUALI, V2, P22; VUORI H, 1970, THESIS SAIRAALALIITO; 1984, NURSING STANDARDS BE; 1982, PRINCIPLES DEV MODEL; 1985, PRINCIPLES QUALITY A; 1985, SWEDISH MED CARE PRO	8	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					162	164		10.1136/bmj.304.6820.162	http://dx.doi.org/10.1136/bmj.304.6820.162			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737163	Bronze, Green Published			2022-12-28	WOS:A1992HA97900024
J	KENNAWAY, A				KENNAWAY, A			HANDICAPS TO BRITISH INNOVATION	NATURE			English	Editorial Material											KENNAWAY, A (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,DEPT MECH ENGN,LONDON SW7 2AZ,ENGLAND.								0	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					198	200		10.1038/355198a0	http://dx.doi.org/10.1038/355198a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731212				2022-12-28	WOS:A1992GZ69400028
J	JONES, R; LYDEARD, S				JONES, R; LYDEARD, S			IRRITABLE-BOWEL-SYNDROME IN THE GENERAL-POPULATION	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; PSYCHOSOCIAL FACTORS; SYMPTOMS; DYSFUNCTION; DYSPEPSIA; PREVALENCE; DISORDERS; DIAGNOSIS; BEHAVIOR	Objective - To determine the prevalence of symptoms compatible with a clinical diagnosis of irritable bowel syndrome in the general population. Design - Validated postal questionnaire sent to 2280 subjects randomly selected in 10 year age bands from the lists of eight general practitioners. The Manning criteria were used to define irritable bowel syndrome. Setting - Urban population in Southampton and mixed urban-rural population in Andover, Hampshire. Results - A response of 71% yielded 1620 questionnaires for analysis, of which 412 (25%) reported more than six episodes of abdominal pain in the preceding year, with 350 (22%) reporting symptoms consistent with the diagnosis of irritable bowel syndrome. The male: female ratio was 1:1.38. More subjects with irritable bowel syndrome had constipation and diarrhoea and 35% with the syndrome reported rectal bleeding compared with an overall prevalence of 20%. Other symptoms and conditions including heartburn, dyspepsia, flushing, palpitations, migraine, and urinary symptoms were significantly more common in the group with irritable bowel syndrome. Abdominal pain in childhood was more common in the subjects with irritable bowel syndrome (12%) than without (3%). One third of the group with irritable bowel syndrome had sought medical advice during the study period (male: female ratio 1:1.21); consultation behaviour was influenced by age and the presence of associated symptoms, varied considerably among patients registered with different general practitioners, and was poorly correlated with symptom severity. Conclusion - Symptoms consistent with a diagnosis of irritable bowel syndrome are present in almost one quarter of the general population and tend to be associated with a number of other complaints and conditions, some of which may reflect smooth muscle dysfunction.	UNIV SOUTHAMPTON,PRIMARY MED CARE,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton								Bordie A K, 1972, J Indian Med Assoc, V58, P451; DENT OF, 1986, DIS COLON RECTUM, V29, P243, DOI 10.1007/BF02553027; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1982, GASTROENTEROLOGY, V83, P529; GOUDY WJ, 1976, 3 IOW AGR HOM EC EXP; HEATON KW, 1991, GUT, V32, P73, DOI 10.1136/gut.32.1.73; INGHAM JG, 1979, J EPIDEMIOL COMMUN H, V33, P191, DOI 10.1136/jech.33.3.191; ISGAR B, 1983, GUT, V24, P190, DOI 10.1136/gut.24.3.190; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MACDONALD L, 1986, FAM PRACT, V3, P80, DOI 10.1093/fampra/3.2.80; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MENDIS BLJ, 1983, CEYLON MED J, V27, P171; MITCHELL CM, 1987, GASTROENTEROLOGY, V92, P1282, DOI 10.1016/S0016-5085(87)91099-7; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SMITH RC, 1991, GASTROENTEROLOGY, V100, P591, DOI 10.1016/0016-5085(91)80002-Q; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; Thompson, 1989, INTERPRETATION SYMPT; THOMPSON WG, 1984, GUT, V25, P1089, DOI 10.1136/gut.25.10.1089; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; WHITE AM, 1991, GASTROENTEROLOGY, V100, P68, DOI 10.1016/0016-5085(91)90584-8; WHORWELL PJ, 1986, GUT, V27, P1014, DOI 10.1136/gut.27.9.1014; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37	25	496	513	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					87	90		10.1136/bmj.304.6819.87	http://dx.doi.org/10.1136/bmj.304.6819.87			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737146	Green Published, Bronze			2022-12-28	WOS:A1992HA17100022
J	ANDERSEN, WK; SILVERS, DN				ANDERSEN, WK; SILVERS, DN			MELANOMA - IT CANT BE MELANOMA - A SUBSET OF MELANOMAS THAT DEFIES CLINICAL RECOGNITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MALIGNANT-MELANOMA; DIAGNOSIS	We diagnosed histologically 178 cases of malignant melanoma in 1990. Thirteen cases were recorded in which the diagnosis of malignant melanoma was not considered by the clinician prior to biopsy or, in retrospect, following pathologic diagnosis. Eight of the 13 lesions were amelanotic. The majority were deeply invasive at the time of biopsy, implying poor prognosis. Despite improvements in early detection of malignant melanoma, a significant subcategory of melanomas escapes clinical diagnosis.	COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	SILVERS, DN (corresponding author), COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032, USA.							BECKER SW, 1954, AMA ARCH DERM SYPH, V69, P11, DOI 10.1001/archderm.1954.01540130013002; Clark WH., 1967, ADV BIOL SKIN, P621; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; MCMULLAN FH, 1956, ARCH DERMATOL, V74, P618, DOI 10.1001/archderm.1956.01550120038009; MIHM MC, 1971, NEW ENGL J MED, V284, P1078, DOI 10.1056/NEJM197105132841907; STEINER A, 1988, ARCH DERMATOL, V24, P1534; SWERDLOW M, 1952, AM J CLIN PATHOL, V22, P1054; THORN M, 1989, JNCI-J NATL CANCER I, V81, P611, DOI 10.1093/jnci/81.8.611; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2	9	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3463	3465		10.1001/jama.266.24.3463	http://dx.doi.org/10.1001/jama.266.24.3463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744961				2022-12-28	WOS:A1991GV87800033
J	CARTER, AJ				CARTER, AJ			THOMAS,HUGH,OWEN - THE CRIPPLES CHAMPION	BRITISH MEDICAL JOURNAL			English	Editorial Material									HARTSHILL ORTHOPAED HOSP,STOKE ON TRENT ST4 7NZ,ENGLAND									BELL J, 1893, EDINBURGH HOSPITAL R, V1, P467; HUGHES BJ, 1851, MONTHLY J MED SCI, V2, P163; HUNT A, 1935, REMINISCENCES, P65; JONES R, 1961, HERITAGE OSWESTRY, P34; KOSKY J, 1989, MUTUAL FRIENDS C DIC, P57; Le Vay D, 1956, LIFE HO THOMAS; MCCRAE AK, 1935, HO THOMAS HIS PRINCI, P61; OSMONDCLARKE H, 1950, J BONE JOINT SURG BR, V32, P627; SHEPHERD D, 1979, HIST LIVERPOOL MED I, P161; SMITH S, 1912, CHILD, V3, P728; THOMAS HO, 1878, DISEASE HIP KNEE ANK, pN169; THOMAS HO, 1919, BMJ, V1, P110; THOMAS HO, 1886, CONTRIBUTIONS SURGER, V6, P93; THOMAS HO, 1891, LANCET, V1, P174; Watson F., 1934, HO THOMAS PERSONAL S; Watson F., 1934, LIFE R JONES; WATSONJONES R, 1948, J BONE JOINT SURG BR, V30, P710; 1872, ROYAL ALEXANDRA HOSP; 1870, ALEXANDRA HOSPITAL C	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1578	1581		10.1136/bmj.303.6817.1578	http://dx.doi.org/10.1136/bmj.303.6817.1578			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773176	Bronze, Green Published			2022-12-28	WOS:A1991GX95600008
J	BANSAL, A; GIERASCH, LM				BANSAL, A; GIERASCH, LM			THE NPXY INTERNALIZATION SIGNAL OF THE LDL RECEPTOR ADOPTS A REVERSE-TURN CONFORMATION	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; IMMUNOGENIC PEPTIDE-FRAGMENTS; CYTOPLASMIC DOMAIN; AMINO-ACID; INSULIN-RECEPTOR; WATER SOLUTION; COATED PITS; PROTEINS; ENDOCYTOSIS; SPECTROSCOPY	Peptides corresponding to the proposed coated pit internalization signal of the native low density lipoprotein receptor, NPVY, take up in aqueous solution a reverse-turn conformation with the Asn in position i and the Tyr in position i + 3. By contrast, peptides derived from receptors that are defective for endocytosis do not adopt the reverse turn. These internalization-defective receptors include those with a nonaromatic residue substituted for the Tyr and those with Asn --> Ala or Pro --> Ala substitutions. While the tendency of an Asn-Pro sequence to induce a reverse turn was anticipated, the structural importance of an aromatic residue in position i + 3 was not. The sequences associated with the internalization signal thus appear to play a critical conformational role that is required for endocytosis, probably by enabling binding to adaptor molecules. With the results presented in the accompanying paper on lysosomal acid phosphatase, we now have direct evidence for previous proposals of a general correlation of internalization signals with a turn conformational motif.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BANSAL, A (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 27616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANSAL A, 1989, CURRENT RES PROTEIN, P331; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RICHARDSON JS, 1988, PREDICTION PROTEIN S, P1; Stewart JM, 1984, SOLID PHASE PEPTIDE; THIES RS, 1990, J BIOL CHEM, V265, P10132; WAGNER G, 1981, EUR J BIOCHEM, V114, P375, DOI 10.1111/j.1432-1033.1981.tb05157.x; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUETHRICH K, 1984, J MOL BIOL, V180, P715	36	224	226	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1195	1201		10.1016/0092-8674(91)90295-A	http://dx.doi.org/10.1016/0092-8674(91)90295-A			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760844				2022-12-28	WOS:A1991GX16400017
J	SHEWELL, PC; NANCARROW, JD				SHEWELL, PC; NANCARROW, JD			DOGS THAT BITE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To study the circumstances of dog bites and identify risk factors. Design - Postal questionnaire survey and case note review of victims of dog bites referred between 1982 and 1989. Setting - One referral based regional plastic surgery unit. Patients - 146 consecutive patients referred for primary treatment of dog bites, for whom current addresses were available for 133, 107 (81%) of whom returned the questionnaire. Results - The male to female ratio was 74:72; 79 (54%) patients were aged below 15 years. The commonest dogs producing bites were Staffordshire bull terriers (15 cases), Jack Russell terriers (13), medium sized mongrels (10), and Alsatians (nine). 82 of 96 (85%) dogs were male. 29 of 47 (62%) adults were bitten at home and 45 of 60 (75%) children at a friend's, neighbour's, or relative's house. 91 of 107 (85%) bites occurred in the dog's home. Bites occurred during playing with 13 (12%), petting 14 (13%), or waking 16 (15%) dogs. 45 (42%) bites were judged as unprovoked. 32 bites were identified as severe and 11 attacks as sustained. Conclusions - Most victims are bitten by male dogs which they either own or have had frequent contact with, and the bite occurs in the dog's home.	WORDSLEY HOSP,W MIDLANDS REG PLAST & JAW SURG UNIT,STOURBRIDGE,W MIDLANDS,ENGLAND		SHEWELL, PC (corresponding author), ROYAL ORTHOPAED HOSP,WOODLANDS,BIRMINGHAM B31 2AP,ENGLAND.							BAACK BR, 1989, J TRAUMA, V29, P517, DOI 10.1097/00005373-198904000-00019; BARCLAY T L, 1956, Br J Plast Surg, V9, P34, DOI 10.1016/S0007-1226(56)80006-4; CARITHERS HA, 1958, AMA J DIS CHILD, V95, P150, DOI 10.1001/archpedi.1958.02060050152007; CHUN YT, 1982, PEDIATRICS, V69, P119; HERVEY E, 1977, BRIT MED J, V2, P53; LAUER EA, 1982, AM J DIS CHILD, V136, P202, DOI 10.1001/archpedi.1982.03970390016003; PALMER J, 1983, BRIT J PLAST SURG, V36, P315; THOMAS PR, 1987, MED J AUSTRALIA, V147, P536, DOI 10.5694/j.1326-5377.1987.tb133676.x; ZAKOWSKI D, 1986, PEDIATR EMERG CARE, V2, P85	9	32	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1512	1513		10.1136/bmj.303.6816.1512	http://dx.doi.org/10.1136/bmj.303.6816.1512			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782490	Green Published, Bronze			2022-12-28	WOS:A1991GV47600022
J	KAWABATA, S; HIGGINS, GA; GORDON, JW				KAWABATA, S; HIGGINS, GA; GORDON, JW			RETRACTED: AMYLOID PLAQUES, NEUROFIBRILLARY TANGLES AND NEURONAL LOSS IN BRAINS OF TRANSGENIC MICE OVEREXPRESSING A C-TERMINAL FRAGMENT OF HUMAN AMYLOID PRECURSOR PROTEIN (RETRACTED ARTICLE. SEE VOL 356, PG 265, 1992)	NATURE			English	Article; Retracted Publication							ALZHEIMERS-DISEASE; DIFFERENTIAL REGULATION; GENE-EXPRESSION; DOWNS-SYNDROME; MOUSE EMBRYOS; THY-1 GENE; DNA; INJECTION; RECEPTOR	ALZHEIMER's disease (AD) affects more than 30% of people over 80 years of age 1,2. The aetiology and pathogenesis of this progressive dementia is poorly understood, but symptomatic disease is associated histopathologically with amyloid plaques, neurofibrillary tangles and neuronal loss primarily in the temporal lobe and neocortex of the brain. The core of the extracellular plaque is a derivative of the amyloid precursor protein (App) 3, referred to as beta/A4 (refs 4-6), and contains the amino-acid residues 29-42 that are normally embedded in the membrane-spanning region of the precursor 3. The cellular source of APP and the relationship of its deposition to the neuropathology of AD is unknown. To investigate the relationship between APP overexpression and amyloidogenesis, we have developed a vector to drive expression specifically in neurons of a C-terminal fragment of APP that contains the beta/A4 region, and have used a transgenic mouse system 7,8 to insert and express this construct. We report here that overexpression of this APP transgene in neurons is sufficient to produce extracellular dense-core amyloid plaques, neurofibrillary tangles and neuronal degeneration similar to that in the AD brain.	MT SINAI MED CTR, DEPT GERIATR & ADULT DEV, 2056 ANNENBERG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA; YAMANOUCHI PHARMACEUT CO LTD, TOKYO 103, JAPAN; NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Astellas Pharmaceuticals; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	GORDON, JW (corresponding author), MT SINAI MED CTR, DEPT GERIATR & ADULT DEV, 2056 ANNENBERG, NEW YORK, NY 10029 USA.			Higgins, Gerry/0000-0002-0434-1465				Bielschowsky M, 1904, J PSYCHOL NEUROL, V3, P169; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HIGGINS GA, 1990, NEUROBIOL AGING, V11, P61, DOI 10.1016/0197-4580(90)90064-7; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; HIGGINS GA, 1989, NEURON, V3, P247, DOI 10.1016/0896-6273(89)90038-X; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1991, FASEB J, V5, P278, DOI 10.1096/fasebj.5.3.2001787; KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MOTTE J, 1989, ACTA NEUROPATHOL, V77, P535, DOI 10.1007/BF00687256; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSURUSHITA N, 1988, GENE, V62, P135, DOI 10.1016/0378-1119(88)90587-2; WIRAK DO, 1991, SCIENCE, V253, P323, DOI 10.1126/science.1857970; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	30	89	116	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					476	478		10.1038/354476a0	http://dx.doi.org/10.1038/354476a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1793460				2022-12-28	WOS:A1991GV07800059
J	ADAM, S; HAGARD, S				ADAM, S; HAGARD, S			WHAT THE GOVERNMENT SHOULD DO	BRITISH MEDICAL JOURNAL			English	Article									HLTH EDUC AUTHOR,LONDON WC1,ENGLAND		ADAM, S (corresponding author), NW THAMES REG HLTH AUTHOR,LONDON W2 3QR,ENGLAND.							BARNES R, 1990, SETTING STRATEGIC HL; Blaxter M., 1990, HLTH LIFESTYLES; MCLELLAN DL, 1991, BRIT MED J, V303, P355, DOI 10.1136/bmj.303.6798.355; SMITH A, 1991, NATIONAL HLTH SERVIC; SULLIVAN LW, 1990, HLTH PEOPLE 2000; 1991, RES HLTH RES DEV STR; 1990, HLTH UPDATE, V1; 1977, 3TH WORLD HLTH ASS R; 1991, CM1523; 1991, SMOKING AMONG SECOND; 1991, EL91103 DEP HLTH; 1991, 3RD HOUS COMM SEL CO, V1	12	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1120	1123		10.1136/bmj.303.6810.1120	http://dx.doi.org/10.1136/bmj.303.6810.1120			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GN209	1747583	Green Published, Bronze			2022-12-28	WOS:A1991GN20900029
J	SOLOMON, SA; RAMSAY, LE; YEO, WW; PARNELL, L; MORRISJONES, W				SOLOMON, SA; RAMSAY, LE; YEO, WW; PARNELL, L; MORRISJONES, W			BETA-BLOCKADE AND INTERMITTENT CLAUDICATION - PLACEBO CONTROLLED TRIAL OF ATENOLOL AND NIFEDIPINE AND THEIR COMBINATION	BRITISH MEDICAL JOURNAL			English	Article							CALF BLOOD-FLOW; PERIPHERAL VASCULAR-DISEASE; VISUAL ANALOG SCALES; ADRENERGIC-BLOCKADE; HYPERTENSIVE PATIENTS; BLOCKING-DRUGS; PROPRANOLOL; METOPROLOL; PINDOLOL; CIRCULATION	Objective - To determine the effects of the beta-1 selective adrenoceptor blocker atenolol, the dihydropyridine calcium antagonist nifedipine, and the combination of atenolol plus nifedipine on objective and subjective measures of walking performance and foot temperature in patients with intermittent claudication. Design - Randomised controlled double blind four way crossover trial. Setting - Royal Hallamshire Hospital, Sheffield. Subjects - 49 patients (40 men) aged 39-70 with chronic stable intermittent claudication. Interventions - Atenolol 50 mg twice daily; slow release nifedipine 20 mg twice daily; atenolol 50 mg plus slow release nifedipine 20 mg twice daily; placebo. Each treatment was given for four weeks with no washout interval between treatments. Main outcome measures - Claudication and walking distances on treadmill; skin temperature of feet as measured by thermistor and probe; blood pressure before and after exercise; subjective assessments of walking difficulty and foot coldness with visual analogue scales. Results - Atenolol did not significantly alter claudication distance (mean change -6%; 95% confidence interval 1% to -13%), walking distance (-2%; 4% to -8%), or foot temperature. Nifedipine did not alter claudication distance (-4%; 3% to -11%), walking distance (-4%; 3% to -10%), or foot temperature. Atenolol plus nifedipine did not alter claudication distance but significantly reduced walking distance (-9%; -3% to -15% (p < 0.003)) and skin temperature of the more affected foot (-1.1-degrees-C; 0 to -2.2-degrees-C (p = 0.05)). These effects on walking distance and foot temperature seemed unrelated to blood pressure changes. Conclusions - There was no evidence of adverse or beneficial effects of atenolol or nifedipine, when given singly, on peripheral vascular disease. The combined treatment, however, affected walking ability and foot temperature adversely. This may have been due to beta-blockade plus reduced vascular resistance, which might also explain the reported adverse effects of pindolol and labetalol on claudication.	UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,FLOOR L,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT SURG,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield				Yeo, Wilfred/0000-0001-9554-5203				AOKI K, 1978, AM HEART J, V96, P218, DOI 10.1016/0002-8703(78)90089-3; ATTERHOG JH, 1976, AM J MED, V60, P872, DOI 10.1016/0002-9343(76)90907-4; BOGAERT MG, 1983, EUR HEART J, V4, P203, DOI 10.1093/oxfordjournals.eurheartj.a061440; CAMERON HA, 1988, BRIT J CLIN PHARMACO, V26, P569, DOI 10.1111/j.1365-2125.1988.tb05297.x; DIPERRI T, 1984, INTER ANGIO, V3, P61; FINDLAY IN, 1983, POSTGRAD MED J, V59, P70; FISHER MM, 1984, CLIN RES, V32, pA828; FOGOROS RN, 1980, NEW ENGL J MED, V302, P1089; FROHLICH ED, 1969, J AMER MED ASSOC, V208, P2471; GILLESPIE JA, 1959, LANCET, V2, P995; GOKAL R, 1979, BRIT MED J, V1, P721, DOI 10.1136/bmj.1.6165.721-a; HIATT WR, 1985, CIRCULATION, V72, P1226, DOI 10.1161/01.CIR.72.6.1226; HUGHSON WG, 1978, BRIT MED J, V1, P1379, DOI 10.1136/bmj.1.6124.1379; INGRAM DM, 1982, MED J AUSTRALIA, V1, P509, DOI 10.5694/j.1326-5377.1982.tb124145.x; KANNEL WB, 1970, CIRCULATION, V41, P875, DOI 10.1161/01.CIR.41.5.875; KENDALL MJ, 1981, J ROY COLL PHYS LOND, V15, P33; LEPANTALO M, 1984, BRIT J CLIN PHARMACO, V18, P90, DOI 10.1111/j.1365-2125.1984.tb05027.x; LEPANTALO M, 1985, CLIN PHARMACOL THER, V37, P7, DOI 10.1038/clpt.1985.3; LEPANTALO M, 1983, ANGIOLOGY, V34, P401, DOI 10.1177/000331978303400604; LEPANTALO M, 1983, CLIN PHYSIOL, V3, P35, DOI 10.1111/j.1475-097X.1983.tb00696.x; Lewis P, 1989, Eur J Vasc Surg, V3, P159, DOI 10.1016/S0950-821X(89)80012-X; LEWIS RV, 1985, BRIT J CLIN PHARMACO, V19, P255, DOI 10.1111/j.1365-2125.1985.tb02639.x; LEWIS RV, 1984, BRIT J CLIN PHARMACO, V18, P325, DOI 10.1111/j.1365-2125.1984.tb02471.x; LORENTSEN E, 1983, ANGIOLOGY, V34, P46, DOI 10.1177/000331978303400106; MCSORLEY PD, 1978, BRIT MED J, V2, P1598, DOI 10.1136/bmj.2.6152.1598; RAMSAY LE, 1979, J ROY COLL PHYS LOND, V13, P100; REICHERT N, 1975, CLIN PHARMACOL THER, V17, P612; ROBERTS DH, 1987, LANCET, V2, P650; RODGER JC, 1976, BRIT MED J, V1, P1125, DOI 10.1136/bmj.1.6018.1125; Schalekamp MA, 1983, J CARDIOVASC PHAR S1, V5, pS30; SMITH RS, 1982, J CARDIOVASC PHARM, V4, P2, DOI 10.1097/00005344-198201000-00002; SVENDSEN TL, 1986, ACTA MED SCAND, V219, P161; VALE JA, 1978, LANCET, V1, P1216; YAMADA T, 1981, JPN J EXP MED, V58, P239	34	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1100	1104		10.1136/bmj.303.6810.1100	http://dx.doi.org/10.1136/bmj.303.6810.1100			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747577	Bronze, Green Published			2022-12-28	WOS:A1991GN20900021
J	MACKENZIE, A; BARNES, G				MACKENZIE, A; BARNES, G			RANDOMIZED CONTROLLED TRIAL COMPARING ORAL AND INTRAVENOUS REHYDRATION THERAPY IN CHILDREN WITH DIARRHEA	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES	Objective - To determine the effectiveness of oral rehydration in children with moderate dehydration caused by gastroenteritis, and to compare the complications of oral and intravenous treatment. Design - Randomised controlled trial. Setting - Emergency department and infectious diseases ward in a large urban teaching hospital. Patients - 111 children aged 3-36 months who had been previously healthy, had had diarrhoea for seven days or less, had clinical signs of dehydration, and were not in shock. Six children were withdrawn because the diagnosis was incorrect (four in oral group, two in intravenous group) and one (oral group) was withdrawn at her parents' request. Interventions - Oral rehydration fluid was given by mouth or nasogastric tube, or both to 52 children. The remaining 52 received intravenous rehydration fluids but were allowed to drink. Main outcome measures - Success or failure of rehydration. Number of times child vomited or passed stool after starting treatment. Time taken to rehydrate. Results - Oral treatment failed in two children (failure rate 3.8%, upper 95% confidence limit 11.6%) and intravenous treatment in none. Vomiting was more common in the oral group (p < 0.01): 26 of 50 children (52%) in the oral group and 11 of 50 (22%) in the intravenous group vomited during rehydration. There was no significant difference between the two treatment groups in the number of stools passed during rehydration (p = 0.09). None of the children had serious complications of treatment. Conclusion - Rehydration by mouth or nasogastric tube is a safe and effective treatment for moderately dehydrated children with gastroenteritis.	ROYAL CHILDRENS HOSP,DEPT GASTROENTEROL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne								ARMITAGE P, 1987, STATISTICAL METHODS, P119; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P197; CANDY CE, 1987, J ADV NURS, V12, P95, DOI 10.1111/j.1365-2648.1987.tb01307.x; COLTON T, 1974, STAT MED, P162; ECCKELS R, 1989, SPECIALISED BIBLIO S, V13; LISTERNICK R, 1986, AM J DIS CHILD, V140, P211, DOI 10.1001/archpedi.1986.02140170037024; MACKENZIE A, 1989, LANCET, V2, P605; PIZARRO D, 1991, NEW ENGL J MED, V324, P517, DOI 10.1056/NEJM199102213240802; ROBINSON MJ, 1986, PRACTICAL PAEDIATRIC, P482; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; Santosham M, 1987, Pediatr Rev, V8, P273, DOI 10.1542/pir.8-9-273; TAMER AM, 1985, J PEDIATR-US, V107, P14, DOI 10.1016/S0022-3476(85)80606-5; VESIKARI T, 1987, ACTA PAEDIATR SCAND, V76, P300, DOI 10.1111/j.1651-2227.1987.tb10464.x; WALKERSMITH JA, 1988, DRUGS S4, V36, P99; 1983, RESIDENTS HDB	16	42	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					393	396		10.1136/bmj.303.6799.393	http://dx.doi.org/10.1136/bmj.303.6799.393			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1789830	Bronze, Green Published			2022-12-28	WOS:A1991GB59900016
J	HUGHES, RG; BARKER, DC; REYNOLDS, RC				HUGHES, RG; BARKER, DC; REYNOLDS, RC			ARE WE MORTGAGING THE MEDICAL-PROFESSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SCHOOL FINANCES; INDEBTEDNESS; CHOICE				HUGHES, RG (corresponding author), ROBERT WOOD JOHNSON FDN,COLL RD,POB 2316,PRINCETON,NJ 08543, USA.							Bazzoli G J, 1985, Health Aff (Millwood), V4, P98, DOI 10.1377/hlthaff.4.2.98; BAZZOLI GJ, 1985, J HEALTH ECON, V4, P1, DOI 10.1016/0167-6296(85)90020-7; BAZZOLI GJ, 1986, J MED EDUC, V61, P285; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; DIAL TH, 1987, J MED EDUC, V62, P316; Jolly H P, 1983, JAMA, V250, P1524; JOLLY HP, 1985, JAMA-J AM MED ASSOC, V254, P1573; JOLLY HP, 1984, JAMA-J AM MED ASSOC, V252, P1533; JOLLY HP, 1982, JAMA-J AM MED ASSOC, V248, P3261; JOLLY P, 1990, JAMA-J AM MED ASSOC, V264, P813; Jolly P, 1988, JAMA, V260, P1077; JOLLY P, 1987, JAMA-J AM MED ASSOC, V258, P1022; Jolly P, 1988, Health Aff (Millwood), V7, P144, DOI 10.1377/hlthaff.7.2.144; Jolly P, 1986, JAMA, V256, P1570; JOLLY P, 1990, AAMC DATA BOOK STATI; PETERSDORF RG, 1991, ACAD MED, V66, P61, DOI 10.1097/00001888-199102000-00001; PETERSDORF RG, 1990, ACAD MED, V65, P663, DOI 10.1097/00001888-199011000-00001; SILBERGER AB, 1988, HEALTH AFFAIR, V7, P121, DOI 10.1377/hlthaff.7.2.121; TAKSEL L, 1989, JAMA-J AM MED ASSOC, V262, P1020; ZOBELL DC, 1989, DEBTS CAREER PLANS O; 1981, JAMA-J AM MED ASSOC, V246, P2913; 1991, 1990 GRADUATION QUES, P18; 1976, JAMA-J AM MED ASSOC, V236, P2957; 1980, JAMA-J AM MED ASSOC, V244, P2810; 1980, JAMA-J AM MED ASSOC, V243, P849; 1977, JAMA-J AM MED ASSOC, V238, P2767	26	25	25	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 8	1991	325	6					404	407		10.1056/NEJM199108083250606	http://dx.doi.org/10.1056/NEJM199108083250606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ804	1801773				2022-12-28	WOS:A1991FZ80400006
J	EARLE, K; WALKER, J; HILL, C; VIBERTI, G				EARLE, K; WALKER, J; HILL, C; VIBERTI, G			FAMILIAL CLUSTERING OF CARDIOVASCULAR-DISEASE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES AND NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SODIUM-LITHIUM COUNTERTRANSPORT; CORONARY-ARTERY DISEASE; INDEPENDENT RISK FACTOR; HEART-DISEASE; BLOOD-PRESSURE; RENAL-DISEASE; MELLITUS; HISTORY; HYPERTENSION; GROWTH	Background. Patients who have insulin-dependent diabetes mellitus and nephropathy have an excess of cardiovascular disease. Familial factors may in part account for this phenomenon. Methods. We identified 61 white patients under 65 years of age with insulin-dependent diabetes who had nephropathy, and then matched them with 61 diabetic patients without nephropathy. We determined the prevalence of cardiovascular disease in the parents of these patients with use of information obtained from death certificates or from the World Health Organization questionnaire for cardiovascular disease. Results. The rates of ascertainment of information were 96 percent (n = 117) for the parents of diabetic patients with nephropathy and 95 percent (n = 116) for the parents of patients without nephropathy. Cardiovascular disease was more often a direct cause of death among the parents of diabetic patients with nephropathy (40 percent vs. 22 percent, P < 0.03), and the combined morbidity and mortality from cardiovascular disease in this group was greater than that in the parents of diabetic patients without nephropathy (31 percent vs. 14 percent, P < 0.01). The age-adjusted and sex-adjusted relative risk of cardiovascular disease in this group of parents was 2.9 (95 percent confidence interval, 1.5 to 5.5; P < 0.001). Moreover, a paternal history of cardiovascular disease was associated with a significantly increased risk of nephropathy in the diabetic patient after the analysis was adjusted for age, sex, and duration of diabetes (odds ratio, 3.2; 95 percent confidence interval, 1.3 to 7.9; P < 0.01). Among the diabetic patients with nephropathy, those who had a cardiovascular event were much more likely to have a family history of cardiovascular disease (odds ratio, 6.2; 95 percent confidence interval, 2.0 to 19.0; P < 0.005) than those who had not had such an event. Conclusions. Among patients with insulin-dependent diabetes, a parental history of cardiovascular disease is significantly associated with the development of nephropathy and, among those with nephropathy, increases the likelihood of cardiovascular disease.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,4TH FLOOR HUNTS HOUSE,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CAMBIEN F, 1980, REV EPIDEMIOL SANTE, V28, P21; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; CARR SJ, 1989, EUR J CLIN INVEST, V19, P101, DOI 10.1111/j.1365-2362.1989.tb00203.x; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; HASSTEDT SJ, 1988, AM J HUM GENET, V43, P14; JENSEN JS, 1990, DIABETOLOGIA, V33, P619, DOI 10.1007/BF00400206; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JONES SL, 1990, HYPERTENSION, V15, P570, DOI 10.1161/01.HYP.15.6.570; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; KHOURY MJ, 1988, AM J EPIDEMIOL, V127, P674, DOI 10.1093/oxfordjournals.aje.a114842; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KOSCHINSKY T, 1987, DIABETES METAB, V13, P318; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LAMBERTON RP, 1984, DIABETES, V33, P125, DOI 10.2337/diabetes.33.2.125; LI LK, 1990, KIDNEY INT, V37, P199; MANGILI R, 1988, NEW ENGL J MED, V318, P146, DOI 10.1056/NEJM198801213180304; MORGAN DB, 1986, J HYPERTENS, V4, P609, DOI 10.1097/00004872-198610000-00014; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; NORGAARD K, 1991, DIABETOLOGIA, V34, P370, DOI 10.1007/BF00405012; PETTITT DJ, 1990, DIABETOLOGIA, V33, P438, DOI 10.1007/BF00404096; PHILLIPS AN, 1988, EUR HEART J, V9, P243, DOI 10.1093/oxfordjournals.eurheartj.a062492; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SHEA S, 1984, J AM COLL CARDIOL, V4, P793, DOI 10.1016/S0735-1097(84)80408-8; VIBERTI GC, 1987, BRIT MED J, V295, P515, DOI 10.1136/bmj.295.6597.515; WALKER JD, 1990, BRIT MED J, V301, P635, DOI 10.1136/bmj.301.6753.635; YAP L, 1989, J HYPERTENS, V7, P667, DOI 10.1097/00004872-198908000-00011	35	203	206	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					673	677		10.1056/NEJM199203053261005	http://dx.doi.org/10.1056/NEJM199203053261005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736105				2022-12-28	WOS:A1992HG11700005
J	LISTERNICK, R; FRISONE, L; SILVERMAN, BL				LISTERNICK, R; FRISONE, L; SILVERMAN, BL			DELAYED DIAGNOSIS OF INFANTS WITH ABNORMAL NEONATAL SCREENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL HYPOTHYROIDISM; NEWBORN	Objective. - To identify infants who were diagnosed clinically with a condition that previously had been detected by a state neonatal screening program, but who had failed to receive medical attention in a timely fashion. Design. - A descriptive case series of infants over a 2-year period from 1989 to 1991. Setting. - An academically affiliated tertiary care pediatric hospital, a major referral center for children with abnormal results on state neonatal screening tests. Patients. - All patients who (1) had a diagnosis suspected clinically, (2) had confirmation of disease, and (3) were subsequently found to have had abnormal screening results. Main Outcome Measures. - Age at clinical diagnosis, morbidity due to delay in diagnosis, and postnatal medical follow-up. Results. -Ten children were identified, three with 21-hydroxylase deficiency and seven with a hemoglobinopathy. In each case, the screening program had clear documentation that the office of the physician of record had received prompt telephone communication of the abnormal results. The mean age at clinical diagnosis was 32 days for the children with 21-hydroxylase deficiency and 215 days for those with sickle cell anemia, substantially longer than is mandated by proper neonatal screening practice. Potentially life-threatening complications of the underlying disease were present in six children. Conclusions. - A significant number of neonates who have metabolic disorders appropriately identified by a neonatal screening test may fail to receive timely treatment. Consideration should be given to implementing a system of directly contacting the parents of all presumptive positive cases by the state screening program.	NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DIV HEMATOL,CHICAGO,IL 60614; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DIV ENDOCRINOL,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	LISTERNICK, R (corresponding author), NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,DIV GEN ACAD & EMERGENCY PEDIAT,CHICAGO,IL 60614, USA.							ALLEN DB, 1988, AM J DIS CHILD, V142, P232, DOI 10.1001/archpedi.1988.02150020134049; BOWLING FG, 1986, J INHERIT METAB DIS, V9, P99, DOI 10.1007/BF01813911; FRANKENB.WK, 1974, PEDIATRICS, V54, P612; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GROVER R, 1986, AM J PUBLIC HEALTH, V76, P1236, DOI 10.2105/AJPH.76.10.1236; Guthrie R., 1964, PHENYLKETONURIA DETE; HOLTZMAN C, 1986, PEDIATRICS, V78, P553; PANG S, 1988, PEDIATRICS, V81, P866; Pearson H A, 1986, Adv Pediatr, V33, P381; TUERCK JM, 1987, AM J PUBLIC HEALTH, V77, P1528, DOI 10.2105/AJPH.77.12.1528; Weatherall DJ, 1981, THALASSEMIA SYNDROME; 1984, J PEDIATR, V104, P539; 1990, OVERVIEW NEWBORN SCR	13	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1095	1099		10.1001/jama.267.8.1095	http://dx.doi.org/10.1001/jama.267.8.1095			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735927				2022-12-28	WOS:A1992HE39100025
J	MCNAGNY, SE; PARKER, RM				MCNAGNY, SE; PARKER, RM			HIGH PREVALENCE OF RECENT COCAINE USE AND THE UNRELIABILITY OF PATIENT SELF-REPORT IN AN INNER-CITY WALK-IN CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DRUG-ABUSE; SPECIFICITY; PREGNANCY	Objective. - To determine the prevalence of recent cocaine use and the reliability of patient self-reported cocaine use. Design. - A survey with blinded comparison to a criterion standard. Setting. - Walk-in clinic of a large public hospital in metropolitan Atlanta, Ga. Participants. -Male patients, aged 18 to 39 years, presenting to the triage desk for immediate care during weekdays. Of the 415 eligible men who agreed to participate (acceptance rate, 82%), the average age was 29.5 years, 91.6% were black, and 89% were uninsured. Intervention. - None. Main Outcome Measures. - Comparison of self-reported illicit drug use with results from urinary immunoassays for benzoylecgonine, a major cocaine metabolite. Determination of which drug history questions produce the most accurate responses using anonymous urine testing as the criterion standard. Results. - Thirty-nine percent of patients tested positive for the presence of benzoylecgonine and were statistically more likely to be older, black, and have a prior history of sexually transmitted disease (P<.01). Seventy-two percent of men with positive urinary assays denied illicit drug use in the 3 days prior to sampling. When queried with several formats, subjects with positive urine assays were more likely to admit to "any illegal drug" use (87.5%) than to the more specific "any form of cocaine" use (60.6%) within the prior year (P<.0001). Conclusions. - These results underscore the magnitude of cocaine abuse among black, inner-city men. Patient self-report of illicit drug use is highly inaccurate. Accuracy of self-report may be increased by asking less specific questions.			MCNAGNY, SE (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,GLENN MEM BLDG,69 BUTLER ST,ATLANTA,GA 30322, USA.		Parker, Ruth M/S-4583-2017	Parker, Ruth M/0000-0001-9685-6396				ALLEN LV, 1981, CLIN TOXICOL, V18, P1043, DOI 10.3109/15563658108990335; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CONE DJ, 1989, J FORENSIC SCI, V34, P415; CONE EJ, 1989, J FORENSIC SCI, V34, P32; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DEAN A, 1990, EPI INFO, V5; FISCHMAN MW, 1985, JANAL TOXICOL, V9, P241; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; Johnson B D, 1989, NIDA Res Monogr, V95, P326; KAKU DA, 1990, ANN INTERN MED, V113, P821, DOI 10.7326/0003-4819-113-11-821; MCNAGNY SE, IN PRESS J INFECT DI; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; WELCH RD, 1991, ANN EMERG MED, V20, P154, DOI 10.1016/S0196-0644(05)81215-6; 1989, MMWR, V38, P780; 1991, ADM911839 US DEP HLT; 1991, ADM911788 US DEP HLT; 1988, FED REG         0401, V53, P11970	20	122	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1106	1108		10.1001/jama.267.8.1106	http://dx.doi.org/10.1001/jama.267.8.1106			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE391	1735928				2022-12-28	WOS:A1992HE39100027
J	BREO, DL				BREO, DL			MUDD, THE GRANDSON, FIGHTS TO CLEAR NAME OF FAMED ANCESTOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		MUDD R, SA MUDD HIS DESCENDA	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					988	989		10.1001/jama.267.7.988	http://dx.doi.org/10.1001/jama.267.7.988			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734114				2022-12-28	WOS:A1992HD15500036
J	ELSADR, W; CAPPS, L				ELSADR, W; CAPPS, L			THE CHALLENGE OF MINORITY RECRUITMENT IN CLINICAL-TRIALS FOR AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; RANDOMIZED TRIAL; DOUBLE-BLIND; PENTAMIDINE; ZIDOVUDINE; INFECTION; EFFICACY; THERAPY		COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University	ELSADR, W (corresponding author), HARLEM HOSP MED CTR,DIV INFECT DIS,ROOM 3107,506 LENOX AVE,NEW YORK,NY 10037, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095029] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-95029] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; CONTE JE, 1990, ANN INTERN MED, V113, P203, DOI 10.7326/0003-4819-113-3-203; EASTERBROOK PJ, 1991, JAMA-J AM MED ASSOC, V266, P2713, DOI 10.1001/jama.266.19.2713; FAUCI AS, 1989, ACAD MED, V64, P115, DOI 10.1097/00001888-198903000-00002; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; HAMILTON JD, IN PRESS N ENGL J ME; HOO GWS, 1990, ANN INTERN MED, V113, P195, DOI 10.7326/0003-4819-113-3-195; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEVINE RJ, 1986, ETHICS REGULATIONS C, P67; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MOSER M, 1982, CLIN PHARMACOL THER, V32, P307, DOI 10.1038/clpt.1982.165; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; SMITH WM, 1964, ANN INTERN MED, V61, P829, DOI 10.7326/0003-4819-61-5-829; SVENSSON CK, 1989, JAMA-J AM MED ASSOC, V261, P263, DOI 10.1001/jama.261.2.263; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALLE T, 1985, CLIN PHARMACOL THER, V38, P509, DOI 10.1038/clpt.1985.216; 1970, JAMA-J AM MED ASSOC, V213, P1143; 1990, MMWR, V39, P81; 1982, BR J CLIN PHARM, V14, P97; 1979, JAMA-J AM MED ASSOC, V242, P2562	26	122	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					954	957		10.1001/jama.267.7.954	http://dx.doi.org/10.1001/jama.267.7.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734108				2022-12-28	WOS:A1992HD15500029
J	HALAZONETIS, TD; KANDIL, AN				HALAZONETIS, TD; KANDIL, AN			PREDICTED STRUCTURAL SIMILARITIES OF THE DNA-BINDING DOMAINS OF C-MYC AND ENDONUCLEASE ECO RI	SCIENCE			English	Article							LEUCINE ZIPPER; PROTEIN; MYOD	The c-Myc oncoprotein belongs to a family of proteins whose DNA binding domains contain a bask region-helix-loop-helix (bHLH) motif. Systematic mutagenesis of c-Myc revealed that dimerized bHLH motifs formed a parallel four-helix bundle with the amino termini of helices 1 and 2 directed toward the inner and outer nucleotides of the DNA binding site, respectively. Both the bask region and the carboxyl-terminal end of the loop contributed to DNA binding specificity. The DNA binding domain of c-Myc may therefore be structurally similar to that of restriction endonuclease Eco RI.			HALAZONETIS, TD (corresponding author), MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486, USA.		Halazonetis, Thanos/D-7923-2011					BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O	17	42	43	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					464	466		10.1126/science.1734524	http://dx.doi.org/10.1126/science.1734524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734524				2022-12-28	WOS:A1992HA59000041
J	SORGER, PK; MURRAY, AW				SORGER, PK; MURRAY, AW			S-PHASE FEEDBACK-CONTROL IN BUDDING YEAST INDEPENDENT OF TYROSINE PHOSPHORYLATION OF P34CDC28	NATURE			English	Article							FISSION YEAST; CELL-CYCLE; MITOSIS	IN somatic cells, entry into mitosis depends on the completion of DNA synthesis. This dependency is established by S-phase feedback controls that arrest cell division when damaged or unreplicated DNA is present 1. In the fission yeast Schizosaccharomyces pombe, mutations that interfere with the phosphorylation of tyrosine 15 (Y15) of p34cdc2,the protein kinase subunit of maturation promoting factor, accelerate the entry into mitosis and abolish the ability of unreplicated DNA to arrest cells in G2 (ref. 2). Because the tyrosine phosphorylation of p34cdc2 is conserved in S. pombe 3, Xenopus 4, chicken 5 and human 6 cells, the regulation of p34cdc2-Y15 phosphorylation could be a universal mechanism mediating the S-phase feedback control and regulating the initiation of Mitosis 7,8. We have investigated these phenomena in the budding yeast Saccharomyces cerevisiae. We report here that the CDC28 gene product (the S. cerevisiae homologue of cdc2) is phosphorylated on the equivalent tyrosine (Y19) during S phase but that mutations that prevent tyrosine phosphorylation do not lead to premature mitosis and do not abolish feedback controls. We have therefore demonstrated a mechanism that does not involve tyrosine phosphorylation of p34 by which cells arrest their division in response to the presence of unreplicated or damaged DNA. We speculate that this mechanism may not involve the inactivation of p34 catalytic activity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SORGER, PK (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Sorger, Peter/0000-0002-3364-1838				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; DRACETTA G, 1988, NATURE, V336, P738; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V	19	249	254	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					365	368		10.1038/355365a0	http://dx.doi.org/10.1038/355365a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731250				2022-12-28	WOS:A1992HA59100073
J	CRAWSHAW, R				CRAWSHAW, R			REQUIEM FOR AN UNKNOWN LEPER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3411	3412						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744951				2022-12-28	WOS:A1991GV87800008
J	STARR, DB; HAWLEY, DK				STARR, DB; HAWLEY, DK			TFIID BINDS IN THE MINOR GROOVE OF THE TATA BOX	CELL			English	Article							RNA POLYMERASE-II; ECO RI ENDONUCLEASE; TRANSCRIPTION FACTOR; PROMOTER SEQUENCES; FUNCTIONAL DOMAINS; DNA; PROTEIN; YEAST; GENE; INITIATION	We have analyzed the interaction of the general RNA polymerase II transcription factor TFIID with its DNA-binding site, the TATA box (consensus sequence TATAAAA). We have demonstrated that TFIID, unlike most sequence-specific DNA-binding proteins, interacts primarily within the minor groove of the DNA helix. This was established by a novel approach involving complete replacement of the thymines and adenines in the TATA box with cytosines and inosines, respectively. This substitution exchanged the major groove of TATAAAA for that of the sequence CGCGGGG, without altering the surface of the minor groove. The unusual DNA-binding properties of TFIID revealed by this study have important implications for TFIID specificity and function and, more generally, for sequence-specific recognition by DNA-binding proteins.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	STARR, DB (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.							ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FIRE A, 1984, J BIOL CHEM, V259, P2509; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KILPATRICK MW, 1986, J BIOL CHEM, V261, P1350; LU AL, 1981, J BIOL CHEM, V256, P3200; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIT KH, 1967, BIOCHIM BIOPHYS ACTA, V149, P344, DOI 10.1016/0005-2787(67)90162-1; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	60	187	188	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1231	1240		10.1016/0092-8674(91)90299-E	http://dx.doi.org/10.1016/0092-8674(91)90299-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760847				2022-12-28	WOS:A1991GX16400021
J	SMEAL, T; BINETRUY, B; MERCOLA, DA; BIRRER, M; KARIN, M				SMEAL, T; BINETRUY, B; MERCOLA, DA; BIRRER, M; KARIN, M			ONCOGENIC AND TRANSCRIPTIONAL COOPERATION WITH HA-RAS REQUIRES PHOSPHORYLATION OF C-JUN ON SERINE-63 AND SERINE-73	NATURE			English	Article							EXPRESSION; GENE; PEA1	RECENT advances indicate a link between tumour promoters, transformation, and AP-1 activity 1. Protein kinase C activation increases AP-1 DNA-binding activity independently of new protein synthesis 2,3. AP-1 is also stimulated by transforming oncoproteins and growth factors 4-6. These proteins are thought to participate in a signalling cascade affecting the nuclear AP-1 complex composed of the Jun and Fos proteins 1,7,8. Because c-Jun is the most potent transactivator in the AP-1 complex 9-12 and is elevated in Ha-ras-transformed cells, in which c-Fos is downregulated 13,14, we focused on it as a potential target. c-Jun could convert input from an oncogenic signalling cascade into changes in gene expression. Indeed, transformation of rat embryo fibroblasts by c-Jun requires an intact transcriptional activation domain 15 and cooperation with oncogenic Ha-ras 16. Expression of oncogenic Ha-ras augments transactivation by c-Jun and stimulates its phosphorylation 14. Here we describe the mapping of the Ha-ras-responsive phosphorylation sites to serines 63 and 73 of c-Jun. Site-directed mutagenesis indicates that phosphorylation of these serines is essential for stimulation of c-Jun activity and for cooperation with Ha-ras in ocogenic transformation.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; NCI, DIV CANC PREVENT & CONTROL, BETHESDA, MD 20814 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; University of California System; University of California San Diego	KARIN, M (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.		mercola, dan/L-4182-2013; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/S-2062-2019	mercola, dan/0000-0002-0281-9840; Binetruy, Bernard/0000-0001-8012-7092				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, IN PRESS MOL CELL BI; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, IN PRESS METH ENZYM; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; YANG-YEN H-F, 1990, New Biologist, V2, P351	26	772	781	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					494	496		10.1038/354494a0	http://dx.doi.org/10.1038/354494a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749429				2022-12-28	WOS:A1991GV07800065
J	CHITTY, LS; HUNT, GH; MOORE, J; LOBB, MO				CHITTY, LS; HUNT, GH; MOORE, J; LOBB, MO			EFFECTIVENESS OF ROUTINE ULTRASONOGRAPHY IN DETECTING FETAL STRUCTURAL ABNORMALITIES IN A LOW-RISK POPULATION	BRITISH MEDICAL JOURNAL			English	Article							MALFORMATIONS; DIAGNOSIS	Objective - To review the efficacy of routine prenatal ultrasonography for detecting fetal structural abnormalities. Design - Retrospective study of the ultrasonographic findings and outcome of all pregnancies in women scanned in 1988-9. Setting - Maternity ultrasonography department of a district general hospital. Subjects - 8785 fetuses. Main outcome measures - Correlation of prenatal ultrasonographic findings with outcome in the neonate. Results - 8733 babies were born during 1988-9, and 52 pregnancies were terminated after a fetal malformation was identified. 8432 (95%) of the fetuses were examined by ultrasonography in the second trimester. 130 fetuses (1.5%) were found to have an abnormality at birth or after termination of pregnancy, 125 of which had been examined in the second trimester. In 93 cases the abnormality was detected before 24 weeks (sensitivity 74.4%, 95% confidence interval to 66.7% to 82.1%. Two false positive diagnoses occurred, in both cases the pregnancies were not terminated and apparently normal infants were born. This gives a specificity of 99.98% (99.9% to 99.99%). The positive predictive value of ultrasonography in the second trimester was 97.9% (92.6% to 99.7%). Of the 125 abnormalities, 87 were lethal or severely disabling; 72 of the 87 were detected by the routine screening programme (sensitivity 82.8%, 73.2% to 90.0%). Conclusion - Routine fetal examination by ultrasonography in a low risk population detects many fetal structural abnormalities but can present several dilemmas in counselling.	LUTON & DUNSTABLE HOSP,LUTON LU4 0DZ,BEDS,ENGLAND; INST CHILD HLTH,DEPT CLIN GENET,LONDON WC1 1EH,ENGLAND	University of London; University College London				chitty, lyn/0000-0002-4857-7138				ASH P, 1977, LANCET, V1, P849; BENACERRAF BR, 1988, RADIOLOGY, V169, P858, DOI 10.1148/radiology.169.3.3055042; BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P573, DOI 10.1016/0002-9378(87)90053-6; BENACERRAF BR, 1991, ULTRASOUND OBST GYN, V1, P66, DOI 10.1046/j.1469-0705.1991.01010066.x; CAMPBELL S, 1983, PRENATAL DIAGNOSIS, P325; CHITTY LS, 1991, ULTRASOUND OBST GYN, V1, P115, DOI 10.1046/j.1469-0705.1991.01020115.x; CHITTY LS, 1989, ARCH DIS CHILD, V64, P1036, DOI 10.1136/adc.64.7.1036; CHITTY LS, 1990, LANCET, P875; DEWALS P, 1984, EUROCAT GUIDE, P65; Gardner MJ, 1989, STAT CONFIDENCE, P28; JONES LJ, 1988, SMITHS RECOGNISABLE, P662; LEVI S, 1989, LANCET, V1, P678; NICOLAIDES KH, 1987, BAILLIERE CLIN OB GY, V1, P591, DOI 10.1016/S0950-3552(87)80008-1; PERSSON PH, 1983, AM J OBSTET GYNECOL, V146, P942, DOI 10.1016/0002-9378(83)90970-5; ROSENDAHL H, 1989, OBSTET GYNECOL, V73, P947; SAARIKEMPPAINEN A, 1990, LANCET, P387	16	221	231	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1165	1169		10.1136/bmj.303.6811.1165	http://dx.doi.org/10.1136/bmj.303.6811.1165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747613	Green Published, Bronze			2022-12-28	WOS:A1991GP48800022
J	ESCOVITZ, GH				ESCOVITZ, GH			THE HEALTH TRANSITION IN DEVELOPING-COUNTRIES - A ROLE FOR INTERNISTS FROM THE DEVELOPED WORLD	ANNALS OF INTERNAL MEDICINE			English	Article						HEALTH PLANNING; WORLD HEALTH; PRIMARY HEALTH CARE; EDUCATION, MEDICAL; DEVELOPING COUNTRIES; CHRONIC ADULT DISEASES		Demographic and epidemiologic changes that have occurred in the past five decades in many developing countries provide new opportunities for internists from developed countries to contribute to improvements in international health. These changes, called the "health transition," are characterized by major growth in the number and proportion of middle-aged and elderly persons and in the frequency of the chronic diseases that occur in these age groups. The health transition is the result of concentrated national and international efforts to improve maternal and child health by emphasizing primary care and community-organized outreach services. In many developing countries, such efforts have been responsible for a decrease in the birth rate; reduced maternal mortality; improved preventive services; and a vigorous therapeutic approach to infantile diarrhea and respiratory infection, which, in turn, have resulted in the reduced infant mortality and the increased life expectancy that defines the health transition. These changes, often accompanied by increasing urbanization and industrialization, are creating health problems similar to those seen in the "developed" world but are occurring in countries that have far fewer resources. Internists interested in working in developing countries can therefore bring their skills, experience, and perspective to bear on these problems, primarily by working within well-structured programs, the aim of which is to strengthen the capacity of the organizations and institutions within these countries to cope with the rising tide of chronic adult diseases.			ESCOVITZ, GH (corresponding author), MED COLL PENN, 3200 HENRY AVE, PHILADELPHIA, PA 19129 USA.							ABEDABO AO, 1990, ANN RHEUM DIS, V49, P813; ARAL SO, 1991, SCI AM, V264, P62, DOI 10.1038/scientificamerican0291-62; BENNETT KJ, 1988, J GEN INTERN MED, V3, P171, DOI 10.1007/BF02596127; BIRDSALL N, 1990, WORLD MAKE DEV PERSP, P86; BODADILLA JL, IN PRESS DISEASE CON; BULATAO RA, IN PRESS DISEASE CON; EINTERZ RM, 1990, J GEN INTERN MED, V5, P427, DOI 10.1007/BF02599433; EVANS JG, 1989, ACAD MED, V64, P75, DOI 10.1097/00001888-198902000-00006; FEACHAM RG, IN PRESS HLTH ADULTS; FOEGE WH, 1990, AM J TROP MED HYG, V42, P293, DOI 10.4269/ajtmh.1990.42.293; Halstead S, 1985, GOOD HLTH LOW COST; HEYSE SP, 1990, RHEUM DIS CLIN N AM, V16, P763; JAMISON DT, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.1.15; LOPEZ AD, IN PRESS DISEASE CON; MASNYK IJ, 1988, J NATL CANCER I, V80, P1366, DOI 10.1093/jnci/80.17.1366; MOSLEY WH, 1990, ANNU REV PUBL HEALTH, V11, P335; SELZER R, 1987, TAKING WORLD REPAIRS; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; WARREN KS, 1990, 1990 BRITANNICA BOOK, P21; 1990, HLTH RES ESSENTIAL L; 1988, REPORT TASK FORCE IN	21	15	15	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					499	504		10.7326/0003-4819-116-6-499	http://dx.doi.org/10.7326/0003-4819-116-6-499			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739241				2022-12-28	WOS:A1992HJ59800011
J	KRAHN, AD; MANFREDA, J; TATE, RB; MATHEWSON, FAL; CUDDY, TE				KRAHN, AD; MANFREDA, J; TATE, RB; MATHEWSON, FAL; CUDDY, TE			THE NATURAL-HISTORY OF ELECTROCARDIOGRAPHIC PREEXCITATION IN MEN - THE MANITOBA FOLLOW-UP-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						PREEXCITATION SYNDROMES; ELECTROCARDIOGRAPHY; ARRHYTHMIA; WOLFF-PARKINSON-WHITE SYNDROME; CORONARY DISEASE	PARKINSON-WHITE SYNDROME; POPULATION	Objective: To examine the natural history of preexcitation occurring on the routine electrocardiogram (ECG). Design: A longitudinal cohort study of 3983 originally healthy men followed prospectively for 40 years. Setting: Free-living (community-dwelling) study members residing predominantly in Canada. Participants: Nineteen male study members with preexcitation occurring during routine examination in the 40-year follow-up of the Manitoba Follow-up Study. Measurements: Routinely requested clinical examinations and ECGs, supplemented by information supplied by the study member or his physician. Main Results: Ten study members were found to have preexcitation at enrollment, for a prevalence of 2.5 per 1000 (95% CI, 1.2 to 4.6). A delta wave was first detected during follow-up in an additional nine study members. Seventeen of 19 study members did not have the delta wave at some later time, and preexcitation was intermittently present in most of these members. Over time there was a loss of preexcitation, with 15 of 19 study members no longer exhibiting a delta wave by the end of follow-up. Five of 11 study members with symptoms had physician confirmation of an arrhythmia. Fourteen study members remain alive, and none of the five deaths was attributed to preexcitation. Conclusions: Preexcitation found on routine ECG in our originally healthy male study group did not confer excess morbidity or mortality, even in those study members who developed symptomatic arrhythmias. Most preexcitation was intermittent and disappeared over time.	MANITOBA FOLLOW UP STUDY, 148-770 BANNATYNE AVE, WINNIPEG R3E 0W3, MANITOBA, CANADA									AVERILL KH, 1960, AM J CARDIOL, V6, P108, DOI 10.1016/0002-9149(60)90041-2; BERKMAN NL, 1968, NEW ENGL J MED, V278, P492, DOI 10.1056/NEJM196802292780906; FLEISS JL, 1981, STAT METHODS RATES P, P237; FLENSTED.E, 1969, ACTA MED SCAND, V186, P65; GALLAGHER JJ, 1978, PROG CARDIOVASC DIS, V20, P285, DOI 10.1016/0033-0620(78)90015-4; GUIZE L, 1985, ANN MED INTERNE, V136, P474; HISS RG, 1962, CIRCULATION, V25, P947, DOI 10.1161/01.CIR.25.6.947; HURST JW, 1986, HEART, P415; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN GJ, 1989, NEW ENGL J MED, V320, P1230; KLEIN GJ, 1983, AM J CARDIOL, V52, P292, DOI 10.1016/0002-9149(83)90125-X; KOSSMANN CE, 1967, CIRCULATION, V35, P583, DOI 10.1161/01.CIR.35.3.583; MATHEWSON FAL, 1960, CIRCULATION, V21, P196, DOI 10.1161/01.CIR.21.2.196; MUNGER TM, 1990, CIRCULATION, V82, P317; Prineas R., 1982, MINNESOTA CODE MANUA; PROUDFIT WL, 1989, CLEV CLIN J MED, V56, P601, DOI 10.3949/ccjm.56.6.601; REED JC, 1947, AM HEART J, V33, P701; SEARS GA, 1962, CAN MED ASSOC J, V87, P1213; SMITH RF, 1964, CIRCULATION, V29, P672, DOI 10.1161/01.CIR.29.5.672; SORIA R, 1989, ARCH MAL COEUR VAISS, V82, P331; WELLENS HJJ, 1983, MOD CONC CARDIOV DIS, V52, P53; Wilson FN, 1915, ARCH INTERN MED, V16, P1008; Wolff L, 1930, AM HEART J, V5, P685, DOI 10.1016/S0002-8703(30)90086-5	23	65	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					456	460		10.7326/0003-4819-116-6-456	http://dx.doi.org/10.7326/0003-4819-116-6-456			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739235				2022-12-28	WOS:A1992HJ59800004
J	URBA, WJ; LONGO, DL				URBA, WJ; LONGO, DL			MEDICAL PROGRESS - HODGKINS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CHEMOTHERAPY PLUS RADIOTHERAPY; STEM-CELL TRANSPLANTATION; SOUTHWEST-ONCOLOGY-GROUP; FIELD RADIATION-THERAPY; 2ND MALIGNANT NEOPLASMS; HIGH-DOSE CHEMOTHERAPY; CLINICAL STAGE-I; TERM FOLLOW-UP		NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	URBA, WJ (corresponding author), DYNCORP, PROGRAM RESOURCES INC,CLIN IMMUNOL SERV,BLDG 560, RM 11-62, POB B, FREDERICK, MD 21702 USA.		Longo, Dan L./F-6022-2011		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED T, 1989, LEUKEMIA, V3, P19; ANDRIEU JM, 1990, J CLIN ONCOL, V8, P1148, DOI 10.1200/JCO.1990.8.7.1148; APPELBAUM FR, 1985, J CLIN ONCOL, V3, P1490, DOI 10.1200/JCO.1985.3.11.1490; ARMITAGE JO, 1986, CANCER TREAT REP, V70, P871; BARTOLUCCI AA, 1983, CANCER, V52, P2209, DOI 10.1002/1097-0142(19831215)52:12<2209::AID-CNCR2820521206>3.0.CO;2-6; BERGSAGEL DE, 1982, CANCER TREAT REP, V66, P717; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BONADONNA G, 1985, CANCER SURV, V4, P439; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; BOOKMAN MA, 1986, CANCER TREAT REV, V13, P77, DOI 10.1016/0305-7372(86)90015-0; CANELLOS GP, 1988, P AN M AM SOC CLIN, V7, pA230; CARBONE PP, 1971, CANCER RES, V31, P1860; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; CASTELLINO RA, 1984, AM J ROENTGENOL, V143, P37, DOI 10.2214/ajr.143.1.37; CASTELLINO RA, 1974, ANN INTERN MED, V80, P593, DOI 10.7326/0003-4819-80-5-593; CHARAK BS, 1990, CANCER, V65, P1903, DOI 10.1002/1097-0142(19900501)65:9<1903::AID-CNCR2820650905>3.0.CO;2-#; CHOU MY, 1983, CANCER, V51, P1546, DOI 10.1002/1097-0142(19830415)51:8<1546::AID-CNCR2820510832>3.0.CO;2-A; CIMINO G, 1989, J CLIN ONCOL, V7, P732, DOI 10.1200/JCO.1989.7.6.732; COLTMAN CA, 1982, CANCER TREAT REP, V66, P1023; CORNBLEET MA, 1985, J CLIN ONCOL, V3, P758, DOI 10.1200/JCO.1985.3.6.758; CRNKOVICH MJ, 1986, J CLIN ONCOL, V4, P472, DOI 10.1200/JCO.1986.4.4.472; CRNKOVICH MJ, 1987, J CLIN ONCOL, V5, P1041, DOI 10.1200/JCO.1987.5.7.1041; CROWTHER D, 1984, J CLIN ONCOL, V2, P892, DOI 10.1200/JCO.1984.2.8.892; CULINE S, 1989, EUR J CANCER CLIN ON, V25, P551, DOI 10.1016/0277-5379(89)90269-1; DELANEY TF, 1987, CANCER PRINCIPLES PR, V1, P1; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; EINHORN LH, 1983, CANCER, V51, P1348, DOI 10.1002/1097-0142(19830415)51:8<1348::AID-CNCR2820510804>3.0.CO;2-7; EKERT H, 1988, J CLIN ONCOL, V6, P1845, DOI 10.1200/JCO.1988.6.12.1845; EVANS AS, 1984, INT J CANCER, V34, P149, DOI 10.1002/ijc.2910340203; FISHER RI, 1979, ANN INTERN MED, V90, P761, DOI 10.7326/0003-4819-90-5-761; GAMS RA, 1986, CANCER, V58, P1963, DOI 10.1002/1097-0142(19861101)58:9<1963::AID-CNCR2820580902>3.0.CO;2-P; GAUSE A, 1991, ANN ONCOL, V2, P43, DOI 10.1093/annonc/2.suppl_2.43; GHERLINZONI F, 1987, HAEMATOLOGICA, V72, P237; GINGRICH RD, 1990, BLOOD, V75, P2276; GLICK J, 1990, BLOOD S, V76, pA350; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; GOMEZ GA, 1984, AM J CLIN ONCOL-CANC, V7, P65, DOI 10.1097/00000421-198402000-00009; GRIBBEN JG, 1989, BLOOD, V73, P340; GROZEA PN, 1982, RECENT RES CANCER, V80, P83; HAGEMEISTER FB, 1987, J CLIN ONCOL, V5, P556, DOI 10.1200/JCO.1987.5.4.556; HAGEMEISTER FB, 1990, CANCER, V65, P1090, DOI 10.1002/1097-0142(19900301)65:5<1090::AID-CNCR2820650509>3.0.CO;2-#; HANCOCK SL, 1988, ANN INTERN MED, V109, P183, DOI 10.7326/0003-4819-109-3-183; HANCOCK SL, 1991, ANN INTERN MED, V114, P810, DOI 10.7326/0003-4819-114-9-810; HARKER WG, 1984, ANN INTERN MED, V101, P440, DOI 10.7326/0003-4819-101-4-440; HELLMAN S, 1978, CANCER, V42, P971, DOI 10.1002/1097-0142(197808)42:2+<971::AID-CNCR2820420720>3.0.CO;2-I; HOPPE RT, 1982, BLOOD, V59, P455; HOPPE RT, 1990, SEMIN ONCOL, V17, P704; HOPPE RT, 1982, CANCER TREAT REP, V66, P743; HOPPER KD, 1988, RADIOLOGY, V169, P17, DOI 10.1148/radiology.169.1.3420256; HORNING SJ, 1988, J CLIN ONCOL, V6, P1822, DOI 10.1200/JCO.1988.6.12.1822; HSU SM, 1990, BLOOD, V75, P1742; JAGANNATH S, 1989, J CLIN ONCOL, V7, P179, DOI 10.1200/JCO.1989.7.2.179; JOCHELSON M, 1985, J CLIN ONCOL, V3, P637, DOI 10.1200/JCO.1985.3.5.637; JONES RJ, 1990, J CLIN ONCOL, V8, P527, DOI 10.1200/JCO.1990.8.3.527; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KANT JA, 1986, J CLIN ONCOL, V4, P284, DOI 10.1200/JCO.1986.4.3.284; KESSINGER A, 1989, BLOOD, V74, P1260; KINSELLA TJ, 1989, J CLIN ONCOL, V7, P718, DOI 10.1200/JCO.1989.7.6.718; KINZIE JJ, 1983, CANCER, V52, P2223, DOI 10.1002/1097-0142(19831215)52:12<2223::AID-CNCR2820521209>3.0.CO;2-D; KLIMO P, 1988, SEMIN HEMATOL, V25, P34; KORBLING M, 1990, J CLIN ONCOL, V8, P978; KRAUSE JR, 1985, CANCER, V55, P512, DOI 10.1002/1097-0142(19850201)55:3<512::AID-CNCR2820550307>3.0.CO;2-Z; KRIKORIAN JG, 1979, NEW ENGL J MED, V300, P452, DOI 10.1056/NEJM197903013000902; KRIKORIAN JG, 1986, J CLIN ONCOL, V4, P1551, DOI 10.1200/JCO.1986.4.10.1551; LAVEY RS, 1990, CANCER, V66, P80, DOI 10.1002/1097-0142(19900701)66:1<80::AID-CNCR2820660116>3.0.CO;2-9; LEE CKK, 1980, CANCER-AM CANCER SOC, V46, P2403, DOI 10.1002/1097-0142(19801201)46:11<2403::AID-CNCR2820461116>3.0.CO;2-9; LEIBENHAUT MH, 1989, J CLIN ONCOL, V7, P81, DOI 10.1200/JCO.1989.7.1.81; LEVIS A, 1987, CANCER, V60, P1713, DOI 10.1002/1097-0142(19871015)60:8<1713::AID-CNCR2820600804>3.0.CO;2-C; LIST AF, 1985, J CLIN ONCOL, V3, P215, DOI 10.1200/JCO.1985.3.2.215; LISTER, 1990, J CLIN ONCOL, V8, P1602; LISTER TA, 1983, J CLIN ONCOL, V1, P745, DOI 10.1200/JCO.1983.1.12.745; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LONGO D, 1988, P AN M AM SOC CLIN, V7, pA226; LONGO DL, 1982, CANCER TREAT REP, V66, P925; LONGO DL, 1991, J CLIN ONCOL, V9, P906, DOI 10.1200/JCO.1991.9.6.906; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; LONGO DL, 1991, J CLIN ONCOL, V9, P227, DOI 10.1200/JCO.1991.9.2.227; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; LONGO DL, 1990, SEMIN ONCOL, V17, P716; MANSFIELD CM, 1990, CANCER, V66, P2295, DOI 10.1002/1097-0142(19901201)66:11<2295::AID-CNCR2820661107>3.0.CO;2-S; MAUCH P, 1987, J CLIN ONCOL, V5, P544, DOI 10.1200/JCO.1987.5.4.544; MAUCH P, 1978, CANCER-AM CANCER SOC, V42, P1039, DOI 10.1002/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R; MAUCH P, 1988, J CLIN ONCOL, V6, P1576, DOI 10.1200/JCO.1988.6.10.1576; MAUCH P, 1985, J CLIN ONCOL, V3, P1166, DOI 10.1200/JCO.1985.3.9.1166; MAUCH PM, 1985, J CLIN ONCOL, V3, P501, DOI 10.1200/JCO.1985.3.4.501; MEAD GM, 1982, CANCER, V50, P829, DOI 10.1002/1097-0142(19820901)50:5<829::AID-CNCR2820500504>3.0.CO;2-R; MORGAN GW, 1985, INT J RADIAT ONCOL, V11, P1925, DOI 10.1016/0360-3016(85)90273-1; MUELLER N, 1991, ANN ONCOL, V2, P23, DOI 10.1093/annonc/2.suppl_2.23; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; ODWYER PJ, 1985, DEV ONCOLOGY, V32, P329; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PAPA G, 1984, BRIT J HAEMATOL, V58, P43, DOI 10.1111/j.1365-2141.1984.tb06057.x; PAVLOVSKY S, 1988, JNCI-J NATL CANCER I, V80, P1466, DOI 10.1093/jnci/80.18.1466; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PETERSEN FB, 1990, J CLIN ONCOL, V8, P638, DOI 10.1200/JCO.1990.8.4.638; PEYLANRAMU N, 1989, J CLIN ONCOL, V7, P1800, DOI 10.1200/JCO.1989.7.12.1800; PHILIP T, 1986, BRIT J CANCER, V53, P737, DOI 10.1038/bjc.1986.127; PHILLIPS GL, 1989, J CLIN ONCOL, V7, P1039, DOI 10.1200/JCO.1989.7.8.1039; PHILLIPS GL, 1989, BLOOD, V73, P2086; PIGA A, 1984, CANCER TREAT REP, V68, P947; PILLAI GN, 1985, CANCER, V55, P691, DOI 10.1002/1097-0142(19850215)55:4<691::AID-CNCR2820550403>3.0.CO;2-Q; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; PROSNITZ LR, 1988, J CLIN ONCOL, V6, P603, DOI 10.1200/JCO.1988.6.4.603; PROSNITZ LR, 1985, INT J RADIAT ONCOL, V11, P1431, DOI 10.1016/0360-3016(85)90329-3; RADFORD JA, 1988, J CLIN ONCOL, V6, P940, DOI 10.1200/JCO.1988.6.6.940; REDMAN JR, 1987, J CLIN ONCOL, V5, P233, DOI 10.1200/JCO.1987.5.2.233; REE HJ, 1991, CANCER-AM CANCER SOC, V67, P1614, DOI 10.1002/1097-0142(19910315)67:6<1614::AID-CNCR2820670624>3.0.CO;2-#; ROACH M, 1987, J CLIN ONCOL, V5, P550, DOI 10.1200/JCO.1987.5.4.550; RUBIN P, 1986, J CLIN ONCOL, V4, P455, DOI 10.1200/JCO.1986.4.4.455; RUBIN P, 1986, INT J RADIAT ONCOL, V12, P153, DOI 10.1016/0360-3016(86)90088-X; SANTORO A, 1986, CANCER TREAT REP, V70, P343; SANTORO A, 1986, SEMIN ONCOL, V13, P23; SANTORO A, 1982, ANN INTERN MED, V96, P139, DOI 10.7326/0003-4819-96-2-139; SCHIMPFF SC, 1980, ANN INTERN MED, V92, P91, DOI 10.7326/0003-4819-92-1-91; SCHOMBERG PJ, 1984, CANCER-AM CANCER SOC, V53, P324, DOI 10.1002/1097-0142(19840115)53:2<324::AID-CNCR2820530225>3.0.CO;2-E; SHIN MS, 1983, CANCER, V51, P30, DOI 10.1002/1097-0142(19830101)51:1<30::AID-CNCR2820510108>3.0.CO;2-6; SPECHT L, 1988, EUR J HAEMATOL, V40, P396; STEIN H, 1991, ANN ONCOL, V2, P33, DOI 10.1093/annonc/2.suppl_2.33; STEIN RS, 1980, ANN INTERN MED, V92, P159, DOI 10.7326/0003-4819-92-2-159; STEWART JR, 1984, PROG CARDIOVASC DIS, V27, P173; STRAUS DJ, 1990, J CLIN ONCOL, V8, P1173, DOI 10.1200/JCO.1990.8.7.1173; STRAUS DJ, 1984, AM J MED, V76, P270, DOI 10.1016/0002-9343(84)90784-8; SUNDEEN J, 1987, BLOOD, V70, P96; SUTCLIFFE SB, 1978, BRIT MED J, V1, P679, DOI 10.1136/bmj.1.6114.679; TANNIR N, 1983, J CLIN ONCOL, V1, P432, DOI 10.1200/JCO.1983.1.7.432; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; TILLY H, 1991, BLOOD, V77, P1298; TSENG A, 1987, CANCER TREAT REP, V71, P475; TUBIANA M, 1985, INT J RADIAT ONCOL, V11, P23, DOI 10.1016/0360-3016(85)90358-X; TUBIANA M, 1989, BLOOD, V73, P47; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VALAGUSSA P, 1982, BLOOD, V59, P488; VANDERVELDEN JW, 1988, INT J CANCER, V42, P252, DOI 10.1002/ijc.2910420218; VANLEEUWEN FE, 1987, LANCET, V2, P210; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1987, J CLIN ONCOL, V5, P1624, DOI 10.1200/JCO.1987.5.10.1624; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; VINCIGUERRA V, 1986, J CLIN ONCOL, V4, P1521, DOI 10.1200/JCO.1986.4.10.1521; VIVIANI S, 1985, EUR J CANCER CLIN ON, V21, P601, DOI 10.1016/0277-5379(85)90088-4; VIVIANI S, 1990, ANN ONCOL, V1, P123, DOI 10.1093/oxfordjournals.annonc.a057689; VIVIANI S, 1991, ANN ONCOL, V2, P55, DOI 10.1093/annonc/2.suppl_2.55; VOSE J, 1988, AM J CLIN ONCOL-CANC, V11, P423, DOI 10.1097/00000421-198808000-00001; WILLETT CG, 1987, CANCER, V59, P27, DOI 10.1002/1097-0142(19870101)59:1<27::AID-CNCR2820590110>3.0.CO;2-2; WILLETT CG, 1987, CANCER, V59, P1107, DOI 10.1002/1097-0142(19870315)59:6<1107::AID-CNCR2820590611>3.0.CO;2-W; YAHALOM J, 1991, ANN ONCOL, V2, P67, DOI 10.1093/annonc/2.suppl_2.67; YOUNG RC, 1978, CANCER, V42, P1001, DOI 10.1002/1097-0142(197808)42:2+<1001::AID-CNCR2820420723>3.0.CO;2-Z; 1975, BMJ, V3, P413	152	232	233	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					678	687		10.1056/NEJM199203053261006	http://dx.doi.org/10.1056/NEJM199203053261006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736106				2022-12-28	WOS:A1992HG11700006
J	BING, RJ				BING, RJ			AN INVESTIGATORS JOURNEY IN CARDIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BING, RJ (corresponding author), HUNTINGTON MED RES INST,734 FAIRMONT AVE,PASADENA,CA 91105, USA.							HARRISON T, FAILURE CIRCULATION; Lewis Sinclair, ARROWSMITH	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					969	972		10.1001/jama.267.7.969	http://dx.doi.org/10.1001/jama.267.7.969			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734111				2022-12-28	WOS:A1992HD15500032
J	BOCK, LC; GRIFFIN, LC; LATHAM, JA; VERMAAS, EH; TOOLE, JJ				BOCK, LC; GRIFFIN, LC; LATHAM, JA; VERMAAS, EH; TOOLE, JJ			SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN	NATURE			English	Article							HUMAN ALPHA-THROMBIN; PROTEIN; RNA; SEQUENCES; INVITRO; LIGANDS; GENOME	APTAMERS 1 are double-stranded DNA or single-stranded RNA molecules that bind specific molecular targets. Large randomly generated populations can be enriched in aptamers by in vitro selection and polymerase chain reaction 1-11. But so far single-stranded DNA has not been investigated for aptamer properties, nor has a target protein been considered that does not interact physiologically with nucleic acid. Here we describe the isolation of single-stranded DNA aptamers to the protease thrombin of the blood coagulation cascade and report binding affinities in the range 25-200 nM. Sequence data from 32 thrombin aptamers, selected from a pool of DNA containing 60 nucleotides of random sequence, displayed a highly conserved 14-17-base region. Several of these aptamers at nanomolar concentrations inhibited thrombin-catalysed fibrin-clot formation in vitro using either purified fibrinogen or human plasma.	GILEAD SCI INC,346 LAKESIDE DR,FOSTER CITY,CA 94404	Gilead Sciences								BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GREEN R, 1990, NATURE, V347, P467; HULTMAN T, 1988, NUCLEOS NUCLEOT, V7, P629, DOI 10.1080/07328318808056299; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	15	2019	2306	30	1173	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					564	566		10.1038/355564a0	http://dx.doi.org/10.1038/355564a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741036				2022-12-28	WOS:A1992HC52600065
J	STORY, RM; STEITZ, TA				STORY, RM; STEITZ, TA			STRUCTURE OF THE RECA PROTEIN-ADP COMPLEX	NATURE			English	Article							ESCHERICHIA-COLI; ADENYLATE KINASE; BINDING; DNA; RESOLUTION; HYDROLYSIS; SEQUENCES; SUBUNITS; DOMAIN; TU	THE recA protein catalyses the ATP-driven homologous pairing and strand exchange of DNA molecules 1-3. It is an allosteric enzyme: the ATPase activity is DNA-dependent 4,5, and ATP-bound recA protein has a high affinity for DNA, whereas the ADP-bound form has a low affinity 6. In the absence of ATP hydrolysis, recA protein can still promote homologous pairing, apparently through the formation of a triple-stranded intermediate 1,7-9. The exact role of ATP hydrolysis is not clear, but it presumably drives the triplex intermediate towards products 1,9,10. Here we determine the position of bound ADP diffused into the recA crystal. We show that only the phosphates are bound in the same way as in other NTPases containing the G/AXXXXGKT/S motif. We propose that recA protein may change its conformation upon ATP hydrolysis in a manner analogous to one such protein, the p21 protein from the ras oncogene. A model is presented to account for the allosteric stimulation of DNA binding by ATP. The mechanism by which nucleoside triphosphate hydrolysis is coupled to the binding of another ligand in recA protein and p21 may be typical of the large class of NTPases containing this conserved motif.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	STORY, RM (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Steitz, Thomas A./C-6559-2009					DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCKAY DB, 1980, J BIOL CHEM, V255, P6662; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILNERWHITE EJ, 1991, J MOL BIOL, V221, P751; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; ROBERTS JW, 1979, COLD SPRING HARB SYM, V43, P917, DOI 10.1101/SQB.1979.043.01.100; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TONG L, 1991, J MOL BIOL, V221, P751; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	30	579	586	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					374	376		10.1038/355374a0	http://dx.doi.org/10.1038/355374a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731253				2022-12-28	WOS:A1992HA59100076
J	BARRIE, JL; MARSH, DR				BARRIE, JL; MARSH, DR			QUALITY OF DATA IN THE MANCHESTER ORTHOPEDIC DATABASE	BRITISH MEDICAL JOURNAL			English	Article							MICROCOMPUTER; ACCURACY; SYSTEM; AUDIT	Objective - To determine the completeness and accuracy of data in a computerised clinical information system (Manchester orthopaedic database) in comparison with the data available through the Hospital Activity Analysis. Design - Retrospective review of case notes, computer data, and Hospital Activity Analysis data. Setting - Orthopaedic unit in a district general hospital in Manchester. Subjects - 200 random patient records distributed through the period of use of the computer system (1 October 1988 to 31 March 1990) and 121 records for random admissions between 1 April 1989 and 31 March 1990,71 of which were included in the previous sample. Main outcome measures - Conformity of the computer record key words and Hospital Activity Analysis codes to an ideal key word record and ideal code record drawn up by one investigator from the clinical notes; overall quality (completeness times accuracy). Results - Overall completeness of the data in the orthopaedic database was 62% and the accuracy was 96%. Completeness improved after feedback to doctors on the use of key words in regular audit meetings. Completeness was higher in inpatient than outpatient records (69.9% v 53.7%, p < 0.001) and when a new key word was required compared with missing and incorrect key words (both p < 0.001). Completeness was lower when the key word was required of a senior registrar (p < 0.05). Accuracy was not significantly different. The completeness of Hospital Activity Analysis data was 90.5% and accuracy 69.5%. Thus the overall data quality was similar in both systems. Conclusions - Even in a system designed for simple and efficient data capture, compliance by users was poor. Accuracy was high, suggesting that users understood the principles of data entry. Completeness of data capture can be improved by providing feedback to users on use of the system and performance. Improvements in future versions of the software should improve performance.	UNIV MANCHESTER,ORTHOPAED SURG,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester								BRAND DA, 1990, CLIN ORTHOPAEDICS, V252, P262; COLEMAN NP, IN PRESS JR COLL SUR; DUNN DC, 1988, BRIT MED J, V296, P687, DOI 10.1136/bmj.296.6623.687; ELLIS BW, 1987, J ROY SOC MED, V80, P157, DOI 10.1177/014107688708000311; HEATH DA, 1990, BRIT MED J, V300, P651, DOI 10.1136/bmj.300.6725.651; KURTZ D, 1983, COMPUT BIOMED RES, V16, P209, DOI 10.1016/0010-4809(83)90022-8; KUSLICH SD, 1988, ORTHOP CLIN N AM, V17, P527; LYONS C, 1990, BRIT MED J, V300, P563; MARSH DR, 1990, J BONE JOINT SURG V, V72, P933; REES JL, 1982, BRIT MED J, V284, P1856, DOI 10.1136/bmj.284.6332.1856; SMITH RP, 1989, OBSTET GYNECOL, V73, P803; SUNDERLAND R, 1985, ARCH DIS CHILD, V60, P593, DOI 10.1136/adc.60.6.593; WHATES PD, 1982, BRIT MED J, V284, P1857, DOI 10.1136/bmj.284.6332.1857; YATES JM, 1984, BRIT MED J, V288, P1935, DOI 10.1136/bmj.288.6434.1935; 1983, JR COLL PHYSICIANS L, V17, P208	15	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					159	162		10.1136/bmj.304.6820.159	http://dx.doi.org/10.1136/bmj.304.6820.159			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737162	Bronze, Green Published			2022-12-28	WOS:A1992HA97900023
J	MCPHERSON, GAD; WOLFE, JHN				MCPHERSON, GAD; WOLFE, JHN			ABC OF VASCULAR DISEASES - ACUTE-ISCHEMIA OF THE LEG	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	MCPHERSON, GAD (corresponding author), WYCOMBE GEN HOSP,HIGH WYCOMBE,BUCKS,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					169	172		10.1136/bmj.304.6820.169	http://dx.doi.org/10.1136/bmj.304.6820.169			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737164	Green Published, Bronze			2022-12-28	WOS:A1992HA97900027
J	PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA				PELL, ACH; MILLER, HC; ROBERTSON, CE; FOX, KAA			EFFECT OF FAST TRACK ADMISSION FOR ACUTE MYOCARDIAL-INFARCTION ON DELAY TO THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; GENERAL-PRACTITIONER; CARE UNIT; STREPTOKINASE; THERAPY; REDUCTION; PATIENT; POLICY; TIME	Objective - To evaluate the impact of a fast track triage system for patients with acute myocardial infarction. Design - Comparison of delays in admission to hospital and in receiving thrombolytic treatment before and after introducing fast track system with delays recorded in 1987-8. Patients fulfilling clinical and electrocardiographic criteria for myocardial infarction were selected for rapid access to the cardiac care team, bypassing evaluation by the medical registrar. Setting - Major accident and emergency, cardiac and trauma centre. Subjects - 359 patients admitted to the cardiac care unit during 1 February to 31 July 1990 with suspected acute infarction. Main outcome measures - Accuracy of diagnosis and delay from arrival at hospital to thrombolytic treatment. Results - 248 of the 359 patients had myocardial infarction confirmed, of whom 127 received thrombolytic treatment. The fast track system correctly identified 79 out of 127 (62%) patients who subsequently required thrombolytic treatment. 95% (79/83) of patients treated with thrombolysis after fast track admission had the diagnosis confirmed by electrocardiography and enzyme analysis. The median delay from hospital admission to thrombolytic treatment fell from 93 minutes in 1987-8 to 49 minutes in fast track patients (p < 0.001). Delay in admission to the cardiac care unit was reduced by 47% for fast track patients (median 60 minutes in 1987-8 v 32 minutes in 1990, p < 0.001) and by 25% for all patients (60 minutes v 45 minutes, p < 0.001). Conclusion - This fast track system requires no additional staff or equipment, and it halves in-hospital delay to thrombolytic treatment without affecting the accuracy of diagnosis among patients requiring thrombolysis.	ROYAL INFIRM, DEPT CARDIOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh				Fox, Keith/0000-0002-0140-2752				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; BURNS JMA, 1989, BRIT HEART J, V61, P322; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FOX KAA, 1990, BMJ-BRIT MED J, V300, P867, DOI 10.1136/bmj.300.6728.867; KNABB RM, 1987, J NUCL MED, V28, P1563; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACCALLUM AG, 1990, EUR HEART J, V11, P48, DOI 10.1093/eurheartj/11.suppl_F.48; MCNEILL AJ, 1991, Q J MED, V79, P487; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; PELL A C H, 1990, Health Bulletin (Edinburgh), V48, P225; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RIDKER P, 1990, Journal of the American College of Cardiology, V15, p167A; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SHEEHAN FH, 1983, AM J CARDIOL, V52, P431, DOI 10.1016/0002-9149(83)90002-4; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WILCOX RG, 1988, LANCET, V2, P525	22	99	97	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1992	304	6819					83	87		10.1136/bmj.304.6819.83	http://dx.doi.org/10.1136/bmj.304.6819.83			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737145	Green Published, Bronze			2022-12-28	WOS:A1992HA17100021
J	WILENSKY, GR				WILENSKY, GR			FINANCING CARE FOR PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3404	3404						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1744948				2022-12-28	WOS:A1991GV87800005
J	GRACE, P				GRACE, P			1ST AMONG WOMEN	BRITISH MEDICAL JOURNAL			English	Editorial Material											GRACE, P (corresponding author), ROYAL COLL SURG IRELAND,DEPT SURG,DUBLIN 9,IRELAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1582	1583		10.1136/bmj.303.6817.1582	http://dx.doi.org/10.1136/bmj.303.6817.1582			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773177	Green Published, Bronze			2022-12-28	WOS:A1991GX95600009
J	PENNINGTON, E; PENNINGTON, S				PENNINGTON, E; PENNINGTON, S			MODIFYING CHICKENPOX	BRITISH MEDICAL JOURNAL			English	Article							ACYCLOVIR											BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BOYD K, 1988, BRIT MED J, V296, P393, DOI 10.1136/bmj.296.6619.393-a; HEALSMITH MF, 1990, BMJ, V301, P1286; PETERSLUND NA, 1988, AM J MED, V85, P74	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1614	1614		10.1136/bmj.303.6817.1614	http://dx.doi.org/10.1136/bmj.303.6817.1614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773194	Green Published, Bronze			2022-12-28	WOS:A1991GX95600027
J	WONG, D; NYE, K; HOLLIS, P				WONG, D; NYE, K; HOLLIS, P			MICROBIAL-FLORA ON DOCTORS WHITE COATS	BRITISH MEDICAL JOURNAL			English	Article							NURSES	Objective - To determine the level and type of microbial contamination present on the white coats of doctors in order to assess the risk of transmission of pathogenic micro-organisms by this route in a hospital setting. Design - Cross sectional survey of the bacterial contamination of white coats in a general hospital. Setting - East Birmingham Hospital, an urban general hospital with 800 beds. Subjects - 100 doctors of different grades and specialties. Results - The cuffs and pockets of the coats were the most highly contaminated areas. The level of bacterial contamination did not vary with the length of time a coat had been in use, but it increased with the degree of usage by the individual doctor. Staphylococcus aureus was isolated from a quarter of the coats examined, more commonly from those belonging to doctors in surgical specialties than medical specialties. Pathogenic Gram negative bacilli and other pathogenic bacteria were not isolated. Conclusions - White coats are a potential source of cross infection, especially in surgical areas. Scrupulous hand washing should be observed before and after attending patients and it may be advisable to remove the white coat and put on a plastic apron before examining wounds. There is little microbiological reason for recommending a more frequent change of white coat than once a week, nor for excluding the wearing of white coats in non-clinical areas.			WONG, D (corresponding author), E BIRMINGHAM DIST GEN HOSP,PUBL HLTH LAB,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND.							AYLIFFE GAJ, 1967, J HYG-CAMB, V65, P515, DOI 10.1017/S0022172400046052; BABB JR, 1983, J HOSP INFECT, V4, P149, DOI 10.1016/0195-6701(83)90044-0; HAMBRAEUS A, 1973, J HYG-CAMBRIDGE, V71, P799, DOI 10.1017/S0022172400023068; LIDWELL OM, 1974, J APPL BACTERIOL, V37, P649, DOI 10.1111/j.1365-2672.1974.tb00489.x; NICOLES PS, 1970, AM J PUBLIC HEALTH, V60, P2175; Nystrom B, 1981, J Hosp Infect, V2, P167, DOI 10.1016/0195-6701(81)90025-6; RANSJO U, 1979, J HYG-CAMBRIDGE, V82, P369, DOI 10.1017/S0022172400053900; ROBINTON ED, 1968, AM J PUBLIC HEALTH N, V58, P1452, DOI 10.2105/AJPH.58.8.1452; SPEERS R, 1969, LANCET, V2, P233	9	115	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1602	1604		10.1136/bmj.303.6817.1602	http://dx.doi.org/10.1136/bmj.303.6817.1602			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773186	Green Published, Bronze			2022-12-28	WOS:A1991GX95600019
J	AARONS, EJ; BEECHING, NJ				AARONS, EJ; BEECHING, NJ			SURVEY OF DO NOT RESUSCITATE ORDERS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY RESUSCITATION; SURVIVAL	Objective - To evaluate the local use of written "Do not resuscitate" orders to designate inpatients unsuitable for cardiopulmonary resuscitation in the event of cardiac arrest. Design - Point prevalence questionnaire survey of inpatients' medical and nursing records. Setting - 10 acute medical and six acute surgical wards of a district general hospital. Participants - Questionnaires were filled in anonymously by nurses and doctors working on the wards surveyed. Main outcome measures - Responses to questionnaire items concerning details about each patient, written orders not to resuscitate in the medical case notes and nursing records, whether prognosis had been discussed with patients' relatives, whether a "crash call" was perceived as appropriate for each patient, and whether the "crash team" would be called in the event of arrest. Results - Information was obtained on 297 (93.7%) of 317 eligible patients. Prognosis had been discussed with the relatives of 32 of 88 patients perceived by doctors as unsuitable for resuscitation. Of these 88 patients, 24 had orders not to resuscitate in their medical notes, and only eight of these had similar orders in their nursing notes. Conclusions - In the absence of guidelines on decisions about resuscitation, orders not to resuscitate are rarely included in the notes of patients for whom cardiopulmonary resuscitation is thought to be inappropriate. Elective decisions not to resuscitate are not effectively communicated to nurses. There should be more discussion of patients' suitability for resuscitation between doctors, nurses, patients, and patients' relatives. Suitability for resuscitation should be reviewed on every consultant ward round.	FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND		BEECHING, NJ (corresponding author), FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND.		Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				ASPLUND K, 1990, J INTERN MED, V228, P139; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; Halligan M, 1985, Health Prog, V66, P26; HALLIGAN M, 1985, HLTH PROGR, V66, P600; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; KEATINGE RM, 1989, J ROY SOC MED, V82, P402, DOI 10.1177/014107688908200711; MCCLUNG JA, 1990, NEW ENGL J MED, V323, P270, DOI 10.1056/NEJM199007263230411; PEATFIELD RC, 1977, LANCET, V1, P1223; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; URBURG M, 1987, J FAM PRACTICE, V25, P41; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1984, CODE PROFESSIONAL CO	14	45	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1504	1506		10.1136/bmj.303.6816.1504	http://dx.doi.org/10.1136/bmj.303.6816.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782488	Bronze, Green Published			2022-12-28	WOS:A1991GV47600019
J	ENNIS, M				ENNIS, M			TRAINING AND SUPERVISION OF OBSTETRIC SENIOR HOUSE OFFICERS	BRITISH MEDICAL JOURNAL			English	Article											ENNIS, M (corresponding author), UNIV LONDON UNIV COLL,DEPT PSYCHOL,LONDON WC1E 6BT,ENGLAND.							ENNIS M, 1990, BRIT MED J, V300, P1365, DOI 10.1136/bmj.300.6736.1365; GRANT J, 1989, BRIT MED J, V299, P1263, DOI 10.1136/bmj.299.6710.1263; MARTEAU TM, 1990, BRIT MED J, V300, P849, DOI 10.1136/bmj.300.6728.849; WYNNE G, 1987, BRIT MED J, V294, P1198, DOI 10.1136/bmj.294.6581.1198; 1987, RECOMMENDATIONS TRAI	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1442	1443		10.1136/bmj.303.6815.1442	http://dx.doi.org/10.1136/bmj.303.6815.1442			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773149	Green Published, Bronze			2022-12-28	WOS:A1991GU38500024
J	REICHARD, P; BRITZ, A; ROSENQVIST, U				REICHARD, P; BRITZ, A; ROSENQVIST, U			INTENSIFIED CONVENTIONAL INSULIN-TREATMENT AND NEUROPSYCHOLOGICAL IMPAIRMENT	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIC BRAIN INJURY; DIABETES-MELLITUS; MICROSCOPIC FINDINGS; GLUCOSE-LEVELS; THRESHOLDS; RAT; DAMAGE; IDDM	Objective - To assess whether intensified insulin treatment, with an increased frequency of hypoglycaemic episodes, leads to cognitive deterioration. Design - Prospective randomised trial of intensified conventional treatment and standard treatment. Setting - Outpatient clinic for patients with insulin dependent diabetes. Subjects - 96 patients with insulin dependent diabetes, high blood glucose concentrations, and non-proliferative retinopathy were randomised to intensified conventional treatment (n = 44) or standard treatment (n = 52). Main outcome measures - Glycated haemoglobin concentration (metabolic control); the number of hypoglycaemic episodes reported by patients at each visit; results of computerised neuropsychological tests performed at entry and after five years. Results - M an glycated haemoglobin concentration during the study was 7.2% (SE 0.1%) with intensified conventional treatment and 8.7 (0.1%) with standard treatment (p < 0.001). During five years 34 (77%, 95% confidence interval 53% to 100%) of the patients given intensified treatment and 29 (56%, 36% to 75%) of the others had at least one episode of serious hypoglycaemia (p < 0.05). The intensified conventional treatment group had a mean of 1.1 episodes of serious hypoglycaemia per patient per year compared with 0.4 episodes in the standard treatment group. Results of the neuropsychological tests were similar in the two groups after five years. Conclusions - Intensified conventional insulin treatment led to lower blood glucose concentrations and a higher frequency of hypoglycaemic episodes, but patients showed no signs of cognitive deterioration.	STOCKHOLM CTY COUNCIL,TEACHING CTR DIABET,STOCKHOLM,SWEDEN	Stockholm County Council	REICHARD, P (corresponding author), SODER SJUKHUSET,DEPT INTERNAL MED 2,S-11883 STOCKHOLM,SWEDEN.		Rosenqvist, Urban/Q-1986-2016					AGARDH CD, 1980, ACTA NEUROPATHOL, V50, P31, DOI 10.1007/BF00688532; AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; BALE RN, 1973, BRIT J PSYCHIAT, V122, P337, DOI 10.1192/bjp.122.3.337; COHEN L, 1959, ARCH NEURO PSYCHIATR, V81, P765, DOI 10.1001/archneurpsyc.1959.02340180099013; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; ELITHORN A, 1982, INT J MAN MACH STUD, V17, P247, DOI 10.1016/S0020-7373(82)80026-6; FRUHSTORFER H, 1976, J NEUROL NEUROSUR PS, V39, P1071, DOI 10.1136/jnnp.39.11.1071; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GERICH JE, 1988, DIABETES, V37, P1608, DOI 10.2337/diabetes.37.12.1608; GOLDBERG JM, 1979, J NEUROL NEUROSUR PS, V42, P793, DOI 10.1136/jnnp.42.9.793; GRILL V, 1990, AM J PHYSIOL, V258, pE813, DOI 10.1152/ajpendo.1990.258.5.E813; HEROLD KC, 1985, DIABETES, V34, P677, DOI 10.2337/diabetes.34.7.677; HOLMES CS, 1983, DIABETES CARE, V6, P180, DOI 10.2337/diacare.6.2.180; HOLMES CS, 1986, PSYCHONEUROENDOCRINO, V11, P353, DOI 10.1016/0306-4530(86)90021-1; HOLMES CS, 1988, DIABETIC MED, V5, P634, DOI 10.1111/j.1464-5491.1988.tb01071.x; KALIMO H, 1980, ACTA NEUROPATHOL, V50, P43, DOI 10.1007/BF00688533; LAGER I, 1986, DIABETIC MED, V3, P322, DOI 10.1111/j.1464-5491.1986.tb00772.x; LEVANDER S, 1985, EUR J CLIN PHARMACOL, V28, P523, DOI 10.1007/BF00544062; Levander S, 1987, AUTOMATED PSYCHOL TE; LEVANDER SE, 1985, PERCEPT MOTOR SKILL, V61, P479, DOI 10.2466/pms.1985.61.2.479; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A, P556; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A, P25; LUDIN HP, 1980, ELECTROMYOGRAPHY PRA; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; REICHARD P, 1989, J INTERN MED, V226, P81, DOI 10.1111/j.1365-2796.1989.tb01359.x; REICHARD P, 1990, J INTERN MED, V228, P511, DOI 10.1111/j.1365-2796.1990.tb00271.x; REICHARD P, 1991, J INTERN MED, V229, P9, DOI 10.1111/j.1365-2796.1991.tb00299.x; REICHARD P, 1988, ACTA MED SCAND, V224, P115; RYAN C, 1985, PEDIATRICS, V75, P921; THORSTEINSSON B, 1986, DIABETIC MED, V3, P147, DOI 10.1111/j.1464-5491.1986.tb00726.x; WREDLING R, 1990, DIABETOLOGIA, V33, P152, DOI 10.1007/BF00404042; [No title captured]	33	45	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1439	1442		10.1136/bmj.303.6815.1439	http://dx.doi.org/10.1136/bmj.303.6815.1439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GU385	1773148	Bronze, Green Published			2022-12-28	WOS:A1991GU38500023
J	SEAGROATT, V; TAN, HS; GOLDACRE, M; BULSTRODE, C; NUGENT, I; GILL, L				SEAGROATT, V; TAN, HS; GOLDACRE, M; BULSTRODE, C; NUGENT, I; GILL, L			ELECTIVE TOTAL HIP-REPLACEMENT - INCIDENCE, EMERGENCY READMISSION RATE, AND POSTOPERATIVE MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							PRIVATE SECTOR; SURGERY; ENGLAND; WALES	Objectives - To report the incidence of elective total hip replacement and postoperative mortality, emergency readmission rates, and the demographic factors associated with these rates in a large defined population. Design - Analysis of linked, routine abstracts of hospital inpatient records and death certificates. Setting - 10 hospitals in six districts in Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 11607 total hip replacements performed electively in 1976-85. Main outcome measures - Incidence of operation, postoperative mortality, relative mortality ratios, and incidence of emergency readmission. Results - NHS operation rates increased over time from 43 to 58 operations/100 000 population. Variation in operation rates between districts reduced over time. Operation rates were on average 25% higher in women than men. There were 93 deaths (11/1000 operations) within 90 days of the operation and 208 emergency readmissions (28/1000 operations) within 28 days of discharge. Postoperative mortality and emergency readmission rates increased with age. No significant trend with time was found. Mortality in the 90 days after the operation was 2.5-fold higher (1.9 to 3.0) than in the rest of the first postoperative year. This represented an estimated excess of 6.5 (4.2 to 8.8) early postoperative deaths/1000 operations. Most deaths were ascribed to cardiovascular events. Thromboembolic disease was the commonest reason for emergency readmission. Conclusions - The pronounced increase in operations in districts with initially low rates suggests a trend towards greater equity in the local provision of NHS hip arthroplasty. The early postoperative clusters of deaths attributed to cardiovascular disease and of readmissions for thromboembolic disease suggest that there is scope for investigating ways of reducing the incidence of major adverse postoperative events.	NUFFIELD ORTHOPAED CTR,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 7LD,ENGLAND	Nuffield Orthopaedic Centre	SEAGROATT, V (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.							BAKER RJ, 1978, GLIM SYSTEM; BRADY LP, 1986, CLIN ORTHOP RELAT R, V211, P51; CHANDLER HP, 1981, J BONE JOINT SURG AM, V63, P1426, DOI 10.2106/00004623-198163090-00008; CHARNLEY J, 1975, CLIN ORTHOP RELAT R, V111, P105; CORNELL CN, 1986, J BONE JOINT SURG AM, V68A, P1430, DOI 10.2106/00004623-198668090-00017; DORR LD, 1983, J BONE JOINT SURG AM, V65, P474, DOI 10.2106/00004623-198365040-00007; FRANKEL W, 1991, 2 U BRIST REP; Gustilo R B, 1982, Hip, P27; HENDERSON J, 1989, BRIT MED J, V299, P709, DOI 10.1136/bmj.299.6701.709; LASSEN MR, 1991, LANCET, P618; NICHOLL JP, 1989, BRIT MED J, V298, P243, DOI 10.1136/bmj.298.6668.243; NICHOLL JP, 1984, LANCET, V2, P89; RANAWAT CS, 1984, J BONE JOINT SURG AM, V66A, P745, DOI 10.2106/00004623-198466050-00014; SALVATI EA, 1981, J BONE JOINT SURG AM, V63, P753, DOI 10.2106/00004623-198163050-00010; TERAYAMA K, 1986, CLIN ORTHOP RELAT R, V211, P79; WELCH RB, 1988, ORTHOP CLIN N AM, V19, P551; WROBLEWSKI BM, 1986, CLIN ORTHOP RELAT R, V201, P37; [No title captured]; 1975, CLASSIFICATION SURGI; HOSPITAL PATIENT ENQ; [No title captured]	21	175	179	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1431	1435		10.1136/bmj.303.6815.1431	http://dx.doi.org/10.1136/bmj.303.6815.1431			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773147	Green Published, Bronze			2022-12-28	WOS:A1991GU38500021
J	WILLIAMS, RB; BURDGE, AH; JONES, SL				WILLIAMS, RB; BURDGE, AH; JONES, SL			SKIN BIOPSY IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											WILLIAMS, RB (corresponding author), MAELOR GEN HOSP,WREXHAM LL13 7TD,CLWYD,WALES.							Brundel K H, 1990, Derm Beruf Umwelt, V38, P54; Paver R D, 1990, Aust Fam Physician, V19, P699	2	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1179	1180		10.1136/bmj.303.6811.1179	http://dx.doi.org/10.1136/bmj.303.6811.1179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747617	Bronze, Green Published			2022-12-28	WOS:A1991GP48800027
J	MORRISON, JM; GILMOUR, H; SULLIVAN, F				MORRISON, JM; GILMOUR, H; SULLIVAN, F			CHILDREN SEEN FREQUENTLY OUT OF HOURS IN ONE GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To identify reasons why some children receive more out of hours visits than most. Design - A one year prospective study to identify the study group. This was followed by a case-control study involving a record search and personal interviews. Setting - One three doctor urban general practice in West Lothian with 4812 patients. Subjects - 40 children aged under 10 years identified as high users of the out of hours service (more than two visits a year) and 40 age and sex matched controls. Main outcome measures - Numbers of visits; social factors such as lone motherhood, low educational attainment; score for management response to clinical vignette. Results - 147/756 (19%) out of hours visits in the study year were to children aged under 10 years; 109 (74%) to 41 children (6%). Problems seen were mainly minor, and little active management was required. Family and social factors which were significantly more common for the cases than for the controls included a lone mother (15 v 4), low educational attainment by the mother (25 v 14), receipt of income support (22 v 7), and non-ownership of the home (45 v 22) or a car (19 v 9). Mothers of the cases were more likely to choose to contact a doctor when presented with vignettes describing common childhood illnesses (median score for 16 vignettes 16.5 for cases v 14.5 for controls, Wilcoxon signed rank test, p = 0.01). Conclusions - Children seen more frequently than expected out of hours came from more socially disadvantaged families and their mothers were more likely to seek medical advice about minor childhood illness. Maternal education, to promote confidence in managing minor illness, may reduce their use of the out of hours service.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow	MORRISON, JM (corresponding author), UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,SCOTLAND.		Sullivan, Frank/L-8286-2019; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; 				BHOPAL JS, 1989, J ROY COLL GEN PRACT, V39, P156; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; CAMPION PD, 1985, SOC SCI MED, V20, P325, DOI 10.1016/0277-9536(85)90005-X; DUNCAN JK, 1987, J ROY COLL GEN PRACT, V37, P251; GARDNER MJ, 1989, STATISTICS CONFIDENC; MACHIN D, 1987, STATISTICAL TABLES D; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; USHERWOOD TP, 1991, BRIT J GEN PRACT, V41, P58; WALKER RD, 1985, J ROY COLL GEN PRACT, V35, P427; WESTHEAD JN, 1985, J ROY COLL GEN PRACT, V35, P337; WILLIAMS DJ, 1988, BRIT MED J, V296, P1197, DOI 10.1136/bmj.296.6630.1197; 1986, MINITAB STATISTICAL	14	21	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1111	1114		10.1136/bmj.303.6810.1111	http://dx.doi.org/10.1136/bmj.303.6810.1111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747581	Green Published, Bronze			2022-12-28	WOS:A1991GN20900025
J	DEMAGISTRIS, MT; ALEXANDER, J; COGGESHALL, M; ALTMAN, A; GAETA, FCA; GREY, HM; SETTE, A				DEMAGISTRIS, MT; ALEXANDER, J; COGGESHALL, M; ALTMAN, A; GAETA, FCA; GREY, HM; SETTE, A			ANTIGEN ANALOG MAJOR HISTOCOMPATIBILITY COMPLEXES ACT AS ANTAGONISTS OF THE T-CELL RECEPTOR	CELL			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; IMMUNOGENIC PEPTIDES; MHC BINDING; ACTIVATION; MOLECULES; IA; COMPETITION; SPECIFICITY; RECOGNITION	A novel mechanism for inhibition of T cell responses is described. Using the recognition of the influenza hemagglutinin (HA) 307-319 peptide in the context of DR1 class II major histocompatibility complex molecules, we have found that nonstimulatory analogs of the HA peptide preferentially inhibit HA-specific T cells in inhibition of antigen presentation assays. This antigen-specific effect could be generalized to another DR1-restricted peptide, Tetanus toxoid 830-843. Direct binding and cellular experiments indicated that the mechanism responsible was distinct from competition for binding to DRI molecules. Likewise, negative signaling and induction of T cell tolerance could also be excluded as effector mechanisms. Thus, the most likely mechanism for this effect is engagement of antigen-specific T cell receptors by DR1-peptide analog complexes, which results in antigen-specific competitive blocking of T cell responses by virtue of their capacity to compete with DR1-antigen complexes for binding to the T cell receptor.	LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037	La Jolla Institute for Immunology	DEMAGISTRIS, MT (corresponding author), CYTEL,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022		NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI28197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GRAY HM, 1989, CLIN IMMUNOL IMMUNOP, V53, pS47; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HARDING CV, 1988, IMMUNOL REV, V106, P77, DOI 10.1111/j.1600-065X.1988.tb00774.x; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KURATA A, 1990, J IMMUNOL, V144, P4526; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LAMONT AG, 1990, J IMMUNOL, V145, P1687; LAMONT AG, 1990, J IMMUNOL, V144, P2493; LEIGHTON J, 1991, J IMMUNOL, V147, P198; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PROUST JJ, 1991, EUR J IMMUNOL, V21, P335, DOI 10.1002/eji.1830210214; SAKAI K, 1989, P NATL ACAD SCI USA, V86, P9470, DOI 10.1073/pnas.86.23.9470; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Sette A, 1991, Semin Immunol, V3, P195; SMILEK DE, 1990, IMMUNOL REV, V118, P37, DOI 10.1111/j.1600-065X.1990.tb00813.x; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1	40	504	516	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					625	634		10.1016/0092-8674(92)90139-4	http://dx.doi.org/10.1016/0092-8674(92)90139-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739971				2022-12-28	WOS:A1992HF44000004
J	LINDAN, CP; ALLEN, S; SERUFILIRA, A; LIFSON, AR; VANDEPERRE, P; CHENRUNDLE, A; BATUNGWANAYO, J; NSENGUMUREMYI, F; BOGAERTS, J; HULLEY, S				LINDAN, CP; ALLEN, S; SERUFILIRA, A; LIFSON, AR; VANDEPERRE, P; CHENRUNDLE, A; BATUNGWANAYO, J; NSENGUMUREMYI, F; BOGAERTS, J; HULLEY, S			PREDICTORS OF MORTALITY AMONG HIV-INFECTED WOMEN IN KIGALI, RWANDA	ANNALS OF INTERNAL MEDICINE			English	Article						RWANDA; AFRICA; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; SEXUALLY TRANSMITTED DISEASES; PREGNANCY COMPLICATIONS, INFECTIOUS; WOMENS HEALTH SERVICES	HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL CASE-DEFINITION; SUB-SAHARAN AFRICA; NUTRITIONAL-STATUS; LATENCY PERIOD; HOMOSEXUAL MEN; SURVIVAL-TIME; BISEXUAL MEN; RISK-FACTORS; AIDS	Objective: To better characterize the natural history of disease due to human immunodeficiency virus (HIV) infection in African women. Design: Prospective cohort study over a 2-year follow-up period. Participants: A total of 460 HIV-seropositive women and a comparison cohort of HIV-seronegative women recruited from prenatal and pediatric clinics in Kigali, Rwanda in 1988. Measurements: Clinical signs and symptoms of HIV disease, AIDS, and mortality. Main Results: Follow-up data at 2 years were available for 93% of women who were still alive. At enrollment, many seropositive women reported symptoms listed in the World Health Organization (WHO) clinical case definition of AIDS, but these were nonspecific and often improved over time. The 2-year mortality among HIV-infected women by Kaplan-Meier survival analysis was 7% (95% Cl, 5% to 10%) overall, and 21% (Cl, 8% to 34%) for the 40 women who fulfilled the WHO case definition of AIDS at entry. In comparison, the 2-year mortality in women not infected with HIV was only 0.3% (Cl, 0% to 7%). Independent baseline predictors of mortality in seropositive women by Cox proportional hazards modeling were, in order of descending risk factor prevalence: a body mass index of 21 kg/m2 or less (relative hazard, 2.3; Cl, 1.1 to 4.8), low income (relative hazard, 2.3; Cl, 1.1 to 4.5), an erythrocyte sedimentation rate exceeding 60 mm/h (relative hazard, 4.9; Cl, 2.2 to 10.9), chronic diarrhea (relative hazard, 2.6; Cl, 1.1 to 5.7), a history of herpes zoster (relative hazard 5.3; Cl, 2.5 to 11.4), and oral candida (relative hazard, 7.3; Cl, 1.6 to 33.3). Human immunodeficiency virus disease was the cause of death in 38 of the 39 HIV-positive women who died, but only 25 met the WHO definition of AIDS before death. Conclusions: Human immunodeficiency virus disease now accounts for 90% of all deaths among child-bearing urban Rwandan women. Many symptomatic seropositive patients may show some clinical improvement and should not be denied routine medical care. Easily diagnosed signs and symptoms and inexpensive laboratory tests can be used in Africa to identify those patients with a particularly good or bad prognosis.	PROJET SAN FRANCISCO, KIGALI, RWANDA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94131 USA; RWANDAN NATL AIDS PROGRAM, KIGALI, RWANDA; CTR HOSP KIGALI, KIGALI, RWANDA; MINIST HLTH KIGALI, KIGALI, RWANDA	University of California System; University of California San Francisco	LINDAN, CP (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, 74 NEW MONTGOMERY ST, SUITE 600, SAN FRANCISCO, CA 94105 USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline; PHS HHS [A123980] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; ANZALA A, 1991, 6 INT C AIDS FLOR, P103; BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; CARAEL M, 1988, AIDS, V2, P201; CARSWELL JW, 1988, BRIT MED BULL, V44, P183, DOI 10.1093/oxfordjournals.bmb.a072240; CHIN J, 1989, B WORLD HEALTH ORGAN, V67, P1; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; GILKS CF, 1991, BRIT MED J, V303, P1189, DOI 10.1136/bmj.303.6811.1189; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HEBERT JR, 1988, MED HYPOTHESES, V27, P51, DOI 10.1016/0306-9877(88)90083-7; HEBERT JR, 1990, J SUBST ABUSE TREAT, V7, P161; HESSOL NA, 1990, J ACQ IMMUN DEF SYND, V3, P1078; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; HUNTER SS, 1990, SOC SCI MED, V31, P681, DOI 10.1016/0277-9536(90)90250-V; LANGE JMA, 1989, AIDS, V3, pS153, DOI 10.1097/00002030-198901001-00023; LEFRERE JJ, 1988, AIDS, V2, P63, DOI 10.1097/00002030-198802000-00013; LEFRERE JJ, 1989, AIDS, V3, P603, DOI 10.1097/00002030-198909000-00008; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; LUCAS SB, 1987, ADV MED, V23, P102; MAMUN KZ, 1989, AIDS, V3, P323, DOI 10.1097/00002030-198905000-00017; MBAGA JM, 1990, E AFR MED J, V67, P95; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MCLEOD DT, 1990, RESP MED, V84, P225, DOI 10.1016/S0954-6111(08)80039-X; MELBYE M, 1987, LANCET, V1, P728; MELBYE M, 1986, LANCET, V2, P1113; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULLER O, 1990, LANCET, V335, P236, DOI 10.1016/0140-6736(90)90339-7; MURRAY HW, 1989, AM J MED, V86, P533, DOI 10.1016/0002-9343(89)90380-X; NELSON JA, 1990, AIDS, V4, P1, DOI 10.1097/00002030-199001000-00001; NGALY B, 1990, J ACQ IMMUN DEF SYND, V3, P430; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; PALLANGYO KJ, 1987, LANCET, V2, P972; PHAIR J, 1991, 6 INT C AIDS FLOR; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; VANDEPERRE P, 1989, LANCET, V1, P941; VANDEPERRE P, 1987, AIDS, V1, P207; VANGRIENSVEN GJP, 1990, AM J EPIDEMIOL, V132, P203; WENGER JD, 1988, J GEN INTERN MED, V3, P464, DOI 10.1007/BF02595923; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1989, DRAFT REPORT INFORMA; 1987, MMWR S, V36, pS3; 1986, WEEKLY EPIDEMIOL REC, V61, P69; REPORTED AIDS CASES	56	139	140	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					320	328		10.7326/0003-4819-116-4-320	http://dx.doi.org/10.7326/0003-4819-116-4-320			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733389				2022-12-28	WOS:A1992HD54600010
J	SCHLENKER, TL; BAIN, C; BAUGHMAN, AL; HADLER, SC				SCHLENKER, TL; BAIN, C; BAUGHMAN, AL; HADLER, SC			MEASLES HERD-IMMUNITY - THE ASSOCIATION OF ATTACK RATES WITH IMMUNIZATION RATES IN PRESCHOOL-CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES	Objective. - To examine the association between incidence of measles and immunization coverage among preschool-age children. Design. - An ecological study in which measles incidence was compared with immunization coverage among census tracts. The independent effects of race and population density were controlled for. Setting. - A recent measles outbreak in Milwaukee, Wis. immunization coverage data were estimated from a retrospective, school-based survey of Milwaukee grade school students. Patients. - One thousand eleven persons (less-than-or-equal-to 17 years) who had confirmed measles from September 1989 through June 1990. Main Outcome Measures. - Confirmed measles cases grouped by census tract, corresponding census tract preoutbreak immunization coverage, racial breakdown, and population density. Results. - Census tracts stratified into four levels, with mean immunization rates of 50.4%, 60.2%, 69.9%, and 81.0%, had respective median attack rates of 11.6, 5.0, 1.7, and 0.0 cases per 1000 persons (P < .01). The association between immunization coverage and measles attack rate remained significant even after controlling for race and population density. Conclusions. - Modest improvements in low levels of immunization coverage among 2-year-olds confer substantial protection against measles outbreaks. Coverage of 80% or less may be sufficient to prevent sustained measles outbreaks in an urban community.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,DATA MANAGEMENT BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	SCHLENKER, TL (corresponding author), MILWAUKEE HLTH DEPT,841 N BROADWAY,MILWAUKEE,WI 53202, USA.							BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; EMERSON JD, 1983, UNDERSTANDING ROBUST, P33; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; Hedrich AW, 1933, AM J HYG, V17, P613, DOI 10.1093/oxfordjournals.aje.a117929; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hollander M., 1973, NONPARAMETRIC STAT, P114; INMAN RL, 1979, TECHNOMETRICS, V21, P499; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P314; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MASSEY DS, 1989, DEMOGRAPHY, V26, P373, DOI 10.2307/2061599; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Schlenker T, 1990, Wis Med J, V89, P403; SENCER DJ, 1967, PUBLIC HEALTH REP, V82, P253, DOI 10.2307/4592985; THACKER SB, 1991, AM J EPIDEMIOL, V133, P517, DOI 10.1093/oxfordjournals.aje.a115923; 1987, MMWR, V36, P45; 1990, MMWR, V39, P317; 1991, MEASLES EPIDEMIC PRO; 1985, PHC802243 US DEP COM; 1989, MMWR, V38, P1; 1990, MMWR, V39, P353; 1991, MMWR, V40, P93; 1991, MMWR, V40, P36	23	69	69	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					823	826		10.1001/jama.267.6.823	http://dx.doi.org/10.1001/jama.267.6.823			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732654				2022-12-28	WOS:A1992HC48400027
J	DEVER, TE; FENG, L; WEK, RC; CIGAN, AM; DONAHUE, TF; HINNEBUSCH, AG				DEVER, TE; FENG, L; WEK, RC; CIGAN, AM; DONAHUE, TF; HINNEBUSCH, AG			PHOSPHORYLATION OF INITIATION FACTOR-2-ALPHA BY PROTEIN-KINASE GCN2 MEDIATES GENE-SPECIFIC TRANSLATIONAL CONTROL OF GCN4 IN YEAST	CELL			English	Article							AMINO-ACID BIOSYNTHESIS; DOUBLE-STRANDED-RNA; POLYPEPTIDE-CHAIN INITIATION; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; FACTOR-II; MESSENGER-RNA; FACTOR EIF-2; START-SITE; EXPRESSION	We show that phosphorylation of the a subunit of eukaryotic translation initiation factor 2 (eIF-2) by the protein kinase GCN2 mediates translational control of the yeast transcriptional activator GCN4. In vitro, GCN2 specifically phosphorylates the alpha-subunit of rabbit or yeast eIF-2. In vivo, phosphorylation of eIF-2-alpha increases in response to amino acid starvation, which is dependent on GCN2. Substitution of Ser-51 with alanine eliminates phosphorylation of eIF-2-alpha by GCN2 in vivo and in vitro and abolishes increased expression of GCN4 and amino acid biosynthetic genes under its control in amino acid-starved cells. The Asp-51 substitution mimics the phosphorylated state and derepresses GCN4 in the absence of GCN2. Thus, an established mechanism for regulating total protein synthesis in mammalian cells mediates gene-specific translational control in yeast.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	DEVER, TE (corresponding author), NICHHD, MOLEC GENET LOWER EUKARYOTES SECT, BETHESDA, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032263] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32263] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; ERNST H, 1987, J BIOL CHEM, V262, P1206; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; HANNIG EM, 1990, GENETICS, V126, P549; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LONDON IM, 1987, ENZYMES, V18, P359; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MESSENGUY F, 1976, EUR J BIOCHEM, V67, P335, DOI 10.1111/j.1432-1033.1976.tb10696.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; NIEDERBERGER P, 1983, J GEN MICROBIOL, V129, P2571; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SIKORSKI RS, 1989, GENETICS, V122, P19; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	47	593	606	2	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					585	596		10.1016/0092-8674(92)90193-G	http://dx.doi.org/10.1016/0092-8674(92)90193-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739968				2022-12-28	WOS:A1992HD39800017
J	HOGERZEIL, HV; BATTERSBY, A; SRDANOVIC, V; STJERNSTROM, NE				HOGERZEIL, HV; BATTERSBY, A; SRDANOVIC, V; STJERNSTROM, NE			STABILITY OF ESSENTIAL DRUGS DURING SHIPMENT TO THE TROPICS	BRITISH MEDICAL JOURNAL			English	Article							SOLID-PHASE; DECOMPOSITION; DEGRADATION; KINETICS	Objective - To determine whether present methods of international transport of essential drugs by sea adversely affect their quality. Design - Controlled longitudinal study of drug shipments sent by sea from Unicef in Copenhagen to Lagos; to Mombasa and by land to Kampala; and to Bangkok. 11 essential drugs were stored in four locations on board the ships. Setting - Main shipping routes from Unicef, Copenhagen, to tropical countries. Main outcome measures - Temperature and relative humidity in the test packs during the journey. Amount of active ingredient in the drugs before and after shipment. Results - Temperatures recorded within the test packs range from -3.5-degrees-C to 42.4-degrees-C and were 3-12-degrees-C higher than the ambient temperature. Relative humidity within the packs ranged from 20% to 88%. Differences between the locations on board were negligible. Ergometrine injection, methylergometrine injection, and retinol capsules lost 1.5-5.8% of their activity. Ampoules of ergometrine showed a large variation in the amount of active ingredient after shipment, with three of 80 samples having concentrations 60% below those stated. Ampicillin, benzylpenicillin, phenoxymethylpenicillin, and tetracycline were not affected by transport. Conclusions - Drugs were exposed to a much higher temperature and humidity than is recommended by the manufacturer, especially in tropical harbours and during inland transport. Except for ergometrine and methylergometrine the transport would not affect clinical effectiveness.	UNICEF,DIV SUPPLY,DK-2100 COPENHAGEN,DENMARK; MED PROD AGCY,CHEM LABS,S-75125 UPPSALA,SWEDEN	Medical Products Agency	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.							Abu Reid I, 1990, INT PHARM J, V4, P6; ALKER GJA, 1988, LANCET, V2, P393; [Anonymous], 1986, WHOPHARM86529; BECKER G, 1983, PHARM ZEITUNG, V15, P794; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; HOGERZEIL HV, 1991, WHODAP911; LONGLAND PW, 1987, PHARM J, P147; PAWELCZYK E, 1980, POL J PHARMACOL PHAR, V32, P47; PAWELCZYK E, 1980, POL J PHARMACOL PHAR, V32, P55; PIKAL MJ, 1977, J PHARM SCI, V66, P1312, DOI 10.1002/jps.2600660927; SMALLENBROEK H, 1983, STABILITY DRUGS TROP; YORK P, 1977, PHARMAZIE, V32, P101; 1990, WHOMCH907; 1990, ESSENTIAL DRUGS PRIC; 1990, WHO TECH REP SER, V790	15	38	39	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					210	212		10.1136/bmj.304.6821.210	http://dx.doi.org/10.1136/bmj.304.6821.210			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739795	Green Published, Bronze			2022-12-28	WOS:A1992HA98000021
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - SWIMMING - THE HAZARDS OF TAKING A DIP	BRITISH MEDICAL JOURNAL			English	Article											WALKER, A (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,LONDON W2 1NY,ENGLAND.							BALARAJAN R, 1991, BRIT MED J, V303, P144; CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; DUNLOP JM, 1991, BRIT MED J, V302, P671, DOI 10.1136/bmj.302.6778.671; HALL C, 1990, RUNNING WATER; MORRIS J, 1991, WATER B, V465, P7; PIKE EB, 1991, 2736MP WAT RES CTR D; PIKE EB, 1990, 2518MP WAT RES CTR D; WHEELER D, 1990, LAB PRACT, V39, P19; 1959, J HYGIENE, V57, P435; 1990, POLLUTION BEACHES 4T; 1991, WATER INFORMATION WA; 1991, BATHING WATER QUALIT; 1990, TOXIC BLUE GREEN ALG	13	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					242	245		10.1136/bmj.304.6821.242	http://dx.doi.org/10.1136/bmj.304.6821.242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739802	Green Published, Bronze			2022-12-28	WOS:A1992HA98000031
J	ERIKSSON, AE; BAASE, WA; WOZNIAK, JA; MATTHEWS, BW				ERIKSSON, AE; BAASE, WA; WOZNIAK, JA; MATTHEWS, BW			A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTEINS; DYNAMICS; PACKING	THE hydrophobic cores of proteins are generally well packed, with few cavities 1,2. Mutations in which a bulky buried residue such as leucine or phenylalanine is replaced with a small residue such as alanine can create cavities in the core of a protein (our unpublished results). The sizes and shapes of such cavities can vary substantially depending on factors such as local geometry, whether or not a cavity already exists at the site of substitution, and the degree to which the protein structure relaxes to occupy the space vacated by the substituted residue. We show by crystallographic and thermodynamic analysis that the cavity created by the replacement Leu 99 --> Ala in T4 lysozyme is large enough to bind benzene and that ligand binding increases the melting temperature of the protein by 6.0-degrees-C at Ph 3.0. Benzene does not, however, bind to the cavity created by the Phe 153 --> Ala replacement. The results show that cavities can be engineered in proteins and suggest that such cavities might be tailored to bind specific ligands. The binding of benzene at an internal site 7 angstrom from the molecular surface also illustrates the dynamic nature of proteins, even in crystals.	UNIV OREGON,HOWARD HUGHES MED INST,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	Howard Hughes Medical Institute; University of Oregon; University of Oregon								BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CAMPBELL ID, 1975, PROC R SOC SER B-BIO, V189, P503, DOI 10.1098/rspb.1975.0070; CONNOLLY ML, 1986, INT J PEPT PROT RES, V28, P360; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; Eisenberg H, 1976, Adv Protein Chem, V30, P101, DOI 10.1016/S0065-3233(08)60479-9; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; HERMANS J, 1961, J AM CHEM SOC, V83, P3283, DOI 10.1021/ja01476a025; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; KRETSINGER RH, 1968, J MOL BIOL, V31, P305, DOI 10.1016/0022-2836(68)90446-4; LAKOWICZ JR, 1966, BIOCHEMISTRY-US, V21, P287; LUMRY RW, 1975, C INT CNRS LEAU SYST, V246, P53; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RINGE D, 1985, PROG BIOPHYS MOL BIO, V45, P197, DOI 10.1016/0079-6107(85)90002-1; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SNYDER GH, 1976, BIOCHEMISTRY-US, V15, P2275, DOI 10.1021/bi00656a005; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059; WUTHRICH K, 1975, FEBS LETT, V50, P265, DOI 10.1016/0014-5793(75)80504-7	23	241	243	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					371	373		10.1038/355371a0	http://dx.doi.org/10.1038/355371a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731252				2022-12-28	WOS:A1992HA59100075
J	WROE, SJ; SANDERCOCK, P; BAMFORD, J; DENNIS, M; SLATTERY, J; WARLOW, C				WROE, SJ; SANDERCOCK, P; BAMFORD, J; DENNIS, M; SLATTERY, J; WARLOW, C			DIURNAL-VARIATION IN INCIDENCE OF STROKE - OXFORDSHIRE COMMUNITY STROKE PROJECT	BRITISH MEDICAL JOURNAL			English	Article							SUDDEN CARDIAC DEATH; ACUTE CEREBROVASCULAR-DISEASE; CIRCADIAN VARIATION; MYOCARDIAL-INFARCTION; ISCHEMIC STROKE; MORNING INCREASE; ONSET; FREQUENCY; REGISTRY	Objective - To determine whether diurnal variation occurs in the onset of stroke. Design - Community based study over four years. Setting - Oxfordshire, United Kingdom. Subjects - 105 000 people, of whom 675 had a first ever stroke. 545 had a cerebral infarction, 66 had primary intracerebral haemorrhage, 33 had subarachnoid haemorrhage, and in 31 the type of stroke was not known. Main outcome measures - Time of stroke and degree of activity at onset. Results - In the 578 patients for whom it was known whether onset occurred while asleep or awake, the proportion with onset during sleep was 25% (135/545) for cerebral infarction, 17% (11/66) for primary intracerebral haemorrhage, and 0% (0/33) for subarachnoid haemorrhage. This difference persisted if patients in whom it was not known whether they were asleep or awake at onset were classed as asleep. For all stroke types together there was a significant (chi-2 = 218.7, p < 0.001) diurnal variation with a morning peak between 0800 and 1000, which persisted even after allowing for strokes first noted on waking by redistributing the hour of onset through the preceding eight hours (chi-2 = 47, p < 0.001). A significant diurnal variation was also found in the onset of cerebral infarction (peak 0800-1000, chi-2 = 208.4, p < 0.001). Fewer patients had other forms of stroke and the diurnal variations for primary intracerebral haemorrhage (peak 1000-1200) and subarachnoid haemorrhage (peaks 0800-1000 and 1800-2000) were not significant. There seemed to be a second smaller peak for all types of stroke. Conclusions - All types of stroke are most likely to occur after waking in the morning. The cause of the circadian variation requires further study.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND; ST JAMES UNIV HOSP, DEPT NEUROL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	University of Edinburgh; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Saint James's University Hospital			sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				AGNOLI A, 1975, REV NEUROL, V131, P597; ALLEN CMC, 1983, Q J MED, V52, P515; ANDREOTTI F, 1988, BRIT HEART J, V59, P99; ARBOIX A, 1990, STROKE, V21, P826, DOI 10.1161/str.21.5.826a; ARGENTINO C, 1990, STROKE, V21, P387, DOI 10.1161/01.STR.21.3.387; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CAPLAN LR, 1983, STROKE, V14, P530, DOI 10.1161/01.STR.14.4.530; COLANTONIO D, 1989, AM J CARDIOL, V64, P403, DOI 10.1016/0002-9149(89)90548-1; FREEDMAN LS, 1979, J EPIDEMIOL COMMUN H, V33, P223, DOI 10.1136/jech.33.3.223; GARDNER MJ, 1989, STATISTICS CONFIDENC; HERDERSCHEE D, 1991, CEREBROVASC DIS, V1, P165, DOI 10.1159/000108835; KUBOTA K, 1987, STROKE, V18, P812, DOI 10.1161/str.18.4.812b; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MARSH EE, 1990, ARCH NEUROL-CHICAGO, V47, P1178, DOI 10.1001/archneur.1990.00530110032012; MARSHALL J, 1977, STROKE, V8, P230, DOI 10.1161/01.STR.8.2.230; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Olivares L, 1973, STROKE, V4, P773, DOI 10.1161/01.STR.4.5.773; ROCCO MB, 1987, CIRCULATION, V75, P395, DOI 10.1161/01.CIR.75.2.395; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TORVIK A, 1976, STROKE, V7, P255, DOI 10.1161/01.STR.7.3.255; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; WILLICH SN, 1989, DEUT MED WOCHENSCHR, V114, P613, DOI 10.1055/s-2008-1066644; WINDT C, 1988, J NEUROL NEUROSUR PS, V51, P109	28	117	119	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					155	157		10.1136/bmj.304.6820.155	http://dx.doi.org/10.1136/bmj.304.6820.155			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737160	Green Published, Bronze			2022-12-28	WOS:A1992HA97900021
J	HOPKINS, NFG; WOLFE, JHN				HOPKINS, NFG; WOLFE, JHN			ABC OF VASCULAR DISEASES - DEEP VENOUS INSUFFICIENCY AND OCCLUSION	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	HOPKINS, NFG (corresponding author), CRAWLEY HOSP,W SUSSEX,ENGLAND.								0	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					107	110		10.1136/bmj.304.6819.107	http://dx.doi.org/10.1136/bmj.304.6819.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737110	Bronze, Green Published			2022-12-28	WOS:A1992HA17100031
J	WITKE, W; SCHLEICHER, M; NOEGEL, AA				WITKE, W; SCHLEICHER, M; NOEGEL, AA			REDUNDANCY IN THE MICROFILAMENT SYSTEM - ABNORMAL-DEVELOPMENT OF DICTYOSTELIUM CELLS LACKING 2 F-ACTIN CROSS-LINKING PROTEINS	CELL			English	Article							MYOSIN HEAVY-CHAIN; SITE-A-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; BINDING PROTEINS; ALPHA-ACTININ; HOMOLOGOUS RECOMBINATION; CHEMOTACTIC STIMULATION; GELATION FACTOR; DISCOIDEUM; AGGREGATION	We generated by gene disruption Dictyostelium cells that lacked both the F-actin cross-linking proteins, alpha-actinin and gelation factor. Several major cell functions, such as growth, chemotaxis, phagocytosis, and pinocytosis, were apparently unaltered. However, in all double mutants, development was greatly impaired. After formation of aggregates, cells were very rarely able to form fruiting bodies. This ability was rescued when mutant and wild-type strains were mixed in a ratio of 70 to 30. The developmental program in the mutant was not arrested, since the expression pattern of early and late genes remained unchanged. Development of the mutant was rendered normal when a functional actin-actinin gene was introduced and expressed, showing the morphogenetic defect to be due to the absence of the two F-actin cross-linking proteins. These findings suggest the existence of a functional network allowing mutual complementation of certain actin-binding proteins.			WITKE, W (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.							ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BERTHOLDT G, 1985, CELL DIFFER DEV, V16, P187, DOI 10.1016/0045-6039(85)90516-0; BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BRAY D, 1989, NATURE, V338, P203, DOI 10.1038/338203a0; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; CONDEELIS J, 1981, NATURE, V292, P161; COUKELL MB, 1975, MOL GEN GENET, V142, P119, DOI 10.1007/BF00266094; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FECHHEIMER M, 1982, CELL MOTIL CYTOSKEL, V2, P287, DOI 10.1002/cm.970020308; GERISCH G, 1991, ANNU REV PHYSIOL, V53, P607, DOI 10.1146/annurev.physiol.53.1.607; GERISCH G, 1981, J CELL SCI, V52, P1; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HARRINGTON BJ, 1968, APPL MICROBIOL, V16, P106, DOI 10.1128/AEM.16.1.106-113.1968; JERMYN KA, 1991, DEVELOPMENT, V111, P779; KAY RR, 1989, DEVELOPMENT S, P81; KNECHT DA, 1988, DEV BIOL, V128, P178, DOI 10.1016/0012-1606(88)90280-1; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1033; LANGANGER G, 1983, MIKROSKOPIE, V40, P237; LODISH HF, 1982, DEV DICTYOSTELIUM DI, P325; Loomis W F, 1978, Birth Defects Orig Artic Ser, V14, P497; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MORRISSEY JH, 1984, DEV BIOL, V103, P414, DOI 10.1016/0012-1606(84)90329-4; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; NOEGEL A, 1985, EMBO J, V4, P3805, DOI 10.1002/j.1460-2075.1985.tb04151.x; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; Noegel AA, 1991, CURR OPIN CELL BIOL, V3, P18, DOI 10.1016/0955-0674(91)90161-Q; PETERS DJM, 1988, DEV BIOL, V128, P158, DOI 10.1016/0012-1606(88)90278-3; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHLEICHER M, 1988, J CELL SCI, V90, P59; SCHLEICHER M, 1988, DEV GENET, V9, P521, DOI 10.1002/dvg.1020090428; SPUDICH JA, 1989, CELL REGUL, V1, P1; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; VOGEL G, 1987, METHOD CELL BIOL, V28, P129; WALLACE JS, 1984, CELL DIFFER DEV, V14, P205, DOI 10.1016/0045-6039(84)90047-2; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; WEBER AT, 1971, DEV BIOL, V26, P606, DOI 10.1016/0012-1606(71)90143-6; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS KL, 1976, GENETICS, V82, P287; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; WITKE W, 1991, NOVEL CALCIUM BINDIN, P321; YANAGISAWA K, 1967, EXP CELL RES, V46, P328, DOI 10.1016/0014-4827(67)90070-5	58	135	137	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					53	62		10.1016/0092-8674(92)90205-Q	http://dx.doi.org/10.1016/0092-8674(92)90205-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732064				2022-12-28	WOS:A1992GZ58300008
J	LIGHT, DW				LIGHT, DW			EFFECTIVENESS AND EFFICIENCY UNDER COMPETITION - THE COCHRANE TEST	BRITISH MEDICAL JOURNAL			English	Editorial Material											LIGHT, DW (corresponding author), UNIV MED & DENT NEW JERSEY,DIV SOCIAL BEHAV MED,CAMDEN,NJ 08103, USA.							[Anonymous], 1990, SHORT CUT BETTER SER; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; GONNELLA JS, 1990, ACAD MED, V65, P314, DOI 10.1097/00001888-199005000-00012; LIGHT DW, 1990, HLTH SERVICE J, V5221, P1470; LIGHT DW, IN PRESS LANCET; LIGHT DW, 1990, HLTH SERVICE J, V5222, P1513	6	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1253	1254		10.1136/bmj.303.6812.1253	http://dx.doi.org/10.1136/bmj.303.6812.1253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747651	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200032
J	LEE, CA; PHILLIPS, AN; ELFORD, J; JANOSSY, G; GRIFFITHS, P; KERNOFF, P				LEE, CA; PHILLIPS, AN; ELFORD, J; JANOSSY, G; GRIFFITHS, P; KERNOFF, P			PROGRESSION OF HIV DISEASE IN A HEMOPHILIC COHORT FOLLOWED FOR 11 YEARS AND THE EFFECT OF TREATMENT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe the progression of HIV disease in a haemophilic cohort and to show the influence of treatment. Design - 11 year longitudinal clinical and laboratory study. Setting - A haemophilia centre. Patients - 111 patients infected with HIV during October 1979 to July 1985. Main outcome measures - Symptoms of HIV infection, AIDS, and death. Interventions - 26 asymptomatic patients started taking zidovudine or placebo (1000 mg/day) during November 1988 to February 1990; 10 patients with CD4+ counts of 0.2 x 10(9)/l started zidovudine 500 mg/day during january to November 1990. 35 patients used pentamidine for primary or secondary prophylaxis. Results - At 11 years from seroconversion the estimated rate of progression to AIDS was 42% (95% confidence interval 27% to 57%); to symptoms 85% (75% to 95%); and to death 41% (25% to 57%). Progression to AIDS was significantly faster in patients aged 25 and over than in those aged less than 25 (relative risk 5.0 (2.4 to 10.4); p < 0.00001) and in those with previous cytomegalovirus infection than in those not infected (relative risk 3.0 (1.4 to 6.8); p = 0.006). 16 of 27 (59%) patients with p24 antigenaemia developed AIDS compared with 17 of 84 (20%) patients without p24 antigen (p < 0.001). The risk of progression to AIDS before 30 November 1988 in patients with CD4+ counts less-than-or-equal-to 0.2 x 10(9)/l was higher than after November 1988 (relative risk 1.9 (0.85 to 4.43); p = 0.1). For 1989 and 1990 the observed cumulative numbers of AIDS cases (among 81 patients with sufficient CD4+ counts) were 22 and 25 compared with 29 and 37 predicted from the rate of fall of CD4+ counts up to the end of 1988 (p = 0.03). Conclusion - Treatment seems to be reducing the progression of HIV disease in this haemophilic cohort.	ROYAL FREE HAMPSTEAD & ROYAL FREE HOSP SCH MED, HAEMOSTASIS UNIT, LONDON NW3 2QG, ENGLAND	University of London; University College London	LEE, CA (corresponding author), ROYAL FREE HAMPSTEAD & ROYAL FREE HOSP SCH MED, CTR HAEMOPHILIA, LONDON NW3 2QG, ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				BARNASS S, 1989, LANCET, V2, P336; BEARD J, 1988, BRIT J HAEMATOL, V68, P303, DOI 10.1111/j.1365-2141.1988.tb04206.x; Breslow N E, 1987, IARC Sci Publ, P1; CHEINGSONGPOPOV R, 1991, BMJ-BRIT MED J, V302, P23, DOI 10.1136/bmj.302.6767.23; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JACKSON JB, 1988, TRANSFUSION, V28, P187, DOI 10.1046/j.1537-2995.1988.28288179029.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, LANCET, V335, P425, DOI 10.1016/0140-6736(90)90273-8; LEE CA, 1989, BRIT J HAEMATOL, V72, P235, DOI 10.1111/j.1365-2141.1989.tb07688.x; LEVER AML, 1987, BRIT MED J, V295, P1519, DOI 10.1136/bmj.295.6612.1519-a; LIM SG, 1990, CLIN LAB HAEMATOL, V12, P367; LIM SG, 1990, CLIN LAB HAEMATOL, V12, P237; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, IN PRESS J ACQUIR IM; POTTAGE JC, 1988, JAMA-J AM MED ASSOC, V260, P3045, DOI 10.1001/jama.260.20.3045; PROCTOR SJ, 1988, LANCET, V1, P947; RUGMAN FP, 1989, LANCET, V2, P631; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SIMONDS AK, 1989, LANCET, V2, P953; SIMONDS AK, 1990, AM REV RESPIR DIS, V141, P827, DOI 10.1164/ajrccm/141.4_Pt_1.827; SWART AM, 1990, BRIT MED J, V301, P825, DOI 10.1136/bmj.301.6756.825; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1989, LANCET, V2, P681; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	37	83	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1991	303	6810					1093	1096		10.1136/bmj.303.6810.1093	http://dx.doi.org/10.1136/bmj.303.6810.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1781870	Bronze, Green Published			2022-12-28	WOS:A1991GN20900019
J	NEWMAN, AJ; NORMAN, C				NEWMAN, AJ; NORMAN, C			U5 SNRNA INTERACTS WITH EXON SEQUENCES AT 5' AND 3' SPLICE SITES	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; COMPENSATORY BASE CHANGE; II CATALYTIC INTRONS; U1 SNRNA; U2 SNRNP; CLEAVAGE SITE; TACTAAC BOX; 2'-OME RNA; YEAST	U5 snRNA is an essential pre-mRNA splicing factor whose function remains enigmatic. Specific mutations in a conserved single-stranded loop sequence in yeast U5 snRNA can activate cleavage of G1 --> A mutant pre-mRNAs at aberrant 5' splice sites and facilitate processing of dead-end lariat intermediates to mRNA. Activation of aberrant 5' cleavage sites involves base pairing between U5 snRNA and nucleotides upstream of the cleavage site. Processing of dead-end lariat intermediates to mRNA correlates with base pairing between U5 and the first two bases in exon 2. The loop sequence in U5 snRNA may therefore be intimately involved in the transesterification reactions at 5' and 3' splice sites. This pattern of interactions is strikingly reminiscent of exon recognition events in group II self-splicing introns and is consistent with the notion that U5 snRNA may be related to a specific functional domain from a group II-like self-splicing ancestral intron.			NEWMAN, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; MICHEL F, 1987, COLD SPRING HARB SYM, V52, P201, DOI 10.1101/SQB.1987.052.01.025; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TYSTRAUSS E, 1991, GENE DEV, V5, P629; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	56	335	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					743	754		10.1016/0092-8674(92)90149-7	http://dx.doi.org/10.1016/0092-8674(92)90149-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739979				2022-12-28	WOS:A1992HF44000014
J	NEWMAN, EB; DARI, R; LIN, RT				NEWMAN, EB; DARI, R; LIN, RT			THE LEUCINE-LRP REGULON IN ESCHERICHIA-COLI - A GLOBAL RESPONSE IN SEARCH OF A RAISON DETRE	CELL			English	Review							ESCHERICHIA-COLI; PROTEIN; OPERON; LOCUS		UNIV PARIS 07,INST JACQUES MONOD,CNRS,F-75251 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	NEWMAN, EB (corresponding author), CONCORDIA UNIV,DEPT BIOL,MONTREAL H3G 1M8,QUEBEC,CANADA.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				ANDERSON JJ, 1976, J BACTERIOL, V126, P80, DOI 10.1128/JB.126.1.80-90.1976; ANDREWS JC, 1986, J BACTERIOL, V165, P434, DOI 10.1128/jb.165.2.434-442.1986; BERTIN P, 1990, BIOCHIMIE, V72, P889, DOI 10.1016/0300-9084(90)90008-5; BRAATEN BA, 1991, J BACTERIOL, V173, P1789, DOI 10.1128/jb.173.5.1789-1800.1991; BRAATEN BA, 1992, IN PRESS P NATL ACAD; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; PLATKO JV, 1990, J VACTERIOL, V172, P4529; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; RNSTING BR, 1992, IN PRESS J BACTERIOL; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SATISHCHANDRAN C, 1990, J BACTERIOL, V172, P4489, DOI 10.1128/jb.172.8.4489-4496.1990; STIRLING CJ, 1988, EMBO J, V7, P4389, DOI 10.1002/j.1460-2075.1988.tb03338.x; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685	16	101	101	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					617	619		10.1016/0092-8674(92)90135-Y	http://dx.doi.org/10.1016/0092-8674(92)90135-Y			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739970				2022-12-28	WOS:A1992HF44000002
J	HERSKOWITZ, A; WILLOUGHBY, SB; BAUGHMAN, KL; SCHULMAN, SP; BARTLETT, JD				HERSKOWITZ, A; WILLOUGHBY, SB; BAUGHMAN, KL; SCHULMAN, SP; BARTLETT, JD			CARDIOMYOPATHY ASSOCIATED WITH ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV-INFECTION - A REPORT OF 6 CASES	ANNALS OF INTERNAL MEDICINE			English	Note						HUMAN IMMUNODEFICIENCY VIRUS; CARDIOMYOPATHY, CONGESTIVE; ZIDOVUDINE; DIDEOXYINOSINE; DIDEOXYCYTIDINE	ACQUIRED IMMUNODEFICIENCY SYNDROME; HEART; VIRUS; AIDS	Dilated cardiomyopathy has been noted with increasing frequency in patients infected with the human immunodeficiency virus type 1 (HIV). The role of direct HIV cytotoxicity, coinfection with other viruses (such as coxsackievirus and cytomegalovirus), other nonviral opportunistic infections, drug hypersensitivity and toxicity, nutritional deficiencies, and autonomic dysfunction in HIV-associated cardiomyopathy is poorly understood. We describe six cases of cardiomyopathy clinically associated with antiretroviral therapy using either zidovudine, 2'-3'-dideoxyinosine (ddI) or 2'-3'-dideoxycytidine (ddC). These cases suggest that drug-induced cardiotoxicity may occur in a subgroup of HIV-infected patients treated with these structurally related nucleoside analogs.	JOHNS HOPKINS UNIV HOSP, DIV INFECT DIS, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, DIV CARDIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH PUBL HLTH, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	HERSKOWITZ, A (corresponding author), JOHNS HOPKINS UNIV, SCH HYG, DEPT IMMUNOL & INFECT DIS, 615 N WOLFE ST, ROOM 5017D, BALTIMORE, MD 21205 USA.				NCRR NIH HHS [M01-RR007722] Funding Source: Medline; NHLBI NIH HHS [R01-HL4151] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DW, 1990, HUM PATHOL, V21, P253, DOI 10.1016/0046-8177(90)90224-S; BAROLDI G, 1988, J AM COLL CARDIOL, V12, P463, DOI 10.1016/0735-1097(88)90420-2; BESCHORNER WE, 1990, AM J PATHOL, V137, P1365; COHEN IS, 1986, NEW ENGL J MED, V315, P628, DOI 10.1056/NEJM198609043151007; CORALLO S, 1988, EUR HEART J, V9, P887, DOI 10.1093/oxfordjournals.eurheartj.a062583; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S; LEWIS W, 1991, LAB INVEST, V65, P228; REILLY JM, 1988, AM J CARDIOL, V62, P789, DOI 10.1016/0002-9149(88)91223-4	9	137	137	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					311	313		10.7326/0003-4819-116-4-311	http://dx.doi.org/10.7326/0003-4819-116-4-311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733387				2022-12-28	WOS:A1992HD54600008
J	HUNTER, CP; WOOD, WB				HUNTER, CP; WOOD, WB			EVIDENCE FROM MOSAIC ANALYSIS OF THE MASCULINIZING GENE HER-1 FOR CELL-INTERACTIONS IN C-ELEGANS SEX DETERMINATION	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; POLARITY GENE; DROSOPHILA; HERMAPHRODITE; INHIBITOR; LINEAGES; NEMATODE; EVENTS	SEX in Caenorhabditis elegans is determined by a regulatory cascade of seven interacting autosomal genes controlled by three X-linked genes in response to the X chromosome-to-autosome (X/A) ratio 1,2. XX animals (high X/A) develop as self-fertile hermaphrodites, and XO animals (low X/A) develop as males. The activity of the first gene in the sex-determining cascade, her-1, is required for male sexual development 3. XO her-1 loss-of-function mutants develop as self-fertile hermaphrodites, whereas XX her-1 gain-of-function mutants develop as masculinized intersexes 4. By genetic mosaic analysis using a fused free duplication linking her-1 to a cell-autonomous marker gene, we show here that her-1 expression in a sexually dimorphic cell is neither necessary nor sufficient for that cell to adopt a male fate. Our results suggest that her-1 is expressed in many, possibly all, cells and that its gene product can function non-autonomously through cell interactions to determine male sexual development.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder								AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; Cigarroa FG, 1989, GROWTH FACTORS, V1, P179, DOI 10.3109/08977198909029127; DONIACH T, 1986, GENETICS, V114, P53; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HERMAN RK, 1976, GENETICS, V83, P91; HODGKIN J, 1984, Journal of Embryology and Experimental Morphology, V83, P103; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; HUNTER CP, 1990, THESIS U COLORADO; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; MEYER BJ, 1988, TRENDS GENET, V4, P337, DOI 10.1016/0168-9525(88)90053-4; MOHLER J, 1988, GENETICS, V120, P1061; OBRIEN SJ, 1990, GENETIC MAPS, V5; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; PATEK CE, 1991, DEVELOPMENT, V113, P311; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; SCHEDIN P, 1988, THESIS U COLORADO; SCHEDIN P, 1991, DEVELOPMENT, V112, P833; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRENT C, 1988, GENETICS, V120, P145; VILLENEUVE AM, 1990, GENETICS, V124, P91; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	32	74	80	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					551	555		10.1038/355551a0	http://dx.doi.org/10.1038/355551a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741033				2022-12-28	WOS:A1992HC52600061
J	[Anonymous]				[Anonymous]			UNIVERSITIES - DEMOCRACY A MIXED BLESSING	NATURE			English	Editorial Material																			0	0	0	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1992	355	6359					390	390						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734274				2022-12-28	WOS:A1992HB53000024
J	STJOHNSTON, D; NUSSLEINVOLHARD, C				STJOHNSTON, D; NUSSLEINVOLHARD, C			THE ORIGIN OF PATTERN AND POLARITY IN THE DROSOPHILA EMBRYO	CELL			English	Review							NF-KAPPA-B; SEGMENTATION GENE HUNCHBACK; DORSAL-VENTRAL PATTERN; MATERNAL-EFFECT MUTATIONS; RECEPTOR TYROSINE KINASE; PLATELET GLYCOPROTEIN-IB; FEMALE-STERILE MUTATIONS; DNA-BINDING SUBUNIT; WILD-TYPE CYTOPLASM; FAINT-LITTLE-BALL		MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	Max Planck Society; University of Cambridge	STJOHNSTON, D (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENDER M, 1987, DEV BIOL, V119, P418, DOI 10.1016/0012-1606(87)90046-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BROCKES J, 1991, NATURE, V350, P15, DOI 10.1038/350015a0; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GANS M, 1975, GENETICS, V81, P683; GAUL U, 1989, DEVELOPMENT, V107, P651; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HAENLIN M, 1987, EMBO J, V6, P801, DOI 10.1002/j.1460-2075.1987.tb04822.x; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IP YT, 1991, CELL, V64, P439; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; KONRAD KD, 1988, DEV BIOL, V127, P133, DOI 10.1016/0012-1606(88)90195-9; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOHLER J, 1989, EMBO J, V8, P1539, DOI 10.1002/j.1460-2075.1989.tb03538.x; MULLERHOLTKAMP F, 1985, DEV BIOL, V110, P238, DOI 10.1016/0012-1606(85)90080-6; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1983, DEV BIOL, V100, P365, DOI 10.1016/0012-1606(83)90231-2; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAPP UR, 1991, ONCOGENE, V6, P495; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUGIYAMA S, 1990, ROUX ARCH DEV BIOL, V198, P402, DOI 10.1007/BF00376159; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; VICENTE V, 1990, J BIOL CHEM, V265, P274; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITFIELD WGF, 1989, NATURE, V338, P334; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; Wilson E.B., 1906, CELL DEV INHERITANCE	146	1100	1123	4	74	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					201	219						19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733499				2022-12-28	WOS:A1992HB35300004
J	LIFTON, RP; DLUHY, RG; POWERS, M; RICH, GM; COOK, S; ULICK, S; LALOUEL, JM				LIFTON, RP; DLUHY, RG; POWERS, M; RICH, GM; COOK, S; ULICK, S; LALOUEL, JM			A CHIMERIC 11-BETA-HYDROXYLASE ALDOSTERONE SYNTHASE GENE CAUSES GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM AND HUMAN HYPERTENSION	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DNA; CLONING; IDENTIFICATION; 18-OXOCORTISOL; POLYMORPHISMS; CDNA; RNA	GLUCOCORTICOID-REMEDIABLE aldosteronism (GRA), an autosomal dominant disorder, is characterized by hypertension with variable hyperaldosteronism 1,2 and by high levels of the abnormal adrenal steroids 18-oxocortisol and 18-hydroxycortisol 3-5, which are all under control of adrenocorticotropic hormone and suppressible by glucocorticoids 6. These abnormalities could result from ectopic expression of aldosterone synthase, which is normally expressed only in adrenal glomerulosa, in the adrenal fasciculata. Genes encoding aldosterone synthase 7-9 and steroid 11-beta-hydroxylase 7 (expressed in both adrenal fasciculata and glomerulosa), which are 95% identical 7 and lie on chromosome 8q (refs 7, 10), are therefore candidate genes for GRA. Here we demonstrate complete linkage of GRA in a large kindred to a gene duplication arising from unequal crossing over, fusing the 5' regulatory region of 11-beta-hydroxylase to the coding sequences of aldosterone synthase (maximum lod score 5.23 for complete linkage, odds ratio of 170,000:1). This mutation can account for all the physiological abnormalities of GRA. Our result represents the demonstration of a mutation causing hypertension in otherwise phenotypically normal animals or humans.	BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; VET AFFAIRS HOSP,BRONX,NY 10468	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	LIFTON, RP (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,SUITE 6200,SALT LAKE CITY,UT 84132, USA.							BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; CHU MD, 1982, J BIOL CHEM, V257, P2218; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOMEZSANCHEZ CE, 1984, J CLIN ENDOCR METAB, V59, P1022, DOI 10.1210/jcem-59-5-1022; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; LIFTON RP, 1990, GENOMICS, V7, P131, DOI 10.1016/0888-7543(90)90530-8; MORNET E, 1989, J BIOL CHEM, V264, P20961; NEW MI, 1967, J CLIN ENDOCR METAB, V27, P300, DOI 10.1210/jcem-27-2-300; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PICKERING GW, 1990, HYPERTENSION PATHOPH, P18; PLATT ROBERT, 1967, P9; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; ULICK S, 1991, J STEROID BIOCHEM, V38, P59, DOI 10.1016/0960-0760(91)90401-P; ULICK S, 1990, J CLIN ENDOCR METAB, V71, P1151, DOI 10.1210/jcem-71-5-1151; ULICK S, 1983, J BIOL CHEM, V258, P5498; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436	21	929	943	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					262	265		10.1038/355262a0	http://dx.doi.org/10.1038/355262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731223				2022-12-28	WOS:A1992GZ69400071
J	MARSHALL, M; GATH, D				MARSHALL, M; GATH, D			WHAT HAPPENS TO HOMELESS MENTALLY-ILL PEOPLE - FOLLOW-UP OF RESIDENTS OF OXFORD HOSTELS FOR THE HOMELESS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives - To follow up severely mentally ill residents of hostels for the homeless to determine their social and psychiatric outcome. Design - Follow up at 18 months of hostel residents previously assessed with psychiatric and behavioural measures. Setting - Two Oxford hostels for the homeless. Subjects - 48 hostel residents previously identified as disabled by mental illness. Main outcome measures - Current housing, admissions to psychiatric hospital, violent or antisocial behaviour, and score on standardised behavioural rating. Results - 45 of the 48 residents were traced. 27 had remained in the hostels; only 10 had been rehoused, mainly in bedsits or with their families. 16 had a poor outcome as judged by death (four subjects), lengthy hospital readmission (two), marked deterioration in behaviour (six), sleeping rough (one), or disappearance (three). Conclusion - More effort is needed to provide suitable housing for homeless mentally ill people.			MARSHALL, M (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER R, 1988, SCHIZOPHRENIA BULL, V14, P97, DOI 10.1093/schbul/14.1.97; FISCHER PJ, 1986, INT J MENT HEALTH, V14, P6; LEACH J, 1979, COMMUNITY CARE MENTA; LOWRY S, 1989, BRIT MED J, V298, P209; MARSHALL M, 1989, BRIT MED J, V299, P706, DOI 10.1136/bmj.299.6701.706; PRIEST RG, 1976, BRIT J PSYCHIAT, V10, P233; TIMMS PW, 1989, HLTH TRENDS, V3, P70	7	9	9	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1992	304	6819					79	80		10.1136/bmj.304.6819.79	http://dx.doi.org/10.1136/bmj.304.6819.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737143	Green Published			2022-12-28	WOS:A1992HA17100019
J	PILGRIM, JA; STANSFELD, S; MARMOT, M				PILGRIM, JA; STANSFELD, S; MARMOT, M			LOW BLOOD-PRESSURE, LOW MOOD	BRITISH MEDICAL JOURNAL			English	Article							GENERAL HEALTH QUESTIONNAIRE; HYPERTENSION; DEPRESSION; HOSTILITY	Objective - To determine whether a set of physical symptoms is associated with low blood pressure and to investigate the possible role of psychological factors in their occurrence. Design - Analysis of data collected by questionnaire and physical screening from the first phase of the Whitehall II study, a cohort study of an employed population. Setting - 23 civil service departments in London. Subjects - 10314 male and female London based civil servants aged between 35 and 55. Main outcome measures - Symptoms of dizziness-giddiness and unexplained tiredness; psychological functioning as measured by the 30 item general health questionnaire in which the response "no more than usual" to an item about disease was scored as indicating chronic illness. Results - Dizziness-giddiness in men and unexplained tiredness in both men and women were significantly related to low systolic blood pressure. There was a highly significant inverse relation between general health questionnaire score and systolic blood pressure for both men and women, which persisted after controlling for potentially confounding variables, including age, body mass index, drug treatment, physical illness, and exercise. This association of low blood pressure with physical symptoms was no longer significant when general health questionnaire score was controlled for. Conclusions - There seems a strong relation between low systolic blood pressure and minor psychological dysfunction. Associated physical symptoms seem to be secondary to the primary disturbance in mental state.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, ACAD DEPT PSYCHIAT, LONDON, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London	PILGRIM, JA (corresponding author), UCL, UNIV COLL & MIDDLESEX SCH MED, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; COCHRANE R, 1973, J PSYCHOSOM RES, V17, P215, DOI 10.1016/0022-3999(73)90026-3; Dembroski T M, 1978, J Behav Med, V1, P159, DOI 10.1007/BF00846637; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOLDBERG EL, 1980, PSYCHOL MED, V10, P243, DOI 10.1017/S0033291700044007; GOODCHILD ME, 1985, BRIT J PSYCHIAT, V146, P55, DOI 10.1192/bjp.146.1.55; HUPPERT FA, 1988, PSYCHOL MED, V18, P1001, DOI 10.1017/S0033291700009922; MANN AH, 1977, PSYCHOL MED, V7, P653, DOI 10.1017/S0033291700006309; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; NAKAGAWARA M, 1987, PSYCHIAT RES, V21, P85, DOI 10.1016/0165-1781(87)90065-5; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; RABKIN JG, 1983, AM J PSYCHIAT, V140, P1072; ROBBINS JM, 1982, SOC SCI MED, V16, P27, DOI 10.1016/0277-9536(82)90420-8; STANSFELD S, IN PRESS PSYCHOL MED; WESSELY S, 1990, BMJ-BRIT MED J, V301, P18; 1967, RECOMMENDATIONS HUMA	16	120	121	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					75	78		10.1136/bmj.304.6819.75	http://dx.doi.org/10.1136/bmj.304.6819.75			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737142	Bronze, Green Published			2022-12-28	WOS:A1992HA17100018
J	LANDESMAN, S; WEIBLEN, B; MENDEZ, H; WILLOUGHBY, A; GOEDERT, JJ; RUBINSTEIN, A; MINKOFF, H; MOROSO, G; HOFF, R				LANDESMAN, S; WEIBLEN, B; MENDEZ, H; WILLOUGHBY, A; GOEDERT, JJ; RUBINSTEIN, A; MINKOFF, H; MOROSO, G; HOFF, R			CLINICAL UTILITY OF HIV-IGA IMMUNOBLOT ASSAY IN THE EARLY DIAGNOSIS OF PERINATAL HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INVITRO PRODUCTION; INFANTS BORN; CHILDREN; ANTIBODY; MOTHERS; RISK	Objective. - To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design. - Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting. - Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients. - Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure. - Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results. - The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100%-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9%) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62%) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77%) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion. - The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.	NIAID,DIV AIDS,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY; THEOBALD SMITH RES INST,BOSTON,MA; NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; NCI,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT PEDIAT,BROOKLYN,NY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	LANDESMAN, S (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,450 CLARKSON AVE,BOX 122,BROOKLYN,NY 11203, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD082917, R01HD025714, N01HD082913] Funding Source: NIH RePORTER; NICHD NIH HHS [N0-1-HD-8-2913, N0-1-HD-8-2917, R0-HD-25714-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMADORI A, 1988, LANCET, V1, P852; AMADORI A, 1990, PEDIATR INFECT DIS J, V9, P26, DOI 10.1097/00006454-199001000-00006; BORKOWSKY W, 1989, J PEDIATR, V114, P942; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; ESCAICH S, 1991, J ACQ IMMUN DEF SYND, V4, P130; HUSSON RN, 1990, PEDIATRICS, V86, P1; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KATZ SL, 1989, NEW ENGL J MED, V320, P1687, DOI 10.1056/NEJM198906223202509; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAURE F, 1988, LANCET, V2, P538; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MOK JQ, 1987, LANCET, V1, P1164; PALOMBA E, 1990, LANCET, V336, P940, DOI 10.1016/0140-6736(90)92310-E; PYUN KH, 1987, NEW ENGL J MED, V317, P611, DOI 10.1056/NEJM198709033171006; RAKUSAN TA, 1991, J ACQ IMMUN DEF SYND, V4, P116; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; 1991, MMWR, V40, pRR2; 1991, LANCET, V337, P253; 1987, MMWR, V36, P225; 1991, NEW ENGL J MED, V325, P73	25	67	67	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3443	3446		10.1001/jama.266.24.3443	http://dx.doi.org/10.1001/jama.266.24.3443			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744958				2022-12-28	WOS:A1991GV87800029
J	HUBBARD, SR; BISHOP, WR; KIRSCHMEIER, P; GEORGE, SJ; CRAMER, SP; HENDRICKSON, WA				HUBBARD, SR; BISHOP, WR; KIRSCHMEIER, P; GEORGE, SJ; CRAMER, SP; HENDRICKSON, WA			IDENTIFICATION AND CHARACTERIZATION OF ZINC-BINDING SITES IN PROTEIN-KINASE-C	SCIENCE			English	Article							SEQUENCE; GENE; ONCOGENE; FINGER; DOMAIN; CELLS; GAL4	Metal ion coordination in the regulatory domain of protein kinase C (PKC) is suggested by the conservation of six cysteines and two histidines in two homologous regions found therein. By monitoring x-ray fluorescence from a purified sample of rat PKC-beta-I overexpressed in insect cells, direct evidence has been obtained that PKC-beta-I tightly binds four zinc ions (Zn2+) per molecule. Extended x-ray absorption fine structure (EXAFS) data are best fit by an average Zn2+ coordination of one nitrogen and three sulfur atoms. Of the plausible Zn2+ coordination models, only those featuring nonbridged Zn2+ sites accommodate the EXAFS data and all of the conserved potential ligands.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10027 USA; SCHERING PLOUGH CORP, BLOOMFIELD, NJ 07003 USA; UNIV CALIF DAVIS, DEPT APPL SCI, DAVIS, CA 95616 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV APPL SCI, BERKELEY, CA 94720 USA	Columbia University; Merck & Company; Schering Plough Corporation; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	HUBBARD, SR (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10027 USA.			George, Simon/0000-0002-4864-5479				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BINSTEAD N, 1990, SERC DARESBURY LABOR; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; Cramer S. P., 1979, PROG INORG CHEM, V25, P1, DOI [DOI 10.1002/9780470166260.CH1, 10.1002/9780470166260.ch1]; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; CREMERS TL, 1980, ACTA CRYSTALLOGR B, V36, P3097, DOI 10.1107/S0567740880010898; DERHEYDE TPE, 1984, ACTA CRYSTALLOGR B, V40, P582; ECCLES TK, 1977, THESIS STANFORD U; Hasnain S S, 1987, Experientia Suppl, V52, P227; HASNAIN SS, 1990, SYNCHROTRON RAD BIOP, pCH4; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KING TE, 1967, METHOD ENZYMOL, V10, P634; Kitano T, 1986, Methods Enzymol, V124, P349; KOENEN M, 1988, ONCOGENE, V2, P179; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; OSADA S, 1990, J BIOL CHEM, V265, P22434; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; POVEY JF, 1990, FEBS LETT, V266, P142, DOI 10.1016/0014-5793(90)81525-S; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHEARMAN MS, 1989, METHOD ENZYMOL, V168, P347; Summers MD, 1987, MANUAL METHODS BACUL; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; WATSON AD, 1985, INORG CHEM, V24, P2820, DOI 10.1021/ic00212a024; 1987, MANUAL METHODS BACUL	37	181	181	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1776	1779						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763327				2022-12-28	WOS:A1991GW31600038
J	GODLEE, F				GODLEE, F			AIR-POLLUTION .1. FROM PEA SOUPER TO PHOTOCHEMICAL SMOG	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; BRONCHITIS; ASTHMA											[Anonymous], [No title captured]; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BRUNEKREEF B, 1989, JAPCA J AIR WASTE MA, V39, P1444, DOI 10.1080/08940630.1989.10466638; DERRIENNIC F, 1989, INT J EPIDEMIOL, V18, P186, DOI 10.1093/ije/18.1.186; FRENCH HF, 1989, STATE WORLD 1990 WOR, P100; GOREN AI, 1988, ENVIRON RES, V45, P28, DOI 10.1016/S0013-9351(88)80004-5; HATZAKIS A, 1986, INT J EPIDEMIOL, V15, P73, DOI 10.1093/ije/15.1.73; HERTZMAN C, 1990, 90 U BRIT COL HLTH P; HOLLAND WW, 1979, AM J EPIDEMIOL, V110, P525, DOI 10.1093/oxfordjournals.aje.a112836; HOLMAN C, 1989, AIR POLLUTION HLTH, P1; IMAI M, 1986, ARCH ENVIRON HEALTH, V41, P29, DOI 10.1080/00039896.1986.9935762; LAWTHER PJ, 1970, THORAX, V25, P525, DOI 10.1136/thx.25.5.525; LUNN JE, 1967, BRIT J PREV SOC MED, V21, P7; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; PONKA A, 1990, ENVIRON RES, V52, P34, DOI 10.1016/S0013-9351(05)80149-5; RUSSELL J, 1990, ENV ISSUES E EUROPE; VANDENHOUT KD, 1986, DIESEL EXHAUST AIR P; 1987, AIR QUALITY GUIDELIN; 1988, ASSESSMENT URBAN AIR; 1989, MONOGRAPHS EVALUATIO, V46	20	10	10	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1991	303	6815					1459	1461		10.1136/bmj.303.6815.1459	http://dx.doi.org/10.1136/bmj.303.6815.1459			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773157	Green Published, Bronze			2022-12-28	WOS:A1991GU38500033
J	MCIVER, B; CONNACHER, A; WHITTLE, I; BAYLIS, P; THOMPSON, C				MCIVER, B; CONNACHER, A; WHITTLE, I; BAYLIS, P; THOMPSON, C			ADIPSIC HYPOTHALAMIC DIABETES-INSIPIDUS AFTER CLIPPING OF ANTERIOR COMMUNICATING ARTERY ANEURYSM	BRITISH MEDICAL JOURNAL			English	Article							ANTI-DIURETIC HORMONE; VASOPRESSIN RELEASE; THIRST; OSMOREGULATION; HYPERNATREMIA; SECRETION; FLUID		ROYAL INFIRM,DEPT MED,EDINBURGH EM3 9YW,SCOTLAND; WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; ROYAL VICTORIA INFIRM,ENDOCRINE UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Newcastle University - UK			whittle, ian/AAX-7309-2021					BAYLIS PH, 1980, J ROY SOC MED, V73, P255, DOI 10.1177/014107688007300408; BAYLIS PH, 1984, MED INTERNE, V11, P444; DOCZI T, 1981, NEUROSURGERY, V9, P394, DOI 10.1227/00006123-198110000-00008; HAMMOND DN, 1986, NEW ENGL J MED, V315, P433, DOI 10.1056/NEJM198608143150706; MOSES AM, 1982, ADV INTERNAL MED, V27, P73; MOSES AM, 1984, NEUROHYPOPHYSIS, P115; PELMUTTER D, 1976, J NEUROSURG, V45, P259; RAMSAY DJ, 1985, VASOPRESSIN, P291; ROBERTSON GL, 1984, KIDNEY INT, V25, P460, DOI 10.1038/ki.1984.39; ROBERTSON GL, 1982, AM J MED, V72, P339, DOI 10.1016/0002-9343(82)90825-7; SPIRO SG, 1971, BRIT MED J, V3, P411, DOI 10.1136/bmj.3.5771.411; TAKAKU A, 1979, SURG NEUROL, V11, P349; THOMPSON CJ, 1986, CLIN SCI, V71, P651, DOI 10.1042/cs0710651; THOMPSON CJ, 1989, BAILLIERE CLIN ENDOC, V3, P473, DOI 10.1016/S0950-351X(89)80012-6; THOMPSON CJ, 1987, POSTGRAD MED J, V63, P979, DOI 10.1136/pgmj.63.745.979; THOMPSON CJ, 1987, QJM, V246, P853; THRASHER TN, 1989, ACTA PHYSIOL SCAND, V136, P141; WEBSTER J E, 1960, Arch Neurol, V2, P19	18	33	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1465	1467		10.1136/bmj.303.6815.1465	http://dx.doi.org/10.1136/bmj.303.6815.1465			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773159	Green Published, Bronze			2022-12-28	WOS:A1991GU38500035
J	HOPKINS, NFG; WOLFE, JHN				HOPKINS, NFG; WOLFE, JHN			ABC OF VASCULAR DISEASES - THROMBOSIS AND PULMONARY-EMBOLISM	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	HOPKINS, NFG (corresponding author), CRAWLEY HOSP,W SUSSEX,ENGLAND.							1987, SURGERY OXFORD, V1, P967	1	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1260	1262		10.1136/bmj.303.6812.1260	http://dx.doi.org/10.1136/bmj.303.6812.1260			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747655	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200036
J	MOULTON, C; PENNYCOOK, A; MAKOWER, R				MOULTON, C; PENNYCOOK, A; MAKOWER, R			RELATION BETWEEN GLASGOW COMA SCALE AND THE GAG REFLEX	BRITISH MEDICAL JOURNAL			English	Article											MOULTON, C (corresponding author), GLASGOW ROYAL INFIRM,DEPT ACCID & EMERGENCY,GLASGOW G4 0SF,SCOTLAND.							Diagnosis of brain death, 1976, BMJ-BRIT MED J, V2, P1187; PALLIS C, 1982, BRIT MED J, V285, P1641, DOI 10.1136/bmj.285.6355.1641; TEASDALE G, 1974, LANCET, V2, P81; YATES DW, 1985, LECTURE NOTES ACCIDE	4	40	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1240	1241		10.1136/bmj.303.6812.1240	http://dx.doi.org/10.1136/bmj.303.6812.1240			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747645	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200024
J	STEINBERG, MH				STEINBERG, MH			ERYTHROPOIETIN FOR ANEMIA OF RENAL-FAILURE IN SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							RECOMBINANT HUMAN ERYTHROPOIETIN; ERYTHROKINETICS; SEVERITY; TRIAL				STEINBERG, MH (corresponding author), DEPT VET AFFAIRS MED CTR,JACKSON,MS 39216, USA.			Steinberg, Martin/0000-0001-8800-8020				BROMBERG PA, 1967, J LAB CLIN MED, V70, P480; COTES PM, 1989, Q J MED, V70, P113; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; HORNE MK, 1981, AM J MED, V70, P288, DOI 10.1016/0002-9343(81)90764-6; LEIGHT L, 1954, CIRCULATION, V10, P653, DOI 10.1161/01.CIR.10.5.653; LIM VS, 1989, ANN INTERN MED, V110, P108, DOI 10.7326/0003-4819-110-2-108; SERJEANT GR, 1985, SICKLE CELL DISEASE; SHERWOOD JB, 1986, BLOOD, V67, P46; STEINBERG MH, 1984, BLOOD, V63, P1353; STEINBERG MH, 1977, AM J HEMATOL, V2, P17, DOI 10.1002/ajh.2830020103	10	45	46	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1369	1370						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	1759999				2022-12-28	WOS:A1991FK18600019
J	POWELL, AC; GOLD, MR; BROOKS, R; GARAN, H; RUSKIN, JN; MCGOVERN, BA				POWELL, AC; GOLD, MR; BROOKS, R; GARAN, H; RUSKIN, JN; MCGOVERN, BA			ELECTROPHYSIOLOGIC RESPONSE TO MORICIZINE IN PATIENTS WITH SUSTAINED VENTRICULAR ARRHYTHMIAS	ANNALS OF INTERNAL MEDICINE			English	Article							CONGESTIVE HEART-FAILURE; LONG-TERM; ETHMOZINE; EFFICACY; HCL; TACHYCARDIA; SAFETY; DRUG; TACHYARRHYTHMIAS; FLECAINIDE	Objective: To assess the short-term efficacy and safety of moricizine in patients receiving electrophysiologically guided therapy for sustained ventricular arrhythmias refractory to treatment with class IA antiarrhythmic agents. Design: Uncontrolled clinical trial. Setting: Referral-based teaching medical center. Patients: Twenty-one patients (18 of whom had coronary artery disease) with a mean left ventricular ejection fraction of 32% +/- 11% who presented with sustained ventricular tachycardia (13 patients), syncope (4 patients), or cardiac arrest (4 patients). Interventions: Moricizine, 743 +/- 85 mg daily. Measurements: Electrophysiologic testing in the drug-free state and after administration of moricizine unless sustained arrhythmias occurred. Main Results: Sustained ventricular tachycardia was inducible in the absence of antiarrhythmic drugs in 20 patients and was not suppressed by moricizine in any patient. Four patients had six episodes of spontaneous ventricular tachycardia while receiving moricizine. A probable proarrhythmic response occurred in four patients. Conclusion: In patients with compromised left ventricular function caused by coronary artery disease in whom class IA antiarrhythmics were ineffective, moricizine was ineffective in suppressing sustained ventricular arrhythmias and resulted in proarrhythmic effects in some patients.	MASSACHUSETTS GEN HOSP, CARDIAC ARRHYTHMIA SERV, 32 FRUIT ST, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital								[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, AM J CARDIOL, V61, P501; BIGGER JT, 1990, AM J CARDIOL, V65, pD15; COOPER MJ, 1988, J AM COLL CARDIOL, V11, P101, DOI 10.1016/0735-1097(88)90174-X; GRITSENKO AN, 1971, CHEM PHARM J, V6, P17; HERRE JM, 1990, ANN INTERN MED, V113, P671, DOI 10.7326/0003-4819-113-9-671; HESSION MJ, 1987, AM J CARDIOL, V60, pF59; HOROWITZ LN, 1990, AM J CARDIOL, V65, pD41; KAVERINA NV, 1972, FARMAKOL TOKSIKOL, V35, P182; KENNEDY HL, 1990, AM J CARDIOL, V65, pD47; KUCHAR DL, 1988, J AM COLL CARDIOL, V12, P982, DOI 10.1016/0735-1097(88)90465-2; MCPHERSON CA, 1985, AM J CARDIOL, V55, P689, DOI 10.1016/0002-9149(85)90138-9; MORGANROTH J, 1986, J AM COLL CARDIOL, V8, P607, DOI 10.1016/S0735-1097(86)80190-5; MORGANROTH J, 1984, AM J CARDIOL, V53, pB89, DOI 10.1016/0002-9149(84)90509-5; MORGANROTH J, 1979, AM HEART J, V98, P621, DOI 10.1016/0002-8703(79)90288-6; MORGANROTH J, 1989, AM J CARDIOL, V63, P172, DOI 10.1016/0002-9149(89)90280-4; PODRID PJ, 1990, AM J CARDIOL, V65, pD56; PODRID PJ, 1980, CIRCULATION, V61, P450, DOI 10.1161/01.CIR.61.2.450; PRATT CM, 1987, AM J CARDIOL, V60, pF73; PRATT CM, 1984, CIRCULATION, V69, P288, DOI 10.1161/01.CIR.69.2.288; PRATT CM, 1983, AM HEART J, V106, P85, DOI 10.1016/0002-8703(83)90444-1; PRATT CM, 1990, AM HEART J, V119, P1, DOI 10.1016/S0002-8703(05)80073-0; PRATT CM, 1986, CIRCULATION, V73, P718, DOI 10.1161/01.CIR.73.4.718; PRATT CM, 1990, AM J CARDIOL, V65, pD51; SLATER W, 1988, AM J CARDIOL, V61, P349, DOI 10.1016/0002-9149(88)90943-5; SMETNEV AS, 1987, AM J CARDIOL, V60, pF40; SOYKA LF, 1986, AM J CARDIOL, V58, pC96, DOI 10.1016/0002-9149(86)90111-6; STAVENS CS, 1985, AM HEART J, V110, P24, DOI 10.1016/0002-8703(85)90509-5; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WOOSLEY RL, 1987, AM J CARDIOL, V60, pF35; WYNDHAM CRC, 1987, AM J CARDIOL, V60, pF67	31	10	10	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					382	387		10.7326/0003-4819-116-5-382	http://dx.doi.org/10.7326/0003-4819-116-5-382			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736771				2022-12-28	WOS:A1992HF26800006
J	GRIFFIN, JE; FLIER, J; ORAHILLY, S; FEDERMAN, D				GRIFFIN, JE; FLIER, J; ORAHILLY, S; FEDERMAN, D			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - ANDROGEN RESISTANCE - THE CLINICAL AND MOLECULAR-SPECTRUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INCOMPLETE MALE PSEUDOHERMAPHRODITISM; RECEPTOR GENE; 5-ALPHA-REDUCTASE DEFICIENCY; DIHYDROTESTOSTERONE BINDING; TESTICULAR FEMINIZATION; QUALITATIVE ABNORMALITY; PREMATURE TERMINATION; SKIN FIBROBLASTS; POINT MUTATION; INFERTILE MEN				GRIFFIN, JE (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Flier, jeffrey/AAG-6223-2019; O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449	NIDDK NIH HHS [DK03892] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIMAN J, 1979, NEW ENGL J MED, V300, P223, DOI 10.1056/NEJM197902013000503; AIMAN J, 1982, J CLIN ENDOCR METAB, V54, P725, DOI 10.1210/jcem-54-4-725; AMRHEIN JA, 1976, P NATL ACAD SCI USA, V73, P891, DOI 10.1073/pnas.73.3.891; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; [Anonymous], METABOLIC BASIS INHE; BOYAR RM, 1978, J CLIN ENDOCR METAB, V47, P1116, DOI 10.1210/jcem-47-5-1116; BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; BROWN TR, 1988, P NATL ACAD SCI USA, V85, P8151, DOI 10.1073/pnas.85.21.8151; BROWN TR, 1982, J CLIN ENDOCR METAB, V55, P61, DOI 10.1210/jcem-55-1-61; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CHANG YT, 1991, 73RD ANN M END SOC W, P37; DEBELLIS A, 1991, 73RD ANN M END SOC W, P316; DONAHOE PK, 1987, RECENT PROG HORM RES, V43, P431; GEORGE FW, 1989, ENDOCRINOLOGY, V125, P2434, DOI 10.1210/endo-125-5-2434; GRIFFIN JE, 1982, J CLIN ENDOCR METAB, V55, P465, DOI 10.1210/jcem-55-3-465; GRIFFIN JE, 1992, WILLIAMS TXB ENDOCRI, P799; GRINO PB, 1989, J CLIN ENDOCR METAB, V68, P578, DOI 10.1210/jcem-68-3-578; GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; GRINO PB, 1988, J CLIN ENDOCR METAB, V66, P754, DOI 10.1210/jcem-66-4-754; IMPERATOMCGINLEY J, 1979, NEW ENGL J MED, V300, P1233, DOI 10.1056/NEJM197905313002201; JOHNSON L, 1986, J CLIN ENDOCR METAB, V63, P1091, DOI 10.1210/jcem-63-5-1091; KEENAN BS, 1974, J CLIN ENDOCR METAB, V38, P1143, DOI 10.1210/jcem-38-6-1143; KOVACS WJ, 1983, ENDOCRINOLOGY, V113, P1574, DOI 10.1210/endo-113-5-1574; LESHIN M, 1978, J CLIN INVEST, V62, P685, DOI 10.1172/JCI109176; LUBAHN DB, 1990, P NATL ACAD SCI USA, V87, P4411; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MACDONALD PC, 1979, J CLIN ENDOCR METAB, V49, P905, DOI 10.1210/jcem-49-6-905; MADDEN JD, 1975, J CLIN ENDOCR METAB, V41, P751, DOI 10.1210/jcem-41-4-751; MARCELLI M, 1990, J CLIN INVEST, V85, P1522, DOI 10.1172/JCI114599; MARCELLI M, 1991, J CLIN ENDOCR METAB, V73, P318, DOI 10.1210/jcem-73-2-318; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; MCCLEAN HE, 1990, 1990 END SOC AUSTR P, P33; MCPHAUL MJ, 1991, J CLIN INVEST, V87, P1413, DOI 10.1172/JCI115147; MOORE RJ, 1979, J CLIN INVEST, V63, P351, DOI 10.1172/JCI109310; MORRIS JM, 1953, AM J OBSTET GYNECOL, V65, P1192, DOI 10.1016/0002-9378(53)90359-7; MORROW AF, 1987, J CLIN ENDOCR METAB, V64, P1115, DOI 10.1210/jcem-64-6-1115; NOWAKOWSKI H, 1961, RECENT PROG HORM RES, V17, P53; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PETERSON RE, 1977, AM J MED, V62, P170, DOI 10.1016/0002-9343(77)90313-8; PINSKY L, 1989, American Journal of Human Genetics, V45, pA212; PRICE P, 1984, J CLIN INVEST, V74, P1496, DOI 10.1172/JCI111563; QUIGLEY CA, 1990, 72ND ANN M END SOC A, P223; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RISSTALPERS C, 1990, P NATL ACAD SCI USA, V87, P7866, DOI 10.1073/pnas.87.20.7866; ROSS G T, 1985, P206; SAI T, 1990, AM J HUM GENET, V46, P1095; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806; WALSH PC, 1979, NEW ENGL J MED, V300, P253, DOI 10.1056/NEJM197902013000510; WIEACKER P, 1987, HUM GENET, V76, P248; WILBERT DM, 1983, J CLIN ENDOCR METAB, V56, P113, DOI 10.1210/jcem-56-1-113; WILKINS L, 1957, DIAGNOSIS TREATMENT, P258; Wilson J D, 1980, Adv Intern Med, V25, P1; WILSON JD, 1973, ENDOCRINOLOGY, V92, P1182, DOI 10.1210/endo-92-4-1182; WILSON JD, 1974, NEW ENGL J MED, V290, P1097, DOI 10.1056/NEJM197405162902001; WILSON JD, 1975, HDB PHYSL 7, V5, P491; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZOPPI S, 1991, 73RD ANN M END SOC W, P94	64	186	190	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					611	618						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734252				2022-12-28	WOS:A1992HF63300006
J	LOPEZZENO, JA; PEACEMAN, AM; ADASHEK, JA; SOCOL, ML				LOPEZZENO, JA; PEACEMAN, AM; ADASHEK, JA; SOCOL, ML			A CONTROLLED TRIAL OF A PROGRAM FOR THE ACTIVE MANAGEMENT OF LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CESAREAN-SECTION RATE; BIRTH-RATE	Background. Over the past two decades, the rate of cesarean section in the United States has risen from 5 percent to 25 percent of deliveries, primarily because of the increased frequency of dystocia (arrest of labor). One strategy that has been proposed for increasing the rate of vaginal delivery is a program of active management of labor that encourages early amniotomy, early diagnosis of slow progress in labor, and the use of higher than usual doses of oxytocin; the efficacy and safety of this approach are uncertain, however. Methods. We conducted a randomized trial in which nulliparous women in spontaneous labor at term were randomly assigned to either active management of labor or traditional management. With active management, amniotomy was performed within one hour of the diagnosis of labor, and when the rate of cervical dilation was less than 1 cm per hour, oxytocin was infused at an initial rate of 6 mU per minute. The dose was increased by 6 mU per minute every 15 minutes (to a maximum of 36 mU per minute) until there were seven contractions every 15 minutes. Results. For the women assigned to active management (n = 351), the cesarean-section rate was 10.5 percent, as compared with 14.1 percent for those assigned to traditional management (n = 354, P = 0.18). The 26 percent reduction in the cesarean-section rate was due primarily to a decrease in dystocia. After we controlled for potential confounding variables, the reduction in the rate of delivery by cesarean section was statistically significant (odds ratio for women given active as compared with traditional management, 0.57; 95 percent confidence interval, 0.36 to 0.95). With active management, the average length of labor was shortened by 1.66 hours, principally because of earlier amniotomy and earlier use of oxytocin. There was no increase in maternal or neonatal morbidity, and there were significantly fewer infectious complications in the mothers. Conclusions. The program we studied for the active management of labor reduces the incidence of dystocia and increases the rate of vaginal delivery without increasing maternal or neonatal morbidity.	NORTHWESTERN UNIV,NW MEM HOSP,SCH MED,DEPT OBSTET & GYNECOL,MATERNAL FETAL MED SECT,CHICAGO,IL 60611	Northwestern Memorial Hospital; Northwestern University				Peaceman, Alan/0000-0002-4515-4850				AKOURY HA, 1988, AM J OBSTET GYNECOL, V158, P255, DOI 10.1016/0002-9378(88)90133-0; BOTTOMS SF, 1980, NEW ENGL J MED, V302, P559, DOI 10.1056/NEJM198003063021006; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; KENNELL J, 1991, JAMA-J AM MED ASSOC, V265, P2197, DOI 10.1001/jama.265.17.2197; LEVENO KJ, 1985, AM J OBSTET GYNECOL, V153, P838, DOI 10.1016/0002-9378(85)90686-6; NEUHOFF D, 1989, OBSTET GYNECOL, V73, P915; ODRISCOLL K, 1984, OBSTET GYNECOL, V63, P485; ODRISCOLL K, 1969, BMJ-BRIT MED J, V2, P477, DOI 10.1136/bmj.2.5655.477; STANLEY FJ, 1988, AM J OBSTET GYNECOL, V158, P89, DOI 10.1016/0002-9378(88)90784-3; TAFFEL SM, 1990, NEW ENGL J MED, V323, P199; THORP JA, 1988, AM J OBSTET GYNECOL, V159, P670, DOI 10.1016/S0002-9378(88)80032-2; TURNER MJ, 1988, OBSTET GYNECOL, V71, P150	12	175	182	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					450	454		10.1056/NEJM199202133260705	http://dx.doi.org/10.1056/NEJM199202133260705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732771				2022-12-28	WOS:A1992HD16400005
J	RISCH, NJ; DEVLIN, B				RISCH, NJ; DEVLIN, B			ON THE PROBABILITY OF MATCHING DNA FINGERPRINTS	SCIENCE			English	Article							LOCI	Forensic scientists commonly assume that DNA fingerprint patterns are infrequent in the general population and that genotypes are independent across loci. To test these assumptions, the number of matching DNA patterns in two large databases from the Federal Bureau of Investigation (FBI) and from Lifecodes was determined. No deviation from independence across loci in either database was apparent. For the Lifecodes database, the probability of a three-locus match ranges from 1 in 6,233 in Caucasians to 1 in 119,889 in Blacks. When considering all trios of five loci in the FBI database, there was only a single match observed out of more than 7.6 million comparisons. If independence is assumed, the probability of a five-locus match ranged from 1.32 x 10(-12) in Southeast Hispanics to 5.59 x 10(-14) in Blacks, implying that the minimum number of possible patterns for each ethnic group is several orders of magnitude greater than their corresponding population sizes in the United States. The most common five-locus pattern can have a frequency no greater than about 10(-6). Hence, individual five-locus DNA profiles are extremely uncommon, if not unique.	YALE UNIV,DEPT GENET,NEW HAVEN,CT 06510	Yale University	RISCH, NJ (corresponding author), YALE UNIV,DEPT EPIDEMIOL & BIOSTAT,DIV BIOSTAT,POB 3333,60 COLL ST,NEW HAVEN,CT 06510, USA.				NATIONAL CANCER INSTITUTE [R01CA045052] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NCI NIH HHS [CA45052] Funding Source: Medline; NHGRI NIH HHS [HG00348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BALAZS I, 1989, AM J HUM GENET, V44, P182; BUDOWLE B, 1991, AM J HUM GENET, V48, P841; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; COHEN JE, 1991, SCIENCE, V253, P1037, DOI 10.1126/science.1887220; COHEN JE, 1990, AM J HUM GENET, V46, P358; DEVLIN B, 1990, SCIENCE, V249, P1416, DOI 10.1126/science.2205919; DEVLIN B, 1991, SCIENCE, V253, P1039, DOI 10.1126/science.253.5023.1039; DEVLIN B, 1991, AM J HUM GENET, V48, P662; DEVLIN B, IN PRESS J AM STAT A; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; FLINT J, 1989, HUM GENET, V83, P257, DOI 10.1007/BF00285167; GREEN P, 1991, SCIENCE, V253, P1038, DOI 10.1126/science.253.5023.1038; KIDD JR, 1991, HUM BIOL, V63, P775; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040	16	99	98	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					717	720		10.1126/science.1738844	http://dx.doi.org/10.1126/science.1738844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738844				2022-12-28	WOS:A1992HC50600038
J	COYNE, JA				COYNE, JA			GENETICS AND SPECIATION	NATURE			English	Review							REPRODUCTIVE ISOLATION; DROSOPHILA-PSEUDOOBSCURA; SEXUAL ISOLATION; POSTZYGOTIC ISOLATION; HYBRIDS; STERILITY; POPULATIONS; CHARACTER; EVOLUTION; SIMULANS				COYNE, JA (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							Barton N.H., 1989, P229; BARTON NH, 1984, ANNU REV ECOL SYST, V15, P133, DOI 10.1146/annurev.es.15.110184.001025; BARTON NH, 1981, HEREDITY, V47, P367, DOI 10.1038/hdy.1981.98; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; Butlin R., 1989, P158; CARSON HL, 1984, ANNU REV ECOL SYST, V15, P97, DOI 10.1146/annurev.es.15.110184.000525; CARSON HL, 1975, AM NAT, V109, P73; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; Coyne J.A., 1989, P180; COYNE JA, 1990, NATURE, V344, P30, DOI 10.1038/344030a0; COYNE JA, 1986, HEREDITY, V57, P243, DOI 10.1038/hdy.1986.114; COYNE JA, 1983, EVOLUTION, V37, P1101, DOI 10.1111/j.1558-5646.1983.tb00225.x; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; COYNE JA, 1989, HEREDITY, V62, P97, DOI 10.1038/hdy.1989.13; COYNE JA, 1989, EVOLUTION, V43, P362, DOI [10.2307/2409213, 10.1111/j.1558-5646.1989.tb04233.x]; COYNE JA, 1986, GENETICS, V114, P485; COYNE JA, 1991, EVOLUTION, V45, P1710, DOI [10.2307/2409792, 10.1111/j.1558-5646.1991.tb02677.x]; COYNE JA, 1989, HEREDITY, V63, P155, DOI 10.1038/hdy.1989.87; COYNE JA, 1985, GENET RES, V46, P169, DOI 10.1017/S0016672300022643; Diehl S.R., 1989, P345; Dobzhansky T, 1936, GENETICS, V21, P113; Dobzhansky T., 1937; DODD DMB, 1989, EVOLUTION, V43, P1308, DOI 10.1111/j.1558-5646.1989.tb02577.x; EHRMAN L, 1965, EVOLUTION, V19, P59; FEDER JL, 1988, NATURE, V336, P61, DOI 10.1038/336061a0; FRANK SA, 1991, EVOLUTION, V45, P262, DOI 10.1111/j.1558-5646.1991.tb04401.x; Futuyama D.J., 1989, P557; Futuyma D J, 1983, Science, V219, P1059, DOI 10.1126/science.219.4588.1059; FUTUYMA DJ, 1980, SYST ZOOL, V29, P254, DOI 10.2307/2412661; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; HANDELMAN SL, 1987, COMMUNITY DENT ORAL, V15, P1, DOI 10.1111/j.1600-0528.1987.tb00470.x; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOIKKALA A, 1984, BEHAV GENET, V14, P257, DOI 10.1007/BF01065545; HURST LD, 1991, GENETICS, V128, P841; HUTTER P, 1990, GENETICS, V124, P909; JOHNSON N, IN PRESS GENETICS; KHADEM M, 1991, HEREDITY, V67, P157, DOI 10.1038/hdy.1991.75; KILIAS G, 1980, EVOLUTION, V34, P730, DOI 10.1111/j.1558-5646.1980.tb04012.x; KYRIACOU CP, 1982, ANIM BEHAV, V30, P794, DOI 10.1016/S0003-3472(82)80152-8; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LANDE R, 1982, EVOLUTION, V36, P213, DOI 10.1111/j.1558-5646.1982.tb05034.x; LANDER ES, 1989, GENETICS, V121, P185; LEWIS WH, 1979, POLYPLOIDY BIOL RELE; MACNAIR MR, 1983, HEREDITY, V50, P295, DOI 10.1038/hdy.1983.31; Margulis Lynn, 1991, SYMBIOSISOURCE EVO, P1; Mayr E., 1963, ANIMAL SPECIES EVOLU; Mayr E, 1942, SYSTEMATICS ORIGIN S; Muller HJ, 1942, BIOL S, V6, P71; NAVIERA H, 1991, HEREDITY, V66, P233; NEL M, 1972, AM NAT, V106, P282; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; ORR HA, 1991, EVOLUTION, V45, P764, DOI 10.1111/j.1558-5646.1991.tb04345.x; ORR HA, 1989, GENETICS, V121, P527; ORR HA, 1989, EVOLUTION, V43, P180, DOI 10.1111/j.1558-5646.1989.tb04216.x; ORR HA, 1989, HEREDITY, V63, P231, DOI 10.1038/hdy.1989.96; ORR HA, 1987, GENETICS, V116, P555; ORR HA, IN PRESS GENET RES; Pontecorvo G, 1943, J GENET, V45, P51, DOI 10.1007/BF02982774; POWELL JR, 1978, EVOLUTION, V32, P465, DOI 10.1111/j.1558-5646.1978.tb04589.x; PRAKASH S, 1972, GENETICS, V72, P143; Rice WR, 1987, EVOL ECOL, V1, P301, DOI 10.1007/BF02071555; RICE WR, 1990, EVOLUTION, V44, P1140, DOI 10.1111/j.1558-5646.1990.tb05221.x; RICE WR, 1984, EVOLUTION, V38, P1251, DOI 10.1111/j.1558-5646.1984.tb05647.x; RINGO J, 1985, AM NAT, V126, P642, DOI 10.1086/284445; ROELOFS W, 1987, P NATL ACAD SCI USA, V84, P7585, DOI 10.1073/pnas.84.21.7585; ROSE MR, 1983, SCIENCE, V220, P157, DOI 10.1126/science.220.4593.157; SPENCER HG, 1986, AM NAT, V128, P241, DOI 10.1086/284557; SUBBARAO SK, RECENT DEV GENETICS, P313; SZYMURA JM, 1991, EVOLUTION, V45, P237, DOI 10.1111/j.1558-5646.1991.tb04400.x; Tauber C.A., 1989, P307; TEMPLETON AR, 1980, GENETICS, V94, P1011; TEMPLETON AR, 1977, EVOLUTION, V31, P630, DOI 10.1111/j.1558-5646.1977.tb01052.x; WASSERMAN M, 1977, EVOLUTION, V31, P812, DOI 10.1111/j.1558-5646.1977.tb01073.x; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; White M.J.D., 1978, MODES SPECIATION; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; ZOUROS E, 1981, GENETICS, V97, P703	77	609	624	7	149	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					511	515		10.1038/355511a0	http://dx.doi.org/10.1038/355511a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741030				2022-12-28	WOS:A1992HC52600046
J	MACDOUGALL, IC; CAVILL, I; HULME, B; BAIN, B; MCGREGOR, E; MCKAY, P; SANDERS, E; COLES, GA; WILLIAMS, JD				MACDOUGALL, IC; CAVILL, I; HULME, B; BAIN, B; MCGREGOR, E; MCKAY, P; SANDERS, E; COLES, GA; WILLIAMS, JD			DETECTION OF FUNCTIONAL IRON-DEFICIENCY DURING ERYTHROPOIETIN TREATMENT - A NEW APPROACH	BRITISH MEDICAL JOURNAL			English	Article							ANEMIA		CARDIFF ROYAL INFIRM,DEPT NEPHROL,CARDIFF CF2 1SZ,S GLAM,WALES; CARDIFF ROYAL INFIRM,DEPT HAEMATOL,CARDIFF CF2 1SZ,S GLAM,WALES; ST MARYS HOSP,HAEMATOL,LONDON,ENGLAND; W WALES GEN HOSP,CARMARTHEN,WALES; UNIV HOSP WALES,CARDIFF,WALES; WESTERN INFIRM & ASSOCIATED HOSP,NEPHROL,GLASGOW G11 6NT,SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP,HAEMATOL,GLASGOW G11 6NT,SCOTLAND	Cardiff Royal Infirmary; Cardiff Royal Infirmary; Imperial College London; Cardiff University								CAVILL I, 1982, CLIN HAEMATOL, V2, P259; ESCHBACH JW, 1989, CONTRIB NEPHROL, V76, P160; MACDOUGALL IC, 1989, BRIT MED J, V299, P157, DOI 10.1136/bmj.299.6692.157; MOREB J, 1983, NEPHRON, V35, P196, DOI 10.1159/000183074; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43	5	237	240	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					225	226		10.1136/bmj.304.6821.225	http://dx.doi.org/10.1136/bmj.304.6821.225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739797	Bronze, Green Published			2022-12-28	WOS:A1992HA98000025
J	TSE, A; HILLE, B				TSE, A; HILLE, B			GNRH-INDUCED CA2+ OSCILLATIONS AND RHYTHMIC HYPERPOLARIZATIONS OF PITUITARY GONADOTROPES	SCIENCE			English	Article							MEMBRANE CURRENTS; CA-2+ TRANSIENTS; K+ CHANNELS; LH-RELEASE; HORMONE; RAT; CELLS	Secretion of gonadotropic hormones from pituitary gonadotropes in response to gonadotropin-releasing hormone (GnRH) is essential for regulation of reproductive potential. Gonadotropes from male rats exhibited an unusual form of cellular excitation that resulted from periodic membrane hyperpolarization. GnRH induced an oscillatory release of intracellular Ca2+ via a guanosine triphosphate (GTP) binding protein-coupled phosphoinositide pathway and hyperpolarized the gonadotrope periodically by opening apamin-sensitive Ca2+-activated K+ (SK) channels. Each hyperpolarization was terminated by firing of a few action potentials that may result from removal of inactivation from voltage-gated Na+ and Ca2+ channels.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Tse, Amy/C-3142-2013	Tse, Amy/0000-0002-0847-7466				BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOSMA MM, UNPUB; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHEN C, 1989, NEUROCHEM INT, V15, P265, DOI 10.1016/0197-0186(89)90132-0; CROXTON TL, 1988, ENDOCRINOLOGY, V123, P1783, DOI 10.1210/endo-123-4-1783; CROXTON TL, 1989, METHOD ENZYMOL, V168, P145; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; MASON WT, 1985, NEUROENDOCRINOLOGY, V41, P258, DOI 10.1159/000124186; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NUSSINOVITCH I, 1988, J PHYSIOL-LONDON, V395, P303, DOI 10.1113/jphysiol.1988.sp016920; PALADE P, 1989, MOL PHARMACOL, V36, P673; PFAFFINGER P, 1988, J NEUROSCI, V8, P3343; PFAFFINGER PJ, 1988, NEURON, V1, P477, DOI 10.1016/0896-6273(88)90178-X; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; POULSEN JH, 1976, NATURE, V263, P156, DOI 10.1038/263156a0; RIVIER JE, 1978, LIFE SCI, V23, P869, DOI 10.1016/0024-3205(78)90522-2; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; SMITH CE, 1987, FEBS LETT, V225, P247, DOI 10.1016/0014-5793(87)81167-5; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STOJILKOVIC SS, 1990, P NATL ACAD SCI USA, V87, P8855, DOI 10.1073/pnas.87.22.8855; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, UNPUB	28	163	164	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					462	464		10.1126/science.1734523	http://dx.doi.org/10.1126/science.1734523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734523				2022-12-28	WOS:A1992HA59000040
J	WARBURG, A; MILLER, LH				WARBURG, A; MILLER, LH			SPOROGONIC DEVELOPMENT OF A MALARIA PARASITE INVITRO	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; PLASMODIUM; MOSQUITO; CULTURE	The sporogonic cycle of the avian malaria parasite Plasmodium gallinaceum was completed in vitro. Ookinetes (motile zygotes) were seeded onto a murine basement membrane-like gel (Matrigel) in coculture with Drosophila melanogaster cells (Schneider's L2). Transformation into oocysts as well as subsequent growth and differentiation were observed in parasites attached to Matrigel and depended on the presence of L2 cells. Sporozoites were first observed on day 10 in culture. Specific circumsporozoite protein antigenicity was identified in mature oocysts and in sporozoites. It is now possible to follow the entire life cycle of Plasmodium in vitro.			WARBURG, A (corresponding author), NIAID,PARASIT DIS LAB,MALARIA SECT,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.		Warburg, Alon/ABE-9946-2020	Warburg, Alon/0000-0001-7929-3114				CHAO J, 1964, AM J TROP MED HYG, V13, P181, DOI 10.4269/ajtmh.1964.13.181; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; HOLLINGDALE MR, 1987, IN VITRO METHODS PAR, P180; KAUSHAL DC, 1983, MOL BIOCHEM PARASIT, V8, P53, DOI 10.1016/0166-6851(83)90034-8; KLEINMAN HK, 1987, ANAL BIOCHEM, V166, P1, DOI 10.1016/0003-2697(87)90538-0; KLEINMAN HK, IN PRESS CELLULAR AS; KRETTLI AU, 1988, PARASITE IMMUNOL, V10, P523, DOI 10.1111/j.1365-3024.1988.tb00240.x; LUNSTRUM GP, 1988, J BIOL CHEM, V263, P18318; MELHORN H, 1980, PROTISTOLOGICA, V16, P135; MONS B, 1990, PARASITOL TODAY, V6, P3, DOI 10.1016/0169-4758(90)90377-G; PONNUDURAI T, 1987, IN VITRO METHODS PAR, P153; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEIDER I, 1980, MALARIA, V2, P235; SINDEN RE, 1984, EXPERIENTIA, V40, P1330, DOI 10.1007/BF01951886; SINDEN RE, 1985, PARASITOLOGY, V91, P227, DOI 10.1017/S0031182000057334; TERZAKIS JA, 1967, J CELL BIOL, V34, P311, DOI 10.1083/jcb.34.1.311; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERBERG JP, 1977, B WORLD HEALTH ORGAN, V55, P377; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; WARBURG A, UNPUB; 1963, AM TYPE CULTURE COLL	21	59	64	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					448	450		10.1126/science.1734521	http://dx.doi.org/10.1126/science.1734521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734521				2022-12-28	WOS:A1992HA59000035
J	AMOS, A; BOSTOCK, Y				AMOS, A; BOSTOCK, Y			FOR DEBATE - POLICY ON CIGARETTE ADVERTISING AND COVERAGE OF SMOKING AND HEALTH IN EUROPEAN WOMENS MAGAZINES	BRITISH MEDICAL JOURNAL			English	Article											AMOS, A (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							AITKEN PP, 1990, BRIT J ADDICT, V85, P399; AITKEN PP, 1991, BRIT J ADDICT, V86, P383; AITKEN PP, 1987, BRIT J ADDICT, V82, P615; Amos A, 1990, World Health Forum, V11, P416; AMOS A, 1991, LANCET, V337, P93, DOI 10.1016/0140-6736(91)90747-D; AMOS A, 1991, HLTH ED J, V50, P26; AMOS A, 1991, PUTTING WOMEN PICTUR; BAAM R, 1990, ROKEN WELBESCHOUWD; CHAPMAN S, 1982, AM J PUBLIC HEALTH, V72, P491, DOI 10.2105/AJPH.72.5.491; Charlton A., 1986, HLTH ED J, V45, P75; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; EARNSTER VL, 1985, NY STATE J MED, V85, P335; GODDARD E, 1990, SMOKING SECONDARY SC; GODDARD E, 1987, SMOKING SECONDARY SC; JACOBSON B, 1988, BEATING LADYKILLERS; JACOBSON B, 1985, SMOKE GETS YOUR EYES; LOCK S, 1990, BRIT MED J, V301, P1405, DOI 10.1136/bmj.301.6766.1405; NUTBEAM D, 1988, PLANNING SMOKE FREE; ROGERS D, 1987, TOBACCO REPORTER FEB, P8; WARNER KE, 1985, NEW ENGL J MED, V312, P384, DOI 10.1056/NEJM198502073120627; WARNER KE, 1990, 7TH P WORLD C TOB HL, P765; 1990, IT CAN BE DONE SMOKE; 1983, TOBACCO REPORTER APR, P44; 1989, NATIONAL READERSHIP; 1987, EUROPE CANCER SURVEY; 1987, SMOKE FREE EUROPE 5; 1986, SCOTTISH HLTH STATIS; 1989, HLTH TOBACCO; 1989, SMOKING WISH STOP FI	29	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					99	101		10.1136/bmj.304.6819.99	http://dx.doi.org/10.1136/bmj.304.6819.99			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA171	1737152	Green Published, Bronze			2022-12-28	WOS:A1992HA17100028
J	RAZAY, G; HEATON, KW; BOLTON, CH; HUGHES, AO				RAZAY, G; HEATON, KW; BOLTON, CH; HUGHES, AO			ALCOHOL-CONSUMPTION AND ITS RELATION TO CARDIOVASCULAR RISK-FACTORS IN BRITISH WOMEN	BRITISH MEDICAL JOURNAL			English	Article							DENSITY-LIPOPROTEIN SUBFRACTIONS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CHOLESTEROL; MORTALITY; ETHANOL; SMOKING; GLUCOSE; LIPIDS; MEN	Objective - To examine the relation between alcohol consumption and risk factors for coronary heart disease in women. Design - Cross sectional study of a stratified random sample of the population grouped into five categories of habitual alcohol consumption. Setting - People registered with general practitioners at two large health centres in east Bristol, England. Subjects - 1048 women aged 25-69 years. Main outcome measures - Fasting plasma concentrations of insulin, total cholesterol, total triglycerides, and high density lipoprotein cholesterol, including its subfractions HDL2 and HDL3, and body mass index. Results - Compared with non-drinkers women consuming a moderate amount of alcohol (1-20 g/day) had lower plasma concentrations of triglycerides, by 0.19 mmol/l (95% confidence interval 0.07 to 0.5); cholesterol, by 0.4 mmol/l (0.19 to 0.61); and insulin, by 1.4 mU/l (0.43 to 1.97) and a lower body mass index, by 1.2 kg/m2 (0.43 to 1.97). They also had higher concentrations of high density lipoprotein cholesterol, by 0-09 mmol/l (0.03 to 0.15); HDL2 cholesterol by 0.05 mmol/l (-0.02 to 0.10) and HDL3 cholesterol, by 0.06 mmol/l (0.06 to 0.11). All these were independent of body mass index, smoking habits, and taking oral contraceptives. Conclusions - Moderate alcohol consumption is associated with lower levels of cardiovascular risk factors in women. Insulin may have a central role.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND	University of Bristol	RAZAY, G (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BELFRAGE P, 1977, EUR J CLIN INVEST, V7, P127, DOI 10.1111/j.1365-2362.1977.tb01584.x; CASTELLI WP, 1977, LANCET, V2, P153; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; DIETSCHY JM, 1974, J LIPID RES, V15, P508; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; EVANS SJW, 1991, BRIT MED J, V302, P302, DOI 10.1136/bmj.302.6772.302; FEHILY AM, 1988, EUR J CLIN NUTR, V42, P405; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HENNEKENS CH, 1987, CIRCULATION, V76, P501; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; MARMOT MG, 1981, LANCET, V1, P580; METZ R, 1969, DIABETES, V18, P517, DOI 10.2337/diab.18.8.517; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MILLER NE, 1988, J EPIDEMIOL COMMUN H, V42, P220, DOI 10.1136/jech.42.3.220; OETTLE GJ, 1987, AM J CLIN NUTR, V45, P86, DOI 10.1093/ajcn/45.1.86; OHLER G, 1982, INT J OBES S1, V6, P137; PATEL DG, 1979, METABOLISM, V28, P85, DOI 10.1016/0026-0495(79)90173-2; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P121; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEINER G, 1986, AM J CARDIOL, V57, P27; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; THORNTON J, 1983, LANCET, V2, P819; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; 1989, REFERENCE MANUAL REL	33	94	95	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					80	83		10.1136/bmj.304.6819.80	http://dx.doi.org/10.1136/bmj.304.6819.80			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737144	Green Published, Bronze			2022-12-28	WOS:A1992HA17100020
J	SUMNERS, D; KELSEY, M; CHAIT, I				SUMNERS, D; KELSEY, M; CHAIT, I			PSYCHOLOGICAL-ASPECTS OF LOWER URINARY-TRACT INFECTIONS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							URETHRAL SYNDROME	Objective - To determine whether women with the urethral syndrome can be distinguished from those with urinary tract infection by case notes, clinical symptoms, or psychiatric state. Design - Longitudinal survey of consecutive women presenting with dysuria and frequency. Setting - General practice and community. Subjects - 58 patients with the urethral syndrome and 44 patients with a urinary tract infection, mean age 39.9 years. Main outcome measures - Results of analysis of serial midstream urine specimens, patients' self rated physical symptoms and responses to 60 item general health questionnaire at presentation and after resolution of symptoms, and results of psychiatric assessment with the clinical psychiatric interview. Results - 4 of 42 patients with a urinary tract infection had recently changed sexual partner compared with none of 58 with the urethral syndrome. Dysuria and nocturia were more common in patients with urinary tract infections than those with the urethral syndrome (mean (SD) score for dysuria 5-37 (2.39) v 4.57 (2.13), p < 0.05; nocturia in 39/44 (88%) patients v 40/58 (69%), chi-2 = 5.5, p < 0.02). Both groups showed transient high levels of distress which resolved with the physical symptoms, but no psychiatric difference distinguished them. Conclusion - The urethral syndrome is not associated with increased psychiatric morbidity.	WHITTINGTON HOSP,LONDON N19 5NF,ENGLAND; ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	SUMNERS, D (corresponding author), NAPSBURY HOSP,LONDON AL2 1AA,HERTS,ENGLAND.							BORCHAM P, 1984, J R SOC MED, V77, P111; BROOKS D, 1978, BACTERIOLOGICAL EXAM, P39; BRUMFITT W, 1991, BRIT MED J, V303, P1, DOI 10.1136/bmj.303.6793.1; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FINLAYJONES RA, 1979, BRIT J PSYCHIAT, V134, P609, DOI 10.1192/bjp.134.6.609; FROST D, 1981, BRIT J PSYCHIAT, V138, P292; FRY J, 1980, COMMON DISEASES THEI; GALLAGHER DJ, 1965, BMJ-BRIT MED J, V1, P622, DOI 10.1136/bmj.1.5435.622; GOLDBERG DP, 1970, BRIT J PREV SOC MED, V24, P18; Goldberg DP., 1972, DETECTION PSYCHIATRI; GRAY LA, 1956, JAMA-J AM MED ASSOC, V162, P1361, DOI 10.1001/jama.1956.02970320009003; MASON E, 1977, J IRISH MED ASSOC, V70, P335; ODOWD TC, 1984, BMJ, V288, P208; REES DLP, 1977, BRIT J UROL, V49, P651, DOI 10.1111/j.1464-410X.1977.tb04547.x; SCHMIDT RA, 1985, UROL CLIN N AM, V12, P349; SCOTTI RJ, 1984, CLIN OBSTET GYNECOL, V27, P515, DOI 10.1097/00003081-198406000-00025; WATERS WE, 1969, BR J PREV SOC MED, V23, P293; 1979, BMJ, V2, P717	18	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					17	19		10.1136/bmj.304.6818.17	http://dx.doi.org/10.1136/bmj.304.6818.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734984	Green Published, Bronze			2022-12-28	WOS:A1992GY90900026
J	LOFTUS, LS; ARNOLD, WN				LOFTUS, LS; ARNOLD, WN			VANGOGH,VINCENT ILLNESS - ACUTE INTERMITTENT PORPHYRIA	BRITISH MEDICAL JOURNAL			English	Article									UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center	LOFTUS, LS (corresponding author), UNIV MISSOURI,KANSAS CITY SCH MED,2411 HOLMES RD,KANSAS CITY,MO 64108, USA.							ARNOLD WN, 1989, SCI AM, V260, P112, DOI 10.1038/scientificamerican0689-112; ARNOLD WN, 1988, JAMA-J AM MED ASSOC, V260, P3042, DOI 10.1001/jama.260.20.3042; BICKERS DR, 1975, NEW ENGL J MED, V292, P1115, DOI 10.1056/NEJM197505222922109; GRANICK S, 1966, J BIOL CHEM, V241, P1359; HEMPHILL RE, 1961, P ROY SOC MED, V54, P1083, DOI 10.1177/003591576105401206; HULSKER J, 1990, VINCENT THEO VANGOGH; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KNUDSEN KB, 1967, NEW ENGL J MED, V277, P350, DOI 10.1056/NEJM196708172770706; Kolb L., 1982, MODERN CLIN PSYCHIAT; LAIWAH AACY, 1983, Q J MED, V52, P92; Lubin A. J., 1987, STRANGER EARTH PSYCH; MOORE MR, 1980, INT J BIOCHEM, V12, P1089, DOI 10.1016/0020-711X(80)90218-9; PETERS HA, 1986, CURRENT THERAPY NEUR, P317; STOKVIS BJ, 1889, NED TIJDSCHR GENEES, V2, P409; TRALBAUT ME, 1981, V VANGOGH; WALDENSTROM J, 1957, AM J MED, V22, P758, DOI 10.1016/0002-9343(57)90126-2; WELLAND FH, 1964, METABOLISM, V13, P232, DOI 10.1016/0026-0495(64)90103-9; WITH TK, 1980, INT J BIOCHEM, V11, P189, DOI 10.1016/0020-711X(80)90219-0; 1978, COMPLETE LETT V VANG	19	39	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1589	1591		10.1136/bmj.303.6817.1589	http://dx.doi.org/10.1136/bmj.303.6817.1589			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	GX956	1773180	Bronze, Green Published			2022-12-28	WOS:A1991GX95600012
J	WRIGHT, V				WRIGHT, V			IN DEFENSE OF EPONYMS	BRITISH MEDICAL JOURNAL			English	Article											WRIGHT, V (corresponding author), UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,ENGLAND.							[Anonymous], 1976, SERONEGATIVE POLYART; BECHTEREW VM, 1893, NEUROL ZENTRALBLAT, V12, P426; Brodie BC, 1818, PATHOLOGICAL SURGICA, P54; Crohn BB, 1932, J AMER MED ASSOC, V99, P1323, DOI 10.1001/jama.1932.02740680019005; Felty AR, 1924, B JOHNS HOPKINS HOSP, V35, P16; HUSKISSON EC, 1973, JOINT DISEASE ALL AR; KEAT AC, 1979, Q J MED, V48, P323; MARIE P, 1898, REV MED, V18, P285; MIELANTS H, 1990, Current Opinion in Rheumatology, V2, P570; Paronen I, 1948, ACTA MED SCAND  S212, V212, P1; Reiter H, 1916, DEUT MED WOCHENSCHR, V42, P1535, DOI 10.1055/s-0028-1135542; SCOTT JT, 1986, COPEMANS TXB RHEUMAT, P787; SHARP JT, ARTHRITIS ALLIED CON, P1229; Still G F, 1897, Med Chir Trans, V80, P47; Strumpell A, 1897, DTSCH Z NERVENH, V11, P338, DOI 10.1007/BF01674127; THOMPSON P, 1980, MISTER LEPROSY; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382	17	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1600	1602		10.1136/bmj.303.6817.1600	http://dx.doi.org/10.1136/bmj.303.6817.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773185	Green Published, Bronze			2022-12-28	WOS:A1991GX95600018
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - DANGERS OF OZONE DEPLETION	BRITISH MEDICAL JOURNAL			English	Article																		ELWOOD MJ, 1989, OZONE DEPLETION HLTH, P179; GILES GG, 1988, BRIT MED J, V296, P13, DOI 10.1136/bmj.296.6614.13; ISAKSEN ISA, 1989, OZONE DEPLETION HLTH, P24; Jensen O M, 1980, World Health Stat Q, V33, P2; JONES RR, 1989, OZONE DEPLETION HLTH, P214; KAR RA, 1991, SCIENCE, V252, P204; SHIEL AG, 1986, WORLD J SURG, V10, P389; VANDELEUN JC, 1989, OZONE DEPLETION HLTH; WATSON RT, 1989, OZONE DEPLETION HLTH, P51; 1987, ASSESSING RISKS RACE	10	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1326	1328		10.1136/bmj.303.6813.1326	http://dx.doi.org/10.1136/bmj.303.6813.1326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747679	Green Published, Bronze			2022-12-28	WOS:A1991GT01100029
J	LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA; TORNBERG, S				LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA; TORNBERG, S			SERUM SIALIC-ACID CONCENTRATION AND SMOKING - A POPULATION BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article									UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT GEN ONCOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; HESS EL, 1957, J CLIN INVEST, V36, P449, DOI 10.1172/JCI103442; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; 1971, VARMLAND SURVEY	5	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1306	1307		10.1136/bmj.303.6813.1306	http://dx.doi.org/10.1136/bmj.303.6813.1306			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747673	Green Published, Bronze			2022-12-28	WOS:A1991GT01100022
J	STERN, M; GEDDES, DM; COLLINS, JV; EVANS, T; GREEN, M				STERN, M; GEDDES, DM; COLLINS, JV; EVANS, T; GREEN, M			ROYAL-BROMPTON GRAND ROUNDS - UNSTABLE ASTHMA AND THEOPHYLLINE	BRITISH MEDICAL JOURNAL			English	Discussion							NOCTURNAL ASTHMA; DIURNAL-VARIATION				STERN, M (corresponding author), ROYAL BROMPTON & NATL HEART HOSP,LONDON SW3 6HP,ENGLAND.							ARKINSTALL WW, 1987, AM REV RESPIR DIS, V135, P316; BATEMAN JRM, 1975, THORAX, V30, P300; FAIRSHTER RD, 1988, AM J MED, V85, P54, DOI 10.1016/0002-9343(88)90243-4; FLING JA, 1989, ANN ALLERGY, V62, P35; HELM SG, 1987, IMMUNOL ALLERGY PRAC, V9, P414; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HOPPER GE, 1986, AM CLIN PRODUCT REV, P36; MACKAY AD, 1983, AM REV RESPIR DIS, V127, P609, DOI 10.1164/arrd.1983.127.5.609; MANNING PJ, 1987, MED SCI RES-BIOCHEM, V15, P627; MARTIN RJ, 1989, AM REV RESPIR DIS, V139, P475, DOI 10.1164/ajrccm/139.2.475; MCWILLIAMS BC, 1984, AM REV RESPIR DIS, V130, P193; PETTY TL, 1988, AM J MED, V85, P21, DOI 10.1016/0002-9343(88)90237-9; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; VATHENEN AS, 1988, LANCET, V1, P554; VAUGHAN LM, 1986, LANCET, V1, P184; WELSH PW, 1986, AM J MED, V80, P1098, DOI 10.1016/0002-9343(86)90671-6; WOODCOCK AA, 1983, LANCET, V2, P610	17	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1317	1319		10.1136/bmj.303.6813.1317	http://dx.doi.org/10.1136/bmj.303.6813.1317			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747676	Green Published, Bronze			2022-12-28	WOS:A1991GT01100026
J	TAYLOR, PR; WOLFE, JHN				TAYLOR, PR; WOLFE, JHN			ABC OF VASCULAR DISEASES - TREATING AORTIC-ANEURYSMS	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	TAYLOR, PR (corresponding author), GUYS HOSP,LONDON SE1 9RT,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1127	1129		10.1136/bmj.303.6810.1127	http://dx.doi.org/10.1136/bmj.303.6810.1127			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747586	Bronze, Green Published			2022-12-28	WOS:A1991GN20900032
J	HEIN, HA				HEIN, HA			DO WE HAVE THE INFANT-MORTALITY RATE WE DESIRE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PREGNANCY; EDUCATION; BIRTH		UNIV IOWA,COLL MED,COLL MED,IOWA STATEWIDE PERINATAL CARE PROGRAM,IOWA CITY,IA 52242	University of Iowa								BAKER SL, 1989, J RURAL HEALTH, V5, P155; FURSTENBERG FF, 1985, AM J PUBLIC HEALTH, V75, P1331, DOI 10.2105/AJPH.75.11.1331; GOLDENBERG RL, 1983, AM J OBSTET GYNECOL, V146, P450, DOI 10.1016/0002-9378(83)90827-X; GORDON RR, 1988, BMJ-BRIT MED J, V297, P774, DOI 10.1136/bmj.297.6651.774; GORTMAKER S, 1985, AM J OBSTET GYNECOL, V152, P517, DOI 10.1016/0002-9378(85)90618-0; HEIN HA, 1990, OBSTET GYNECOL, V76, P763, DOI 10.1097/00006250-199011000-00007; HOLDEN C, 1987, SCIENCE, V238, P887, DOI 10.1126/science.3672132; IAMS JD, 1988, AM J OBSTET GYNECOL, V159, P796, DOI 10.1016/S0002-9378(88)80138-8; PANZARINE S, 1988, J OBSTET GYNAECOL, V17, P279; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; QUEENAN JT, 1989, CONTEMP OBSTET GYNEC, V33, P9; STAHLMAN MT, 1989, NEW ENGL J MED, V320, P1551, DOI 10.1056/NEJM198906083202309; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; WISE PH, 1990, PEDIATR PERINATAL EP, V4, P392; 1988, OTAH346 PUBL, P8; 1988, DEATH LIFE TRAGEDY I; 1987, BLESSED EVENTS BOTTO, P6	17	11	11	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					114	115						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	1789824				2022-12-28	WOS:A1991FT93400038
J	COLLINS, RH; COOPER, B; NIKAEIN, A; KLINTMALM, G; FAY, JW				COLLINS, RH; COOPER, B; NIKAEIN, A; KLINTMALM, G; FAY, JW			GRAFT-VERSUS-HOST DISEASE IN A LIVER-TRANSPLANT RECIPIENT	ANNALS OF INTERNAL MEDICINE			English	Note						LIVER TRANSPLANTATION; GRAFT VS HOST DISEASE; PANCYTOPENIA; IMMUNOSUPPRESSION; ANTIINFLAMMATORY AGENTS; NONSTEROIDAL		Thirty-five days after an orthotopic liver transplant, a patient developed fever; a skin rash involving the trunk, face, palms, and soles; pancytopenia; and diarrhea. A skin biopsy showed histologic findings consistent with acute graft-versus-host disease. HLA typing of circulating peripheral blood lymphocytes showed complete donor chimerism and established the diagnosis of liver allograft-induced graft-versus-host disease. The patient died despite treatment with large doses of corticosteroids. Although graft-versus-host disease in this setting appears lo be infrequent, it is possible that the syndrome is under-recognized. Because of the increasing frequency with which orthotopic liver transplantation is being done, careful prospective study to determine the incidence and spectrum of the syndrome is warranted.			COLLINS, RH (corresponding author), BAYLOR COLL MED, BONE MARROW TRANSPLANT BRANCH, HOUSTON, TX 77030 USA.							BHADURI BR, 1990, TRANSPLANT P, V22, P2378; Billingham R E, 1966, Harvey Lect, V62, P21; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; BYERS VS, 1990, BLOOD, V75, P1426; JAMIESON NV, 1991, TRANSPLANT INT, V4, P67, DOI 10.1111/j.1432-2277.1991.tb01950.x; KRUSKALL MS, 1990, NEW ENGL J MED, V322, P1005; MARUBAYASHI S, 1990, TRANSPLANTATION, V50, P709; RAMSEY G, 1984, NEW ENGL J MED, V311, P1167, DOI 10.1056/NEJM198411013111807; ROBERTS JP, 1991, HEPATOLOGY, V14, P274, DOI 10.1016/0270-9139(91)91415-W; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105	10	49	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					391	392		10.7326/0003-4819-116-5-391	http://dx.doi.org/10.7326/0003-4819-116-5-391			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736772				2022-12-28	WOS:A1992HF26800008
J	TANAKA, M; LAI, JS; HERR, W				TANAKA, M; LAI, JS; HERR, W			PROMOTER-SELECTIVE ACTIVATION DOMAINS IN OCT-1 AND OCT-2 DIRECT DIFFERENTIAL ACTIVATION OF AN SNRNA AND MESSENGER-RNA PROMOTER	CELL			English	Article							BINDING PROTEIN OCT-1; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; POLYMERASE-II; SV40 ENHANCER; DNA-BINDING; POU DOMAIN; OCTAMER MOTIF; HELA-CELLS; B-CELLS	The promoter specificity of transcriptional activators is generally thought to be conferred by the specificity of the DNA-binding domain, which brings the activation domain to the appropriate promoter sequence. We show here, however, that Oct-1 and Oct-2 can differentially activate transcription not through DNA binding specificity but instead through the use of promoter-selective activation domains. These distinct activation domains lead to stimulation of the U2 small nuclear RNA promoter by Oct-1 and an mRNA promoter by Oct-2. An Oct-2 variant, called Oct-2B, differs from Oct-2 by an Oct-1 -related C-terminal extension that results from alternative splicing. This variant gains the ability to activate the U2 small nuclear RNA promoter. Thus, the promoter selectivity of a transcriptional activator can be changed, in this case by alternative splicing, without affecting its DNA binding specificity.	SUNY STONY BROOK,GENET PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	TANAKA, M (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA 13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GERTSER T, 1990, EMBO J, V9, P1635; GODING CR, 1989, VIROLOGY, V173, P363; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HSIEH CL, 1990, GENOMICS, V6, P666, DOI 10.1016/0888-7543(90)90502-L; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x	54	206	207	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					755	767		10.1016/0092-8674(92)90150-B	http://dx.doi.org/10.1016/0092-8674(92)90150-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739980				2022-12-28	WOS:A1992HF44000015
J	COREY, L; FLEMING, TR				COREY, L; FLEMING, TR			TREATMENT OF HIV-INFECTION - PROGRESS IN PERSPECTIVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; ZIDOVUDINE AZT; DOUBLE-BLIND; PHASE-I; 3'-AZIDO-3'-DEOXYTHYMIDINE; 2',3'-DIDEOXYCYTIDINE; SENSITIVITY; EFFICACY				COREY, L (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98195, USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436				BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; PELLEGRINO MG, 1991, J BIOL CHEM, V266, P1783; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SKOWRON G, 1990, AM J MED, V88, pS20, DOI 10.1016/0002-9343(90)90417-C; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1988, LANCET, V1, P76; 1992, NEW ENGL J MED, V326, P213	20	17	17	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					484	486		10.1056/NEJM199202133260710	http://dx.doi.org/10.1056/NEJM199202133260710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732776				2022-12-28	WOS:A1992HD16400010
J	VANESSEN, DC; ANDERSON, CH; FELLEMAN, DJ				VANESSEN, DC; ANDERSON, CH; FELLEMAN, DJ			INFORMATION-PROCESSING IN THE PRIMATE VISUAL-SYSTEM - AN INTEGRATED SYSTEMS PERSPECTIVE	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; SUPERIOR TEMPORAL SULCUS; MACAQUE MONKEY; CORTICAL CONNECTIONS; EXTRASTRIATE CORTEX; RESPONSE PROPERTIES; RHESUS-MONKEY; AREA MT; CELLS; COLOR	The primate visual system contains dozens of distinct areas in the cerebral cortex and several major subcortical structures. These subdivisions are extensively interconnected in a distributed hierarchical network that contains several intertwined processing streams. A number of strategies are used for efficient information processing within this hierarchy. These include linear and nonlinear filtering, passage through information bottlenecks, and coordinated use of multiple types of information. In addition, dynamic regulation of information flow within and between visual areas may provide the computational flexibility needed for the visual system to perform a broad spectrum of tasks accurately and at high resolution.	CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; UNIV TEXAS, SCH MED, DEPT NEUROBIOL & ANAT, HOUSTON, TX 77030 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Texas System	VANESSEN, DC (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							ANDERSON CH, 1987, P NATL ACAD SCI USA, V84, P6297, DOI 10.1073/pnas.84.17.6297; ANDERSON CH, 1985, SPIE P INTELL ROBOTS, V579, P71; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BLAKEMORE C, 1986, J PHYSIOL-LONDON, V380, P453, DOI 10.1113/jphysiol.1986.sp016297; BOUSSAUD D, 1991, J COMP NEUROL, V296, P462; BROGAN D, IN PRESS 2ND P INT C; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; CRICK F, 1984, P NATL ACAD SCI-BIOL, V81, P4586, DOI 10.1073/pnas.81.14.4586; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; DESIMONE R, 1990, COLD SPRING HARB SYM, V55, P963; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; DeValois RL, 1988, SPATIAL VISION; DEYOE E A, 1991, Society for Neuroscience Abstracts, V17, P1282; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; EMERSON RC, IN PRESS VISION RES; FELLEMAN D J, 1991, Society for Neuroscience Abstracts, V17, P1282; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1991, INVEST OPHTH VIS SCI, V32, P1117; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1991, P R SOC LONDON B, V55, P651; JONES JP, 1987, J NEUROPHYSIOL, V58, P1223; Kaas J.H., 1988, P327; Kaplan E., 1990, Progress in Retinal Research, V9, P273, DOI 10.1016/0278-4327(90)90009-7; KOCH C, 1985, HUM NEUROBIOL, V4, P219; KUSAMA T, 1970, STEREOTOXIC ATLAS BR; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MACKAY DM, 1981, NATURE, V289, P117, DOI 10.1038/289117a0; MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; MARR D, 1980, PROC R SOC SER B-BIO, V207, P187, DOI 10.1098/rspb.1980.0020; MARROCCO RT, 1982, J NEUROSCI, V2, P1275; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MCLEAN J, 1989, VISION RES, V29, P674; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, NATO ADV SCI I A-LIF, V203, P117; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MULLEN KT, 1985, J PHYSIOL-LONDON, V359, P381, DOI 10.1113/jphysiol.1985.sp015591; NELSON ME, 1990, TRENDS NEUROSCI, V13, P403, DOI 10.1016/0166-2236(90)90119-U; NOORLANDER C, 1983, VISION RES, V23, P1, DOI 10.1016/0042-6989(83)90035-4; PERRY VH, 1984, NEUROSCIENCE, V12, P1101, DOI 10.1016/0306-4522(84)90006-X; PETERSEN SE, 1987, NEUROPSYCHOLOGIA, V25, P97, DOI 10.1016/0028-3932(87)90046-7; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; SAITO H, 1986, J NEUROSCI, V6, P145; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Simoncelli E. P., 1991, SUBBAND IMAGE CODING, P143; THIBOS LN, 1987, VISION RES, V27, P2193, DOI 10.1016/0042-6989(87)90134-9; TOOTELL RBH, 1983, SCIENCE, V220, P737, DOI 10.1126/science.6301017; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; van Essen D., 1990, INTRO NEURAL ELECTRO, P43; van Essen D.C., 1985, P259; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; VANESSEN DC, 1991, SPIE, V1473, P17; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; WASSLE H, 1991, VISION RES, V11, P1897; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1990, COLD SPRING HARB SYM, V55, P651	62	778	787	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					419	423		10.1126/science.1734518	http://dx.doi.org/10.1126/science.1734518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734518				2022-12-28	WOS:A1992HA59000028
J	MOTTONEN, J; STRAND, A; SYMERSKY, J; SWEET, RM; DANLEY, DE; GEOGHEGAN, KF; GERARD, RD; GOLDSMITH, EJ				MOTTONEN, J; STRAND, A; SYMERSKY, J; SWEET, RM; DANLEY, DE; GEOGHEGAN, KF; GERARD, RD; GOLDSMITH, EJ			STRUCTURAL BASIS OF LATENCY IN PLASMINOGEN-ACTIVATOR INHIBITOR-1	NATURE			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; SERPINS; ALPHA-1-ANTITRYPSIN; MODEL; ANTITHROMBIN; PLAKALBUMIN; REFINEMENT; OVALBUMIN; MUTANTS	HuMAN plasminogen activator inhibitor-1 (PAI-1) 1,2 is the fast-acting inhibitor of tissue plasminogen activator and urokinase 3 and is a member of the serpin family of protease inhibitors 4. Serpins normally form complexes with their target proteases that dissociate very slowly as cleaved species and then fold into a highly stable inactive state 5 in which the residues that flank the scissile bond (P1 and P1'; ref. 6) are separated by about 70 angstrom (refs 7-9). PAI-1 also spontaneously folds into a stable 10 inactive state without cleavage; this state is termed 'latent' because inhibitory activity can be restored through denaturation and renaturation 2,10. Here we report the structure of intact latent PAI-1 determined by single-crystal X-ray diffraction to 2.6 angstrom resolution. The three-dimensional structure reveals that residues on the N-terminal side of the primary recognition site are inserted as a central strand of the largest beta-sheet, in positions similar to the corresponding residues in the cleaved form of the serpin alpha-1-proteinase inhibitor (alpha-1-PI) 7. Residues C-terminal to the recognition site occupy positions on the surface of the molecule distinct from those of the corresponding residues in cleaved serpins 7-9 or in the intact inactive serpin homologue, ovalbumin 11, and its cleavage product, plakal-bumin 12. The structure of latent PAI-1 is similar to one formed after cleavage in other serpins, and the stability of both latent PAI-1 and cleaved serpins may be derived from the same structural features 13,14.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA; PFIZER INC, DIV CENT RES, DEPT MOLEC GENET & PROT CHEM, GROTON, CT 06340 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Brookhaven National Laboratory; Pfizer; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1969, ACTA CRYSTALL B-STRU, VB 25, P2571, DOI 10.1107/S0567740869006091; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRANKE AE, 1990, BIOCHIM BIOPHYS ACTA, V1037, P16, DOI 10.1016/0167-4838(90)90096-X; GOLDSMITH EJ, 1991, PROTEINS, V9, P225, DOI 10.1002/prot.340090308; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JONES TA, 1991, VERSION 54; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KRESS LF, 1979, J BIOL CHEM, V254, P5317; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; MUNCH M, IN PRESS EMBO J; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PAPAMOKOS E, 1982, J MOL BIOL, V158, P515, DOI 10.1016/0022-2836(82)90212-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WRIGHT HT, 1990, J MOL BIOL, V213, P513	33	536	551	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					270	273		10.1038/355270a0	http://dx.doi.org/10.1038/355270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731226				2022-12-28	WOS:A1992GZ69400074
J	SNOWDEN, RJ; HAMMETT, ST				SNOWDEN, RJ; HAMMETT, ST			SUBTRACTIVE AND DIVISIVE ADAPTATION IN THE HUMAN VISUAL-SYSTEM	NATURE			English	Article							SPATIAL-FREQUENCY; CORTICAL-NEURONS; STRIATE CORTEX; INHIBITION; ORIENTATION; CAT; CONTRAST; SPECIFICITY; SELECTIVITY; CELLS	SENSORY systems can adapt to the conditions imposed on them 1. In the visual system, adapting to a pattern increases the threshold of the ability to see that pattern, and reduces the perceived contrast of the pattern above threshold 2-4. Most neurons of the striate cortex reduce their responsiveness after being stimulated for some time by a high-contrast pattern 5-7. Such an effect may lie behind these psychophysical adaptation phenomena 2-4. These adaptation effects have been reported to be confined to patterns of similar orientation, which is understandable in that the visual neurons that adapt are only excited by a small range of orientations 8. Neurophysiological evidence suggests that neurons with different orientation preferences have inhibitory interconnections 9-13. It is therefore of interest to explore the possible effects of these connections on perception. Here we show that adapting to a horizontal pattern can reduce the perceived contrast of a vertical test pattern more than a horizontal test pattern. These 'cross-orientation' effects are modelled by a division-like process, whereas the more normal 'similar-orientation' effects are modelled by a subtractive process.			SNOWDEN, RJ (corresponding author), UNIV WALES COLL CARDIFF,SCH PSYCHOL,POB 901,CARDIFF CF1 3YG,WALES.							ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; BENEVENTO LA, 1972, NATURE-NEW BIOL, V238, P124, DOI 10.1038/newbio238124a0; BLAKEMORE C, 1971, J PHYSIOL-LONDON, V213, P157, DOI 10.1113/jphysiol.1971.sp009374; BLAKEMORE C, 1973, VISION RES, V13, P1915, DOI 10.1016/0042-6989(73)90063-1; BLAKEMORE CB, 1971, SCIENCE, V166, P245; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; DEALY RS, 1974, J PHYSIOL-LONDON, V241, P261, DOI 10.1113/jphysiol.1974.sp010652; DEAN AF, 1980, J PHYSIOL-LONDON, V308, P84; GEORGESON M A, 1985, Spatial Vision, V1, P103, DOI 10.1163/156856885X00125; Gibson JJ, 1937, J EXP PSYCHOL, V20, P453, DOI 10.1037/h0059826; GILINSKY AS, 1968, J OPT SOC AM, V58, P13, DOI 10.1364/JOSA.58.000013; GREENLEE MW, 1988, VISION RES, V28, P1303, DOI 10.1016/0042-6989(88)90061-2; HEELEY DW, 1979, VISION RES, V29, P1229; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MOLLON J, 1974, New Scientist, V61, P479; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; MORRONE MC, 1986, NATURE, V321, P235, DOI 10.1038/321235a0; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; RAMOA AS, 1986, NATURE, V321, P237, DOI 10.1038/321237a0; SILLITO AM, 1979, TRENDS NEUROSCI, V2, P196, DOI 10.1016/0166-2236(79)90078-X; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TOLHURST DJ, 1981, EXP BRAIN RES, V41, P414	24	49	49	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					248	250		10.1038/355248a0	http://dx.doi.org/10.1038/355248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731220				2022-12-28	WOS:A1992GZ69400066
J	HISS, J; ARENSBURG, B				HISS, J; ARENSBURG, B			SUFFOCATION FROM MISUSE OF GAS MASKS DURING THE GULF WAR	BRITISH MEDICAL JOURNAL			English	Article									TEL AVIV UNIV,SACKLER SCH MED,DEPT ANAT & ANTHROPOL,TEL AVIV,ISRAEL; L GREENBERG NATL INST FORENS MED,TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine								Di Maio D.J., 1989, FORENSIC PATHOLOGY, P207; POLSON CJ, 1985, ESSENTIALS FORENSIC, P449	2	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					92	92		10.1136/bmj.304.6819.92	http://dx.doi.org/10.1136/bmj.304.6819.92			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737149	Bronze, Green Published			2022-12-28	WOS:A1992HA17100025
J	RICHARDS, T				RICHARDS, T			MEDICINE IN EUROPE .6. WHO SPEAKS FOR WHOM	BRITISH MEDICAL JOURNAL			English	Article																		[Anonymous], 1991, Lancet, V338, P219; BEECHAM L, 1991, BRIT MED J, V303, P1220; BEECHAM L, 1990, BMJ, V301, P935; BREARLEY S, 1991, BRIT MED J, V302, P1221, DOI 10.1136/bmj.302.6787.1221; LEIDL R, 1991, BRIT MED J, V303, P1081, DOI 10.1136/bmj.303.6810.1081; RICHARDS T, 1991, BRIT MED J, V303, P877; RICHARDS T, 1991, BRIT MED J, V302, P1296; 1991, EUROPEAN CITIZE 0916	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					103	106		10.1136/bmj.304.6819.103	http://dx.doi.org/10.1136/bmj.304.6819.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737109	Green Published, Bronze			2022-12-28	WOS:A1992HA17100030
J	HAND, R; SENER, S; IMPERATO, J; CHMIEL, JS; SYLVESTER, J; FREMGEN, A				HAND, R; SENER, S; IMPERATO, J; CHMIEL, JS; SYLVESTER, J; FREMGEN, A			HOSPITAL VARIABLES ASSOCIATED WITH QUALITY OF CARE FOR BREAST-CANCER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPARING TOTAL MASTECTOMY; COMMUNITY HOSPITALS; WOMEN; RECEPTORS; MODALITY; BLACK; AGE	Objective. - To determine the degree of compliance with clinical standards among hospitals for care of breast cancer patients and account for variations in compliance. Design. - Analysis of cancer registry data submitted to the American Cancer Society, Illinois Division, Chicago, for a concurrent prospective descriptive study of breast cancer, supplemented by other hospital data from public sources. Setting. - Ninety-nine Illinois hospitals evenly distributed among rural counties, counties with small cities outside the Chicago metropolitan area, exurban counties in the Chicago metropolitan area, suburban Cook County, and urban Chicago. Patients. - A total of 5766 newly diagnosed patients with histologically confirmed breast cancer in 1988, representing 84% of the estimated 6900 new cases in the state for that year. Main Outcome Measures. - Descriptive statistics and multiple linear regression analyses of five dependent quality variables from clinical indicators related to early diagnosis, hormone receptor determination, adjuvant therapy, radiation therapy, and axillary lymph node dissection. Results. - At the hospitals studied, (1) late stage (IIb through IV) at diagnosis was associated with urban location, higher proportion of poorly insured patients, fewer breast cancer cases treated, and lower oncology charges (proportion of variance explained, R2 = .50, P < .00001). (2) omission of hormone receptor test for stages 11 through IV was associated with urban location and higher proportion of poorly insured patients (R2 = .18, P < .00003); and (3) omission of indicated radiation therapy was associated with urban location and fewer breast cancer cases (R2 = .21, P < .00001). Omission of adjuvant therapy and omission of axillary lymph node dissection were not significantly associated with any of the hospital variables examined. Conclusions. - The findings suggest that there is a group of urban hospitals, generally small and marginally reimbursed, where comprehensive diagnosis and treatment of breast cancer are not obtained.	UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60680; NORTHWESTERN UNIV,SCH MED,DEPT SURG,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT RADIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,CTR CANC,BIOMETRY SECT,CHICAGO,IL 60611	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Northwestern University; Northwestern University	HAND, R (corresponding author), AMER CANC SOC,CANC INCIDENCE & END RESULTS COMM,ILLINOIS DIV,77 E MONROE ST,NEW YORK,NY 10017, USA.							ANDERSSON I, 1980, RADIOLOGE, V20, P608; CADY B, 1990, CANCER, V65, P634, DOI 10.1002/1097-0142(19900201)65:3+<634::AID-CNCR2820651306>3.0.CO;2-X; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; CLARK GM, 1988, SEMIN ONCOL, V15, P20; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; Fisher E R, 1981, Breast Cancer Res Treat, V1, P37, DOI 10.1007/BF01807890; FORD LG, 1989, CANCER, V64, P219, DOI 10.1002/1097-0142(19890701)64:1+<219::AID-CNCR2820641308>3.0.CO;2-S; Gore S M, 1988, Recent Results Cancer Res, V111, P149; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HORM JM, 1984, SEER PROGRAM CANCER; Lazarus E S, 1990, Med Anthropol, V12, P269; MAMON JA, 1990, PREV MED, V19, P363, DOI 10.1016/0091-7435(90)90036-J; MCPHEE S J, 1990, Journal of General Internal Medicine, V5, pS116, DOI 10.1007/BF02600856; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; SAWYER JA, 1990, J GEN INTERN MED, V5, P115, DOI 10.1007/BF02600510; SCANLON EF, 1991, TXB CLIN ONCOLOGY, P177; STOMPER PC, 1989, HEMATOL ONCOL CLIN N, V3, P611, DOI 10.1016/S0889-8588(18)30523-9; 1991, JAMA-J AM MED ASSOC, V265, P391; 1988, COUNTY CITY DATA BOO, pF15; 1988, MANUAL STAGING CANCE; 1989, JAMA-J AM MED ASSOC, V261, P2535; 1988, CANCER FACTS FIGURES; 1987, 1987 SURVEY PUBLIC A; 1985, CONSENSUS DEV C STAT; 1991, JOINT COMMISSION PER, V11, pA1	33	92	92	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3429	3432		10.1001/jama.266.24.3429	http://dx.doi.org/10.1001/jama.266.24.3429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744956				2022-12-28	WOS:A1991GV87800026
J	COOTER, M				COOTER, M			COUNTDOWN TO THE BMJ	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1615	1619		10.1136/bmj.303.6817.1615	http://dx.doi.org/10.1136/bmj.303.6817.1615			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773195	Green Published, Bronze			2022-12-28	WOS:A1991GX95600028
J	GROGONO, BJS				GROGONO, BJS			CHANGING THE HIDEOUS FACE OF WAR	BRITISH MEDICAL JOURNAL			English	Editorial Material																		BENNETT J, 1986, BRIT J PLAST SURG, V39, P1; BENNETT JB, 1986, P ROY SOC MED, V76, P153; BROWN RF, 1989, BRIT J PLAST SURG, V42, P700, DOI 10.1016/0007-1226(89)90085-4; Gilies H., 1920, PLASTIC SURG FACE, P22; Jones R, 1917, NOTES MILITARY ORTHO; JONES R, 1923, ORTHOPAEDIC SURGERY; MCINDOE A, 1983, B J PLAST SURG, V41, P422; Pound R., 1964, GILLIES SURGEON EXTR; TAGLIOCOZZI G, 1597, CURTORUM CHIRURGIA I; WALLACE AK, 1988, BR J PLAST SURG, V41, P441	10	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1586	1588		10.1136/bmj.303.6817.1586	http://dx.doi.org/10.1136/bmj.303.6817.1586			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX956	1773179	Green Published, Bronze			2022-12-28	WOS:A1991GX95600011
J	LACY, PE; HEGRE, OD; GERASIMIDIVAZEOU, A; GENTILE, FT; DIONNE, KE				LACY, PE; HEGRE, OD; GERASIMIDIVAZEOU, A; GENTILE, FT; DIONNE, KE			MAINTENANCE OF NORMOGLYCEMIA IN DIABETIC MICE BY SUBCUTANEOUS XENOGRAFTS OF ENCAPSULATED ISLETS	SCIENCE			English	Article							ARTIFICIAL ENDOCRINE PANCREAS; TISSUE REACTION; RATS; TRANSPLANTATION; IMPLANTS; INSULIN; CELLS	The goal of islet transplantation in human diabetes is to maintain the islet grafts in the recipients without the use of immunosuppression. One approach is to encapsulate the donor islets in permselective membranes. Hollow fibers fabricated from an acrylic copolymer were used to encapsulate small numbers of rat islets that were immobilized in an alginate hydrogel for transplantation in diabetic mice. The fibers were biocompatible, prevented rejection, and maintained normoglycemia when transplanted intraperitoneally; hyperglycemia returned when the fibers were removed at 60 days. Normoglycemia was also maintained by subcutaneous implants that had an appropriately constructed outer surface on the fibers.	CELLULAR TRANSPLANTS,PROVIDENCE,RI 02906		LACY, PE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK001226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN JJ, 1986, DIABETES, V35, P625, DOI 10.2337/diabetes.35.6.625; ARCHER J, 1980, J SURG RES, V28, P77, DOI 10.1016/0022-4804(80)90086-4; CABASSO I, 1980, KIRK OTHMERS ENCY CH, V12, P492; CHICK WL, 1977, SCIENCE, V197, P780, DOI 10.1126/science.407649; CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704; DIONNE KE, 1991, BIOTECHNOL PROGR, V7, P359, DOI 10.1021/bp00010a011; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; KEMP CB, 1973, DIABETOLOGIA, V9, P486, DOI 10.1007/BF00461694; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LACY PE, 1972, DIABETES, V21, P987, DOI 10.2337/diab.21.10.987; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; MAZAHERI R, 1991, TRANSPLANTATION, V51, P750, DOI 10.1097/00007890-199104000-00002; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SULLIVAN SJ, 1991, SCIENCE, V252, P718, DOI 10.1126/science.2024124; SUN AM, 1977, DIABETES, V26, P1136, DOI 10.2337/diabetes.26.12.1136; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; TZE WJ, 1976, NATURE, V264, P466, DOI 10.1038/264466a0; WARNOCK GL, 1989, LANCET, V2, P570; WINN SR, 1989, J BIOMED MATER RES, V23, P31, DOI 10.1002/jbm.820230104	19	296	365	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1782	1784		10.1126/science.1763328	http://dx.doi.org/10.1126/science.1763328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763328				2022-12-28	WOS:A1991GW31600040
J	BUNDRED, NJ; RATCLIFFE, WA; WALKER, RA; COLEY, S; MORRISON, JM; RATCLIFFE, JG				BUNDRED, NJ; RATCLIFFE, WA; WALKER, RA; COLEY, S; MORRISON, JM; RATCLIFFE, JG			PARATHYROID-HORMONE RELATED PROTEIN AND HYPERCALCEMIA IN BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT HYPERCALCEMIA; IMMUNOHISTOCHEMICAL LOCALIZATION; REASSESSMENT; MECHANISMS; CARCINOMA	Objective - To see whether parathyroid hormone related protein has a humoral role in breast cancer. Design - Plasma concentrations and tumour expression of parathyroid hormone related protein were determined (by two site immunoradiometric assay and immunohistochemistry respectively) in women with breast cancer and related to the presence of bone metastases and serum calcium concentrations. Subjects - Plasma concentrations of parathyroid hormone related protein were measured in 57 women with early breast cancer without apparent bone metastases, 28 women with bone metastases, and 13 women with bone metastases and hypercalcaemia. Tissue positivity for parathyroid hormone related protein was determined retrospectively in 106 primary breast tumours from women without apparent bone metastases and 72 tumours from women with bone metastases, 25 of whom subsequently developed hypercalcaemia. Results - Plasma parathyroid hormone related protein concentrations were detectable (> 0.23 pmol/l) in 12 (92%) of the 13 hypercalcaemic patients with bone metastases compared with 10 (36%) of the 28 normocalcaemic patients with bone metastases and five (9%) of the 57 normocalcaemic patients without bone metastases. Parathyroid hormone related protein concentrations were significantly higher in hypercalcaemic than normocalcaemic patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases who later developed hypercalcaemia compared with 25 (53%) of the 47 from women in this group who remained normocalcaemic and 55 (52%) of the 106 early breast cancers from women without known metastases. Conclusion - Tumour derived parathyroid hormone related protein may have an important humoral role in hypercalcaemia associated with metastatic breast cancer.	SELLY OAK HOSP,DEPT SURG,BIRMINGHAM B29 6JD,ENGLAND; QUEEN ELIZABETH MED CTR,WOLFSON RES LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; ROYAL INFIRM,DEPT PATHOL,LEICESTER LE1 5WW,ENGLAND	Birmingham City University; University of Birmingham	BUNDRED, NJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT SURG,TEACHING & RES BLOCK,MANCHESTER M20 8LR,LANCS,ENGLAND.							BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; COLEMAN RE, 1988, EUR J SURG ONCOL, V14, P423; DANKS JA, 1989, J BONE MINER RES, V4, P273; GALLACHER SJ, 1990, ANN CLIN BIOCHEM, V27, P551, DOI 10.1177/000456329002700605; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; ISALES C, 1987, AM J MED, V82, P1143, DOI 10.1016/0002-9343(87)90216-6; KRAMER S, 1991, ENDOCRINOLOGY, V128, P1927, DOI 10.1210/endo-128-4-1927; LEGHA SS, 1981, CANCER, V47, P2803, DOI 10.1002/1097-0142(19810615)47:12<2803::AID-CNCR2820471208>3.0.CO;2-A; MARTIN TJ, 1989, CLIN ENDOCRINOL, V31, P631, DOI 10.1111/j.1365-2265.1989.tb01288.x; MARTIN TJ, 1990, Q J MED, V76, P771; MUNDY GR, 1984, NEW ENGL J MED, V310, P1718; MUNDY GR, 1988, J CLIN INVEST, V82, P1, DOI 10.1172/JCI113555; PERCIVAL RC, 1985, BMJ-BRIT MED J, V291, P776, DOI 10.1136/bmj.291.6498.776; POWELL GJ, 1991, CANCER RES, V51, P3059; RALSTON SH, 1991, J CLIN PATHOL, V44, P472, DOI 10.1136/jcp.44.6.472; RATCLIFFE WA, 1991, CLIN CHEM, V37, P678; SATO K, 1988, J CLIN ENDOCR METAB, V67, P592, DOI 10.1210/jcem-67-3-592; SOUTHBY J, 1990, CANCER RES, V50, P7710; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983	21	75	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1506	1509		10.1136/bmj.303.6816.1506	http://dx.doi.org/10.1136/bmj.303.6816.1506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782489	Green Published, Bronze			2022-12-28	WOS:A1991GV47600020
J	ROSE, G				ROSE, G			ABC OF VASCULAR DISEASES - EPIDEMIOLOGY OF ATHEROSCLEROSIS	BRITISH MEDICAL JOURNAL			English	Article											ROSE, G (corresponding author), ST MARYS HOSP,MED & EPIDEMIOL,LONDON,ENGLAND.								0	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1537	1539		10.1136/bmj.303.6816.1537	http://dx.doi.org/10.1136/bmj.303.6816.1537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782502	Bronze, Green Published			2022-12-28	WOS:A1991GV47600034
J	WU, SM; CHEUNG, WF; FRAZIER, D; STAFFORD, DW				WU, SM; CHEUNG, WF; FRAZIER, D; STAFFORD, DW			CLONING AND EXPRESSION OF THE CDNA FOR HUMAN GAMMA-GLUTAMYL CARBOXYLASE	SCIENCE			English	Article							K-DEPENDENT CARBOXYLASE; RAT-LIVER; PROTEINS; METABOLISM; SEQUENCES; ENZYME	The cDNA for human gamma-glutamyl carboxylase, which accomplishes the post-translational modification required for the activity of all of the vitamin K-dependent proteins, was cloned. The enzyme is a 758-residue integral membrane protein and appears to have three transmembrane domains near its amino terminus. The hydrophilic COOH-terminal half of the carboxylase has 19.3 percent identity with soybean seed lipoxygenase. Expression of the cloned cDNA resulted in an increase in carboxylase activity in microsomes of transfected cells compared to mock-transfected cells.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	STAFFORD, DW (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRODY T, 1987, BIOCHIM BIOPHYS ACTA, V923, P1, DOI 10.1016/0304-4165(87)90118-8; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GIRARDOT JM, 1982, J BIOL CHEM, V257, P5008; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABENER JF, 1988, P NATL ACAD SCI USA, V85, P1735, DOI 10.1073/pnas.85.6.1735; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Maniatis T., 1982, MOL CLONING; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236	13	166	182	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1634	1636		10.1126/science.1749935	http://dx.doi.org/10.1126/science.1749935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749935				2022-12-28	WOS:A1991GV07300042
J	ISON, CA; BRANLEY, NS; KIRTLAND, K; EASMON, CSF				ISON, CA; BRANLEY, NS; KIRTLAND, K; EASMON, CSF			SURVEILLANCE OF ANTIBIOTIC-RESISTANCE IN CLINICAL ISOLATES OF NEISSERIA-GONORRHOEAE	BRITISH MEDICAL JOURNAL			English	Article											ISON, CA (corresponding author), ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND.							GILL MJ, 1988, J CLIN PATHOL, V41, P978, DOI 10.1136/jcp.41.9.978; GRANSDEN WR, 1991, J MED MICROBIOL, V34, P23, DOI 10.1099/00222615-34-1-23; JEPHCOTT AE, 1990, LANCET, V335, P165, DOI 10.1016/0140-6736(90)90035-4; LEWIN CS, 1990, J MED MICROBIOL, V31, P153, DOI 10.1099/00222615-31-3-153	4	19	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1307	1307		10.1136/bmj.303.6813.1307	http://dx.doi.org/10.1136/bmj.303.6813.1307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747674	Bronze, Green Published			2022-12-28	WOS:A1991GT01100023
J	THORNTON, JG; ONWUDE, JL				THORNTON, JG; ONWUDE, JL			PREECLAMPSIA - DISCORDANCE AMONG IDENTICAL-TWINS	BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; GENETICS				THORNTON, JG (corresponding author), ST JAMES UNIV HOSP,DEPT OBSTET & GYNAECOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		ONWUDE, JOSEPH LOZE/ABA-4929-2021; ONWUDE, JOSEPH Loze/AFM-0527-2022; ONWUDE, JOSEPH LOZE/ABF-7876-2021; ONWUDE, JOSEPH Loze/AAH-2903-2022; Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; CHESLEY LC, 1986, BRIT J OBSTET GYNAEC, V93, P898, DOI 10.1111/j.1471-0528.1986.tb08006.x; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; THOMPSON B, 1988, TWINNING TWINS, P253; THORNTON JG, 1990, LANCET, V336, P1319, DOI 10.1016/0140-6736(90)93004-9	5	65	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1241	1242		10.1136/bmj.303.6812.1241	http://dx.doi.org/10.1136/bmj.303.6812.1241			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747646	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200025
J	THOMAS, A				THOMAS, A			USING THE POTENTIAL OF ALL STAFF	BRITISH MEDICAL JOURNAL			English	Article											THOMAS, A (corresponding author), SUNLEY RES CTR,LONDON W6 8LW,ENGLAND.							1991, JUNIOR DOCTORS NEW D; 1991, INAPPROPRIATE DUTIES	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1123	1124		10.1136/bmj.303.6810.1123	http://dx.doi.org/10.1136/bmj.303.6810.1123			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747584	Bronze, Green Published			2022-12-28	WOS:A1991GN20900030
J	HESS, JF; PARISI, MA; BENNETT, JL; CLAYTON, DA				HESS, JF; PARISI, MA; BENNETT, JL; CLAYTON, DA			IMPAIRMENT OF MITOCHONDRIAL TRANSCRIPTION TERMINATION BY A POINT MUTATION ASSOCIATED WITH THE MELAS SUBGROUP OF MITOCHONDRIAL ENCEPHALOMYOPATHIES	NATURE			English	Article							TRANSFER RNALYS; DNA-SEQUENCE; BINDING; INVITRO; PURIFICATION; SELECTION; EPILEPSY; GENOME	DEFECTS in mitochondrial DNA (mtDNA) are associated with several different human diseases, including the mitochondrial encephalomyopathies. The mutations include deletions but also duplications and point mutations 1. Individuals with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) carry a common A-to-G substitution in a highly conserved portion of the gene for transfer RNA(Leu(UUR)) (refs 2, 3). Although the MELAS mutation may be comparable to the defect in the tRNA(Lys) gene associated with MERRF (refs 4, 5) (myoclonus epilepsy associated with ragged-red fibres), it is also embedded in the middle of a tridecamer sequence necessary for the formation of the 3' ends of 16S ribosomal RNA in vitro 6. We found that the MELAS mutation results in severe impairment of 16S rRNA transcription termination, which correlates with a reduced affinity of the partially purified termination protein for the MELAS template. This suggests that the molecular defect in MELAS is the inability to produce the correct type and quantity of rRNA relative to other mitochondrial gene products.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMYN A, 1987, CURR TOP BIOENERG, V15, P295; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P78; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDER ES, 1990, CELL, V61, P925, DOI 10.1016/0092-8674(90)90055-J; Maxam A M, 1980, Methods Enzymol, V65, P499; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; YONEDA M, 1990, BIOCHEM INT, V21, P789	19	217	220	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					236	239		10.1038/351236a0	http://dx.doi.org/10.1038/351236a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1755869				2022-12-28	WOS:A1991FL99000058
J	GASTINNE, H; WOLFF, M; DELATOUR, F; FAURISSON, F; CHEVRET, S				GASTINNE, H; WOLFF, M; DELATOUR, F; FAURISSON, F; CHEVRET, S			A CONTROLLED TRIAL IN INTENSIVE-CARE UNITS OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT WITH NONABSORBABLE ANTIBIOTICS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTINUOUS MECHANICAL VENTILATION; ORGAN-SYSTEM FAILURE; INTESTINAL DECONTAMINATION; ARTIFICIAL-VENTILATION; RESPIRATORY-TRACT; PREVENTION; INFECTION; COLONIZATION; PNEUMONIA; BACTERIA	Background. Selective decontamination of the digestive tract with topical nonabsorbable antibiotics has been reported to prevent nosocomial infections in patients receiving mechanical ventilation, and the procedure is used widely in Europe. However, it is unclear whether selective decontamination improves survival. Methods. We conducted a randomized, double-blind multicenter study in which 445 patients receiving mechanical ventilation in 15 intensive care units were given either prophylactic nonabsorbable antibiotics (n = 220) or a placebo (n = 225). Topical antibiotics (tobramycin, colistin sulfate, and amphotericin B) or placebo was administered through a nasogastric tube and applied to the oropharynx throughout the period of ventilation. The main end points were the mortality rate in the intensive care unit and the mortality rate within 60 days of randomization. Results. A total of 142 patients died in the intensive care unit: 75 (34 percent) in the treatment group and 67 (30 percent) in the placebo group (P = 0.37). Mortality within 60 days of randomization was similar in the two groups (P = 0.40), even after adjustment for factors that were either unbalanced or individually predictive of survival in the two groups (P = 0.70). Pneumonia developed in 59 patients (13 percent) in the intensive care unit within 30 days of enrollment in the study (33 in the placebo group and 26 in the treatment group, P = 0.42). Pneumonia acquired in the intensive care unit and due to gram-negative bacilli was less frequent (P = 0.01) in the treatment group than in the placebo group. The total charges for antibiotics were 2.2 times higher in the treatment group. Conclusions. Selective decontamination of the digestive tract does not improve survival among patients receiving mechanical ventilation in the intensive care unit, although it substantially increases the cost of their care.			GASTINNE, H (corresponding author), HOP UNIV DUPUYTREN,SERV REANIMAT,2 AVE ALEXIS CARREL,F-87042 LIMOGES,FRANCE.		Misset, Benoit/P-7817-2018	Misset, Benoit/0000-0001-6466-0065; chevret, sylvie/0000-0001-6449-4730				ATHERTON ST, 1978, LANCET, V2, P968; BODEY GP, 1981, REV INFECT DIS, V3, pS259; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; COX DR, 1972, J R STAT SOC B, V34, P187; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DEITCH EA, 1990, ARCH SURG-CHICAGO, V125, P403; DUMOULIN GC, 1982, LANCET, V1, P242; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; GASTINNE H, 1991, INTENS CARE MED, V17, P215, DOI 10.1007/BF01709880; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HARTENAUER U, 1991, CRIT CARE MED, V19, P463, DOI 10.1097/00003246-199104000-00003; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KONRAD F, 1988, INTENS CARE MED S, V14, P311; LEDINGHAM IM, 1988, LANCET, V1, P785; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MANSHIP L, 1984, AM SURGEON, V50, P94; MEAKINS JL, 1986, ARCH SURG-CHICAGO, V121, P197; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAUSS A, 1990, MED DECIS MAKING, V10, P155, DOI 10.1177/0272989X9001000302; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; SYDOW M, 1988, INTENS CARE MED S, V14, P310; TETTEROO GWM, 1990, INTENS CARE MED, V16, pS224, DOI 10.1007/BF01709705; THULIG D, 1989, INFECTION CONTROL SE, P120; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANSAENE JJM, 1989, INFECTION CONTROL SE, P128; VANUFFELEN R, 1984, INTENS CARE MED, V10, P233, DOI 10.1007/BF00256259	31	262	269	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					594	599		10.1056/NEJM199202273260903	http://dx.doi.org/10.1056/NEJM199202273260903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734249	Bronze			2022-12-28	WOS:A1992HF63300003
J	LESSELL, S				LESSELL, S			CORTICOSTEROID TREATMENT OF ACUTE OPTIC NEURITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MULTIPLE-SCLEROSIS; INJECTION				LESSELL, S (corresponding author), MASSACHUSETTS EYE & EAR HOSP,BOSTON,MA 02114, USA.							BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BOWDEN AN, 1974, J NEUROL NEUROSUR PS, V37, P869, DOI 10.1136/jnnp.37.8.869; EBERS GC, 1986, DIS NERV SYST, V2, P1278; FLEISHMAN JA, 1987, OPHTHALMOLOGY, V94, P1029; GOULD ES, 1977, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.6075.1495; PERCY AK, 1972, ARCH OPHTHALMOL-CHIC, V87, P135, DOI 10.1001/archopht.1972.01000020137004; Perkin GD, 1979, OPTIC NEURITIS ITS D; RAWSON MD, 1969, LANCET, V2, P222; RAWSON MD, 1966, LANCET, V2, P1044; RIZZO JF, 1991, ARCH OPHTHALMOL-CHIC, V109, P1668, DOI 10.1001/archopht.1991.01080120052024; RIZZO JF, 1988, NEUROLOGY, V38, P185, DOI 10.1212/WNL.38.2.185; 1991, ARCH OPHTHALMOL-CHIC, V109, P1673	12	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					634	635		10.1056/NEJM199202273260909	http://dx.doi.org/10.1056/NEJM199202273260909			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734254				2022-12-28	WOS:A1992HF63300009
J	HALL, MA				HALL, MA			REFORMING THE HEALTH-INSURANCE MARKET FOR SMALL BUSINESSES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											HALL, MA (corresponding author), ARIZONA STATE UNIV,COLL LAW,TEMPE,AZ 85287, USA.							BLUMENTHAL D, 1991, NEW ENGL J MED, V325, P198, DOI 10.1056/NEJM199107183250309; COTTON P, 1991, JAMA-J AM MED ASSOC, V265, P2451; ECKHOLM D, 1991, NY TIMES        0926, pA1; FOLEY JD, 1991, UNINSURED US NONELDE; FREUDENHEIM M, 1990, NY TIMES        0205, pA1; HIMMELSTEIN DU, 1991, JAMA-J AM MED ASSOC, V266, P399, DOI 10.1001/jama.266.3.399; KOSTERLITZ J, 1991, NATL J          0406, P796; LIPPERT C, 1991, CRITICAL DISTINCTION; LYLE TA, 1991, EMPHASIS, P2; MCCALL N, 1987, J HEALTH POLIT POLIC, V12, P53, DOI 10.1215/03616878-12-1-53; PEAR R, 1991, NY TIMES        0924, pA26; REINHARDT UE, 1991, HEALTH AFFAIR, V10, P96, DOI 10.1377/hlthaff.10.2.96; RICH S, 1991, WASHINGTON POST 0606, pA4; Rich Spencer, 1991, WP              1003, pA21; SCHRAMM CJ, 1991, JAMA-J AM MED ASSOC, V265, P3296, DOI 10.1001/jama.265.24.3296; SULLIVAN CB, 1991, HEALTH AFFAIR, V10, P104, DOI 10.1377/hlthaff.10.2.104; TODD JS, 1991, JAMA-J AM MED ASSOC, V265, P2503; 1991, HLTH CARE RESOURCE B; 1990, 101114 PEPP COMM BIP; 1991, HLTH AM CHALLENGE ST	20	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					565	570		10.1056/NEJM199202203260812	http://dx.doi.org/10.1056/NEJM199202203260812			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HD658	1732796				2022-12-28	WOS:A1992HD65800012
J	THORPE, KE; HENDRICKS, A; GARNICK, D; DONELAN, K; NEWHOUSE, JP				THORPE, KE; HENDRICKS, A; GARNICK, D; DONELAN, K; NEWHOUSE, JP			REDUCING THE NUMBER OF UNINSURED BY SUBSIDIZING EMPLOYMENT-BASED HEALTH-INSURANCE - RESULTS FROM A PILOT-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Objective. - To evaluate whether employers who do not provide health insurance would offer such benefits after a 50% reduction in the price of health insurance. Design. - Using a survey of 530 firms at two sites in New York State, we estimate the number of firms that added insurance during 1988 as a percentage of firms that were eligible for the subsidy. We use this proportion as an estimate for the number of firms that would have added insurance in the absence of the subsidy program. We then estimate the number of firms adding insurance during the initial year of the program, 1989. Setting. - The subsidized health insurance pilot projects were available in Brooklyn and in the Albany-Plattsburgh-Poughkeepsie region of New York State. Intervention. - New York State subsidized the price of health insurance, reducing it by 50%. Eligible employers were responsible for paying the remaining portion of the premium. Results. - The subsidized health insurance products increased the number of small firms (under 20 employees) offering insurance by a small amount, approximately a 3.5 percentage point increase. When fully implemented and assuming all eligible employers were aware of the program, the subsidy would increase the proportion of firms offering insurance by 16.5 percentage points. We view this as an upper boundary. Conclusions. - Increased program visibility and allowing the employee to share in the premium payment may increase the number of employers offering insurance. Even under ideal conditions, however, the results highlight the limitations of voluntary programs to increase the number of employers offering health insurance.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; JOHN F KENNEDY SCH GOVT,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	THORPE, KE (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT HLTH POLICY & ADM,CB 7400,CHAPEL HILL,NC 27599, USA.		Garnick, Deborah w/I-9009-2012; Donelan, Karen/R-6162-2019; Newhouse, Joseph/AGJ-5632-2022					Pauly M.V., 1976, ROLE HLTH INSURANCE, P73; PAULY MV, 1990, J POLIT ECON, V98, P153, DOI 10.1086/261673; THORPE KE, 1988, INQUIRY-J HEALTH CAR, V25, P344; WOODBURY SA, 1983, AM ECON REV, V73, P166; 1990, CALL ACTION FINAL RE, P27; 1990, CURRENT POPULATION S; 1985, STATE SMALL BUSINESS; 1986, HLTH BENEFITS DATA B	8	37	37	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					945	948		10.1001/jama.267.7.945	http://dx.doi.org/10.1001/jama.267.7.945			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HD155	1734107				2022-12-28	WOS:A1992HD15500027
J	FRANGIONI, JV; BEAHM, PH; SHIFRIN, V; JOST, CA; NEEL, BG				FRANGIONI, JV; BEAHM, PH; SHIFRIN, V; JOST, CA; NEEL, BG			THE NONTRANSMEMBRANE TYROSINE PHOSPHATASE PTP-1B LOCALIZES TO THE ENDOPLASMIC-RETICULUM VIA ITS 35 AMINO-ACID C-TERMINAL SEQUENCE	CELL			English	Article							HUMAN-PLACENTA; PROTEIN-KINASE; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; KIDNEY-CELLS; EXPRESSION; RECEPTOR; GENE; PURIFICATION; ANTIBODIES	We report the first intracellular characterization of an endogenous nontransmembrane protein tyrosine phosphatase (PTP). Using affinity-purified polyclonal antibodies, we have identified PTP-1B as a 50 kd serine phosphoprotein in immunoprecipitation and immunoblotting assays. Surprisingly, indirect immunofluorescence experiments indicate that PTP-1B is localized predominantly i n the endoplasmic reticulum (ER). Subcellular fractionation is consistent with this localization and establishes that PTP-IB is tightly associated with microsomal membranes, with its phosphatase domain oriented towards the cytoplasm. The C-terminal 35 amino acids of PTP-1B are both necessary and sufficient for targeting to the ER. The finding of a tyrosine phosphatase on the ER suggests new possibilities for cellular events controlled by tyrosine phosphorylation.			FRANGIONI, JV (corresponding author), BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAILEY HA, 1981, J BIOL CHEM, V256, P3951; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P220; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE SK, 1991, BIOCHIM BIOPHYS ACTA, V1061, P26, DOI 10.1016/0005-2736(91)90264-9; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0	55	546	561	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					545	560		10.1016/0092-8674(92)90190-N	http://dx.doi.org/10.1016/0092-8674(92)90190-N			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739967				2022-12-28	WOS:A1992HD39800014
J	ROTHMAN, JE; ORCI, L				ROTHMAN, JE; ORCI, L			MOLECULAR DISSECTION OF THE SECRETORY PATHWAY	NATURE			English	Review							GTP-BINDING-PROTEIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; DEPENDENT RETROGRADE TRANSPORT; SENSITIVE FUSION PROTEIN; BREFELDIN-A SUGGESTS; ER RECYCLING PATHWAY; CELL-FREE SYSTEM; ACYL-COENZYME-A; ENDOPLASMIC-RETICULUM; GOLGI STACK		UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	ROTHMAN, JE (corresponding author), MEM SLOAN KETTERING CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA.							AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENTZ J, 1991, DRUG ANESTHETIC EFFE, P259; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, IN PRESS NATURE; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GOUND B, 1990, NATURE, V345, P533; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, UNPUB; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, IN PRESS CELL; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRYER N K, 1990, Journal of Cell Biology, V111, p325A; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STZUL E, 1991, CELL, V64, P81; SWIFT AM, IN PRESS J CELL BIOL; TAGAYA M, UNPUB; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHART SW, UNPUB; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DJ, UNPUB; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	110	937	942	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1992	355	6359					409	415		10.1038/355409a0	http://dx.doi.org/10.1038/355409a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734280				2022-12-28	WOS:A1992HB53000056
J	DEMELKER, RA				DEMELKER, RA			DIAGNOSTIC-VALUE OF MICROTYMPANOMETRY IN PRIMARY CARE	BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; PRESCHOOL-CHILDREN; EFFUSION; EAR; IDENTIFICATION; TYMPANOMETRY; MANAGEMENT	Objective - To determine the reliability, validity, and feasibility of a new hand held microtympanometer. Design - Comparison of microtympanometry by two independent observations of a general practitioner and a nurse, and against a validated reference instrument. Setting - Primary care health centre of a school for the deaf in the United States. Subjects - 111 schoolchildren receiving a regular check up. Main outcome measures - Tympanometry with the Grason Stadler 28, classified with a slightly modified Jerger's classification. Results - Interobserver reliability was 0.95 (Cohen's X). Results of microtympanometry were highly comparable with results of the reference instrument (likelihood ratio of positive results, 161.2). Conclusions - The microtympanometer could be used in general practice: it is hand held, child friendly, easy to handle, and accurate.			DEMELKER, RA (corresponding author), UNIV UTRECHT,DEPT GEN PRACTICE,3511 ZC UTRECHT,NETHERLANDS.							BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; BLUESTONE CD, 1979, ANN OTO RHINOL LARYN, V88, P13, DOI 10.1177/00034894790880S503; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BURKE P, 1989, J ROY COLL GEN PRACT, V39, P377; CANTEKIN EI, 1977, ANN OTO RHINOL LARYN, V86, P16, DOI 10.1177/00034894770864S202; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CASSELBRANT ML, 1985, LARYNGOSCOPE, V95, P428; Chalmers D., 1989, OTITIS MEDIA EFFUSIO; DEMELKER RA, 1988, FAM PRACT, V5, P307, DOI 10.1093/fampra/5.4.307; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; GARDNER MJ, 1989, STATISTICS CONFIDENC; GATES GA, 1986, ANN OTO RHINOL LARYN, V95, P46, DOI 10.1177/000348948609500110; KARMA PH, 1988, RECENT ADV OTITIS ME; KELSEY JL, 1986, METHODS OBSERVATIONA; MARGOLIS RH, 1989, INT J AUDITORY COMMU, V26, P197; REVES R, 1985, BMJ-BRIT MED J, V290, P1953, DOI 10.1136/bmj.290.6486.1953; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; VANDELISDONK EH, 1990, ZIEKTEN HUISARTSPRAK; WAZEN JJ, 1988, ANN RHINOL LARY S133, V97, P20; WILMOT JF, 1988, J ROY COLL GEN PRACT, V38, P149; ZIELHUIS G A, 1989, Scandinavian Journal of Primary Health Care, V7, P33, DOI 10.3109/02813438909103668; ZIELHUIS GA, 1990, CLIN OTOLARYNGOL, V15, P147, DOI 10.1111/j.1365-2273.1990.tb00448.x; 1990, LANCET, V336, P23	23	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					96	98		10.1136/bmj.304.6819.96	http://dx.doi.org/10.1136/bmj.304.6819.96			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737151	Bronze, Green Published			2022-12-28	WOS:A1992HA17100027
J	SIBBALD, B; WILKIE, P; RAFTERY, J; ANDERSON, S; FREELING, P				SIBBALD, B; WILKIE, P; RAFTERY, J; ANDERSON, S; FREELING, P			PRESCRIBING AT THE HOSPITAL-GENERAL PRACTICE INTERFACE .2. IMPACT OF HOSPITAL OUTPATIENT DISPENSING POLICIES IN ENGLAND ON GENERAL-PRACTITIONERS AND HOSPITAL CONSULTANTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the impact on general practitioners and hospital consultants of hospital outpatient dispensing policies in England. Design - Postal questionnaire and telephone interview survey of general practitioners and hospital consultants in January 1991. Setting - 94 selected major acute hospitals in England. Participants - 20 general practitioners in the vicinity of each of 94 selected hospitals and eight consultants from each, selected by chief pharmacists. Main outcome measures - Proportions of general practitioners unable to assume responsibility for specialist drugs and of consultants wishing to retain responsibility; association between dispensing restrictions and the frequency of general practitioners being asked to prescribe hospital initiated treatments. Results - Completed questionnaires were obtained from 1207 (64%) of 1887 general practitioners and 457 (63%) of 729 consultants. 570 (46%) general practitioners felt unable to take responsibility for certain treatments, principally because of difficulty in detecting side effects (367, 30%), uncertainty about explaining treatment to patients (332, 28%), and difficulty monitoring dosage (294, 24%). Among consultants 328 (72%) wished to retain responsibility, principally because of specialist need for monitoring (93, 20%), urgent need to commence treatment (64, 14%), and specialist need to initiate or stabilise treatment (63, 14%). The more restricted the drug supply to outpatients, the more frequently consultants asked general practitioners to prescribe (p < 0.01) and complete a short course of treatment initiated by the hospital (p < 0.001). Conclusions - Restrictive hospital outpatient dispensing shifts clinical responsibility on to general practitioners. Hospital doctors should be able to retain responsibility for prescribing when the general practitioner is unfamiliar with the drug or there is a specialist need to initiate, stabilise, or monitor treatment.			SIBBALD, B (corresponding author), ST GEORGE HOSP,SCH MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND.			Anderson, Stuart/0000-0002-4621-0615				BEECHAM L, 1989, BMJ, V299, P863; CROUCH A, 1991, PRESCRIBER      0619, P55; GRIFFITHS H, 1990, PULSE           0929, P33; PENNINGTON S, 1990, GP              0601, P3; WICK A, 1991, PULSE           0608, P3; WILKIE P, 1992, BRIT MED J, V304, P29, DOI 10.1136/bmj.304.6818.29; 1987, CMND249; 1987, DA8710 NHS MAN BOARD; 1989, CMND555	9	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					31	34		10.1136/bmj.304.6818.31	http://dx.doi.org/10.1136/bmj.304.6818.31			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734993	Bronze, Green Published			2022-12-28	WOS:A1992GY90900033
J	DCRUZ, IA				DCRUZ, IA			DAORTA,GARCIA IN GOA - PIONEERING TROPICAL MEDICINE	BRITISH MEDICAL JOURNAL			English	Editorial Material											DCRUZ, IA (corresponding author), MED COLL GEORGIA,MED,AUGUSTA,GA 30912, USA.							BEHREN RH, 1991, BMJ, V302, P1039; CYBOXER CR, 1963, LECTURE SERIES, V1, P25; Levine M.M., 1991, LANCET, V338, P45	3	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1593	1594		10.1136/bmj.303.6817.1593	http://dx.doi.org/10.1136/bmj.303.6817.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773182	Green Published, Bronze			2022-12-28	WOS:A1991GX95600014
J	FARRAR, GJ; KENNA, P; JORDAN, SA; KUMARSINGH, R; HUMPHRIES, MM; SHARP, EM; SHEILS, DM; HUMPHRIES, P				FARRAR, GJ; KENNA, P; JORDAN, SA; KUMARSINGH, R; HUMPHRIES, MM; SHARP, EM; SHEILS, DM; HUMPHRIES, P			A 3-BASE-PAIR DELETION IN THE PERIPHERIN-RDS GENE IN ONE FORM OF RETINITIS-PIGMENTOSA	NATURE			English	Article							RHODOPSIN GENE; PREVALENCE; MUTATIONS	THE group of retinopathies termed retinitis pigmentosa (RP) greatly contribute to visual dysfunction in man with a frequency of roughly 1 in 4,000 (refs 1, 2). We mapped the first autosomal dominant RP (adRP) gene to chromosome 3q (refs 3, 4), close to the gene encoding rhodopsin, a rod photoreceptor pigment protein. Subsequently, mutations in this gene have been implicated as responsible for some forms of adRP 5-9. Another adRP gene has been mapped to chromosome 8p (ref. 10). A third adRP gene in a large Irish pedigree has been mapped to chromosome 6p (refs 11, 12), showing tight linkage with the gene for peripherin 13,14, a photoreceptor cell-specific glycoprotein, which is thus a strong candidate for the defective gene. We have now identified a three-base-pair deletion which results in the loss of one of a pair of highly conserved cysteine residues in the predicted third transmembrane domain of peripherin. This deletion segregates with the disease phenotype but is not present in unaffected controls, and suggests that mutant peripherin gives rise to retinitis pigmentosa.			FARRAR, GJ (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT GENET,LINCOLN PL GATE,DUBLIN 2,IRELAND.		Farrar, G Jane/B-9832-2011; Bateson, Jane Farrar/AAO-6147-2020	Kumar-Singh, Rajendra/0000-0002-7754-0713	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLANTON SH, IN PRESS GENOMICS; BUNDEY S, 1984, J MED GENET, V21, P417, DOI 10.1136/jmg.21.6.417; BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; FARRAR GJ, 1990, GENOMICS, V8, P35; FARRAR GJ, IN PRESS GENOMICS; INGLEHEARN CF, 1991, AM J HUM GENET, V48, P26; JORDAN SA, IN PRESS AM J HUM GE; MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0	17	348	364	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					478	480		10.1038/354478a0	http://dx.doi.org/10.1038/354478a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749427				2022-12-28	WOS:A1991GV07800060
J	KAY, GF; ASHWORTH, A; PENNY, GD; DUNLOP, M; SWIFT, S; BROCKDORFF, N; RASTAN, S				KAY, GF; ASHWORTH, A; PENNY, GD; DUNLOP, M; SWIFT, S; BROCKDORFF, N; RASTAN, S			A CANDIDATE SPERMATOGENESIS GENE ON THE MOUSE Y-CHROMOSOME IS HOMOLOGOUS TO UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							L-CELL DEFECT; X-CHROMOSOME; SEX DETERMINATION; DNA-REPLICATION; SHORT ARM; EXPRESSION; DIFFERENTIATION; COMPLEMENTS; CLONING; ANTIGEN	THE human X-linked gene A1S9 (refs 1-3) complements a temperature-sensitive cell-cycle mutation in mouse L cells 4, and encodes the ubiquitin-activating enzyme E1 (refs 5-7). The gene has been reported to escape X-chromosome inactivation 8, but there is some conflicting evidence 9. We have isolated part of the mouse A1s9 gene, mapped it to the proximal portion of the X chromosome and shown that it undergoes normal X-inactivation. We also detected two copies of the gene on the short arm of the mouse Y chromosome (A1s9Y-1 and A1s9Y-2). The functional A1s9Y gene (Als9Y-1) is expressed in testis and is lost in the deletion mutant Sxr(b) (ref. 10). Therefore A1s9Y-1 is a candidate for the spermatogenesis gene, Spy, which maps to this region. A1s9X is similar to the Zfx gene in undergoing X-inactivation 11,12, yet having homologous sequences on the short arm of the Y chromosome 13,14, which are expressed in the testis. These Y-linked genes may form part of a coregulated group of genes which function during spermatogenesis.	MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Medical Research Council Clinical Trials Unit; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	RASTAN, S (corresponding author), MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ADLER DA, 1991, P NATL ACAD SCI USA, V88, P4592, DOI 10.1073/pnas.88.11.4592; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BISHOP CE, 1988, PHILOS T ROY SOC B, V322, P119, DOI 10.1098/rstb.1988.0119; BROCKDORFF N, 1991, GENOMICS, V10, P17, DOI 10.1016/0888-7543(91)90478-W; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P173, DOI 10.1007/BF01535079; BROWN CJ, 1990, AM J HUM GENET, V46, P273; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; EVANS EP, 1982, NATURE, V300, P443, DOI 10.1038/300443a0; GOODFELLOW PN, 1988, DEVELOPMENT, V102, P251; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; KAY G, IN PRESS GENOMICS; KOOPMAN P, 1991, TRENDS GENET, V7, P132, DOI 10.1016/0168-9525(91)90458-3; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; MCLAREN A, 1983, BRIT SOC DEV BIOL, P225; MONESI V, 1965, EXP CELL RES, V39, P197, DOI 10.1016/0014-4827(65)90023-6; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; REICHSTEINER M, 1988, UBUITIN; SIMPSON E, 1984, TRANSPLANTATION, V37, P17, DOI 10.1097/00007890-198401000-00007; SINGH L, 1982, CELL, V28, P205, DOI 10.1016/0092-8674(82)90338-5; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; THOMPSON LH, 1970, P NATL ACAD SCI USA, V66, P377, DOI 10.1073/pnas.66.2.377; ZACKSENHAUS E, 1988, SOMAT CELL MOLEC GEN, V14, P371, DOI 10.1007/BF01534645; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; ZACKSENHAUS E, 1989, SOMAT CELL MOLEC GEN, V15, P545, DOI 10.1007/BF01534915	30	114	116	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					486	489		10.1038/354486a0	http://dx.doi.org/10.1038/354486a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749428				2022-12-28	WOS:A1991GV07800063
J	HJORTDAHL, P; BORCHGREVINK, CF				HJORTDAHL, P; BORCHGREVINK, CF			CONTINUITY OF CARE - INFLUENCE OF GENERAL-PRACTITIONERS KNOWLEDGE ABOUT THEIR PATIENTS ON USE OF RESOURCES IN CONSULTATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the relation between general practitioners' knowledge about their patients and the use of resources in consultations. Design - A cross sectional evaluation of consultations. Setting and subjects - A representative sample of 133 Norwegian general practitioners were each asked to record 30 consecutive consultations. 131 did so, and of 3990 possible registrations, 3918 (98%) were evaluated. Main outcome measures - The influence, as assessed by the doctor, of accumulated knowledge on the use of laboratory tests, expectant management, prescriptions, sickness certification, referrals, and time spent in the consultation. Results - Accumulated knowledge was a substantial factor in saving time, especially in consultations with children, the elderly, patients with psychosocial problems. and those with chronic diseases. It also influenced the overall use of laboratory tests, expectant management, sickness certification, and referrals, and to a lesser degree the use of medication. Conclusion - The findings imply strong but complex associations between accumulated knowledge and the use of resources in the consultation.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							ANDREWS FM, 1984, PUBLIC OPIN QUART, V48, P409, DOI 10.1086/268840; Bentsen B G, 1986, Scand J Prim Health Care, V4, P43, DOI 10.3109/02813438609013970; CARTWRIGHT A, 1976, J R COLL GEN PRACT, V26, P895; Hjortdahl P, 1990, Fam Med, V22, P361; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MCWHINNEY I, 1982, J FAM PRACTICE, V15, P847; McWhinney IR, 1989, TXB FAMILY MED; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; Nylenna M, 1985, Scand J Prim Health Care, V3, P155, DOI 10.3109/02813438509013938; NYLENNA M, 1986, FAM PRACT, V3, P240, DOI 10.1093/fampra/3.4.240; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; Polanyi M., 2009, TACIT DIMENSION; ROSENBERG EE, 1985, FAM PRACT, V2, P23, DOI 10.1093/fampra/2.1.23; RUTLE O, 1983, 11983 STAT I FOLK RA; Schon D.A, 2017, REFLECTIVE PRACTITIO; SHELDON M, 1985, DECISION MAKING GENE; YAFFE MJ, 1985, MED CARE, V23, P1276, DOI 10.1097/00005650-198511000-00006; 1989, WORKING PATIENTS; 1988, JAMA-J AM MED ASSOC, V260, P1272	19	119	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1181	1184		10.1136/bmj.303.6811.1181	http://dx.doi.org/10.1136/bmj.303.6811.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP488	1747619	Bronze, Green Published			2022-12-28	WOS:A1991GP48800029
J	SIMON, MA; KATTAPURAM, SV; SCULLY, RE; SPRINGFIELD, DS; ROSENBERG, AE				SIMON, MA; KATTAPURAM, SV; SCULLY, RE; SPRINGFIELD, DS; ROSENBERG, AE			A 72-YEAR-OLD MAN WITH A MASS IN THE POSTERIOR THIGH - ANEURYSM OF PERSISTENT SCIATIC ARTERY, WITH THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							SOFT-TISSUE TUMORS; COMPUTED-TOMOGRAPHY; MR; DIAGNOSIS; BIOPSY; BONE				SIMON, MA (corresponding author), UNIV CHICAGO,MED CTR,ORTHOPAED SURG & REHABIL MED SECT,CHICAGO,IL 60637, USA.							BARKIN JS, 1987, DIGEST DIS SCI, V32, P1196, DOI 10.1007/BF01300206; BERNARDINO ME, 1981, RADIOLOGY, V139, P53, DOI 10.1148/radiology.139.1.7208941; BERQUIST TH, 1989, CLIN ORTHOP RELAT R, V244, P101; BILOTTA W, 1991, SKELETAL RADIOL, V20, P71; CEROFOLINI E, 1991, J COMPUT ASSIST TOMO, V15, P593, DOI 10.1097/00004728-199107000-00013; CHIEN WY, 1989, CHANG KENG I HSUEH, V412, P161; COLLIN C, 1987, J CLIN ONCOL, V5, P601, DOI 10.1200/JCO.1987.5.4.601; DAMATI G, 1991, CARDIOVASC PATHOL, P267; FRIEDMAN AC, 1982, SKELETAL RADIOL, V7, P289, DOI 10.1007/BF00361990; GAVIN PM, 1984, RADIOLOGY, V152, P607, DOI 10.1148/radiology.152.3.6463240; KRANSDORF MJ, 1989, AM J ROENTGENOL, V153, P541, DOI 10.2214/ajr.153.3.541; KRAUSS HR, 1982, J CLIN NEURO-OPHTHAL, V2, P169; LANGE TA, 1987, J BONE JOINT SURG AM, V69A, P100, DOI 10.2106/00004623-198769010-00017; MANKIN HJ, 1982, J BONE JOINT SURG AM, V64, P1121, DOI 10.2106/00004623-198264080-00002; MANSFIELD AO, 1990, CAUSE MANAGEMENT ANE, P5; MARTEL W, 1973, CANCER, V32, P352, DOI 10.1002/1097-0142(197308)32:2<352::AID-CNCR2820320211>3.0.CO;2-8; MYHREJENSEN O, 1981, ACTA ORTHOP SCAND, V52, P287, DOI 10.3109/17453678109050105; PERRY HD, 1977, ARCH OPHTHALMOL-CHIC, V95, P281, DOI 10.1001/archopht.1977.04450020082014; QUINN SF, 1991, AM J ROENTGENOL, V156, P539, DOI 10.2214/ajr.156.3.1899752; ROSENTHAL DI, 1982, CRC CR REV DIAGN IM, V18, P243; RYDHOLM A, 1983, ACTA ORTHOP SCAND, V54, P924; RYDOLM A, 1991, J BONE JOINT SURG BR, V73, P662; SIMON MA, 1982, J BONE JOINT SURG AM, V64, P1253, DOI 10.2106/00004623-198264080-00020; THOMAS ML, 1978, RADIOLOGY, V128, P55, DOI 10.1148/128.1.55; 1990, ORTHOPAEDIC HNOWLEDG, V3, P118	25	9	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					412	418						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1732774				2022-12-28	WOS:A1992JG35600009
J	GALLAHER, MM; FLEMING, DW; BERGER, LR; SEWELL, CM				GALLAHER, MM; FLEMING, DW; BERGER, LR; SEWELL, CM			PEDESTRIAN AND HYPOTHERMIA DEATHS AMONG NATIVE-AMERICANS IN NEW-MEXICO - BETWEEN BAR AND HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; INDIANS; MORTALITY; INJURY; ABUSE	Objective. - To determine the nature of excess injury mortality among Native Americans in New Mexico. Design. - Retrospective review of death certificates for deaths from unintentional injuries. Setting. - The state of New Mexico. Subjects. - New Mexico residents who died of unintentional injuries between January 1, 1980, and December 31, 1989. Main Outcome Measure. - Cause-specific mortality rates. Results. - Over half of the excess mortality from all unintentional injuries among Native Americans resulted from hypothermia and from pedestrian-motor vehicle crashes. New Mexico Native Americans were nearly eight times more likely to die in pedestrian-motor vehicle crashes and were 30 times more likely to die of hypothermia compared with other New Mexico residents. At death, 90% of those Native Americans tested were highly intoxicated (median blood alcohol concentrations of 0.24 and 0.18 mg/dL for pedestrian and hypothermia deaths, respectively). Despite the fact that most Native Americans in New Mexico live on reservations, most deaths occurred at off-reservation sites in border towns and on roads leading back to the reservation. Conclusions. - The possession and sale of alcohol is illegal on many Native American reservations. This policy forces Native Americans who want to drink to travel long distances to obtain alcohol. These data suggest that this policy is also the likely explanation for the markedly increased risk of death from hypothermia and pedestrian-motor vehicle crashes in this population.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD SERV,ATLANTA,GA 30333; LOVELACE FDN MED EDUC & RES,ALBUQUERQUE,NM	Centers for Disease Control & Prevention - USA; Lovelace Respiratory Research Institute	GALLAHER, MM (corresponding author), NEW MEXICO DEPT HLTH,OFF EPIDEMIOL,POB 26110,1190 ST FRANCIS DR,SANTA FE,NM 87502, USA.		Duran, Bonnie m/A-3029-2009					BAILAR JC, 1964, BIOMETRICS, V20, P639; BAKER SP, 1974, AM J PUBLIC HEALTH, V64, P319; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DEAN AG, 1990, WORLD PROCESSING DAT; FLEISS JL, 1981, STATISTICAL METHODS, P244; GALLAHER MM, 1989, JAMA-J AM MED ASSOC, V262, P2243; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; MAY P A, 1977, Plains Anthropologist, V22, P223; May P. A, 1977, AM INDIAN LAW REV, V5, P217; MAY PA, 1986, J STUD ALCOHOL, V47, P187, DOI 10.15288/jsa.1986.47.187; MAY PA, 1988, J STUD ALCOHOL, V49, P324, DOI 10.15288/jsa.1988.49.324; MAY PA, 1982, INT J ADDICT, V17, P1185, DOI 10.3109/10826088209056349; MAY PA, 1989, MOTOR VEHICLE CRASHE, P207; OLSON JS, 1984, NATIVE AM 20TH CENTU, P186; OLSON S, 1985, ALCOHOL AM TAKING AC, P2; RANGO N, 1984, AM J PUBLIC HEALTH, V74, P1159, DOI 10.2105/AJPH.74.10.1159; SEWELL CM, 1989, WESTERN J MED, V150, P708; SMART RG, 1979, J STUD ALCOHOL, V40, P908, DOI 10.15288/jsa.1979.40.908; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WOODHOUSE P, 1989, LANCET, V2, P1201; 1988, MMMWR, V37, P780; 1980, INT CLASSIFICATION D, V1; 1982, MMWR, V31, P669; 1988, PHS0218547 HLTH HUM; 1990, INJURIES AM INDIANS; 1983, MMWR, V32, P46; 1943, 16TH CENSUS US 1940, V2; 1981, PC801B33 US BUR CENS	28	58	59	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1345	1348		10.1001/jama.267.10.1345	http://dx.doi.org/10.1001/jama.267.10.1345			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG678	1740855				2022-12-28	WOS:A1992HG67800026
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			HOW SURE IS SURE ENOUGH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; EMERGENCY		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOSTON,MA 02111, USA.							CAIRNS JS, 1989, CHEST S, V2, pS73; Fisch Ch, 1988, HEART DISEASE, P180; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; PAUKER SG, 1975, NEW ENGL J MED, V293, P229, DOI 10.1056/NEJM197507312930505; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; YUSUF S, 1990, CIRCULATION, V82, P117	9	13	13	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					688	691		10.1056/NEJM199203053261007	http://dx.doi.org/10.1056/NEJM199203053261007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736107				2022-12-28	WOS:A1992HG11700007
J	DAMLE, R; LEVINE, J; MATOS, J; GREENBERG, S; BROOKS, R; FRUMKIN, W; GOLDBERGER, J; KADISH, AH				DAMLE, R; LEVINE, J; MATOS, J; GREENBERG, S; BROOKS, R; FRUMKIN, W; GOLDBERGER, J; KADISH, AH			EFFICACY AND RISKS OF MORICIZINE IN INDUCIBLE SUSTAINED VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIARRHYTHMIC DRUG-THERAPY; ETHMOZINE; ARRHYTHMIAS; ELECTROPHYSIOLOGY; HYDROCHLORIDE; PROARRHYTHMIA; FIBRILLATION; FLECAINIDE; ENCAINIDE; SAFETY	Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27%) developed life-threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.	NW MEM HOSP, 250 E SUPER ST, WESLEY PAVILLION, SUITE 524, CHICAGO, IL 60611 USA; ST FRANCIS HOSP, MED CTR, ROSLYN, NY USA; LENOX HILL HOSP, NEW YORK, NY 10021 USA	Northwestern Memorial Hospital; Northwell Health								[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1990, AM J CARDIOL, V65, pD15; CALVO R, 1985, CLIN PHARMACOL THER, V37, P186; DOHERTY JU, 1984, CIRCULATION, V70, P440; DORIAN P, 1986, AM HEART J, V112, P327, DOI 10.1016/0002-8703(86)90270-X; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; HERRE JM, 1990, ANN INTERN MED, V113, P671, DOI 10.7326/0003-4819-113-9-671; HOROWITZ LN, 1990, AM J CARDIOL, V65, pD41; HOROWITZ LN, 1987, AM J CARDIOL, V59, pE45, DOI 10.1016/0002-9149(87)90201-3; KAVANAGH KM, 1991, J AM COLL CARDIOL, V17, P391, DOI 10.1016/S0735-1097(10)80104-4; LEVINE JH, 1989, CIRCULATION, V80, P1063, DOI 10.1161/01.CIR.80.4.1063; MANN DE, 1984, J AM COLL CARDIOL, V3, P537; MANN DE, 1984, AM HEART J, V107, P674, DOI 10.1016/0002-8703(84)90314-4; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIURA DS, 1986, AM HEART J, V111, P661, DOI 10.1016/0002-8703(86)90095-5; MORGANROTH J, 1984, AM J CARDIOL, V53, pB89, DOI 10.1016/0002-9149(84)90509-5; MORGANROTH J, 1990, AM J CARDIOL, V65, pD26; MORGANROTH J, 1989, AM J CARDIOL, V63, P172, DOI 10.1016/0002-9149(89)90280-4; PODRID PJ, 1987, AM J CARDIOL, V59, pE38, DOI 10.1016/0002-9149(87)90200-1; PODRID PJ, 1984, J CARDIOVASC PHARM, V65, P313; PRATT CM, 1989, AM HEART J, V118, P433, DOI 10.1016/0002-8703(89)90254-8; PRATT CM, 1986, CIRCULATION, V73, P718, DOI 10.1161/01.CIR.73.4.718; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WYNDHAM CRC, 1987, AM J CARDIOL, V60, pF67	24	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					375	381		10.7326/0003-4819-116-5-375	http://dx.doi.org/10.7326/0003-4819-116-5-375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736770				2022-12-28	WOS:A1992HF26800005
J	DELBANCO, TL				DELBANCO, TL			ENRICHING THE DOCTOR-PATIENT-RELATIONSHIP BY INVITING THE PATIENTS PERSPECTIVE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CLINICAL DECISION-MAKING; MEDICAL-CARE; CARDIOPULMONARY RESUSCITATION; CHRONIC DISEASE; BYPASS-SURGERY; OUTCOMES; SATISFACTION; QUALITY; PARTICIPATION; INVOLVEMENT	Doctors and patients alike are saddened and angered by the distance that increasingly interferes with their interactions. Two complementary strategies may enhance the human quality of clinical care and improve outcomes. First, the doctor and patient can undertake a systematic "patient's review" that addresses seven dimensions of care: 1) respect for patient's values, preferences, and expressed needs; 2) communication and education; 3) coordination and integration of care; 4) physical comfort; 5) emotional support and alleviation of fears and anxieties; 6) involvement of family and friends; and 7) continuity and transition. Incorporating the "review" into the clinical encounter encourages both patient and doctor to confront individual preferences and values and offers patients an explicit framework for participating actively in their care. Second, using survey instruments designed to solicit focused reports from patients that address each dimension of care, doctors can gather aggregate feedback about their practices. Such reports move beyond anecdote and can serve as screening tests that uncover areas in doctors' practices that merit improvement. In addition, patients can join doctors in developing solutions to problems uncovered by patients' reports.			DELBANCO, TL (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02215 USA.							ARNOLD R, IN PRESS MED INTERVI; BARON RJ, 1985, ANN INTERN MED, V103, P606, DOI 10.7326/0003-4819-103-4-606; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; Berwick D. M, 1990, CURING HLTH CARE NEW; BRODY DS, 1980, ANN INTERN MED, V93, P718, DOI 10.7326/0003-4819-93-5-718; BRODY DS, 1989, J GEN INTERN MED, V4, P506, DOI 10.1007/BF02599549; BRODY DS, 1980, J MED EDUC, V55, P34; BROYARD A, 1990, NY TIMES MAGAZI 0826, P33; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; Candib L M, 1987, Fam Med, V19, P23; CARTER WB, 1982, MED CARE, V20, P550, DOI 10.1097/00005650-198206000-00002; Cassell E.J., 1985, TALKING PATIENTS, VVol. 1; Check W A, 1982, JAMA, V247, P945, DOI 10.1001/jama.247.7.945; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COSER RL, 1958, AM SOCIOL REV, V23, P56, DOI 10.2307/2088624; DOHERTY WJ, 1983, J FAM PRACTICE, V17, P837; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; DONABEDIAN A, 1989, MILBANK Q, V67, P233, DOI 10.2307/3350139; DONNELLY WJ, 1986, PERSPECT BIOL MED, V30, P81; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; EVANS RL, 1988, STROKE, V19, P1243, DOI 10.1161/01.STR.19.10.1243; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRIECO AJ, 1990, PATIENT EDUC COUNS, V15, P3, DOI 10.1016/0738-3991(90)90003-4; HATHAWAY D, 1986, NURS RES, V35, P269; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KAPLAN SH, 1990, COMMUNICATING PATIEN, P228; KAPLAN SH, 1989, PROVIDING QUALITY CA, P25; KASS LR, 1990, HASTINGS CENT REP, V20, P5, DOI 10.2307/3562966; KULIK JA, 1987, HEALTH PSYCHOL, V6, P525, DOI 10.1037/0278-6133.6.6.525; LINN LS, 1984, MED CARE, V22, P804, DOI 10.1097/00005650-198409000-00004; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MATTHEWS DA, 1988, AM J MED SCI, V295, P159, DOI 10.1097/00000441-198803000-00001; METERKO M, 1990, Medical Care (Philadelphia), V28, pS1; PALMER RH, 1983, MED DECIS MAKING, V3, P299, DOI 10.1177/0272989X8300300306; PUNTILLO KA, 1990, HEART LUNG, V19, P526; PUTNAM SM, 1985, MED CARE, V23, P74, DOI 10.1097/00005650-198501000-00008; SALZ CC, 1988, GERONTOLOGIST, V28, P344; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SMITH DM, 1988, MED CARE, V26, P699, DOI 10.1097/00005650-198807000-00005; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STEWART MJ, 1989, SOC SCI MED, V28, P1275, DOI 10.1016/0277-9536(89)90346-8; Stoeckle J, 1987, ENCOUNTERS PATIENTS; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; WARTMAN SA, 1983, MED CARE, V21, P886, DOI 10.1097/00005650-198309000-00005; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; 1973, DHEW PUBLICATION, V7388, P67	51	172	177	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					414	418		10.7326/0003-4819-116-5-414	http://dx.doi.org/10.7326/0003-4819-116-5-414			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736775				2022-12-28	WOS:A1992HF26800012
J	SIEGEL, D; HULLEY, SB; BLACK, DM; CHEITLIN, MD; SEBASTIAN, A; SEELEY, DG; HEARST, N; FINE, R				SIEGEL, D; HULLEY, SB; BLACK, DM; CHEITLIN, MD; SEBASTIAN, A; SEELEY, DG; HEARST, N; FINE, R			DIURETICS, SERUM AND INTRACELLULAR ELECTROLYTE LEVELS, AND VENTRICULAR ARRHYTHMIAS IN HYPERTENSIVE MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUDDEN CARDIAC DEATH; SYSTEMIC HYPERTENSION; INDUCED HYPOKALEMIA; EXTRA-SYSTOLES; POTASSIUM; MAGNESIUM; THERAPY; HYDROCHLOROTHIAZIDE; PLASMA; TRIAL	Objective. - To investigate the patterns of electrlyte abnormalities resulting from thiazide administration and whether they cause ventricular arrhythmias, and to help resolve the controversy over whether clinicians should routinely prescribe potassium-conserving therapy to all patients treated with thiazides. Design. - Double-blind, randomized controlled trial. Participants. - A total of 233 hypertensive men aged 35 to 70 years. Interventions. - Participants were withdrawn from prior diuretic treatment and were replenished with oral potassium chloride and magnesium oxide. They were then randomized to 2 months of treatment with (1) hydrochlorothiazide; (2) hydrochlorothiazide with oral potassium; (3) hydrochlorothiazide with oral potassium and magnesium; (4) hydrochlorothiazide and triamterene; (5) chlorthalidone; or (6) placebo. Main Outcome Measures. - Ventricular arrhythmias on 24-hour Holter monitoring and serum and intracellular potassium and magnesium levels. Results. - Of the 233 participants, 212 (91%) completed the study. Serum potassium levels were 0.4 mmol/L lower in the hydrochlorothiazide group than in the placebo group (P < .01), and this mean difference was not affected by supplementation with potassium, with potassium and magnesium, or with triamterene. However, the supplements did prevent the occasional occurrence of marked hypokalemia; all 12 of the men who developed serum potassium levels of 3.0 mmol/L or less were among the 90 who received diuretics without supplementation (P < .01). Similarly, the overall proportion of men with ventricular arrhythmias was not affected by randomized treatment, but there was a twofold increase in the proportion with arrhythmias among the 12 men with serum potassium levels of 3.0 mmol/L or less (P = .02). Serum magnesium and intracellular potassium and magnesium levels were not reduced by hydrochlorothiazide, nor were they related to ventricular arrhythmias. Conclusions. - In the majority of hypertensive patients, treatment with 50 mg/d of hydrochlorothiazide does not cause marked hypokalemia or ventricular arrhythmias. However, because some individuals will develop hypokalemia after starting diuretic therapy, serum potassium levels should be monitored and potassium-sparing strategies should be used when indicated.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL36821, HL02081] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDALLA ISH, 1987, AM J CARDIOL, V60, P1036, DOI 10.1016/0002-9149(87)90348-1; ABRAHAM AS, 1986, AM J MED, V81, P983, DOI 10.1016/0002-9343(86)90392-X; ARAOYE MA, 1978, AM HEART J, V96, P731, DOI 10.1016/0002-8703(78)90005-4; BERGSTROM J, 1973, ACTA MED SCAND, V194, P427; BIGGER JT, 1984, AM J CARDIOL, V53, pB8, DOI 10.1016/0002-9149(84)90494-6; BIGGER JT, 1984, AM J CARDIOL, V54, pD3; Classen H G, 1984, Magnesium, V3, P257; COHEN JD, 1987, AM J CARDIOL, V60, P548, DOI 10.1016/0002-9149(87)90303-1; DYCKNER T, 1978, ACTA MED SCAND, V204, P375; DYCKNER T, 1979, AM HEART J, V97, P12, DOI 10.1016/0002-8703(79)90108-X; ELIN RJ, 1985, CLIN CHEM, V31, P377; Fleiss JL, 1981, STATISTICAL METHODS, P217; FREIS ED, 1989, ARCH INTERN MED, V149, P2640, DOI 10.1001/archinte.149.12.2640; FRISHMAN WH, 1987, AM J CARDIOL, V56, P615; GROSS TP, 1989, HYPERTENSION S1, V13, P113; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; HOLLIFIELD JW, 1984, AM J MED, V77, P28, DOI 10.1016/S0002-9343(84)80005-4; HOLLIFIELD JW, 1981, ACTA MED SCAND S, V647, P67; KAPLAN NM, 1985, NEW ENGL J MED, V312, P746, DOI 10.1056/NEJM198503213121203; KAPLAN NM, 1989, ARCH INTERN MED, V149, P2649, DOI 10.1001/archinte.149.12.2649; KOCHAR MS, 1990, ARCH INTERN MED, V150, P1009, DOI 10.1001/archinte.150.5.1009; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; LOWN B, 1975, CIRCULATION       S3, V51, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN BJ, 1987, ARCH INTERN MED, V147, P1768, DOI 10.1001/archinte.147.10.1768; MESSERLI FH, 1989, ARCH INTERN MED, V149, P1263, DOI 10.1001/archinte.149.6.1263; MORGAN DB, 1980, BRIT MED J, V280, P905, DOI 10.1136/bmj.280.6218.905; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; PAPADEMETRIOU V, 1985, AM HEART J, V110, P595, DOI 10.1016/0002-8703(85)90080-8; PAPADEMETRIOU V, 1983, AM J CARDIOL, V52, P1017, DOI 10.1016/0002-9149(83)90523-4; POOLEWILSON PA, 1987, J HYPERTENS, V5, pS51; RYAN MP, 1986, MAGNESIUM, V5, P282; RYAN MP, 1981, ACTA MED SCAND S, V647, P153; SCHNAPER HW, 1989, ARCH INTERN MED, V149, P2677, DOI 10.1001/archinte.149.12.2677; Snyder D W, 1980, Adv Cardiol, V27, P322; WHELTON PK, 1984, DRUGS, V28, P54, DOI 10.2165/00003495-198400281-00006; WHELTON PK, 1985, AM J CARDIOL, V55, P221, DOI 10.1016/0002-9149(85)90333-9; 1988, DRUG TOPICS RED BOOK; 1985, AM J CARDIOL, V55, P1; 1988, ARCH INTERN MED, V148, P1023	40	133	134	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1083	1089		10.1001/jama.267.8.1083	http://dx.doi.org/10.1001/jama.267.8.1083			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735925				2022-12-28	WOS:A1992HE39100023
J	STEIN, D; NUSSLEINVOLHARD, C				STEIN, D; NUSSLEINVOLHARD, C			MULTIPLE EXTRACELLULAR ACTIVITIES IN DROSOPHILA EGG PERIVITELLINE FLUID ARE REQUIRED FOR ESTABLISHMENT OF EMBRYONIC DORSAL-VENTRAL POLARITY	CELL			English	Article							FEMALE STERILE MUTATIONS; DNA-BINDING SUBUNIT; TOLL GENE-PRODUCT; NF-KAPPA-B; SERINE PROTEASE; REL ONCOGENE; TRANSMEMBRANE PROTEIN; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; MELANOGASTER	Twelve maternal effect genes (the dorsal group and cactus) are required for the establishment of the embryonic dorsal-ventral axis in the Drosophila embryo. Embryonic dorsal-ventral polarity is defined within the perivitelline compartment surrounding the embryo by the ventral formation of a ligand for the Toll receptor. Here, by transplantation of perivitelline fluid we demonstrate the presence of three separate activities present in the perivitelline fluid that can restore dorsal-ventral polarity to mutant easter, snake, and spatzle embryos, respectively. These activities are not capable of defining the polarity of the dorsal-ventral axis; instead they restore structures according to the intrinsic dorsal-ventral polarity of the mutant embryos. They appear to be involved in the ventral formation of a ligand for the Toll protein. This process requires serine proteolytic activity; the infection of serine protease inhibitors into the perivitelline space of wild-type embryos results in the formation of dorsalized embryos.			STEIN, D (corresponding author), MAX PLANCK ENTWICKLUNGSBIOL,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1984, PATTERN FORMATION, P269; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DOYLE HJ, 1986, NATURE, V323, P76, DOI 10.1038/323076a0; ERDELYI M, 1989, GENETICS, V122, P111; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; IP YT, 1991, CELL, V64, P439; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KONRAD KD, 1988, ROUX ARCH DEV BIOL, V197, P75, DOI 10.1007/BF00375930; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; Poulson D. F., 1950, BIOL DROSOPHILA, P168; RICE TB, 1973, THESIS YALE U NEW HA; Roberts D.B., 1986, P1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; Sonnenblick B., 1950, BIOL DROSOPHILA; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wieschaus E., 1986, P199; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	53	104	105	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					429	440		10.1016/0092-8674(92)90181-B	http://dx.doi.org/10.1016/0092-8674(92)90181-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739964				2022-12-28	WOS:A1992HD39800005
J	BRINCHMANNHANSEN, O; DAHLJORGENSEN, K; SANDVIK, L; HANSSEN, KF				BRINCHMANNHANSEN, O; DAHLJORGENSEN, K; SANDVIK, L; HANSSEN, KF			BLOOD-GLUCOSE CONCENTRATIONS AND PROGRESSION OF DIABETIC-RETINOPATHY - THE 7 YEAR RESULTS OF THE OSLO STUDY	BRITISH MEDICAL JOURNAL			English	Article							SUBCUTANEOUS INSULIN INFUSION; LONG-TERM; GLYCEMIC CONTROL; METABOLIC CONTROL; 4-YEAR INCIDENCE; COMPLICATIONS; DETERIORATION; EXPERIENCE; NEUROPATHY; DIAGNOSIS	Objective - To study insulin dependent diabetic patients for change in non-proliferative retinopathy and its relation to glycaemic control and to various clinical background data. Design - Prospective study with follow up for seven years. Setting - Outpatient departments of university hospitals. Main outcome measures - Glycated haemoglobin concentration; degree of retinopathy. Results - Retinopathy worsened by an overall increase in counts of microaneurysms and haemorrhages from 17 (SD 25) to 45 (58) (p = 0.005). Intensified insulin treatment and home blood glucose monitoring improved concentrations of glycated haemoglobin (HbA1) from 11.2% (2.2%) at the start of the study to a mean of 9-5% (1.5%) over the seven years of the study (p < 0.0001). A mean value for HbA1 > 10% was associated with an increased risk of progression of retinopathy and a mean value < 8.7% was associated with a diminished risk. Multiple regression analysis identified four independent variables as indicative of outcome of retinopathy after seven years: HbA1 value at baseline; the change in HbA1 from start to the mean level through the seven years; duration of diabetes; and retinopathy at start. Age, blood pressure, and urinary albumin excretion were not related to the presence or progression of retinopathy. Conclusion - Secondary intervention by long term lowering of glycated haemoglobin has a beneficial impact on non-proliferative retinopathy. A four factor regression model can determine patients at high risk of severe retinopathy.	AKER UNIV HOSP,OSLO,NORWAY; MEDSTAT LTD,OSLO,NORWAY	University of Oslo	BRINCHMANNHANSEN, O (corresponding author), TRONDHEIM REG & UNIV HOSP,DEPT OPHTHALMOL,N-7006 TRONDHEIM,NORWAY.							BECKNIELSEN H, 1985, DIABETES CARE, V8, P585, DOI 10.2337/diacare.8.6.585; BRINCHMANNHANSE.O, 1987, BR J OPHTHALMOL, V72, P666; BRINCHMANNHANSEN O, 1985, AM J OPHTHALMOL, V100, P644; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; BRINCHMANNHANSEN O, 1988, OPHTHALMOLOGY, V95, P1358; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DAHLJORGENSEN K, 1982, SCAND J CLIN LAB INV, V42, P27; DOFT BH, 1984, OPHTHALMOLOGY, V91, P763; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FRIBERG TR, 1985, OPHTHALMOLOGY, V92, P1051; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; JOB D, 1976, DIABETES, V25, P463, DOI 10.2337/diab.25.5.463; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1780, DOI 10.1001/archopht.1989.01070020862028; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KOHNER EM, 1970, EUR J CLIN INVEST, V1, P167, DOI 10.1111/j.1365-2362.1970.tb00613.x; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LAURITZEN T, 1983, LANCET, V1, P200; MCCANCE DR, 1989, LANCET, V2, P824; OLSEN T, 1987, ACTA OPHTHALMOL, V65, P185; OLSEN T, 1985, ACTA OPHTHALMOL, V63, P315; PICKUP JC, 1980, DIABETES CARE, V3, P290, DOI 10.2337/diacare.3.2.290; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; REICHARD P, 1988, ACTA MED SCAND, V224, P115; REICHARD P, 1991, INT MED, V230, P101; ROSENLUND EF, 1988, AM J OPHTHALMOL, V105, P618, DOI 10.1016/0002-9394(88)90054-2; TAMBORLANE WV, 1982, DIABETES CARE, V5, P58; VANBALLEGOOIE E, 1984, DIABETES CARE, V7, P236, DOI 10.2337/diacare.7.3.236; 1988, JAMA-J AM MED ASSOC, V260, P37; 1984, NEW ENGL J MED, V311, P365	33	136	140	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					19	22		10.1136/bmj.304.6818.19	http://dx.doi.org/10.1136/bmj.304.6818.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734985	Bronze, Green Published			2022-12-28	WOS:A1992GY90900027
J	BREO, DL				BREO, DL			BLOOD, MONEY, AND HEMOPHILIACS - THE FATAL STORY OF FRANCES AIDSGATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		DESFORGES J, 1983, NEW ENGLAND J MED	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3477	3482		10.1001/jama.266.24.3477	http://dx.doi.org/10.1001/jama.266.24.3477			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744965				2022-12-28	WOS:A1991GV87800037
J	BABINET, J; GAY, F; BUSTOS, D; DUBARRY, M; JAULMES, D; NGUYEN, L; GENTILINI, M				BABINET, J; GAY, F; BUSTOS, D; DUBARRY, M; JAULMES, D; NGUYEN, L; GENTILINI, M			TRANSMISSION OF PLASMODIUM-FALCIPARUM BY HEART-TRANSPLANT	BRITISH MEDICAL JOURNAL			English	Article							MALARIA		GRP HOSP PITIE SALPETRIERE,DEPT PARASITOL,F-75651 PARIS 13,FRANCE; ETABLISSEMENT CABANEL,INST NATL TRANSFUS SANGUINE,F-75739 PARIS 15,FRANCE; GRP HOSP PITIE SALPETRIERE,INSERM,U313,F-75651 PARIS 13,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	BABINET, J (corresponding author), GRP HOSP PITIE SALPETRIERE,CTR TRANSFUS SANGUINE GRP,F-75651 PARIS 13,FRANCE.							Cruz I, 1978, J Natl Med Assoc, V70, P105; DHARMASENA F, 1986, TRANSPLANTATION, V42, P228, DOI 10.1097/00007890-198608000-00027; HOLZER B, 1984, TRANSPLANTATION, V39, P315; JOHNSTON IDA, 1981, BRIT MED J, V282, P780, DOI 10.1136/bmj.282.6266.780; LEFAVOUR GS, 1980, JAMA-J AM MED ASSOC, V244, P1820, DOI 10.1001/jama.244.16.1820	5	31	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1515	1516		10.1136/bmj.303.6816.1515	http://dx.doi.org/10.1136/bmj.303.6816.1515			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782492	Green Published, Bronze			2022-12-28	WOS:A1991GV47600025
J	DONALDSON, C; MOONEY, G				DONALDSON, C; MOONEY, G			NEEDS ASSESSMENT, PRIORITY SETTING, AND CONTRACTS FOR HEALTH-CARE - AN ECONOMIC-VIEW	BRITISH MEDICAL JOURNAL			English	Article							QALYS				DONALDSON, C (corresponding author), UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND.			Donaldson, Cam/0000-0003-4670-5340				BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; DONALDSON C, 1988, J HEALTH ECON, V7, P239, DOI 10.1016/0167-6296(88)90027-6; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MOONEY G, 1991, PROVIDING HLTH CARE; Secretary of State for Social Services, 1988, PUBLIC HLTH ENGLAND; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; Williams A., 1987, HLTH EC, P1; 1991, WORKING HLTH LOCAL H; 1986, OPCS DH1, V16; 1989, WORKING PATIENTS HLT	11	52	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1529	1530		10.1136/bmj.303.6816.1529	http://dx.doi.org/10.1136/bmj.303.6816.1529			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782499	Bronze, Green Published			2022-12-28	WOS:A1991GV47600031
J	GILKS, CF				GILKS, CF			WHAT USE IS A CLINICAL CASE DEFINITION FOR AIDS IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							ZAIRE; TUBERCULOSIS; INFECTION		KENYA GOVT MED RES CTR,NAIROBI,KENYA	Kenya Medical Research Institute			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123				BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1988, AIDS, V2, P219; GILKES CF, IN PRESS Q J MED; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; GILKS CF, 1991, IN PRESS TROPICAL DO; GILKS CF, IN PRESS AIDS; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; MANN JM, 1986, LANCET, V2, P707; REEVE PA, 1989, BRIT MED J, V298, P1567, DOI 10.1136/bmj.298.6687.1567; ROSE G, 1978, BRIT MED J, V2, P873, DOI 10.1136/bmj.2.6141.873; SWAI ABM, 1989, LANCET, V2, P976; WABWIREMANGEN F, 1989, AIDS, V3, P462, DOI 10.1097/00002030-198907000-00013; WIDIWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286; 1987, MMWR S1, V36, pS4; 1986, WEEKLY EPIDEMIOLOGIC, V61, P69	20	19	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1189	1190		10.1136/bmj.303.6811.1189	http://dx.doi.org/10.1136/bmj.303.6811.1189			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747621	Green Published, Bronze			2022-12-28	WOS:A1991GP48800031
J	DUNEA, G				DUNEA, G			BURNING DOWN THEIR HOUSES	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1141	1141						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747602				2022-12-28	WOS:A1991GN20900076
J	KLEINMAN, LC				KLEINMAN, LC			TO END AN EPIDEMIC - LESSONS FROM THE HISTORY OF DIPHTHERIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS PREVENTION; STRATEGIES; DISEASE				KLEINMAN, LC (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024, USA.		Kleinman, Lawrence/AAS-6934-2021					ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BIGGS HM, 1895, SCI B HLTH DEP, V1, P11; BOARDMAN EI, 1926, ONE DISEASE LESS CHI; CAILLE A, 1890, T AM PEDIATR SOC, V2, P136; CAILLE A, 1888, MED REC, V33, P183; Caulfield Ernest, 1939, TRUE HIST TERRIBLE E; COATES TJ, 1990, J CONSULT CLIN PSYCH, V58, P57, DOI 10.1037/0022-006X.58.1.57; DAN BB, 1987, JAMA-J AM MED ASSOC, V258, P1940, DOI 10.1001/jama.258.14.1940; DICKENS BM, 1988, SCIENCE, V239, P580, DOI 10.1126/science.3340844; EMERSON J, 1939, YALE J BIOL MED BEAU, P70; ENGLISH PC, 1985, PEDIATRICS, V76, P1; FITCH J, 1736, ACCOUNT NUMBERS HAVE; FRANKEL LK, 1925, MAY ANN M STAT COMM; FREUDENBERG N, 1990, INT J HEALTH SERV, V20, P589, DOI 10.2190/W70D-28M1-C62K-K60R; JACOBI A, 1880, TREATISE DIPHTHERIA, P2; KIM JH, 1988, AM J MED, V84, P135, DOI 10.1016/0002-9343(88)90021-6; MORANTZSANCHEZ RM, 1985, SYMPATHY SCI WOMEN P, P187; NELKIN D, 1987, REV INFECT DIS, V9, P980; PARK WH, 1892, MED REC, V42, P141; PELLEGRINO ED, 1987, JAMA-J AM MED ASSOC, V258, P1939, DOI 10.1001/jama.258.14.1939; PRUDDEN TM, 1889, AM J MED SCI, V97, P329; PRUDDEN TM, 1889, AM J MED SCI, V97, P450; ROSENBERG C, 1972, NEW YORK TIMES, P2; RUSSEL WT, 1943, MED RES COUNCIL SPEC, V247; SCHILLING RF, 1989, PUBLIC HEALTH REP, V104, P2; SMITH JL, 1890, TREATISE DISEASES IN; Vaughan HF, 1935, AM J PUBLIC HEALTH N, V25, P681, DOI 10.2105/AJPH.25.6.681; VOGEL MJ, 1980, INVENTION MODERN HOS, P61; WELCH WH, 1891, MED NEWS, V58, P551; WOOD WB, 1961, MIASMAS MOL, P29; 1903, RESTRICTION PREVENTI; 1930, PAU DIPHTHERIA STORY; 1932, SAVING CHILDRENS LIV; ED106122825M CONN ST; 1926, DIPHTHERIA CURABLE P; CARREID SERUM NOME	37	17	18	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					773	777		10.1056/NEJM199203123261118	http://dx.doi.org/10.1056/NEJM199203123261118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH064	1738395				2022-12-28	WOS:A1992HH06400033
J	LUFT, BJ; STEINMAN, CR; NEIMARK, HC; MURALIDHAR, B; RUSH, T; FINKEL, MF; KUNKEL, M; DATTWYLER, RJ				LUFT, BJ; STEINMAN, CR; NEIMARK, HC; MURALIDHAR, B; RUSH, T; FINKEL, MF; KUNKEL, M; DATTWYLER, RJ			INVASION OF THE CENTRAL-NERVOUS-SYSTEM BY BORRELIA-BURGDORFERI IN ACUTE DISSEMINATED INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYME-DISEASE; MANIFESTATIONS; POLYMERASE; DIAGNOSIS; DNA	Objective. - To determine central nervous system (CNS) involvement in acutely disseminated Borrelia burgdorferi infection by measurement of borrelia-specific DNA using the polymerase chain-reaction (PCR) assay and to compare the results of this with standard serological tests. Design. - Prospective study with laboratory investigators blinded to clinical data. Setting. - Multicenter office practice with a central reference laboratory. Patients. - Cerebrospinal fluid (CSF) was collected from 12 patients with acute disseminated Lyme borreliosis with less than 2 weeks of active disease. The normal control specimens came from 16 patients whose CSF samples had been sent to the clinical laboratory for tests unrelated to the present study. Main Outcome Measures. - Clinical evidence of disease and laboratory abnormalities. Results. - Eight of the 12 patients (four of six with multiple areas of erythema migrans and four of six with cranial neuritis without erythema migrans) had B burgdorferi-specific DNA in their CSF. Among the 12 patients studied, nine had acute cranial neuritis and six had multiple erythema migrans lesions. Just four of the eight who were found to have spirochetal DNA in their CSF had complaints suggestive of CNS infection. In three of the PCR-positive CSF samples, no other abnormalities were noted. None of 16 samples from controls were positive in the PCR assay. Conclusion. - B burgdorferi can invade the CNS early in the course of infection. Careful consideration should be given to choosing antibiotics that achieve adequate CSF levels in patients with disseminated infection.	PHELPS MEM HOSP CTR, DEPT INFECT DIS, TARRYTOWN, NY USA; SUNY DOWNSTATE MED CTR, DEPT IMMUNOL, BROOKLYN, NY 11203 USA; MIDELFORT CLIN, DEPT NEUROL, EAU CLAIRE, WI USA; SUNY DOWNSTATE MED CTR, DEPT MICROBIOL, BROOKLYN, NY 11203 USA; DANBURY HOSP, DEPT INFECT DIS, DANBURY, CT 06810 USA	Northwell Health; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	LUFT, BJ (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, T-15 080, STONY BROOK, NY 11794 USA.		Dattwyler, Raymond/ABH-2292-2021	Dattwyler, Raymond/0000-0002-1983-1301; Luft, Benjamin/0000-0001-9008-7004				BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; CHEN K, 1989, FEMS MICROBIOL LETT, V57, P19, DOI 10.1016/S0378-1097(97)00476-X; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GASSMANN GS, 1989, NUCLEIC ACIDS RES, V17, P3590, DOI 10.1093/nar/17.9.3590; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HUPPERTZ HI, 1989, EUR J PEDIATR, V148, P428, DOI 10.1007/BF00595904; JAULHAC B, 1991, NEW ENGL J MED, V324, P1440; LUFT BJ, 1990, CURR CLIN TOP INFECT, V10, P56; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STIERNSTEDT G, 1988, ANN NY ACAD SCI, V539, P46, DOI 10.1111/j.1749-6632.1988.tb31837.x; WILSKE B, 1986, J INFECT DIS, V153, P304, DOI 10.1093/infdis/153.2.304	18	149	150	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1364	1367		10.1001/jama.267.10.1364	http://dx.doi.org/10.1001/jama.267.10.1364			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740859				2022-12-28	WOS:A1992HG67800030
J	PROCKOP, DJ; FLIER, J				PROCKOP, DJ; FLIER, J			MUTATIONS IN COLLAGEN GENES AS A CAUSE OF CONNECTIVE-TISSUE DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							LETHAL OSTEOGENESIS IMPERFECTA; ABDOMINAL AORTIC-ANEURYSMS; MILD CHONDRODYSPLASIA; I COLLAGEN; OSTEOPOROSIS; COL2A1				PROCKOP, DJ (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA.		Flier, jeffrey/AAG-6223-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188, P01AR039740] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39740, AR38188] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; BYERS PH, 1988, AM J HUM GENET, V42, P237; BYERS PH, 1983, CLIN MED, P1; CONSTANTINOU CD, 1989, CYTOGENET CELL GENET, V51, P979; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749-6632.1990.tb17927.x; FRANCOMANO C A, 1987, Genomics, V1, P293, DOI 10.1016/0888-7543(87)90027-9; HARRISON D, 1990, AM J HUM GENET S, V47, pA219; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KELLY TF, 1981, ANN SURG, V193, P686, DOI 10.1097/00000658-198106000-00003; KHILLAN JS, IN PRESS J BIOL CHEM; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PROCKOP DJ, 1988, ARTHRITIS RHEUM, V31, P1, DOI 10.1002/art.1780310101; PROCKOP DJ, 1987, HARRISONS PRINCIPLES, P1680; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROWE DW, 1985, J CLIN INVEST, V76, P604, DOI 10.1172/JCI112012; RUTHERFORD RB, 1988, SEMIN VASC SURG, V1, P131; SHAPIRO JR, 1989, CONNECT TISSUE RES, V21, P447, DOI 10.3109/03008208909050002; SILLENCE D, 1981, CLIN ORTHOP RELAT R, P11; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SPOTILA LD, 1991, P NATL ACAD SCI USA, V88, P5423, DOI 10.1073/pnas.88.12.5423; SPRANGER J, 1976, CLIN ORTHOP RELAT R, P46; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; VANDENBERG P, 1991, P NATL ACAD SCI USA, V88, P7640, DOI 10.1073/pnas.88.17.7640; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WENSTRUP RJ, 1990, AM J HUM GENET, V46, P975; YOUNG ID, 1987, J MED GENET, V24, P386, DOI 10.1136/jmg.24.7.386; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z	41	106	107	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					540	546						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1732793				2022-12-28	WOS:A1992HD65800007
J	LONDON, SJ; CONNOLLY, JL; SCHNITT, SJ; COLDITZ, GA				LONDON, SJ; CONNOLLY, JL; SCHNITT, SJ; COLDITZ, GA			A PROSPECTIVE-STUDY OF BENIGN BREAST DISEASE AND THE RISK OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LESIONS; WOMEN	Objective. - To examine the relation between proliferative benign breast disease with and without atypical hyperplasia and the subsequent risk of breast cancer. Design. - Case-control study nested within a prospective cohort study. Median follow-up after breast biopsy was 8 years (25th to 75th percentile, 5 to 14 years). Participants. - Selected from a prospective cohort of 121 700 US registered nurses followed up from 1976 to 1986. Cases were women with breast cancer who had a prior biopsy for benign breast disease. Controls were randomly selected and matched on year of biopsy and year of birth from among women in the cohort who had a benign breast biopsy but who did not develop breast cancer. Included in the analysis were 121 cases and 488 controls. Main Outcome Measure. - Development of breast cancer. Results. - Slides from the first benign breast biopsy were reviewed by two breast pathologists blinded to the outcome, The multiply adjusted relative risks (RRs) for breast cancer, relative to women with no proliferative disease, were 1.6 for proliferative disease without atypia (95% confidence interval [Cl], 1.0 to 2.5) and 3.7 for atypical hyperplasia (95% Cl, 2.1 to 6.8). Breast cancer risk was more strongly associated with atypical hyperplasia among premenopausal women (RR = 5.9; 95% Cl, 2.9 to 13.2) than postmenopausal women (RR = 2.3; 95% CI, 0.9 to 5.9), but the association of breast cancer risk with proliferative disease without atypia did not differ across menopausal status. Conclusion. - These results confirm the marked increase in breast cancer risk among women with atypical hyperplasia, particularly in premenopausal women, and suggest that these women should be encouraged to undergo frequent breast cancer screening.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	LONDON, SJ (corresponding author), UNIV SO CALIF, SCH MED, DEPT PREVENT MED, 1420 SAN PABLO ST, PMB B306, LOS ANGELES, CA 90033 USA.		London, Stephanie/C-3734-2019; Colditz, Graham/A-3963-2009	London, Stephanie/0000-0003-4911-5290; Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R01CA046475, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356, CA 09001, CA 46475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1986, Arch Pathol Lab Med, V110, P171; BLACK MM, 1972, CANCER, V29, P338, DOI 10.1002/1097-0142(197202)29:2&lt;338::AID-CNCR2820290212&gt;3.0.CO;2-U; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; DONNELLY PK, 1975, MAYO CLIN PROC, V50, P650; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1989, HUM PATHOL, V20, P723, DOI 10.1016/0046-8177(89)90063-4; FOOTE FW, 1945, ANN SURG, V121, P197, DOI 10.1097/00000658-194502000-00009; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KODLIN D, 1977, CANCER, V39, P2603, DOI 10.1002/1097-0142(197706)39:6<2603::AID-CNCR2820390645>3.0.CO;2-T; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105	14	373	384	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					941	944		10.1001/jama.267.7.941	http://dx.doi.org/10.1001/jama.267.7.941			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734106				2022-12-28	WOS:A1992HD15500026
J	WARSHAW, AL; FERNANDEZDELCASTILLO, C				WARSHAW, AL; FERNANDEZDELCASTILLO, C			PANCREATIC-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MALIGNANT OBSTRUCTIVE-JAUNDICE; NEEDLE ASPIRATION BIOPSY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; SERUM IMMUNOREACTIVE ELASTASE; HORMONE-RELEASING HORMONE; POLYPEPTIDE ANTIGEN TPA; PAST MEDICAL HISTORY; PHASE-II TRIAL; DUCTAL ADENOCARCINOMA; DIABETES-MELLITUS		HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	WARSHAW, AL (corresponding author), MASSACHUSETTS GEN HOSP, SURG SERV, ACC-336, BOSTON, MA 02114 USA.		Castillo, Carlos Fenandez-del/AAO-2602-2020					ALANEN KA, 1990, J PATHOL, V160, P313, DOI 10.1002/path.1711600407; ALKAISI N, 1989, ACTA CYTOL, V33, P145; ALLISON DC, 1991, ANN SURG, V214, P648, DOI 10.1097/00000658-199112000-00002; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDERSEN JR, 1989, GUT, V30, P1132, DOI 10.1136/gut.30.8.1132; ANDRENSANDBERG A, 1990, ACTA CHIR SCAND, V156, P549; ANDRENSANDBERG A, 1983, ANN SURG, V198, P605, DOI 10.1097/00000658-198311000-00008; [Anonymous], 1987, Cancer, V59, P2006; ARBUCK SG, 1990, INT J PANCREATOL, V7, P209; ATHLIN L, 1990, ACTA CHIR SCAND, V156, P91; BAISCH H, 1990, VIRCHOWS ARCH A, V417, P145, DOI 10.1007/BF02190532; BAKKEVOLD KE, 1990, BRIT J SURG, V77, P725, DOI 10.1002/bjs.1800770704; BALTHAZAR EJ, 1990, AM J GASTROENTEROL, V85, P343; BAUM RP, 1989, HEPATO-GASTROENTEROL, V36, P459; BAUM RP, 1990, HEPATO-GASTROENTEROL, V37, P154; BEAHRS OH, 1988, MANUAL STAGING CANCE; BELL ET, 1957, AM J PATHOL, V33, P499; BERNARDINO ME, 1982, CANCER, V50, P2681; BIRT DF, 1983, J NATL CANCER I, V71, P355; BLUMBERG N, 1990, TRANSFUSION, V30, P291, DOI 10.1046/j.1537-2995.1990.30490273432.x; BOERMA EJ, 1990, BRIT J SURG, V77, P299, DOI 10.1002/bjs.1800770319; BOYLE P, 1989, INT J PANCREATOL, V5, P327, DOI 10.1007/BF02924298; BRAASCH JW, 1986, ANN SURG, V204, P411, DOI 10.1097/00000658-198610000-00009; BROOKS JR, 1989, ANN SURG, V209, P405, DOI 10.1097/00000658-198904000-00003; BURNEY PGJ, 1989, AM J CLIN NUTR, V49, P895, DOI 10.1093/ajcn/49.5.895; CAMERON JL, 1991, AM J SURG, V161, P120, DOI 10.1016/0002-9610(91)90371-J; CONNOLLY MM, 1987, ANN SURG, V206, P366, DOI 10.1097/00000658-198709000-00015; CRAIGHEAD CC, 1958, ANN SURG, V147, P931; CRIST DW, 1987, ANN SURG, V206, P358, DOI 10.1097/00000658-198709000-00014; CUBILLA AL, 1978, J SURG ONCOL, V10, P465, DOI 10.1002/jso.2930100602; Cubilla AL, 1984, ATLAS TUMOR PATHOLOG; CUSCHIERI A, 1988, EUR J SURG ONCOL, V14, P41; CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312; Del Favero G, 1988, Int J Pancreatol, V3 Suppl 1, pS107; DELCASTILLO CF, 1990, PANCREAS, V5, P693, DOI 10.1097/00006676-199011000-00009; DELMASCHIO A, 1991, RADIOLOGY, V178, P95, DOI 10.1148/radiology.178.1.1984331; DOBELBOWER RR, 1991, INT J RADIAT ONCOL, V20, P113, DOI 10.1016/0360-3016(91)90146-U; DOBERNECK RC, 1987, ARCH SURG-CHICAGO, V122, P827; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; ECKHAUSER FE, 1986, SURGERY, V100, P978; ENDO Y, 1974, GASTROENTEROLOGY, V67, P944; ESKELINEN M, 1991, PANCREAS, V6, P90, DOI 10.1097/00006676-199101000-00012; ESSOP AR, 1984, J CLIN GASTROENTEROL, V6, P61; FABRIS C, 1988, AM J GASTROENTEROL, V83, P549; FALK RT, 1988, AM J EPIDEMIOL, V128, P324, DOI 10.1093/oxfordjournals.aje.a114972; FARROW DC, 1990, INT J CANCER, V45, P816, DOI 10.1002/ijc.2910450504; FARROW DC, 1990, AM J EPIDEMIOL, V132, P423, DOI 10.1093/oxfordjournals.aje.a115677; FEKETE M, 1989, CANCER LETT, V45, P87, DOI 10.1016/0304-3835(89)90141-9; FERNANDEZDELCASTILLO C, 1990, PANCREAS, V5, P515, DOI 10.1097/00006676-199009000-00003; FERRUCCI JT, 1979, RADIOLOGY, V130, P345, DOI 10.1148/130.2.345; FISHER WE, 1990, J SURG RES, V48, P403, DOI 10.1016/0022-4804(90)90003-K; FORTNER JG, 1984, ANN SURG, V199, P418, DOI 10.1097/00000658-198404000-00008; FREBOURG T, 1988, CANCER-AM CANCER SOC, V62, P2287, DOI 10.1002/1097-0142(19881201)62:11<2287::AID-CNCR2820621103>3.0.CO;2-H; FREENY PC, 1988, RADIOLOGY, V166, P125, DOI 10.1148/radiology.166.1.2827228; FREENY PC, 1988, AM J ROENTGENOL, V150, P975, DOI 10.2214/ajr.150.5.975; FREENY PC, 1989, RADIOL CLIN N AM, V27, P121; FUNOVICS JM, 1989, HEPATO-GASTROENTEROL, V36, P450; GHADIRIAN P, 1991, CANCER-AM CANCER SOC, V67, P2664, DOI 10.1002/1097-0142(19910515)67:10&lt;2664::AID-CNCR2820671043&gt;3.0.CO;2-K; GIRARD RM, 1981, CAN MED ASSOC J, V125, P576; GLENN J, 1988, J CLIN ONCOL, V6, P462, DOI 10.1200/JCO.1988.6.3.462; GOLD EB, 1985, CANCER-AM CANCER SOC, V55, P460, DOI 10.1002/1097-0142(19850115)55:2<460::AID-CNCR2820550229>3.0.CO;2-V; GONZALEZBARCENA D, 1989, BIOMED PHARMACOTHER, V43, P313, DOI 10.1016/0753-3322(89)90014-0; GOODING GAW, 1987, SURGICAL DISEASES PA, P101; GORDIS L, 1990, CANCER LETT, V52, P1, DOI 10.1016/0304-3835(90)90070-E; GRACE PA, 1990, BRIT J SURG, V77, P968, DOI 10.1002/bjs.1800770906; GRACE PA, 1986, AM J SURG, V151, P141, DOI 10.1016/0002-9610(86)90024-3; GREEN RC, 1958, DIABETES, V7, P308, DOI 10.2337/diab.7.4.308; GREENWAY BA, 1987, BRIT J SURG, V74, P441, DOI 10.1002/bjs.1800740602; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; GUDJONSSON B, 1978, CANCER, V42, P2494, DOI 10.1002/1097-0142(197811)42:5<2494::AID-CNCR2820420554>3.0.CO;2-R; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; GULLO L, 1989, PANCREAS, V4, P335, DOI 10.1097/00006676-198906000-00010; GUO HR, 1987, AM SURGEON, V53, P726; HADDOCK G, 1990, BRIT J SURG, V77, P1159, DOI 10.1002/bjs.1800771025; HAMANO H, 1987, DIGEST DIS SCI, V32, P50, DOI 10.1007/BF01296687; HART MJ, 1987, AM J SURG, V154, P134, DOI 10.1016/0002-9610(87)90303-5; HAYASHI Y, 1989, ENDOSCOPY, V21, P121, DOI 10.1055/s-2007-1012919; HEIJMANS HJ, 1989, HEPATO-GASTROENTEROL, V36, P474; HIRAYAMA T, 1989, JPN J CLIN ONCOL, V19, P208; HOWE GR, 1990, INT J CANCER, V45, P604, DOI 10.1002/ijc.2910450405; HOWE GR, 1991, INT J CANCER, V47, P323, DOI 10.1002/ijc.2910470302; HUIBREGTSE K, 1986, GASTROINTEST ENDOSC, V32, P334, DOI 10.1016/S0016-5107(86)71878-6; HYVARINEN H, 1987, HEPATO-GASTROENTEROL, V34, P280; ISHIKAWA O, 1989, CANCER, V64, P1107, DOI 10.1002/1097-0142(19890901)64:5<1107::AID-CNCR2820640523>3.0.CO;2-Y; ISHIKAWA O, 1988, ANN SURG, V208, P215, DOI 10.1097/00000658-198808000-00014; JOYCE F, 1990, INT J RADIAT ONCOL, V19, P1049, DOI 10.1016/0360-3016(90)90032-F; KALSER MH, 1985, CANCER, V56, P397, DOI 10.1002/1097-0142(19850715)56:2<397::AID-CNCR2820560232>3.0.CO;2-I; KAUFMAN AR, 1989, GASTROINTEST ENDOSC, V35, P214, DOI 10.1016/S0016-5107(89)72761-9; KEATING JJ, 1989, BRIT J CANCER, V60, P789, DOI 10.1038/bjc.1989.361; KOHLER H, 1987, PANCREAS, V2, P676, DOI 10.1097/00006676-198701000-00018; LEES WR, 1984, CLIN GASTROENTEROL, V13, P763; LIN A, 1990, ANN INTERN MED, V113, P166, DOI 10.7326/0003-4819-113-2-166; LIN RS, 1981, JAMA-J AM MED ASSOC, V245, P147; LONGNECKER DS, 1990, CANCER RES, V50, P7552; LONGNECKER DS, 1985, J NATL CANCER I, V74, P219; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MACKIE CR, 1979, ANN SURG, V189, P11, DOI 10.1097/00000658-197901000-00003; MACMAHON B, 1981, NEW ENGL J MED, V304, P630, DOI 10.1056/NEJM198103123041102; MAHVI DM, 1988, PANCREAS, V3, P488, DOI 10.1097/00006676-198808000-00020; MALLINSON CN, 1980, BRIT MED J, V281, P1589, DOI 10.1136/bmj.281.6255.1589; MANCUSO TF, 1967, JOM-J OCCUP MED, V9, P277; MANG TS, 1987, PHOTOCHEM PHOTOBIOL, V46, P853, DOI 10.1111/j.1751-1097.1987.tb04859.x; MCCUNE WS, 1968, ANN SURG, V167, P752, DOI 10.1097/00000658-196805000-00013; MEDURI F, 1989, CANCER, V64, P1103, DOI 10.1002/1097-0142(19890901)64:5<1103::AID-CNCR2820640522>3.0.CO;2-C; MEHTA MP, 1990, INT J RADIAT ONCOL, V19, P627, DOI 10.1016/0360-3016(90)90489-7; MERRICK HW, 1990, GASTROENTEROL CLIN N, V19, P935; MICHELASSI F, 1989, ANN SURG, V210, P544, DOI 10.1097/00000658-198910000-00015; MILLS PK, 1988, CANCER-AM CANCER SOC, V61, P2578, DOI 10.1002/1097-0142(19880615)61:12&lt;2578::AID-CNCR2820611232&gt;3.0.CO;2-0; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; MOERTEL CG, 1969, LANCET, V2, P865; MOROHOSHI T, 1983, HISTOPATHOLOGY, V7, P645, DOI 10.1111/j.1365-2559.1983.tb02277.x; MUKAI H, 1991, GASTROINTEST ENDOSC, V37, P275; NAGAI H, 1986, ANN SURG, V204, P65, DOI 10.1097/00000658-198607000-00009; NISHIDA K, 1985, GUT, V26, P450, DOI 10.1136/gut.26.5.450; NIX GAJJ, 1984, GASTROENTEROLOGY, V87, P37; NORELL SE, 1986, AM J EPIDEMIOL, V124, P894, DOI 10.1093/oxfordjournals.aje.a114479; OFFERHAUS GJA, 1988, MODERN PATHOL, V1, P352; PANUCCI A, 1985, BRIT J CANCER, V52, P801, DOI 10.1038/bjc.1985.262; PARSONS L, 1989, ARCH SURG-CHICAGO, V124, P681; PELLEGRINI CA, 1989, ARCH SURG-CHICAGO, V124, P778; PLESKOW DK, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-704; PODOLSKY DK, 1981, NEW ENGL J MED, V304, P1313, DOI 10.1056/NEJM198105283042201; POLLOCK D, 1981, CANCER, V47, P1662, DOI 10.1002/1097-0142(19810315)47:6+<1662::AID-CNCR2820471434>3.0.CO;2-8; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RAO MS, 1987, CANCER METAST REV, V6, P665, DOI 10.1007/BF00047473; RASHLEIGHBELCHER HJC, 1986, BRIT J RADIOL, V59, P182, DOI 10.1259/0007-1285-59-698-182; REMINE WH, 1970, ANN SURG, V172, P595, DOI 10.1097/00000658-197010000-00006; RIVENSON A, 1988, CANCER RES, V48, P6912; ROBLESDIAZ G, 1987, PANCREAS, V2, P684, DOI 10.1097/00006676-198711000-00010; ROBLESDIAZ G, 1991, AM J GASTROENTEROL, V86, P591; ROLDAN GE, 1988, CANCER, V61, P1110, DOI 10.1002/1097-0142(19880315)61:6<1110::AID-CNCR2820610610>3.0.CO;2-6; ROSA JA, 1989, J CLIN GASTROENTEROL, V11, P211, DOI 10.1097/00004836-198904000-00020; ROSENBERG JM, 1985, J SURG ONCOL, V28, P217, DOI 10.1002/jso.2930280315; SARR MG, 1982, SURGERY, V91, P123; SAWADA Y, 1989, ACTA CYTOL, V33, P870; SCHRODER T, 1988, J SURG ONCOL, V38, P4, DOI 10.1002/jso.2930380103; SCUDERA PL, 1990, GASTROINTEST ENDOSC, V36, P281, DOI 10.1016/S0016-5107(90)71024-3; SHARP KW, 1989, SURGERY, V105, P645; SHEMESH E, 1990, CANCER, V65, P893, DOI 10.1002/1097-0142(19900215)65:4<893::AID-CNCR2820650412>3.0.CO;2-G; SHIBATA D, 1990, CANCER RES, V50, P1279; SHIPLEY WU, 1984, ANN SURG, V200, P289, DOI 10.1097/00000658-198409000-00006; SINGH SM, 1990, ANN SURG, V212, P132, DOI 10.1097/00000658-199008000-00003; SMITH AC, 1989, GUT, V30, pA1513; SMITH JP, 1990, DIGEST DIS SCI, V35, P1377, DOI 10.1007/BF01536744; SOEHENDRA N, 1989, WORLD J SURG, V13, P171, DOI 10.1007/BF01658395; SPEER AG, 1987, LANCET, V2, P57, DOI 10.1016/S0140-6736(87)92733-4; STEINBERG W, 1990, AM J GASTROENTEROL, V85, P350; STEINBERG WM, 1986, GASTROENTEROLOGY, V90, P343, DOI 10.1016/0016-5085(86)90930-3; STEINER E, 1989, AM J ROENTGENOL, V152, P487, DOI 10.2214/ajr.152.3.487; SUMI C, 1989, CANCER RES, V49, P2332; SZENDE B, 1990, CANCER RES, V50, P3716; TARAZI RY, 1986, SURGERY, V100, P716; TAYLOR KJW, 1977, ARCH SURG-CHICAGO, V112, P820; TAYLOR PR, 1989, GUT, V30, P1596, DOI 10.1136/gut.30.11.1596; TEMPERO MA, 1990, J CLIN ONCOL, V8, P2019, DOI 10.1200/JCO.1990.8.12.2019; THOMAS PG, 1990, WORLD J SURG, V14, P32, DOI 10.1007/BF01670542; TIO TL, 1990, RADIOLOGY, V175, P455, DOI 10.1148/radiology.175.2.2183284; TOGAWA Y, 1989, JPN J SURG, V19, P398, DOI 10.1007/BF02471619; TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097/00000658-199004000-00011; TSUCHIYA R, 1990, INT J PANCREATOL, V6, P295; TSUCHIYA R, 1986, ANN SURG, V203, P77, DOI 10.1097/00000658-198601000-00013; Tsuda T, 1990, Ann Nucl Med, V4, P71; VANDYKE JA, 1985, ANN INTERN MED, V102, P212, DOI 10.7326/0003-4819-102-2-212; VANHEERDEN JA, 1984, WORLD J SURG, V8, P880, DOI 10.1007/BF01656028; VANHEERDEN JA, 1981, AM J SURG, V142, P308, DOI 10.1016/0002-9610(81)90336-6; VENU RP, 1990, GASTROENTEROLOGY, V99, P1475, DOI 10.1016/0016-5085(90)91178-9; WAGENER DJT, 1989, CANCER CHEMOTH PHARM, V25, P131, DOI 10.1007/BF00692353; WARD EM, 1983, RADIOGRAPHICS, V3, P547; WARSHAW AL, 1988, ANN SURG, V208, P541, DOI 10.1097/00000658-198811000-00001; WARSHAW AL, 1986, AM J SURG, V151, P76, DOI 10.1016/0002-9610(86)90015-2; WARSHAW AL, 1990, ANN SURG, V212, P432, DOI 10.1097/00000658-199010000-00006; WARSHAW AL, 1980, AM J SURG, V139, P27, DOI 10.1016/0002-9610(80)90225-1; WARSHAW AL, 1991, AM J SURG, V161, P26, DOI 10.1016/0002-9610(91)90356-I; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; WEAVER DW, 1987, SURGERY, V102, P608; WEBB TH, 1989, ANN SURG, V209, P25, DOI 10.1097/00000658-198901000-00003; WEGER AR, 1991, GUT, V32, P325, DOI 10.1136/gut.32.3.325; WEISS SM, 1985, ARCH SURG-CHICAGO, V120, P415; WHITTINGTON R, 1981, INT J RADIAT ONCOL, V7, P1639, DOI 10.1016/0360-3016(81)90185-1; WILS JA, 1989, ANTICANCER RES, V9, P1027; WONG A, 1987, CANCER TREAT REP, V71, P749; WORLOCK AJ, 1990, CANCER RES, V50, P7246; WYNDER EL, 1973, JNCI-J NATL CANCER I, V50, P645, DOI 10.1093/jnci/50.3.645; YAMAMOTO K, 1990, J NUCL MED, V31, P1015; 1991, CANCER FACTS FIGURES; 1991, CANCER INCIDENCE SWE; 1991, NIH912789 DEP HLTH H	187	1403	1439	1	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					455	465		10.1056/NEJM199202133260706	http://dx.doi.org/10.1056/NEJM199202133260706			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732772				2022-12-28	WOS:A1992HD16400006
J	PONSONBY, AL; DWYER, T; GIBBONS, LE; COCHRANE, JA; JONES, ME; MCCALL, MJ				PONSONBY, AL; DWYER, T; GIBBONS, LE; COCHRANE, JA; JONES, ME; MCCALL, MJ			THERMAL ENVIRONMENT AND SUDDEN-INFANT-DEATH-SYNDROME - CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; COT DEATH; TEMPERATURE; HYPERTHERMIA	Objective - To compare the thermal environment of infants who died of the sudden infant death syndrome with that of age matched control infants. Design - Case-control study. Infants who died were matched with two controls, one for age and one for age and birth weight. Thermal measurements were conducted at the death scene for cases and at the scene of last sleep for control infants, who were visited unexpectedly within four weeks of the index infant's death on a day of similar climatic conditions. A follow up questionnaire was administered to parents of cases and controls. Setting - The geographical area served by the professional Tasmanian state ambulance service, which includes 94% of the Tasmanian population. Subjects - 41 infants died of the sudden infant death syndrome at home; thermal observations at death scene were available for 28 (68%), parental questionnaire data were available for 40 (96%). 38 controls matched for age and 41 matched for age and birth weight. Results - Cases had more excess thermal insulation for their given room temperature (2.3 togs) than matched controls (0.6 togs) (p = 0.009). For every excess thermal insulation unit (tog) the relative risk of the sudden infant death syndrome was 1.26 (95% confidence interval 1.05 to 1.52). The average thermal bedding value calculated from parental recall was similar to that observed by attendant ambulance officers (mean difference = 0.4 tog, p = 0.39). Cases were more likely to have been found prone (odds ratio 4.58; 1.48 to 14.11). Prone sleeping position was not a confounder or effect modifier of the relation between excess thermal insulation and the syndrome. Conclusions - Overheating and the prone sleeping position are independently associated with an increased risk of the sudden infant death syndrome. Further work on infant thermal balance and sudden infant death is required and guidelines for appropriate infant thermal care need to be developed.	TASMANIAN AMBULANCE SERV,HOBART,TAS 7000,AUSTRALIA		PONSONBY, AL (corresponding author), UNIV TASMANIA,MENZIES CTR POPULAT HLTH RES,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657; Jones, Michael/0000-0001-7479-3451				BACON C, 1979, LANCET, V2, P42; BASS M, 1982, NEW ENGL J MED, V307, P891; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; BONSER RSA, 1978, INT J EPIDEMIOL, V7, P335, DOI 10.1093/ije/7.4.335; Breslow N, 1980, STATISTICAL METHODS, V32; Burton A.C., 1955, MAN COLD ENV; CAMPBELL MJ, 1989, MED J AUSTRALIA, V151, P365, DOI 10.5694/j.1326-5377.1989.tb101216.x; CLULOW E, 1978, TEXTILES, V1, P2; EISER C, 1985, ARCH DIS CHILD, V60, P465, DOI 10.1136/adc.60.5.465; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Golding J., 1985, SUDDEN INFANT DEATH; GREENBERG MA, 1973, AM J EPIDEMIOL, V98, P412, DOI 10.1093/oxfordjournals.aje.a121570; GUNTHEROTH WG, 1990, BRIT MED J, V301, P494, DOI 10.1136/bmj.301.6750.494-a; HARAGUCHI S, 1983, ANN OTO RHINOL LARYN, V92, P24, DOI 10.1177/000348948309200106; HASSALL IB, 1987, MED J AUSTRALIA, V147, P214, DOI 10.5694/j.1326-5377.1987.tb133408.x; HEY EN, 1969, J PHYSIOL-LONDON, V200, P605, DOI 10.1113/jphysiol.1969.sp008711; MURPHY MFG, 1987, J EPIDEMIOL COMMUN H, V41, P63, DOI 10.1136/jech.41.1.63; Nelson E A, 1989, Paediatr Perinat Epidemiol, V3, P146, DOI 10.1111/j.1365-3016.1989.tb00508.x; NELSON EAS, 1989, LANCET, V1, P199; PARMEGGIANI PL, 1987, SLEEP, V10, P526; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCOTT S, 1990, BRIT MED J, V301, P493, DOI 10.1136/bmj.301.6750.493-b; SOUTHALL D, 1990, BRIT MED J, V301, P492; STANTON AN, 1984, LANCET, V2, P1199; STANTON AN, 1980, LANCET, V1, P1054; SUNDERLAND R, 1981, LANCET, V2, P176; TUOHY PG, 1990, NEW ZEAL MED J, V103, P36; WAILOO MP, 1989, ARCH DIS CHILD, V64, P600, DOI 10.1136/adc.64.4.600; 1987, NATIONAL ENERGY SURV	29	165	167	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					277	282		10.1136/bmj.304.6822.277	http://dx.doi.org/10.1136/bmj.304.6822.277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739826	Bronze, Green Published			2022-12-28	WOS:A1992HC70800018
J	HERMANOWSKIVOSATKA, A; VANSTRIJP, JAG; SWIGGARD, WJ; WRIGHT, SD				HERMANOWSKIVOSATKA, A; VANSTRIJP, JAG; SWIGGARD, WJ; WRIGHT, SD			INTEGRIN MODULATING FACTOR-I - A LIPID THAT ALTERS THE FUNCTION OF LEUKOCYTE INTEGRINS	CELL			English	Article							FATTY-ACID DEFICIENCY; INCREASED SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; HUMAN-NEUTROPHILS; CELL-ADHESION; POLYMORPHONUCLEAR LEUKOCYTES; COMPLEMENT RECEPTORS; TRANSIENT ADHESION; GLYCOPROTEIN-IIIA; HUMAN-MONOCYTES	The avidity of integrin CR3 (also known as alpha(M)beta-2, Mac-1, Mo-1, and CD11b/CD18) may be reversibly altered without changes in the number of cell surface receptors. Here we describe a molecule termed integrin modulating factor (IMF-1), which controls CR3 avidity. Addition of IMF-1 to polymorphonuclear leukocytes (PMNs) or to purified CR3 causes enhanced binding of ligand. IMF-1 is not present in resting PMNs, but stimulation of cells results in a transient rise in IMF-1 content that parallels a transient rise in CR3 activity. We suggest that PMNs control adhesivity by controlling synthesis of IMF-1, which then acts as an allosteric activator of leukocyte integrins. IMF-1 is an acidic, amphiphilic molecule of M(r) 340 +/- 16 that does not contain ester, phosphate, amide, sialic acid, or glycosidic or vicinal hydroxyl functionalities, but does contain a carbon-carbon double bond. These results suggest that IMF-1 is an unsaturated fatty acid or an isoprenoid acid.			HERMANOWSKIVOSATKA, A (corresponding author), ROCKEFELLER UNIV, NEW YORK, NY 10021 USA.		van Strijp, Jos A.G./J-9549-2014	van Strijp, Jos A.G./0000-0001-6253-0830	NIAID NIH HHS [AI24775, AI22003] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022003, P01AI024775] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BUYON JP, 1988, J IMMUNOL, V140, P3156; CHAN KFJ, 1989, J BIOL CHEM, V264, P18632; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DANA N, 1986, J IMMUNOL, V137, P3259; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; Guindon Y, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P554; GYLLENHAMMAR H, 1988, LIPIDS, V23, P89, DOI 10.1007/BF02535286; HARLAN JM, 1985, BLOOD, V66, P167; HENSON PM, 1988, INFLAMMATION BASIC P, P363; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIELCZYNSKI W, 1991, P NATL ACAD SCI USA, V88, P1991, DOI 10.1073/pnas.88.5.1991; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LANIER LL, 1985, EUR J IMMUNOL, V15, P713, DOI 10.1002/eji.1830150714; LEFKOWITH JB, 1988, J IMMUNOL, V140, P228; LEFKOWITH JB, 1991, J BIOL CHEM, V266, P1071; LINDSTROM P, 1988, J CLIN LAB IMMUNOL, V25, P77; LO SK, 1989, J IMMUNOL, V143, P3325; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; NEURGEBAUER KM, 1991, NATURE, V350, P68; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PATARROYO M, 1989, SCAND J IMMUNOL, V30, P129, DOI 10.1111/j.1365-3083.1989.tb01197.x; PATARROYO M, 1987, FEBS LETT, V210, P127, DOI 10.1016/0014-5793(87)81321-2; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SCHREINER GF, 1989, J IMMUNOL, V143, P3192; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Spaethe S.M., 1988, CELLULAR MOL ASPECTS, P153; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; TODD RF, 1988, HEMATOL ONCOL CLIN N, V2, P13; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WALSH CE, 1981, J BIOL CHEM, V256, P7228; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1990, LEUKOCYTE ADHESION MOLECULES, P190; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876	61	155	156	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					341	352		10.1016/0092-8674(92)90475-R	http://dx.doi.org/10.1016/0092-8674(92)90475-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733503				2022-12-28	WOS:A1992HB35300013
J	THACH, RE				THACH, RE			CAP RECAP - THE INVOLVEMENT OF EIF-4F IN REGULATING GENE-EXPRESSION	CELL			English	Review							MESSENGER-RNA; TRANSLATIONAL REPRESSION; INITIATION FACTOR-4E; PROTEIN-SYNTHESIS; BINDING PROTEIN; PHOSPHORYLATION; COMPLEX; LEADER; CELLS				THACH, RE (corresponding author), WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA.							AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AMALDI F, 1990, ENZYME, V44, P93, DOI 10.1159/000468750; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P2383; BRAUN RE, 1990, ENZYME, V44, P120, DOI 10.1159/000468752; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HONGO S, 1991, DEV BIOL, V145, P338, DOI 10.1016/0012-1606(91)90132-M; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; STANDART N, 1990, ENZYME, V44, P106, DOI 10.1159/000468751; STEEL LF, 1991, DEV GENET, V12, P98, DOI 10.1002/dvg.1020120117; Trachsel H., 1991, TRANSLATION EUKARYOT; VANDENHEUVEL JJ, 1990, YEAST, V6, P473, DOI 10.1002/yea.320060604; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	39	126	127	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					177	180		10.1016/0092-8674(92)90461-K	http://dx.doi.org/10.1016/0092-8674(92)90461-K			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733496				2022-12-28	WOS:A1992HB35300001
J	WANG, GJ; PORTA, C; CHEN, ZG; BAKER, TS; JOHNSON, JE				WANG, GJ; PORTA, C; CHEN, ZG; BAKER, TS; JOHNSON, JE			IDENTIFICATION OF A FAB INTERACTION FOOTPRINT SITE ON AN ICOSAHEDRAL VIRUS BY CRYOELECTRON MICROSCOPY AND X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							CRYO-ELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; NEUTRALIZATION; RECONSTRUCTION; RESOLUTION; POLIOVIRUS; SPECIMENS; ROTAVIRUS; 3.0-A	BIOLOGICAL processes frequently require the formation of multiprotein or nucleoprotein complexes. Some of these complexes have been produced in homogeneous form, crystallized, and analysed at high resolution by X-ray crystallography (for example, see refs 1-3). Most, however, are too large or too unstable to crystallize. Individual components of such complexes can often be purified and analysed by crystallography. Here we report how the coordinated application of cryoelectron microscopy, three-dimensional image reconstruction, and X-ray crystallography provides a powerful approach to study large, unstable macromolecular complexes. Three-dimensional reconstructions of native cowpea mosaic virus (CMPV) and a complex of CPMV saturated with a Fab fragment of a monoclonal antibody against the virus have been determined at 23 angstrom resolution from low-irradiation images of unstained, frozen-hydrated samples. Despite the nominal resolution of the complex, the physical footprint of the Fab on the capsid surface and the orientation and position of the Fab have been determined to within a few angstroms by fitting atomic models of CPMV 4 and Fab (Kol) 5 to reconstructed density maps.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				, Timothy/0000-0001-6543-8968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM033050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BAKER TS, 1990, J VIROL, V64, P563, DOI 10.1128/JVI.64.2.563-573.1990; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; HOLNESS CL, 1989, VIROLOGY, V172, P311, DOI 10.1016/0042-6822(89)90133-5; ICENOGLE J, 1983, VIROLOGY, V127, P412, DOI 10.1016/0042-6822(83)90154-X; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KRAULIS P, IN PRESS J APPL CRYS; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; MOSSER AG, 1989, MOL ASPECTS PICORNAV, P00155; PAGE GS, 1988, J VIROL, V62, P1781, DOI 10.1128/JVI.62.5.1781-1794.1988; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; YEAGER M, 1990, J CELL BIOL, V110, P2133, DOI 10.1083/jcb.110.6.2133; [No title captured]	21	88	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					275	278		10.1038/355275a0	http://dx.doi.org/10.1038/355275a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731227	Green Published, Green Accepted			2022-12-28	WOS:A1992GZ69400076
J	WILKIE, P; SIBBALD, B; RAFTERY, J; ANDERSON, S; FREELING, P				WILKIE, P; SIBBALD, B; RAFTERY, J; ANDERSON, S; FREELING, P			PRESCRIBING AT THE HOSPITAL-GENERAL PRACTICE INTERFACE .1. HOSPITAL OUTPATIENT DISPENSING POLICIES IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe the outpatient dispensing policies of major acute hospitals in England. Design - Postal questionnaire survey in November 1990. Setting - All (278) major acute hospitals in England with more than 250 beds, excluding maternity, paediatric, or psychiatric hospitals; nine hospitals declined. Participants - Hospital chief pharmacists. Main outcome measures - Current dispensing policy and exceptions to it; when the policy was formed; and who was involved in its formation. Results - Completed questionnaires were received from 200 (72%) of the hospitals approached. The quantities of drugs dispensed to outpatients ranged from zero in 12 hospitals to unlimited amounts in nine; nearly half (92) dispensed a 14 days' supply of drugs. The greater the restriction on outpatient dispensing, the more recently the policy had been introduced (chi-2 for trend = 7.15; df = 1; p < 0.01). Permissible exceptions to the policy included the consultant's specific request (134 hospitals), difficulty in obtaining drugs in the community (102), urgent need for start of treatment (49), and certain types of patients (41) or drugs or their regimens (104). Groups who were neither represented on the hospital committee concerned with policy formation nor consulted before policy changes included regional health authorities in 122 hospitals, district health authorities in 101 hospitals, and general practitioners in 32 hospitals. Conclusions - Outpatient dispensing policies varied considerably among the hospitals surveyed, but they seemed to be moving towards greater restrictions on the supply of drugs given to out patients.	ST GEORGE HOSP,SCH MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	St Georges University London				Anderson, Stuart/0000-0002-4621-0615				BEECHAM L, 1989, BMJ, V299, P863; KATELY GD, 1987, PHARM MANAGEMENT, V13, P5; 1989, LANCET, V1, P981; 1990, IMPROVING PRESCRIBIN	4	10	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					29	31		10.1136/bmj.304.6818.29	http://dx.doi.org/10.1136/bmj.304.6818.29			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734991	Green Published, Bronze			2022-12-28	WOS:A1992GY90900032
J	FRAUENFELDER, H; SLIGAR, SG; WOLYNES, PG				FRAUENFELDER, H; SLIGAR, SG; WOLYNES, PG			THE ENERGY LANDSCAPES AND MOTIONS OF PROTEINS	SCIENCE			English	Article							X-RAY-DIFFRACTION; MOLECULAR-DYNAMICS; CARBON-MONOXIDE; HEME-PROTEINS; SPIN-GLASS; LOW-TEMPERATURES; LIGAND-BINDING; MODEL; MYOGLOBIN; RELAXATION	Recent experiments, advances in theory, and analogies to other complex systems such as glasses and spin glasses yield insight into protein dynamics. The basis of the understanding is the observation that the energy landscape is complex: Proteins can assume a large number of nearly isoenergetic conformations (conformational substates). The concepts that emerge from studies of the conformational substates and the motions between them permit a quantitative discussion of one simple reaction, the binding of small ligands such as carbon monoxide to myoglobin.	UNIV ILLINOIS, BECKMAN INST, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	FRAUENFELDER, H (corresponding author), UNIV ILLINOIS, CTR ADV STUDY, URBANA, IL 61801 USA.							ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Atkins WM, 1991, CURR OPIN STRUC BIOL, V1, P611, DOI 10.1016/S0959-440X(05)80085-5; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BINDER K, 1986, REV MOD PHYS, V58, P801, DOI 10.1103/RevModPhys.58.801; BRAWER S, 1985, RELAXATION VISCOUS L; BROOKS CL, 1988, PROTEINS THEORETICAL; BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CAMPBELL BF, 1988, BIOCHEMISTRY-US, V27, P3507; CARERI G, 1979, ANNU REV BIOPHYS BIO, V8, P69, DOI 10.1146/annurev.bb.08.060179.000441; CASE DA, 1988, PROG BIOPHYS MOL BIO, V52, P39, DOI 10.1016/0079-6107(88)90007-7; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHANCE MR, 1986, J BIOL CHEM, V261, P5689; DEDOMINICIS C, 1985, J PHYS LETT-PARIS, V46, pL463, DOI 10.1051/jphyslet:019850046011046300; DERRIDA B, 1981, PHYS REV B, V24, P2613, DOI 10.1103/PhysRevB.24.2613; EATON WA, 1991, P NATL ACAD SCI USA, V88, P4472, DOI 10.1073/pnas.88.10.4472; EIGEN M, 1986, CHEM SCRIPTA, V26B, P13; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; ENGLANDER SW, 1979, Q REV BIOPHYS, V8, P521; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FERRY JD, 1953, J APPL PHYS, V24, P911, DOI 10.1063/1.1721401; Fischer KH., 1991, SPIN GLASSES, DOI [10.1017/CBO9780511628771, DOI 10.1017/CBO9780511628771]; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; FRAUENFELDER H, 1989, INT J QUANTUM CHEM, V35, P711, DOI 10.1002/qua.560350606; FRAUENFELDER H, 1989, CHEM SCRIPTA, V29A, P145; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; GAREL T, 1988, EUROPHYS LETT, V6, P307, DOI 10.1209/0295-5075/6/4/005; GO N, 1989, CHEM SCRIPTA, V29A, P151; GOLDANSKII VI, 1983, DOKL AKAD NAUK SSSR+, V272, P978; GROSS DJ, 1984, NUCL PHYS B, V240, P431, DOI 10.1016/0550-3213(84)90237-2; GROSS DJ, 1985, PHYS REV LETT, V55, P304, DOI 10.1103/PhysRevLett.55.304; Gurd F R, 1979, Adv Protein Chem, V33, P73, DOI 10.1016/S0065-3233(08)60459-3; HARTMANN H, 1982, P NATL ACAD SCI-BIOL, V79, P4967, DOI 10.1073/pnas.79.16.4967; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; JACKLE J, 1986, REP PROG PHYS, V49, P171, DOI 10.1088/0034-4885/49/2/002; JANKOWIAK R, 1987, SCIENCE, V237, P618, DOI 10.1126/science.237.4815.618; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KIRKPATRICK TR, 1987, PHYS REV B, V36, P8552, DOI 10.1103/PhysRevB.36.8552; KIRKPATRICK TR, 1989, PHYS REV A, V40, P1045, DOI 10.1103/PhysRevA.40.1045; KNOWLES J, 1991, WORKSHOP STRUCTURE F; KOHLER W, 1989, J CHEM PHYS, V90, P1270, DOI 10.1063/1.456131; KOPER GJM, 1987, EUROPHYS LETT, V3, P1213, DOI 10.1209/0295-5075/3/11/010; KUBO R, 1966, REP PROG PHYS, V29, P255, DOI 10.1088/0034-4885/29/1/306; Landau LD, 1980, STATISTICAL PHYSICS; Leventhal C, 1969, MOSSBAUER SPECTROSCO, P22; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LEVITT M, 1983, J MOL BIOL, V168, P621, DOI 10.1016/S0022-2836(83)80306-4; Linderstrom-Lang K, 1959, ENZYMES, P443; LYONS KB, 1982, HEMOGLOBIN OXYGEN BI, P333; MAKINEN MW, 1979, P NATL ACAD SCI USA, V76, P6042, DOI 10.1073/pnas.76.12.6042; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCCOY S, 1971, PROBES STRUCTURE FUN, V2, P323; MEZARD M, 1987, SPIN GLASS THEORY BE; Moerner W. E., 1988, PERSISTENT SPECTRAL; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; ORMOS P, 1990, BIOPHYS J, V57, P191, DOI 10.1016/S0006-3495(90)82522-4; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PETSKO GA, 1984, ANNU REV BIOPHYS BIO, V13, P331; Phillips W. A., 1981, AMORPHOUS SOLIDS; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SCHER H, 1991, PHYS TODAY, V44, P26, DOI 10.1063/1.881289; SHAKHNOVICH EI, 1989, EUROPHYS LETT, V8, P327, DOI 10.1209/0295-5075/8/4/005; SHAKHNOVICH EI, 1989, EUROPHYS LETT, V9, P569, DOI 10.1209/0295-5075/9/6/013; SINGH GP, 1984, Z PHYS B CON MAT, V55, P23, DOI 10.1007/BF01307496; SRAJER V, 1988, J AM CHEM SOC, V110, P6656, DOI 10.1021/ja00228a009; STEIN DL, 1985, P NATL ACAD SCI USA, V82, P3670, DOI 10.1073/pnas.82.11.3670; STEIN DL, 1989, SCI AM, V261, P52, DOI 10.1038/scientificamerican0789-52; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STILLINGER FH, 1984, SCIENCE, V225, P983, DOI 10.1126/science.225.4666.983; TOULOUSE G, 1986, P NATL ACAD SCI USA, V83, P1695, DOI 10.1073/pnas.83.6.1695; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WOLYNES PG, IN PRESS SPIN GLASSE; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013; ZALLEN R, 1983, PHYSICS AMORPHOUS SO; ZWANZIG R, 1988, P NATL ACAD SCI USA, V85, P2029, DOI 10.1073/pnas.85.7.2029	94	2583	2608	8	389	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1598	1603		10.1126/science.1749933	http://dx.doi.org/10.1126/science.1749933			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749933				2022-12-28	WOS:A1991GV07300033
J	KINLEN, LJ; HUDSON, C				KINLEN, LJ; HUDSON, C			CHILDHOOD LEUKEMIA AND POLIOMYELITIS IN RELATION TO MILITARY ENCAMPMENTS IN ENGLAND AND WALES IN THE PERIOD OF NATIONAL MILITARY SERVICE, 1950-63	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA	Objective - To determine if any excess of childhood leukaemia was associated with the large and increasing numbers of national military servicemen in 1949 and 1950, particularly in rural districts. This would be a further test of the hypothesis that childhood leukaemia can originate in an infection, the transmission of which is facilitated by an increased number of unaccustomed contacts in the community. Design - Rural and urban districts, aggregated by county, were ranked by proportion of servicemen, and five groups containing similar numbers of children were created. In addition, individual local authority districts were ranked and grouped in tenths. Mortality from childhood leukaemia 1950-3 was examined in these groups. Data on infectious diseases were also examined, as well as data on leukaemia in later periods. Setting - England and Wales. Subjects - Children aged under 15 years. Results - In 1950-3 but not subsequently a significant excess of leukaemia in children under 15 was found in the fifth of county groupings with the highest proportions of servicemen. This was due mainly to a significant excess in children under 2 years (and especially in those under 1 year) in rural districts. It was confirmed among the tenth of local authority districts with the highest proportion of servicemen. These rural areas showed significantly more notifications of, and deaths from, poliomyelitis among children than the rural average. Conclusions - The findings support the infection hypothesis. That the excess of leukaemia was greatest in children under 1 year suggests transmission of infection among adults and thence to the fetus. The pattern of spread of poliomyelitis may also have been influenced by the presence of large numbers of servicemen.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH MED,CANC RES CAMPAIGN,CANC EPIDEMIOL RES GRP,OXFORD OX2 6HE,ENGLAND.							ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BRESLOW N, 1987, IARC SCI PUBL, V82, P93; CAMPBELL D, 1984, UNSINKABLE AIRCRAFT; Coburn AFY, 1949, EPIDEMIOLOGY HEMOLYT; GLOVER JA, 1915, CEREBRO SPINAL FEVER; GREAVES MF, 1988, LEUKEMIA, V2, P120; Greaves MF, 1984, PATHOGENESIS LEUKEMI, P129; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; ROBISON LL, 1989, CANCER, V63, P1904; ROYLE T, 1986, BEST YEASTS THEIR LI; TITMUSS RM, 1950, HIST 2ND WORLD WAR, P245; Werner B., 1984, POPULATION TRENDS, V38, P18; 1958, DECENNIAL SUPPLEMENT; 1952, STATISTICAL REV EN 1; 1957, DECENNIAL SUPPLEME 2, V2; 1953, STATISTICAL REV EN 1; 1956, CENSUS 1951 ENGLAND	19	57	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1357	1362		10.1136/bmj.303.6814.1357	http://dx.doi.org/10.1136/bmj.303.6814.1357			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760600	Green Published, Bronze			2022-12-28	WOS:A1991GU38400017
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - WASTE-DISPOSAL - FRESH LOOKS AT A ROTTING PROBLEM	BRITISH MEDICAL JOURNAL			English	Article																		CROFT B, 1990, 1990 P HARW WAST MAN; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; GUSTAVSSON P, 1989, AM J IND MED, V15, P245, DOI 10.1002/ajim.4700150302; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; LAGAKOS SW, 1986, J AM STAT ASSOC, V81, P583, DOI 10.2307/2288982; LOWRY S, 1990, BRIT MED J, V300, P177, DOI 10.1136/bmj.300.6718.177; PAIGEN B, 1987, HUM BIOL, V59, P489; WALDRON HA, 1985, BRIT MED J, V290, P1285, DOI 10.1136/bmj.290.6477.1285; 1990, SOCIAL TRENDS, V20; 1991, URBAN SOLID WASTE MA; 1985, 11TH ROYAL COMM ENV; 1988, ASSESSMENT GROUNDWAT; 1989, 2ND REPORT HOUS COMM; 1990, CODE PRACTICE SAFE U; 1991, CLIN WASTE APPRAISAL; 1989, HAZARDOUS WASTE HUMA	16	9	9	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1391	1394		10.1136/bmj.303.6814.1391	http://dx.doi.org/10.1136/bmj.303.6814.1391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760610	Bronze, Green Published			2022-12-28	WOS:A1991GU38400027
J	FRANKEL, S; COAST, J; BAKER, T; COLLINS, C				FRANKEL, S; COAST, J; BAKER, T; COLLINS, C			BOOKED ADMISSIONS AS A REPLACEMENT FOR WAITING LISTS IN THE NEW NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									FRENCHAY HOSP,BRISTOL BS16 1LE,AVON,ENGLAND; TAUNTON & SOMERSET HOSP,MUSGROVE PK BRANCH,TAUNTON TA1 5DA,SOMERSET,ENGLAND	Musgrove Park Hospital	FRANKEL, S (corresponding author), DEPT EPIDEMIOL & PUBL HLTH MED,HLTH CARE EVALUAT UNIT,BRISTOL BS8 2PR,ENGLAND.			Coast, Joanna/0000-0002-3537-5166				DEAN M, 1991, LANCET, V337, P480, DOI 10.1016/0140-6736(91)93408-2; DEVLIN HB, 1980, WAITING HOSPITAL TRE, P18; FRANKEL S, 1989, BRIT MED J, V299, P598, DOI 10.1136/bmj.299.6699.598; HOUGHTON PWJ, 1989, BRIT MED J, V299, P1139, DOI 10.1136/bmj.299.6708.1139-a; LIGHT D, 1990, HLTH SERVICE J  1101, P1649; SOUTHAM JA, 1980, BMJ, V2, P808	6	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1257	1258		10.1136/bmj.303.6812.1257	http://dx.doi.org/10.1136/bmj.303.6812.1257			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747653	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200034
J	SONNEX, C; SCHOLEFIELD, JH; KOCJAN, G; KELLY, G; WHATRUP, C; MINDEL, A; NORTHOVER, JMA				SONNEX, C; SCHOLEFIELD, JH; KOCJAN, G; KELLY, G; WHATRUP, C; MINDEL, A; NORTHOVER, JMA			ANAL HUMAN PAPILLOMAVIRUS INFECTION IN HETEROSEXUALS WITH GENITAL WARTS - PREVALENCE AND RELATION WITH SEXUAL-BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							MEN		UNIV COLL & MIDDLESEX HOSP SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1,ENGLAND; ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,LONDON EC1,ENGLAND; UNIV COLL & MIDDLESEX HOSP SCH MED,DEPT HISTOPATHOL,LONDON W1,ENGLAND									FRAZER IH, 1986, LANCET, V2, P657; GOORNEY BP, 1987, GENITOURIN MED, V63, P216; ORIEL JD, 1971, BRIT J VENER DIS, V47, P1; ORIEL JD, 1971, BR J VENER DIS, V47, P273; SONNEX C, 1991, GENITOURIN MED, V67, P21	5	30	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1243	1243		10.1136/bmj.303.6812.1243	http://dx.doi.org/10.1136/bmj.303.6812.1243			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747648	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200027
J	GODLEE, F; WALKER, A				GODLEE, F; WALKER, A			IMPORTANCE OF A HEALTHY ENVIRONMENT	BRITISH MEDICAL JOURNAL			English	Article																		[Anonymous], [No title captured]; BROWN L, 1989, STATE WORLD 1989 WOR; BROWN LR, 1991, STATE WORLD 1991 WOR; ELMAN RS, 1989, OZONE DEPLETION HLTH; FERGUSSON M, 1989, ATMOSPHERIC EMISSION, V1; FLAVIN C, 1991, STATE WORLD 1991 WOR; GUSTAVSSON P, 1989, AM J IND MED, V15, P245, DOI 10.1002/ajim.4700150302; HAINES A, 1991, J PUBLIC HLTH MED, V13; Houghton J.T., 1990, CLIMATE CHANGE IPCC; JONES RR, 1989, OZONE DEPLETION HLTH; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; PIKE EB, 1990, DOE2518MP WAT RES CT; READ C, 1991, AIR POLLUTION HLTH; WATSON RT, 1989, OZONE DEPLETION HLTH; WHEELER D, 1990, ANN S I WATER ENV MA; WILSON EO, 1989, SCI AM, V261, P108, DOI 10.1038/scientificamerican0989-108; 1991, HAZARDOUS WASTE HUMA; 1988, INVESTIGATION POSSIB; 1987, AIR QUALITY GUIDELIN; 1991, STATE WORLD POPULATI; 1989, REPORT INCIDENCE CHI; 1989, WORLD POPULATION TUR; 1984, INVESTIGATION POSSIB	23	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1124	1126		10.1136/bmj.303.6810.1124	http://dx.doi.org/10.1136/bmj.303.6810.1124			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747585	Green Published, Bronze			2022-12-28	WOS:A1991GN20900031
J	BORTIN, MM; HOROWITZ, MM; RIMM, AA				BORTIN, MM; HOROWITZ, MM; RIMM, AA			INCREASING UTILIZATION OF ALLOGENEIC BONE-MARROW TRANSPLANTATION - RESULTS OF THE 1988-1990 SURVEY	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; LEUKEMIA; LYMPHOMA; ANEMIA, APLASTIC	CHRONIC MYELOGENOUS LEUKEMIA; DONORS; PROPHYLAXIS; THERAPY	Objective: To determine the pattern and frequency of allogeneic bone marrow transplantation from related and unrelated donors from 1988 to 1990. Design and Setting: Survey of 342 institutions in 47 countries. Measurements: Numbers of patients receiving bone marrow transplantation for specific disease categories at institutions with active allogeneic bone marrow transplant programs. Main Results: Patients (14 745) received allogeneic bone marrow transplantation between 1988 and 1990; of these, 1153 (8%) were from unrelated donors. Reasons for transplantation were acute leukemia (47%), chronic myelogenous leukemia (27%), lymphoma and other malignancies (1 0%), severe aplastic anemia (9%), and other nonmalignant diseases (7%). The number of allogeneic bone marrow transplants per million persons differed among countries, averaging 7.7 per million in North America and 5.7 per million in western Europe. Conclusions: The use of allogeneic bone marrow transplantation continued to increase at a rate of more than 600 additional patients and 25 new transplant teams annually. This rise is due in part to increasing use of unrelated volunteers as donors. Resources allocated for transplants vary widely among countries.			BORTIN, MM (corresponding author), MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, POB 26509, MILWAUKEE, WI 53226 USA.		horowitz, Mary/ABH-2173-2021		NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASH RC, 1991, BONE MARROW TRANSPL, V7, P443; ASH RC, 1990, NEW ENGL J MED, V322, P485, DOI 10.1056/NEJM199002223220801; BACH FH, 1968, LANCET, V2, P1364; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1989, BONE MARROW TRANSPL, V4, P287; BODMER WF, 1978, BRIT MED BULL, V34, P309, DOI 10.1093/oxfordjournals.bmb.a071518; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BORTIN MM, 1986, TRANSPLANTATION, V42, P229, DOI 10.1097/00007890-198609000-00001; BORTIN MM, 1981, INT BONE MARROW TRAN; BOWDEN RA, 1990, SEMIN HEMATOL, V27, P17; CAMITTA BM, 1979, BLOOD, V53, P504; GALE RP, 1991, BONE MARROW TRANSPL, V7, P153; GATTI RA, 1968, LANCET, V2, P1366; GOLDMAN JM, 1985, LANCET, V2, P1295; GORIN NC, 1989, LANCET, V2, P317; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; HOROWITZ MM, 1992, IN PRESS BLOOD; JAMES DCO, 1984, TRANSPLANTATION BLOO, P131; McCullough J, 1989, BONE MARROW TRANSPL, P641; MCGLAVE P, 1987, BLOOD, V70, P877; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SPECK B, 1984, LANCET, V1, P665; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; THOMAS ED, 1982, LANCET, V2, P227; 1991, BONE MARROW TRANSPL, V8, P197; 1991, BONE MARROW DONORS W; [No title captured]	27	133	134	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					505	512		10.7326/0003-4819-116-6-505	http://dx.doi.org/10.7326/0003-4819-116-6-505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739242				2022-12-28	WOS:A1992HJ59800012
J	HOFFMAN, GS; KERR, GS; LEAVITT, RY; HALLAHAN, CW; LEBOVICS, RS; TRAVIS, WD; ROTTEM, M; FAUCI, AS				HOFFMAN, GS; KERR, GS; LEAVITT, RY; HALLAHAN, CW; LEBOVICS, RS; TRAVIS, WD; ROTTEM, M; FAUCI, AS			WEGENER GRANULOMATOSIS - AN ANALYSIS OF 158 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Review						WEGENERS GRANULOMATOSIS; CYCLOPHOSPHAMIDE; GLUCOCORTICOIDS; GLOMERULONEPHRITIS; DRUG TOXICITY	CONTROLLED CLINICAL-TRIAL; RHEUMATOID-ARTHRITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; LUPUS NEPHRITIS; ANTICYTOPLASMIC AUTOANTIBODIES; INTRAVENOUS CYCLOPHOSPHAMIDE; IMMUNODIAGNOSTIC VALUE; PULSE METHOTREXATE; THERAPY; DIAGNOSIS	Objective: To prospectively study the clinical features, pathophysiology, treatment, and prognosis of Wegener granulomatosis. Design: Of the 180 patients with Wegener granulomatosis referred to the National Institute of Allergy and Infectious Diseases during the past 24 years, 158 have been followed for 6 months to 24 years (a total of 1229 patient-years). Measurements: Characteristics of clinical presentation, surgical pathology, course of illness, laboratory and radiographic findings, and the results of medical and surgical treatment have been recorded in a computer-based information retrieval system. Setting: The Warren Magnuson Clinical Center of the National Institutes of Health. Main Results: Men and women were equally represented; 97% of patients were white, and 85% were more than 19 years of age. The mean period of follow-up was 8 years. One hundred and thirty-three patients (84%) received "standard" therapy with daily low-dose cyclophosphamide and glucocorticoids. Eight (5.0%) received only low-dose cyclophosphamide. Six (4.0%) never received cyclophosphamide and were treated with other cytotoxic agents and glucocorticoids. Ten patients (6.0%) were treated with only glucocorticoids. Ninety-one percent of patients experienced marked improvement, and 75% achieved complete remission. Fifty percent of remissions were associated with one or more relapses. Of 99 patients followed for > 5 years, 44% had remissions of > 5 years duration. Thirteen percent of patients died of Wegener granulomatosis, treatment-related causes, or both. Almost all patients had serious morbidity from irreversible features of their disease (86%) or side effects of treatment (42%). Conclusions: The course of Wegener granulomatosis has been dramatically improved by daily treatment with cyclophosphamide and glucocorticoids. Nonetheless, disease- and treatment-related morbidity is often profound. Alternative forms of therapy have not yet achieved the high rates of remission induction and successful maintenance that have been reported with daily cyclophosphamide treatment. Despite continued therapeutic success with cyclophosphamide, our long-term follow-up of patients with Wegener granulomatosis has led to increasing concerns about toxicity resulting from prolonged cyclophosphamide therapy and has encouraged investigation of other therapeutic regimens.			HOFFMAN, GS (corresponding author), NIH, BLDG 10, ROOM 11B12, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489; ANTONOVYCH TT, 1989, MODERN PATHOL, V2, P349; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BALTARO RJ, 1991, AM REV RESPIR DIS, V143, P275, DOI 10.1164/ajrccm/143.2.275; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; DEVANEY KO, 1990, AM J SURG PATHOL, V14, P555, DOI 10.1097/00000478-199006000-00006; ESPINOZA LR, 1986, J AM ACAD DERMATOL, V15, P508, DOI 10.1016/S0190-9622(86)70202-8; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; HAMDY H, 1987, ARTHRITIS RHEUM, V30, P361, DOI 10.1002/art.1780300401; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; HOFFMAN GS, 1991, AM REV RESPIR DIS, V143, P401, DOI 10.1164/ajrccm/143.2.401; HOLLANDER D, 1967, ANN INTERN MED, V67, P393, DOI 10.7326/0003-4819-67-2-393; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P132, DOI 10.1007/BF02205561; Klinger H, 1931, FRANKFURT Z PATHOL, V42, P455; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LEAVITT RY, 1988, ARTHRITIS RHEUM, V31, P1073, DOI 10.1002/art.1780310822; LUDEMANN J, 1990, NETH J MED, V36, P157; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PINCHING AJ, 1983, Q J MED, V52, P435; REZA MJ, 1975, ARTHRITIS RHEUM, V18, P501, DOI 10.1002/art.1780180513; SESSOMS SL, 1984, CLIN EXP RHEUMATOL, V2, P247; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; STEPPAT D, 1989, KLIN WOCHENSCHR, V67, P666, DOI 10.1007/BF01718027; TERVAERT JWC, 1990, LANCET, V336, P709; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P315, DOI 10.1097/00000478-199104000-00001; TRAVIS WD, 1990, AM J SURG PATHOL, V14, P1112, DOI 10.1097/00000478-199012000-00003; TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1990, NETH J MED, V36, P169; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WATANABE T, 1981, JPN J NEPHROL, V23, P921; Wegener F, 1939, BEITR PATHOL ANAT AL, V102, P36; Wegener F, 1936, VERHANDLUNGEN DTSCH, V29, P202; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WEINSTEIN A, 1985, AM J MED, V79, P331, DOI 10.1016/0002-9343(85)90312-2; WEISS MA, 1984, HUM PATHOL, V15, P943, DOI 10.1016/S0046-8177(84)80124-0; WEST BC, 1987, ANN INTERN MED, V106, P840, DOI 10.7326/0003-4819-106-6-840; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; YUASA K, 1988, AM J MED, V84, P371, DOI 10.1016/0002-9343(88)90450-0	45	2182	2276	4	47	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					488	498		10.7326/0003-4819-116-6-488	http://dx.doi.org/10.7326/0003-4819-116-6-488			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739240				2022-12-28	WOS:A1992HJ59800010
J	STEINBERG, EP; MOORE, RD; POWE, NR; GOPALAN, R; DAVIDOFF, AJ; LITT, M; GRAZIANO, S; BRINKER, JA				STEINBERG, EP; MOORE, RD; POWE, NR; GOPALAN, R; DAVIDOFF, AJ; LITT, M; GRAZIANO, S; BRINKER, JA			SAFETY AND COST-EFFECTIVENESS OF HIGH-OSMOLALITY AS COMPARED WITH LOW-OSMOLALITY CONTRAST MATERIAL IN PATIENTS UNDERGOING CARDIAC ANGIOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CALCIUM-BINDING ADDITIVES; CORONARY ANGIOGRAPHY; VENTRICULAR-FIBRILLATION; REDUCED INCIDENCE; ADVERSE REACTIONS; MEDIA; AGENTS; DIATRIZOATE; IOPAMIDOL; CATHETERIZATION	Background and Methods. Low-osmolality contrast agents produce fewer hemodynamic and electrophysiologic alterations during cardiac angiography, but they are 20 times more expensive than high-osmolality contrast agents. In a randomized, double-blind trial comparing a nonionic, low-osmolality contrast agent (Omnipaque 350) with a high-osmolality agent that does not avidly bind calcium (Hypaque 76) in 505 patients undergoing cardiac angiography, we determined the incidence of minor, mild, moderate, and severe adverse reactions, identified risk factors for such reactions, and evaluated the cost effectiveness of various strategies for the use of contrast material. Results. The 253 patients who received a high-osmolality contrast agent were three times more likely to have a moderate adverse reaction (95 percent confidence interval for the relative risk, 1.6 to 5.5) but no more likely to have a severe reaction (95 percent confidence interval, 0.2 to 2.3) than the 252 patients who received a low-osmolality agent. All 10 severe reactions occurred in patients who were older than 60 years or had unstable angina. Patients with these characteristics were also 3.5 times more likely (95 percent confidence interval, 1.8 to 6.8) to have a moderate reaction (44 of 310 patients, or 14 percent) than those without either characteristic (8 of 195 patients, or 4 percent). We estimated that the incremental cost of each moderate reaction avoided would be $1,698 with a strategy that involved giving a low-osmolality contrast agent only to patients who were over 60 years of age or had unstable angina, instead of giving a high-osmolality agent to all patients. The incremental cost per moderate reaction avoided by giving a low-osmolality contrast agent to all patients rather than only to those over 60 or with unstable angina would be $5,842. Conclusions. The use of contrast agents with low rather than high osmolality during cardiac angiography reduces the risk of moderate, but not of severe, adverse reactions to the agent used. A strategy of reserving low-osmolality contrast agents for use in patients at high risk for adverse reactions would be more cost effective than one requiring their use in all patients.	JOHNS HOPKINS UNIV,SCH MED,DEPT RADIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,PROGRAM MED TECHNOL & PRACTICE ASSESSMENT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,PHARMACOEPIDEMIOL UNIT,BALTIMORE,MD 21218; BAPTIST HOSP,DIV CARDIOL,JACKSONVILLE,FL	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	STEINBERG, EP (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,1830 E MONUMENT ST,RM 8068,BALTIMORE,MD 21205, USA.							BASHORE TM, 1988, CARDIO, V5, P6; BETTMANN MA, 1984, RADIOLOGY, V153, P583, DOI 10.1148/radiology.153.3.6387783; BETTMANN MA, 1985, INVEST RADIOL, V20, pS70, DOI 10.1097/00004424-198501002-00017; DAVIDSON CJ, 1990, AM J CARDIOL, V65, P1481, DOI 10.1016/0002-9149(90)91359-E; FELDMAN RL, 1988, AM J CARDIOL, V61, P1334, DOI 10.1016/0002-9149(88)91179-4; Higgins C B, 1983, Acta Radiol Suppl, V366, P111; HIRSHFELD JW, 1989, INVEST RADIOL, V24, P138, DOI 10.1097/00004424-198902000-00010; HIRSHFELD JW, 1983, J AM COLL CARDIOL, V2, P954, DOI 10.1016/S0735-1097(83)80245-9; HIRSHFELD JW, 1990, AM J CARDIOL, V66, pF9, DOI 10.1016/0002-9149(90)90635-E; HIRSHFELD JW, 1990, AM J CARDIOL, V66, P355, DOI 10.1016/0002-9149(90)90849-V; HLATKY MA, 1990, J AM COLL CARDIOL, V16, P871, DOI 10.1016/S0735-1097(10)80335-3; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P148; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KINNISON ML, 1989, RADIOLOGY, V170, P381, DOI 10.1148/radiology.170.2.2643140; MANCINI GBJ, 1983, AM J CARDIOL, V51, P1218; MCCLENNAN BL, 1987, RADIOLOGY, V162, P1; MISSRI J, 1990, CATHETER CARDIO DIAG, V19, P4, DOI 10.1002/ccd.1810190103; MURDOCK CJ, 1990, CATHETER CARDIO DIAG, V19, P179, DOI 10.1002/ccd.1810190306; MURDOCK DK, 1985, CATHETER CARDIO DIAG, V11, P153, DOI 10.1002/ccd.1810110206; POWE NR, 1988, RADIOLOGY, V169, P163, DOI 10.1148/radiology.169.1.3420254; REAGAN K, 1988, RADIOLOGY, V167, P409, DOI 10.1148/radiology.167.2.3282261; REUTER SR, 1988, AM J ROENTGENOL, V151, P529; SALEM DN, 1986, AM HEART J, V111, P533, DOI 10.1016/0002-8703(86)90059-1; VIKMO H, 1988, CATHETER CARDIO DIAG, V14, P143, DOI 10.1002/ccd.1810140302; WOLF GL, 1983, J AM COLL CARDIOL, V1, P1489, DOI 10.1016/S0735-1097(83)80053-9; ZUKERMAN LS, 1987, J AM COLL CARDIOL, V10, P1249	26	128	128	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					425	430		10.1056/NEJM199202133260701	http://dx.doi.org/10.1056/NEJM199202133260701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732769				2022-12-28	WOS:A1992HD16400001
J	FINKELSTEIN, A; KOSTRUB, CF; LI, J; CHAVEZ, DP; WANG, BQ; FANG, SM; GREENBLATT, J; BURTON, ZF				FINKELSTEIN, A; KOSTRUB, CF; LI, J; CHAVEZ, DP; WANG, BQ; FANG, SM; GREENBLATT, J; BURTON, ZF			A CDNA-ENCODING RAP74, A GENERAL INITIATION-FACTOR FOR TRANSCRIPTION BY RNA POLYMERASE-II	NATURE			English	Article							ACCURATE INITIATION; PROTEINS; BINDING; PROMOTER	RAP30/74 (also known as TFIIF (refs 1, 2), beta-gamma (ref. 3) and FC (ref. 4)) is one of several general factors required for initiation by RNA polymerase II (reviewed in refs 5-7). The small RAP30 subunit of RAP30/74 binds directly to polymerase and appears structurally and functionally homologous to bacterial sigma factors in their RNA polymerase-binding region 8-10. RAP30/74 or recombinant RAP30 suppresses nonspecific binding of RNA polymerase II to DNA (refs 10, 11) and is required for RNA polymerase II to assemble stably into a preinitiation complex containing promoter DNA and the general factors TFIID, TFIIA and TFIIB (refs 2, 12, 13); both RAP30 and RAP74 are physical components of the preinitiation complex 2. A complementary DNA encoding human RAP30 has been isolated 8, and here we report the isolation of a cDNA encoding human RAP74. RAP30 and RAP74 produced in Escherichia coli can be used in place of natural human RAP30/74 to direct accurate transcription initiation by RNA polymerase II in vitro.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,AGR EXPT STN,E LANSING,MI 48824; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	Michigan State University; Michigan State University; Michigan State University AgBioResearch; University of Toronto; University of Toronto								BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAJIMA S, NUCLEIC ACIDS RES, V18, P4843; KILLEEN MT, IN PRESS MOL CELL BI; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0	28	91	92	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					464	467		10.1038/355464a0	http://dx.doi.org/10.1038/355464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734284				2022-12-28	WOS:A1992HB53000075
J	RONDEAU, JM; TETEFAVIER, F; PODJARNY, A; REYMANN, JM; BARTH, P; BIELLMANN, JF; MORAS, D				RONDEAU, JM; TETEFAVIER, F; PODJARNY, A; REYMANN, JM; BARTH, P; BIELLMANN, JF; MORAS, D			NOVEL NADPH-BINDING DOMAIN REVEALED BY THE CRYSTAL-STRUCTURE OF ALDOSE REDUCTASE	NATURE			English	Article							X-RAY; PROTEIN; EVOLUTION; MUSCLE; CDNAS; FORMS; GENE	ALDOSE reductase is the first enzyme in the polyol pathway and catalyses the NADPH-dependent reduction Of D-glucose to D-sorbitol. Under normal physiological conditions aldose reductase participates in osmoregulation 1, but under hyperglycaemic conditions it contributes to the onset and development of severe complications in diabetes 2. Here we present the crystal structure of pig lens aldose reductase refined to an R-factor of 0.232 at 2.5-angstrom resolution. It exhibits a single domain folded in an eight-stranded parallel alpha/beta-barrel, similar to that in triose phosphate isomerase 3 and a score of other enzymes. Hence, aldose reductase does not possess the expected canonical dinucleotide-binding domain 4. Crystallographic analysis of the binding of 2'-monophosphoadenosine-5'-diphosphoribose, which competitively inhibits NADPH binding reveals that it binds into a cleft located at the C-terminal end of the strands of the alpha/beta-barrel. This represents a new type of binding for nicotinamide adenine dinucleotide coenzymes.	CNRS,INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,15 RUE R DESCARTES,F-67084 STRASBOURG,FRANCE; BIOSTRUCT SA,ALGORITHMES,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV STRASBOURG 1,INST CHIM,CHIM ORGAN BIOL LAB,F-67008 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Favier, Frederique/B-3090-2013	Favier, Frederique/0000-0003-3249-997X; Podjarny, Alberto/0000-0002-7685-1077				ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHUNG S, 1989, J BIOL CHEM, V264, P14775; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DVORNIK D, 1987, ALDOSE REDUCTASE INH; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FUJII Y, 1990, J BIOL CHEM, V266, P9914; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; Nishimura C, 1989, Prog Clin Biol Res, V290, P211; OECHSNER U, 1988, FEBS LETT, V238, P123, DOI 10.1016/0014-5793(88)80240-0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RONDEAU JM, 1987, J MOL BIOL, V195, P945, DOI 10.1016/0022-2836(87)90498-0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	30	192	199	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					469	472		10.1038/355469a0	http://dx.doi.org/10.1038/355469a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734286				2022-12-28	WOS:A1992HB53000077
J	RUTTER, P; WOLFE, JHN				RUTTER, P; WOLFE, JHN			ABC OF VASCULAR DISEASES - LATE COMPLICATIONS OF ARTERIAL GRAFTS	BRITISH MEDICAL JOURNAL			English	Article											RUTTER, P (corresponding author), ST MARYS HOSP,SURG,LONDON,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					246	249		10.1136/bmj.304.6821.246	http://dx.doi.org/10.1136/bmj.304.6821.246			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739803	Bronze, Green Published			2022-12-28	WOS:A1992HA98000032
J	BARKER, DJP; MEADE, TW; FALL, CHD; LEE, A; OSMOND, C; PHIPPS, K; STIRLING, Y				BARKER, DJP; MEADE, TW; FALL, CHD; LEE, A; OSMOND, C; PHIPPS, K; STIRLING, Y			RELATION OF FETAL AND INFANT GROWTH TO PLASMA-FIBRINOGEN AND FACTOR-VII CONCENTRATIONS IN ADULT LIFE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; RISK	Objective - To determine whether reduced fetal and infant growth are associated with higher plasma fibrinogen and factor VII concentrations in adult life. Design - Follow up study of men born during 1920-30 whose weights at birth and at 1 year had been recorded by health visitors, and men born during 1935-43 whose size at birth had been measured in detail. Setting - Hertfordshire and Preston, England. Subjects - 591 men born in east Hertfordshire who still lived there and 148 men born in Preston who still lived in or close to the city. Main outcome measures - Plasma fibrinogen and factor VII concentrations. Results - Among men in Hertfordshire mean plasma fibrinogen and factor VII concentrations fell with increasing weight at 1 year (from 3.21 g/l in men of less-than-or-equal-to 18 lb to 2-93 g/l in men of greater-than-or-equal-to 27 lb and from 122% of standard to 103%; p < 0.001, p < 0.005 respectively). The trends were independent of cigarette smoking, alcohol consumption, body mass index, and social class. Neither plasma fibrinogen nor factor VII concentration was related to birth weight. In men in Preston, however, fibrinogen concentration fell progressively as the ratio of placental weight to birth weight decreased (p = 0.01). Conclusions - Reduced growth in fetal life and infancy is strongly related to high plasma concentrations of the haemostatic factors fibrinogen and factor VII. This may be a persisting response to impaired liver development during a critical early period.	NORTHWICK PK HOSP & CLIN RES CTR, MRC, EPIDEMIOL & MED CARE UNIT, HARROW HA1 3UJ, MIDDX, ENGLAND	Imperial College London	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON S09 4XY, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ANDREW M, 1990, AM J PEDIAT HEMATOL, V12, P95; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, IN PRESS PAEDIATR PE; BROZOVIC M, 1977, BRIT MED BULL, V33, P231, DOI 10.1093/oxfordjournals.bmb.a071441; BROZOVIC M, 1974, BRIT J HAEMATOL, V28, P381, DOI 10.1111/j.1365-2141.1974.tb00819.x; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; DUBOS R, 1966, PEDIATRICS, V38, P789; GRUENWALD P, 1963, BIOL NEONATORUM, V5, P215; GUREWICH V, 1976, THROMB HAEMOSTASIS, V36, P605; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOLMES GE, 1977, AM J DIS CHILD, V131, P1078, DOI 10.1001/archpedi.1977.02120230024003; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1987, THROMB DIATH HAEMO, P37; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; VILLAR J, 1984, PEDIATRICS, V74, P783; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300	25	198	203	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1992	304	6820					148	152		10.1136/bmj.304.6820.148	http://dx.doi.org/10.1136/bmj.304.6820.148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737158	Green Published, Bronze			2022-12-28	WOS:A1992HA97900019
J	NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT				NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT			SOCIAL AND FUNCTIONAL IMPACT OF MINOR FRACTURES IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									ARROWE PK HOSP,DEPT GERIATR MED,WIRRAL L49 5PE,ENGLAND; SALFORD UNIV,DEPT BEHAV SCI,SALFORD M6 6PU,ENGLAND	University of Salford	NANKHONYA, JM (corresponding author), 24 COLMORE AVE,WIRRAL L63 9NL,ENGLAND.		Newton, Jonathon T/B-7015-2009					ANDREWS K, 1989, CLIN NEUROLOGY OLD A, P479; Dove A F, 1986, Health Trends, V18, P86; Roberts NA, 1990, CLIN REHABIL, V4, P37; ROWLAND K, 1990, AGE AGEING, V19, P415, DOI 10.1093/ageing/19.6.415; 1989, FRACTURED NECK FEMUR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1514	1515		10.1136/bmj.303.6816.1514-a	http://dx.doi.org/10.1136/bmj.303.6816.1514-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782491	Bronze, Green Published			2022-12-28	WOS:A1991GV47600024
J	HAUSMANN, N; RICHARD, G				HAUSMANN, N; RICHARD, G			EFFECT OF HIGH-DOSE STEROID BOLUS ON OCCLUSION OF OCULAR CENTRAL ARTERY - ANGIOGRAPHIC STUDY	BRITISH MEDICAL JOURNAL			English	Article									UNIV MAINZ,DEPT OPHTHALMOL,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	HAUSMANN, N (corresponding author), LANDESKRANKENHAUS FELDKIRCH,DEPT OPHTHALMOL,A-6807 FELDKIRCH,AUSTRIA.							BRAUGHLER JM, 1985, J NEUROSURG, V62, P805; HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P818, DOI 10.1136/bjo.64.11.818; MAGARGAL LE, 1977, SURG FORUM, V28, P518; NEUBAUER H, 1962, Klin Monbl Augenheilkd Augenarztl Fortbild, V141, P70; RICHARD G, 1989, FLUORESZENZANGIOGRAP, P19	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1445	1446		10.1136/bmj.303.6815.1445	http://dx.doi.org/10.1136/bmj.303.6815.1445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773152	Bronze, Green Published			2022-12-28	WOS:A1991GU38500027
J	FINKELSTEIN, JS; NEER, RM; BILLER, BMK; CRAWFORD, JD; KLIBANSKI, A				FINKELSTEIN, JS; NEER, RM; BILLER, BMK; CRAWFORD, JD; KLIBANSKI, A			OSTEOPENIA IN MEN WITH A HISTORY OF DELAYED PUBERTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL CONTENT; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; DUAL PHOTON-ABSORPTIOMETRY; ALKALINE-PHOSPHATASE; PHYSICAL-ACTIVITY; TOTAL-BODY; DENSITY; OSTEOPOROSIS; WOMEN; MASS	Background and Methods. The effect of delayed puberty on peak bone mineral density in men is unknown. To determine whether such a delay reduces normal peak bone density and leads to osteopenia during adulthood, we measured radial bone mineral density by single-photon absorptiometry and spinal bone mineral density by dual-energy x-ray absorptiometry in 23 men who had a history of constitutionally delayed puberty and 21 men who underwent normal puberty. Their mean ages were 26 and 24 years, respectively. The groups were matched for other factors known to affect bone mass. Results. The mean (+/- SD) radial bone mineral density was significantly lower in the men with a history of delayed puberty than in the normal men (0.73 +/- 0.07 vs. 0.80 +/- 0.05 g per square centimeter; P < 0.0002). Spinal bone mineral density was also significantly lower in the men with delayed puberty than in the normal men (1.03 +/- 0.10 vs. 1.13 +/- 0.11 g per square centimeter; P < 0.003). Radial bone density was at least 1 SD below the mean value for the normal men in 15 of the 23 men with a history of delayed puberty, and spinal bone density was similarly decreased in 10 of the 23. Conclusions. Adult men with a history of constitutionally delayed puberty have decreased radial and spinal bone mineral density. These findings suggest that the timing of puberty is an important determinant of peak bone density in men. Because the peak bone mineral density achieved during young adulthood is a major determinant of bone density in later life, men in whom puberty was delayed may be at increased risk for osteoporotic fractures when they are older.	MASSACHUSETTS GEN HOSP,DEPT MED,NEUROENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	FINKELSTEIN, JS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BULFINCH 3,BOSTON,MA 02114, USA.		Finkelstein, Joel/M-6463-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD021204, R01HD021204] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NICHD NIH HHS [HD-21204] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; COOPER DS, 1979, J CLIN INVEST, V64, P1669, DOI 10.1172/JCI109629; DHUPER S, 1990, J CLIN ENDOCR METAB, V71, P1083, DOI 10.1210/jcem-71-5-1083; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; FINKELSTEIN JS, 1990, TESTOSTERONE ACTION, P204; FORESTA C, 1983, HORM METAB RES, V15, P56, DOI 10.1055/s-2007-1018630; GARDSELL P, 1990, BONE, V11, P229, DOI 10.1016/8756-3282(90)90074-9; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; GILSANZ V, 1988, RADIOLOGY, V166, P847, DOI 10.1148/radiology.166.3.3340782; GORDON M, 1982, J PEDIATR-US, V101, P477, DOI 10.1016/S0022-3476(82)80093-0; GOTFREDSEN A, 1985, J COMPUT ASSIST TOMO, V9, P631, DOI 10.1097/00004728-198505000-00072; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; GREENSPAN SL, 1986, ANN INTERN MED, V104, P77; Greulich WW., 1959, CALIF MED, V91, P53; HALIOUA L, 1989, AM J CLIN NUTR, V49, P534, DOI 10.1093/ajcn/49.3.534; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANDERS B, 1988, J BONE MINER RES, V3, P145; KELLY PJ, 1990, J BONE MINER RES, V5, P1169; KELLY TL, 1988, J CLIN ENDOCR METAB, V67, P839, DOI 10.1210/jcem-67-4-839; KRABBE S, 1984, ACTA PAEDIATR SCAND, V73, P745, DOI 10.1111/j.1651-2227.1984.tb17769.x; KRABBE S, 1979, ARCH DIS CHILD, V54, P950, DOI 10.1136/adc.54.12.950; KRABBE S, 1980, ACTA PAEDIATR SCAND, V69, P49, DOI 10.1111/j.1651-2227.1980.tb07028.x; LARSEN PR, 1973, J CLIN ENDOCR METAB, V37, P177, DOI 10.1210/jcem-37-2-177; LIEL Y, 1988, J CLIN ENDOCR METAB, V66, P1247, DOI 10.1210/jcem-66-6-1247; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; MAZESS RB, 1988, ARTHRITIS RHEUM-US, V31, P891, DOI 10.1002/art.1780310710; MAZESS RB, 1974, DHEW NIH75683 PUBL, P228; OTT SM, 1990, J CLIN ENDOCR METAB, V71, pA1082; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSENFIELD RL, 1990, J CLIN ENDOCR METAB, V70, P559, DOI 10.1210/jcem-70-3-559; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104; WARREN MP, 1986, NEW ENGL J MED, V315, P905	40	330	334	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					600	604		10.1056/NEJM199202273260904	http://dx.doi.org/10.1056/NEJM199202273260904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734250				2022-12-28	WOS:A1992HF63300004
J	CHRISPEELS, MJ; RAIKHEL, NV				CHRISPEELS, MJ; RAIKHEL, NV			SHORT PEPTIDE DOMAINS TARGET PROTEINS TO PLANT VACUOLES	CELL			English	Review							AMINO-ACID-SEQUENCE; POTATO; PHYTOHEMAGGLUTININ; TRANSPORT; INHIBITOR; PROTEASE; TOBACCO		MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824	Michigan State University	CHRISPEELS, MJ (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.							BEDNAREK SY, 1991, PLANT CELL, V3, P1195, DOI 10.1105/tpc.3.11.1195; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; CERIOTTI A, 1992, IN PRESS EUR J BIOCH; CHRISPEELS MJ, 1976, ANNU REV PLANT PHYS, V27, P19, DOI 10.1146/annurev.pp.27.060176.000315; CHRISPEELS MJ, 1991, ANN REV PLANT PHYSL, V42, P1; CUNNINGHAM BA, 1975, J BIOL CHEM, V250, P1503; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; FONTES EBP, 1991, PLANT CELL, V3, P483, DOI 10.1105/tpc.3.5.483; HERMAN EM, 1990, PLANTA, V182, P305, DOI 10.1007/BF00197126; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; HUNT DC, 1991, PLANT PHYSIOL, V96, P18, DOI 10.1104/pp.96.1.18; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MATSUOKA M, 1991, P NATL ACAD SCI USA, V88, P834; NEUHAUS JM, 1991, P NATL ACAD SCI USA, V88, P10362, DOI 10.1073/pnas.88.22.10362; RAIKHEL NV, 1991, DEV GENET, V12, P255, DOI 10.1002/dvg.1020120402; RITONJA A, 1990, FEBS LETT, V267, P13, DOI 10.1016/0014-5793(90)80275-N; SAALBACH G, 1991, PLANT CELL, V3, P695, DOI 10.1105/tpc.3.7.695; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; STRUKELJ B, 1990, NUCLEIC ACIDS RES, V18, P4605, DOI 10.1093/nar/18.15.4605; SUH SG, 1990, PLANT PHYSIOL, V94, P40, DOI 10.1104/pp.94.1.40; TAGUE BW, 1990, PLANT CELL, V2, P533, DOI 10.1105/tpc.2.6.533; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; WANDELT CI, 1992, IN PRESS PLANT J; WILKINS TA, 1990, PLANT CELL, V2, P301, DOI 10.1105/tpc.2.4.301; YAMAGISHI K, 1991, PLANT MOL BIOL, V17, P287, DOI 10.1007/BF00039507	28	160	171	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					613	616		10.1016/0092-8674(92)90134-X	http://dx.doi.org/10.1016/0092-8674(92)90134-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739969				2022-12-28	WOS:A1992HF44000001
J	GILLISSEN, B; BERGEMANN, J; SANDMANN, C; SCHROEER, B; BOLKER, M; KAHMANN, R				GILLISSEN, B; BERGEMANN, J; SANDMANN, C; SCHROEER, B; BOLKER, M; KAHMANN, R			A 2-COMPONENT REGULATORY SYSTEM FOR SELF NON-SELF RECOGNITION IN USTILAGO-MAYDIS	CELL			English	Article							DNA-BINDING SPECIFICITY; MATING-TYPE LOCUS; AMINO-ACID; HOMEODOMAIN; GENE; ORGANIZATION; ALPHA-2	In U. maydis the multiallelic b locus controls sexual and pathogenic development. In the b locus a gene coding for a regulatory protein had been identified, and it was suggested that the interaction of two b polypeptides specified by different alleles programs sexual development in this fungus. We now demonstrate the existence of a second regulatory gene in the b locus. We term this gene bW and refer to the former as the bE gene. Both genes exist in many alleles. Although unrelated in primary sequence, both genes are similar in their overall organization. The gene products display allele-specific variability in their N-terminal domains, show a high degree of sequence conservation in the C-terminal domains, and contain a homeodomain-related motif. Genetic evidence is provided to show that the pair of bE and bW polypeptides encoded by different b alleles is the key regulatory species.			GILLISSEN, B (corresponding author), INST GENBIOL FORSCH BERLIN GMBH,IHNESTR 63,W-1000 BERLIN 33,GERMANY.			Gillissen, Bernhard/0000-0002-1815-2091				Ballance DJ, 1991, MOL IND MYCOLOGY SYS, P1; BANUETT F, 1991, P NATL ACAD SCI USA, V88, P3922, DOI 10.1073/pnas.88.9.3922; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLKER M, 1992, IN PRESS CELL, V68; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINNEY M, 1990, CELL, V60, P5, DOI 10.1016/0092-8674(90)90708-M; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMER JE, 1987, MOL CELL BIOL, V7, P2352, DOI 10.1128/MCB.7.7.2352; HOLLIDAY R, 1961, GENET RES, V2, P204, DOI 10.1017/S0016672300000719; Holliday R., 1974, HDB GENETICS, P575, DOI 10.1007/978-1-4899-1710-2_31; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P1384; MAY G, 1991, GENETICS, V128, P529; MUTASA ES, 1990, CURR GENET, V18, P223, DOI 10.1007/BF00318385; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; TREISMAN J, 1989, CELL, V59, P553; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; ULLRICH RC, 1991, IN PRESS GENETIC ENG, V13; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WONG GJ, 1985, T BRIT MYCOL SOC, V84, P95, DOI 10.1016/S0007-1536(85)80223-0; [No title captured]	37	263	272	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					647	657		10.1016/0092-8674(92)90141-X	http://dx.doi.org/10.1016/0092-8674(92)90141-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739973	hybrid			2022-12-28	WOS:A1992HF44000006
J	DAMASIO, AR				DAMASIO, AR			APHASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WORD ORDER PROBLEM; BASAL GANGLIA; BROCA APHASIA; LANGUAGE; COMPREHENSION; AGRAMMATISM; ORGANIZATION; LESIONS; RECOVERY; CONSEQUENCES				DAMASIO, AR (corresponding author), UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA.		Damasio, Antonio/AAD-1342-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS019632] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERT ML, 1973, ARCH NEUROL-CHICAGO, V29, P130, DOI 10.1001/archneur.1973.00490260074018; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALEXANDER MP, 1980, NEUROLOGY, V30, P1193, DOI 10.1212/WNL.30.11.1193; ALEXANDER MP, 1980, ARCH NEUROL-CHICAGO, V37, P97, DOI 10.1001/archneur.1980.00500510055010; ARAM DM, 1983, ARCH NEUROL-CHICAGO, V40, P614, DOI 10.1001/archneur.1983.04050090050007; ARBIB MA, 1979, BEHAV BRAIN SCI, V2, P449, DOI 10.1017/S0140525X0006369X; BARAT M, 1981, REV NEUROL, V137, P343; BASSO A, 1979, ARCH NEUROL-CHICAGO, V36, P190, DOI 10.1001/archneur.1979.00500400044005; BELLUGI V, 1983, HUM NEUROBIOL, V2, P155; BENSON DF, 1973, ARCH NEUROL-CHICAGO, V28, P339, DOI 10.1001/archneur.1973.00490230075011; Benton AL., 1983, MULTILINGUAL APHASIA; BERNDT RS, 1980, APPL PSYCHOLINGUIST, V1, P225, DOI 10.1017/S0142716400000552; BLUMSTEIN SE, 1977, NEUROPSYCHOLOGIA, V15, P371, DOI 10.1016/0028-3932(77)90089-6; Bradley DC, 1980, SYNTACTIC DEFICITS B, P269; BRUNNER RJ, 1982, BRAIN LANG, V16, P281, DOI 10.1016/0093-934X(82)90087-6; CAPLAN D, 1986, BRAIN LANG, V27, P117, DOI 10.1016/0093-934X(86)90008-8; CAPPA SF, 1979, CORTEX, V15, P121, DOI 10.1016/S0010-9452(79)80012-X; CARAMAZZA A, 1976, BRAIN LANG, V3, P572, DOI 10.1016/0093-934X(76)90048-1; Damasio A. R., 1983, NEUROPSYCHOLOGY HUMA, P85; DAMASIO AR, 1990, COLD SH Q B, V55, P1039; DAMASIO AR, 1980, NEUROLOGY, V30, P359; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DAMASIO AR, 1989, HDB NEUROPSYCHOLOGY, V2, P317; DAMASIO AR, 1991, TRENDS NEUROSCI, V17, P4; DAMASIO H, 1984, SEMIN NEUROL, V4, P151, DOI 10.1055/s-2008-1041544; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; Damasio H, 1989, LESION ANAL NEUROPSY; Freud Sigmund, 1953, APHASIA CRITICAL STU; FROMKIN VA, 1971, LANGUAGE, V47, P27, DOI 10.2307/412187; FROMM D, 1985, ARCH NEUROL-CHICAGO, V42, P943, DOI 10.1001/archneur.1985.04060090025009; GALABURDA AM, 1983, J COMP NEUROL, V221, P169, DOI 10.1002/cne.902210206; GARDNER H, 1976, NEUROPSYCHOLOGIA, V14, P275, DOI 10.1016/0028-3932(76)90023-3; GARDNER H, 1983, COGNITIVE PROCESSING, P169; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; GLEASON JB, 1975, BRAIN LANG, V2, P451, DOI 10.1016/S0093-934X(75)80083-6; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GOODGLASS H, 1960, J SPEECH HEAR RES, V3, P257, DOI 10.1044/jshr.0303.257; Goodglass H., 1983, ASSESSMENT APHASIA R, V2nd; GRAFFRADFORD NR, 1985, BRAIN, V108, P485, DOI 10.1093/brain/108.2.485; GRODZINSKY Y, 1984, COGNITION, V16, P99, DOI 10.1016/0010-0277(84)90001-5; HELMESTABROOKS N, 1982, J SPEECH HEAR DISORD, V47, P385, DOI 10.1044/jshd.4704.385; HELMESTABROOKS N, 1986, BRIT J DISORD COMMUN, V21, P39; HOLLAND AL, 1980, COMMUNICATION ABILIT; Jakobson R., 1956, FUND LANG; KEAN ML, 1977, COGNITION, V5, P9, DOI 10.1016/0010-0277(77)90015-4; KERTESZ A, 1979, BRAIN LANG, V8, P34, DOI 10.1016/0093-934X(79)90038-5; KERTESZ A, 1979, APHASIA ASS DISORDER; KNOPMAN DS, 1984, NEUROLOGY, V34, P1461, DOI 10.1212/WNL.34.11.1461; Kosslyn S. M., 1980, IMAGE MIND; KURTZKE JF, 1982, NEUROLOGY, V32, P1207, DOI 10.1212/WNL.32.11.1207; LAPLANE D, 1977, J NEUROL SCI, V34, P301, DOI 10.1016/0022-510X(77)90148-4; LECOURS AR, 1976, BRAIN LANG, V3, P88, DOI 10.1016/0093-934X(76)90008-0; LEVINE DN, 1979, NEUROLOGY, V29, P927, DOI 10.1212/WNL.29.7.927; Lichtheim Ludwig, 1885, BRAIN, V7, P433, DOI DOI 10.1093/BRAIN/7.4.433; MARIN OSM, 1976, ANN NY ACAD SCI, V280, P868, DOI 10.1111/j.1749-6632.1976.tb25550.x; MOHR JP, 1978, NEUROLOGY, V28, P311, DOI 10.1212/WNL.28.4.311; MOHR JP, 1975, BRAIN LANG, V2, P3, DOI 10.1016/S0093-934X(75)80050-2; NAESER MA, 1986, ARCH PHYS MED REHAB, V67, P393; NAESER MA, 1978, NEUROLOGY, V28, P545, DOI 10.1212/WNL.28.6.545; NAESER MA, 1982, ARCH NEUROL-CHICAGO, V39, P2, DOI 10.1001/archneur.1982.00510130004002; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; Penfield W., 1959, SPEECH BRAIN MECHANI; Porch B. E, 1981, PORCH INDEX COMMUNIC, V2; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; ROSS ED, 1979, ARCH NEUROL-CHICAGO, V36, P144, DOI 10.1001/archneur.1979.00500390062006; RUBENS A, 1986, OCT AC APH M NASHV; Saffran E. M., 1980, LANGUAGE PRODUCTION, V1, P221; SAFFRAN EM, 1980, BRAIN LANG, V10, P263, DOI 10.1016/0093-934X(80)90056-5; Sarno MT, 1969, FUNCTIONAL COMMUNICA; SCHIFF HB, 1983, ARCH NEUROL-CHICAGO, V40, P720, DOI 10.1001/archneur.1983.04050110038005; Schuell H., 1972, MINNESOTA TEST DIFFE; SCHWARTZ MF, 1980, BRAIN LANG, V10, P249, DOI 10.1016/0093-934X(80)90055-3; SELNES OA, 1985, ANN NEUROL, V17, P549, DOI 10.1002/ana.410170604; SELNES OA, 1984, BRAIN LANG, V21, P72, DOI 10.1016/0093-934X(84)90037-3; SELNES OA, 1983, ANN NEUROL, V13, P558, DOI 10.1002/ana.410130515; Shepard RN., 1982, J HIST BEHAV SCI, V19, P301, DOI 10.2307/1422825; SHEWAN CM, 1984, BRAIN LANG, V23, P272, DOI 10.1016/0093-934X(84)90068-3; Spreen O., 1977, NEUROSENSORY CTR COM; TONKONOGY J, 1981, ARCH NEUROL-CHICAGO, V38, P486, DOI 10.1001/archneur.1981.00510080048005; TRANEL D, 1987, ARCH NEUROL-CHICAGO, V44, P304, DOI 10.1001/archneur.1987.00520150050021; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; TUCKER DM, 1977, NEUROLOGY, V27, P947, DOI 10.1212/WNL.27.10.947; VIGNOLO LA, 1986, CORTEX, V22, P55, DOI 10.1016/S0010-9452(86)80032-6; Wernicke C., 1874, APHASISCHE SYMPTOMEN; YETERIAN EH, 1978, BRAIN RES, V139, P43, DOI 10.1016/0006-8993(78)90059-8	86	315	322	4	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					531	539		10.1056/NEJM199202203260806	http://dx.doi.org/10.1056/NEJM199202203260806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1732792				2022-12-28	WOS:A1992HD65800006
J	STEIN, PE; BOODHOO, A; TYRRELL, GJ; BRUNTON, JL; READ, RJ				STEIN, PE; BOODHOO, A; TYRRELL, GJ; BRUNTON, JL; READ, RJ			CRYSTAL-STRUCTURE OF THE CELL-BINDING B-OLIGOMER OF VEROTOXIN-1 FROM ESCHERICHIA-COLI	NATURE			English	Article							SHIGA TOXIN; PROTEIN; IDENTIFICATION; FEATURES	THE Shiga toxin family, a group of cytotoxins associated with diarrhoeal diseases and the haemolytic uraemic syndrome, includes Shiga toxin from Shigella dysenteriae type I and verotoxins 1 produced by enteropathogenic Escherichia coli. The family belongs to the A-B class of bacterial toxins, which includes the cholera toxin family, pertussis and diphtheria toxins. These toxins all have bipartite structures consisting of an enzymatic A subunit associated with a B oligomer which binds to specific cell-surface receptors, but their amino-acid sequences and pathogenic mechanisms differ. We have determined the crystal structure of the B oligomer of verotoxin-1 from E. coli. The structure unexpectedly resembles that of the B oligomer of the cholera toxin-like heat-labile enterotoxin from E. coli 2, despite the absence of detectable sequence similarity between these two proteins. This result implies a distant evolutionary relationship between the Shiga toxin and cholera toxin families. We suggest that the cell surface receptor-binding site lies in a cleft between adjacent subunits of the B pentamer, providing a potential target for drugs and vaccines to prevent toxin binding and effect.	UNIV ALBERTA, DEPT MED MICROBIOL & INFECT DIS, EDMONTON T6G 2H7, ALBERTA, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MICROBIOL, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT MED, TORONTO M5S 1A1, ONTARIO, CANADA	University of Alberta; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Read, Randy J/L-1418-2013; Tyrrell, Gregory/ABA-7203-2021	Read, Randy J/0000-0001-8273-0047; 				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOODHOO A, 1991, J MOL BIOL, V221, P729, DOI 10.1016/0022-2836(91)80166-R; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNTON JL, 1990, BACTERIA, V11, P377; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; HART PJ, 1991, J MOL BIOL, V218, P691, DOI 10.1016/0022-2836(91)90256-6; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; JACKSON MP, 1990, J BACTERIOL, V172, P653, DOI 10.1128/jb.172.2.653-658.1990; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; OTWINOWSKI Z, 1990, 1990 AM CRYST ASS AN; PERERA LP, 1991, J BACTERIOL, V173, P1151, DOI 10.1128/jb.173.3.1151-1160.1991; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RAMOTAR K, 1990, BIOCHEM J, V273, P805; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; TYRRELL GJ, IN PRESS P NATN ACAD; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3	24	265	282	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					748	750		10.1038/355748a0	http://dx.doi.org/10.1038/355748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741063				2022-12-28	WOS:A1992HE60400072
J	DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; CHURCH, MS; STUKEL, TA; PANDEY, MR				DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; CHURCH, MS; STUKEL, TA; PANDEY, MR			CHILDHOOD MORTALITY AFTER A HIGH-DOSE OF VITAMIN-A IN A HIGH-RISK POPULATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; COMMUNITY; TRIAL	Objectives - To determine whether a single high dose of vitamin A given to all children in communities with high mortality and malnutrition could affect mortality and to assess whether periodic community wide supplementation could be readily incorporated into an ongoing primary health programme. Design - Opportunistic controlled trial. Setting - Jumla district, Nepal. Subjects - All children aged under 5 years; 3786 in eight subdistricts given single dose of vitamin A and 3411 in remaining eight subdistricts given no supplementation. Main outcome measures - Mortality and cause of death in the five months after supplementation. Results - Risk of death for children aged 1-59 months in supplemented communities was 26% lower (relative risk 0.74, 95% confidence interval 0.55 to 0.99) than in unsupplemented communities. The reduction in mortality was greatest among children aged 6-11 months: death rate (deaths/1000 child years at risk) was 133-8 in supplemented children and 260.8 in unsupplemented children (relative risk 0.51, 0.30 to 0.89). The death rate from diarrhoea was also reduced (63.5 supplemented v 97.5 unsupplemented; relative risk 0.65, 0.44 to 0.95). The extra cost per death averted was about $11. Conclusion - The results support a role for Vitamin A in increasing child survival. The supplementation programme was readily integrated with the ongoing community health programme at little extra cost.	CTR DIS CONTROL, PUBL HLTH PROGRAMME, ATLANTA, GA 30333 USA; CTR DIS CONTROL, PROGRAMME AGAINST MICRONUTR MALNUTR, ATLANTA, GA 30333 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA; MRIGENDRA MED TRUST, Kathmandu, NEPAL	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Dartmouth College	DAULAIRE, NMP (corresponding author), INT CTR PREVENT & TREATMENT MAJOR CHILDHOOD DIS, POB 168, HANOVER, NH 03755 USA.			Stukel, Therese/0000-0002-2951-1360				ACHARIA JR, 1990, 12TH P IVACG M KATHM; BRESLOW NE, 1987, IARC SCI PUBL, V82, P49; BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375; COLEMAN MP, 1989, PERSON YEARS PYRS FO; DEROMANA GL, 1989, AM J EPIDEMIOL, V129, P769, DOI 10.1093/oxfordjournals.aje.a115192; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; FEACHEM RG, 1987, TROPICAL DISEASE B, V84, P3; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; McCullagh P, 1989, GEN LINEAR MODELS, P198; MUHILAL, 1988, AM J CLIN NUTR, V48, P1271, DOI 10.1093/ajcn/48.5.1271; PANDEY MR, 1991, LANCET, V338, P993, DOI 10.1016/0140-6736(91)91847-N; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; WEST KP, 1989, ANNU REV NUTR, V9, P63, DOI 10.1146/annurev.nu.09.070189.000431; ZERFAS AJ, 1975, AM J CLIN NUTR, V28, P782, DOI 10.1093/ajcn/28.7.782; 1988, VITAMIN SUPPLEMENTS	19	130	133	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1992	304	6821					207	210		10.1136/bmj.304.6821.207	http://dx.doi.org/10.1136/bmj.304.6821.207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739794	Green Published, Bronze			2022-12-28	WOS:A1992HA98000020
J	WALSH, C; CEPKO, CL				WALSH, C; CEPKO, CL			WIDESPREAD DISPERSION OF NEURONAL CLONES ACROSS FUNCTIONAL REGIONS OF THE CEREBRAL-CORTEX	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; CELL LINEAGE; SOMATOSENSORY CORTEX; MIGRATION PATTERNS; CORTICAL BARRELS; NERVOUS-SYSTEM; RAT; RETROVIRUS; HINDBRAIN; NEOCORTEX	The cerebral cortex of the mammalian brain has expanded rapidly during the course of evolution and acquired structurally distinguishable areas devoted to separate functions. In some brain regions, topographic restrictions to cell intermixing occur during embryonic development. As a means of examining experimentally whether such restrictions occur during formation of functional subdivisions in the rat neocortex, clonally related neocortical cells were marked by retroviral-mediated transfer of a histochemical marker gene. Clonal boundaries were determined by infection of the developing brain with a library of genetically distinct viruses and amplification of single viral genomes by the polymerase chain reaction. Many clonally related neurons in the cerebral cortex became widely dispersed across functional areas of the cortex. Specification of cortical areas therefore occurs after neurogenesis.	HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Walsh, Christopher/0000-0002-0156-2238	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023021] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23021] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1990, EXP NEUROL, V107, P36, DOI 10.1016/0014-4886(90)90061-V; ALTMAN J, 1991, NEOCORTICAL DEV; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BARBE MF, 1991, J NEUROSCI, V11, P519; BAYER SA, 1991, J COMP NEUROL, V307, P487, DOI 10.1002/cne.903070311; BERRY M, 1965, J ANAT, V99, P691; CEPKO CL, 1990, COLD SH Q B, V55, P265; CEPKO CL, 1989, NEUROMETHODS MOL NEU, V16; COOPER M W, 1989, Society for Neuroscience Abstracts, V15, P808; CRANDELL JE, 1991, EXP NEUROL, V239, P185; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAWSON DR, 1987, J COMP NEUROL, V256, P246, DOI 10.1002/cne.902560205; FIELDSBERRY S, IN PRESS P NATL ACAD; FISHELL G, 1990, DEV BIOL, V141, P70, DOI 10.1016/0012-1606(90)90102-O; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROST DO, 1985, NATURE, V317, P162, DOI 10.1038/317162a0; GASSER UE, 1990, P NATL ACAD SCI USA, V87, P4543, DOI 10.1073/pnas.87.12.4543; GOLDOWITZ D, 1987, DEV BRAIN RES, V35, P1, DOI 10.1016/0165-3806(87)90002-2; GROVE E A, 1991, Society for Neuroscience Abstracts, V17, P11; HOGG RV, 1978, INTRO MATH STATISTIC, P96; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KRUSHEL L A, 1989, Society for Neuroscience Abstracts, V15, P598; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PARNAVELAS J G, 1990, Society for Neuroscience Abstracts, V16, P1272; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RAKIC P, 1974, NATURE, V250, P31, DOI 10.1038/250031a0; RYDER E F, 1988, Society for Neuroscience Abstracts, V14, P892; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, UNPUB; WALSH C, 1991, EXPERIENTIA, V46, P940; WELKER C, 1976, J COMP NEUROL, V166, P173, DOI 10.1002/cne.901660205; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WONGRILEY MTT, 1980, P NATL ACAD SCI-BIOL, V77, P2333, DOI 10.1073/pnas.77.4.2333; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; 1972, ANAT REC, V166, P257	53	444	452	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					434	440		10.1126/science.1734520	http://dx.doi.org/10.1126/science.1734520			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734520				2022-12-28	WOS:A1992HA59000031
J	QUINN, TC; KLINE, RL; HALSEY, N; HUTTON, N; RUFF, A; BUTZ, A; BOULOS, R; MODLIN, JF				QUINN, TC; KLINE, RL; HALSEY, N; HUTTON, N; RUFF, A; BUTZ, A; BOULOS, R; MODLIN, JF			EARLY DIAGNOSIS OF PERINATAL HIV-INFECTION BY DETECTION OF VIRAL-SPECIFIC IGA ANTIBODIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; CHILDREN; WOMEN; MOTHERS; AIDS; TRANSMISSION; TYPE-1; BLOOD	Objectives. - To evaluate the clinical utility of a human immunodeficiency virus (HIV)-IgA serological assay for diagnosis of perinatally acquired HIV infection. Design. - Coded serum samples prospectively collected from children born to HIV-infected mothers and uninfected mothers were analyzed by HIV-IgA immunoblot. Setting. - A university hospital in Baltimore, Md, and an outpatient clinic in Port-au-Prince, Haiti. Population. - Five hundred thirty-nine serum samples were obtained sequentially from 278 children born to HIV-infected women (116 from The Johns Hopkins Hospital and 62 from Port-au-Prince) and from 42 control children born to HIV-seronegative children in Port-au-Prince. Outcome Measures. - Results from the HIV-IgA serological assays were compared with the known infection status of the child at 15 months of age as determined by the standard IgG Western blot and the clinical classification of the Centers for Disease Control. Sensitivity, specificity, and predictive values were calculated at different ages and collectively for children 3 months of age or older. Results. - The HIV-IgA assay was positive in one of six specimens from HIV-infected children under 1 month of age, six of nine specimens from infected children at 3 months of age, and 160 of 161 specimens from 47 HIV-infected children 6 months of age or older. Of 334 specimens from 243 uninfected children, 333 were negative by the HIV-IgA assay. The overall sensitivity and the specificity of the IgA assay for children older than 3 months of age were 97.6% and 99.7%, and the positive and negative predictive values were 99.4% and 98.7%, respectively. Conclusion. - Although the HIV-IgA assay had a low sensitivity within the first months of life, the high sensitivity, specificity, and predictive values of this assay demonstrate its utility for the diagnosis of perinatally acquired HIV infection after the third month of age. Early diagnosis with this relatively simple and inexpensive serological assay should aid in the implementation of antiviral therapy and provide useful information for the care of children born to HIV-infected mothers in both developing and developed countries.	CTR DEV & HLTH,PORT AU PRINCE,HAITI; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NURSING,BALTIMORE,MD 21205	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	QUINN, TC (corresponding author), JOHNS HOPKINS UNIV HOSP,BLALOCK 1111,600 N WOLFE ST,BALTIMORE,MD 21205, USA.				PHS HHS [1R01A126521] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADORI A, 1988, LANCET, V1, P852; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; HUSSON RN, 1990, PEDIATRICS, V86, P1; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; NEWELL M-L, 1990, AIDS (London), V4, pS111; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; QUINN TC, 1990, AIDS, V4, P709, DOI 10.1097/00002030-199008000-00001; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; 1990, MMWR, V39, P850; 1989, MMWR, V38, pS1; 1991, MMWR, V40, P195; 1990, MMWR, V39, P845; 1991, HIV AIDS SURVEILLANC, P9; 1991, LANCET, V338, P253; 1990, MMWR, V39, P1	27	81	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3439	3442		10.1001/jama.266.24.3439	http://dx.doi.org/10.1001/jama.266.24.3439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744957				2022-12-28	WOS:A1991GV87800028
J	DOROZYNSKI, A				DOROZYNSKI, A			MEDECINS-SANS-FRONTIERES - 20 YEARS OLD	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1591	1592		10.1136/bmj.303.6817.1591	http://dx.doi.org/10.1136/bmj.303.6817.1591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773181	Bronze, Green Published			2022-12-28	WOS:A1991GX95600013
J	FRY, J				FRY, J			THE KEPPEL-CLUB (1952-74) - LESSONS FROM THE PAST FOR THE FUTURE	BRITISH MEDICAL JOURNAL			English	Article																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1596	1598		10.1136/bmj.303.6817.1596	http://dx.doi.org/10.1136/bmj.303.6817.1596			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773183	Green Published, Bronze			2022-12-28	WOS:A1991GX95600016
J	NORMAND, C				NORMAND, C			ECONOMICS, HEALTH, AND THE ECONOMICS OF HEALTH	BRITISH MEDICAL JOURNAL			English	Article											NORMAND, C (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY,LONDON WC1E 7HT,ENGLAND.			Normand, Charles/0000-0002-0885-5754				AKEHURST R, 1987, REPORT REV HOSPITAL; Akelof G.A., 1970, Q J ECON, V84, P488, DOI DOI 10.2307/1879431; Arrow K., 1963, SOCIAL CHOICE INDIVI; Bacon R., 1976, BRITAINS EC PROBLEM; BAYLEY H, 1989, CARE ELDERLY LINCOLN; BOOTH T, 1985, HOME TRUTHS OLD PEOP; BRAZIER JE, 1991, SCOT J POLIT ECON, V38, P96, DOI 10.1111/j.1467-9485.1991.tb00303.x; CAIRNS J, 1991, HERU9114 U AB DISC P; Cohen DR, 1988, HLTH PREVENTION EC; FETTER RB, 1980, MED CARE S, V2, P1; FORDHAM R, IN RESS J PUBLIC HLT; GRAY AM, 1988, CHEHEC46 U YORK DISC; JUDGE K, 1991, BRIT MED J, V302, P1163, DOI 10.1136/bmj.302.6786.1163; KERNOHAN WG, 1990, MANAGEMENT MED, V4, P230; McGuire A, 1988, EC HLTH CARE; Scitovsky T, 1976, JOYLESS EC; WILLIAMSON R, 1991, WHATS NEW GENE THERA; 1987, OPTION APPRAISAL HOS	18	15	15	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1572	1577		10.1136/bmj.303.6817.1572	http://dx.doi.org/10.1136/bmj.303.6817.1572			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX956	1773175	Green Published, Bronze			2022-12-28	WOS:A1991GX95600007
J	STERN, R; FERNANDEZ, M				STERN, R; FERNANDEZ, M			GROUP COGNITIVE AND BEHAVIORAL TREATMENT FOR HYPOCHONDRIASIS	BRITISH MEDICAL JOURNAL			English	Article							ANXIETY	Objective - To assess the feasibility of carrying out group cognitive and behavioural treatment for hypochondriasis in a general hospital setting. Design - Assessment of patients referred for therapy. Setting - District general hospital. Patients - Six patients aged 35 to 55 (mean 43) years with a mean duration of symptoms of 12 years who fulfilled the Diagnostic and Statistical Manual for Mental Disorders (DSM III-R) criteria for hypochrondriasis. Main outcome measures - Number of visits to their doctors, time spent thinking about illness, and scores on the hospital anxiety and depression scales. Results - The mean number of visits to a doctor fell significantly after treatment (3 before treatment v 0.8 after treatment; p = 0.03) as did the time spent thinking about illness (57.3 v 40.6; p = 0.14). The depression and anxiety scores also fell, although the differences were not significant (depression: 9.5 before v 8.5 after; anxiety: 13 before v 12 after). Conclusion - It is feasible to carry out group cognitive and behavioural treatment in patients with hypochondriasis, and controlled studies are now indicated.	ST HELIER HOSP,CARSHALTON SM5 1AA,SURREY,ENGLAND	St Helier Hospital								BARSKY AJ, 1983, AM J PSYCHIAT, V140, P273; BARSKY AJ, 1990, BRIT J PSYCHIAT, V157, P404, DOI 10.1192/bjp.157.3.404; BARSKY AJ, 1988, GEN HOSP PSYCHIAT, V10, P322, DOI 10.1016/0163-8343(88)90003-5; BASS C, 1990, J ROY SOC MED, V83, P203, DOI 10.1177/014107689008300401; BECK AT, 1979, COGNITIVE THERAPY DE; CRISP AH, 1968, POSTGRAD MED J, V44, P267; Ellis A., 1962, REASON EMOTION PSYCH; GOLDBERG DP, 1988, J PSYCHOSOM RES, V32, P137, DOI 10.1016/0022-3999(88)90048-7; SALKOVSKIS PM, 1986, BEHAV RES THER, V24, P597, DOI 10.1016/0005-7967(86)90041-0; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1987, DIAGNOSTIC STATISTIC	11	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1229	1231		10.1136/bmj.303.6812.1229	http://dx.doi.org/10.1136/bmj.303.6812.1229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747641	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200020
J	DOROZYNSKI, A				DOROZYNSKI, A			CRIMINAL CHARGES OVER HIV IN FRENCH BLOOD-TRANSFUSIONS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1091	1091						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GN209	1747576				2022-12-28	WOS:A1991GN20900016
J	MCNINCH, AW; TRIPP, JH				MCNINCH, AW; TRIPP, JH			HEMORRHAGIC-DISEASE OF THE NEWBORN IN THE BRITISH-ISLES - 2 YEAR PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the incidence of haemorrhagic disease of the newborn in the British Isles, study risk factors, and examine the effect of vitamin K prophylaxis. Design - Prospective survey of all possible cases of haemoffhagic disease of the newborn as reported by consultant paediatricians using the monthly notification cards of the British Paediatric Surveillance Unit and a follow up questionnaire for each case to validate the diagnosis and accrue further data. Setting - Britain (England, Scotland, and Wales) and Ireland (Northern Ireland and the Irish Republic) during December 1987 to March 1990. Patients - 27 infants classified as having confirmed (n = 25) or probable (n = 2) haemoffhagic disease of the newborn. Results - 24 of the 27 infants were solely breast fed. 10 suffered intracranial haemorrhage; two of these died and there was clinical concern about the remainder. 20 infants had received no vitamin K prophylaxis, and seven had received oral prophylaxis. Relative risk ratios for these groups compared with babies who had received intramuscular vitamin K were 81:1 and 13:1 respectively. Six infants had hepatitis (alpha-1 antitrypsin deficiency in four), unsuspected until presentation with haemorrhagic disease of the newborn, of whom four had received oral prophylaxis. One other baby had prolonged jaundice. One mother had taken phenytoin during pregnancy. Conclusions - All newborn infants should receive vitamin K prophylaxis. Intramuscular vitamin K is more effective than oral prophylactic regimens currently used in the British Isles.	POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter	MCNINCH, AW (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.							DAM H, 1952, ADV PEDIATR, V5, P129; EKELUND H, 1991, ACTA PAEDIATR SCAND, V80, P966, DOI 10.1111/j.1651-2227.1991.tb11763.x; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; Hall S M, 1988, Arch Dis Child, V63, P344; HANAWA Y, 1990, Acta Paediatrica Japonica, V32, P51; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; MARTIN J, 1988, INFANT FEEDING 1985; MOUNTAIN KR, 1970, LANCET, V1, P265; SUTHERLAND JM, 1967, AM J DIS CHILD, V113, P524, DOI 10.1001/archpedi.1967.02090200056003; TONZ O, 1988, SCHWEIZ MED WSCHR, V118, P1747; TRIPP JH, 1987, ARCH DIS CHILD, V62, P426; VONKRIES R, 1988, EUR J PEDIATR, V147, P106; 1988, BPSU3RD BRIT PAED SU	13	132	135	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1105	1109		10.1136/bmj.303.6810.1105	http://dx.doi.org/10.1136/bmj.303.6810.1105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747578	Bronze, Green Published			2022-12-28	WOS:A1991GN20900022
J	LEE, SP; NICHOLLS, JF; PARK, HZ				LEE, SP; NICHOLLS, JF; PARK, HZ			BILIARY SLUDGE AS A CAUSE OF ACUTE-PANCREATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECURRENT PANCREATITIS; GALLBLADDER; PATHOGENESIS; SYSTEM; STONES; BILE	Background. In about 20 to 40 percent of cases of acute pancreatitis, no cause can be found, and these are labeled idiopathic. In this study, we sought to determine the frequency with which patients with acute idiopathic pancreatitis have biliary sludge, a suspension of cholesterol monohydrate crystals or calcium bilirubinate granules that is found predominantly in the gallbladder. Methods. Between 1980 and 1988, we prospectively studied 86 patients who had acute pancreatitis. In patients with no known cause of pancreatitis and no ultrasonographic evidence of gallstones or dilatation of the biliary ducts, we determined how often biliary sludge was present and its subsequent fate by repeated microscopical examinations of bile samples and abdominal ultrasonography. The outcome of patients treated by cholecystectomy or papillotomy was compared with that of untreated patients. Results. The pancreatitis was considered idiopathic in 31 of the 86 patients (36 percent), of whom 23 had microscopical evidence of biliary sludge. Biliary sludge was detected by ultrasonography in only 11 of the 23 patients (48 percent). The sludge detected by ultrasonography was composed of calcium bilirubinate granules in 10 and cholesterol monohydrate crystals in 1 (P = 0.003). Calcium bilirubinate granules were found more frequently in men (nine men vs. four women, P < 0.001). Of the 21 patients in whom biliary sludge was the only finding (2 patients also had dilated bile ducts when restudied), the 6 treated by cholecystectomy and the 4 treated by papillotomy had fewer recurrences of acute pancreatitis during follow-up (up to seven years) than the 11 untreated patients (P = 0.011). The presence of biliary sludge appeared to increase the likelihood of recurrent attacks of pancreatitis (P = 0.020). Conclusions. Biliary sludge is an underestimated cause of acute idiopathic pancreatitis.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND	University of Washington; University of Washington Seattle; University of Auckland								ACOSTA JM, 1980, SURGERY, V88, P118; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CONRAD MR, 1979, AM J ROENTGENOL, V132, P967, DOI 10.2214/ajr.132.6.967; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; DIMAGNO EP, 1987, HDB GASTROINTESTINAL, P176; FREUND H, 1976, ARCH SURG-CHICAGO, V111, P1106; GOODMAN AJ, 1985, GUT, V26, P125, DOI 10.1136/gut.26.2.125; HOLZBACH RT, 1983, GASTROENTEROLOGY, V84, P1055; HOUSSIN D, 1983, SURG GYNECOL OBSTET, V157, P20; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEE SP, 1987, AM J PHYSIOL, V252, pG374, DOI 10.1152/ajpgi.1987.252.3.G374; LEE SP, 1986, GASTROENTEROLOGY, V90, P677, DOI 10.1016/0016-5085(86)91123-6; LEE SP, 1990, HEPATOLOGY, V12, pS200; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARINGHINI A, 1988, GASTROENTEROLOGY, V95, P1160, DOI 10.1016/0016-5085(88)90218-1; MAYER AD, 1984, BRIT J SURG, V71, P905; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; Mittelstaedt CA, 1987, ABDOMINAL ULTRASOUND; NEOPTOLEMOS JP, 1988, BRIT J SURG, V75, P450, DOI 10.1002/bjs.1800750517; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SHIFFMAN M L, 1990, Gastroenterology, V98, pA262; SOERGEL KH, 1989, GASTROINTESTINAL DIS, P1814; TRAPNELL JE, 1975, BRIT MED J, V2, P179, DOI 10.1136/bmj.2.5964.179; VENU RP, 1989, DIGEST DIS SCI, V34, P56, DOI 10.1007/BF01536154	25	382	393	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					589	593		10.1056/NEJM199202273260902	http://dx.doi.org/10.1056/NEJM199202273260902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734248				2022-12-28	WOS:A1992HF63300002
J	NOVACK, AH				NOVACK, AH			ANTIMICROBIAL TREATMENT OF THE UMBILICAL-CORD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BACTERIAL-COLONIZATION; CARE REGIMENS				NOVACK, AH (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98195, USA.							BARRETT FF, 1979, J PEDIATR-US, V94, P796, DOI 10.1016/S0022-3476(79)80159-6; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; GLADSTONE IM, 1988, CLIN PEDIATR, V27, P127, DOI 10.1177/000992288802700302; SPECK WT, 1980, CHEMOTHERAPY, V26, P372, DOI 10.1159/000237929; SPECK WT, 1977, AM J DIS CHILD, V131, P1005, DOI 10.1001/archpedi.1977.02120220071012	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					1008	1008						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734090				2022-12-28	WOS:A1992HD15500038
J	YIP, R; SCANLON, K; TROWBRIDGE, F				YIP, R; SCANLON, K; TROWBRIDGE, F			IMPROVING GROWTH STATUS OF ASIAN REFUGEE CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCHOOL-CHILDREN; PHYSICAL GROWTH; BIRTH-WEIGHT; HEIGHT	Objective. - To analyze the trend and pattern of the nutrition status of Southeast Asian refugee children and other low-income children in the United States. Design. - Descriptive analysis of the growth data from the Pediatric Nutrition Surveillance System of the Centers for Disease Control, Atlanta, Ga, from 1980 through 1989. Subjects. - Children under 5 years of age from low-income families enrolled in public health clinics in 12 selected states. Measurements and Main Results. - Asian refugee children experienced a progressive and significant decline in the prevalence of low birth weight, low height-for-age, and low weight-for-age, while these nutritional indexes remained stable for low-income white, black, and Hispanic children. By 1989, the growth status of Asian children was near that of other ethnic groups. Conclusions. - The marked improvement of growth status among Asian refugee children over a short period suggests that the poor growth status often observed among recently immigrated Asian children is primarily related to nutritional and health factors, rather than genetic factors. In assessing the growth of Asian or immigrant children, it would be helpful to take their family and early childhood background into account.			YIP, R (corresponding author), CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR,MAIL STOP K-26,ATLANTA,GA 30333, USA.							BALDWIN LM, 1988, AM J DIS CHILD, V142, P526, DOI 10.1001/archpedi.1988.02150050064033; BINKIN NJ, 1988, PEDIATRICS, V82, P828; DAVIES DP, 1988, LINEAR GROWTH RETARD, P75; DEWEY KG, 1986, AM J PUBLIC HEALTH, V76, P806, DOI 10.2105/AJPH.76.7.806; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; Eveleth P.B., 1976, WORLDWIDE VARIATION, V8; GAYLE HD, 1988, PUBLIC HEALTH REP, V103, P143; GRAITCEN PL, 1988, LANCET, V2, P297; HABICHT JP, 1974, LANCET, V1, P611; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; KELLER W, 1988, LINEAR GROWTH RETARD, P17; LI DK, 1990, AM J PUBLIC HEALTH, V80, P685, DOI 10.2105/AJPH.80.6.685; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P198; OLNESS K, 1984, AM J DIS CHILD, V138, P544, DOI 10.1001/archpedi.1984.02140440028006; PECK RE, 1981, AM J PUBLIC HEALTH, V71, P1144, DOI 10.2105/AJPH.71.10.1144; ROUJIA C, 1989, J TROP PEDIATRICS, V35, P255, DOI 10.1093/tropej/35.5.255; SCHUMACHER LB, 1987, PEDIATRICS, V80, P861; YIP R, 1987, JAMA-J AM MED ASSOC, V258, P1619, DOI 10.1001/jama.258.12.1619; YIP R, 1991, PEDIATRICS, V87, P688; YIP R, 1989, 14TH P INT C NUTR SE; 1979, MMWR, V28, P386; 1983, CDC838295 US DEP HLT	23	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					937	940		10.1001/jama.267.7.937	http://dx.doi.org/10.1001/jama.267.7.937			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734105				2022-12-28	WOS:A1992HD15500025
J	BARTON, NJ; HOOPER, G; NOBLE, J; STEEL, WM				BARTON, NJ; HOOPER, G; NOBLE, J; STEEL, WM			OCCUPATIONAL CAUSES OF DISORDERS IN THE UPPER LIMB	BRITISH MEDICAL JOURNAL			English	Review							TENNIS ELBOW; HUMERAL EPICONDYLITIS; TENOSYNOVITIS; PREVALENCE		PRINCESS MARGARET ROSE ORTHOPAED HOSP,EDINBURGH EH10 7ED,MIDLOTHIAN,SCOTLAND; HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND; N STAFFORDSHIRE HOSP,STOKE ON TRENT ST4 4LN,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust	BARTON, NJ (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,DEPT ORTHOPAED & ACCID SURG,NOTTINGHAM NG7 2UH,ENGLAND.							BARNES W E, 1964, Plast Reconstr Surg, V34, P570, DOI 10.1097/00006534-196412000-00004; Birkbeck M Q, 1975, Rheumatol Rehabil, V14, P218, DOI 10.1093/rheumatology/14.4.218; CHARD MD, 1989, BRIT J RHEUMATOL, V28, P186; CUETTER AC, 1989, MUSCLE NERVE, V12, P410, DOI 10.1002/mus.880120512; DIMBERG L, 1987, ERGONOMICS, V30, P573, DOI 10.1080/00140138708969746; EARLY PF, 1962, J BONE JOINT SURG BR, V44, P602, DOI 10.1302/0301-620X.44B3.602; ENGLISH CJ, 1989, CLIN EPIDEMIOLOGICAL; FELDMAN RG, 1987, J HAND SURG-AM, V12A, P849, DOI 10.1016/S0363-5023(87)80247-2; FERGUSON D, 1971, BRIT J IND MED, V28, P280; FISK G, 1985, GEM MONOGRAPH, P104; FRY HJH, 1986, MED J AUSTRALIA, V144, P182, DOI 10.5694/j.1326-5377.1986.tb128353.x; Goldie I., 1964, ACTA CHIR SCAND    S, V57, P1; GRANDJEAN E, 1969, ERGONOMICS HLTH MODE, P444; HADLER NM, 1985, J HAND SURG-AM, V10A, P451, DOI 10.1016/S0363-5023(85)80065-4; HAMILTON PG, 1986, J ROY COLL GEN PRACT, V36, P464; HAWKINS RJ, 1987, ORTHOP CLIN N AM, V18, P373; HAWKINS RJ, 1980, AM J SPORTS MED, V8, P57; HELAL B, 1987, J ROY SOC MED, V80, P68, DOI 10.1177/014107688708000203; HOOPER G, IN PRESS TUMOURS WRI; HUESTON JT, 1985, GEM MONOGRAPH, P75; IDE CW, 1989, RHEUMATOLOGY PRA OCT, P24; IRELAND DCR, 1988, J HAND SURG-BRIT EUR, V13B, P5, DOI 10.1016/0266-7681(88)90041-1; JACKSON JP, 1990, MEDICOLEGAL REPORTIN, P447; James JIP, 1969, HAND, V1, P47; JAMES JIP, 1985, GEM MONOGRAPH, P94; KIVI P, 1984, SCAND J RHEUMATOL, V13, P101, DOI 10.3109/03009748409100371; LAURENCE JS, 1969, ANN RHEUM DIS, V28, P121; LAURENCE JS, 1961, BR J IND MED, V18, P270; LEAO L, 1958, J BONE JOINT SURG AM, V40, P1063, DOI 10.2106/00004623-195840050-00008; LING RSM, 1963, J BONE JOINT SURG BR, V45, P709, DOI 10.1302/0301-620X.45B4.709; LUOPAJARVI T, 1979, SCAND J WORK ENV HEA, V5, P48, DOI 10.5271/sjweh.2675; MCFARLAND GB, 1990, SURGERY MUSCULOSKELE, P962; NATHAN PA, 1988, J HAND SURG-BRIT EUR, V13B, P167, DOI 10.1016/0266-7681(88)90130-1; NEAL NC, 1987, J HAND SURG-BRIT EUR, V12B, P229, DOI 10.1016/0266-7681(87)90020-9; NEVIASER JS, 1980, ORTHOP CLIN N AM, V11, P327; NOBLE J, 1984, J BONE JOINT SURG BR, V66, P322, DOI 10.1302/0301-620X.66B3.6725338; NOBLE J, IN PRESS J HAND SURG; Rathbun J B, 1970, J Bone Joint Surg Br, V52, P540; SALAN A, 1991, J HAND SURG-BRIT, V16, P436; SEMPLE JC, 1986, J HAND SURG B, V11, P155; SMYTHE H, 1988, J RHEUMATOL, V15, P1604; THOMPSON AR, 1951, BRIT J IND MED, V8, P150; THOMPSON D, 1990, OCCURRENCE MECHANISM; VIIKARIJUNTURA E, 1984, SCAND J WORK ENV HEA, V10, P443, DOI 10.5271/sjweh.2314; 1987, J HAND SURG AM A S, V12, P821	45	42	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					309	311		10.1136/bmj.304.6822.309	http://dx.doi.org/10.1136/bmj.304.6822.309			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739835	Green Published, Bronze			2022-12-28	WOS:A1992HC70800028
J	LOWNDES, NF; MCINERNY, CJ; JOHNSON, AL; FANTES, PA; JOHNSTON, LH				LOWNDES, NF; MCINERNY, CJ; JOHNSON, AL; FANTES, PA; JOHNSTON, LH			CONTROL OF DNA-SYNTHESIS GENES IN FISSION YEAST BY THE CELL-CYCLE GENE CDC10+	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; DIVISION CYCLE; HO GENE; TRANSCRIPTION; COMMITMENT; REGULATORS; MITOSIS; PROTEIN	IN the budding yeast Saccharomyces cerevisiae, cell-cycle control over DNA synthesis occurs partly through the coordinate expression in late G1 phase of many, if not all, of the genes required for DNA synthesis 1-3. A cis-acting hexamer element ACGCGT (an MluI restriction site) is responsible for coordinating transcriptional regulation of these genes at the G1/S phase boundary 1,4 and we have identified a binding activity, DSC1, that recognizes these sequences in a cell-cycle-dependent manner 1. In the distantly related fission yeast 5 Schizosaccharomyces pombe, only one of the known DNA synthesis genes, cdc22+, which encodes a subunit of ribonucleotide reductase, is periodically expressed in late G1 (ref. 6). The promoter region of cdc22+ has two MluI sites and five related sequences, suggesting that similar controls over DNA synthesis genes could occur in fission yeast. We report here a binding activity in fission yeast that is very similar to DSC1 in budding yeast. We also show that the fission yeast cdc10+ gene product, which is required for Start and entry into S phase 7,8, is a component of this binding activity.	NATL INST MED RES,YEAST GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; UNIV EDINBURGH,INST CELL & MOLEC BIOL,EDINBURGH EH9,SCOTLAND	MRC National Institute for Medical Research; University of Edinburgh			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427; /0000-0002-9201-3479				ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; FERNANDEZSARABIA MJ, 1990, TRENDS GENET, V6, P275, DOI 10.1016/0168-9525(90)90214-Q; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; JOHNSTON LH, IN PRESS COLD SPRING; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MACINTOSH E, 1991, MOL CELL BIOL, V11, P329; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RUSSELL PR, 1983, NATURE, V301, P167, DOI 10.1038/301167a0; SIMANIS V, 1989, J CELL SCI, V92, P51; SPICZKI M, 1989, MOL BIOL FISSION YEA, P431; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WHITE JHM, 1986, EMBO J, V5, P1706	20	208	211	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					449	453		10.1038/355449a0	http://dx.doi.org/10.1038/355449a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734281				2022-12-28	WOS:A1992HB53000070
J	JACK, DB; SOPPITT, AJ				JACK, DB; SOPPITT, AJ			GIVE A DRUG A BAD NAME	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,DEPT GASTROENTEROL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		JACK, DB (corresponding author), FIDIA RES LABS,SCI INFORMAT SERV,I-35031 ABANO TERME,ITALY.							BLAIN J, 1990, REV PRESCRIRE    OCT; Eliot T. S., 1939, OLD POSSUMS BOOK PRA; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; Heller J., 1962, CATCH 22; HOFFMAN JP, 1990, NEW ENGL J MED, V323, P1428; KURTH MC, 1990, NEW ENGL J MED, V323, P1776; TOLSTOI LN, 1954, ANNA KARENINA; 1990, INDEX NOMINUM; 1991, BRIT NATIONAL FORMUL, V21	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1606	1608		10.1136/bmj.303.6817.1606	http://dx.doi.org/10.1136/bmj.303.6817.1606			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773189	Green Published, Bronze			2022-12-28	WOS:A1991GX95600022
J	KELLY, MJ				KELLY, MJ			SEEING FOR THEMSELVES	BRITISH MEDICAL JOURNAL			English	Article											KELLY, MJ (corresponding author), LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1598	1600		10.1136/bmj.303.6817.1598	http://dx.doi.org/10.1136/bmj.303.6817.1598			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773184	Bronze, Green Published			2022-12-28	WOS:A1991GX95600017
J	ENGELMAN, A; MIZUUCHI, K; CRAIGIE, R				ENGELMAN, A; MIZUUCHI, K; CRAIGIE, R			HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLIC DIGUANYLIC ACID; RETROVIRAL DNA; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; CHEMICAL SYNTHESIS; PROTEIN; INVITRO; RECOMBINATION; SEQUENCES	Retroviral DNA integration involves a coordinated set of DNA cutting and joining reactions. Linear viral DNA is cleaved at each 3' end to generate the precursor ends for integration. The resulting recessed 3' ends are inserted into target DNA by a subsequent DNA strand transfer reaction. Purified HIV-1 integration protein carries out both of these steps in vitro. Two novel forms of the dinucleotide cleaved from HIV-1 DNA were identified and one, a cyclic dinucleotide, was used to analyze the stereochemical course of viral DNA cleavage. Both viral DNA cleavage and DNA strand transfer display inversion at chiral phosphorothioates during the course of the reaction. These results suggest that both reactions occur by a one-step mechanism without involvement of a covalent protein-DNA intermediate.			ENGELMAN, A (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							Berg DE, 1989, MOBILE DNA; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HONG T, 1991, J VIROL, V65, P551, DOI 10.1128/JVI.65.1.551-555.1991; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; PAUZA CD, 1990, VIROLOGY, V179, P886; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1990, J BIOL CHEM, V265, P18933; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; VARMUS H, 1989, MOBILE DNA, P53; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990	43	550	568	2	42	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1211	1221		10.1016/0092-8674(91)90297-C	http://dx.doi.org/10.1016/0092-8674(91)90297-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760846				2022-12-28	WOS:A1991GX16400019
J	ROCHE, P; DEBELLE, F; MAILLET, F; LEROUGE, P; FAUCHER, C; TRUCHET, G; DENARIE, J; PROME, JC				ROCHE, P; DEBELLE, F; MAILLET, F; LEROUGE, P; FAUCHER, C; TRUCHET, G; DENARIE, J; PROME, JC			MOLECULAR-BASIS OF SYMBIOTIC HOST SPECIFICITY IN RHIZOBIUM-MELILOTI - NODH AND NODPQ GENES ENCODE THE SULFATION OF LIPO-OLIGOSACCHARIDE SIGNALS	CELL			English	Article							NODULATION GENES; NUCLEOTIDE-SEQUENCE; COMMON VETCH; SHORT ROOTS; RAT-LIVER; SULFOTRANSFERASE; LEGUMINOSARUM; CLONING; EXPRESSION; PROTEIN	The symbiosis between Rhizobium and legumes is highly specific. For example, R. meliloti elicits the formation of root nodules on alfalfa and not on vetch. We recently reported that R. meliloti nodulation (nod) genes determine the production of acylated and sulfated glucosamine oligosaccharide signals. We now show that the biochemical function of the major host-range genes, nodH and nodPQ, is to specify the 6-O-sulfation of the reducing terminal glucosamine. Purified Nod factors (sulfated or not) from nodH+ or nodH- strains exhibited the same plant specificity in a variety of bioassays (root hair deformations, nodulation, changes in root morphology) as the bacterial cells from which they were purified. These results provide strong evidence that the molecular mechanism by which the nodH and nodPQ genes mediate host specificity is by determining the sulfation of the extracellular Nod signals.	INRS, CNRS, BIOL MOLEC RELAT PLANTES MICROORGANISMES LAB, F-31326 CASTANET TOLOSAN, FRANCE	Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)	ROCHE, P (corresponding author), CNRS, CTR RECH BIOCHIM & GENET CELLULAIRE, LP8201, 118 ROUTE NARBONNE, F-31062 TOULOUSE, FRANCE.							BAEV N, 1991, MOL GEN GENET, V228, P113, DOI 10.1007/BF00282455; BANFALVI Z, 1989, PLANT MOL BIOL, V13, P1, DOI 10.1007/BF00027330; BROUGHTON WJ, 1991, ADV MOL GENETICS PLA, V1, P162; CERVANTES E, 1989, MOL MICROBIOL, V3, P745, DOI 10.1111/j.1365-2958.1989.tb00223.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dagnelie P., 1970, THEORIE METHODES STA, V2; DEBELLE F, 1988, J BACTERIOL, V170, P5718, DOI 10.1128/jb.170.12.5718-5727.1988; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DEBELLE F, 1986, J BACTERIOL, V168, P1075, DOI 10.1128/jb.168.3.1075-1086.1986; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DENARIE J, 1991, MOL SIGNALS PLANT MI, P295; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DUDLEY ME, 1987, PLANTA, V171, P289, DOI 10.1007/BF00398674; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FAUCHER C, 1988, J BACTERIOL, V170, P5489, DOI 10.1128/jb.170.12.5489-5499.1988; FAUCHER C, 1989, MOL PLANT MICROBE IN, V2, P291, DOI 10.1094/MPMI-2-291; FISHER RF, 1989, J BACTERIOL, V171, P5492, DOI 10.1128/jb.171.10.5492-5502.1989; GOREN MB, 1990, HDB LIPID RES, V6, P363; GYORGYPAL Z, 1988, MOL GEN GENET, V212, P85, DOI 10.1007/BF00322448; HONMA MA, 1990, J BACTERIOL, V172, P901, DOI 10.1128/jb.172.2.901-911.1990; HONMA MA, 1987, P NATL ACAD SCI USA, V84, P8558, DOI 10.1073/pnas.84.23.8558; HORVATH B, 1987, EMBO J, V6, P841, DOI 10.1002/j.1460-2075.1987.tb04829.x; HORVATH B, 1986, CELL, V46, P335, DOI 10.1016/0092-8674(86)90654-9; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; JOHN M, 1988, EMBO J, V7, P583, DOI 10.1002/j.1460-2075.1988.tb02850.x; Keen N., 1991, Advances in molecular genetics of plant-microbe interactions. Volume I. Proceedings of the 5th International Symposium, Interlaken, Switzerland, 9-14 September 1990., P37; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBAYASHI DY, 1990, MOL PLANT MICROBE IN, V3, P94, DOI 10.1094/MPMI-3-094; KONDOROSI E, 1984, MOL GEN GENET, V193, P445, DOI 10.1007/BF00382082; Kredich N.M., 1987, ESCHERICHIA COLI SAL, P419; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; LONG SR, 1982, NATURE, V298, P485, DOI 10.1038/298485a0; LUGTENBERG BJJ, 1991, ADV MOL GENETICS PLA, V1, P174; MARTIN MO, 1984, J BACTERIOL, V159, P125, DOI 10.1128/JB.159.1.125-129.1984; MARTINEZ E, 1990, CRIT REV PLANT SCI, V9, P59, DOI 10.1080/07352689009382282; MULLIGAN JT, 1989, GENETICS, V122, P7; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; NASH AR, 1988, AUST J BIOL SCI, V41, P507; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; ROCHE P, 1991, J BIOL CHEM, V266, P10933; RODRIGUEZQUINONES F, 1987, PLANT MOL BIOL, V8, P61, DOI 10.1007/BF00016435; ROSENBERG C, 1981, MOL GEN GENET, V184, P326, DOI 10.1007/BF00272926; RUVKUN GB, 1981, NATURE, V289, P85, DOI 10.1038/289085a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHERES B, 1990, PLANT CELL, V2, P687, DOI 10.1105/tpc.2.8.687; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1991, ADV MOL GENETICS PLA, V1, P142; SWANSON JA, 1987, GENETICS, V117, P181; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VINCENT J. M., 1970, A Manual for the Practical Study of the Root- Bacteria.; WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132; ZAAT SAJ, 1987, J BACTERIOL, V169, P3388, DOI 10.1128/jb.169.7.3388-3391.1987	63	340	361	3	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1131	1143		10.1016/0092-8674(91)90290-F	http://dx.doi.org/10.1016/0092-8674(91)90290-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760841				2022-12-28	WOS:A1991GX16400012
J	MADDOX, J				MADDOX, J			THE PARTY DEAD, BUT THE PARTY GOES ON	NATURE			English	Editorial Material																			0	0	0	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					499	500		10.1038/354499a0	http://dx.doi.org/10.1038/354499a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1758488	Bronze			2022-12-28	WOS:A1991GW75100001
J	HOFFMAN, M				HOFFMAN, M			HEPATITIS-A VACCINE SHOWS PROMISE	SCIENCE			English	Editorial Material																			0	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1581	1582		10.1126/science.1749931	http://dx.doi.org/10.1126/science.1749931			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749931				2022-12-28	WOS:A1991GV07300012
J	RETHANS, JJ; STURMANS, F; DROP, R; VANDERVLEUTEN, C; HOBUS, P				RETHANS, JJ; STURMANS, F; DROP, R; VANDERVLEUTEN, C; HOBUS, P			DOES COMPETENCE OF GENERAL-PRACTITIONERS PREDICT THEIR PERFORMANCE - COMPARISON BETWEEN EXAMINATION SETTING AND ACTUAL PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							SIMULATED PATIENTS; STANDARDIZED PATIENTS; CLINICAL COMPETENCE; PHYSICIANS	Objective - To study the differences and the relation between what a doctor actually does in daily practice (performance) and what he or she is capable of doing (competence) by using national standards for general practice. Design - General practitioners were consulted by four standardised (simulated) patients portraying four different cases during normal surgery hours. Later the doctors participated in a controlled practice test, for which they were asked to perform to the best of their ability. In the test they saw exactly the same standardised cases but in different patients. The patients reported on the consultations. Setting - Province of Limburg, the Netherlands. Subjects - 442 general practitioners invited by a letter. 137 (31%) agreed to participate, of whom 36 were selected and visited. Main outcome measures - Number of actions taken during the consultations across complaints and for each category of complaint: the competence and performance total scores. Combination of scores with duration of consultations (efficiency-time score). Correlation between scores in the competence and performance part. Results - Mean (SD) total score across complaints for competence was 49% higher than in the performance test (81.8 (11) compared with 54.7 (10.1), p < 0.0001). The Pearson correlation across complaints between the competence total score and the performance total score of the participating physicians was -0.04 (not significant). When efficiency and consultation time of the consultations were taken into account, the correlation was 0.45 (p < 0.01). Conclusions - Assessment of competence under examination circumstances can have predictive value for performance in actual practice only when factors such as efficiency and consultation time are taken into account. Below standard performance of physicians does not necessarily reflect a lack of competence. Performance and competence should be considered as distinct constructs.	UNIV LIMBURG,DEPT EPIDEMIOL,6200 MD MAASTRICHT,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,CTR QUAL ASSURANCE RES GEN PRACTICE,NIJMEGEN,NETHERLANDS; UNIV LIMBURG,DEPT MED SOCIOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT EDUC DEV & RES,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Radboud University Nijmegen; Hasselt University; Hasselt University								GROL R, 1986, KWALITEITSBEWAKING H; GROL R, 1988, PEER REV GENERAL PRA, P87; HOBUS PPM, 1987, MED EDUC, V21, P471, DOI 10.1111/j.1365-2923.1987.tb01405.x; KUNDEL HL, 1987, INVEST RADIOL, V13, P175; LLOYDS JS, 1979, DEFINITIONS COMPETEN; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MAGUIRE P, 1989, BRIT MED J, V298, P4, DOI 10.1136/bmj.298.6665.4; MCCLURE CL, 1985, J FAM PRACTICE, V20, P457; Neufeld VR, 1985, ASSESSING CLIN COMPE; NORMAN G, IN PRESS NEW DIRECTI; NORMAN GR, 1982, J MED EDUC, V57, P708; NORMAN GR, 1985, J MED EDUC, V60, P925; NORMAN GR, 1989, ARCH DERMATOL, V125, P175; RETHANS JJ, 1990, FAM PRACT, V7, P168, DOI 10.1093/fampra/7.3.168; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P94; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P97; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; SCHMIDT HG, 1988, 10TH P C COGN SCI SO, P139; SENIOR JR, 1976, MEASUREMENT COMPETEN; STILLMAN PL, 1987, ARCH INTERN MED, V147, P1049, DOI 10.1001/archinte.147.6.1049; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]	22	146	146	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1377	1380		10.1136/bmj.303.6814.1377	http://dx.doi.org/10.1136/bmj.303.6814.1377			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760606	Bronze, Green Published			2022-12-28	WOS:A1991GU38400023
J	SMITH, SRG; WOLFE, JHN				SMITH, SRG; WOLFE, JHN			ABC OF VASCULAR DISEASES - CONVALESCENT PROBLEMS IN ARTERIAL-SURGERY	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	SMITH, SRG (corresponding author), SELLY OAK HOSP,BIRMINGHAM,ENGLAND.							BREWSTER, 1983, ARCH SURG-CHICAGO, V118, P1104	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1388	1391		10.1136/bmj.303.6814.1388	http://dx.doi.org/10.1136/bmj.303.6814.1388			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760609	Green Published, Bronze			2022-12-28	WOS:A1991GU38400026
J	BROWNER, WS; WESTENHOUSE, J; TICE, JA				BROWNER, WS; WESTENHOUSE, J; TICE, JA			WHAT IF AMERICANS ATE LESS FAT - A QUANTITATIVE ESTIMATE OF THE EFFECT ON MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MAMMARY CARCINOGENESIS; SERUM-CHOLESTEROL; RISK-FACTORS; DIETARY-FAT; BREAST-CANCER; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; PLASMA-LIPIDS	Americans consume an average of 37% of their energy intake as fat. Many authorities recommend restricting fat intake to 30% of energy intake to reduce the rates of coronary heart disease and perhaps of cancers of the breast, colon, and prostate. Based on the assumptions that underlie those recommendations, we estimated the effect of this dietary change on mortality. If all Americans restricted their intake of dietary fat by reducing consumption of saturated fat and accompanying dietary cholesterol, the corresponding reductions in serum cholesterol levels could reduce coronary heart disease mortality rates by 5% to 20%, depending on age. If the relationship between dietary fat and cancer is as strong as has been observed in some studies, the proportional effects on mortality from fat-related cancers could be even greater, although the absolute effects - given the lower mortality rates - would be smaller. Overall, if the assumptions are correct, about 42 000 of the 2.3 million deaths that would have occurred in adults each year in the United States could be deferred. This 2% benefit, equivalent to an increase in average life expectancy of 3 to 4 months, would accrue chiefly to people over the age of 65 years. If recent concerns about the possibly harmful effects of cholesterol lowering on mortality from noncardiovascular causes - which mainly affect younger persons - are valid, these relatively modest benefits would be overestimates of the actual effect.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BROWNER, WS (corresponding author), VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA.			Tice, Jeffrey/0000-0002-9857-2028				ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BANSAL BR, 1978, CANCER RES, V38, P3293; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BRADEN LM, 1986, LIPIDS, V21, P285, DOI 10.1007/BF02536414; BROWNER WS, 1986, AM J EPIDEMIOL, V123, P143, DOI 10.1093/oxfordjournals.aje.a114208; BULL AW, 1979, CANCER RES, V39, P4956; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHAN PC, 1983, CANCER RES, V43, P1079; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DAO TL, 1983, J NATL CANCER I, V71, P201; ERNST N, 1980, LANCET, V2, P111; FISHER M, 1989, ARCH INTERN MED, V149, P1726, DOI 10.1001/archinte.149.8.1726; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; GRAHAM S, 1983, JNCI-J NATL CANCER I, V70, P687; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HESHMAT MY, 1985, PROSTATE, V6, P7, DOI 10.1002/pros.2990060103; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HILL AB, 1971, PRINCIPLES MED STATI, P220; HOPKINS GJ, 1981, J NATL CANCER I, V66, P517; INGRAM D M, 1981, Nutrition and Cancer, V3, P75; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JAIN M, 1980, INT J CANCER, V26, P757, DOI 10.1002/ijc.2910260609; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; JONES DY, 1987, AM J CLIN NUTR, V45, P1451, DOI 10.1093/ajcn/45.6.1451; KANNEL WB, 1988, CLIN CHEM, V34, pB53; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KEYS A, 1974, AM J CLIN NUTR, V27, P188, DOI 10.1093/ajcn/27.2.188; KEYS A, 1965, METABOLIS, V14, P759, DOI 10.1016/0026-0495(65)90002-8; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; KRITCHEVSKY D, 1984, CANCER RES, V44, P3174; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MARTIN MJ, 1986, LANCET, V2, P933; MILLER AB, 1978, AM J EPIDEMIOL, V107, P499, DOI 10.1093/oxfordjournals.aje.a112569; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PAGE IH, 1961, CIRCULATION, V23, P133, DOI 10.1161/01.CIR.23.1.133; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; Ravenholt R T, 1985, Am J Prev Med, V1, P4; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTSON L, 1983, INJUIRES CAUSES CONT, P9; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SNOWDON DA, 1984, AM J EPIDEMIOL, V120, P244, DOI 10.1093/oxfordjournals.aje.a113886; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; VANTVEER P, 1990, INT J EPIDEMIOL, V19, P12, DOI 10.1093/ije/19.1.12; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILLETT WC, 1984, NEW ENGL J MED, V310, P633, DOI 10.1056/NEJM198403083101006; WILLETT WC, 1984, NEW ENGL J MED, V310, P697, DOI 10.1056/NEJM198403153101106; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; 1988, NCI NIH882789 US DEP; 1966, DIETARY FAT HUMAN HL; 1988, SURGEON GENERALS REP; 1984, NUTRITION CANCER CAU; 1988, US BUREAU CENSUS P25, V1000; 1984, NCI NIH842671 US DEP; 1985, KJAMA, V253, P2080; [No title captured]; 1983, DHHHS PHS831681 US D; 1977, 052070039132 PUBL; 1985, INJURY AM CONTINUING, P23; 1979, DHEW PHS7955071 PUBL; 1984, CIRCULATION, V70, pA153; 1988, VITAL STATISTICS U A, V2	77	79	81	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3285	3291		10.1001/jama.265.24.3285	http://dx.doi.org/10.1001/jama.265.24.3285			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1801770				2022-12-28	WOS:A1991FR83500036
J	SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS				SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS			A CASE CONTROL STUDY OF SCREENING SIGMOIDOSCOPY AND MORTALITY FROM COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CERVICAL-CANCER; FOLLOW-UP; EFFICACY; DEFINITION; POLYPS	Background. The efficacy of sigmoidoscopic screening in reducing mortality from colorectal cancer remains uncertain. A randomized trial would be ideal for clarifying this issue but is very difficult to conduct. Case-control studies provide an alternative method of estimating the efficacy of screening sigmoidoscopy. Methods. Using data on the 261 members of the Kaiser Permanente Medical Care Program who died of cancer of the rectum or distal colon from 1971 to 1988, we examined the use of screening by rigid sigmoidoscopy during the 10 years before the diagnosis and compared it with the use of screening in 868 control subjects matched with the case subjects for age and sex. Results. Only 8.8 percent of the case subjects had undergone screening by sigmoidoscopy, as compared with 24.2 percent of the controls (matched odds ratio, 0.30; 95 percent confidence interval, 0.19 to 0.48). Adjustment for potential confounding factors increased the odds ratio to 0.41 (95 percent confidence interval, 0.25 to 0.69). The negative association was as strong when the most recent sigmoidoscopy was 9 to 10 years before diagnosis as it was when examinations were more recent. By contrast, for 268 subjects with fatal colon cancer above the reach of the sigmoidoscope and for 268 controls, the adjusted odds ratio was 0.96 (95 percent confidence interval, 0.61 to 1.50). The specificity of the negative association for cancer within the reach of the sigmoidoscope is consistent with a true efficacy of screening rather than a confounding by unmeasured selection factors. Conclusions. Screening by sigmoidoscopy can reduce mortality from cancer of the rectum and distal colon. Screening once every 10 years may be nearly as efficacious as more frequent screening.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3451 PIEDMONT AVE, OAKLAND, CA 94611 USA.				NATIONAL CANCER INSTITUTE [R35CA049761, R01CA046569] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46569, R35 CA49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; BOHLMAN TW, 1977, GASTROENTEROLOGY, V72, P644; CLARKE EA, 1979, LANCET, V2, P1; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GILLESPIE PE, 1979, GUT, V20, P240, DOI 10.1136/gut.20.3.240; GLICK SN, 1989, AM J ROENTGENOL, V152, P513, DOI 10.2214/ajr.152.3.513; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; KOZUKA S, 1975, DIS COLON RECTUM, V18, P494, DOI 10.1007/BF02587218; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; MACGREGOR JE, 1985, BMJ-BRIT MED J, V290, P1543, DOI 10.1136/bmj.290.6481.1543; MORRISON AS, 1982, AM J EPIDEMIOL, V115, P6; MORRISON AS, 1985, SCREENING CHRONIC DI, P108; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1989, AM J EPIDEMIOL, V130, P827; RHOADS GG, 1984, AM J EPIDEMIOL, V120, P803, DOI 10.1093/oxfordjournals.aje.a113952; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SCHAPIRO M, 1984, DIGEST DIS SCI, V29, P159, DOI 10.1007/BF01317058; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; VERBEEK ALM, 1984, LANCET, V1, P1222; VERNON SW, 1990, J OCCUP ENVIRON MED, V32, P46, DOI 10.1097/00043764-199001000-00013; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; WILLIAMS CB, 1990, J GASTROEN HEPATOL, V5, P144, DOI 10.1111/j.1440-1746.1990.tb01787.x; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584; 1987, GASTROINTEST ENDOSC, V33, P167; 1979, CAN MED ASS J, V121, P1193	29	1422	1445	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					653	657		10.1056/NEJM199203053261001	http://dx.doi.org/10.1056/NEJM199203053261001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736103				2022-12-28	WOS:A1992HG11700001
J	NEEDLEMAN, SW; SORACE, J; POUSSINROSILLO, H				NEEDLEMAN, SW; SORACE, J; POUSSINROSILLO, H			LOW-DOSE SPLENIC IRRADIATION IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA IN HIV-INFECTED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Note						PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; HUMAN IMMUNODEFICIENCY VIRUS; PREDNISONE; THROMBOCYTOPENIA; RADIOTHERAPY; SPLENECTOMY	RISK	Autoimmune thrombocytopenic purpura (AITP) can complicate the course of human immunodeficiency virus type-1 (HIV)-infected patients. Treatment of these patients with prednisone is problematic because the drug is immunosuppressive. Other modalities are available, but patients often must have splenectomy, which yields effective long-term control comparable to that seen in AITP that is not associated with HIV infection. Splenectomy, however, exposes the patient to substantial perioperative morbidity and mortality. We reasoned that low-dose splenic irradiation may be an effective alternative to splenectomy and obviate the invasive complications of surgery. We present three patients who had splenic irradiation instead of splenectomy and tolerated it well. Howell-Jolly bodies did not appear at any time after the radiation, and durable remission of the AITP was achieved. We conclude that low-dose splenic irradiation may be a safe and effective alternative to splenectomy in HIV-infected patients who suffer from AITP, and that it should be studied further.	UNIV MARYLAND HOSP, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	NEEDLEMAN, SW (corresponding author), BALTIMORE DEPT VET AFFAIRS MED CTR, MED SERV 111, 3900 LOCH RAVEN BLVD, BALTIMORE, MD 21218 USA.							ABOULAFIA DM, 1991, HEMATOL ONCOL CLIN N, V5, P195, DOI 10.1016/S0889-8588(18)30436-2; KARPATKIN S, 1990, HEMATOL ONCOL CLIN N, V4, P193, DOI 10.1016/S0889-8588(18)30513-6; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROBINETTE CD, 1977, LANCET, V2, P127; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SHAFER RW, 1985, LANCET, V1, P934; STRICKER RB, 1985, NEW ENGL J MED, V313, P1375, DOI 10.1056/NEJM198511283132202; WALSH CM, 1984, NEW ENGL J MED, V311, P635, DOI 10.1056/NEJM198409063111004; WOLF BC, 1989, DISORDERS SPLEEN, P39; YU JR, 1986, J CLIN INVEST, V77, P1756, DOI 10.1172/JCI112498	10	11	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					310	311		10.7326/0003-4819-116-4-310	http://dx.doi.org/10.7326/0003-4819-116-4-310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733386				2022-12-28	WOS:A1992HD54600007
J	SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA				SCHOR, JD; LEVKOFF, SE; LIPSITZ, LA; REILLY, CH; CLEARY, PD; ROWE, JW; EVANS, DA			RISK-FACTORS FOR DELIRIUM IN HOSPITALIZED ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CONFUSIONAL STATES; BACTERIAL-MENINGITIS; DEMENTIA; AGE	Objective. - To determine risk factors for delirium in elderly hospitalized patients. Design. - Cohort analytic study. Using a reliable and valid instrument for detection of delirium, we prospectively followed up a cohort of elderly patients admitted to an acute care hospital. Using standardized criteria, we collected risk factor data from patient medical records. Setting. - General medical and surgical wards of a tertiary-care hospital. Patients. - Patients (n = 325) were 65 years of age or older, from either a geographically defined community or a long-term-care institution. We studied those patients (n = 291) not delirious on first evaluation. Fifty-seven patients or their families refused participation. Main Outcome Measures. - Incidence of delirium and risk factors calculated as adjusted odds ratios (ORs). Main Results. - Delirium developed in 91 patients. By stepwise logistic regression, the independent risk factors for in-hospital delirium included prior cognitive impairment (OR, 8.97; 95% confidence interval [Cl], 3.99 to 20.14), age over 80 years (OR, 5.22; 95% Cl, 2.60 to 10.46), fracture on admission (OR, 6.57; 95% Cl, 2.23 to 19.33), symptomatic infection (OR, 2.96; 95% Cl, 1.42 to 6.15), and male sex (OR, 2.40; 95% Cl, 1.19 to 4.84). Among medication groups, only neuroleptic use (OR, 4.48; 95% Cl, 1.82 to 10.45) and narcotic use (OR, 2.54; 955 Cl, 1.24 to 5.18) were independently associated with delirium. Anticholinergic use was not associated with delirium. Conclusions. - Delirium in hospitalized patients is most closely associated with factors already present on admission such as prior cognitive impairment, advanced age, and fracture. In the hospital, use of neuroleptics and narcotics and the presence of infection are less strongly associated with this syndrome.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CTR RES HLTH & AGING, CHICAGO, IL 60612 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	Rush University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai			Cleary, Paul/AAF-7048-2019					ALBERT MS, IN PRESS J GERIATR P; BERGMANN K, 1974, Age and Ageing, V3, P174, DOI 10.1093/ageing/3.3.174; BERNSTEIN S, 1967, NEW ENGL J MED, V277, P638, DOI 10.1056/NEJM196709212771206; BILBERT VE, 1968, METABOLISM, V17, P943; BOHR V, 1983, J INFECTION, V7, P21, DOI 10.1016/S0163-4453(83)90894-0; BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DJOKOVIC JL, 1979, JAMA-J AM MED ASSOC, V242, P2301, DOI 10.1001/jama.242.21.2301; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; ENGEL G L, 1959, J Chronic Dis, V9, P260, DOI 10.1016/0021-9681(59)90165-1; ERKINJUNTTI T, 1986, ARCH INTERN MED, V146, P1923, DOI 10.1001/archinte.146.10.1923; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; JOHNSON JC, 1990, J GERONTOL, V45, pM113, DOI 10.1093/geronj/45.3.M113; KADLECOVA O, 1974, J HYG EPID MICROB IM, V18, P472; LEVKOFF SE, IN PRESS ARCH INTERN; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; LIPOWSKI ZJ, 1990, DELIRIUM ACUTE CONFU, P229; NORMAN DC, 1983, J AM GERIATR SOC, V31, P677, DOI 10.1111/j.1532-5415.1983.tb04154.x; SEYMOUR DG, 1980, AGE AGEING, V9, P137, DOI 10.1093/ageing/9.3.137; SIESJO BK, 1976, CRIT CARE MED, V4, P283, DOI 10.1097/00003246-197611000-00001; SIMON ALEXANDER, 1963, PSYCHIAT RES REPTS, V16, P8; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1988, BRAIN RES REV, V13, P371, DOI 10.1016/0165-0173(88)90013-6; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; VERGHESE A, 1983, MEDICINE, V62, P271, DOI 10.1097/00005792-198309000-00002; VERGHESE A, 1985, AM J MED, V79, P370, DOI 10.1016/0002-9343(85)90316-X; 1987, DIAGNOSTIC STATISTIC, P100	34	344	351	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					827	831		10.1001/jama.267.6.827	http://dx.doi.org/10.1001/jama.267.6.827			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732655				2022-12-28	WOS:A1992HC48400028
J	ESTUS, S; GOLDE, TE; KUNISHITA, T; BLADES, D; LOWERY, D; EISEN, M; USIAK, M; QU, XM; TABIRA, T; GREENBERG, BD; YOUNKIN, SG				ESTUS, S; GOLDE, TE; KUNISHITA, T; BLADES, D; LOWERY, D; EISEN, M; USIAK, M; QU, XM; TABIRA, T; GREENBERG, BD; YOUNKIN, SG			POTENTIALLY AMYLOIDOGENIC, CARBOXYL-TERMINAL DERIVATIVES OF THE AMYLOID PROTEIN-PRECURSOR	SCIENCE			English	Article							ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; IDENTIFICATION; PHOSPHORYLATION; BIOGENESIS; SULFATE; PEPTIDE	The 39- to 43-amino acid amyloid beta-protein (beta-AP), which is deposited as amyloid in Alzheimer's disease, is encoded as an internal peptide that begins 99 residues from the carboxyl terminus of a 695- to 770-amino acid glycoprotein referred to as the amyloid beta-protein precursor (beta-APP). To clarify the processing that produces amyloid, carboxyl-terminal derivatives of the beta-APP were analyzed. This analysis showed that the beta-APP is normally processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives. The two largest derivatives in human brain have the entire beta-AP at or near their amino terminus and are likely to be intermediates in the pathway leading to amyloid deposition.	NATL INST NEUROSCI,KODAIRA,TOKYO 187,JAPAN; UPJOHN CO,KALAMAZOO,MI 49001	National Center for Neurology & Psychiatry - Japan; Pfizer	ESTUS, S (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.			Lowery, David/0000-0001-5111-4719	NIA NIH HHS [AG06656, AG08012, AG08992] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006656, P50AG008012, R35AG008992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HARLOW E, 1988, ANTIBODIES LABORATOR; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	18	410	437	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					726	728		10.1126/science.1738846	http://dx.doi.org/10.1126/science.1738846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738846				2022-12-28	WOS:A1992HC50600041
J	GLIMCHER, PW; SPARKS, DL				GLIMCHER, PW; SPARKS, DL			MOVEMENT SELECTION IN ADVANCE OF ACTION IN THE SUPERIOR COLLICULUS	NATURE			English	Article							EYE-MOVEMENTS; BEHAVING MONKEY; DISCRIMINATION; NEURONS	THE primate superior colliculus contains a map of saccadic eye movements 1,2. Saccades are high-velocity eye movements to selected targets in the visual field, but little is known about the neural mechanisms responsible for target selection or the related problem of choosing a particular movement from the oculomotor repertoire. Two classes of neurons have been described in the superior colliculus which show bursts of activity before the saccade: discrete bursters display a vigorous pre-saccadic burst and prelude bursters 3 show low-frequency activity as a prelude to burst onset. We have designed experiments to test whether prelude activity is related to saccade selection. Our tasks use a cue to specify which of two physically identical visual stimuli is the goal of an impending saccade. This cue is spatially and temporally isolated from the potential targets as well as from visual cues signalling movement initiation. Our results show that prelude activity occurs shortly after information is available for correct saccade selection and, more importantly, the activity is predictive of saccade choice. The results thus suggest that the superior colliculus participates in the process of saccade selection.			GLIMCHER, PW (corresponding author), UNIV PENN,DEPT PSYCHOL,PHILADELPHIA,PA 19104, USA.			Glimcher, Paul/0000-0001-7872-3856				BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; FUNAHASHI S, 1991, J NEUROPHYSIOL, V65, P1464, DOI 10.1152/jn.1991.65.6.1464; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1972, J NEUROPHYSIOL, V35, P560, DOI 10.1152/jn.1972.35.4.560; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MAYS LE, 1980, SCIENCE, V208, P1163, DOI 10.1126/science.6769161; OTTES FP, 1985, VISION RES, V25, P849, DOI 10.1016/0042-6989(85)90193-2; OTTES FP, 1987, EXP BRAIN RES, V66, P465, DOI 10.1007/BF00270679; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; SPARKS DL, 1987, J NEUROPHYSIOL, V58, P300, DOI 10.1152/jn.1987.58.2.300; SPARKS DL, 1976, BRAIN RES, V113, P21, DOI 10.1016/0006-8993(76)90003-2; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	13	229	231	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					542	545		10.1038/355542a0	http://dx.doi.org/10.1038/355542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741032				2022-12-28	WOS:A1992HC52600057
J	DANESHMEND, TK; HAWKEY, CJ; LANGMAN, MJS; LOGAN, RFA; LONG, RG; WALT, RP				DANESHMEND, TK; HAWKEY, CJ; LANGMAN, MJS; LOGAN, RFA; LONG, RG; WALT, RP			OMEPRAZOLE VERSUS PLACEBO FOR ACUTE UPPER GASTROINTESTINAL-BLEEDING RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							PEPTIC-ULCER; HEMORRHAGE; SOMATOSTATIN; COLONIZATION; HEMATEMESIS; MORTALITY	Objective - To investigate the possible therapeutic role of omeprazole, a powerful proton pump inhibitor, in unselected patients presenting with upper gastrointestinal bleeding. Design - Double blind placebo controlled parallel group study. Active treatment was omeprazole 80 mg intravenously immediately, then three doses of 40 mg intravenously at eight hourly intervals, then 40 mg orally at 12 hourly intervals. Treatment was started within 12 hours of admission and given for four days or until surgery, discharge, or death. Setting - The medical wards of University and City Hospitals, Nottingham. Subjects - 1147 consecutive patients aged 18 years or more admitted over 40 months with acute upper gastrointestinal bleeding. Main outcome measures - Mortality from all causes; rate of rebleeding, transfusion requirements, and operation rate; effect of treatment on endoscopic appearances at initial endoscopy. Results - Of 1147 patients included in the intention to treat analysis, 569 received placebo and 578 omeprazole. No significant differences were found between the placebo and omeprazole groups for rates of transfusion (302 (53%) placebo v 298 (52%) omeprazole), rebleeding (100 (18%) v 85 (15%)), operation (63 (11%) v 62 (11%)), and death (30 (5.3%) v 40 (6.9%)). However, there was an unexpected but significant reduction in endoscopic signs of upper gastrointestinal bleeding in patients treated with omeprazole compared with those treated with placebo (236 (45%) placebo v 176 (33%) omeprazole; p < 0.0001). Conclusions - Omeprazole failed to reduce mortality, rebleeding, or transfusion requirements, although the reduction in endoscopic signs of bleeding suggests that inhibition of acid may be capable of influencing intragastric bleeding. Our data do not justify the routine use of acid inhibiting drugs in the management of haematemesis and melaena.	UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT PUBL HLTH,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM NG5 1PD,ENGLAND	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital								ALLAN R, 1976, Q J MED, V45, P533; BARER D, 1983, NEW ENGL J MED, V308, P1571, DOI 10.1056/NEJM198306303082606; BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; CHRISTIANSEN J, 1989, GASTROENTEROLOGY, V97, P568, DOI 10.1016/0016-5085(89)90626-4; CLISSOLD SP, 1988, DRUGS, V34, P1; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P539; FLEISS JL, 1981, STATISTICAL METHODS, P173; FOSTER DN, 1978, BRIT MED J, V1, P1173, DOI 10.1136/bmj.1.6121.1173; GARVEY BM, 1989, CRIT CARE MED, V17, P211, DOI 10.1097/00003246-198903000-00002; GRIFFITHS WJ, 1979, NEW ENGL J MED, V300, P1411, DOI 10.1056/NEJM197906213002503; HENRY DA, 1989, BMJ-BRIT MED J, V298, P1142, DOI 10.1136/bmj.298.6681.1142; HOLMAN RAE, 1990, GUT, V31, P504, DOI 10.1136/gut.31.5.504; HUNT PS, 1979, BRIT MED J, V1, P1239; JAGGER C, 1991, INT J EPIDEMIOL, V20, P234, DOI 10.1093/ije/20.1.234; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P419; MORRIS DL, 1984, BRIT MED J, V288, P1277, DOI 10.1136/bmj.288.6426.1277; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETERSON WL, 1989, GASTROENTEROLOGY, V97, P796, DOI 10.1016/0016-5085(89)90657-4; SANDERSON JD, 1990, GUT, V31, pA1206; SILVERSTEIN FE, 1981, GASTROINTEST ENDOSC, V27, P80, DOI 10.1016/S0016-5107(81)73156-0; SOMERVILLE KW, 1985, LANCET, V1, P130; STOREY DW, 1981, NEW ENGL J MED, V305, P915, DOI 10.1056/NEJM198110153051603; WALT RP, 1985, GUT, V26, P902, DOI 10.1136/gut.26.9.902; WALT RP, 1991, GUT, V32, pA571	26	212	214	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					143	147		10.1136/bmj.304.6820.143	http://dx.doi.org/10.1136/bmj.304.6820.143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737157	Green Published, Bronze			2022-12-28	WOS:A1992HA97900017
J	COX, NH; WAGSTAFF, R; POPPLE, AW				COX, NH; WAGSTAFF, R; POPPLE, AW			USING CLINICOPATHOLOGICAL ANALYSIS OF GENERAL-PRACTITIONER SKIN SURGERY TO DETERMINE EDUCATIONAL REQUIREMENTS AND GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To study the impact of skin surgery in general practice on the workload of a pathology laboratory and to identify what further training might be helpful. Design - Analysis of skin biopsy specimens from general practitioners before and after their new contract to determine numbers of specimens, changes in diagnoses, adequacy of treatment of malignant tumours, and areas of low diagnostic accuracy. Setting - District general hospital. Subjects - All 1017 skin biopsy specimens from general practice for 15 months before and 12 months after the new general practitioner contract. Results - The number of pathology specimens received increased from 16 to 65 per month (median = 6 submitted by each general practitioner in the post-contract year). The proportion of the more common pathological diagnoses was unchanged between the two periods, but the proportion of correctly diagnosed naevi, cysts, and seborrhoeic keratoses increased in the second. Although few diagnoses were overtly incorrect, accurate diagnosis of dermatofibromas and malignancies decreased after the contract, and the overall correct diagnosis rate for seborrhoeic keratoses, dermatofibromas, rashes, and malignancies was below 30%. Only nine out of 21 squamous cell carcinomas were adequately excised with tumour free margins, and follow up of malignant tumours may have been inadequate. Conclusions - Skin surgery in general practice has advantages but matters of concern are the increase in laboratory workload, the excision of some benign lesions, and the inappropriateness of biopsy of rashes. Squamous cell carcinoma and other malignant tumours submitted for pathological examination were often unsuspected and inadequately excised, and heightened suspicion is recommended. Pathology request forms may need redesigning to encourage provision of clinical details.			COX, NH (corresponding author), CUMBERLAND INFIRM,CARLISLE CA2 7HY,ENGLAND.							BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; DANDO P, 1991, J MED DEFENCE UNION, V1, P12; Godfrey E, 1990, Health Trends, V22, P57; HUNT AC, 1991, BMJ, V301, P495; MORGAN DR, 1991, BMJ, V300, P1379; NIXON RL, 1986, MED J AUSTRALIA, V144, P235, DOI 10.5694/j.1326-5377.1986.tb115884.x; Pitcher R., 1991, BR J DERMATOL S38, V125, P93; PRINGLE M, 1991, BRIT MED J, V302, P830, DOI 10.1136/bmj.302.6780.830; RICHARDS T, 1991, BMJ, V301, P307; SHARMAN J, 1986, PRACTITIONER, V230, P27; SHRANK AB, 1990, HLTH TRENDS, V22, P181; SLATER DN, 1991, BMJ, V300, P1074; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; ZOLTIE N, 1991, BRIT MED J, V302, P941, DOI 10.1136/bmj.302.6782.941; 1989, GENERAL PRACTICE NAT	15	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					93	96		10.1136/bmj.304.6819.93	http://dx.doi.org/10.1136/bmj.304.6819.93			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737150	Green Published, Bronze			2022-12-28	WOS:A1992HA17100026
J	BURROWS, M				BURROWS, M			HOW TO HAVE A FEVER OF UNKNOWN ORIGIN	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1605	1606		10.1136/bmj.303.6817.1605	http://dx.doi.org/10.1136/bmj.303.6817.1605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773188	Bronze, Green Published			2022-12-28	WOS:A1991GX95600021
J	BOKOCH, GM; QUILLIAM, LA; BOHL, BP; JESAITIS, AJ; QUINN, MT				BOKOCH, GM; QUILLIAM, LA; BOHL, BP; JESAITIS, AJ; QUINN, MT			INHIBITION OF RAP1A BINDING TO CYTOCHROME-B558 OF NADPH OXIDASE BY PHOSPHORYLATION OF RAP1A	SCIENCE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; RAS-RELATED PROTEIN; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; RAS-P21 GTPASE; COMPONENTS; ACTIVATION; GENE; CELL	Rap1A is a low molecular weight guanosine triphosphate (GTP)-binding protein in human neutrophil membranes whose cellular function is unknown. Rap1A was found to form stoichiometric complexes with the cytochrome b558 component of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system. The (guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S)-bound form of Rap1A bound more tightly to cytochrome b558 than did the guanosine diphosphate-bound form. No complex formation was observed between cytochrome b558 and H-Ras-GTP-gamma-S or Rap1A-GTP-gamma-S that had been heat-inactivated, nor between Rap1A-GTP-gamma-S and hydrophobic proteins serving as controls. Complex formation between Rap1A-GTP-gamma-S and cytochrome b558 was inhibited by phosphorylation of Rap1A with cyclic adenosine monophosphate (cAMP)-dependent protein kinase. These observations suggest that Rap1A may participate in the structure or regulation of the NADPH oxidase system and that this function of the Rap1A protein may be altered by phosphorylation.	MONTANA STATE UNIV, DEPT CHEM, BOZEMAN, MT 59717 USA; MONTANA STATE UNIV, DEPT BIOCHEM, BOZEMAN, MT 59717 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Scripps Research Institute	BOKOCH, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline; PHS HHS [5RO126711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, UNPUB; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; DER CJ, 1989, ONCOGENES, P73; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IGNARRO LJ, 1974, J EXP MED, V139, P1398; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MUELLER H, 1988, MOL PHARMACOL, V34, P347; MUELLER H, 1989, J CELL BIOCHEM, V40, P27; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEVERI P, 1989, BLOOD, V74, P397; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; RIVKIR I, 1975, J IMMUNOL, V115, P112; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TAKAI Y, IN PRESS SIGNAL TRAN, V3; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; YATANI Y, 1991, IN PRESS J BIOL CHEM; ZURIER RB, 1973, J CELL BIOL, V58, P27, DOI 10.1083/jcb.58.1.27	42	109	111	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1794	1796		10.1126/science.1763330	http://dx.doi.org/10.1126/science.1763330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763330				2022-12-28	WOS:A1991GW31600044
J	POWER, RF; MANI, SK; CODINA, J; CONNEELY, OM; OMALLEY, BW				POWER, RF; MANI, SK; CODINA, J; CONNEELY, OM; OMALLEY, BW			DOPAMINERGIC AND LIGAND-INDEPENDENT ACTIVATION OF STEROID-HORMONE RECEPTORS	SCIENCE			English	Article							CHICKEN PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; RAT-BRAIN; COMPLEMENTARY-DNA; ADENYLATE-CYCLASE; RESPONSE ELEMENT; ESTROGEN; GENE; TRANSCRIPTION	The current view of how steroid hormone receptors affect gene transcription is that these receptors, on binding ligand, change to a state in which they can interact with chromatin and regulate transcription of target genes. Receptor activation is believed to be dependent only on this ligand-binding event. Selected steroid hormone receptors can be activated in a ligand-independent manner by a membrane receptor agonist, the neurotransmitter dopamine. In vitro, dopamine faithfully mimicked the effect of progesterone by causing a translocation of chicken progesterone receptor (cPR) from cytoplasm to nucleus. Dual activation by progesterone and dopamine was dissociable, and a serine residue in the cPR was identified that is not necessary for progesterone-dependent activation of cPR, but is essential for dopamine activation of this receptor.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	OMALLEY, BW (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							APERIA A, 1990, AM J HYPERTENS, V3, pS11, DOI 10.1093/ajh/3.6.11S; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEYER C, 1981, PHYSIOL BEHAV, V26, P249, DOI 10.1016/0031-9384(81)90019-6; BLAUSTEIN JD, 1980, NEUROENDOCRINOLOGY, V31, P403, DOI 10.1159/000123110; BOGIC L, 1988, ENDOCRINOLOGY, V122, P2735, DOI 10.1210/endo-122-6-2735; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CONNEELY OM, 1987, BIOCHEM BIOPH RES CO, V149, P493, DOI 10.1016/0006-291X(87)90395-0; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DEKLOFT ER, 1985, EUR J PHARMACOL, V118, P185, DOI 10.1016/0014-2999(85)90679-X; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENNER LA, UNPUB; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELDER CC, 1989, J BIOL CHEM, V264, P8739; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUICHONMANTEL A, 1989, CELL, V57, P1147; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; MOBLEY PL, 1983, J PHARMACOL EXP THER, V226, P71; MOBLEY PL, 1980, NATURE, V286, P608, DOI 10.1038/286608a0; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; O'Malley B W, 1969, Recent Prog Horm Res, V25, P105; OKULICZ WC, 1989, ENDOCRINOLOGY, V125, P930, DOI 10.1210/endo-125-2-930; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARSONS B, 1980, ENDOCRINOLOGY, V107, P774, DOI 10.1210/endo-107-3-774; POWER R, UNPUB; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; REKER CE, 1987, J STEROID BIOCHEM, V26, P653, DOI 10.1016/0022-4731(87)91037-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER M, 1990, TRENDS NEUROSCI, V13, P359, DOI 10.1016/0166-2236(90)90016-4; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHOLL SA, 1986, ENDOCRINOLOGY, V119, P1625, DOI 10.1210/endo-119-4-1625; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEIMER T, 1981, NATURE, V292, P345, DOI 10.1038/292345a0; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULSER F, 1986, J CLIN PSYCHIAT, V10, P13; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TORO MJ, 1987, MOL ENDOCRINOL, V1, P669, DOI 10.1210/mend-1-10-669; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEIGEL N, UNPUB; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	56	528	538	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1636	1639		10.1126/science.1749936	http://dx.doi.org/10.1126/science.1749936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749936				2022-12-28	WOS:A1991GV07300043
J	SMITH, T				SMITH, T			MEDICINE IN EUROPE .3. EUROPEAN HEALTH-CARE SYSTEMS	BRITISH MEDICAL JOURNAL			English	Editorial Material																		SANDIER S, 1989, HLTH CARE FINANCIN S, P33; SCHIEBER GJ, 1991, HLTH AFFAIRS     SPR, P106	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1457	1459		10.1136/bmj.303.6815.1457	http://dx.doi.org/10.1136/bmj.303.6815.1457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GU385	1773156	Bronze, Green Published			2022-12-28	WOS:A1991GU38500032
J	MACDONALD, TM; SHARPE, K; FOWLER, G; LYONS, D; FREESTONE, S; LOVELL, HG; WEBSTER, J; PETRIE, JC				MACDONALD, TM; SHARPE, K; FOWLER, G; LYONS, D; FREESTONE, S; LOVELL, HG; WEBSTER, J; PETRIE, JC			CAFFEINE RESTRICTION - EFFECT ON MILD HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; COFFEE CONSUMPTION; DRINKING	Objective - To determine the effects on blood pressure of modifying dietary caffeine intake in patients with mild and borderline hypertension by monitoring ambulatory and clinic blood pressure. Design - Four way, randomised, crossover trial of four consecutive two week dietary regimens: normal diet, caffeine free diet alone, caffeine free diet with decaffeinated instant coffee, caffeine free diet with caffeinated instant coffee (instant coffee phases conducted double blind). Setting - Hospital hypertension clinic, Scotland. Patients - 52 patients (23 men; aged 26-67 years) with untreated borderline or mild hypertension (diastolic blood pressure 90-105 mm Hg) who normally drank a minimum of three cups of coffee daily. Main outcome measures - Mean ambulatory blood pressure over 24 hours; mean morning, daytime, and night time ambulatory blood pressure; sitting clinic blood pressure at 1700; plasma caffeine concentration at 1700 on the last day of each regimen. Results - Mean 24 hour ambulatory blood pressure was not different between regimens. There was no difference in blood pressure variability between regimens. During the caffeine free diet alone morning ambulatory diastolic blood pressure was higher (2.8 mm Hg) than during the caffeine free diet with caffeinated coffee. Mean sitting clinic systolic blood pressure was higher at 1700 (4.7 mm Hg) with a caffeine free diet than with the caffeine free diet with caffeinated coffee (p < 0.05). Dietary compliance as assessed by plasma caffeine concentration was excellent. There was no significant correlation between plasma caffeine concentration and blood pressure. Conclusions-Drinking caffeinated instant coffee over a two week period does not adversely influence blood pressure in patients with borderline or mild hypertension; abstinence is of no benefit.	ABERDEEN ROYAL INFIRM,DEPT MED & THERAPEUT,CLIN PHARMACOL UNIT,ABERDEEN AB9 2ZD,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT CLIN PHARMACOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of Aberdeen; Royal Infirmary of Edinburgh; University of Edinburgh				MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMMON HPT, 1983, BRIT J CLIN PHARMACO, V15, P701, DOI 10.1111/j.1365-2125.1983.tb01553.x; ARMITAGE P, 1971, STATISTICAL METHODS; BAK AAA, 1990, J HUM HYPERTENS, V4, P259; BEILIN LJ, 1988, CLIN EXP PHARMACOL P, V15, P215, DOI 10.1111/j.1440-1681.1988.tb01064.x; BERTRAND CA, 1978, NEW ENGL J MED, V299, P315; BONATI M, 1982, CLIN PHARMACOL THER, V32, P98, DOI 10.1038/clpt.1982.132; COATS AJS, 1989, CARDIOVASC DRUG THER, V3, P303, DOI 10.1007/BF00148475; CONWAY J, 1989, J HYPERTENS, V7, pS29; DUSSELDORP M, 1989, HYPERTENSION, V14, P563; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; JEONG DU, 1990, AM J HYPERTENS, V3, P749, DOI 10.1093/ajh/3.10.749; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; LANG T, 1983, AM J CARDIOL, V52, P1238, DOI 10.1016/0002-9149(83)90580-5; LELO A, 1986, CLIN PHARMACOL THER, V39, P54, DOI 10.1038/clpt.1986.10; OBRIEN E, 1990, LANCET, V336, P1465, DOI 10.1016/0140-6736(90)93177-Q; OBRIEN E, 1991, J HYPERTENS, V9, P573, DOI 10.1097/00004872-199106000-00016; PERITI M, 1987, CLIN SCI, V72, P443, DOI 10.1042/cs0720443; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124; ROBERTSON D, 1984, AM J MED, V77, P54, DOI 10.1016/0002-9343(84)90435-2; SALVAGGIO A, 1990, J HYPERTENS, V8, P585, DOI 10.1097/00004872-199006000-00013; SMITS P, 1985, BRIT J CLIN PHARMACO, V19, P852, DOI 10.1111/j.1365-2125.1985.tb02729.x; SWALES J D, 1988, European Heart Journal, V9, P45; WHITSETT TL, 1984, AM J CARDIOL, V53, P918, DOI 10.1016/0002-9149(84)90525-3; 1989, J HYPERTENS, V7, P689	26	37	37	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1235	1238		10.1136/bmj.303.6812.1235	http://dx.doi.org/10.1136/bmj.303.6812.1235			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747643	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200022
J	WINTER, R				WINTER, R			EDIT A STAFF ROUND	BRITISH MEDICAL JOURNAL			English	Editorial Material											WINTER, R (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0HS,ENGLAND.							BATES J, 1989, BRIT MED J, V299, P557, DOI 10.1136/bmj.299.6698.557; Cabot R.C., 1911, DIFFERENTIAL DIAGNOS, V1; COX TM, 1990, BRIT MED J, V300, P1512, DOI 10.1136/bmj.300.6738.1512; KINCAIDSMITH PS, 1959, BMJ, V1, P224; LARNER AJ, 1990, BRIT MED J, V300, P317, DOI 10.1136/bmj.300.6720.317; LEVI S, 1989, BRIT MED J, V299, P1093, DOI 10.1136/bmj.299.6707.1093	6	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1258	1259		10.1136/bmj.303.6812.1258	http://dx.doi.org/10.1136/bmj.303.6812.1258			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747654	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200035
J	CALHOUN, K				CALHOUN, K			UNILATERAL VOCAL CORD PARALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CALHOUN, K (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550, USA.							GREEN DC, 1991, ANN OTO RHINOL LARYN, V100, P280, DOI 10.1177/000348949110000404; GREEN DC, 1991, OTOLARYNG HEAD NECK, V104, P453, DOI 10.1177/019459989110400406; KOJIMA H, 1991, ANN OTO RHINOL LARYN, V100, P15, DOI 10.1177/000348949110000103; MAVES MD, 1989, ANN OTO RHINOL LARYN, V98, P577, DOI 10.1177/000348948909800801; MCCAFFREY TB, 1989, LARYNGOSCOPE, V99, P497; MIKAELIAN DO, 1991, LARYNGOSCOPE, V101, P465; SASAKI CT, 1990, LARYNGOSCOPE, V100, P849; TUCKER HM, 1989, ANN OTO RHINOL LARYN, V98, P674, DOI 10.1177/000348948909800903; TUCKER HM, 1990, ANN OTO RHINOL LARYN, V99, P759	9	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1393	1393		10.1001/jama.267.10.1393	http://dx.doi.org/10.1001/jama.267.10.1393			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740865				2022-12-28	WOS:A1992HG67800037
J	KAPOOR, WN; BRANT, N				KAPOOR, WN; BRANT, N			EVALUATION OF SYNCOPE BY UPRIGHT TILT TESTING WITH ISOPROTERENOL - A NONSPECIFIC TEST	ANNALS OF INTERNAL MEDICINE			English	Article							HEAD-UP TILT; UNEXPLAINED SYNCOPE; UNKNOWN ORIGIN; VASOVAGAL SYNCOPE	Objective: To determine the proportion of patients with syncope of unknown etiology who have a positive response to upright tilt testing and to determine the specificity of this test as a marker for vasodepressor syncope. Design: Comparison of upright tilt testing with isoproterenol in patients with syncope of unknown etiology and in controls. Setting: Outpatient clinics of a tertiary care center. Patients: A total of 20 patients with syncope of unknown etiology and 40 controls matched by age, sex, and lack of underlying cardiovascular or other diseases had upright tilt testing with isoproterenol infusion. Controls consisted of two groups (groups I and II) who had slightly different methods of tilt testing in conjunction with isoproterenol. Interventions: Upright tilt testing at 80 degrees from horizontal was done for up to 15 minutes. If end points were not reached, infusion of isoproterenol was started at 1-mu-g/min and increased with graded increments in infusion rates up to 5-mu-g/min. Measurements: The development of syncope or presyncope in association with hypotension, bradycardia, or both. Main Results: Positive response to tilt testing in patients with syncope was 75% (95% Cl, 55% to 95%); it was 65% in control group I (Cl, 44% to 86%) and 45% in control group II (Cl, 20% to 70%). Case patients and controls with positive tilt-test responses were similar with respect to time to completion of the test, mean total isoproterenol dose, mean isoproterenol dose level at completion, average mean blood pressure at completion, mean heart rate at completion, mean decline in systolic blood pressure, and decline in mean blood pressure or heart rate (P > 0.05 for all comparisons). Further, symptoms during tilt testing in case patients with positive responses were similar to those in controls with positive tilt-test results. Conclusions: The rate of positive tilt testing in patients with syncope is equivalent to that in controls without a history of syncope. The low specificity of this test makes its use as a marker for vasodepressor syncope questionable.			KAPOOR, WN (corresponding author), UNIV PITTSBURGH, DEPT MED, ROOM 100, LOTHROP HALL, PITTSBURGH, PA 15261 USA.				NHLBI NIH HHS [R01-HL36735] Funding Source: Medline; PHS HHS [K04L 01899] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036735] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; CHOSY JJ, 1965, J PSYCHOSOM RES, V9, P189, DOI 10.1016/0022-3999(65)90032-2; DAVIS TL, 1990, ARCH INTERN MED, V150, P2027, DOI 10.1001/archinte.150.10.2027; EAGLE KA, 1983, YALE J BIOL MED, V56, P1; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; GULAMHUSEIN S, 1982, AM J MED, V73, P700, DOI 10.1016/0002-9343(82)90413-2; KAPOOR WN, 1989, AM J CARDIOL, V63, P730, DOI 10.1016/0002-9149(89)90260-9; KAPOOR WN, 1991, AM J MED, V90, P91; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KENNY RA, 1986, LANCET, V1, P1352; KLIGFIELD P, 1991, J AM COLL CARDIOL, V17, P131, DOI 10.1016/0735-1097(91)90715-L; PONGIGLIONE G, 1990, J AM COLL CARDIOL, V16, P165, DOI 10.1016/0735-1097(90)90474-4; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; SCHERRER U, 1990, NEW ENGL J MED, V322, P602, DOI 10.1056/NEJM199003013220906; SHVARTZ E, 1968, AEROSPACE MED, V39, P1094; SHVARTZ E, 1970, AEROSPACE MED, V41, P253; STRASBERG B, 1989, AM HEART J, V118, P923, DOI 10.1016/0002-8703(89)90225-1; VINGERHOETS AJJM, 1984, PSYCHOSOM MED, V46, P95; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; WEISSLER AM, 1959, AM HEART J, V57, P786, DOI 10.1016/0002-8703(59)90190-5; 1987, DIAGNOSTIC STATISTIC	25	205	207	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					358	363		10.7326/0003-4819-116-5-358	http://dx.doi.org/10.7326/0003-4819-116-5-358			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736767				2022-12-28	WOS:A1992HF26800002
J	SUNG, P; PRAKASH, L; PRAKASH, S				SUNG, P; PRAKASH, L; PRAKASH, S			RENATURATION OF DNA CATALYZED BY YEAST DNA-REPAIR AND RECOMBINATION PROTEIN RAD10	NATURE			English	Article							EXCHANGE STIMULATORY FACTOR; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UNWINDING PROTEIN; GENE; EXCISION; INCISION; BINDING; PRODUCT; STRAND	THE RAD10 gene of Saccharomyces cerevisiae is required for the incision step of excision repair of ultraviolet-damaged DNA (refs 1, 2), and it functions in mitotic recombination 3. RAD10 has homology to the human excision repair gene ERCC-1 (ref. 4). Here we describe the purification of the protein encoded by RAD10 and show that it is a DNA-binding protein with a strong preference for single-stranded DNA. We also show that RAD10 promotes the renaturation of complementary DNA strands.	UNIV ROCHESTER,DEPT BIOL,RIVER CAMPUS STN,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; HINTON DM, 1986, J BIOL CHEM, V261, P5663; Kowalczykowski S.C., 1981, ENZYMES, V14, P373; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCPHERSON A, 1979, J MOL BIOL, V134, P379, DOI 10.1016/0022-2836(79)90359-0; MORANELLI F, 1980, P NATL ACAD SCI-BIOL, V77, P3201, DOI 10.1073/pnas.77.6.3201; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P5450, DOI 10.1073/pnas.78.9.5450; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; VANDUIN M, 1986, CELL, V44, P912; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	25	40	42	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					743	745		10.1038/355743a0	http://dx.doi.org/10.1038/355743a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741062				2022-12-28	WOS:A1992HE60400070
J	GOLDE, TE; ESTUS, S; YOUNKIN, LH; SELKOE, DJ; YOUNKIN, SG				GOLDE, TE; ESTUS, S; YOUNKIN, LH; SELKOE, DJ; YOUNKIN, SG			PROCESSING OF THE AMYLOID PROTEIN-PRECURSOR TO POTENTIALLY AMYLOIDOGENIC DERIVATIVES	SCIENCE			English	Article							ALZHEIMERS-DISEASE	The approximately 120-kilodalton amyloid beta-protein precursor (beta-APP) is processed into a complex set of 8- to 12-kilodalton carboxyl-terminal derivatives that includes potentially amyloidogenic forms with the approximate 4-kilodalton amyloid beta-protein (beta-AP) at or near their amino terminus. In order to determine if these derivatives are processed in a secretory pathway or by the endosomal-lysosomal system, (i) deletion mutants that produce the normal set of carboxyl-terminal derivatives and shortened secreted derivatives were analyzed and (ii) the effect of inhibitors of endosomal-lysosomal processing was examined. In the secretory pathway, cleavage of the beta-APP occurs at a single site within the beta-AP to generate one secreted derivative and one nonamyloidogenic carboxyl-terminal fragment, whereas, in the endosomal-lysosomal system, a complex set of carboxyl-terminal derivatives is produced that includes the potentially amyloidogenic forms.	HARVARD UNIV,SCH MED,DEPT NEUROL NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GOLDE, TE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106, USA.							BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; COLE GM, 1990, MOL BIOL GENETICS AL, P113; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; ESTUS S, 1992, SCIENCE, V248, P492; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; KAWAI M, IN PRESS AM J PATHOL; LUCOTTE G, 1991, NATURE, V351, P530, DOI 10.1038/351530b0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865	17	704	727	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					728	730		10.1126/science.1738847	http://dx.doi.org/10.1126/science.1738847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738847				2022-12-28	WOS:A1992HC50600042
J	HORVITZ, HR; HERSKOWITZ, I				HORVITZ, HR; HERSKOWITZ, I			MECHANISMS OF ASYMMETRIC CELL-DIVISION - 2 BS OR NOT 2 BS, THAT IS THE QUESTION	CELL			English	Review							NEMATODE CAENORHABDITIS-ELEGANS; YEAST HO GENE; C-ELEGANS; BACILLUS-SUBTILIS; CAULOBACTER-CRESCENTUS; CYCLE REGULATION; FISSION YEAST; HETEROCYST DIFFERENTIATION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE		UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	HORVITZ, HR (corresponding author), MIT, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ALLEY MRK, 1991, GENETICS, V129, P333; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREWER BJ, 1984, MOL CELL BIOL, V4, P2529, DOI 10.1128/MCB.4.11.2529; BUIKEMA WJ, 1991, GENE DEV, V5, P321, DOI 10.1101/gad.5.2.321; BUIKEMA WJ, 1991, J BACTERIOL, V173, P1879, DOI 10.1128/jb.173.6.1879-1885.1991; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; Conklin E.G., 1905, J ACAD NAT SCI PHILA, V12, P1, DOI DOI 10.5962/BHL.TITLE.4801; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; Davidson E. H., 1986, GENE ACTIVITY EARLY; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EGEL R, 1984, CURR GENET, V8, P205, DOI 10.1007/BF00417817; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EVINGER M, 1979, P NATL ACAD SCI USA, V76, P175, DOI 10.1073/pnas.76.1.175; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GOBER JW, 1991, BIOESSAYS, V13, P277, DOI 10.1002/bies.950130604; GOLDEN JW, 1985, NATURE, V314, P419, DOI 10.1038/314419a0; GOLDEN JW, 1988, J BACTERIOL, V170, P5034, DOI 10.1128/jb.170.11.5034-5041.1988; GOMES SL, 1984, J MOL BIOL, V178, P551, DOI 10.1016/0022-2836(84)90238-9; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GURDON JB, 1987, DEVELOPMENT, V99, P285; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HERMAN M, 1991, THESIS MIT CAMBRIDGE; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HILL DP, 1990, DEVELOPMENT, V108, P159; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; HORVITZ HR, 1990, HARVEY LECT, V84, P65; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; Kimble J., 1979, Cell lineage, stem cells and cell determination. (Proc. Internat. Workshop on cell lineage, stem cells and cell determination, Seillac, France, 20-24 May 1979. - Inserm Symposium No.10), P59; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KIRK DL, 1991, DEVELOPMENT, P67; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, 1991, THESIS U CALIFORNIA; KUNKEL B, 1990, GENE DEV, V4, P525, DOI 10.1101/gad.4.4.525; KUNKEL B, 1989, GENE DEV, V3, P1735, DOI 10.1101/gad.3.11.1735; KUNKEL B, 1991, TRENDS GENET, V7, P167, DOI 10.1016/0168-9525(91)90106-Z; KUWADA JY, 1985, DEV BIOL, V110, P114, DOI 10.1016/0012-1606(85)90069-7; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LOSICK R, 1992, IN PRESS NATURE; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MILHAUSEN M, 1983, NATURE, V302, P630, DOI 10.1038/302630a0; MINNICH SA, 1987, P NATL ACAD SCI USA, V84, P1142, DOI 10.1073/pnas.84.5.1142; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NEWTON A, 1990, ANNU REV MICROBIOL, V44, P689; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OHTA N, 1985, J MOL BIOL, V186, P107, DOI 10.1016/0022-2836(85)90261-X; Pall M.L, 1975, DEV BIOL PATTERN FOR, P148; PAWSON T, 1991, TRENDS GENET, V7, P343, DOI 10.1016/0168-9525(91)90252-L; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; SOMMER JM, 1989, J BACTERIOL, V171, P392, DOI 10.1128/jb.171.1.392-401.1989; SOMMER JM, 1991, GENETICS, V129, P623; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1989, INT REV CYTOL, V114, P81; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; SWOBODA UK, 1982, J GEN MICROBIOL, V128, P279; TKACZ JS, 1972, J GEN MICROBIOL, V72, P243, DOI 10.1099/00221287-72-2-243; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Whitman C. O., 1878, Q J MICROSC SCI, V18, P215; WILCOX M, 1973, J CELL SCI, V12, P707; WILCOX M, 1975, MICROBIOLOGY 1975, P453; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D; [No title captured]	114	449	465	0	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					237	255		10.1016/0092-8674(92)90468-R	http://dx.doi.org/10.1016/0092-8674(92)90468-R			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733500				2022-12-28	WOS:A1992HB35300006
J	LASIC, DD				LASIC, DD			MIXED MICELLES IN DRUG DELIVERY	NATURE			English	Article							AMPHOTERICIN-B				LASIC, DD (corresponding author), LIPOSOME TECHNOL INC,1050 HAMILTON COURT,MENLO PK,CA 94025, USA.							BRODIN A, 1982, ACTA PHARM SUEC, V19, P267; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; FIELDING RM, 1991, ANTIMICROB AGENTS CH, V35, P1208, DOI 10.1128/AAC.35.6.1208; FIELDING RM, IN PRESS ANTIMICROB; GUENTERT TW, 1987, BRIT J CLIN PHARMACO, V23, P569, DOI 10.1111/j.1365-2125.1987.tb03093.x; GUO LSS, 1991, INT J PHARM, V75, P45, DOI 10.1016/0378-5173(91)90249-N; JANOFF AS, 1988, P NATL ACAD SCI USA, V85, P6122, DOI 10.1073/pnas.85.16.6122; LASIC DD, 1982, BIOCHIM BIOPHYS ACTA, V692, P501, DOI 10.1016/0005-2736(82)90404-7; LASIC DD, 1988, BIOCHEM J, V256, P1; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1991, PERIOD BIOL, V93, P287; LOPEZBERESTEIN G, 1985, J INFECT DIS, V151, P704, DOI 10.1093/infdis/151.4.704; PAPAHADJOPOULOS P, 1991, P NATL ACAD SCI USA, V88, P11460; Prescott L.F., 1989, NOVEL DRUG DELIVERY; YOKOYAMA M, 1990, CANCER RES, V50, P1693	15	151	165	2	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					279	280		10.1038/355279a0	http://dx.doi.org/10.1038/355279a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731228				2022-12-28	WOS:A1992GZ69400077
J	IBRAHIM, SA; MUSTAFA, D; MOHAMED, AO; MOHED, MB				IBRAHIM, SA; MUSTAFA, D; MOHAMED, AO; MOHED, MB			HOMOZYGOUS HEMOGLOBIN-O DISEASE AND CONJUGATED HYPERBILIRUBINEMIA IN A SUDANESE FAMILY	BRITISH MEDICAL JOURNAL			English	Article									FAC MED KHARTOUM,DEPT MED,KHARTOUM,SUDAN		IBRAHIM, SA (corresponding author), FAC MED KHARTOUM,DEPT BIOCHEM,POB 102,KHARTOUM,SUDAN.			Bajilan, Suzan Ibrahim Ali/0000-0003-1632-6104				COQUELET ML, 1978, NOUV REV FR HEMATOL, V20, P465; KOSKELO P, 1967, CLIN CHEM, V13, P1006; LEHMANN H, 1963, NATURE, V198, P492, DOI 10.1038/198492b0; RANOT B, 1960, BMJ, V2, P1262; VELLA F, 1966, NATURE, V209, P309	5	8	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					26	27		10.1136/bmj.304.6818.26	http://dx.doi.org/10.1136/bmj.304.6818.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734988	Green Published, Bronze			2022-12-28	WOS:A1992GY90900029
J	BULL, AD; CROSS, SS; JAMES, DS; SILCOCKS, PB				BULL, AD; CROSS, SS; JAMES, DS; SILCOCKS, PB			DO PATHOLOGISTS HAVE EXTRASENSORY PERCEPTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,CTR MEDICO LEGAL,DEPT FORENS PATHOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; SHEFFIELD UNIV,SCH MED,DEPT PUBL HLTH MED,SHEFFIELD S10 2UL,ENGLAND	University of Sheffield; University of Sheffield	BULL, AD (corresponding author), SHEFFIELD UNIV,SCH MED,DEPT HISTOPATHOL,SHEFFIELD S10 2UL,ENGLAND.		Schnoeller, Thomas/H-4465-2014	Schnoeller, Thomas/0000-0003-3617-1111; Cross, Simon/0000-0003-2044-1754				DIACONIS P, 1983, SCI AM, V248, P6; FLEISS JL, 1981, STAT METHODS RATES P, P230; LIGHT RJ, 1971, PSYCHOL BULL, V76, P365, DOI 10.1037/h0031643; LYONS AS, 1987, MED ILLUSTRATED HIST, P583; UNDERWOOD JCE, 1987, INTRO BIOPSY INTERPR, P2	5	8	8	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1604	1605		10.1136/bmj.303.6817.1604	http://dx.doi.org/10.1136/bmj.303.6817.1604			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773187	Green Published, Bronze			2022-12-28	WOS:A1991GX95600020
J	BEREK, C; BERGER, A; APEL, M				BEREK, C; BERGER, A; APEL, M			MATURATION OF THE IMMUNE-RESPONSE IN GERMINAL-CENTERS	CELL			English	Article							MEMORY B-CELLS; ANTIGEN-DRIVEN SELECTION; BALB-C MICE; SOMATIC MUTATION; PRIMARY IMMUNIZATION; LYMPHOID-TISSUE; V-GENES; ANTIBODY; 2-PHENYLOXAZOLONE; REPERTOIRE	Germinal centers develop in peripheral lymphatic tissue during the primary immune response and may play a crucial role in affinity maturation. We have compared the diversification of the antigen-specific repertoire of B cells, both from within and from outside the germinal centers, during the murine response to 2-phenyl-oxazolone (phOx). By sequencing V(kappa)Ox1 L-chains characteristic of phOx-specific antibodies, we show that somatic mutations accumulate in germinal center B cells and that a mutation conferring high affinity binding is found with increasing frequency. An analysis of V/D/J rearrangements suggests that this mutation occurred independently in many B cells, which were then preferentially expanded. We conclude that, although the hypermutation mechanism may be activated before germinal centers develop, affinity maturation by hypermutation and selection takes place in the germinal centers.			BEREK, C (corresponding author), INST GENET,WEYERTAL 121,O-5000 COLOGNE 41,GERMANY.							ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; APEL M, 1990, INT IMMUNOL, V2, P813, DOI 10.1093/intimm/2.9.813; APEL M, 1991, LYMPHATIC TISSUES AND IN VIVO IMMUNE RESPONSES, P355; BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; Coffman R L, 1982, Immunol Rev, V69, P5; COICO RF, 1983, J IMMUNOL, V131, P2254; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; DELL CL, 1989, J IMMUNOL, V143, P3364; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; EVEN J, 1985, EMBO J, V4, P3439, DOI 10.1002/j.1460-2075.1985.tb04102.x; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; KAARTINEN M, 1988, EUR J IMMUNOL, V18, P1095, DOI 10.1002/eji.1830180719; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Kroese F G, 1990, Curr Top Pathol, V84 ( Pt 1), P103; KROESE FGM, 1991, RES IMMUNOL, V142, P249, DOI 10.1016/0923-2494(91)90069-U; KUNKL A, 1981, IMMUNOLOGY, V43, P371; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MALPIERO UV, 1987, IMMUNOL REV, V96, P59; MANSER T, 1986, EUR J IMMUNOL, V16, P1439, DOI 10.1002/eji.1830161120; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MOORE W, 1986, HDB EXPT IMMUNOLOGY, V1; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Shlomchik MJ, 1989, PROG IMMUNOL, VVII, P415; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; TAO W, 1990, J IMMUNOL, V145, P3216; TEW JG, 1980, IMMUNOL REV, V53, P175; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681; WYSOCKI L, 1986, P NATL ACAD SCI USA, V83, P1847, DOI 10.1073/pnas.83.6.1847; ZAITOUN AM, 1980, J ANAT, V130, P131; ZHANG J, 1988, IMMUNOL LETT, V18, P297, DOI 10.1016/0165-2478(88)90178-2	43	757	767	1	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1121	1129		10.1016/0092-8674(91)90289-B	http://dx.doi.org/10.1016/0092-8674(91)90289-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760840				2022-12-28	WOS:A1991GX16400011
J	VANVACTOR, DL; CAGAN, RL; KRAMER, H; ZIPURSKY, SL				VANVACTOR, DL; CAGAN, RL; KRAMER, H; ZIPURSKY, SL			INDUCTION IN THE DEVELOPING COMPOUND EYE OF DROSOPHILA - MULTIPLE MECHANISMS RESTRICT R7 INDUCTION TO A SINGLE RETINAL PRECURSOR CELL	CELL			English	Article							RECEPTOR TYROSINE KINASE; PATTERN-FORMATION; ECTOPIC EXPRESSION; SEVENLESS PROTEIN; PUTATIVE RECEPTOR; GENE; ENCODES; MELANOGASTER; DOMAIN; ROUGH	The development of the Drosophila R7 photoreceptor cell is determined by a specific inductive interaction between the R8 photoreceptor cell and a single neighboring precursor cell. This process is mediated by bride of sevenless (boss), a cell-surface bound ligand, and the sevenless (sev) tyrosine kinase receptor. The boss ligand is expressed specifically on the surface of the R8 cell, whereas the sev receptor is expressed on 5 cells contacting the developing R8 cell and other cells not in contact with R8. By altering the spatial and temporal expression of boss, we demonstrate that sev-expressing cells that do not contact R8 can assume an R7 cell fate. By contrast, the sev-expressing precursor cells to the R1-R6 photoreceptor cells that do contact R8 are nonresponsive to the inductive cue. Using the rough and N(spl) mutations, we demonstrate that an early commitment to an R1-R6 cell fate blocks the pathway of sev activation in these cells.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, HOWARD HUGHES MED INST, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Cagan, Ross/0000-0001-5297-450X; Van Vactor, Jr., David L./0000-0001-8156-9482; Zipursky, Stephen/0000-0001-5630-7181				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAGAN RL, 1992, DETERMINANTS NEURONA; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LIPOSITS Z, 1984, NEUROSCIENCE, V13, P513, DOI 10.1016/0306-4522(84)90245-8; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Spemann H., 1938, EMBRYONIC DEV INDUCT; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0	42	145	145	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1145	1155		10.1016/0092-8674(91)90291-6	http://dx.doi.org/10.1016/0092-8674(91)90291-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760842				2022-12-28	WOS:A1991GX16400013
J	BREARLEY, S				BREARLEY, S			MEDICINE IN EUROPE - MEDICAL MANPOWER	BRITISH MEDICAL JOURNAL			English	Article									PERMANENT WORKING GRP EUROPEAN JR HOSP DOCTORS,BIRMINGHAM,ENGLAND		BREARLEY, S (corresponding author), 52 CHANTRY RD,BIRMINGHAM B13 8DJ,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1534	1536		10.1136/bmj.303.6816.1534	http://dx.doi.org/10.1136/bmj.303.6816.1534			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782501	Green Published, Bronze			2022-12-28	WOS:A1991GV47600033
J	SMITH, LFP; JEWELL, D				SMITH, LFP; JEWELL, D			ROLES OF MIDWIVES AND GENERAL-PRACTITIONERS IN HOSPITAL INTRAPARTUM CARE, ENGLAND AND WALES, 1988	BRITISH MEDICAL JOURNAL			English	Article											SMITH, LFP (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,GEN PRACTICE UNIT,BRISTOL BS8 2PR,ENGLAND.							CAMPBELL R, 1987, BE BORN DEBATE EVIDE; COUPLAND VA, 1987, BRIT MED J, V295, P1077, DOI 10.1136/bmj.295.6605.1077; ROBINSON S, 1988, MIDWIFE HLTH VISITOR, V21, P274; SMITH LFP, 1991, BRIT MED J, V302, P13, DOI 10.1136/bmj.302.6767.13	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1443	1444		10.1136/bmj.303.6815.1443	http://dx.doi.org/10.1136/bmj.303.6815.1443			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773150	Bronze, Green Published			2022-12-28	WOS:A1991GU38500025
J	TOWNSEND, J; WILKES, H; HAINES, A; JARVIS, M				TOWNSEND, J; WILKES, H; HAINES, A; JARVIS, M			ADOLESCENT SMOKERS SEEN IN GENERAL-PRACTICE - HEALTH, LIFE-STYLE, PHYSICAL MEASUREMENTS, AND RESPONSE TO ANTISMOKING ADVICE	BRITISH MEDICAL JOURNAL			English	Article							PRACTICE RESEARCH FRAMEWORK; SALIVA COTININE; TOBACCO-SMOKE; LUNG-CANCER; PRACTITIONERS; EXPOSURE; PROGRAM; WOMEN	Objective - To compare physical, lifestyle, and health characteristics of adolescent smokers and non-smokers and their initial response to anti-smoking counselling. Design - Adolescents aged 13, 15, and 17 years were identified from age-sex registers and invited by letter for a general practice health check. Setting - Three general practices in the MRC general practice research framework. Main outcome measures - Blood pressure, body mass index, saliva cotinine concentration, peak flow rate, alcohol consumption, exercise, duration of sleep, and stated persistent health problems. Results - 73% of the adolescents (491) attended for the health check. A total of 68 (14%) were regular smokers. Those who had never smoked regularly had a significantly lower systolic blood pressure than regular smokers by age 17 (by 6 mm Hg; p = 0.025) despite a significantly higher body mass index (by 1.5; p < 0.001). Cotinine concentrations increased with smoking exposure, from 0.7 ng/ml when no family member smoked to 155 ng/ml in active smokers of six or more cigarettes a week. Significantly more regular smokers than never regular smokers drank greater-than-or-equal-to 8 g alcohol a day (chi-2 = 15.2 adjusted for age and sex p < 0.001); regular smokers exercised less (1.0 hrs/week in boys and 0.8 hrs/week in girls-upsilon 3.4 hrs/week in boys and 2-2 hrs/week in girls; p < 0.001) and slept less (8.0 hrs/night-upsilon 8.5 hrs/night at age 17; p < 0.005). Persistent health problems, mostly asthma or allergic symptoms, were reported by 25% (17/68) of the smokers and 16% (60/381) of the non-smokers. Of the smokers given counselling, 60% (26/43) made an agreement with the practice doctor or nurse to give up smoking. Conclusion - General practice is an appropriate setting for adolescents to receive advice on healthy lifestyle, which should not focus solely on smoking.	WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND; INST PSYCHIAT,IMPERIAL CANC RES FUND,HLTH BEHAV UNIT,LONDON SE5 8AF,ENGLAND	University of London; University College London; Cancer Research UK; University of London; King's College London	TOWNSEND, J (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Jarvis, Martin J/B-1034-2008	Jarvis, Martin J/0000-0001-9238-8038; Haines, Andy/0000-0002-8053-4605				BALDING J, 1989, YOUNG PEOPLE 1988; Catford J C, 1984, Community Med, V6, P264; CLEARY PD, 1986, ADOLESCENT SMOKING R; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; CUTLER SF, 1988, ALCOHOL ALCOHOLISM, V23, P441; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; DONOVAN C, 1988, HLTH TRENDS, V2, P64; DONOVAN CF, 1988, HLTH TRENDS, V2, P20; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; JARVIS MJ, 1985, BRIT MED J, V291, P927, DOI 10.1136/bmj.291.6500.927; KERSHAW CR, 1987, J ROY SOC MED, V80, P683, DOI 10.1177/014107688708001108; LADER D, 1991, SMOKING SECONDARY SC; MACFARLANE A, 1987, ARCH DIS CHILD, V62, P1125, DOI 10.1136/adc.62.11.1125; MCNEILL AD, 1987, BRIT J ADDICT, V82, P1355; MURRAY M, 1984, J EPIDEMIOL COMMUN H, V38, P247, DOI 10.1136/jech.38.3.247; RICHMOND R, 1985, INT J EPIDEMIOL, V14, P396, DOI 10.1093/ije/14.3.396; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; STGEORGE IM, 1991, BRIT MED J, V302, P89, DOI 10.1136/bmj.302.6768.89; TOWNSEND J, 1987, HEALTH ECON, P139; TOWNSEND JL, 1978, J R STAT SOC A STAT, V141, P95, DOI 10.2307/2344780; WALLACE PG, 1987, BRIT MED J, V294, P940, DOI 10.1136/bmj.294.6577.940; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; 1988, PACKING IT IN; 1987, SMOKERS GUIDE GIVING; 1990, CIGARETTE SMOKING 19	27	70	71	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1991	303	6808					947	950		10.1136/bmj.303.6808.947	http://dx.doi.org/10.1136/bmj.303.6808.947			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL127	1755876	Bronze, Green Published			2022-12-28	WOS:A1991GL12700018
J	WELCH, HG; MEEHAN, KR; GOODNOUGH, LT				WELCH, HG; MEEHAN, KR; GOODNOUGH, LT			PRUDENT STRATEGIES FOR ELECTIVE RED-BLOOD-CELL TRANSFUSION	ANNALS OF INTERNAL MEDICINE			English	Review							RECOMBINANT-HUMAN-ERYTHROPOIETIN; OPEN-HEART SURGERY; ACUTE NORMOVOLEMIC ANEMIA; STAGE RENAL-DISEASE; AUTOLOGOUS BLOOD; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; OXYGEN-TRANSPORT; CLINICAL-TRIAL; FIBRIN GLUE	Objective: To review the literature on the appropriateness of red blood cell transfusion and current physician practice, with emphasis on the physiologic and symptomatic implications of elective transfusion in the treatment of anemia. Data Sources: Studies on the therapeutic use of red blood cell transfusion were identified through a search of MEDLINE (1966 to the present) and through a manual review of bibliographies of identified articles. In addition, evidence was solicited from selected experts in the field and recent consensus panels that have developed transfusion guidelines. Data Synthesis: No controlled trials of blood transfusion were identified, but data were available on four issues relevant to transfusion practice: current physician practice and evidence for excessive use of red blood cell transfusion; physiologic adaptation to anemia; human tolerance of low hemoglobin levels; and strategies for reducing homologous transfusion requirements. Conclusions: Despite the recent decline in red blood cell use because of concerns about infection, current transfusion practice remains variable because physicians have disparate views about its appropriateness. The remarkable human tolerance of anemia suggests that clinicians can accept hemoglobin levels above 70 g/L (7 g/dL) in most patients with self-limited anemia. In patients with impaired cardiovascular status or with anemias that will not resolve spontaneously, however, the data are insufficient to determine minimum acceptable hemoglobin levels, and therapy must be guided by the clinical situation. Several therapeutic strategies and pharmacologic interventions are available in the peri-operative and non-operative settings to further reduce red blood cell use.	DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA; UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA	Dartmouth College; University Hospitals of Cleveland; Case Western Reserve University	WELCH, HG (corresponding author), VET AFFAIRS HOSP, MED SERV, N HARTLAND RD, WHITE RIVER JCT, VT 05001 USA.							ALEXIU O, 1975, ANAESTHESIA, V30, P609, DOI 10.1111/j.1365-2044.1975.tb00920.x; ALLEN JB, 1982, INT ANESTHESIOL CLIN, V20, P1, DOI 10.1097/00004311-198220040-00003; ALLEN JG, 1972, NEW ENGL J MED, V287, P984, DOI 10.1056/NEJM197211092871914; Allen JR, 1987, TRANSFUSION TRANSMIT, P37; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BAKER JW, 1987, ANN THORAC SURG, V43, P564, DOI 10.1016/S0003-4975(10)60214-7; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BAYER WL, 1980, ANN THORAC SURG, V29, P117, DOI 10.1016/S0003-4975(10)61648-7; BERNE RM, 1986, CARDIOVASCULAR PHYSL, P204; BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V257, P1777; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P551; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; BLUM L, 1955, Bull N Y Acad Med, V31, P671; BRANNON ES, 1945, J CLIN INVEST, V24, P332, DOI 10.1172/JCI101610; BRAZIER J, 1974, SURGERY, V75, P508; CARSON JL, 1988, LANCET, V1, P727; CHAPLER CK, 1986, CAN J PHYSIOL PHARM, V64, P7, DOI 10.1139/y86-002; CHAPLIN H, 1969, NEW ENGL J MED, V281, P364, DOI 10.1056/NEJM196908142810707; CICERO JL, 1991, AM SURGEON, V57, P165; COFFIN C, 1989, TRANSFUSION, V29, P298, DOI 10.1046/j.1537-2995.1989.29489242793.x; CORDELL AR, 1981, ANN THORAC SURG, V31, P421, DOI 10.1016/S0003-4975(10)60992-7; Deniston O L, 1990, ASAIO Trans, V36, pM157; DIETHRICH EB, 1965, TRANSFUSION, V5, P82, DOI 10.1111/j.1537-2995.1965.tb01138.x; DUKE M, 1969, CIRCULATION, V39, P503, DOI 10.1161/01.CIR.39.4.503; EEROLA R, 1979, ANN CHIR GYNAECOL, V68, P109; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCOBAR E, 1966, AM J PHYSIOL, V211, P877, DOI 10.1152/ajplegacy.1966.211.4.877; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; FINCH CA, 1972, NEW ENGL J MED, V286, P407, DOI 10.1056/NEJM197202242860806; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FOWLER NO, 1975, J APPL PHYSIOL, V39, P453, DOI 10.1152/jappl.1975.39.3.453; FRIEDMAN BA, 1978, TRANSFUSION, V18, P193, DOI 10.1046/j.1537-2995.1978.18278160583.x; FRIEDMAN BA, 1980, TRANSFUSION, V20, P179, DOI 10.1046/j.1537-2995.1980.20280169958.x; FULLERTON WT, 1962, LANCET, V1, P75; GEHA AS, 1976, SURGERY, V80, P47; GIBBLE JW, 1990, TRANSFUSION, V30, P741, DOI 10.1046/j.1537-2995.1990.30891020337.x; GOLLUB S, 1966, JAMA-J AM MED ASSOC, V198, P149; GOODNOUGH L T, 1990, Transfusion Medicine Reviews, V4, P288, DOI 10.1016/S0887-7963(90)70271-4; GOODNOUGH LT, 1990, AM J SURG, V159, P602, DOI 10.1016/S0002-9610(06)80079-6; GOODNOUGH LT, 1991, ANN THORAC SURG, V51, P703, DOI 10.1016/0003-4975(91)90108-3; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GOODNOUGH LT, 1990, J LAB CLIN MED, V115, P28; GOODNOUGH LT, 1990, VOX SANG, V59, P65, DOI 10.1111/j.1423-0410.1990.tb05010.x; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; GRINDON AJ, 1985, JAMA-J AM MED ASSOC, V253, P540, DOI 10.1001/jama.253.4.540; HACKMANN T, 1989, NEW ENGL J MED, V321, P1437, DOI 10.1056/NEJM198911233212104; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; HEDDERICH GS, 1990, CAN J SURG, V33, P33; HILLMAN RS, 1985, RED CELL MANUAL, P22; JAMIESON WRE, 1982, CAN J SURG, V25, P538; JESSEN C, 1985, ANN THORAC SURG, V39, P521, DOI 10.1016/S0003-4975(10)61991-1; KAFER ER, 1986, ANESTH ANALG       S, V65, pS76; KAHN RC, 1986, INTENS CARE MED, V12, P22, DOI 10.1007/BF00315364; KANDEL G, 1983, ARCH INTERN MED, V143, P1400, DOI 10.1001/archinte.143.7.1400; KAWAGUCHI A, 1984, CIRCULATION, V70, P30; KEELING MM, 1983, ANN SURG, V197, P536, DOI 10.1097/00000658-198305000-00006; KEITT AS, 1985, CECIL TXB MED, P870; KENNEDY AC, 1954, J CLIN INVEST, V33, P1372, DOI 10.1172/JCI103014; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; KLEINMAN KS, 1989, AM J KIDNEY DIS, V14, P486, DOI 10.1016/S0272-6386(89)80149-0; KOBRINSKY NL, 1987, ANN INTERN MED, V107, P446, DOI 10.7326/0003-4819-107-4-446; KOWALYSHYN TJ, 1972, ANESTH ANAL CURR RES, V51, P75; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LENFANT C, 1990, TRANSFUSION, V30, P97, DOI 10.1046/j.1537-2995.1990.30290162913.x; LEVINE E, 1990, TRANSFUSION, V30, P11, DOI 10.1046/j.1537-2995.1990.30190117621.x; LEVINE EA, 1991, ANN THORAC SURG, V51, P764, DOI 10.1016/0003-4975(91)90121-6; LILLEAASEN P, 1978, ANN THORAC SURG, V25, P127, DOI 10.1016/S0003-4975(10)63505-9; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; MESSMER K, 1973, RES EXP MED, V159, P152, DOI 10.1007/BF01851543; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; MOZES B, 1989, TRANSFUSION, V29, P473, DOI 10.1046/j.1537-2995.1989.29689318442.x; MURRAY JF, 1969, AM J PHYSIOL, V216, P638, DOI 10.1152/ajplegacy.1969.216.3.638; MYHRE BA, 1980, JAMA-J AM MED ASSOC, V244, P1333; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963; PALERMO G, 1980, TRANSFUSION, V20, P704, DOI 10.1046/j.1537-2995.1980.20681057160.x; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; POPOVSKY MA, 1985, MAYO CLIN PROC, V60, P125, DOI 10.1016/S0025-6196(12)60299-7; RAINE AEG, 1988, LANCET, V1, P97; REECE RL, 1966, JAMA-J AM MED ASSOC, V195, P113; RODMAN T, 1960, ANN INTERN MED, V52, P295, DOI 10.7326/0003-4819-52-2-295; ROY SB, 1963, CIRCULATION, V28, P346, DOI 10.1161/01.CIR.28.3.346; Royston D, 1990, Blood Coagul Fibrinolysis, V1, P55, DOI 10.1097/00001721-199003000-00009; SALEMSCHATZ SR, 1990, JAMA-J AM MED ASSOC, V264, P476, DOI 10.1001/jama.264.4.476; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SEHGAL LR, 1984, SURGERY, V95, P433; SHAH DM, 1982, J TRAUMA, V22, P741, DOI 10.1097/00005373-198209000-00004; SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993; SMOLLER BR, 1986, NEW ENGL J MED, V314, P1233, DOI 10.1056/NEJM198605083141906; SOHMER PR, 1979, CRC CR REV CL LAB SC, V11, P107, DOI 10.3109/10408367909105855; STARK J, 1984, ANN THORAC SURG, V38, P411, DOI 10.1016/S0003-4975(10)62298-9; STEHLING L, 1990, TRANSFUSION, V30, P1, DOI 10.1046/j.1537-2995.1990.30190117620.x; STEHLING LC, 1987, VOX SANG, V52, P60, DOI 10.1111/j.1423-0410.1987.tb02990.x; STUDZINSKI T, 1980, Acta Physiologica Polonica, V31, P365; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1989, TRANSFUSION, V29, P761, DOI 10.1046/j.1537-2995.1989.29990070178.x; SURGENOR DM, 1988, TRANSFUSION, V28, P513, DOI 10.1046/j.1537-2995.1988.28689059022.x; SURGENOR DM, 1991, TRANSFUSION, V31, P531, DOI 10.1046/j.1537-2995.1991.31691306252.x; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TYSON GS, 1989, ANN SURG, V209, P736, DOI 10.1097/00000658-198906000-00011; VARAT MA, 1972, AM HEART J, V83, P415, DOI 10.1016/0002-8703(72)90445-0; VERSKA JJ, 1974, ANN THORAC SURG, V18, P72, DOI 10.1016/S0003-4975(10)65720-7; WASMAN J, 1987, JAMA-J AM MED ASSOC, V258, P3135, DOI 10.1001/jama.258.21.3135; WHITAKER W, 1956, Q J MED, V25, P175; WILHELM JA, 1986, J INFECT DIS, V154, P169, DOI 10.1093/infdis/154.1.169; WILKERSON DK, 1988, SURGERY, V103, P665; WINSLOW RM, 1989, TRANSFUSION, V29, P753, DOI 10.1046/j.1537-2995.1989.29990070175.x; WOODMAN RC, 1990, BLOOD, V76, P1680; WOODSON RD, 1982, J APPL PHYSIOL, V53, P1299, DOI 10.1152/jappl.1982.53.5.1299; WRIGHT CJ, 1976, SURGERY, V79, P299; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; ZUCK TF, 1990, ARCH PATHOL LAB MED, V114, P309; 1989, TRANSFUSION, V29, P711; 1988, ACCREDITATION MANUAL, P120; 1983, NATIONAL I HLTH GUID; 1986, JAMA-J AM MED ASSOC, V256, P2378	120	283	292	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					393	402		10.7326/0003-4819-116-5-393	http://dx.doi.org/10.7326/0003-4819-116-5-393			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736773				2022-12-28	WOS:A1992HF26800009
J	HILL, A; WARD, S; DEINO, A; CURTIS, G; DRAKE, R				HILL, A; WARD, S; DEINO, A; CURTIS, G; DRAKE, R			EARLIEST HOMO	NATURE			English	Article							FOSSIL HOMINIDS; KENYA; CALIBRATION; PLIOCENE; TURKANA; BARINGO; REGION; EAST	THE origin of our own genus, Homo, has been tentatively correlated with worldwide climatic cooling documented at about 2.4 Myr (million years) (refs 1-5). It has also been conjectured that members of Homo made the first stone tools, currently dated at 2.6 - 2.4 Myr (refs 6-8). But fossil specimens clearly attributable to Homo before about 1.9 Myr have been lacking. In 1967 a fossil hominoid temporal bone (KNM-BC1) from the Chemeron Formation of Kenya was described as family Hominidae gen. et sp. indet. 9. Although a surface find, its provenance within site JM85 (BPRP site K002) was established and a stratigraphic section provided indicating the specimen's position 9. This evidence has been affirmed (see for example refs 10-12) but the exact age of the fossil was never determined, and the absence of suitable comparative hominid material has precluded a more definitive taxonomic assignment. Here we present 40Ar/39Ar age determinations on material from the hominid site indicating an age of 2.4 Myr. In addition, comparative studies allow us to assign KNM-BC1 to the genus Homo, making it the earliest securely known fossil of our own genus found so far.	NORTHEASTERN OHIO UNIV, COLL MED, DEPT HUMAN ANAT, ROOTSTOWN, OH 44272 USA; INST HUMAN ORIGINS, CTR GEOCHRONOL, BERKELEY, CA 94709 USA	Northeast Ohio Medical University (NEOMED)	HILL, A (corresponding author), YALE UNIV, DEPT ANTHROPOL, NEW HAVEN, CT 06520 USA.		Klein, Richard G/B-5910-2009					Dean C. M., 1988, EVOLUTIONARY HIST RO, P107; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; GENTRY AW, 1978, GEOLOGICAL BACKGROUN, P293; HARRIS J, 1980, CAMBRIDGE ENCY ARCHA, P62; Harris J.W.K., 1983, AFR ARCHAEOL REV, V1, P3, DOI DOI 10.1007/BF01116770; HILL A, 1988, YEARB PHYS ANTHROPOL, V31, P49; HILL A, 1985, NATURE, V315, P222, DOI 10.1038/315222a0; HILL A, 1987, J HUM EVOL, V16, P583, DOI 10.1016/0047-2484(87)90014-5; HOWELL FC, 1987, J HUM EVOL, V16, P665; ISAAC G, 1978, SCI AM, V238, P90, DOI 10.1038/scientificamerican0478-90; Kimbel W.H., 1988, P175; KIMBEL WH, 1985, AM J PHYS ANTHROPOL, V66, P31, DOI 10.1002/ajpa.1330660104; Kimbel WH, 1986, THESIS KENT STATE U; LEAKEY LSB, EXCAVATION REPORT; Leakey M.G., 1978, KOOBI FORA RES PROJE, P191; Leakey R.E.F., 1973, Symposia Zool Soc Lond, VNo. 33, P53; LEAKEY REF, 1988, AM J PHYS ANTHROPOL, V76, P1, DOI 10.1002/ajpa.1330760102; MARTYN J, 1967, NATURE, V215, P476, DOI 10.1038/215476a0; Martyn J.E., 1969, THESIS U LONDON; McCall G.J.H., 1967, LATE TERTIARY QUATER, P191; MERRICK HV, 1973, NATURE, V242, P572, DOI 10.1038/242572a0; MERRICK HV, 1976, HUMAN ORIGINS L LEAK, P461; OAKLEY K, 1977, CATALOGUE FOSSIL HOM, P223; PICKFORD M, 1983, AM J PHYS ANTHROPOL, V60, P337, DOI 10.1002/ajpa.1330600306; PICQ P, 1985, THESIS U PARIS; Prentice M.L., 1988, P383; ROCHE H, 1980, 8TH P PAN C PREH QUA, P194; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHERWOOD RJ, 1989, AM J PHYS ANTHROPOL, V78, P301; Susman R.L., 1988, P149; SUSMAN RL, 1988, SCIENCE, V240, P781, DOI 10.1126/science.3129783; Thunell RC, 1983, UTRECHT MICROPALEONT, V30, P111; Vrba E.S., 1988, P405; VRBA ES, 1985, S AFR J SCI, V81, P229; Walker A.C., 1988, P247; WARD S, 1987, AM J PHYS ANTHROPOL, V72, P21, DOI 10.1002/ajpa.1330720104; YORK D, 1969, EARTH PLANET SC LETT, V5, P320	38	119	122	0	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					719	722		10.1038/355719a0	http://dx.doi.org/10.1038/355719a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741057				2022-12-28	WOS:A1992HE60400061
J	HENKIN, Y; COMO, JA; OBERMAN, A				HENKIN, Y; COMO, JA; OBERMAN, A			SECONDARY DYSLIPIDEMIA - INADVERTENT EFFECTS OF DRUGS IN CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIGH-DENSITY-LIPOPROTEIN; TRIPHASIC ORAL-CONTRACEPTIVES; ESTROGEN REPLACEMENT THERAPY; RENAL-TRANSPLANT RECIPIENTS; DEPENDENT DIABETES-MELLITUS; HEPATIC LIPASE ACTIVITY; PLASMA-LIPID CHANGES; SERUM-LIPIDS; LONG-TERM; CYPROTERONE-ACETATE	Objective. - To examine the available literature on commonly prescribed drugs and their effects on blood lipid and lipoprotein levels. Data Sources. - The review was based on searches of English-language articles from 1975 to 1990 by Medlars II and MEDLINE programs, the Index Medicus for 1980 to 1990, and references from identified articles. Relevant journals published within the last 6 months were also examined. Study Selection. - More than 500 articles were identified for inclusion. Articles were selected on the basis of appropriateness of design to demonstrate significant results, determined by consensus when necessary. Data Extraction. - Studies were classified according to type (observational or interventional), length of follow-up, and type of controls. Quantitative analysis of lipid, lipoprotein, and apoprotein changes induced by drugs was computed as the percentage of change observed during the course of the study (interventional) or compared with the controls at a given time (observational). Data Synthesis. - Steroid hormones that have strong progestogenic and androgenic properties, retinoids, cyclosporine A, and phenothiazines are potentially atherogenic. Steroid hormones with dominant estrogenic properties, several anticonvulsants, biguanides, high-dose ketoconazole, and aminosalicylic acid are potentially antiatherogenic. Corticosteroids appear to elevate all the lipoprotein cholesterol levels. Oral estrogens, retinoids, and corticosteroids also can elevate triglyceride levels. Other drugs with questionable effects on lipoprotein metabolism are reviewed. Conclusion. - Although the long-term implications of drug-induced lipoprotein changes are still undefined, physicians need to consider these effects in clinical practice.	UNIV ALABAMA, DIV GEN & PREVENT MED,UAB STN,MED EDUC BLDG, ROOM 621, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PHARM, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								ALBERT SG, 1987, J AM COLL CARDIOL, V9, P175, DOI 10.1016/S0735-1097(87)80098-0; AMES R, 1988, DRUGS, V36, P33, DOI 10.2165/00003495-198800362-00007; AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; BAGDADE JD, 1990, J CLIN ENDOCR METAB, V70, P1132, DOI 10.1210/jcem-70-4-1132; BALDOENZI G, 1990, METABOLISM, V39, P203, DOI 10.1016/0026-0495(90)90076-O; BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53; BARON H, 1977, LANCET, V1, P761; BECKER DM, 1988, AM J MED, V85, P632; BERSHAD S, 1985, NEW ENGL J MED, V313, P981, DOI 10.1056/NEJM198510173131604; BISHOP N, 1988, DIABETIC MED, V32, P133; BORDEN EC, 1987, J INTERFERON RES, V7, P591, DOI 10.1089/jir.1987.7.591; BRADLEY DD, 1978, NEW ENGL J MED, V299, P17, DOI 10.1056/NEJM197807062990104; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; BROWN WV, 1991, DRUG TREATMENT HYPER, P189; BRUN LD, 1986, CANCER, V57, P2123, DOI 10.1002/1097-0142(19860601)57:11<2123::AID-CNCR2820571106>3.0.CO;2-2; BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; BUCKMAN MT, 1980, METABOLISM, V29, P803, DOI 10.1016/0026-0495(80)90117-1; BURKMAN RT, 1988, OBSTET GYNECOL, V71, P33; BURRY KA, 1989, AM J OBSTET GYNECOL, V160, P1454, DOI 10.1016/0002-9378(89)90870-3; CAIRNS SA, 1977, DIABETES METAB, V3, P183; CATTRAN DC, 1979, ANN INTERN MED, V91, P554, DOI 10.7326/0003-4819-91-4-554; CERNA O, 1978, LANCET, V1, P1055; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; CHEZ RA, 1989, AM J OBSTET GYNECOL, V160, P1296, DOI 10.1016/S0002-9378(89)80016-X; CLAIN JE, 1977, GASTROENTEROLOGY, V73, P556; CLARK ML, 1960, J CLIN ENDOCR METAB, V20, P641, DOI 10.1210/jcem-20-4-641; CLARK ML, 1967, PSYCHOSOM MED, V29, P634, DOI 10.1097/00006842-196711000-00008; CLARKSON TB, 1989, AM J OBSTET GYNECOL, V160, P1280, DOI 10.1016/S0002-9378(89)80013-4; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CONNOR SL, 1974, ANN INTERN MED, V81, P619; CRIST D M, 1985, Annals of Sports Medicine, V2, P125; CURTIS JJ, 1982, KIDNEY INT, V22, P42, DOI 10.1038/ki.1982.130; DICKEN CH, 1980, ARCH DERMATOL, V116, P951; DUJOVNE CA, 1991, AM J MED, V91, pS25, DOI 10.1016/0002-9343(91)90053-Z; ELLIS CN, 1986, JAMA-J AM MED ASSOC, V256, P3110, DOI 10.1001/jama.256.22.3110; ELSHABOURY AH, 1973, BMJ-BRIT MED J, V2, P85, DOI 10.1136/bmj.2.5858.85; ETTINGER WH, 1988, METABOLISM, V37, P1055, DOI 10.1016/0026-0495(88)90067-4; FANHRAEUS L, 1988, OBSTET GYNECOL S5, V72, pS18; FANHRAEUS L, 1986, FERTIL STERIL, V45, P503; FANHRAEUS L, 1982, ACTA ENDOCRINOL-COP, V101, P597; FANHRAEUS L, 1983, EUR J CLIN INVEST, V13, P447; FARISH E, 1983, CLIN CHIM ACTA, V132, P193; GINTER E, 1975, ANN NY ACAD SCI, V258, P410, DOI 10.1111/j.1749-6632.1975.tb29299.x; GLUECK CJ, 1972, METABOLISM, V21, P657, DOI 10.1016/0026-0495(72)90089-3; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; GRAINGER SL, 1988, PHARMACOLOGY, V36, P420, DOI 10.1159/000138331; HAFFNER SM, 1983, METABOLISM, V32, P413, DOI 10.1016/0026-0495(83)90052-5; HAMAZAKI T, 1985, ATHEROSCLEROSIS, V55, P107, DOI 10.1016/0021-9150(85)90170-4; HART DM, 1984, MATURITAS, V5, P271, DOI 10.1016/0378-5122(84)90021-5; HARVENGT C, 1988, CONTRACEPTION, V37, P565, DOI 10.1016/0010-7824(88)90003-0; HAVEL RJ, 1990, CIRCULATION, V81, P694, DOI 10.1161/01.CIR.81.2.694; HELDENBERG D, 1983, CLIN RHEUMATOL, V2, P387, DOI 10.1007/BF02041560; HELDENBERG D, 1983, NEUROLOGY, V33, P510, DOI 10.1212/WNL.33.4.510; HENZL MR, 1988, NEW ENGL J MED, V318, P485, DOI 10.1056/NEJM198802253180805; HIRVONEN E, 1981, NEW ENGL J MED, V304, P560, DOI 10.1056/NEJM198103053041002; HIRVONEN E, 1987, MATURITAS, V9, P69, DOI 10.1016/0378-5122(87)90054-5; HOOGWERF BJ, 1984, CLIN PHARMACOL THER, V36, P217, DOI 10.1038/clpt.1984.165; HOOPER PL, 1981, NEW ENGL J MED, V305, P1455, DOI 10.1056/NEJM198112103052406; HOPPE G, 1990, AM J OBSTET GYNECOL, V163, P388, DOI 10.1016/0002-9378(90)90588-X; HOWARD BV, 1985, AM J MED, V79, P78, DOI 10.1016/S0002-9343(85)80012-7; HOWARD BV, 1987, J LIPID RES, V28, P613; HUUPPONEN R, 1987, MED TOXICOL ADV DRUG, V2, P190, DOI 10.1007/BF03259864; ILLINGWORTH DR, 1987, DRUGS, V33, P259, DOI 10.2165/00003495-198733030-00003; JACQUES PF, 1987, ANN NY ACAD SCI, V498, P100, DOI 10.1111/j.1749-6632.1987.tb23754.x; JEFFERYS DB, 1980, POSTGRAD MED J, V56, P491, DOI 10.1136/pgmj.56.657.491; JELICIVANOVIC Z, 1985, CLIN CHEM, V31, P1141; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; JOHNSON BF, 1989, MED CLIN N AM, V73, P449, DOI 10.1016/S0025-7125(16)30682-4; KASIM SE, 1987, J CLIN ENDOCR METAB, V65, P183, DOI 10.1210/jcem-65-1-183; KASTE M, 1983, STROKE, V14, P525, DOI 10.1161/01.STR.14.4.525; KAUKOLA S, 1981, J CARDIOVASC PHARM, V3, P207, DOI 10.1097/00005344-198101000-00019; KLOOSTERBOER HJ, 1990, AM J OBSTET GYNECOL, V163, P370, DOI 10.1016/0002-9378(90)90584-T; KNOPP RH, 1981, J CLIN ENDOCR METAB, V53, P1123, DOI 10.1210/jcem-53-6-1123; KNOPP RH, 1988, AM J OBSTET GYNECOL, V158, P1630, DOI 10.1016/0002-9378(88)90201-3; KRAEMER FB, 1986, AM J MED, V6, P179; KRONE W, 1988, AM HEART J, V116, P1729, DOI 10.1016/0002-8703(88)90222-0; KUUSI T, 1985, ATHEROSCLEROSIS, V54, P251, DOI 10.1016/0021-9150(85)90119-4; LALOR BC, 1990, DIABETIC MED, V7, P242, DOI 10.1111/j.1464-5491.1990.tb01378.x; LARSSONCOHN U, 1986, ACTA OBSTET GYN SCAN, V65, P125, DOI 10.3109/00016348609158366; LINDBERG UB, 1987, HORM METAB RES, V19, P222, DOI 10.1055/s-2007-1011783; LIPSON A, 1986, CONTRACEPTION, V34, P121, DOI 10.1016/0010-7824(86)90065-X; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; LORBER M, 1985, BRIT J RHEUMATOL, V24, P250; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LUOMA PV, 1988, PHARMACOL TOXICOL, V62, P243, DOI 10.1111/j.1600-0773.1988.tb01882.x; MALLOY MJ, 1978, PEDIATRICS, V61, P365, DOI 10.1542/peds.61.3.365; MANOLIO TA, 1989, CRICULATION S, V80, P329; MANTELL G, 1990, AM J CARDIOL, V66, pB11, DOI 10.1016/0002-9149(90)90435-4; MARKELL MS, 1989, TRANSPLANT P, V21, P1497; MARKELL MS, 1989, AM J MED, V87; MARSDEN JR, 1989, PHARMACOL THERAPEUT, V40, P55, DOI 10.1016/0163-7258(89)90074-0; MARZ W, 1985, AM J OBSTET GYNECOL, V153, P287, DOI 10.1016/S0002-9378(85)80114-9; MCKENNEY JM, 1986, PHARMACOTHERAPY, V6, P179; MCKILLOP G, 1987, INT J CARDIOL, V17, P281, DOI 10.1016/0167-5273(87)90077-5; MELANDER A, 1987, EUR J PHARMACOL, V33, P279; MELNIK BC, 1987, J INVEST DERMATOL, V88, pS39, DOI 10.1111/1523-1747.ep12468920; MEYSKENS FL, 1990, NEW ENGL J MED, V323, P825, DOI 10.1056/NEJM199009203231210; MICCOLI R, 1989, CONTRACEPTION, V39, P643, DOI 10.1016/0010-7824(89)90039-5; MICHAELSSON G, 1981, BRIT J DERMATOL, V105, P201, DOI 10.1111/j.1365-2133.1981.tb01206.x; MIETTINEN TA, 1979, J CLIN INVEST, V64, P1485, DOI 10.1172/JCI109607; MUURONEN A, 1985, BRIT MED J, V291, P1481, DOI 10.1136/bmj.291.6507.1481; NIKKILA EA, 1978, BRIT MED J, V2, P99, DOI 10.1136/bmj.2.6130.99; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V160, P1269, DOI 10.1016/S0002-9378(89)80012-2; ONEILL B, 1982, ACTA NEUROL SCAND, V65, P104; OSEI K, 1984, AM J MED, V77, P1002, DOI 10.1016/0002-9343(84)90179-7; OTTOSSON UB, 1985, AM J OBSTET GYNECOL, V151, P746, DOI 10.1016/0002-9378(85)90509-5; OTTOSSON UB, 1986, GYNECOL OBSTET INVES, V22, P198, DOI 10.1159/000298914; PAISEY R, 1978, DIABETOLOGIA, V15, P81, DOI 10.1007/BF00422249; PATSCH W, 1989, AM J OBSTET GYNECOL, V161, P1396, DOI 10.1016/0002-9378(89)90703-5; PATTISON NS, 1989, AUST NZ J OBSTET GYN, V29, P62, DOI 10.1111/j.1479-828X.1989.tb02879.x; POLITI A, 1984, BRIT MED J, V288, P285, DOI 10.1136/bmj.288.6413.285; POWELL MG, 1984, OBSTET GYNECOL, V63, P764; RAINE AEG, 1987, TRANSPLANT P, V19, P1820; REDDY MN, 1985, P SOC EXP BIOL MED, V180, P359; REINHARDT D J 3rd, 1962, Del Med J, V34, P318; ROCCELLA EJ, 1991, ANN INTERN MED, V114, P224, DOI 10.7326/0003-4819-114-3-224; ROLLMAN O, 1985, EUR J CLIN PHARMACOL, V29, P241, DOI 10.1007/BF00547430; ROSS RK, 1989, AM J OBSTET GYNECOL, V160, P1301, DOI 10.1016/S0002-9378(89)80017-1; Sabesin SM, 1987, PHARMACOTHERAPY, V7, P116, DOI 10.1002/j.1875-9114.1987.tb03535.x; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SARTOR G, 1987, EUR J CLIN PHARMACOL, V33, P279, DOI 10.1007/BF00637562; SASAKI J, 1984, ATHEROSCLEROSIS, V51, P163, DOI 10.1016/0021-9150(84)90164-3; SASAKI J, 1985, CLIN PHARMACOL THER, V37, P684, DOI 10.1038/clpt.1985.113; SCHAEFER EJ, 1983, J CLIN ENDOCR METAB, V57, P262, DOI 10.1210/jcem-57-2-262; SCHNEIDER J, 1990, ATHEROSCLEROSIS, V82, P97, DOI 10.1016/0021-9150(90)90148-C; SCHONI M, 1984, PEDIATR RES, V18, P66; SCHWARTZ SL, 1987, AM J MED, V83, P22, DOI 10.1016/0002-9343(87)90800-X; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SMALL M, 1982, THROMB RES, V28, P27, DOI 10.1016/0049-3848(82)90030-5; SOMMARIVA D, 1981, INT J CLIN PHARM TH, V19, P112; SPAGNOLI LG, 1990, ATHEROSCLEROSIS, V82, P27, DOI 10.1016/0021-9150(90)90140-E; SPERBER AD, 1991, AM J MED, V91, P597, DOI 10.1016/0002-9343(91)90212-G; SPERBER AD, 1988, CURR THER RES CLIN E, V44, P426; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; STOUT RW, 1974, METABOLISM, V23, P815, DOI 10.1016/0026-0495(74)90115-2; TAN MH, 1977, DIABETES, V26, P561, DOI 10.2337/diabetes.26.6.561; TASKINEN MR, 1983, J CLIN ENDOCR METAB, V57, P619, DOI 10.1210/jcem-57-3-619; TELIMAA S, 1989, FERTIL STERIL, V52, P31; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; TIKKANEN MJ, 1987, MATURITAS, V9, P81, DOI 10.1016/0378-5122(87)90055-7; TIKKANEN MJ, 1981, ATHEROSCLEROSIS, V40, P365, DOI 10.1016/0021-9150(81)90147-7; TOBERT JA, 1988, NEW ENGL J MED, V318, P48; VAHLQUIST C, 1988, ACTA DERM-VENEREOL, V68, P300; VAHLQUIST C, 1985, BRIT J DERMATOL, V112, P69, DOI 10.1111/j.1365-2133.1985.tb02293.x; VANDERVANGE N, 1987, BRIT J OBSTET GYNAEC, V94, P559; VATHSALA A, 1989, TRANSPLANTATION, V48, P37, DOI 10.1097/00007890-198907000-00009; VERMEULEN A, 1988, CONTRACEPTION, V38, P419, DOI 10.1016/0010-7824(88)90083-2; VEXIAU P, 1988, HORM METAB RES, V20, P765, DOI 10.1055/s-2007-1010943; WAHL P, 1983, NEW ENGL J MED, V308, P862, DOI 10.1056/NEJM198304143081502; WAHLBERG G, 1982, ATHEROSCLEROSIS, V43, P283, DOI 10.1016/0021-9150(82)90029-6; WALLACE RB, 1979, LANCET, V2, P111; WALLACE RB, 1986, CIRCULATION, V73, P70; WEBB OL, 1984, METABOLISM, V33, P971, DOI 10.1016/0026-0495(84)90222-1; WEIDMANN P, 1988, DRUGS, V35, P118, DOI 10.2165/00003495-198800356-00017; WHITEHEAD MI, 1990, LANCET, V335, P310, DOI 10.1016/0140-6736(90)90605-5; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; WYNN V, 1982, AM J OBSTET GYNECOL, V142, P766; WYNN V, 1986, CLIN ENDOCRINOL, V24, P183, DOI 10.1111/j.1365-2265.1986.tb00761.x; ZIMMERMAN J, 1984, METABOLISM, V33, P521, DOI 10.1016/0026-0495(84)90006-4; 1988, CONTRACEPTION, V38, P605	161	65	67	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					961	968		10.1001/jama.267.7.961	http://dx.doi.org/10.1001/jama.267.7.961			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734110				2022-12-28	WOS:A1992HD15500031
J	WELLS, VD; WONG, ES; MURRAY, BE; COUDRON, PE; WILLIAMS, DS; MARKOWITZ, SM				WELLS, VD; WONG, ES; MURRAY, BE; COUDRON, PE; WILLIAMS, DS; MARKOWITZ, SM			INFECTIONS DUE TO BETA-LACTAMASE-PRODUCING, HIGH-LEVEL GENTAMICIN-RESISTANT ENTEROCOCCUS-FAECALIS	ANNALS OF INTERNAL MEDICINE			English	Article						ENTEROCOCCUS-FAECALIS; BETA-LACTAMASES; DRUG RESISTANCE, MICROBIAL; GENTAMICINS; CROSS INFECTION; DISEASE OUTBREAKS; COMMUNICABLE DISEASE CONTROL	STREPTOCOCCUS-FAECALIS; ENDOCARDITIS; STRAINS	Objective: To investigate the risk factors, clinical features, molecular epidemiology, and treatment outcomes associated with an outbreak of infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Design: Case-control and molecular genetics study. Setting: Tertiary care Veterans Affairs hospital. Patients: Sixty-five patients infected or colonized with beta-lactamase-producing high-level gentamicin-resistant E. faecalis (case patients) were matched and compared with 65 randomly selected patients infected or colonized with beta-lactamase-negative, gentamicin-susceptible E. faecalis. Measurements and Main Results: During the 20-month study period, 124 of 1506 isolates (8.2%) of E. faecalis from 70 patients were found to produce beta-lactamase. Univariate analysis showed older age, higher APACHE II score, nosocomial acquisition, recent surgical procedure, total parenteral nutrition, and antibiotic treatment to be significantly associated with the acquisition of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis. A multivariate analysis, done using stepwise multiple logistic regressions, showed that only two variables remained significant: an APACHE II score > 6 (odds ratio, 9.5; 95% Cl, 4.4 to 20.3) and antibiotic treatment (odds ratio, 10.2; Cl, 4.5 to 23.2). The mortality rate for case patients was 7.7% (5 of 65 patients; Cl, 1.2% to 14.2%); no control patient died. Of 23 infections occurring in case patients, 13 were treated with "inappropriate" antibiotics (regimens that included a beta-lactamase-unstable antibiotic); 2 patients improved and 11 had complete resolution of disease. "Appropriate" treatments (regimens that included a beta-lactamase-stable antibiotic) were used in 10 patients; 5 of 10 infections were fatal. Restriction enzyme digests of total chromosomal DNA showed nearly identical patterns for selected isolates of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis, suggesting dissemination through the hospital of a single strain of E. faecalis. Conclusions: Fatal infections were observed despite treatment with beta-lactamase-stable antibiotics. The risk for infection or colonization with beta-lactamase-producing, high-level gentamicin-resistant E. faecalis was strongly associated with severe underlying disease (acute physiology and chronic health evaluation [APACHE] II score, > 6) and previous antibiotic treatment. These results may be useful in targeting high-risk patients for infection-control interventions.	DEPT VET AFFAIRS MED CTR, INFECT DIS SECT 111C, 1201 BROAD ROCK BLVD, RICHMOND, VA 23249 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV INFECT DIS, RICHMOND, VA 23298 USA; UNIV TEXAS, HLTH SCI CTR, PROGRAM INFECT DIS & CLIN MICROBIOL, HOUSTON, TX 77225 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; University of Texas System; University of Texas Health Science Center Houston								BUSH LM, 1988, ANTIMICROB AGENTS CH, V32, P877, DOI 10.1128/AAC.32.6.877; DOUGHERTY SH, 1983, ARCH SURG-CHICAGO, V118, P232; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HOFFMANN SA, 1987, ANN INTERN MED, V106, P757, DOI 10.7326/0003-4819-106-5-757; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; INGERMAN M, 1987, J INFECT DIS, V155, P1226, DOI 10.1093/infdis/155.6.1226; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARKOWITZ SM, 1991, ANTIMICROB AGENTS CH, V35, P1075, DOI 10.1128/AAC.35.6.1075; MURRAY BE, 1986, ANTIMICROB AGENTS CH, V30, P861, DOI 10.1128/AAC.30.6.861; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; PATTERSON JE, 1988, ANTIMICROB AGENTS CH, V32, P122, DOI 10.1128/AAC.32.1.122; PATTERSON JE, 1990, ANTIMICROB AGENTS CH, V34, P302, DOI 10.1128/AAC.34.2.302; PATTERSON JE, 1989, ANTIMICROB AGENTS CH, V33, P251, DOI 10.1128/AAC.33.2.251; PATTERSON JE, 1988, J INFECT DIS, V158, P1144, DOI 10.1093/infdis/158.5.1144; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1983, MMWR S455, V32, P155; 1985, PROC IML VERSION 5	20	83	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					285	292		10.7326/0003-4819-116-4-285	http://dx.doi.org/10.7326/0003-4819-116-4-285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733382				2022-12-28	WOS:A1992HD54600003
J	CUNNINGHAM, CW; BLACKSTONE, NW; BUSS, LW				CUNNINGHAM, CW; BLACKSTONE, NW; BUSS, LW			EVOLUTION OF KING CRABS FROM HERMIT-CRAB ANCESTORS	NATURE			English	Article							DNA; PHYLOGENY; SIZE	KING crabs (Family Lithodidae) are among the world's largest arthropods, having a crab-like morphology and a strongly calcified exoskeleton 1-6. The hermit crabs, by contrast, have depended on gastropod shells for protection for over 150 million years 5,7. Shell living has constrained the morphological evolution of hermit crabs by requiring a decalcified asymmetrical abdomen capable of coiling into gastropod shells and by preventing crabs from growing past the size of the largest available shells 1-6. Whereas reduction in shell-living and acquisition of a crab-like morphology (carcinization) has taken place independently in several hermit crab lineages, and most dramatically in king crabs 1-6, the rate at which this process has occurred was entirely unknown 2,7. We present molecular evidence that king crabs are not only descended from hermit crabs, but are nested within the hermit crab genus Pagurus. We estimate that loss of the shell-living habit and the complete carcinization of king crabs has taken between 13 and 25 million years.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511; YALE UNIV,DEPT GEOL & GEOPHYS,NEW HAVEN,CT 06511	Yale University; Yale University			Cunningham, Clifford/B-9807-2014	Cunningham, Clifford/0000-0002-5434-5122				ALBERCH P, 1979, PALEOBIOLOGY, V5, P296, DOI 10.1017/S0094837300006588; BLACKSTONE NW, 1986, BIOL BULL, V171, P379, DOI 10.2307/1541680; BLACKSTONE NW, 1989, J ZOOL, V217, P477, DOI 10.1111/j.1469-7998.1989.tb02503.x; BLACKSTONE NW, 1985, THESIS YALE U; Borradaile L. A., 1916, Nat Hist Rep Zool, VNo.3; CUNNINGHAM CW, 1991, EVOLUTION, V46, P1301; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; GLAESSNER MF, 1969, ARTHROPODA, V4, pR400; Hart JFL, 1982, BC PROV MUS HDB, V40; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hillis David M., 1990, P502; Kafanov A. I., 1984, CANADIAN TRANSLATION, V5052, P1; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; MACDONALD J. D., 1957, PROC ZOOL SOC LONDON, V128, P209; MARTIN AP, 1990, MOL BIOL EVOL, V7, P485; MARTIN JW, 1986, J CRUSTACEAN BIOL, V6, P576, DOI 10.2307/1548195; McLaughlin P. A., 1974, ZOOL VERHANDEL LEIDE, V130, P1; MCLAUGHLIN PA, 1983, J CRUSTACEAN BIOL, V3, P608, DOI 10.2307/1547956; Palumbi S, 1991, SIMPLE FOOLS GUIDE P; PIKE R. B., 1960, PUBBL STAZ ZOOL NAPOLI, V31, P493; REESE ES, 1968, SCIENCE, V161, P385, DOI 10.1126/science.161.3839.385; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEVCIC Z, 1971, SYST ZOOL, V20, P331, DOI 10.2307/2412345; SWOFFORD DL, 1991, PAUP VERSION 3 0Q; Vermeij G.J., 1987, EVOLUTION ESCALATION; VERMEIJ GJ, 1991, SCIENCE, V253, P1099, DOI 10.1126/science.253.5024.1099; Williams A.B., 1984, SHRIMPS LOBSTERS CRA; Wolff T., 1961, Galathea Report, V4, P11	29	219	225	5	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					539	542		10.1038/355539a0	http://dx.doi.org/10.1038/355539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741031				2022-12-28	WOS:A1992HC52600056
J	BRADLEY, CP				BRADLEY, CP			UNCOMFORTABLE PRESCRIBING DECISIONS - A CRITICAL INCIDENT STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To explore the discomfort experienced by general practitioners in relation to decisions about whether or not to prescribe. Design - Focused interviews of general practitioners about prescribing decisions that made them uncomfortable. Analysis based on the critical incident technique. Setting - One family practitioner committee area in the north of England. Respondents - 69 principals and five trainee general practitioners. Main outcome measures - Drugs and clinical problems associated with prescribing discomfort. Reasons given by doctors for making the prescribing decisions they did and reasons for feeling uncomfortable. Results - Antibiotics, tranquillisers, hypnotics, and symptomatic remedies were most often associated with discomfort, but any prescribeable item could be associated with discomfort. Respiratory diseases, musculoskeletal problems, and anxiety were most often associated with discomfort, but again any condition could be associated. The main reasons given for the decisions made were patient expectation, clinical appropriateness, factors related to the doctor-patient relationship, and precedents. The main reasons given for feeling uncomfortable were concern about drug toxicity, failure to live up to the general practitioner's own expectations, concern about the appropriateness of treatment, and ignorance or uncertainty. Conclusions - Many considerations, including medical, social, and logistic ones, influence the decision to prescribe in general practice. The final action taken depends on a complex interaction of these disparate influences.			BRADLEY, CP (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,ENGLAND.			Bradley, Colin/0000-0002-3595-9567				BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRADLEY CP, IN PRESS FAM PRACT; BRADLEY CP, 1990, THESIS U DUBLIN; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Glaser B.G., 1965, AWARENESS DYING; HARRIS CM, 1980, BRIT MED J, V281, P57; HEMMINKI E, 1975, MED CARE, V13, P150, DOI 10.1097/00005650-197502000-00006; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; PARISH PA, 1973, ROY SOC HEALTH J, V93, P213, DOI 10.1177/146642407309300414; 1986, 1981 1982 MORBIDITY; 1989, HLTH PERSONAL SOCIAL; 1987, BMA GUIDE LIVING RIS	12	145	146	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					294	296		10.1136/bmj.304.6822.294	http://dx.doi.org/10.1136/bmj.304.6822.294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739831	Green Published, Bronze			2022-12-28	WOS:A1992HC70800024
J	HILLIS, DM; BULL, JJ; WHITE, ME; BADGETT, MR; MOLINEUX, IJ				HILLIS, DM; BULL, JJ; WHITE, ME; BADGETT, MR; MOLINEUX, IJ			EXPERIMENTAL PHYLOGENETICS - GENERATION OF A KNOWN PHYLOGENY	SCIENCE			English	Article							PARSIMONY	Although methods of phylogenetic estimation are used routinely in comparative biology, direct tests of these methods are hampered by the lack of known phylogenies. Here a system based on serial propagation of bacteriophage T7 in the presence of a mutagen was used to create the first completely known phylogeny. Restriction-site maps of the terminal lineages were used to infer the evolutionary history of the experimental lines for comparison to the known history and actual ancestors. The five methods used to reconstruct branching pattern all predicted the correct topology but varied in their predictions of branch lengths; one method also predicts ancestral restriction maps and was found to bc greater than 98 percent accurate.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	HILLIS, DM (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.		Hillis, David M/B-4278-2008; Hillis, David/L-5421-2019					ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; Brooks DR, 1991, PHYLOGENY ECOLOGY BE; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Cochran W.G, 1957, STAT METHODS, V6th ed; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Eldredge N., 1980, PHYLOGENETIC PATTERN; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1985, SCIENCE, V228, P1169, DOI 10.1126/science.4001935; FITCH WM, 1987, MOL MORPHOLOGY EVOLU, P203; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HUELSENBECK JP, 1991, SYST ZOOL, V40, P257, DOI 10.2307/2992321; LAKE JA, 1987, MOL BIOL EVOL, V4, P167; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; STUDIER FW, 1980, CELLS BEHAVIOR VIEW, P72; Swofford David L., 1990, P411; SWOFFORD DL, 1990, PHYLOGENETIC ANAL US; WHITE ME, 1991, 4TH P INT C SYST EV, P935; [No title captured]	21	214	215	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					589	592		10.1126/science.1736360	http://dx.doi.org/10.1126/science.1736360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736360				2022-12-28	WOS:A1992HB53100040
J	MOHANTYHEJMADI, P; DUTTA, SK; MAHAPATRA, P				MOHANTYHEJMADI, P; DUTTA, SK; MAHAPATRA, P			LIMBS GENERATED AT SITE OF TAIL AMPUTATION IN MARBLED BALLOON FROG AFTER VITAMIN-A TREATMENT	NATURE			English	Article							REGENERATING AXOLOTL LIMB; RETINOIC ACID; LOCAL APPLICATION; TADPOLES	NIAZI and Saxena 1 first observed that vitamin A has an inhibitory and modifying influence on tail regeneration in Bufo andersonii tadpoles. A positive relationship was later found between the inhibiting influence of vitamin A and the developmental stage of the regenerating tail in the same species 2. There have been several subsequent reports 3-7 on the effects of vitamin A and its derivatives on limb development and regeneration. Thus in regenerating amphibian limbs, application of retinoids produces pattern duplication in the proximodistal and anteroposterior axes of the limb 3,8,9, and local application of retinoic acid to the anterior side of developing chick limbs causes duplications in the anteroposterior axis of limb 10,11. Here we show that vitamin A can cause limb development when applied to amputated tail stumps of the tadpoles of the marbled balloon frog Uperodon systoma (Anura Microhylidae). This is the first report of homeotic transformation mediated through vitamin A in vertebrates.			MOHANTYHEJMADI, P (corresponding author), UTKAL UNIV, DEPT ZOOL, BHUBANESWAR 751004, ORISSA, INDIA.							DROBERTIS EM, 1990, SCI IT AM, P46; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1985, ROUX ARCH DEV BIOL, V194, P228, DOI 10.1007/BF00848251; MADEN M, 1983, J EMBRYOL EXP MORPH, V77, P273; Mohanty-Hejmadi P., 1977, Prakruti Utkal Univ J Sci, V11, P81; NIAZI IA, 1968, EXPERIENTIA, V24, P852, DOI 10.1007/BF02144915; NIAZI IA, 1984, ROUX ARCH DEV BIOL, V193, P111, DOI 10.1007/BF00848639; NIAZI IA, 1979, J EXP BIOL, V17, P866; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P35; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P19; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; THOMS SD, 1984, DEV BIOL, V103, P319, DOI 10.1016/0012-1606(84)90320-8; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0	13	110	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					352	353		10.1038/355352a0	http://dx.doi.org/10.1038/355352a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731249				2022-12-28	WOS:A1992HA59100068
J	MORRIS, CD; MENASHE, VD				MORRIS, CD; MENASHE, VD			25-YEAR MORTALITY AFTER SURGICAL REPAIR OF CONGENITAL HEART DEFECT IN CHILDHOOD - A POPULATION-BASED COHORT STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR SEPTAL-DEFECT; TERM FOLLOW-UP; GREAT-ARTERIES; SUDDEN-DEATH; TETRALOGY; FALLOT; TRANSPOSITION; COARCTATION; MUSTARD; DYSRHYTHMIAS	Objective. - To determine long-term survival and the cause of death after repair of one of eight congenital heart defects in childhood. Design. - Cohort study. Setting. - General community. Participants. - All Oregon residents with one of eight congenital heart defects, which was repaired surgically between 1958 and 1989 when the patient was aged 18 years or younger, including (1) tetralogy of Fallot; (2) isolated ventricular septal defect; (3) isolated atrial septal defect; (4) coarctation of the aorta; (5) aortic valvular stenosis; (6) pulmonary valvular stenosis; (7) transposition of the great arteries; and (8) patent ductus arteriosus. Follow-up of this cohort of 2701 individuals was obtained from 94%. Main Outcome Measure. - Mortality from cardiac and noncardiac causes. Results. - Age at surgery and operative mortality have decreased significantly over the last 30 years. Late cardiac mortality at 25 years after surgery was 5% for tetralogy of Fallot and isolated ventricular septal defect, 1 0% for coarctation of the aorta, 17% for aortic stenosis, 5% for pulmonic stenosis,and less than 1% for patent ductus arteriosus; there were no late cardiac deaths after atrial septal defect repair. For transposition, late cardiac mortality was 15% at 15 years after the Mustard operation and was 2% at 10 years after the Senning operation. Conclusion. - Surgical repair of most congenital heart defects is associated with lingering cardiac mortality, particularly for aortic stenosis, coarctation, and transposition.	OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201	Oregon Health & Science University	MORRIS, CD (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,DIV CARDIOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036856, R29HL039052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R23 HL36856, R29 HL39052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN HD, 1974, CIRCULATION, V50, P465, DOI 10.1161/01.CIR.50.3.465; BEHL PR, 1987, THORAX, V42, P309, DOI 10.1136/thx.42.4.309; BENDER HW, 1989, ANN THORAC SURG, V47, P218, DOI 10.1016/0003-4975(89)90272-5; CARPENTER MA, 1985, J AM COLL CARDIOL, V6, P879, DOI 10.1016/S0735-1097(85)80498-8; CHANDAR JS, 1990, AM J CARDIOL, V65, P655, DOI 10.1016/0002-9149(90)91047-A; CLARKSON PM, 1976, CIRCULATION, V53, P519, DOI 10.1161/01.CIR.53.3.519; DEANFIELD J, 1988, J THORAC CARDIOV SUR, V96, P569; DEANFIELD JE, 1983, CIRCULATION, V67, P626, DOI 10.1161/01.CIR.67.3.626; DUSTER MC, 1985, AM HEART J, V109, P1323, DOI 10.1016/0002-8703(85)90359-X; FRIEDLI B, 1974, AM J CARDIOL, V33, P403, DOI 10.1016/0002-9149(74)90323-3; FUSTER V, 1980, AM J CARDIOL, V46, P635, DOI 10.1016/0002-9149(80)90514-7; HOFFMAN JIE, 1978, AM J CARDIOL, V42, P641, DOI 10.1016/0002-9149(78)90635-5; JAMES FW, 1975, CIRCULATION, V52, P691, DOI 10.1161/01.CIR.52.4.691; KIRKLIN JW, 1977, CIRCULATION, V56, P612, DOI 10.1161/01.CIR.56.4.612; KOPECKY SL, 1988, CIRCULATION, V78, P1150, DOI 10.1161/01.CIR.78.5.1150; LILLEHEI CW, 1986, ANN THORAC SURG, V41, P4, DOI 10.1016/S0003-4975(10)64489-X; LILLEHEI CW, 1986, ANN SURG, V204, P490, DOI 10.1097/00000658-198610000-00017; MANNING JA, 1980, CARDIOVASC CLIN, V11, P117; MARX GR, 1983, J AM COLL CARDIOL, V1, P476, DOI 10.1016/S0735-1097(83)80076-X; MATSUDA H, 1986, JPN CIRC J, V50, P1040, DOI 10.1253/jcj.50.1040; MURPHY JG, 1990, NEW ENGL J MED, V323, P1645, DOI 10.1056/NEJM199012133232401; MURPHY JG, 1989, CIRCULATION S2, V80, P490; PARSONS JM, 1989, BRIT HEART J, V62, P65; QUATTLEBAUM TG, 1976, CIRCULATION, V54, P289, DOI 10.1161/01.CIR.54.2.289; SIMSOLO R, 1988, AM HEART J, V115, P1268, DOI 10.1016/0002-8703(88)90020-8; 1988, PHS881147 DEP HLTH H; 1977, CIRCULATION S1, V55, P87; 1980, PEDIATRICS, V63, P377	28	105	107	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3447	3452		10.1001/jama.266.24.3447	http://dx.doi.org/10.1001/jama.266.24.3447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744959				2022-12-28	WOS:A1991GV87800030
J	FIRTH, WJ				FIRTH, WJ			CHAOS - PREDICTING THE UNPREDICTABLE	BRITISH MEDICAL JOURNAL			English	Article							DYNAMICS				FIRTH, WJ (corresponding author), UNIV STRATHCLYDE,DEPT PHYS & APPL PHYS,GLASGOW G4 0NG,SCOTLAND.							Conrad M., 1986, CHAOS; FREEMAN WJ, 1988, IEEE T CIRCUITS SYST, V35, P781, DOI 10.1109/31.1822; Gleick J., 1988, CHAOS MAKING NEW SCI; GOLDBERGER AL, 1990, SCI AM           FEB, P35; Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT, P480; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; PEITGEN HO, 1986, BEAUTY FRACTALS; 1988, CHAOS	8	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1565	1568		10.1136/bmj.303.6817.1565	http://dx.doi.org/10.1136/bmj.303.6817.1565			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773173	Green Accepted, Bronze, Green Published			2022-12-28	WOS:A1991GX95600005
J	CARDOZO, L				CARDOZO, L			URINARY-INCONTINENCE IN WOMEN - HAVE WE ANYTHING NEW TO OFFER	BRITISH MEDICAL JOURNAL			English	Review							IDIOPATHIC DETRUSOR INSTABILITY; REFRACTORY URGE INCONTINENCE; STRESS-INCONTINENCE; ADULT ENURESIS; VAGINAL CONES; PLEXUSES; FEMALE; PHENOL; DDAVP				CARDOZO, L (corresponding author), UNIV LONDON KINGS COLL HOSP,LONDON SE5 9RS,ENGLAND.							Appell RA, 1990, INT UROGYNECOL J, V1, P117; BERGMAN A, 1989, AM J OBSTET GYNECOL, V161, P97, DOI 10.1016/0002-9378(89)90242-1; BLACKFORD HN, 1984, BRIT J UROL, V56, P647, DOI 10.1111/j.1464-410X.1984.tb06137.x; BRAMBLE FJ, 1982, BRIT J UROL, V54, P693, DOI 10.1111/j.1464-410X.1982.tb13626.x; Cardozo LD, 1987, NEUROUROL URODYNAM, V6, P256; ERIKSEN BC, 1989, NEUROUROL URODYNAM, V8, P219, DOI 10.1002/nau.1930080305; FANTL JA, 1988, OBSTET GYNECOL, V71, P823; HAYLEN BT, 1989, BRIT J UROL, V64, P147, DOI 10.1111/j.1464-410X.1989.tb05975.x; HILTON P, 1982, BRIT J UROL, V54, P252, DOI 10.1111/j.1464-410X.1982.tb06969.x; HILTON P, 1990, INT UROGYNECOL J PEL, V1, P80; JARVIS GJ, 1980, BRIT J OBSTET GYNAEC, V87, P893, DOI 10.1111/j.1471-0528.1980.tb04443.x; KARAM MM, 1989, OBSTET GYNECOL, V73, P4; KNUDSEN UB, 1989, NEUROUROL URODYNAM, V8, P348; MANTLE J, 1991, BRIT MED J, V302, P753, DOI 10.1136/bmj.302.6779.753; MOORE KH, 1990, BRIT J UROL, V66, P479, DOI 10.1111/j.1464-410X.1990.tb14992.x; MUNDY AR, 1985, BRIT J UROL, V57, P641, DOI 10.1111/j.1464-410X.1985.tb07023.x; NIELSEN KK, 1990, J UROLOGY, V144, P1199, DOI 10.1016/S0022-5347(17)39692-1; OLAH KS, 1990, AM J OBSTET GYNECOL, V162, P87, DOI 10.1016/0002-9378(90)90827-T; PEATTIE AB, 1988, BRIT J OBSTET GYNAEC, V95, P1049, DOI 10.1111/j.1471-0528.1988.tb06512.x; PLEVNIK S, 1986, WORLD J UROL, V4, P24, DOI 10.1007/BF00326737; PLEVNIK S, 1985, 15TH P ANN M INT CON, P267; RAMSDEN PD, 1982, BRIT J UROL, V54, P256, DOI 10.1111/j.1464-410X.1982.tb06970.x; ROSENBAUM TP, 1988, NEUROUROL URODYNAM, V7, P294; ROSENBAUM TP, 1990, UROGYNAECOLOGIA, V4, P134; STANTON SL, 1986, SURGERY FEMALE INCON; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; WALL LL, 1989, BRIT J UROL, V63, P465, DOI 10.1111/j.1464-410X.1989.tb05937.x; WALTER S, 1990, INT UROGYNECOL J, V1, P74; 1990, J AM GERIATR SOC, V38, P265; 1991, SURVEY PREVALENCE AT	30	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1453	1457		10.1136/bmj.303.6815.1453	http://dx.doi.org/10.1136/bmj.303.6815.1453			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773155	Green Published, Bronze			2022-12-28	WOS:A1991GU38500031
J	SMITH, LFP				SMITH, LFP			GP TRAINEES VIEWS ON HOSPITAL OBSTETRIC VOCATIONAL-TRAINING	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; REGION	Objectives - To examine the content of hospital obstetric vocational training for general practice, the beliefs of general practitioner trainees about this training, and their perceived competence at practical obstetric procedures and the effect of training. Design - Confidential postal questionnaire. Subjects - A random one in four sample of all general practitioner trainees in the United Kingdom on vocational training schemes or in training practices in Autumn 1990. Main outcome measures - Trainees' competence and beliefs on Likert scale, numbers of procedures witnessed and performed, type of maternity care trainees intended to provide. Results - Of 1019 trainees sent questionnaires, 765 (75.5%) replied; 517 had done some hospital obstetric training. After six months as a senior house officer 232/367 (63%) believed they were competent to perform a normal delivery unaided, 228 (62%) to manage a severe postpartum haemorrhage, and 227 (62%) to resuscitate a newborn infant. 272 (35.6%) trainees intended to provide intrapartum care and 56 (7.5%) to book home deliveries in the future. Hospital training increased confidence in performing most obstetric procedures in all trainees. However, a greater proportion of trainees who intended to provide full care than shared care felt competent at performing a normal vaginal delivery (63% (170/272) full v 45% (215/473) shared), low forceps delivery (38% (103) v 17% (79)), manual removal of placenta (24% (65) v 17% (82)), and intubating a neonate (42% (114) v 34% (161)). Trainees who had done any obstetric training were less likely to think that training encouraged future provision of intrapartum care (113/509 (22%) training v 65/213 (31%) no training). Conclusion - Hospital vocational obstetric training increases the perceived competence of trainees but fails to encourage them to use obstetric skills.			SMITH, LFP (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,GEN PRACTICE UNIT,BRISTOL BS8 2PR,ENGLAND.							CAMPBELL R, 1987, BE BORN DEBATE EVIDE; COUPLAND VA, 1987, BRIT MED J, V295, P1077, DOI 10.1136/bmj.295.6605.1077; CRAWLEY HS, 1990, BRIT MED J, V300, P911, DOI 10.1136/bmj.300.6729.911; GRANT J, 1989, BRIT MED J, V299, P1263, DOI 10.1136/bmj.299.6710.1263; HARE MJ, 1990, BRIT MED J, V300, P857, DOI 10.1136/bmj.300.6728.857; MARSH GN, 1985, BRIT MED J, V290, P971, DOI 10.1136/bmj.290.6473.971; REEVE H, 1989, BRIT MED J, V298, P1432, DOI 10.1136/bmj.298.6685.1432; RONALDS C, 1981, 4TH NAT TRAIN C LOND; Smith H, 1989, Nurs Times, V85, P75; SMITH LFP, 1991, BRIT MED J, V302, P13, DOI 10.1136/bmj.302.6767.13; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; Towler J, 1984, Midwives Chron, V97, P3; YOUNG GL, 1991, BRIT J GEN PRACT, V41, P266; 1981, REPORT TRAINING OBST; 1982, REPORT RCOG WORKING	15	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1447	1452		10.1136/bmj.303.6815.1447	http://dx.doi.org/10.1136/bmj.303.6815.1447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773153	Green Published, Bronze			2022-12-28	WOS:A1991GU38500029
J	SIMPSON, M; BUCKMAN, R; STEWART, M; MAGUIRE, P; LIPKIN, M; NOVACK, D; TILL, J				SIMPSON, M; BUCKMAN, R; STEWART, M; MAGUIRE, P; LIPKIN, M; NOVACK, D; TILL, J			DOCTOR-PATIENT COMMUNICATION - THE TORONTO CONSENSUS STATEMENT	BRITISH MEDICAL JOURNAL			English	Article							EARLY BREAST-CANCER; INTERVIEWING SKILLS; GENERAL-PRACTICE; CARE; SATISFACTION; STUDENTS; PHYSICIANS; AGREEMENT; FEEDBACK; ILLNESS		UNIV WESTERN ONTARIO,CTR STUDIES FAMILY MED,LONDON N6A 3K7,ONTARIO,CANADA; UNIV TORONTO,TORONTO BAYVIEW REG CANC CTR,TORONTO M5S 1A1,ONTARIO,CANADA; CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,PSYCHOL MED GRP,MANCHESTER M20 9BX,LANCS,ENGLAND; NYU,SCH MED,DEPT MED,NEW YORK,NY 10003; BROWN UNIV,SCH MED,PROVIDENCE,RI 02912; PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA	Western University (University of Western Ontario); University of Toronto; Christie NHS Foundation Trust; Christie Hospital; New York University; Brown University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre				Stewart, Moira/0000-0002-5552-0762; Till, James/0000-0002-6532-6023				Balint M, 1972, DOCTOR HIS PATIENT I; BARTLETT EE, 1984, J CHRON DIS, V37, P755, DOI 10.1016/0021-9681(84)90044-4; BASS MJ, 1986, J FAM PRACTICE, V23, P43; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BLANCHARD CG, 1986, CANCER, V58, P387, DOI 10.1002/1097-0142(19860715)58:2<387::AID-CNCR2820580233>3.0.CO;2-3; Brown J., 1989, CAN FAM PHYSICIAN, V35, P151; BYRNE PS, 1984, DOCTORS TALKING PATI; CARROLL JG, 1979, J MED EDUC, V54, P498; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; DiMatteo MR, 1982, ACHIEVING PATIENT CO; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ENGLER CM, 1981, J MED EDUC, V56, P572; FADEN RR, 1981, MED CARE, V19, P718, DOI 10.1097/00005650-198107000-00003; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FRANCIS V, 1969, NEW ENGL J MED, V280, P535, DOI 10.1056/NEJM196903062801004; FREELING P, 1985, BMJ-BRIT MED J, V290, P1880, DOI 10.1136/bmj.290.6485.1880; GASK L, 1991, MED EDUC, V25, P444, DOI 10.1111/j.1365-2923.1991.tb00093.x; GASK L, 1988, MED EDUC, V22, P132, DOI 10.1111/j.1365-2923.1988.tb00423.x; GASK L, 1991, THESIS U MANCHESTER; GRECO RS, 1966, ONE MANS PRACTICE EF; HUTTER MJ, 1977, J MED EDUC, V52, P328; KAHN GS, 1979, J MED EDUC, V54, P29; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KERN DE, 1989, J GEN INTERN MED, V4, P421, DOI 10.1007/BF02599696; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; LASSEN LC, 1991, FAM PRACT, V8, P154, DOI 10.1093/fampra/8.2.154; LAZARE A, IN PRESS MED INTERVI; Levenstein J.H., 1989, COMMUNICATING MED PA, P107; Ley P., 1988, COMMUNICATING PATIEN; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MACLEOD RM, 1991, THESIS U MANCHESTER; MAGUIRE P, 1990, BRIT J HOSP MED, V43, P215; MAGUIRE P, 1978, PSYCHOL MED, V8, P695, DOI 10.1017/S0033291700018894; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; MAGUIRE P, 1984, COMMUNICATION SKILLS, P153; MATTHEWS DA, 1987, AM J MED, V35, P936; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; NOVACK DH, 1991, COMMUNICATION; ORTH JE, 1987, HEALTH PSYCHOL, V6, P29, DOI 10.1037/0278-6133.6.1.29; Pendleton D., 1984, CONSULTATION APPROAC; PLATT FW, 1979, ANN INTERN MED, V91, P898, DOI 10.7326/0003-4819-91-6-898; REUBEN DB, 1984, PSYCHOSOMATICS, V25, P815, DOI 10.1016/S0033-3182(84)72942-2; Riccardi D. M., 1987, COMMUNICATION COUNSE; RICHARDS T, 1990, BRIT MED J, V301, P1407, DOI 10.1136/bmj.301.6766.1407; ROGERS CR, 1951, CLIENT CENTERED THER; ROTER DL, 1977, HEALTH EDUC QUART, V5, P281, DOI 10.1177/109019817700500402; SCHULBERG HC, 1988, GEN HOSP PSYCHIAT, V10, P79, DOI 10.1016/0163-8343(88)90092-8; SHAPIRO RS, 1989, ARCH INTERN MED, V149, P2190, DOI 10.1001/archinte.149.10.2190; Simpson MA., 1972, MED ED CRITICAL APPR; SIMPSON MA, 1980, CLIN PSYCHOLINGUISTI; SMITH AC, 1989, SOC PSYCHOL QUART, V52, P56, DOI 10.2307/2786904; STARFIELD B, 1979, JAMA-J AM MED ASSOC, V242, P344, DOI 10.1001/jama.242.4.344; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STEWART M, 1989, CAN FAM PHYSICIAN, V35, P159; Stewart M A, 1979, J R Coll Gen Pract, V29, P77; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; TUCKETT D, 1986, M EXPERTS; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WAXLERMORRISON N, 1990, CROSS CULTURAL CARIN; WESTON WW, 1989, CAN FAM PHYSICIAN, V35, P147; WHITEHOUSE CR, 1991, MED EDUC, V25, P311, DOI 10.1111/j.1365-2923.1991.tb00072.x; WILKINSON S, 1991, J ADV NURS, V16, P677, DOI 10.1111/j.1365-2648.1991.tb01726.x; 1986, HEADACHE J, V26, P285	66	565	580	1	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1385	1387		10.1136/bmj.303.6814.1385	http://dx.doi.org/10.1136/bmj.303.6814.1385			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GU384	1760608	Bronze, Green Published			2022-12-28	WOS:A1991GU38400025
J	RICHARDS, T				RICHARDS, T			MEDICINE IN EUROPE - 1992 AND ALL THAT	BRITISH MEDICAL JOURNAL			English	Article																		GRANT G, 1991, EURONEWS        0505, P1; OAKLEY R, 1991, TIMES           1022, P10; RICHARDS T, 1991, BRIT MED J, V302, P1173; SCOTTSAMUEL A, 1991, BRIT MED J, V303, P737; 1991, ECONOMIST       0622, P98; 1991, ECONOMIST       0413, P54; 1991, EURO BRIEF BMA, P283; 1991, INDEPENDENT     0713, P6; 1991, ECONOMIST       0601, P52; 1991, LANCET, V337, P1317; 1989, OFFICIAL J EURO 1105; 1991, INDEPENDENT     0726, P6; 1991, EURO BRIEF BMA, P312	13	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1319	1322		10.1136/bmj.303.6813.1319	http://dx.doi.org/10.1136/bmj.303.6813.1319			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747677	Bronze, Green Published			2022-12-28	WOS:A1991GT01100027
J	ADAMS, R; MCKIE, V; NICHOLS, F; CARL, E; ZHANG, DL; MCKIE, K; FIGUEROA, R; LITAKER, M; THOMPSON, W; HESS, D				ADAMS, R; MCKIE, V; NICHOLS, F; CARL, E; ZHANG, DL; MCKIE, K; FIGUEROA, R; LITAKER, M; THOMPSON, W; HESS, D			THE USE OF TRANSCRANIAL ULTRASONOGRAPHY TO PREDICT STROKE IN SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; DOPPLER ULTRASOUND; CNS INFARCTION; ANEMIA; TRANSFUSION; CHILDREN	Background. Stroke, especially cerebral infarction, is a major cause of morbidity and mortality in children with sickle cell disease. Primary prevention of stroke by transfusion therapy may be feasible if there is a way to identify the patients at greatest risk. Transcranial Doppler ultrasonography can measure flow velocity in the large intracranial arteries, The narrowing of these arteries, which leads to cerebral infarction, is characterized by an increased velocity of flow. Methods. Using transcranial Doppler ultrasonography, we prospectively measured the velocity of cerebral blood flow in children and young adults being followed because of sickle cell disease. The results were classified as either normal or abnormal on the basis of the highest velocity of flow in the middle cerebral artery. Abnormal velocity was defined as a flow greater-than-or-equal-to 170 cm per second, a definition determined by post hoc analysis to maximize the predictive success of the test. The end point was a clinically apparent first cerebral infarction. Results. Two hundred eighty-three transcranial ultrasound examinations were performed in 190 patients with sickle cell disease (age at entry, 3 to 18 years). After an average follow-up of 29 months, cerebral infarction was diagnosed in seven patients. In 23 patients the results of the ultrasound examinations were abnormal, and in 167 patients they were normal. The clinical and hematologic characteristics of the two groups were similar, but six of the seven strokes occurred among the 23 patients with abnormal ultrasound results (P < 0.00001 by Fisher's exact test). In this group, the relative risk of stroke was 44 (95 percent confidence interval, 5.5 to 346). Conclusions. Transcranial ultrasonography can identify the children with sickle cell disease who are at highest risk for cerebral infarction. Periodic ultrasound examinations and the selective use of transfusion therapy could make the primary prevention of stroke an achievable goal.	MED COLL GEORGIA,DEPT PEDIAT,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT RADIOL,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT BIOSTAT,AUGUSTA,GA 30912	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	ADAMS, R (corresponding author), MED COLL GEORGIA,DEPT NEUROL,HB-2060,AUGUSTA,GA 30912, USA.				NHLBI NIH HHS [1PO1 HL 41544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R., 1986, TRANSCRANIAL DOPPLER, P39; ADAMS R J, 1991, Neurology, V41, P182; ADAMS RJ, 1988, STROKE, V19, P518, DOI 10.1161/01.STR.19.4.518; ADAMS RJ, 1988, J CARDIOVASC ULTRAS, V7, P201; ADAMS RJ, 1989, J CARDIOVASC TECHNOL, V8, P97; ADAMS RJ, 1990, AM J PEDIAT HEMATOL, V12, P277; ADAMS RJ, 1988, NEUROLOGY, V38, P1012, DOI 10.1212/WNL.38.7.1012; ADAMS RJ, 1989, VASCULAR DISEASES 3, V55, P503; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; BODE H, 1988, PEDIATRIC APPLICATIO; BOROS L, 1976, J NEUROL NEUROSUR PS, V39, P1236, DOI 10.1136/jnnp.39.12.1236; BRASS LM, 1991, STROKE, V22, P27, DOI 10.1161/01.STR.22.1.27; Bridgers WH, 1939, AM J PATHOL, V15, P353; CHARACHE S, 1989, DHHS NIH892117 PUBL, P22; GERALD B, 1980, AM J ROENTGENOL, V134, P1209, DOI 10.2214/ajr.134.6.1209; GREER M, 1962, NEUROLOGY, V12, P114, DOI 10.1212/WNL.12.2.114; HUISMAN THJ, 1977, CLIN BIOCH ANAL SERI, V6; JEFFRIES BF, 1980, SURG NEUROL, V14, P291; Koshy M, 1990, J Assoc Acad Minor Phys, V1, P71; LEYPOZO J, 1990, ANN NEUROL, V28, P640, DOI 10.1002/ana.410280507; LUSHER JM, 1976, AM J HEMATOL, V1, P265, DOI 10.1002/ajh.2830010210; MAEDA H, 1990, ULTRASOUND MED BIOL, V16, P9, DOI 10.1016/0301-5629(90)90080-V; MERKEL KHH, 1978, STROKE, V9, P45, DOI 10.1161/01.STR.9.1.45; Pavlakis S G, 1989, Adv Pediatr, V36, P247; PAVLAKIS SG, 1988, ANN NEUROL, V23, P125, DOI 10.1002/ana.410230204; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; PROHOVNIK I, 1989, NEUROLOGY, V39, P344, DOI 10.1212/WNL.39.3.344; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SARNAIK S, 1979, AM J DIS CHILD, V133, P1254, DOI 10.1001/archpedi.1979.02130120046009; SARNAIK SA, 1982, AM J PEDIAT HEMATOL, V4, P386; SERJEANT GR, 1985, SICKLE CELL DIS, P233; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; Sydenstricked VP, 1923, AM J DIS CHILD, V26, P132, DOI 10.1001/archpedi.1923.04120140031004; WILSON JB, 1983, J LAB CLIN MED, V102, P174; WIZNITZER M, 1990, J PEDIATR-US, V117, P551, DOI 10.1016/S0022-3476(05)80687-0; 1989, SAS STAT USERS GUIDE	39	453	459	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					605	610		10.1056/NEJM199202273260905	http://dx.doi.org/10.1056/NEJM199202273260905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734251				2022-12-28	WOS:A1992HF63300005
J	BECK, RW; CLEARY, PA; ANDERSON, MM; KELTNER, JL; SHULTS, WT; KAUFMAN, DI; BUCKLEY, EG; CORBETT, JJ; KUPERSMITH, MJ; MILLER, NR; SAVINO, PJ; GUY, JR; TROBE, JD; MCCRARY, JA; SMITH, CH; CHROUSOS, GA; THOMPSON, HS; KATZ, BJ; BRODSKY, MC; GOODWIN, JA; ATWELL, CW				BECK, RW; CLEARY, PA; ANDERSON, MM; KELTNER, JL; SHULTS, WT; KAUFMAN, DI; BUCKLEY, EG; CORBETT, JJ; KUPERSMITH, MJ; MILLER, NR; SAVINO, PJ; GUY, JR; TROBE, JD; MCCRARY, JA; SMITH, CH; CHROUSOS, GA; THOMPSON, HS; KATZ, BJ; BRODSKY, MC; GOODWIN, JA; ATWELL, CW			A RANDOMIZED, CONTROLLED TRIAL OF CORTICOSTEROIDS IN THE TREATMENT OF ACUTE OPTIC NEURITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIPLE-SCLEROSIS; VISUAL FUNCTION; METHYLPREDNISOLONE; INJECTION; THERAPY; TESTS	Background and Methods. The use of corticosteroids to treat optic neuritis is controversial. At 15 clinical centers, we randomly assigned 457 patients with acute optic neuritis to receive oral prednisone (1 mg per kilogram of body weight per day) for 14 days; intravenous methylprednisolone (1 g per day) for 3 days, followed by oral prednisone (1 mg per kilogram per day) for 11 days; or oral placebo for 14 days. Visual function was assessed over a six-month follow-up period. Results. Visual function recovered faster in the group receiving intravenous methylprednisolone than in the placebo group; this was particularly true for the reversal of visual-field defects (P = 0.0001). Although the differences between the groups decreased with time, at six months the group that received intravenous methylprednisolone still had slightly better visual fields (P = 0.054), contrast sensitivity (P = 0.026), and color vision (P = 0.033) but not better visual acuity (P = 0.66). The outcome in the oral-prednisone group did not differ from that in the placebo group. In addition, the rate of new episodes of optic neuritis in either eye was higher in the group receiving oral prednisone, but not the group receiving intravenous methylprednisolone, than in the placebo group (relative risk for oral prednisone vs. placebo, 1.79; 95 percent confidence interval, 1.08 to 2.95). Conclusions. Intravenous methylprednisolone followed by oral prednisone speeds the recovery of visual loss due to optic neuritis and results in slightly better vision at six months. Oral prednisone alone, as prescribed in this study, is an ineffective treatment and increases the risk of new episodes of optic neuritis.			BECK, RW (corresponding author), UNIV S FLORIDA, COLL MED, DEPT OPHTHALMOL, 12901 N BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.		Macedo, Ana/L-9912-2018	Macedo, Ana/0000-0002-6978-8989	NATIONAL EYE INSTITUTE [U01EY007461, U01EY007460, U10EY007460, U10EY007461, U10EY007212, U01EY007212] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BECH RW, 1991, ARCH OPHTHALMOL-CHIC, V109, P1673, DOI 10.1001/archopht.1991.01080120057025; BOWDEN AN, 1974, J NEUROL NEUROSUR PS, V37, P869, DOI 10.1136/jnnp.37.8.869; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.2307/2334776; EBERS GC, 1985, ARCH NEUROL-CHICAGO, V42, P702, DOI 10.1001/archneur.1985.04060070096025; FLEISHMAN JA, 1987, OPHTHALMOLOGY, V94, P1029; GOODIN DS, 1991, NEUROLOGY, V41, P980, DOI 10.1212/WNL.41.7.980; GOULD ES, 1977, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.6075.1495; HERISHANU YO, 1989, ACTA NEUROL SCAND, V80, P569, DOI 10.1111/j.1600-0404.1989.tb03928.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NIKOSKELAINEN E, 1975, ACTA OPHTHALMOL, V53, P254; PERKIN GD, 1979, OPTIC NEURITIS ITS D, P43; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAWSON MD, 1969, LANCET, V2, P222; RAWSON MD, 1966, LANCET, V2, P1044; ROSE AS, 1970, NEUROLOGY, V20, P1; SANDERS EACM, 1986, BRIT J OPHTHALMOL, V70, P918, DOI 10.1136/bjo.70.12.918; SPOOR TC, 1988, OPHTHALMOLOGY, V95, P131; WEI LJ, 1984, J AM STAT ASSOC, V79, P653, DOI 10.2307/2288413; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; 1990, PB90195728	23	853	882	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					581	588		10.1056/NEJM199202273260901	http://dx.doi.org/10.1056/NEJM199202273260901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734247				2022-12-28	WOS:A1992HF63300001
J	CROOK, D; GODSLAND, IF; WYNN, V				CROOK, D; GODSLAND, IF; WYNN, V			CHOLESTEROL, APOLIPOPROTEINS, AND THE RISK OF MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							DENSITY-LIPOPROTEIN SUBCLASSES; PRECIPITATION				CROOK, D (corresponding author), WYNN INST METAB RES,LONDON NW8 9SQ,ENGLAND.			Crook, David/0000-0002-9587-3730				ATGER V, 1990, CLIN CHIM ACTA, V189, P111, DOI 10.1016/0009-8981(90)90081-3; Bachorik P S, 1986, Methods Enzymol, V129, P78; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; WARNICK GR, 1982, CLIN CHEM, V28, P1574	5	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					490	491						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732782				2022-12-28	WOS:A1992HD16400019
J	GRIFFITH, DNW				GRIFFITH, DNW			GERIATRIC VISITING HOURS - LESSONS FOR THE GENERAL WARDS	BMJ-BRITISH MEDICAL JOURNAL			English	Article											GRIFFITH, DNW (corresponding author), UNIV COLL HOSP LONDON, DEPT GERIATR MED, LONDON WC1E 6AU, ENGLAND.							[Anonymous], 1963, LANCET, V1, P597; Garton E J, 1979, Nurs Times, V75, P1747; GRIFFITH DNW, 1988, BRIT MED J, V296, P1303, DOI 10.1136/bmj.296.6632.1303; Hawker R, 1984, Nurs Times, V80, P49; 1976, ORG IN PATIENTS DAY	5	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	1992	304	6822					292	292		10.1136/bmj.304.6822.292	http://dx.doi.org/10.1136/bmj.304.6822.292			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739829	Green Published, Bronze			2022-12-28	WOS:A1992HC70800022
J	[Anonymous]				[Anonymous]			BIOTECHNOLOGY - ENTREPRENEURS LOOK FOR CUSTOMERS	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1992	355	6359					390	390						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734273				2022-12-28	WOS:A1992HB53000025
J	KENDALL, GM; MUIRHEAD, CR; MACGIBBON, BH; OHAGAN, JA; CONQUEST, AJ; GOODILL, AA; BUTLAND, BK; FELL, TP; JACKSON, DA; WEBB, MA; HAYLOCK, RGE; THOMAS, JM; SILK, TJ				KENDALL, GM; MUIRHEAD, CR; MACGIBBON, BH; OHAGAN, JA; CONQUEST, AJ; GOODILL, AA; BUTLAND, BK; FELL, TP; JACKSON, DA; WEBB, MA; HAYLOCK, RGE; THOMAS, JM; SILK, TJ			MORTALITY AND OCCUPATIONAL EXPOSURE TO RADIATION - 1ST ANALYSIS OF THE NATIONAL-REGISTRY-FOR-RADIATION-WORKERS	BRITISH MEDICAL JOURNAL			English	Article							EMPLOYEES; PROGRAM; COHORT; CANCER; PLANT; RISK	Objective - To study cause specific mortality of radiation workers with particular reference to associations between fatal neoplasms and level of exposure to radiation. Design - Cohort study. Setting - United Kingdom. Subjects - 95 217 radiation workers at major sites of the nuclear industry. Main outcome measure - Cause of death. Results - Most standardised mortality ratios were below 100: 83 unlagged, 85 with a 10 year lag for all causes; 84 unlagged, 86 lagged for all cancers; and 80 for all known other causes, indicating a "healthy worker effect." The deficit of lung cancer (75 unlagged, 76 lagged) was significant at the 0.1% level. Standardised mortality ratios were significantly raised (214 unlagged, 303 lagged) for thyroid cancer, but there was no evidence for any trend with external recorded radiation dose. Dose of external radiation and mortality from all cancers were weakly correlated (p = 0.10), and multiple myeloma was more strongly correlated (p = 0.06); for leukaemia, excluding chronic lymphatic, the trend was significant (p = 0.03; all tests one tailed). The central estimates of lifetime risk derived from these data were 10.0% per Sv (90% confidence interval < 0 to 24%) for all cancers and 0.76% per Sv (0.07 to 2.4%) for leukaemia (excluding chronic lymphatic leukaemia). These are, respectively, 2.5 times and 1.9 times the risk estimates recommended by the International Commission on Radiological Protection, but 90% confidence intervals are large and the commission's risk factors fall well within the range. The positive trend with dose for all cancers, from which the risk estimate was derived, was not significant. The positive association between leukaemia (except chronic lymphatic leukaemia) was significant and robust in subsidiary analyses. This study showed no association between radiation exposure and prostatic cancer. Conclusion - There is evidence for an association between radiation exposure and mortality from cancer, in particular leukaemia (excluding chronic lymphatic leukaemia) and multiple myeloma, although mortality from these diseases in the study population overall was below that in the general population. The central estimates of risk from this study lie above the most recent estimates of the International Commission on Radiological Protection for leukaemia (excluding chronic lymphatic leukaemia) and for all malignancies. However, the commission's risk estimates are well within the 90% confidence intervals from this study. Analysis of States indicated lower risk estimates than the commission recommends, and when the American data are combined with our analysis the overall risks are close to those estimated by the commission. This first analysis of the National Registry for Radiation Workers does not provide sufficient evidence to justify a revision in risk estimates for radiological protection purposes.			KENDALL, GM (corresponding author), NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND.			Muirhead, Colin/0000-0001-5394-1267; Butland, Barbara/0000-0001-9952-3108				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; BARRY SF, 1986, BRIT J IND MED, V43, P572; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BINKS K, 1989, RADIATION PROTECTION - THEORY AND PRACTICE, P49; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; Cox DR, 1974, THEORETICAL STATISTI; DARBY SC, 1981, J R STAT SOC A STAT, V144, P298, DOI 10.2307/2981797; DARBY SC, 1981, NRPBR116; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GILBERT E S, 1990, Radiation Research, V124, P348; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; GODWIN P, 1975, NATURE, V255, P517; KENDALL GM, 1992, NRPBR251; MUIRHEAD CR, 1991, RADIAT PROT DOSIM, V36, P321; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; 1971, DECENNIAL SUPPLEMENT; 1978, DS1 OFF POP CENS SUR; 1986, DS6 OFF POP CENS SUR; 1991, ICR PUBLICATION, V60, P1	21	152	161	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					220	225		10.1136/bmj.304.6821.220	http://dx.doi.org/10.1136/bmj.304.6821.220			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739796	Green Published, Bronze			2022-12-28	WOS:A1992HA98000024
J	FERGUSON, BM; FANGMAN, WL				FERGUSON, BM; FANGMAN, WL			A POSITION EFFECT ON THE TIME OF REPLICATION ORIGIN ACTIVATION IN YEAST	CELL			English	Article							S-PHASE; DNA-REPLICATION; CELLS	The chromosomes of eukaryotes are characterized by the mosaic nature of their replication - large regions of DNA that replicate early in S phase are interspersed with regions that replicate late. This pattern of early and late synthesis appears to be the consequence of a temporal program that activates replication origins at different times. The basis of this temporal regulation in the yeast S. cerevisiae has been investigated by changing the chromosomal locations of two origins, one activated early in the S phase (ARS1) and one activated late (ARS501). We show that the cis-acting information controlling time of activation can be separated from the element that determines origin function. For the ARS501 origin, late activation appears to be a consequence of its proximity to the telomere.	UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM18926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018926, R01GM018926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; DUBEY DD, 1991, IN PRESS MOL CELL BI; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; HAND R, 1975, J CELL BIOL, V64, P89, DOI 10.1083/jcb.64.1.89; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARPEN GH, 1990, CELL, V63, P97; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	20	225	227	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					333	339		10.1016/0092-8674(92)90474-Q	http://dx.doi.org/10.1016/0092-8674(92)90474-Q			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733502				2022-12-28	WOS:A1992HB35300012
J	HOWARD, EA; ZUPAN, JR; CITOVSKY, V; ZAMBRYSKI, PC				HOWARD, EA; ZUPAN, JR; CITOVSKY, V; ZAMBRYSKI, PC			THE VIRD2 PROTEIN OF A-TUMEFACIENS CONTAINS A C-TERMINAL BIPARTITE NUCLEAR-LOCALIZATION SIGNAL - IMPLICATIONS FOR NUCLEAR UPTAKE OF DNA IN PLANT-CELLS	CELL			English	Article							SINGLE-STRANDED-DNA; AGROBACTERIUM-TUMEFACIENS; T-DNA; BINDING-PROTEIN; TARGETING SIGNAL; GENE-EXPRESSION; 5' END; MOLECULES; GENERATION; SEQUENCE	Here we show that the VirD2 protein of A. tumefaciens functions as a nuclear localizing protein in plant cells. The nuclear localization signal of VirD2 consists of two regions containing 4-5 basic amino acids (KRPR and RKRER), located within the C-terminal 34 amino acids. These regions conform to the KR/KXR/K motif required for numerous nuclear localized nonplant eukaryotic proteins. Each region independently directs a beta-glucuronidase reporter protein to the nucleus; however, both regions are necessary for maximum efficiency. VirD2 has been shown to be tightly bound to the 5' end of the single-stranded DNA transfer intermediate, T-strand, transferred from Agrobacterium to the plant cell genome. The present results imply that T-strand transport to the plant nucleus is mediated by the tightly attached VirD2 protein via an import pathway common to higher eukaryotes.			HOWARD, EA (corresponding author), UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA.			Citovsky, Vitaly/0000-0003-2024-6844				CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1988, SCIENCE, V240, P501, DOI 10.1126/science.240.4851.501; CITOVSKY VC, 1991, IN PRESS MOL SIGNALS; CLEVER J, 1991, P NATL ACAD SCI USA, V88, P7333, DOI 10.1073/pnas.88.16.7333; DAS A, 1988, P NATL ACAD SCI USA, V85, P2909, DOI 10.1073/pnas.85.9.2909; De Vos G, 1989, Mol Plant Microbe Interact, V2, P43, DOI 10.1094/MPMI-2-043; FROMM M, 1985, P NATL ACAD SCI USA, V82, P5824, DOI 10.1073/pnas.82.17.5824; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GIETL C, 1987, P NATL ACAD SCI USA, V84, P9006, DOI 10.1073/pnas.84.24.9006; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HERRERAESTRELLA A, 1988, EMBO J, V7, P4055, DOI 10.1002/j.1460-2075.1988.tb03299.x; HERRERAESTRELLA A, 1990, P NATL ACAD SCI USA, V87, P9534, DOI 10.1073/pnas.87.24.9534; HIRAYAMA T, 1988, MOL GEN GENET, V213, P229, DOI 10.1007/BF00339586; HOWARD E, 1990, UCLA SYM BI, V129, P1; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; JAYASWAL RK, 1987, J BACTERIOL, V169, P5035, DOI 10.1128/jb.169.11.5035-5045.1987; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STACHEL SE, 1987, EMBO J, V6, P857, DOI 10.1002/j.1460-2075.1987.tb04831.x; STACHEL SE, 1986, NATURE, V322, P706, DOI 10.1038/322706a0; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; STACHEL SE, 1989, NATURE, V340, P190, DOI 10.1038/340190a0; STECK TR, 1990, NUCLEIC ACIDS RES, V18, P6953, DOI 10.1093/nar/18.23.6953; THOMAS W, 1973, HDB PHOTOGRAPHIC SCI; WANG K, 1987, SCIENCE, V235, P587, DOI 10.1126/science.235.4788.587; WANG K, 1990, J BACTERIOL, V172, P4432, DOI 10.1128/jb.172.8.4432-4440.1990; WARD ER, 1988, SCIENCE, V242, P927, DOI 10.1126/science.242.4880.927; YANOFSKY MF, 1986, CELL, V47, P471, DOI 10.1016/0092-8674(86)90604-5; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; ZAMBRYSKI P, 1989, CELL, V56, P193, DOI 10.1016/0092-8674(89)90892-1	48	207	221	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					109	118		10.1016/0092-8674(92)90210-4	http://dx.doi.org/10.1016/0092-8674(92)90210-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732061				2022-12-28	WOS:A1992GZ58300013
J	KOUDELKA, GB; CARLSON, P				KOUDELKA, GB; CARLSON, P			DNA TWISTING AND THE EFFECTS OF NONCONTACTED BASES ON AFFINITY OF 434 OPERATOR FOR 434 REPRESSOR	NATURE			English	Article							TORSIONAL RIGIDITY; DEPENDENCE; RECOGNITION; RESOLUTION; PHAGE-434	THE bacteriophage 434 repressor regulates gene expression by binding with differing affinities to the six operator sites on the phage chromosome 1,2. The symmetrically arrayed outer eight base pairs (four in each half-site) of these 14-base-pair operators are highly conserved but the middle four bases are divergent 3. Although these four base pairs are not in contact with repressor 4,5, operators with A.T or T.A base pairs at these positions bind repressor more strongly than those bearing C.G or G.C 5, suggestiong that these bases are important for the repressor's ability to discriminate between operators. There is evidence that the central base pairs influence operator function by constraining the twisting and/or bending of DNA 5-7. Here we show that there is a relationship between the intrinsic twist of an operator, as determined by the sequence of its central bases, and its affinity for repressor; an operator with a lower affinity is undertwisted relative to an operator with higher affinity. In complex with repressor, the twist of both high- and low-affinity operators is the same. These results indicate that the intrinsic twist of DNA and its twisting flexibility both affect the affinity of 434 operator for repressor.			KOUDELKA, GB (corresponding author), SUNY BUFFALO,DEPT BIOL SCI,COOKE HALL,N CAMPUS,BUFFALO,NY 14260, USA.		Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; ANDERSON JE, 1987, NATURE, V326, P888; AUBLE DT, 1988, J MOL BIOL, V202, P471, DOI 10.1016/0022-2836(88)90279-3; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; DALMAWEISZHAUSZ DD, 1991, NUCLEIC ACIDS RES, V19, P611, DOI 10.1093/nar/19.3.611; DREW HR, 1990, BIOL ASPECTS DNA TOP, P1; FUJIMOTO BS, 1990, NATURE, V344, P175, DOI 10.1038/344175a0; HOGAN ME, 1987, NATURE, V329, P263, DOI 10.1038/329263a0; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Ptashne M., 1986, A GENETIC SWITCH; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; WHARTON RP, 1984, CELL, V38, P361, DOI 10.1016/0092-8674(84)90491-4; WHARTON RP, 1985, THESIS HARVARD U	22	77	78	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					89	91		10.1038/355089a0	http://dx.doi.org/10.1038/355089a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1731202				2022-12-28	WOS:A1992GY22800059
J	EBERLE, W; SANDER, C; KLAUS, W; SCHMIDT, B; VONFIGURA, K; PETERS, C				EBERLE, W; SANDER, C; KLAUS, W; SCHMIDT, B; VONFIGURA, K; PETERS, C			THE ESSENTIAL TYROSINE OF THE INTERNALIZATION SIGNAL IN LYSOSOMAL ACID-PHOSPHATASE IS PART OF A BETA-TURN	CELL			English	Article							TRANSFERRIN RECEPTOR INTERNALIZATION; DENSITY-LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; ENDOCYTOSIS; SEQUENCE; LOCALIZATION; RESOLUTION; TRYPSIN; PROTEIN	For rapid endocytosis lysosomal acid phosphatase requires a Tyr-containing signal in its cytoplasmic domain, as do cell surface receptors mediating endocytosis and clustering in coated pits. To determine the structure of the internalization signal an 18 amino acid peptide representing the cytoplasmic tail of lysosomal acid phosphatase was analyzed by two-dimensional nuclear magnetic resonance spectroscopy. Part of the peptide, 5-PPGY-8, forms a well-ordered beta-turn of type I in solution. Our result and data on the structure of the endocytosis signal of the low density lipoprotein receptor reported by Bansal and Gierasch in the accompanying paper represent experimental determinations of the three-dimensional structure of protein transport signals and suggest that the essential aromatic amino acid of internalization signals is recognized by a putative cytoplasmic receptor in the structural context of a tight turn.	GESELL BIOL FORSCH,O-3300 BRAUNSCHWEIG,GERMANY; UNIV GOTTINGEN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	EBERLE, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Sander, Chris/H-1452-2011	Sander, Chris/0000-0001-6059-6270				BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BRUNGER AT, 1987, METHODS CRYSTALLOGRA; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; SUMNER SCJ, 1990, J BIOMOL STRUCT DYN, V8, P687, DOI 10.1080/07391102.1990.10507836; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WRIGHT CS, 1987, J MOL BIOL, V194, P501, DOI 10.1016/0022-2836(87)90678-4	32	154	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1203	1209		10.1016/0092-8674(91)90296-B	http://dx.doi.org/10.1016/0092-8674(91)90296-B			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760845				2022-12-28	WOS:A1991GX16400018
J	BROCHIER, B; KIENY, MP; COSTY, F; COPPENS, P; BAUDUIN, B; LECOCQ, JP; LANGUET, B; CHAPPUIS, G; DESMETTRE, P; AFIADEMANYO, K; LIBOIS, R; PASTORET, PP				BROCHIER, B; KIENY, MP; COSTY, F; COPPENS, P; BAUDUIN, B; LECOCQ, JP; LANGUET, B; CHAPPUIS, G; DESMETTRE, P; AFIADEMANYO, K; LIBOIS, R; PASTORET, PP			LARGE-SCALE ERADICATION OF RABIES USING RECOMBINANT VACCINIA RABIES VACCINE	NATURE			English	Article							ORAL VACCINATION; FIELD TRIAL; VIRUS GLYCOPROTEIN; FOX RABIES; IMMUNIZATION; WILDLIFE; PROTECTION; EXPRESSION; EFFICACY; SAFETY	RABIES infection of domestic and wild animals is a serious problem throughout the world. The major disease vector in Europe is the red fox (Vulpes vulpes) and rabies control has focused on vaccinating and/or culling foxes. Culling has not been effective, and the distribution of live vaccine baits is the only appropriate method for the vaccination of wild foxes 1. Although some European countries have conducted field vaccination campaigns using attenuated rabies virus strains 2-5, their use has not been extensively approved because they retain pathogenicity for rodents and can revert to virulence 6,7. These strains cannot be used in North America because they are pathogenic for the striped skunk (Mephitis mephitis) 8 and are ineffective in the racoon (Procyon lotor) 9. We have constructed a recombinant vaccinia virus 10, VVTGgRAB, expressing the surface glycoprotein (G) of rabies virus (ERA strain) 11-13. The recombinant was a highly effective vaccine in experimental animals 11-13, in captive foxes 14,15 and in racoons 9. We report here the results of a large-scale campaign of fox vaccination in a 2,200 km2 region of southern Belgium, an area in which rabies is prevalent. After distribution, 81% of foxes inspected were positive for tetracycline, a biomarker included in the vaccine bait and, other than one rabid fox detected close to the periphery of the treated area, no case of rabies, either in foxes or in domestic livestock, has been reported in the area.	TRANSGENE SA,F-67000 STRASBOURG,FRANCE; PASTEUR INST BRABANT,DEPT RABIES,B-1180 BRUSSELS,BELGIUM; RHONE MERIEUX LAB IFFA,F-69342 LYONS,FRANCE; STATE UNIV LIEGE,FAC SCI,INST ZOOL,B-4020 LIEGE,BELGIUM	Transgene SA; University of Liege	BROCHIER, B (corresponding author), STATE UNIV LIEGE,FAC VET MED,DEPT VIROL,45 RUE VET,B-1070 BRUSSELS,BELGIUM.		Kieny, Marie-Paule/N-3914-2017; Kieny, Marie-Paule/Q-1238-2019	Kieny, Marie-Paule/0000-0002-5943-6488; 				ANDERSON RM, 1986, NATURE, V322, P304, DOI 10.1038/322304a0; ANDERSON RM, 1981, NATURE, V289, P765, DOI 10.1038/289765a0; BAER GM, 1975, NATURAL HIST RABIES, V2, P261; BALTAZAR RS, 1987, ANN MED VET, V131, P481; BLANCOU J, 1989, ANN RECH VET, V20, P195; BLANCOU J, 1986, NATURE, V322, P373, DOI 10.1038/322373a0; BROCHIER B, 1990, VACCINE, V8, P101, DOI 10.1016/0264-410X(90)90129-A; BROCHIER B, 1989, J WILDLIFE DIS, V25, P540, DOI 10.7589/0090-3558-25.4.540; BROCHIER B, 1988, VET REC, V123, P618; BROCHIER BM, 1988, VET MICROBIOL, V18, P103, DOI 10.1016/0378-1135(88)90055-7; BROCHIER BM, 1990, VET REC, V127, P165; DEAN DJ, 1974, LABORATORY TECHNIQUE, P75; DESMETTRE P, 1990, VET MICROBIOL, V23, P227, DOI 10.1016/0378-1135(90)90153-M; HARRIS S, 1986, J ANIM ECOL, V55, P575, DOI 10.2307/4740; KAPPELER A, 1988, VACCINATION CONTROL, P55; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; Leblois H., 1988, EUR Publication, Commission of the European Communities, P101; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; NEWMARK P, 1988, NATURE, V336, P416, DOI 10.1038/336416a0; PASTORET PP, 1988, VET REC, V123, P481, DOI 10.1136/vr.123.19.481; RUPPRECHT CE, 1986, P NATL ACAD SCI USA, V83, P7947, DOI 10.1073/pnas.83.20.7947; RUPPRECHT CE, 1990, J WILDLIFE DIS, V26, P99, DOI 10.7589/0090-3558-26.1.99; SCHNEIDER LG, 1983, TIERARZTL UMSCHAU, V38, P315; STECK F, 1982, ZBL VET MED B, V29, P372; THOMAS I, 1990, J GEN VIROL, V71, P37, DOI 10.1099/0022-1317-71-1-37; TOLSON ND, 1988, ARCH VIROL, V102, P297, DOI 10.1007/BF01310835; WANDELER AI, 1982, COMP IMMUNOL MICROB, V5, P173, DOI 10.1016/0147-9571(82)90032-7; WIKTOR TJ, 1984, P NATL ACAD SCI-BIOL, V81, P7194, DOI 10.1073/pnas.81.22.7194; WIKTOR TJ, 1985, ANN INST PASTEUR VIR, V136E, P405, DOI 10.1016/S0769-2617(85)80132-5; Wiktor TJ, 1988, APPLIED VIROLOGY RES, V1, P69; 1989, CONSULTATION REQUIRE	31	220	245	1	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					520	522		10.1038/354520a0	http://dx.doi.org/10.1038/354520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1758494	Green Submitted			2022-12-28	WOS:A1991GW75100013
J	POWIS, SJ; TOWNSEND, ARM; DEVERSON, EV; BASTIN, J; BUTCHER, GW; HOWARD, JC				POWIS, SJ; TOWNSEND, ARM; DEVERSON, EV; BASTIN, J; BUTCHER, GW; HOWARD, JC			RESTORATION OF ANTIGEN PRESENTATION TO THE MUTANT-CELL LINE RMA-S BY AN MHC-LINKED TRANSPORTER	NATURE			English	Article							CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; REGION; ASSOCIATION; PROTEINS; PEPTIDES; INVITRO; CHAINS; HEAVY	IN mammalian cells, short peptides derived from intracellular proteins are displayed on the cell membrane associated with class I molecules of the major histocompatibility complex (MHC). The surface presentation of class I-peptide complexes presumably alerts the immune system to intracellular viral protein synthesis. Peptides derived from the cytosol must reach the cisternae of the endoplasmic reticulum where they are required for the assembly of stable class I molecules 1-11, and it has been proposed that the Products of the two MHC-encoded ATP-binding cassette (ABC) transporter genes 12-15 function to deliver the peptides across the membrane of the endoplasmic reticulum. This idea is supported by experiments in which transfection of a human cell line defective in class I expression with a complementary DNA of one of these genes restored cell surface expression levels 16. Here we show that the complete phenotype of the mouse mutant cell line RMA-S, in which lack of surface expression of stable class I molecules correlates with an inability to present viral peptides originating in the Cytosol 6-10,17, is repaired by the cDNA of the other transporter gene. These results are consistent with the possibility that the two transporter polypeptides form a heterodimer.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND	University of Oxford	POWIS, SJ (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND.			Howard, Jonathan/0000-0003-2756-5143; Powis, Simon/0000-0003-4218-2984; Townsend, Alain/0000-0002-3702-0107				DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KOCH S, 1983, TRANSPLANTATION, V36, P177, DOI 10.1097/00007890-198308000-00013; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; PARHAM P, 1991, NATURE, V351, P271, DOI 10.1038/351271a0; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	27	355	363	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					528	531		10.1038/354528a0	http://dx.doi.org/10.1038/354528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1758495				2022-12-28	WOS:A1991GW75100016
J	AHMED, M; DAVISON, OW				AHMED, M; DAVISON, OW			SEVERE CYSTITIS ASSOCIATED WITH TIAPROFENIC ACID	BRITISH MEDICAL JOURNAL			English	Article									KETTERING & DIST GEN HOSP,UROL,KETTERING NN16 8UZ,NORTHANTS,ENGLAND									ANDRIOLE GL, 1986, J UROLOGY, V135, P44, DOI 10.1016/S0022-5347(17)45509-1; NAVADA T, 1986, UROL INT, V41, P457; SORKIN EM, 1985, DRUGS, V29, P208, DOI 10.2165/00003495-198529030-00002	3	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1376	1376		10.1136/bmj.303.6814.1376	http://dx.doi.org/10.1136/bmj.303.6814.1376			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760605	Bronze, Green Published			2022-12-28	WOS:A1991GU38400022
J	TAUXE, RV; BLAKE, PA				TAUXE, RV; BLAKE, PA			EPIDEMIC CHOLERA IN LATIN-AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VIBRIO-CHOLERAE; TRANSMISSION; PORTUGAL; SLUMS; RISK				TAUXE, RV (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ENTER DIS BRANCH, ATLANTA, GA 30333 USA.							Acra A., 1984, SOLAR DISINFECTION D; BAINE WB, 1974, LANCET, V2, P1370; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; BLAKE PA, 1977, AM J EPIDEMIOL, V105, P344, DOI 10.1093/oxfordjournals.aje.a112392; BLAKE PA, 1977, AM J EPIDEMIOL, V105, P337, DOI 10.1093/oxfordjournals.aje.a112391; CAMPBELLMCINTYRE R, 1979, LANCET, V1, P311; CLEMENS JD, 1989, J INFECT DIS, V159, P770, DOI 10.1093/infdis/159.4.770; CLEMENS JD, 1991, LANCET, V337, P883, DOI 10.1016/0140-6736(91)90207-6; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; DEB BC, 1982, INDIAN J MED RES, V76, P814; Feachem R, 1981, Trop Dis Bull, V78, P865; GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050; GOH KT, 1984, INT J EPIDEMIOL, V13, P210, DOI 10.1093/ije/13.2.210; HORNICK RB, 1972, MALARIA AMEBIASIS CH, V2, P225; HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983; JOHNSTON JM, 1983, NEW ENGL J MED, V309, P523, DOI 10.1056/NEJM198309013090903; KAPER JB, 1989, REV INFECT DIS, V11, pS568; LEVINE W C, 1991, Journal of Food Protection, V54, P71, DOI 10.4315/0362-028X-54.1.71; LOWRY PW, 1989, ARCH INTERN MED, V149, P2079, DOI 10.1001/archinte.149.9.2079; Mead GH., 1936, SOCIAL PSYCHOL SELEC; PARSONNET J, 1989, GASTRIC PEPTIC ULCER, P51; POLLITZER R, 1959, CHOLERA GENEVA, P373; STLOUIS ME, 1990, AM J EPIDEMIOL, V131, P719; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; WACHSMUTH IK, 1991, LANCET, V337, P1097; 1991, MMWR, V40, P108; 1991, MMWR, V40, P287; 1991, MMWR, V40, P258; 1991, MMWR, V40, P225	29	60	63	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1388	1390		10.1001/jama.267.10.1388	http://dx.doi.org/10.1001/jama.267.10.1388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740864				2022-12-28	WOS:A1992HG67800036
J	ATKIN, WS; MORSON, BC; CUZICK, J				ATKIN, WS; MORSON, BC; CUZICK, J			LONG-TERM RISK OF COLORECTAL-CANCER AFTER EXCISION OF RECTOSIGMOID ADENOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYPS; PROCTOSIGMOIDOSCOPY; NEOPLASMS; CARCINOMA	Background and Methods. Surveillance by repeated colonoscopy is currently recommended for patients with colorectal adenomas. We assessed the long-term risk of colorectal cancer after rigid-instrument sigmoidoscopy and polypectomy in 1618 patients with rectosigmoid adenomas (tumors of the rectum or distal sigmoid colon) who did not undergo surveillance. A total of 22,462 person-years of observation were accrued (mean, 14 years per patient). Results. The incidence of subsequent rectal cancer in these patients was similar to that in the general population (standardized incidence ratio, 1.2; 95 percent confidence interval, 0.7 to 2.1). Most rectal cancers developed in patients whose adenomas had been inadequately removed; the risk was very low after complete removal. The risk of subsequent colon cancer depended on the histologic type, size, and number of adenomas in the rectosigmoid. Among 842 patients with a rectosigmoid adenoma that was tubulovillous, villous, or large (greater-than-or-equal-to 1 cm), colon cancer developed in 31 patients. The standardized incidence ratio was 3.6 overall (95 percent confidence interval, 2.4 to 5.0) and 6.6 (95 percent confidence interval, 3.3 to 11.8) if there were multiple rectosigmoid adenomas. Among the remaining 776 patients with only small, tubular adenomas (whether single or multiple), colon cancer developed in only 4 patients. The standardized incidence ratio in this group was 0.5 (95 percent confidence interval, 0.1 to 1.3). Conclusions. Follow-up colonoscopic examinations may be warranted in patients with tubulovillous, villous, or large adenomas in the rectosigmoid, particularly if the adenomas are also multiple. In patients with only a single, small tubular adenoma that is only mildly or moderately dysplastic (43 percent of our series), however, surveillance may not be of value because the risk of cancer is so low.	IMPERIAL CANC RES FUND,DEPT MATH STAT & EPIDEMIOL,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; ST MARKS HOSP,DEPT PATHOL,LONDON EC1V 2PS,ENGLAND	Cancer Research UK; Imperial College London				Atkin, Wendy/0000-0001-9073-9658				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BRAHME F, 1974, DIS COLON RECTUM, V17, P166, DOI 10.1007/BF02588099; BRESLOW NE, 1987, IARC SCI PUBLICATION, V32; CASTRO AF, 1951, SURG GYNECOL OBSTET, V92, P164; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COLVERT JR, 1948, AM J MED SCI, V215, P24, DOI 10.1097/00000441-194801000-00004; COX DR, 1972, J R STAT SOC B, V34, P187; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FUNG CHK, 1970, AM J CLIN PATHOL, V53, P21; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; KONISHI F, 1982, J CLIN PATHOL, V35, P830, DOI 10.1136/jcp.35.8.830; LOFTI AM, 1986, MAYO CLIN P, V61, P337; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MORSON BC, 1976, INT HISTOLOGICAL CLA, V15; PRAGER ED, 1974, DIS COLON RECTUM, V17, P322, DOI 10.1007/BF02586974; QUAN SHQ, 1971, DIS COLON RECTUM, V14, P267, DOI 10.1007/BF02553199; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; SOUTHWOOD W F, 1962, Ann R Coll Surg Engl, V30, P23; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; THOMSON JPS, 1977, DIS COLON RECTUM, V20, P467, DOI 10.1007/BF02586582; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; WILKING N, 1986, CANCER, V57, P669, DOI 10.1002/1097-0142(19860201)57:3<669::AID-CNCR2820570345>3.0.CO;2-W; WILSON GS, 1955, AM J SURG, V90, P834, DOI 10.1016/0002-9610(55)90707-8; WINAWER SJ, 1986, FRONT GASTROINTEST R, V10, P216; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806	25	893	914	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					658	662		10.1056/NEJM199203053261002	http://dx.doi.org/10.1056/NEJM199203053261002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736104				2022-12-28	WOS:A1992HG11700002
J	OSHEA, EK; RUTKOWSKI, R; KIM, PS				OSHEA, EK; RUTKOWSKI, R; KIM, PS			MECHANISM OF SPECIFICITY IN THE FOS-JUN ONCOPROTEIN HETERODIMER	CELL			English	Article							LEUCINE ZIPPER; COILED-COIL; PROTEIN; COMPLEXES; ONCOGENE; AP-1; GENE	Fos and Jun, the protein products of the nuclear proto-oncogenes c-fos and c-jun, associate preferentially to form a heterodimer that binds to DNA and modulates transcription of a wide variety of genes in response to mitogenic stimuli. Both Fos and Jun contain a single leucine zipper region. Previous studies have shown that the leucine zippers of Fos and Jun are necessary and sufficient to mediate preferential heterodimer formation. The leucine zipper regions from Fos and Jun are also known to fold autonomously, most likely as two-stranded, parallel coiled coils. We show here that 8 amino acids from Fos and from Jun are sufficient to mediate preferential heterodimer formation in a background of the GCN4 leucine zipper sequence. Using pH titration and amino acid replacements, we also show that destabilization of the Fos homodimer by acidic residues provides a major thermodynamic driving force for preferential heterodimer formation.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	OSHEA, EK (corresponding author), WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [GM 44162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Cantor C.R., 1980, BIOPHYS CHEM; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRANZA BR, 1987, ONCOGENE, V1, P213; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1991, SCIENCE, V30, P5682; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183	24	413	439	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					699	708		10.1016/0092-8674(92)90145-3	http://dx.doi.org/10.1016/0092-8674(92)90145-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739975				2022-12-28	WOS:A1992HF44000010
J	ROTHBERG, KG; HEUSER, JE; DONZELL, WC; YING, YS; GLENNEY, JR; ANDERSON, RGW				ROTHBERG, KG; HEUSER, JE; DONZELL, WC; YING, YS; GLENNEY, JR; ANDERSON, RGW			CAVEOLIN, A PROTEIN-COMPONENT OF CAVEOLAE MEMBRANE COATS	CELL			English	Article							ROUS-SARCOMA VIRUS; ENDOTHELIAL PLASMALEMMAL VESICLES; LOW-DENSITY LIPOPROTEIN; CAPILLARY ENDOTHELIUM; SARCOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SMOOTH-MUSCLE; MA104 CELLS; RECEPTOR; SURFACE	Caveolae have been implicated in the transcytosis of macromolecules across endothelial cells and in the receptor-mediated uptake of 5-methyltetrahydrofolate. Structural studies indicate that caveolae are decorated on their cytoplasmic surface by a unique array of filaments or strands that form striated coatings. To understand how these nonclathrin-coated pits function, we performed structural analysis of the striated coat and searched for the molecular component(s) of the coat material. The coat cannot be removed by washing with high salt; however, exposure of membranes to cholesterol-binding drugs caused invaginated caveolae to flatten and the striated coat to disassemble. Antibodies directed against a 22 kd substrate for v-src tyrosine kinase in virus-transformed chick embryo fibroblasts decorated the filaments, suggesting that this molecule is a component of the coat. We have named the molecule caveolin. Caveolae represent a third type of coated membrane specialization that is involved in molecular transport.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; UNIV KENTUCKY, COLL MED, MARKEY CANC CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	Washington University (WUSTL); University of Kentucky	ROTHBERG, KG (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.		Eckhardt, Erik/G-1567-2010; Heuser, John/H-5940-2012		NIGMS NIH HHS [GM 29647, GM 43169] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647, R01GM043169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 1991, INFECT DIS HUMANS DY, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; BUNDGAARD M, 1983, MICROVASC RES, V25, P358, DOI 10.1016/0026-2862(83)90025-0; BUNDGAARD M, 1983, FED PROC, V42, P2425; BUNDGAARD M, 1979, P NATL ACAD SCI USA, V76, P6439, DOI 10.1073/pnas.76.12.6439; CLOUGH G, 1991, PROG BIOPHYS MOL BIO, V55, P47, DOI 10.1016/0079-6107(91)90011-G; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; IZUMI T, 1989, J ELECTRON MICROSC, V38, P47; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; NICOL A, 1987, EUR J CELL BIOL, V43, P348; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1961, CIRCULATION, V24, P368; PALADE GE, 1953, J APPL PHYS, V24, P1424; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU M, 1982, J CELL BIOL, V94, P406, DOI 10.1083/jcb.94.2.406; SIMIONESCU N, 1972, J CELL BIOL, V53, P365, DOI 10.1083/jcb.53.2.365; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SOMLYO AP, 1971, J CELL BIOL, V51, P722, DOI 10.1083/jcb.51.3.722; Steer C.J., 1991, INTRACELLULAR TRAFFI, P47; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VALNES K, 1985, J HISTOCHEM CYTOCHEM, V33, P755, DOI 10.1177/33.8.3926864; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	50	1883	1931	4	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					673	682		10.1016/0092-8674(92)90143-Z	http://dx.doi.org/10.1016/0092-8674(92)90143-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739974				2022-12-28	WOS:A1992HF44000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABELING AND PATIENT PACKAGE INSERT FOR TRIAZOLAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732641				2022-12-28	WOS:A1992HC48400006
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - ENVIRONMENTAL RADIATION - A CAUSE FOR CONCERN	BRITISH MEDICAL JOURNAL			English	Article							X-RAYS; NUCLEAR INSTALLATIONS; MORTALITY; CANCER; EMPLOYEES; LEUKEMIA											BEEBE GW, 1978, RADIAT RES, V75, P136; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BOWIE C, 1991, LANCET, V337, P409, DOI 10.1016/0140-6736(91)91177-V; BRANSBYZACHARY MAP, 1989, BRIT MED J, V298, P1294, DOI 10.1136/bmj.298.6683.1294; Caufield Catherine, 1989, MULTIPLE EXPOSURES C; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI P, 1987, STUDIES MED POPULATI, V51; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; ISHIMARU T, 1981, RERF1181 RAD EFF RES; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1977, THERAPEUTIC RADIOLOG, V123, P741; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; RON E, 1980, J NATL CANCER I, V65, P7; ROSCOE RJ, 1989, JAMA-J AM MED ASSOC, V262, P629, DOI 10.1001/jama.262.5.629; SHIMIZU Y, 1987, RAD EFFECTS RES F TE, V12, P1; SMITH PG, 1982, BRIT MED J, V284, P449, DOI 10.1136/bmj.284.6314.449; STAPHER FK, 1988, NRPBR215 NAT RAD PRO; STEWART A, 1970, LANCET, V1, P1185; Sumner D, 1990, Med War, V6, P112, DOI 10.1080/07488009008408915; SUMNER DJ, 1991, RAD RISKS EVALUATION; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; WALL BF, 1980, NRPBR105; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; YOSHIMOTO Y, 1990, JAMA-J AM MED ASSOC, V264, P596, DOI 10.1001/jama.264.5.596; YOSHIMOTO Y, 1990, RERF490 RAD EFF RES; 1991, DOCUMENTS NATIONAL R; 1988, HLTH RISKS RADON OTH; 1988, 2ND REPORT INVESTIGA; 1990, RECOMMENDATIONS ICRP; 1984, RADIOLOGICAL PROTECT, V57, P11; 1987, ICRP PUBLICATION 50, V17; 1990, REPORT ROYAL COLLEGE, P1; 1989, LIVING RAD; 1990, PATIENT DOSE REDUCTI, V1; 1990, HOUSEHOLDERS GUIDE R; 1986, REPORT HLTH MINISTER; 1984, INVESTIGATION POSSIB; 1990, DOCUMENTS NATIONAL R, P1; 1989, 3RD REPORT REPORT IN; 1978, RECOMMENDATIONS ICRP, P1	45	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					299	304		10.1136/bmj.304.6822.299	http://dx.doi.org/10.1136/bmj.304.6822.299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739833	Green Published, Bronze			2022-12-28	WOS:A1992HC70800026
J	BAIER, H; BONHOEFFER, F				BAIER, H; BONHOEFFER, F			AXON GUIDANCE BY GRADIENTS OF A TARGET-DERIVED COMPONENT	SCIENCE			English	Article							RETINAL AXONS; RETINOTECTAL MAP; TECTAL MEMBRANES; GROWTH; NEURITES; XENOPUS; REGENERATION; PROJECTION; AVOIDANCE; ADHESION	Spatial gradients of axon guiding molecules have long been suspected to provide positional and directional cues for retinal ganglion cell axons growing within the optic tectum. With the identification of a guiding activity from tectal cell membranes, it has become possible to investigate the potential physiological significance of molecular gradients for retinal growth cone behavior in vitro. A subset of retinal growth cones, those from the temporal half, were highly sensitive to small concentration changes of the guiding component. The degree of response was correlated with the strength of the gradient. These findings demonstrate that the neural growth cone can read gradients of surface-associated information.			BAIER, H (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,PHYS BIOL LAB,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							ADLER J, 1976, SCI AM, V234, P40, DOI 10.1038/scientificamerican0476-40; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; DAVIES JA, 1990, NEURON, V2, P11; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; FRASER SE, 1980, DEV BIOL, V79, P453, DOI 10.1016/0012-1606(80)90130-X; FUJISAWA H, 1987, J COMP NEUROL, V260, P127, DOI 10.1002/cne.902600110; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; GIERER A, 1987, DEVELOPMENT, V101, P479; GUNDERSEN RW, 1980, J CELL BIOL, V87, P546, DOI 10.1083/jcb.87.3.546; HALFTER W, 1981, NATURE, V292, P67, DOI 10.1038/292067a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HEACOCK AM, 1977, SCIENCE, V198, P64, DOI 10.1126/science.897684; HEFNER CD, 1990, SCIENCE, V247, P217; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; LETOURNEAU PC, 1983, TRENDS NEUROSCI, V6, P451, DOI 10.1016/0166-2236(83)90217-5; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MCNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509; OROURKE NA, 1986, DEV BIOL, V114, P265, DOI 10.1016/0012-1606(86)90191-0; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, COLD SPRING HARB SYM, V55, P351; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J COMP NEUROL, V267, P55, DOI 10.1002/cne.902670105; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	32	269	272	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					472	475		10.1126/science.1734526	http://dx.doi.org/10.1126/science.1734526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734526				2022-12-28	WOS:A1992HA59000044
J	SCHELLING, TC				SCHELLING, TC			ADDICTIVE DRUGS - THE CIGARETTE EXPERIENCE	SCIENCE			English	Article								Cigarettes are among the most addictive substances of abuse and by far the most deadly. In this country smokers know it and try to stop. Their success has been dramatic but partial and excruciatingly slow, and until recently quite uncoerced by government. Cigarettes and nicotine have characteristics distinct among addictive drugs, and some of these help explain why efforts to quit smoking are so often frustrated. Nicotine itself is the most interesting chemical in the treatment of addiction and, in some forms, can pose a dilemma: compromise by settling for pure nicotine indefinitely, or stay with cigarettes and keep trying to quit. Nicotine is not alone among addictive drugs in becoming increasingly identified with the poorer classes.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park	SCHELLING, TC (corresponding author), UNIV MARYLAND,DEPT ECON,COLLEGE PK,MD 20742, USA.							JOHNSTON LD, 1984, DRUGS AM HIGH SCH ST, P12; 1983, HLTH CONSEQUENCES SM; 1982, HLTH CONSEQUENCES SM; 1985, NEWS            1205; 1989, REDUCING HLTH CONSEQ, P465; 1982, HLTH CONSEQUENCES SM, P372; 1985, HLTH CONSEQUENCES SM, P25; 1984, HLTH CONSEQUENCES SM	8	46	49	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					430	433		10.1126/science.1734519	http://dx.doi.org/10.1126/science.1734519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734519				2022-12-28	WOS:A1992HA59000030
J	DAVIDENKO, JM; PERTSOV, AV; SALOMONSZ, R; BAXTER, W; JALIFE, J				DAVIDENKO, JM; PERTSOV, AV; SALOMONSZ, R; BAXTER, W; JALIFE, J			STATIONARY AND DRIFTING SPIRAL WAVES OF EXCITATION IN ISOLATED CARDIAC-MUSCLE	NATURE			English	Article							EXCITABLE MEDIA; CELLULAR AUTOMATON; TACHYCARDIA; MYOCARDIUM; MECHANISM; VORTEX	EXCITABLE media can support spiral waves rotating around an organizing centre 1-7. Spiral waves have been discovered in different types of autocatalytic chemical reactions 8,9 and in biological systems 10-12. The so-called 're-entrant excitation' of myocardial cells 13, causing the most dangerous cardiac arrhythmias, including ventricular tachycardia and fibrillation, could be the result of spiral waves 1,2. Here we use a potentiometric dye 14,15 in combination with CCD (charge-coupled device) imaging technology 16,17 to demonstrate spiral waves in the heart muscle. The spirals were elongated and the rotation period, T(s), was about 180 ms (3-5 times faster than normal heart rate). In most episodes, the spiral was anchored to small arteries or bands of connective tissue, and gave rise to stationary rotations. In some cases, the core drifted away from its site of origin and dissipated at a tissue border. Drift was associated with a Doppler shift in the local excitation period, T, with T ahead of the core being about 20% shorter than T behind the core.			DAVIDENKO, JM (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,750 E ADAMS ST,SYRACUSE,NY 13210, USA.		Jalife, Jose/L-4833-2015; Jalife, Jose/AAJ-9156-2021	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500				ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BURES J, 1983, J NEUROBIOL, V14, P353; CARDINAL R, 1984, CIRCULATION, V70, P136, DOI 10.1161/01.CIR.70.1.136; DAVIDENKO JM, 1990, P NATL ACAD SCI USA, V87, P8785, DOI 10.1073/pnas.87.22.8785; DELGADO C, 1990, CIRC RES, V67, P97, DOI 10.1161/01.RES.67.1.97; DOWNAR E, 1984, J AM COLL CARD, V7, P403; ERMAKOVA EA, 1986, BIOFIZIKA+, V31, P855; FAST VG, 1990, BIOFIZIKA+, V35, P478; FRAZIER DW, 1989, J CLIN INVEST, V83, P1039, DOI 10.1172/JCI113945; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; Gerisch G, 1968, Curr Top Dev Biol, V3, P157; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KEENER JP, 1986, SIAM J APPL MATH, V46, P1039, DOI 10.1137/0146062; KRINSKII VI, 1968, PROBL KIBERN, V20, P59; Krinsky V.I., 1984, SPRINGER SERIES SYNE, VVolume 28, P9; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LI T, 1985, J PHARMACOL EXP THER, V232, P688; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MULLER SC, 1985, SCIENCE, V230, P661, DOI 10.1126/science.230.4726.661; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; WIENER N, 1946, Arch Inst Cardiol Mex, V16, P205; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINREE AT, 1989, J THEOR BIOL, V1388, P353; YAMAGUCHI T, 1991, PHYSICA D, V49, P40, DOI 10.1016/0167-2789(91)90191-B; ZHABOTINSKY A. M, 1971, OSCILLATORY PROCESSE, VII, P279; ZYKOV VS, 1987, SIMULATION WAVE PROC, P93	27	988	1016	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					349	351		10.1038/355349a0	http://dx.doi.org/10.1038/355349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731248				2022-12-28	WOS:A1992HA59100067
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - DRINKING-WATER - DOUBTS ABOUT QUALITY	BRITISH MEDICAL JOURNAL			English	Article																		ANDERSSON Y, 1987, WATER SCI TECHNOL, V19, P575, DOI 10.2166/wst.1987.0237; COLLIER J, 1991, BRIT MED J, V302, P1289, DOI 10.1136/bmj.302.6788.1289; CROFT B, 1990, 1990 P HARW WAST MAN; FORMAN D, 1985, NATURE, V313, P620, DOI 10.1038/313620a0; HALL C, 1989, RUNNING WATER; LEE WR, 1990, BMJ-BRIT MED J, V301, P504, DOI 10.1136/bmj.301.6751.504; MARTYN CN, 1989, LANCET, V1, P59; PACKHAM RF, 1990, ANN S I WATER ENV MA; POCOCK SJ, 1980, BRIT MED J, V280, P1243, DOI 10.1136/bmj.280.6226.1243; WHEELER D, 1990, ANN S I WATER ENV MA; 1991, 1990 DEP ENV DRINK W; 1990, LONDONS DRINKING WAT; 1990, ANN REPORTS ACCOUNTI; 1990, WATER POLLUTION LOWE; 1990, REPORT CRYPTOSPORIDI; 1990, PESTICIDES CHEM HLTH; 1990, WATERFACTS	17	8	8	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					175	178		10.1136/bmj.304.6820.175	http://dx.doi.org/10.1136/bmj.304.6820.175			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737166	Bronze, Green Published			2022-12-28	WOS:A1992HA97900029
J	JOHANNES, CB; KAUFMAN, DW; ROSENBERG, L; PALMER, JR; STOLLEY, PD; LEWIS, JL; ZAUBER, AG; WARSHAUER, ME; SHAPIRO, S				JOHANNES, CB; KAUFMAN, DW; ROSENBERG, L; PALMER, JR; STOLLEY, PD; LEWIS, JL; ZAUBER, AG; WARSHAUER, ME; SHAPIRO, S			SIDE OF ORIGIN OF EPITHELIAL OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							OVULATION		UNIV PENN,SCH MED,DEPT MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNAECOL SERV,NEW YORK,NY 10021; NEW YORK HOSP,CANC CARE & RES PROGRAM,NEW YORK,NY 10021	University of Pennsylvania; Memorial Sloan Kettering Cancer Center; NewYork-Presbyterian Hospital	JOHANNES, CB (corresponding author), BOSTON UNIV,SCH MED,SLONE EPIDEMIOL UNIT,BROOKLINE,MA 02146, USA.			Rosenberg, Lynn/0000-0003-2760-2987; Kaufman, David/0000-0002-2150-5070; Palmer, Julie/0000-0002-6534-335X	NCI NIH HHS [5 R37 CA45762] Funding Source: Medline; FDA HHS [FD-U-000082, UO1 FD01222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CRUICKSHANK DJ, 1990, BMJ-BRIT MED J, V301, P524, DOI 10.1136/bmj.301.6751.524; FATHALLA MF, 1971, LANCET, V2, P163; POTASHNIK G, 1987, BRIT MED J, V294, P219, DOI 10.1136/bmj.294.6566.219; Slone D, 1977, EPIDEMIOLOGICAL EVAL, P59; SNEDECOR GW, 1967, STATISTICAL METHODS, P211	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					27	28		10.1136/bmj.304.6818.27	http://dx.doi.org/10.1136/bmj.304.6818.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734989	Bronze, Green Published			2022-12-28	WOS:A1992GY90900030
J	MALONEY, JV				MALONEY, JV			A CRITICAL ANALYSIS OF THE RESOURCE-BASED RELATIVE VALUE SCALE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE	Background. - There is a general perception that procedural medical services are reimbursed at an inappropriately greater rate than cognitive services. By congressional mandate, the Health Care Financing Administration (HCFA) has been directed to establish a Medicare fee schedule to shift funding under a budget-neutral assumption from procedural to cognitive services. To provide a rational basis for this change, Hsiao et al (Harvard-Hsiao) developed a resource-based relative value scale (RBRVS) that equates the value of a service to the resources necessary to generate the service. Methods. - Instead of focusing on relative values and fee schedules ("price-per-unit-service"), the present study employs the standard commercial/industrial method of determining reimbursement rate (income divided by hours of labor) for 15 medical and surgical specialties. Data from independent sources are used to determine income and hours of professional effort for each of the specialties studied. Harvard-Hsiao and HCFA predicted the percent change in income for each of the specialties under the initial RBRVS and the HCFA fee schedule. The predicted income was then employed in this study to recompute reimbursement rates under the newly proposed payment systems. Results: Current Payment System. - Average annual incomes for medical and surgical specialties are $124500 and $176600, respectively, a 42% difference (P = .03). Average weekly work hours (nominal hours, as adjusted for overtime) for medical and surgical specialties are 70.6 and 87.8, respectively (P = .005). Average hourly reimbursement rates for medical ($33.90) and surgical ($38.80) specialties are not substantially different (P, not significant). The difference in annual income is explained by the 17.2 hours per week of additional work hours by surgeons. The erroneous perception that procedurists are reimbursed at a higher rate than cognitive practitioners likely arises from differences in billing methods by which surgeons shift charges for cognitive work hours to the 1 8% of their time spent in the operating room. Results: Proposed RBRVS and HCFA Payment System. - The income of all specialties is equalized about a mean of $132500 (+/- $21 400 [1 SD]) by varying reimbursement rates in such a way that the effect of working hours is fully discounted. Reimbursement rates under the proposed payment system make no recognition of the hours of professional effort, postgraduate specialty training, or putative differences in the nature of the physician's work. Conclusion. - The RBRVS, and the HCFA fee schedule to the extent that it is based on that scale, are inappropriate bases for the reform of the physician reimbursement system.			MALONEY, JV (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV THORAC SURG,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.							CRANE M, 1988, MED EC SURG, V7, P30; GINSBURG PB, 1990, HEALTH AFFAIR, V9, P178, DOI 10.1377/hlthaff.9.1.178; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; HSIAO WC, 1988, 2 HARV U DEP HLTH S; HSIAO WC, 1988, 1 HARV U DEP HLTH S; LAMSON BG, 1977, 2ND P WORLD C MED IN, P1; LEVY JM, 1990, JAMA-J AM MED ASSOC, V264, P717; MALONEY JV, 1970, SURGERY, V68, P1; MCMAHON LF, 1990, AM J PUBLIC HEALTH, V80, P783; MENDENHALL RC, 1981, LCCCN8280671 RWJ F; OWENS A, 1989, MED ECON, V66, P131; 1986, INTERNIST, V27, P29; 1976, SURGERY US SUMMARY R, P1; 1991, FED REG         0605, V56, P25792; 1990, FED REG         0904, V55, P36177	15	25	25	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3453	3458						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744960				2022-12-28	WOS:A1991GV87800031
J	FAUSTMAN, D; LI, XP; LIN, HY; FU, YE; EISENBARTH, G; AVRUCH, J; GUO, J				FAUSTMAN, D; LI, XP; LIN, HY; FU, YE; EISENBARTH, G; AVRUCH, J; GUO, J			LINKAGE OF FAULTY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I TO AUTOIMMUNE DIABETES	SCIENCE			English	Article							ISLET-CELL ANTIBODIES; INSULIN-DEPENDENT DIABETICS; VIRAL PEPTIDES; PROTEIN-A; T-CELLS; MELLITUS; GENE; SUSCEPTIBILITY; ASSAY; MICE	Pancreatic islet cells are the targets of an autoimmune response in type I diabetes. In the nonobese diabetic (NOD) mouse model of autoimmune diabetes, expression of major histocompatibility complex (MHC) class I proteins was inversely correlated with diabetes; in this mouse a mutation in the MHC class II-linked gene for the putative MHC class I peptide transporter was also present. Mice deficient in MHC class I expression because they do not produce beta-2-microglobulin also developed late onset autoimmune diabetes. In cells from humans with type I diabetes expression of MHC class I was decreased; subsets of prediabetics categorized as most likely to become hyperglycemic also had low MHC class I. T cell responses to self antigens are faulty in diabetics. In sets of genetically identical twins that are discordant for diabetes, the defect appeared to reside with the antigen presenting cell. Thus, a lack of surface MHC class I protein is associated with autoimmune diabetes; the concomitant defect in antigen presentation may impair the development of self tolerance, which could result in autoimmune disease.	MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DIABET UNIT,IMMUNOBIOL LAB,BOSTON,MA 02129; JOSLIN DIABET CTR,BOSTON,MA 02115; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Joslin Diabetes Center, Inc.; Massachusetts Institute of Technology (MIT); Whitehead Institute	FAUSTMAN, D (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115, USA.							BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; COLMAN PG, 1988, DIABETES CARE, V11, P367, DOI 10.2337/diacare.11.4.367; ERLICH HA, 1990, DIABETES, V39, P96, DOI 10.2337/diabetes.39.1.96; FAUSTMAN D, 1989, DIABETES, V38, P1462, DOI 10.2337/diabetes.38.11.1462; FESTENSTEIN H, 1986, NATURE, V322, P64, DOI 10.1038/322064a0; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GLEICHMANN H, 1987, DIABETES, V36, P578, DOI 10.2337/diabetes.36.5.578; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MACCUISH AC, 1974, LANCET, V2, P1529; MAKINO S, 1985, EXP ANIM TOKYO, V34, P425, DOI 10.1538/expanim1978.34.4_425; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOREL PA, 1988, P NATL ACAD SCI USA, V85, P8111, DOI 10.1073/pnas.85.21.8111; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J, 1989, MOL CLONING LABORATO; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SRIKANTA S, 1985, DIABETES, V34, P300, DOI 10.2337/diabetes.34.3.300; SRIKANTA S, 1985, NEW ENGL J MED, V313, P461, DOI 10.1056/NEJM198508223130801; STERKERS G, 1988, P NATL ACAD SCI USA, V85, P6473, DOI 10.1073/pnas.85.17.6473; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TODD JA, 1989, NATURE, V338, P587, DOI 10.1038/338587a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; von Meyenburg H., 1940, SCHWEIZ MED WSCHR, V21, P554; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	37	191	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1756	1761		10.1126/science.1763324	http://dx.doi.org/10.1126/science.1763324			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763324				2022-12-28	WOS:A1991GW31600033
J	ALLISON, DJ; KENNEDY, A				ALLISON, DJ; KENNEDY, A			ABC OF VASCULAR DISEASES - PERIPHERAL ARTERIOVENOUS-MALFORMATIONS	BRITISH MEDICAL JOURNAL			English	Article											ALLISON, DJ (corresponding author), HAMMERSMITH HOSP,DIAGNOST RADIOL,LONDON W12 0HS,ENGLAND.								0	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1191	1194		10.1136/bmj.303.6811.1191	http://dx.doi.org/10.1136/bmj.303.6811.1191			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747622	Green Published, Bronze			2022-12-28	WOS:A1991GP48800032
J	DECOCK, KM; SELIK, RM; SORO, B; GAYLE, H; COLEBUNDERS, RL				DECOCK, KM; SELIK, RM; SORO, B; GAYLE, H; COLEBUNDERS, RL			FOR DEBATE - AIDS SURVEILLANCE IN AFRICA - A REAPPRAISAL OF CASE DEFINITIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL CASE-DEFINITION; HIV INFECTION; IVORY-COAST; TUBERCULOSIS; ABIDJAN; UGANDA; EPIDEMIC; KINSHASA; FOLLOW; ZAIRE		PROJET RETRO CI, ABIDJAN, COTE IVOIRE; INST NATL SANTE PUBL, ABIDJAN, COTE IVOIRE; ROYAL INST TROP MED, ANTWERP, BELGIUM	Institute of Tropical Medicine (ITM)	DECOCK, KM (corresponding author), CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, MAIL STOP E-50, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BRAUN MM, 1990, IN PRESS AM REV RESP; CHIN J, 1990, AIDS (London), V4, pS277, DOI 10.1097/00002030-199001001-00045; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; DONDERO TJ, 1988, PUBLIC HEALTH REP, V103, P213; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; HOWLETT WP, 1989, AIDS, V3, P289, DOI 10.1097/00002030-198905000-00007; LAST JM, 1989, DICT EPIDEMIOLOGY, P9; MAMUN KZ, 1989, AIDS, V3, P323, DOI 10.1097/00002030-198905000-00017; NUNN P, 1990, 6TH INT C AIDS SAN F; PETERMAN TA, 1990, AM J PUBLIC HEALTH, V80, P401, DOI 10.2105/AJPH.80.4.401; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SORO B, 1990, 6TH INT C AIDS SAN F; WABWIREMANGEN F, 1989, AIDS, V3, P462, DOI 10.1097/00002030-198907000-00013; WEYER J, 1987, INFECTION, V15, P413, DOI 10.1007/BF01647217; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1987, MMWR, V36, pS1; 1986, WKLY EPIDEMIOL REC, V61, P69; 1990, EPIDEMIOLOGICAL B, V4, P9; 1986, WKLY EPIDEMIOL REC, V61, P72; 1989, MMWR, V38, P561; 1988, MMWR, V37, pS1	32	38	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1991	303	6811					1185	1188		10.1136/bmj.303.6811.1185	http://dx.doi.org/10.1136/bmj.303.6811.1185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747620	Bronze, Green Published			2022-12-28	WOS:A1991GP48800030
J	HILLAN, KJ; JOHNSON, CP; MORTON, R				HILLAN, KJ; JOHNSON, CP; MORTON, R			EFFECT OF GENERAL-PRACTITIONER CONTRACT ON REFERRAL OF SPECIMENS FOR HISTOLOGICAL EXAMINATION	BRITISH MEDICAL JOURNAL			English	Article											HILLAN, KJ (corresponding author), SO GEN HOSP,DEPT PATHOL,GLASGOW G51 4TF,SCOTLAND.							BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; MILNE R, 1990, BRIT J GEN PRACT, V40, P175; WALL DW, 1987, FAM PRACT, V4, P322, DOI 10.1093/fampra/4.4.322; 1983, COST EFFECTIVENESS G	4	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1180	1180		10.1136/bmj.303.6811.1180	http://dx.doi.org/10.1136/bmj.303.6811.1180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747618	Green Published, Bronze			2022-12-28	WOS:A1991GP48800028
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - POPULATION - MORE THAN A NUMBERS GAME	BRITISH MEDICAL JOURNAL			English	Article																		BROWN LR, 1987, STATE WORLD 1987; EHRLICH PR, 1990, POPULATION EXPLOSION; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; POTTS M, 1990, LANCET, P1227; SMITH T, 1990, BRIT MED J, V301, P681, DOI 10.1136/bmj.301.6754.681; 1990, STATE WORLD 1990; 1991, STATE WORLD POPULATI; 1990, LANCET, P659; 1989, WORLD POPULATION TUR; 1988, ALMA ATA YEAR 2000 R; 1991, STATE WORLDS CHILDRE	11	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1194	1197		10.1136/bmj.303.6811.1194	http://dx.doi.org/10.1136/bmj.303.6811.1194			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747623	Green Published, Bronze			2022-12-28	WOS:A1991GP48800033
J	FAIRBURN, CG; PEVELER, RC; DAVIES, B; MANN, JI; MAYOU, RA				FAIRBURN, CG; PEVELER, RC; DAVIES, B; MANN, JI; MAYOU, RA			EATING DISORDERS IN YOUNG-ADULTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS - A CONTROLLED-STUDY	BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA; BULIMIA-NERVOSA; WOMEN; ADOLESCENTS; ATTITUDES; VALIDITY	Objective-To determine the prevalence of clinical eating disorders and lesser degrees of disturbed eating in young adults with insulin dependent diabetes and a matched sample of non-diabetic female controls. Design-Cross sectional survey of eating habits and attitudes in diabetic and non-diabetic subjects. Setting-Outpatient clinic catering for young adults with diabetes; community sample of non-diabetic women drawn from the lists of two general practices. Subjects-100 patients with insulin dependent diabetes (54 women and 46 men) aged 17-25 and 67 non-diabetic women of the same age. Main outcome measures - Eating habits and eating disorder psychopathology were assessed by standardised research interview adapted for the assessment of patients with diabetes (eating disorder examination). Glycaemic control was assessed by glycated haemoglobin assay. Results-In both non-diabetic and diabetic women disturbed eating was common, and in diabetic women the degree of disturbance was related to control of glycaemia. Twenty of the diabetic women (37%) had omitted or underused insulin to influence their weight. This behaviour was not restricted to those with a clinical eating disorder. None of the men showed any features of eating disorders, and none had misused insulin to influence their weight. Conclusions - There was no evidence that clinical eating disorders are more prevalent in young women with diabetes than in non-diabetic women. Nevertheless, disturbed eating is common and is associated with poor control of glycaemia, and the misuse of insulin to influence body weight is also common in young women with diabetes.			FAIRBURN, CG (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.		Fairburn, Christopher/AAG-6234-2019; Fairburn, Christopher/AAM-9792-2020	Fairburn, Christopher/0000-0002-9673-9795	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COOPER Z, 1989, BRIT J PSYCHIAT, V154, P807, DOI 10.1192/bjp.154.6.807; COOPER Z, 1987, INT J EAT DISORDER, V6, P1, DOI 10.1002/1098-108X(198701)6:1<1::AID-EAT2260060102>3.0.CO;2-9; FAIRBURN CG, 1980, BRIT MED J, V280, P1167, DOI 10.1136/bmj.280.6224.1167-a; FAIRBURN CG, 1990, AM J PSYCHIAT, V147, P401; FLEISS JL, 1987, DIAGNOSTIC STATISTIC; GARNER DM, 1982, PSYCHOL MED, V12, P871, DOI 10.1017/S0033291700049163; HILLARD JR, 1984, PSYCHIAT CLIN N AM, V7, P367; Hsu L. K. G., 1990, EATING DISORDERS; HUDSON JI, 1985, J CLIN PSYCHIAT, V46, P88; KAMINER Y, 1989, PSYCHOSOMATICS, V30, P19, DOI 10.1016/S0033-3182(89)72313-6; LAGRECA AM, 1987, DIABETES CARE, V10, P659; MAYOU RA, IN PRESS PSYCHOL MED; NATHAN DM, 1984, NEW ENGL J MED, V310, P341; PEVELER RC, 1989, BEHAV RES THER, V27, P95, DOI 10.1016/0005-7967(89)90125-3; PEVELER RC, IN PRESS INT J EATIN; ROBERTSON P, 1990, J PSYCHOSOM RES, V34, P535, DOI 10.1016/0022-3999(90)90028-3; RODIN GM, 1985, J PSYCHIAT RES, V19, P381, DOI 10.1016/0022-3956(85)90044-5; ROSEN JC, 1990, INT J EAT DISORDER, V9, P519, DOI 10.1002/1098-108X(199009)9:5&lt;519::AID-EAT2260090507&gt;3.0.CO;2-K; ROSMARK B, 1986, J CLIN PSYCHIAT, V47, P547; STEEL JM, 1987, BRIT MED J, V294, P859, DOI 10.1136/bmj.294.6576.859; STEEL JM, 1989, BRIT J PSYCHIAT, V155, P515, DOI 10.1192/bjp.155.4.515; SZMUKLER GI, 1984, J PSYCHOSOM RES, V28, P365, DOI 10.1016/0022-3999(84)90067-9; SZMUKLER GI, 1983, BRIT J PSYCHIAT, V142, P305, DOI 10.1192/bjp.142.3.305; WILSON GT, 1989, INT J EAT DISORDER, V8, P173; WING RR, 1986, DIABETES CARE, V9, P162, DOI 10.2337/diacare.9.2.162	25	124	126	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					17	20		10.1136/bmj.303.6793.17	http://dx.doi.org/10.1136/bmj.303.6793.17			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FW128	1781827	Green Published, Bronze			2022-12-28	WOS:A1991FW12800019
J	ESLER, M; DUDLEY, F; JENNINGS, G; DEBINSKI, H; LAMBERT, G; JONES, P; CROTTY, B; COLMAN, J; WILLETT, I				ESLER, M; DUDLEY, F; JENNINGS, G; DEBINSKI, H; LAMBERT, G; JONES, P; CROTTY, B; COLMAN, J; WILLETT, I			INCREASED SYMPATHETIC NERVOUS ACTIVITY AND THE EFFECTS OF ITS INHIBITION WITH CLONIDINE IN ALCOHOLIC CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						SYMPATHETIC NERVOUS SYSTEM; CLONIDINE; LIVER CIRRHOSIS; HYPERTENSION; NOREPINEPHRINE	PLASMA NOREPINEPHRINE; SYSTEM ACTIVITY; DECOMPENSATED CIRRHOSIS; WATER-EXCRETION; SODIUM; RELEASE; HUMANS; PRESSURE; LIVER; DOG	Objective: To study disturbances in sympathetic nervous system function in patients with alcoholic cirrhosis and the effect of clonidine on such disturbances. Design: Cross-sectional physiologic and neurochemical evaluation of patients with cirrhosis and of healthy controls; an uncontrolled trial of intravenous clonidine in the cirrhotic patients. Patients: Forty-four hospitalized patients with biopsy-proven alcoholic cirrhosis and 31 healthy controls. Interventions: Intravenous clonidine. Main Outcome Measures: Radiotracer-derived measures of norepinephrine release to plasma, central hemodynamics, wedge hepatic vein pressure, and measures of renal function. Main Results: In patients with cirrhosis, clonidine reduced previously elevated norepinephrine overflow rates for the whole body, kidneys, and hepatomesenteric circulation. This sympathetic inhibition was accompanied by the following potentially clinically beneficial effects: the lowering of renal vascular resistance (median reduction, 24%; 95% CI, 14% to 31%), the elevation of glomerular filtration rate (median increase, 27%; CI, 14% to 39%), and the reduction of portal venous pressure (median reduction, 25%; CI, 18% to 32%). The norepinephrine and hemodynamic responses to graded clonidine dosing (1, 2, and 3-mu-g/kg body weight intravenously) indicated that the sympathetic outflow to the hepatomesenteric circulation was more sensitive to pharmacologic suppression with clonidine than was the sympathetic outflow to the systemic circulation. Conclusions: The sympathetic nerves to the kidneys, heart, and hepatomesenteric circulation are stimulated in patients with cirrhosis. Clonidine inhibits these activated sympathetic outflows differentially, which could possibly provide a basis for the selective pharmacologic treatment of portal hypertension in patients with cirrhosis.	ALFRED HOSP, GASTROENTEROL SERV, PRAHRAN, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health	ESLER, M (corresponding author), BAKER MED RES INST, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA.		Jennings, Garry/B-3914-2009; Lambert, Gavin/Q-4869-2017; Lambert, Gavin W/E-7384-2010	Lambert, Gavin/0000-0003-0315-645X; Lambert, Gavin W/0000-0003-0315-645X; Jennings, Garry/0000-0002-7865-5483				ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x; BETTER OS, 1983, KIDNEY INT, V23, P303, DOI 10.1038/ki.1983.20; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BOYER TD, 1977, GASTROENTEROLOGY, V72, P584; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DANCY M, 1985, LANCET, V1, P1122; DIBONA GF, 1977, AM J PHYSIOL, V233, pF73, DOI 10.1152/ajprenal.1977.233.2.F73; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; EISENHOFER G, 1988, J AUTONOM NERV SYST, V24, P1, DOI 10.1016/0165-1838(88)90130-0; EISENHOFER G, ENDOCRINOLOGY METABO, V24, pE505; EPSTEIN M, 1979, GASTROENTEROLOGY, V76, P622; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; ESLER M, 1982, CLIN SCI, V63, pS285, DOI 10.1042/cs063285s; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; ESLER M, 1984, J AUTONOM NERV SYST, V11, P125, DOI 10.1016/0165-1838(84)90071-7; ESLER M, 1988, PROGR CATECHOLAMIN C, P95; FLORAS JS, 1991, ANN INTERN MED, V114, P373, DOI 10.7326/0003-4819-114-5-373; FRIBERG P, 1990, HYPERTENSION, V16, P121, DOI 10.1161/01.HYP.16.2.121; GORESKY CA, 1989, AM J PHYSIOL, V256, pG107, DOI 10.1152/ajpgi.1989.256.1.G107; GREENWAY CV, 1971, PHYSIOL REV, V51, P23, DOI 10.1152/physrev.1971.51.1.23; HAUSLER G, 1978, N-S ARCH PHARMACOL, V295, P191; HAVEL PJ, 1988, J CLIN INVEST, V82, P1538, DOI 10.1172/JCI113763; HENRIKSEN JH, 1989, AM J PHYSIOL, V257, pE743, DOI 10.1152/ajpendo.1989.257.5.E743; HENRIKSEN JH, 1987, GUT, V28, P1637, DOI 10.1136/gut.28.12.1637; HENRIKSEN JH, 1984, GUT, V25, P1034, DOI 10.1136/gut.25.10.1034; HENRIKSEN JH, 1981, CLIN PHYSIOL, V1, P293, DOI 10.1111/j.1475-097X.1981.tb00898.x; HORTNAGL H, 1984, LANCET, V1, P480; KIOSWKI W, 1985, J CARDIOVASC PHAR S6, V7, P144; MAEKAWA K, 1984, CIRCULATION, V70, P908, DOI 10.1161/01.CIR.70.5.908; MEREDITH IT, 1991, NEW ENGL J MED, V325, P618, DOI 10.1056/NEJM199108293250905; NICHOLLS KM, 1985, CIRC RES, V56, P457, DOI 10.1161/01.RES.56.3.457; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SCHMITT H., 1967, EUR J PHARMACOL, V2, P147, DOI 10.1016/0014-2999(67)90041-6; SHERLOCK S, 1975, DISEASES LIVER BILIA, P66; TSYBENKO VA, 1991, J AUTONOM NERV SYST, V33, P255, DOI 10.1016/0165-1838(91)90026-Y; WILLETT I, 1985, J HEPATOL, V1, P639, DOI 10.1016/S0168-8278(85)80007-6; WILLETT IR, 1986, LANCET, V2, P939; YAMAGUCHI N, 1980, CAN J PHYSIOL PHARM, V58, P1347, DOI 10.1139/y80-204; ZOLLER RP, 1972, J CLIN INVEST, V51, P2967, DOI 10.1172/JCI107121	41	97	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					446	455		10.7326/0003-4819-116-6-446	http://dx.doi.org/10.7326/0003-4819-116-6-446			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739234				2022-12-28	WOS:A1992HJ59800003
J	BIRD, H				BIRD, H			AN AFFAIR OF THE HEART	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					487	488		10.1056/NEJM199202133260712	http://dx.doi.org/10.1056/NEJM199202133260712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732777				2022-12-28	WOS:A1992HD16400012
J	TAYLOR, D				TAYLOR, D			MEDICINE IN EUROPE - PRESCRIBING IN EUROPE - FORCES FOR CHANGE .8.	BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, D (corresponding author), KINGS FUND INST,HLTH POLICY ANAL,LONDON NW1 7NF,ENGLAND.							BURSTALL ML, 1990, 1992 REGULATION PHAR; DIENER F, 1990, PHARM ZEITUNG, V40, P2631; GRIFFIN JP, 1991, J ROY COLL PHYS LOND, V25, P44; OBRIEN B, 1984, PATTERNS EUROPEAN DI; Payer Lynn, 1989, MED CULTURE; SAUER F, 1990, EUROPEAN COMMUNITY P; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; SMITH T, 1985, BRIT MED J, V290, P532, DOI 10.1136/bmj.290.6467.532; Taylor D.G., 1990, MED NHS EUROPE; THOMAS LG, 1989, SPARE ROD SPOIL IND; TROSS J, 1991, SCRIP, V629, P4; 1991, IMPLICATIONS MED DEV; 1991, LANCET, V337, P1571; 1990, HLTH CARE SYSTEMS TR; 1991, PHARMA PIPELINES; 1990, PHARMA FACTS FIGURES; 1991, FINANCIAL TIMES PHAR, V157, P2	17	16	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					239	242		10.1136/bmj.304.6821.239	http://dx.doi.org/10.1136/bmj.304.6821.239			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739801	Green Published, Bronze			2022-12-28	WOS:A1992HA98000030
J	WILSON, A; MCDONALD, P; HAYES, L; COONEY, J				WILSON, A; MCDONALD, P; HAYES, L; COONEY, J			HEALTH PROMOTION IN THE GENERAL-PRACTICE CONSULTATION - A MINUTE MAKES A DIFFERENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TIME CONSTRAINT; PRACTITIONERS; LENGTH; CARE	Objective - To see whether extending appointment length from seven and a half minutes or less to 10 minutes per patient would increase health promotion in general practice consultations. Design - Controlled trial of 10 minute appointments. Consultations were compared with control surgeries in which the same doctors booked patients at their normal rate (median six minutes per patient). Setting - 10 general practices in Nottinghamshire. Subjects - 16 general practitioners were recruited. Entry criteria were a booking rate of eight or more patients an hour, a wish for longer consultations, and plans to increase appointment length. Main outcome measures - Duration of consultations; recording of blood pressure, weight, and cervical cytology in the medical record; recording of advice about smoking, alcohol, diet, exercise, and immunisation in the medical record; reporting of the above activities by patients. Results - Mean consultation times were 8.25 minutes in the experimental sessions and 7.04 and 7.16 minutes in the control sessions. Recording of blood pressure, smoking, alcohol consumption, and advice about immunisation was significantly more frequent in the experimental sessions, and the proportion of consultations in which one or more items of health education were recorded in the medical notes increased by an average of over 6% in these sessions. Patients more often reported discussion of smoking and alcohol consumption and coverage of previous health problems in the experimental sessions. There was little change in discussion of exercise, diet, and weight or cervical cytology activity. Conclusions - Shortage of time is a major factor in general practitioners' failure to realise their potential in health promotion. General practice should be organised so that doctors can run 10 minute appointment sessions.	QUEENS MED CTR, SCH MED, DEPT GEN PRACTICE, NOTTINGHAM NG7 2UH, ENGLAND	University of Nottingham								Boulton M G, 1983, Health Educ J, V42, P57, DOI 10.1177/001789698304200211; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; FLEMING DM, 1985, BRIT MED J, V291, P869, DOI 10.1136/bmj.291.6499.869; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; MORRELL DC, 1987, BMJ-BRIT MED J, V294, P161, DOI 10.1136/bmj.294.6565.161; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; RIDSDALE L, 1989, J ROY COLL GEN PRACT, V39, P488; ROLAND MO, 1986, BRIT MED J, V292, P874, DOI 10.1136/bmj.292.6524.874; Siegel S., 1988, NONPARAMETRIC STAT B; Stott N C, 1979, J R Coll Gen Pract, V29, P201; STOTT NCH, 1983, PRIMARY HLTH CARE BR; Tones K., 1985, J I HLTH ED, V23, P16; WALLACE PG, 1987, BRIT MED J, V294, P940, DOI 10.1136/bmj.294.6577.940; WILSON A, 1991, BRIT J GEN PRACT, V41, P184; WILSON A, 1989, J ROY COLL GEN PRACT, V39, P24; WILSON AD, 1985, BRIT MED J, V290, P1322, DOI 10.1136/bmj.290.6478.1322; 1989, GENERAL PRACTICE NAT; 1981, HLTH PREVENTION PRIM; 1978, 1978 INT C PRIM HLTH	21	69	71	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1992	304	6821					227	230		10.1136/bmj.304.6821.227	http://dx.doi.org/10.1136/bmj.304.6821.227			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739798	Green Published, Bronze			2022-12-28	WOS:A1992HA98000027
J	URBACH, E; ROBERTSON, DL; CHISHOLM, SW				URBACH, E; ROBERTSON, DL; CHISHOLM, SW			MULTIPLE EVOLUTIONARY ORIGINS OF PROCHLOROPHYTES WITHIN THE CYANOBACTERIAL RADIATION	NATURE			English	Article							PROCHLOROTHRIX-HOLLANDICA; GREEN CHLOROPLASTS	THE taxonomic group Prochlorales (Lewin 1977) Burger-Wiersma, Stal and Mur 1989 was established to accommodate a set of prokaryotic oxygenic phototrophs which, like plant, green algal and euglenoid chloroplasts, contain chlorophyll b instead of phycobiliproteins. Prochlorophytes were originally proposed (with concomitant scepticism 1-3) to be a monophyletic group sharing a common ancestry with these 'green' chloroplasts 4-6. Results from molecular sequence phylogenies, however, have suggested that ProchlorothriX hollandica 7 is not on a lineage that leads to plastids 8-12. Our results from 16S ribosomal RNA sequence comparisons, which include new sequences from the marine picoplankter Prochlorococcus marinus 13,14 and the Lissoclinum patella symbiont Prochloron sp. 15, indicate that prochlorophytes are polyphyletic within the cyanobacterial radiation, and suggest that none of the known species is specifically related to chloroplasts. This implies that the three prochlorophytes and the green chloroplast ancestor acquired chlorophyll b and its associated structural proteins in convergent evolutionary events. We report further that the 16S rRNA gene sequence from Prochlorococcus is very similar to those of open ocean Synechococcus strains (marine cluster A (ref. 16)), and to a family of 16S rRNA genes shotgun-cloned from plankton in the north Atlantic and Pacific Oceans 17-19.	UNIV CHICAGO, DEPT MOLEC GENET & CELLULAR BIOL, CHICAGO, IL 60637 USA	University of Chicago	URBACH, E (corresponding author), MIT, RALPH M PARSONS LAB, 48-425, CAMBRIDGE, MA 02139 USA.		Robertson, Deborah/AAF-2512-2020	Chisholm, Sallie/0000-0003-1480-2445				BRITSCHGI TB, 1991, APPL ENVIRON MICROB, V57, P1707, DOI 10.1128/AEM.57.6.1707-1713.1991; BURGERWIERSMA T, 1989, INT J SYST BACTERIOL, V39, P250, DOI 10.1099/00207713-39-3-250; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; CHISHOLM SW, IN PRESS ARCH MICROB; DOUGLAS SE, 1991, J MOL EVOL, V33, P267, DOI 10.1007/BF02100678; DZELZKALNS VA, 1988, PLANT MOL BIOL PRACT, P277; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; GOERICKE R, IN PRESS LIMNOL OCEA; JUKES T H, 1969, P21; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; Krieg NR, 1989, BERGEYS MANUAL SYSTE, V3, P1728; LEWIN R A, 1977, Phycologia, V16, P217, DOI 10.2216/i0031-8884-16-2-217.1; LEWIN RA, 1975, NATURE, V256, P735, DOI 10.1038/256735a0; LEWIN RA, 1981, ANN NY ACAD SCI, V361, P325, DOI 10.1111/j.1749-6632.1981.tb46528.x; Lewin RA, 1989, PROCHLORON MICROBIAL; Margulis L., 1993, SYMBIOSIS CELL EVOLU; MORDEN CW, 1989, NATURE, V339, P400, DOI 10.1038/339400a0; MORDEN CW, 1989, NATURE, V337, P382, DOI 10.1038/337382a0; MORDEN CW, 1991, J MOL EVOL, V32, P379, DOI 10.1007/BF02101278; OHYAMA K, 1986, PL MOL BIOL REP, V4, P148; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSON RJ, 1990, DEEP-SEA RES, V37, P1033, DOI 10.1016/0198-0149(90)90109-9; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT TM, 1991, J BACTERIOL, V173, P4371, DOI 10.1128/JB.173.14.4371-4378.1991; SWIFT H, 1991, SYMBIOSIS, V10, P95; SWOFFORD DL, 1989, PAUP VERSION 30; TOMIOKA N, 1983, MOL GEN GENET, V191, P46, DOI 10.1007/BF00330888; TURNER S, 1989, NATURE, V337, P380, DOI 10.1038/337380a0; VANVALEN LM, 1980, NATURE, V287, P248, DOI 10.1038/287248a0; WHITTON BA, 1982, BIOL CYANOBACTERIA, P1; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	35	233	241	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					267	270		10.1038/355267a0	http://dx.doi.org/10.1038/355267a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731225				2022-12-28	WOS:A1992GZ69400073
J	SELLAR, PW; JOHNSTON, PB				SELLAR, PW; JOHNSTON, PB			OCULAR INJURIES DUE TO EXPLODING BOTTLES OF CARBONATED DRINKS	BRITISH MEDICAL JOURNAL			English	Article											SELLAR, PW (corresponding author), ROYAL VICTORIA HOSP,DEPT OPHTHALMOL,BELFAST BT12 6BA,NORTH IRELAND.							ALSALEM M, 1984, BRIT J OPHTHALMOL, V68, P281, DOI 10.1136/bjo.68.4.281; ARCHER D, 1967, LANCET, V2, P487; AVISAR R, 1978, HAREFUAH, V95, P69; Gupta A K, 1982, Indian J Ophthalmol, V30, P47; GUPTA AK, 1980, J PEDIAT OPHTH STRAB, V17, P394; KOVAL R, 1988, ARCH OPHTHALMOL-CHIC, V106, P776, DOI 10.1001/archopht.1988.01060130846037; MONDINO BJ, 1978, ARCH OPHTHALMOL-CHIC, V96, P2040; MOREIRA CA, 1988, ARCH OPHTHALMOL-CHIC, V106, P781; OFFUTT RL, 1974, ANN OPHTHALMOL, V6, P357; WAIKHOM JS, 1979, ARCH OPHTHALMOL-CHIC, V97, P975	10	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					176	177		10.1136/bmj.303.6795.176	http://dx.doi.org/10.1136/bmj.303.6795.176			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1789827	Green Published, Bronze			2022-12-28	WOS:A1991FX57800030
J	KASLOW, RA				KASLOW, RA			CURRENT PERSPECTIVE ON LYME BORRELIOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHEMA MIGRANS BORRELIOSIS; DISEASE SPIROCHETE; MANIFESTATIONS; ABNORMALITIES; BURGDORFERI				KASLOW, RA (corresponding author), NIAID, DIV MICROBIOL & INFECT DIS, EPIDEMIOL & BIOMETRY BRANCH, BETHESDA, MD 20892 USA.							ACKERMANN R, 1988, ANN NY ACAD SCI, V539, P16, DOI 10.1111/j.1749-6632.1988.tb31834.x; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; DAMROW T, 1989, WESTERN J MED, V150, P580; DORWARD DW, 1991, J CLIN MICROBIOL, V29, P1162, DOI 10.1128/JCM.29.6.1162-1170.1991; DUFFY J, 1990, ANN ALLERGY, V65, P1; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; JOHNSON RC, 1987, ANTIMICROB AGENTS CH, V31, P164, DOI 10.1128/AAC.31.2.164; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MARKOWITZ LE, 1986, JAMA-J AM MED ASSOC, V255, P3394, DOI 10.1001/jama.255.24.3394; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; RUBERTI G, 1991, HUM IMMUNOL, V31, P20, DOI 10.1016/0198-8859(91)90044-A; SCHMID GP, 1985, REV INFECT DIS, V7, P41; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHAPIRO E, 1990, OCT INT C ANT AG CHE; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1985, ANN INTERN MED, V103, P382, DOI 10.7326/0003-4819-103-3-382; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; 1990, WIS EPIDEMIOL B, V13, P1; 1989, MMWR, V38, P668; 1990, MMWR, V39, P397	26	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1381	1383						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740862				2022-12-28	WOS:A1992HG67800034
J	WINTERS, HA; NOTARFRANCESCO, V; BROMBERG, K; RAWSTROM, SA; VETRANO, J; PREGO, V; KUAN, J; RAUFMAN, JP				WINTERS, HA; NOTARFRANCESCO, V; BROMBERG, K; RAWSTROM, SA; VETRANO, J; PREGO, V; KUAN, J; RAUFMAN, JP			GASTRIC SYPHILIS - 5 RECENT CASES AND A REVIEW OF THE LITERATURE	ANNALS OF INTERNAL MEDICINE			English	Review						SYPHILIS; GASTRIC MUCOSA; ABDOMINAL PAIN; STOMACH ULCER; SEXUALLY TRANSMITTED DISEASES; HEMORRHAGE, GASTROINTESTINAL	HUMAN-IMMUNODEFICIENCY-VIRUS; SECONDARY SYPHILIS; BIOPSY SPECIMEN; DIAGNOSIS; MANIFESTATION; GASTROPATHY; TREPONEMA; INFECTION	Objective: To describe five cases of early syphilis with gastric involvement and to review the literature pertaining to this disorder. Data Identification: Five patients were diagnosed with gastric syphilis at Kings County Hospital and the Brooklyn Veterans Affairs Hospital between 1987 and 1990. English-language articles pertaining to gastric syphilis were identified by searching MEDLINE and by manually reviewing bibliographies of retrieved articles. Study Selection: Sources containing information pertinent to the clinical manifestations and diagnosis of gastric syphilis were selected. Data Synthesis: The most common clinical manifestations of gastric syphilis are abdominal pain, vomiting, and weight loss. Endoscopic findings in the stomach range from minimal nodularity and erythema to deep ulceration. Complications of gastric syphilis include hemorrhage, gastric outlet obstruction, and perforation. The diagnosis can be confirmed by serologic testing and by demonstration of spirochetes on silver and immunofluorescent stains of gastric mucosal biopsy specimens. Response to treatment is usually prompt and complete. Conclusions: The current syphilis epidemic will likely result in an increased incidence of gastric syphilis. Unless syphilis is considered as a cause of gastric mucosal inflammation and ulceration, misdiagnosis may delay appropriate treatment, and serious complications can occur.	SUNY HLTH SCI CTR, 450 CLARKSON AVE, BOX 1196, BROOKLYN, NY 11203 USA; BROOKLYN VET AFFAIRS MED CTR, BROOKLYN, NY 11209 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Vetrano, Joseph/0000-0002-3138-8824				ANAI H, 1990, GASTROINTEST ENDOSC, V36, P624, DOI 10.1016/S0016-5107(90)71185-6; BECKMAN JW, 1986, GASTROINTEST ENDOSC, V32, P355, DOI 10.1016/S0016-5107(86)71885-3; BESSES C, 1987, AM J GASTROENTEROL, V82, P773; Bockus HL, 1928, J AMER MED ASSOC, V90, P175, DOI 10.1001/jama.1928.02690300015005; BOCKUS HL, 1929, AM J SYPH, V13, P30; BUTZ WC, 1975, AM J CLIN PATHOL, V63, P895; Eusterman GB, 1931, J AMER MED ASSOC, V96, P173, DOI 10.1001/jama.1931.02720290017005; EUSTERMAN GB, 1918, AM J SYPH, V2, P205; FLEXNER S, 1898, AM J MED SCI, V116, P424; HARRIS S, 1931, SOUTH MED J, V24, P847; HUNTER EF, 1984, ARCH PATHOL LAB MED, V108, P878; KNIGHT WA, 1947, GASTROENTEROLOGY, V9, P17; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MANTEN HD, 1985, GASTROENTEROLOGY, V2, P1328; MITCHELL RM, 1964, ANN INTERN MED, V61, P933, DOI 10.7326/0003-4819-61-5-933; MORIN ME, 1980, AM J GASTROENTEROL, V74, P170; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; MUSHER DM, 1988, ANN INTERN MED, V109, P849, DOI 10.7326/0003-4819-109-11-849; O'Leary PA, 1931, AM J SURG, V11, P286; ORMAND JE, 1990, MAYO CLIN PROC, V65, P414, DOI 10.1016/S0025-6196(12)62541-5; PALMER ED, 1963, CLIN GASTROENTEROL, P154; Palmer WL, 1943, ANN INTERN MED, V18, P393, DOI 10.7326/0003-4819-18-3-393; PATTERSON CO, 1948, GASTROENTEROLOGY, V10, P474; REISMAN TN, 1975, AM J DIG DIS, V20, P588, DOI 10.1007/BF01074943; REYNOLDS FW, 1942, AM J SYPH GON VD, V26, P218; SACHAR DB, 1974, ANN INTERN MED, V80, P512, DOI 10.7326/0003-4819-80-4-512; SCHWARTZ IR, 1948, GASTROENTEROLOGY, V10, P227; SEXTON RL, 1937, T AM THER SOC, V37, P73; Singer HA, 1928, ARCH INTERN MED, V42, P718, DOI 10.1001/archinte.1928.00130220109004; Spellberg M. A., 1944, GASTROENTEROL, V2, P191; SPENCE MR, 1987, ANN INTERN MED, V107, P587, DOI 10.7326/0003-4819-107-4-587; STOKES JH, 1934, MODERN CLIN SYPHILOL, P927; Wile UJ, 1920, ARCH DERMATOL SYPH, V1, P543; Williams C, 1940, J AMER MED ASSOC, V115, P578, DOI 10.1001/jama.1940.02810340006002; 1989, SUMMARY VITAL STATIS; 1988, SUMMARY VITAL STATIS; 1990, MED LETT DRUGS THER, V32, P5; 1989, MMWR, V37, P1	38	22	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					314	319		10.7326/0003-4819-116-4-314	http://dx.doi.org/10.7326/0003-4819-116-4-314			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733388				2022-12-28	WOS:A1992HD54600009
J	LANDI, G; CICCONE, A				LANDI, G; CICCONE, A			GM-1 GANGLIOSIDE FOR SPINAL-CORD INJURY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							METHYLPREDNISOLONE				LANDI, G (corresponding author), UNIV MILAN,I-20122 MILAN,ITALY.							BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601	3	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					493	493						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732786				2022-12-28	WOS:A1992HD16400027
J	SCHONHOFER, PS				SCHONHOFER, PS			GM-1 GANGLIOSIDE FOR SPINAL-CORD INJURY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											SCHONHOFER, PS (corresponding author), INST CLIN PHARMACOL,W-2800 BREMEN,GERMANY.			Ciccone, Alfonso/0000-0002-4590-3575				BERLIT P, 1989, CRONASSIAL TAGL PRAX, V30, P358; BRADLEY WG, 1990, MUSCLE NERVE, V13, P833, DOI 10.1002/mus.880130910; DEGUILLAINBARRE S, 1990, BUTLLETI GROC, V3, P12; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; LACOMBLEZ L, 1989, NEUROLOGY, V39, P1635, DOI 10.1212/WNL.39.12.1635; NAGAI Y, 1976, NEUROSCI LETT, V2, P107, DOI 10.1016/0304-3940(76)90033-1; SCHONHOFER PS, 1991, LANCET, V337, P904; WALKER MD, 1991, NEW ENGL J MED, V324, P1885, DOI 10.1056/NEJM199106273242608; YUKI, 1991, LANCET, V337, P1109	9	13	13	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					493	493						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732787				2022-12-28	WOS:A1992HD16400026
J	LEVIN, LR; HAN, PL; HWANG, PM; FEINSTEIN, PG; DAVIS, RL; REED, RR				LEVIN, LR; HAN, PL; HWANG, PM; FEINSTEIN, PG; DAVIS, RL; REED, RR			THE DROSOPHILA LEARNING AND MEMORY GENE RUTABAGA ENCODES A CA2+/CALMODULIN-RESPONSIVE ADENYLYL CYCLASE	CELL			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; TERM-MEMORY; PROTEIN; MELANOGASTER; DUNCE; IDENTIFICATION; MUTANTS; CHANNEL; BRAIN	Four putative adenylyl cyclase genes from Drosophila melanogaster were identified by virtue of their extensive sequence homology with mammalian cyclases. One corresponds to the learning and memory gene rutabaga and is most similar to the mammalian brain Ca2+/calmodulin (CaM)-responsive cyclase. In a mammalian expression system, rutabaga cyclase activity was stimulated approximately 5-fold by the presence of Ca2+/CaM. A point mutation, identified at this locus in rut1 mutant flies, resulted in loss of detectable adenylyl cyclase activity. New P element insertion-induced rutabaga mutations mapped to within 200 nucleotides of the 5' end of the rutabaga cDNA. These data confirm the identity of the rutabaga locus as the structural gene for the Ca2+/CaM-responsive adenylyl cyclase and show that the inactivation of this cyclase leads to a learning and memory defect.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Johns Hopkins University; Baylor College of Medicine	LEVIN, LR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.		Reed, Russell/HGU-0528-2022; Davis, Ronald/J-4998-2013	Davis, Ronald/0000-0002-5986-7608; Levin, Lonny/0000-0002-5204-6356; Han, Pyung-Lim/0000-0002-1735-6746				ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BELLEN HJ, 1987, DEV BIOL, V121, P432, DOI 10.1016/0012-1606(87)90180-1; BROSTROM CO, 1977, J BIOL CHEM, V252, P5677; BROSTROM CO, 1975, P NATL ACAD SCI USA, V72, P64, DOI 10.1073/pnas.72.1.64; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CALDWELL P C, 1970, P10; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHEUNG WY, 1975, BIOCHEM BIOPH RES CO, V66, P1055, DOI 10.1016/0006-291X(75)90747-0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAUWALDER B, 1991, TRENDS GENET, V7, P224; DAVIS RL, 1981, J CELL BIOL, V90, P101, DOI 10.1083/jcb.90.1.101; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; FEINSTEIN PF, 1992, IN PRESS P NATL ACAD; GAO B, 1992, IN PRESS P NATL ACAD; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KURET J, 1988, J BIOL CHEM, V263, P9149; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MOLLNER S, 1988, EUR J BIOCHEM, V171, P265, DOI 10.1111/j.1432-1033.1988.tb13785.x; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PFEUFFER E, 1989, J BIOL CHEM, V264, P18803; QIU Y, 1991, IN PRESS J MOL BIOL; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; REED R R, 1990, New Biologist, V2, P957; ROSENBERG GB, 1987, J BIOL CHEM, V262, P7623; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Sambrook J, 1989, MOL CLONING LABORATO; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; WESTCOTT KR, 1979, P NATL ACAD SCI USA, V76, P204, DOI 10.1073/pnas.76.1.204; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	55	400	410	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					479	489		10.1016/0092-8674(92)90185-F	http://dx.doi.org/10.1016/0092-8674(92)90185-F			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739965	hybrid			2022-12-28	WOS:A1992HD39800009
J	BANKMANN, M; PRAKASH, L; PRAKASH, S				BANKMANN, M; PRAKASH, L; PRAKASH, S			YEAST RAD14 AND HUMAN XERODERMA-PIGMENTOSUM GROUP-A DNA-REPAIR GENES ENCODE HOMOLOGOUS PROTEINS	NATURE			English	Article							PYRIMIDINE DIMER REMOVAL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; EXCISION; MUTANTS; SEQUENCE; COMPLEMENTATION; RECOMBINATION; INCISION	XERODERMA pigmentosum (XP), a human autosomal recessive disorder, is characterized by extreme sensitivity to sunlight and high incidence of skin cancers. XP cells are defective in the incision step of excision repair of DNA damaged by ultraviolet light. Cell fusion studies have defined seven XP complementation groups, XP-A to XP-G (refs 1,2). Similar genetic complexity of excision repair is observed in the yeast Saccharomyces cerevisiae. Mutations in any one of five yeast genes, RAD1, RAD2, RAD3, RAD4, and RAD10, cause a total defect in incision and an extreme sensitivity to ultraviolet light 3. Here we report the characterization of the yeast RAD14 gene. The available rad14 point mutant is only moderately ultraviolet-sensitive, and it performs a substantial amount of incision of damaged DNA 4,5. Our studies with the rad14 deletion (DELTA) mutation indicate an absolute requirement of RAD14 in incision. RAD14 encodes a highly hydrophilic protein of 247 amino acids containing zinc-finger motifs, and it is similar to the protein encoded by the human XPAC gene that complements XP group A cell lines 6.	UNIV ROCHESTER,DEPT BIOL,RIVER CAMPUS STN,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				BERG JM, 1990, J BIOL CHEM, V265, P6513; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOTSMA D, 1989, MUTAT RES, V218, P149, DOI 10.1016/0921-8777(89)90021-9; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIGGINS DR, 1983, P NATL ACAD SCI-BIOL, V80, P5680, DOI 10.1073/pnas.80.18.5680; JOHNSON RT, 1989, HUM GENET, V81, P203; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; PRAKASH L, 1977, GENETICS, V86, P33; PRAKASH L, 1979, MOL GEN GENET, V176, P351, DOI 10.1007/BF00333097; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; Prakash S, 1990, EUKARYOTIC NUCLEUS, P275; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	23	104	107	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					555	558		10.1038/355555a0	http://dx.doi.org/10.1038/355555a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741034				2022-12-28	WOS:A1992HC52600062
J	SELLECK, SB; GONZALEZ, C; GLOVER, DM; WHITE, K				SELLECK, SB; GONZALEZ, C; GLOVER, DM; WHITE, K			REGULATION OF THE G1-S TRANSITION IN POSTEMBRYONIC NEURONAL PRECURSORS BY AXON INGROWTH	NATURE			English	Article							DROSOPHILA CYCLIN-A; OPTIC-LOBES; NERVOUS-SYSTEM; CELL-DIVISION; MELANOGASTER; PATTERNS; NEUROGENESIS	IN the newly cellularized Drosophila embryo, progress through the cell cycle is regulated at the G2-M transition 1,2. We have examined cell-cycle regulation later in Drosophila development, in a group of postembryonic neuronal precursors. The S-phase precursor cells, which generate photoreceptor target neurons (lamina neurons) in the central nervous system, are not present in the absence of photoreceptor innervation 3. Here we report that axons selectively approach G1-phase precursors. Without axon ingrowth, lamina precursors do not enter their final S phase and by several criteria, arrest in the preceding G1 phase. These findings provide evidence that at this stage in development the control of cell division can occur at the G1-S transition.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	SELLECK, SB (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.		Gonzalez, Cayetano/K-3055-2019; Gonzalez, Cayetano/K-3933-2019	Gonzalez, Cayetano/0000-0002-5259-3608; Glover, David/0000-0003-0956-0103				BAPTISTA CA, 1990, NATURE, V346, P855, DOI 10.1038/346855a0; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; FISCHBACH KF, 1983, DEV BIOL, V95, P1, DOI 10.1016/0012-1606(83)90002-7; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LINDSLEY DI, 1968, CARNEGIE I PUBL, V627; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WHITE K, 1978, DEV BIOL, V65, P296, DOI 10.1016/0012-1606(78)90029-5; WHITE K, 1986, J COMP NEUROL, V247, P430, DOI 10.1002/cne.902470403; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x	16	90	90	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					253	255		10.1038/355253a0	http://dx.doi.org/10.1038/355253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731221				2022-12-28	WOS:A1992GZ69400068
J	BURNS, DA				BURNS, DA			A POTPOURRI OF PARASITES IN POETRY AND PROVERB	BRITISH MEDICAL JOURNAL			English	Article											BURNS, DA (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.							BOTTOMLEY G, 1925, POEMS 30 YEARS, P106; DONNE J, 1986, J DONNE POETRY, P48; GUYS PRM, 1972, ST JOHNS HOSPITAL DE, V58, P113; KINGSLEY J, 1968, POEMS SONGS R BURNS, V1, P193; LEHANE B, 1969, COMPLEAT FLEA, P94; Mellanby K, 1941, Br Med J, V2, P405; MELLANBY K, 1945, HUMAN GUINEA PIGS; MILLIGAN S, 1991, PUFFIN BOOK 20TH CEN, P162; SILCOCK A, 1969, VERSE WORSE, P242; STEVENSON B, 1967, STEVENSONS BOOK QUOT, P1171; SWIFT J, 1967, SWIFT POETICAL WORKS, P578; 1964, PLAGUE PHILISTINES, P146	12	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1611	1614		10.1136/bmj.303.6817.1611	http://dx.doi.org/10.1136/bmj.303.6817.1611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	GX956	1773193	Green Published, Bronze			2022-12-28	WOS:A1991GX95600026
J	CHAKRABORTY, R; KIDD, KK				CHAKRABORTY, R; KIDD, KK			THE UTILITY OF DNA TYPING IN FORENSIC WORK	SCIENCE			English	Editorial Material							GEL-ELECTROPHORESIS; HYPERVARIABLE LOCI; POPULATION; MUTATION; MINISATELLITES; POLYMORPHISM; MARKERS		YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University	CHAKRABORTY, R (corresponding author), UNIV TEXAS, GRAD SCH BIOMED SCI, CTR DEMOG & POPULAT GENET, HOUSTON, TX 77225 USA.				NIGMS NIH HHS [GM 41399] Funding Source: Medline; NIMH NIH HHS [MH 39239] Funding Source: Medline; CSRD VA [NIJ-90-IJ-CX-0038] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039239, R01MH039239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); CSRD VA; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALAZS I, 1989, AM J HUM GENET, V44, P182; BALAZS I, IN PRESS GENETICS; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BOWCOCK AM, IN PRESS GENE GEOGR; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; BUDOWLE B, 1991, AM J HUM GENET, V48, P841; BUDOWLE B, COMMUNICATION; CANN RL, 1982, HUMAN GENETICS A, P157; CASKEY CT, 1991, AM J HUM GENET, V49, P893; CAVALLISFORZA LL, 1958, 10 P INT C GEN MONTR, V1, P389; CERDAFLORES RM, 1991, HUM BIOL, V63, P309; CERDAFLORES RM, IN PRESS AM HUM BIOL; CHAKRABORTY R, 1986, YEARB PHYS ANTHROPOL, V29, P1; CHAKRABORTY R, 1991, Ethnicity and Disease, V1, P245; CHAKRABORTY R, 1991, HUM BIOL, V63, P571; CHAKRABORTY R, 1974, THEOR POPUL BIOL, V5, P460, DOI 10.1016/0040-5809(74)90064-1; CHAKRABORTY R, 1991, AM J HUM GENET, V49, P895; CHAKRABORTY R, IN PRESS HUM GENET; CLARK AG, 1987, AM J HUM GENET, V41, P948; DEKA R, 1991, GENOMICS, V11, P83, DOI 10.1016/0888-7543(91)90104-M; DEVLIN B, 1990, SCIENCE, V249, P1416, DOI 10.1126/science.2205919; DEVLIN B, 1991, AM J HUM GENET, V48, P662; DEVLIN R, IN PRESS J AM STAT S; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FLINT J, 1989, HUM GENET, V83, P257, DOI 10.1007/BF00285167; FORMAN L, 1991, AM J HUM GENET, V49, P64; FRIEDLAENDER JS, 1975, PATTERNS HUMAN VARIA; GAENSSLEN RE, 1985, FBI CRIME LABORATORY, V12, P75; HARMON RP, 1991, AM J HUM GENET, V49, P891; HENKE L, 1991, EXPER SUPPL, V58, P144; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1991, AM J HUM GENET, V49, P64; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEFFREYS AJ, 1991, NATURE, V354, P254; JIN L, 1991, AM J HUM GENET, V49, P14; JONAKAIT RN, 1983, U ILLINOIS LAW REV, P369; KARLIN S, 1981, P NATL ACAD SCI USA, V78, P2664, DOI 10.1073/pnas.78.5.2664; KARLIN S, 1983, P NATL ACAD SCI USA, V80, P647, DOI 10.1073/pnas.80.2.647; Kennedy RJR, 1944, AM J SOCIOL, V49, P331, DOI 10.1086/219427; Kennedy RJR, 1952, AM J SOCIOL, V58, P56, DOI 10.1086/221073; KIDD JR, 1991, HUM BIOL, V63, P775; Kidd K K, 1991, Curr Opin Genet Dev, V1, P99, DOI 10.1016/0959-437X(91)80049-R; KIDD KK, 1991, AM J HUM GENET, V49, P64; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; LANDER ES, 1991, AM J HUM GENET, V48, P819; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LANDER ES, 1989, DNA TECHNOLOGY FOREN, P143; Lewontin R.C., 1972, EVOL BIOL, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040; LI CC, 1976, 1ST COURSE POPULATIO; MOURANT A. E, 1954, DISTRIBUTION HUMAN B; Mourant AE., 1976, DISTRIBUTION HUMAN B; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NEEL JV, 1972, GENETICS, V72, P639; NEI M, 1972, THEOR POPUL BIOL, V3, P460, DOI 10.1016/0040-5809(72)90017-2; NEI M, 1991, EVOLUTION OF LIFE, P415; NEI M, 1990, POPULATION BIOL GENE, P251; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; RAMSHAW JAM, 1979, GENETICS, V93, P1019; Roychoudhury AK, 1988, HUMAN POLYMORPHIC GE; Salzano FM, 1988, S AM INDIANS CASE ST; SMOUSE PE, 1988, QUANTITATIVE GENETIC, P32; SPUHLER JN, 1961, HUM BIOL, V33, P223; Wambaugh J., 1989, BLOODING; WEIR BS, IN PRESS AM J HUM GE; WEIR BS, IN PRESS GENETICS; WOOLEY JR, 1991, AM J HUM GENET S, V49, P392; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754; YAMMAMOTO F, 1990, NATURE, V345, P229; 1988, CRIME LABORATORY DIG, V15; 1990, OTA438 US C OFF TECH; 1990, FORENSIC DNA ANAL IS	75	180	180	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1735	1739		10.1126/science.1763323	http://dx.doi.org/10.1126/science.1763323			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763323				2022-12-28	WOS:A1991GW31600029
J	MENDEL, DB; KHAVARI, PA; CONLEY, PB; GRAVES, MK; HANSEN, LP; ADMON, A; CRABTREE, GR				MENDEL, DB; KHAVARI, PA; CONLEY, PB; GRAVES, MK; HANSEN, LP; ADMON, A; CRABTREE, GR			CHARACTERIZATION OF A COFACTOR THAT REGULATES DIMERIZATION OF A MAMMALIAN HOMEODOMAIN PROTEIN	SCIENCE			English	Article							NUCLEAR FACTOR-I; DNA-BINDING PROTEINS; ALBUMIN TRANSCRIPTION DIFFERS; POU DOMAIN PROTEINS; RAT HEPATOMA-CELLS; 3 SEQUENCE MOTIFS; CHROMOSOMAL LOCALIZATION; FUNCTIONAL DOMAINS; ACTIVATION DOMAIN; OVERLAP EXTENSION	Dimerization among transcription factors has become a recurrent theme in the regulation of eukaryotic gene expression. Hepatocyte nuclear factor-let (HNF-1-alpha) is a homeodomain-containing protein that functions as a dimer. A dimerization cofactor of HNF-1-alpha (DCoH) was identified that displayed a restricted tissue distribution and did not bind to DNA, but, rather, selectively stabilized HNF-1-alpha-dimers. The formation of a stable tetrameric DCoH-HNF-1-alpha-complex, which required the dimerization domain of HNF-1-alpha did not change the DNA binding characteristics of HNF-1-alpha but enhanced its transcriptional activity. However, DCoH did not confer transcriptional activation to the GAL4 DNA binding domain. These results indicate that DCoH regulates formation of transcriptionally active tetrameric complexes and may contribute to the developmental specificity of the complex.	UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	MENDEL, DB (corresponding author), STANFORD UNIV,BECKMAN CTR MOLEC & GENET MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Admon, Arie/0000-0003-0504-3950	NCI NIH HHS [CA 09302] Funding Source: Medline; NHLBI NIH HHS [HL 33942] Funding Source: Medline; NICHD NIH HHS [HD 07201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; BAUMHEUTER S, UNPUB; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CONLEY P, UNPUB; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL D, UNPUB; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309	62	215	219	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1762	1767		10.1126/science.1763325	http://dx.doi.org/10.1126/science.1763325			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763325				2022-12-28	WOS:A1991GW31600034
J	NAMBU, JR; LEWIS, JO; WHARTON, KA; CREWS, ST				NAMBU, JR; LEWIS, JO; WHARTON, KA; CREWS, ST			THE DROSOPHILA SINGLE-MINDED GENE ENCODES A HELIX-LOOP-HELIX PROTEIN THAT ACTS AS A MASTER REGULATOR OF CNS MIDLINE DEVELOPMENT	CELL			English	Article							HAIRY-WING MUTATIONS; ACHAETE-SCUTE COMPLEX; DNA-BINDING PROTEINS; AXON PATHWAYS; IMMUNOGLOBULIN SUPERFAMILY; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; NERVOUS-SYSTEM; FASCICLIN-II; GROWTH CONES	Development of the Drosophila CNS midline cells is dependent upon the function of the single-minded (sim) gene. Sequence analysis shows that sim is a member of the basic-helix-loop-helix class of transcription factors. Cell fate experiments establish that sim is required for early events in midline cell development, including a synchronized cell division, proper formation of nerve cell precursors, and positive autoregulation of its midline expression. Induction of ectopic sim protein under the control of the hsp70 promoter shows that sim can direct cells of the lateral CNS to exhibit midline cell morphology and patterns of gene expression. We propose that sim functions as a master developmental regulator of the CNS midline lineage.			NAMBU, JR (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT BIOL, LOS ANGELES, CA 90024 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042, T32GM007185] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD25251] Funding Source: Medline; NIGMS NIH HHS [GM-08042, GM-07185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1935, EMBRYONIC DEV DROSOP; CAMPUZANO S, 1986, CELL, V44, P303, DOI 10.1016/0092-8674(86)90764-6; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREWS S, 1991, IN PRESS J EXP ZOOL; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FOE VE, 1989, DEVELOPMENT, V107, P1; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JESSELL TM, 1989, CIBA F SYMP, V144, P255; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; Lawrence P.A., 1986, P229; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; MARTINEZ C, 1991, SCIENCE, V251, P1485, DOI 10.1126/science.1900954; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SWEET RM, 1983, J MOL BIOL, V171, P479, DOI 10.1016/0022-2836(83)90041-4; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	60	448	457	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1157	1167		10.1016/0092-8674(91)90292-7	http://dx.doi.org/10.1016/0092-8674(91)90292-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760843				2022-12-28	WOS:A1991GX16400014
J	MCMILLAN, SA; HAUGHTON, DJ; BIGGART, JD; EDGAR, JD; PORTER, KG; MCNEILL, TA				MCMILLAN, SA; HAUGHTON, DJ; BIGGART, JD; EDGAR, JD; PORTER, KG; MCNEILL, TA			PREDICTIVE VALUE FOR CELIAC-DISEASE OF ANTIBODIES TO GLIADIN, ENDOMYSIUM, AND JEJUNUM IN PATIENTS ATTENDING FOR JEJUNAL BIOPSY	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE; DERMATITIS-HERPETIFORMIS; ANTIGLIADIN ANTIBODIES; SCREENING-TEST; IGA; DIAGNOSIS; GLUTEN; SENSITIVITY; MULTICENTER; CHILDREN	Objective - To investigate the extent to which the detection of antibodies to gliadin, endomysium, and jejunum predicts the eventual diagnosis of coeliac disease according to the revised ESPGAN diagnostic criteria in a group of patients in whom there is a high suspicion of coeliac disease. Design - Clinical assessment and laboratory analysis of patients with suspected coeliac disease. Setting - Gastroenterology department of teaching hospital. Patients - 96 adults with suspected coeliac disease attending for jejunal biopsy. Main outcome measures - Diagnosis of coeliac disease with the revised criteria of the European Society of Paediatric Gastroenterology and Nutrition in patients with and without antibodies associated with coeliac disease. Results - 28 patients had a clinical diagnosis of coeliac disease, seven of other gastrointestinal diseases, and 12 of miscellaneous diseases; 49 had no diagnosis. Gliadin IgA detected by ELISA was found in all patients with coeliac disease and none of those without, giving a sensitivity, specificity, positive and negative predictive values, and predictive efficiency of 100% for diagnosing coeliac disease within the group. Endomysial IgA was found in 25 (89%) patients with coeliac disease and jejunal IgA in 21 (75%); neither IgA was found in patients without coeliac disease. Conclusion - Detection of gliadin IgA by ELISA and to a lesser extent the endomysial IgA should allow better selection of patients for jejunal biopsy and thus make diagnosing coeliac disease simpler and more efficient.	QUEENS UNIV BELFAST,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast	MCMILLAN, SA (corresponding author), BELFAST CITY HOSP,REG IMMUNOL LAB,BELFAST BT9 7AD,ANTRIM,NORTH IRELAND.			Edgar, John David Moore/0000-0003-2969-4475				ASCHER H, 1990, J PEDIATR GASTR NUTR, V10, P443, DOI 10.1097/00005176-199005000-00005; BURGINWOLFF A, 1989, EUR J PEDIATR, V148, P496, DOI 10.1007/BF00441541; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; DIAS J, 1987, LANCET, V2, P157; ELEWAUT A, 1989, CLIN CHIM ACTA, V183, P285, DOI 10.1016/0009-8981(89)90362-8; GALLEN RS, 1986, MANUAL CLIN LABORATO, P966; GRODZINSKY E, 1990, INT ARCH ALLER A IMM, V92, P119, DOI 10.1159/000235201; GUANDALINI S, 1989, ARCH DIS CHILD, V64, P1320, DOI 10.1136/adc.64.9.1320; HALLSTROM O, 1989, GUT, V30, P1225, DOI 10.1136/gut.30.9.1225; KARPATI S, 1990, LANCET, P1335; KELLY J, 1987, ARCH DIS CHILD, V62, P469, DOI 10.1136/adc.62.5.469; KOLETZKO S, 1988, EUR J PEDIATR, V148, P113, DOI 10.1007/BF00445915; KUMAR V, 1989, IMMUNOL INVEST, V18, P533, DOI 10.3109/08820138909112261; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; SCOTT H, 1990, SCAND J GASTROENTERO, V25, P287, DOI 10.1080/00365521.1990.12067105; UNSWORTH DJ, 1981, ARCH DIS CHILD, V56, P864, DOI 10.1136/adc.56.11.864; VOLTA U, 1990, CLIN EXP IMMUNOL, V80, P192, DOI 10.1111/j.1365-2249.1990.tb05232.x; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WATSON RGP, 1986, ULSTER MED J, V55, P160; 1991, LANCET, P590	20	122	122	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1163	1165		10.1136/bmj.303.6811.1163	http://dx.doi.org/10.1136/bmj.303.6811.1163			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747612	Green Published, Bronze			2022-12-28	WOS:A1991GP48800021
J	MOORE, GT				MOORE, GT			LETS PROVIDE PRIMARY CARE TO ALL UNINSURED AMERICANS - NOW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH; TERMINATION; CONTINUITY; TRIAL	Gridlock in the political process makes comprehensive health insurance for the uninsured an unlikely prospect in the near future. While the debate continues, we should provide basic primary care services to all uninsured Americans. Primary care is the most economical safety net we can offer our citizens. By prepaying participating physicians, we could provide this needed care at a cost the nation could afford and with excellent prospects for controlling expenditures over time.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	MOORE, GT (corresponding author), HARVARD UNIV,COMMUNITY HLTH PLAN,CTR TEACHING,2 FENWAY PLAZA,BOSTON,MA 02115, USA.							ALPERT JJ, 1968, AM J DIS CHILD, V116, P529, DOI 10.1001/archpedi.1968.02100020533014; BERGMAN DA, 1983, J MED EDUC, V58, P744; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CHARNEY E, 1967, PEDIATRICS, V40, P188; Colwill J M, 1988, Fam Med, V20, P250; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; HOCHHEISER LI, 1971, NEW ENGL J MED, V285, P148, DOI 10.1056/NEJM197107152850305; KEELER EB, 1987, HEALTH SERV RES, V22, P279; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; SWARTZ K, 1989, MED UNINSURED SPECIA; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WEISFELD VD, 1987, 2 RW JOHN F SPEC REP; 1978, MANPOWER POLICY PRIM; 1990, REDUCING DEFICIT S 2, P145; 1990, HLTH CARE SYSTEMS TR; 1989, COMPENDIUM HLTH STAT; 1989, HLTH NATION SHARED R	19	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2108	2109						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	1750874				2022-12-28	WOS:A1991FG90700030
J	PARK, TS; OWEN, JH				PARK, TS; OWEN, JH			CURRENT CONCEPTS - SURGICAL-MANAGEMENT OF SPASTIC DIPLEGIA IN CEREBRAL-PALSY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SELECTIVE POSTERIOR RHIZOTOMY; GESTATIONAL-AGE; BIRTH-WEIGHT; CHILDREN; MUSCLE; ENCEPHALOPATHY; GROWTH; CATS		WASHINGTON UNIV,SCH MED,DIV ORTHOPED,ST LOUIS,MO 63110	Washington University (WUSTL)	PARK, TS (corresponding author), ST LOUIS CHILDRENS HOSP,DEPT NEUROSURG,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.							ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; ARENS LJ, 1989, CHILD NERV SYST, V5, P148, DOI 10.1007/BF00272116; ARMSTRONG R, 1991, DEV MED CHILD NE S64, V33, P27; BANKER BQ, 1962, ARCH NEUROL-CHICAGO, V7, P386, DOI 10.1001/archneur.1962.04210050022004; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BERMAN B, 1990, AM J OCCUP THER, V44, P511, DOI 10.5014/ajot.44.6.511; BINDER H, 1989, ARCH PHYS MED REHAB, V70, P482; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLASCO PA, 1989, NEUROSURGERY STATE A, P371; Bleck E., 1987, ORTHOPAEDIC MANAGEME; BLECK EE, 1990, J BONE JOINT SURG AM, V72A, P140, DOI 10.2106/00004623-199072010-00025; Burke D, 1988, Adv Neurol, V47, P401; BURKE RE, 1980, J NEUROL NEUROSUR PS, V43, P789, DOI 10.1136/jnnp.43.9.789; BYRNE P, 1990, J PEDIATR-US, V117, P694, DOI 10.1016/S0022-3476(05)83323-2; CAHAN LD, 1990, DEV MED CHILD NEUROL, V32, P1037; CASTLE ME, 1979, CLIN ORTHOPAEDICS, V142, P223; DAVIDOFF RA, 1985, ANN NEUROL, V17, P107, DOI 10.1002/ana.410170202; DECTER RM, 1987, J UROLOGY, V138, P1110, DOI 10.1016/S0022-5347(17)43518-X; DEJONG RN, 1970, NEUROLOGIC EXAMINATI, P503; ELLENBERG JH, 1979, AM J DIS CHILD, V133, P1044, DOI 10.1001/archpedi.1979.02130100068014; FASANO VA, 1978, CHILD BRAIN, V4, P289; FASANO VA, 1989, NEUROSURG STATE ART, V4, P409; Foerster O, 1913, SURG GYNECOL OBSTET, V16, P463; GAGE JR, 1990, CLIN ORTHOP RELAT R, V253, P45; Green N E, 1987, Instr Course Lect, V36, P253; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, CLIN DEV MED, V87, P116; HOFFER MM, 1980, CLIN ORTHOPAEDICS, V151, P222; HOFFER MM, 1987, CLIN ORTHOP RELAT R, V219, P70; HULSEBOSCH CE, 1983, BRAIN RES, V265, P187, DOI 10.1016/0006-8993(83)90332-3; LANCE JW, 1965, J NEUROL NEUROSUR PS, V28, P328, DOI 10.1136/jnnp.28.4.328; LEONARD CT, 1991, EXP NEUROL, V111, P379, DOI 10.1016/0014-4886(91)90106-M; LEONARD CT, 1987, DEV BRAIN RES, V32, P15, DOI 10.1016/0165-3806(87)90134-9; NASHNER LM, 1983, EXP BRAIN RES, V49, P393; NELSON KB, 1982, PEDIATRICS, V69, P529; OPPENHEIM WL, 1990, CLIN ORTHOPAEDICS, V253, P20; PARK TS, 1989, NEUROSURGERY STATE A, P485; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PEACOCK WJ, 1991, J NEUROSURG, V74, P380, DOI 10.3171/jns.1991.74.3.0380; Phillips LH, 1989, NEUROSURGERY STATE A, P459; RANG M, 1989, CLIN ORTHOP RELAT R, V247, P55; SCHOUMANCLAEYS E, 1989, BRIT J RADIOL, V62, P248, DOI 10.1259/0007-1285-62-735-248; Stanley F, 1984, CLIN DEV MED, V87, P57; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; VAUGHAN CL, 1991, J NEUROSURG, V74, P178, DOI 10.3171/jns.1991.74.2.0178; WILLIAMS PE, 1984, J ANAT, V138, P343; YOKOCHI K, 1991, DEV MED CHILD NEUROL, V33, P18; YOUNG RSK, 1982, ANN NEUROL, V12, P445; ZIV I, 1984, DEV MED CHILD NEUROL, V26, P94	49	61	64	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					745	749						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738380				2022-12-28	WOS:A1992HH06400006
J	AUSTEN, KF				AUSTEN, KF			SYSTEMIC MASTOCYTOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MAST-CELLS				AUSTEN, KF (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA 02115, USA.							BRESSLER RB, 1989, J IMMUNOL, V143, P135; CRAIG SS, 1988, LAB INVEST, V58, P682; GHILDYAL N, IN PRESS J BIOL CHEM; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS1, DOI 10.1111/1523-1747.ep12468869; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; VALENT P, 1989, BLOOD, V73, P1778; WEIDNER N, IN PRESS AM J PATHOL	9	71	74	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					639	640		10.1056/NEJM199202273260912	http://dx.doi.org/10.1056/NEJM199202273260912			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734257				2022-12-28	WOS:A1992HF63300012
J	BENNETT, HJ				BENNETT, HJ			KEEPING UP WITH THE LITERATURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					920	920						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734095				2022-12-28	WOS:A1992HD15500007
J	BLENOON, RJ; DONELAN, K; KNOX, RA				BLENOON, RJ; DONELAN, K; KNOX, RA			PUBLIC-OPINION AND AIDS - LESSONS FOR THE 2ND DECADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENOON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPINION & HLTH CARE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					ADAMS P, 1991, ADV DATA, V198, P1; BLENDON RJ, 1988, NEW ENGL J MED, V319, P1022, DOI 10.1056/NEJM198810133191522; BROWN ML, 1990, PUBLIC OPIN QUART, V54, P317, DOI 10.1086/269209; DAWSON DA, 1988, ADV DATA VITAL HLTH, V153, P1; DOWNS A, 1974, PUBLIC INTEREST, V4, P38; ROGERS DE, 1991, NY TIMES        0716, pA19; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Slovic P., 1980, SOC RISK ASSESSMENT, P181, DOI [10.1007/978-1-4899-0445-4_9, DOI 10.1007/978-1-4899-0445-4_9]; STORR C, 1969, SCIENCE, V165, P1232; 1990, NATIONAL ATTITUDES T; 1990, TIMES MIRROR     MAY; GENERAL SOCIAL SURVE; 1990, NY TIMES         OCT; 1990, WASHINGTON POST  JAN; 1984, NEWSWEEK         JUN; 1991, NEWSWEEK         JUN; 1988, NY TIMES         SEP; 1987, PEOPLE PRESS POLITIC; 1991, BOSTON GLOBE    0722; 1990, WALL STREET J    JUL; 1990, PUBLIC ATTITUDES PEO; 1991, LOS ANGELES TIM 1121; 1990, GENERAL SOCIAL SURVE; 1983, WASHINGTON POST  JUN; 1988, GALLUP REP       JAN	25	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					981	986		10.1001/jama.267.7.981	http://dx.doi.org/10.1001/jama.267.7.981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734113				2022-12-28	WOS:A1992HD15500035
J	GROVER, SA; ABRAHAMOWICZ, M; JOSEPH, L; BREWER, C; COUPAL, L; SUISSA, S				GROVER, SA; ABRAHAMOWICZ, M; JOSEPH, L; BREWER, C; COUPAL, L; SUISSA, S			THE BENEFITS OF TREATING HYPERLIPIDEMIA TO PREVENT CORONARY HEART-DISEASE - ESTIMATING CHANGES IN LIFE EXPECTANCY AND MORBIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; COST-EFFECTIVENESS; CHOLESTEROL; MEN; HYPERCHOLESTEROLEMIA; GEMFIBROZIL; THERAPY; TRIAL	Objective. - To evaluate the lifetime benefits of reducing total serum cholesterol levels to prevent coronary heart disease (CHD). Design. - We developed a CHD primary prevention computer model to estimate the benefits associated with lifelong risk factor modification. We validated the model by comparing the computer estimates with the observed results of three primary CHD prevention trials. Patients. - Men and women age 35 to 65 years who are free of CHD, with total serum cholesterol levels ranging from 5.2 to 7.8 mmol/L (200 to 300 mg/dL), with or without additional CHD risk factors. Interventions. - Serum cholesterol reduction through dietary modification or diet and medications. Main Outcome Measures. - Changes in life expectancy and the delay of symptomatic CHD. Results. - The computer forecasts for CHD end points closely matched the observed results of the Lipid Research Clinics Trial, the Helsinki Heart Study, and MRFIT. We then applied the computer model to low-risk and high-risk men and women with total serum cholesterol levels between 5.2 and 7.8 mmol/L (200 and 300 mg/dL) and estimated that, after reducing serum cholesterol levels 5% to 33%, the average life expectancy would increase by 0.03 to 3.16 years. We also forecast that the average onset of symptomatic CHD would be delayed among these patient groups by 0.06 to 4.98 years. Conclusion. - We conclude that this computer model accurately estimates the results of clinical trials and can be used to forecast the changes in life expectancy and morbidity (the development of CHD) associated with specific CHD risk reduction interventions. The wide variation surrounding these estimates underscores the need to better define which groups of individuals will gain the most from cholesterol reduction.	MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL H3A 2T5, QUEBEC, CANADA; CTR CARDIOVASC RISK ASSESSMENT, MONTREAL, QUEBEC, CANADA; MONTREAL GEN HOSP, DIV GEN INTERNAL MED, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP, DIV CLIN EPIDEMIOL, 1650 CEDAR AVE, MONTREAL H3G 1A4, QUEBEC, CANADA.			Coupal, Louis/0000-0003-0828-9665; Abrahamowicz, Michal/0000-0002-3172-3952				ABBOTT RD, 1987, US DHEW NIH872284 PU; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BERWICK DM, 1980, CHOLESTEROL CHILDREN, P301; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON T, 1982, AM HEART J, V103, P1031, DOI 10.1016/0002-8703(82)90567-1; GORDON T, 1971, FRAMINGHAM STUDY EPI; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; HJERMANN I, 1981, LANCET, V2, P1303; KANNEL WB, 1988, NIH882969 NAT HEART; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LEWIS B, 1987, EUR HEART J, V8, P77; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P607; OLIVER MF, 1986, CIRCULATION, V73, P1, DOI 10.1161/01.CIR.73.1.1; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; VEGA GL, 1989, JAMA-J AM MED ASSOC, V262, P3148; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; [No title captured]; 1981, HLTH CANADIANS REPOR; 1973, CORONARY RISK HDB ES; 1989, LIFE TABLES CANADA P; 1987, LANCET, V1, P377	36	80	80	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					816	822						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732653				2022-12-28	WOS:A1992HC48400026
J	[Anonymous]				[Anonymous]			RESEARCH PLANS - MONOPOLY THREATENS VARIETY	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1992	355	6359					388	389						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734272				2022-12-28	WOS:A1992HB53000021
J	FORD, C; ILIFFE, S; FRANKLIN, O				FORD, C; ILIFFE, S; FRANKLIN, O			OUTCOME OF PLANNED HOME BIRTHS IN AN INNER-CITY PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PERINATAL-MORTALITY; MATERNITY UNITS; BRADFORD	Objective - To assess the outcome of pregnancy for women booking for home births in an inner London practice between 1977 and 1989. Design - Retrospective review of practice obstetric records. Setting - A general practice in London. Subjects - 285 women registered with the practice or referred by neighbouring general practitioners or local community midwives. Main outcome measures - Place of birth and number of cases transferred to specialist care before, during, and after labour. Results - Of 285 women who booked for home births, eight left the practice area before the onset of labour, giving a study population of 277 women. Six had spontaneous abortions, 26 were transferred to specialist care during pregnancy, another 26 were transferred during labour, and four were transferred in the postpartum period. 215 women (77.6%, 95% confidence interval 72.7 to 82.5) had normal births at home without needing specialist help. Transfer to specialist care during pregnancy was not significantly related to parity, but nulliparous women were significantly more likely to require transfer during labour (p = 0.00002). Postnatal complications requiring specialist attention were uncommon among mothers delivered at home (four cases) and rare among their babies (three cases). Conclusions - Birth at home is practical and safe for a self selected population of multiparous women, but nulliparous women are more likely to require transfer to hospital during labour because of delay in labour. Close cooperation between the general practitioner and both community midwives and hospital obstetricians is important in minimising the risks of trial of labour at home.	WHITTINGTON HOSP,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND	University of London; University College London	FORD, C (corresponding author), 97 BRONDESBURY RD,LONDON NW6 6RY,ENGLAND.		Iliffe, Steve/L-8379-2019	Iliffe, Stephen/0000-0003-2806-3997				BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BRYCE FC, 1990, BRIT MED J, V300, P725, DOI 10.1136/bmj.300.6726.725; CAMBELL R, 1984, BMJ, V289, P721; CHAMBERLAIN G, 1988, PRACTITIONER, V232, P771; DIXON EA, 1982, BRIT MED J, V284, P1753, DOI 10.1136/bmj.284.6331.1753; FRANCIS RB, 1984, AM J NEPHROL, V4, P43; JENKINSON S, 1990, BRIT MED J, V301, P664; JEWELL D, 1989, BRIT MED J, V298, P690, DOI 10.1136/bmj.298.6675.690; JEWELL D, 1990, BRIT MED J, V300, P1140, DOI 10.1136/bmj.300.6732.1140; LILFORD RJ, 1987, BRIT MED J, V295, P1298, DOI 10.1136/bmj.295.6609.1298; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; RHODES JD, 1990, BRIT MED J, V300, P1140, DOI 10.1136/bmj.300.6732.1140-a; ROSS M, 1990, BRIT MED J, V300, P1139; RYAN TDR, 1989, BRIT MED J, V299, P1383, DOI 10.1136/bmj.299.6712.1383; SANGALA V, 1990, BRIT MED J, V301, P418, DOI 10.1136/bmj.301.6749.418; TEW M, 1985, J ROY COLL GEN PRACT, V35, P390; ZANDER L, 1984, PREGNANCY CARE 1980S, P126; 1970, DOMICILIARY MEDWIFER; 1980, PERINATAL NEONATAL M; 1984, MATERNITY CARE ACTIO, V2; 1982, REPORT RCOG WORKING	23	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1517	1519		10.1136/bmj.303.6816.1517	http://dx.doi.org/10.1136/bmj.303.6816.1517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782494	Green Published, Bronze			2022-12-28	WOS:A1991GV47600027
J	VERITY, CM; GOLDING, J				VERITY, CM; GOLDING, J			RISK OF EPILEPSY AFTER FEBRILE CONVULSIONS - A NATIONAL COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEIZURES; CHILDHOOD; BIRTH; FEVER	Objective - To identify children with febrile convulsions, classify their febrile convulsions into simple and complex, and determine the number and type of subsequent afebrile seizures in those children. Design - National population based study. Setting - United Kingdom. Subjects - 16004 neonatal survivors born during one week in April 1970. Main outcome measures - Information about febrile and afebrile seizures obtained from questionnaires at 5 and 10 years of age and from hospital records. Results - Information was available for 14676 of the cohort children. 398 (2.7%) of them had had at least one febrile convulsion. 16 children were known to be neurologically or developmentally abnormal before the first attack. Of the remaining 382 children, 305 had had a simple first febrile convulsion and 77 a complex first febrile convulsion. Thirteen of the 382 had had one or more afebrile seizures, nine of whom had developed epilepsy (recurrent afebrile seizures). A higher proportion of children with complex febrile convulsions (6/95) rather than simple febrile convulsions (3/287) developed epilepsy, the risk being highest for those who had had focal febrile convulsions (5/17; chi-2 = 39.9, p < 0.001). Three of the 32 children who had prolonged febrile convulsions developed afebrile complex partial seizures. Conclusions - The risk of epilepsy after febrile convulsions is much less than reported in many hospital studies, and if febrile convulsions cause brain damage that leads to later epilepsy this is a rare occurrence.	UNIV BRISTOL, INST CHILD HLTH, BRISTOL BS8 1TH, AVON, ENGLAND	University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1980, BMJ, V281, P277; CHAMBERLAIN R, 1975, BRITH BIRTHS 1970, V1; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; LEE K, 1981, ACTA NEUROL SCAND, V63, P231; LEVITON A, 1981, FEBRILE SEIZURES, P65; MELDRUM B S, 1976, P213; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; TAYLOR DC, 1971, EPILEPSIA, V12, P33, DOI 10.1111/j.1528-1157.1971.tb03913.x; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; WALLACE SJ, 1975, ARCH DIS CHILD, V50, P943, DOI 10.1136/adc.50.12.943; WALLACE SJ, 1977, ARCH DIS CHILD, V52, P192, DOI 10.1136/adc.52.3.192; Wallace SJ, 1988, CHILD FEBRILE SEIZUR, P109	19	201	205	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1991	303	6814					1373	1376		10.1136/bmj.303.6814.1373	http://dx.doi.org/10.1136/bmj.303.6814.1373			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760604	Bronze, Green Published			2022-12-28	WOS:A1991GU38400021
J	WARDROPE, J; RYAN, F; CLARK, G; VENABLES, G; CROSBY, AC; REDGRAVE, P				WARDROPE, J; RYAN, F; CLARK, G; VENABLES, G; CROSBY, AC; REDGRAVE, P			THE HILLSBOROUGH TRAGEDY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC ASPHYXIA		ROYAL HALLAMSHIRE HOSP,ACCID & EMERGENCY MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	WARDROPE, J (corresponding author), NO GEN HOSP,ACCID & EMERGENCY MED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							[Anonymous], 1989, BMJ, V298, P651; CHANNER KS, 1989, BRIT MED J, V299, P1379, DOI 10.1136/bmj.299.6712.1379; FRED HL, 1960, AM J MED, V29, P508, DOI 10.1016/0002-9343(60)90046-2; GORENSTEIN L, 1986, J PEDIATR SURG, V21, P753, DOI 10.1016/S0022-3468(86)80358-X; LANCE JW, 1963, BRAIN, V86, P111, DOI 10.1093/brain/86.1.111; LANDERCASPER J, 1985, J TRAUMA, V25, P838, DOI 10.1097/00005373-198509000-00005; OLLIVIER D, 1837, ANN HYGIENE, V18, P486; PLUM F, 1962, ARCH INTERN MED, V110, P18, DOI 10.1001/archinte.1962.03620190020003; PLUM F, 1981, DIAGNOSIS STUPOR COM; SANDIFORD JA, 1974, J TRAUMA, V14, P805, DOI 10.1097/00005373-197409000-00011; SHAPIRO HM, 1986, ANAESTHESIA, V2, P1573; SHARPE DT, 1985, BRIT MED J, V291, P945, DOI 10.1136/bmj.291.6500.945; Taylor P., 1989, HILLSBOROUGH STADIUM; THOMPSON A, 1989, ANN THORAC SURG, V47, P247, DOI 10.1016/0003-4975(89)90279-8; WILLIAMS JS, 1968, ANN SURG, V167, P384, DOI 10.1097/00000658-196803000-00012; 1990, EMERGENCY PLANNING N	16	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1381	1385		10.1136/bmj.303.6814.1381	http://dx.doi.org/10.1136/bmj.303.6814.1381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760607	Green Published, Bronze			2022-12-28	WOS:A1991GU38400024
J	BERKELEY, MIKB; MOFFAT, MAJ; RUSSELL, D				BERKELEY, MIKB; MOFFAT, MAJ; RUSSELL, D			SURVEILLANCE OF ANTIBODY TO RUBELLA-VIRUS IN GRAMPIAN - CLOSING THE IMMUNITY GAP	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY	Objectives - To identify causes for the continuing deficit of rubella immunity in women of childbearing age with a view to further reducing the risk of the congenital rubella syndrome. Design - A questionnaire was sent to the general practitioner and a laboratory follow up study conducted in a one year cohort of women found on screening to have inadequate protection against rubella. Setting - Virus laboratory of the department of medical microbiology, Aberdeen, serving the health board areas of Grampian, Orkney, and Shetland. Patients - 239 women whose concentration of antibodies to rubella virus was either absent or below standard (15 000 IU/l) and whose general practitioner could be contacted to supply a history of infection, immunisation, pregnancy, and antibody testing. Main outcome measures - Whether rubella vaccination was given and whether those vaccinated were tested for seroconversion. Results - Only 122 (55%) of the women for whom information was available received the recommended vaccine; only 74 (61%) of these were tested for seroconversion. Oversight was the reason given for not vaccinating 64 (65%) of the women who remained at risk. Women who were pregnant when tested were significantly less likely to receive vaccine (odds ratio 3.36) than women who were not pregnant, and even if vaccinated were less likely to have a follow up antibody test (odds ratio 1.94). Conclusion - Once women are identified as being unprotected against rubella they are often over-looked and not vaccinated. Prompting mechanisms aimed at general practitioners, such as the one recently set up in Grampian, should reduce the immunity gap and help to eradicate rubella in pregnancy.	UNIV ABERDEEN,DEPT MED MICROBIOL,MED BLDG,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen								COOK GA, 1987, COMMUNITY MED, V9, P254; EDMOND E, 1986, BRIT J OBSTET GYNAEC, V93, P563, DOI 10.1111/j.1471-0528.1986.tb07954.x; FREESTONE DS, 1972, POSTGRAD MED J, V48, P30; MILLER CL, 1985, BRIT MED J, V291, P1398, DOI 10.1136/bmj.291.6506.1398; MILLER E, 1991, REV COMMUNICABLE DIS, V4, pR33; Morgan-Capner P, 1991, CDR (Lond Engl Rev), V1, pR57; TOOKEY PA, 1988, PUBLIC HLTH, V102, P58; 1988, DHSS PLCMO8819 DEP H; 1972, DHSS1772 DEP HLTH SO; 1983, CMO838 CHIEF MED OFF; 1970, DHSS970 DEP HLTH SOC	11	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1174	1176		10.1136/bmj.303.6811.1174	http://dx.doi.org/10.1136/bmj.303.6811.1174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747615	Green Published, Bronze			2022-12-28	WOS:A1991GP48800024
J	BRITTIS, PA; CANNING, DR; SILVER, J				BRITTIS, PA; CANNING, DR; SILVER, J			CHONDROITIN SULFATE AS A REGULATOR OF NEURONAL PATTERNING IN THE RETINA	SCIENCE			English	Article							OPTIC AXONS; PROTEOGLYCANS; GROWTH; INVITRO; CULTURE; INVIVO; NERVE; CELLS	Highly sulfated proteoglycans are correlated with axon boundaries in the developing central nervous system which suggests that these molecules affect neural pattern formation. In the developing mammalian retina, gradual regression of chondroitin sulfate may help control the onset of ganglion cell differentiation and initial direction of their axons. Changes induced by the removal of chondroitin sulfate from intact retinas in culture confirm the function of chondroitin sulfate in retinal histogenesis.			BRITTIS, PA (corresponding author), CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106, USA.							CARBONETTO S, 1983, J NEUROSCI, V3, P2324; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; GOLDBERG S, 1977, EXP EYE RES, V25, P399, DOI 10.1016/0014-4835(77)90107-5; HALFTER W, 1987, J NEUROSCI, V7, P3712; HALFTER W, 1985, J COMP NEUROL, V232, P466, DOI 10.1002/cne.902320405; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HINDS JW, 1974, DEV BIOL, V37, P381, DOI 10.1016/0012-1606(74)90156-0; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; MANN I, 1969, DEV HUMAN EYE; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MORRIS JE, 1987, ARCH BIOCHEM BIOPHYS, V258, P206, DOI 10.1016/0003-9861(87)90337-7; NEWGREEN DF, 1986, CELL TISSUE RES, V244, P299; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sidman RL, 1961, STRUCTURE EYE, P487; SILVER J, 1979, DEV BIOL, V68, P175, DOI 10.1016/0012-1606(79)90252-5; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; THRELKELD A, 1989, DEV BIOL, V132, P559, DOI 10.1016/0012-1606(89)90251-0; WATANABE M, 1991, J NEUROBIOL, V22, P85, DOI 10.1002/neu.480220109; ZAREMBA S, 1990, J NEUROSCI, V10, P2985	21	389	397	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					733	736		10.1126/science.1738848	http://dx.doi.org/10.1126/science.1738848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738848				2022-12-28	WOS:A1992HC50600044
J	SIXMA, TK; PRONK, SE; KALK, KH; VANZANTEN, BAM; BERGHUIS, AM; HOL, WGJ				SIXMA, TK; PRONK, SE; KALK, KH; VANZANTEN, BAM; BERGHUIS, AM; HOL, WGJ			LACTOSE BINDING TO HEAT-LABILE ENTEROTOXIN REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							TOXIN B-SUBUNIT; CHOLERA-TOXIN; ESCHERICHIA-COLI; BACTERIAL TOXINS; GANGLIOSIDE GM1; RECEPTOR; PROTEINS; MEMBRANE; ASSOCIATION; REFINEMENT	RECOGNITION of the oligosaccharide portion of ganglioside G(M1) in membranes of target cells by the heat-labile enterotoxin from Escherichia coli is the crucial first step in its pathogenesis, as it is for the closely related cholera toxin 1-3. These toxins have five B subunits, which are essential for G(M1) binding, and a single A subunit, which needs to be nicked by proteolysis and reduced, yielding an A1-'enzyme' and an A2-'linker' peptide. A1 is translocated across the membrane of intestinal epithelial cells, possibly after endocytosis 4,5, upon which it ADP-ribosylates the G protein G(s-alpha) (reviewed in refs 2, 3, 6). The mechanism of binding and translocation of these toxins has been extensively investigated 1,2,7-20, but how the protein is orientated on binding is still not clear 10-12,18. Knowing the precise arrangement of the ganglioside binding sites of the toxins will be useful for designing drugs against the diarrhoeal diseases caused by organisms secreting these toxins and in the development of oral vaccines against them 21,22. We present here the three-dimensional structure of the E. coli heat-labile enterotoxin complexed with lactose. This reveals the location of the binding site of the terminal galactose of G(M1), which is consistent with toxin binding to the target cell with its A1 fragment pointing away from the membrane. A small helix is identified at the carboxy terminus of A2 which emerges through the central pore of the B subunits and probably comes into contact with the membrane upon binding, whereas the A1 subunit is flexible with respect to the B pentamer.			SIXMA, TK (corresponding author), UNIV GRONINGEN, BIOSON RES INST, DEPT CHEM, NIJENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS.		Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X; Sixma, Titia K/0000-0001-6180-0632				ARNONE A, 1971, J BIOL CHEM, V246, P2302; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLEMENTS JD, 1979, INFECT IMMUN, V24, P760, DOI 10.1128/IAI.24.3.760-769.1979; DEAIZPURUA HJ, 1988, J EXP MED, V167, P440, DOI 10.1084/jem.167.2.440; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5489; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; GOINS B, 1988, BIOCHEMISTRY-US, V27, P2046, DOI 10.1021/bi00406a035; GRIFFITHS SL, 1986, BIOCHEM J, V238, P313, DOI 10.1042/bj2380313; HOLMGREN J, 1982, INFECT IMMUN, V38, P424, DOI 10.1128/IAI.38.2.424-433.1982; JANICOT M, 1991, J BIOL CHEM, V266, P12858; LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985; LESK AM, 1985, METHOD ENZYMOL, V115, P381; LUDWIG DS, 1985, J BIOL CHEM, V260, P2528; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PRONK SE, 1985, J BIOL CHEM, V260, P3580; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANCHEZ J, 1988, GENE, V64, P265, DOI 10.1016/0378-1119(88)90341-1; SATTLER J, 1977, H-S Z PHYSIOL CHEM, V358, P159, DOI 10.1515/bchm2.1977.358.1.159; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SVENNERHOLM AM, 1982, LANCET, V1, P305; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUJI T, 1985, J BIOL CHEM, V260, P8552; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0	36	185	192	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 6	1992	355	6360					561	564		10.1038/355561a0	http://dx.doi.org/10.1038/355561a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1741035				2022-12-28	WOS:A1992HC52600064
J	ELBRECHT, A; SMITH, RG				ELBRECHT, A; SMITH, RG			AROMATASE ENZYME-ACTIVITY AND SEX DETERMINATION IN CHICKENS	SCIENCE			English	Article							MULLERIAN INHIBITING SUBSTANCE; DETERMINING REGION; ESTROGEN; OVARY; CHROMOSOME; ANDROGEN; EMBRYO; GENE	During development, the genotype of the zygote determines the nature of the gonad, which then determines the male or female phenotype. The molecular events underlying this process are just beginning to be defined. A single treatment of chicken embryos with an aromatase inhibitor (which blocks the synthesis of estrogen from testosterone) at a stage when their gonads were bipotential caused genetic females to develop a permanent male phenotype. These sex-reversed females developed bilateral testes that were capable of complete spermatogenesis and had the physical appearance and behavior of normal males. This result identifies aromatase as a key developmental switch in the sex determination of chickens.			ELBRECHT, A (corresponding author), MERCK SHARP & DOHME LTD,DEPT ANIM BIOCHEM & MOLEC BIOL,RAHWAY,NJ 07065, USA.							BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BELL DJ, 1971, MALE REPRODUCTION PH, V3, P1411; BROWNE LJ, 1988, Patent No. 4728645; GEORGE FW, 1978, NATURE, V274, P172, DOI 10.1038/274172a0; GEORGE FW, 1978, J CLIN ENDOCR METAB, V47, P550, DOI 10.1210/jcem-47-3-550; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Haffen K., 1970, Adv Morphogen, V8, P285; HUTSON JM, 1985, GEN COMP ENDOCR, V57, P88, DOI 10.1016/0016-6480(85)90204-7; HUTSON JM, 1983, INT REV PHYSIOL, V27, P177; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; LAKE PE, 1956, Q J MICROSC SCI, V97, P487; Masui K, 1933, SEXING BABY CHICKS; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MILEWICH L, 1977, ENDOCRINOLOGY, V100, P187, DOI 10.1210/endo-100-1-187; SCHUMACHER M, 1991, J NEUROENDOCRINOL, V3, P221, DOI 10.1111/j.1365-2826.1991.tb00266.x; SCHWARZEL WC, 1973, ENDOCRINOLOGY, V92, P866, DOI 10.1210/endo-92-3-866; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMITH RE, UNPUB, P54011; STEELE R E, 1987, Steroids, V50, P147, DOI 10.1016/0039-128X(83)90068-5; TENG CS, 1987, DEV BIOL, V123, P255, DOI 10.1016/0012-1606(87)90447-7; VIGIER B, 1989, P NATL ACAD SCI USA, V86, P3684, DOI 10.1073/pnas.86.10.3684; WOUTERS W, 1989, J STEROID BIOCHEM, V32, P781, DOI 10.1016/0022-4731(89)90453-6; YANG Y, COMMUNICATION	24	423	444	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					467	470		10.1126/science.1734525	http://dx.doi.org/10.1126/science.1734525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734525				2022-12-28	WOS:A1992HA59000042
J	AMON, A; SURANA, U; MUROFF, I; NASMYTH, K				AMON, A; SURANA, U; MUROFF, I; NASMYTH, K			REGULATION OF P34CDC28 TYROSINE PHOSPHORYLATION IS NOT REQUIRED FOR ENTRY INTO MITOSIS IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							CDC2 PROTEIN-KINASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ACTIVATION; DEPHOSPHORYLATION	PROGRESSION from G2 to M phase in eukaryotes requires activation of a protein kinase composed of p34cdc2/CDC28 associated with G1-specific cyclins (reviewed in ref. 1). In some organisms the activation of the kinase at the G2/M boundary is due to dephosphorylation of a highly conserved tyrosine residue at position 15 (Y15) of the cdc2 protein 2-6. Here we report that in the budding yeast Saccharomyces cervisiae, p34CDC28 also undergoes cell-cycle regulated dephosphorylation on an equivalent tyrosine residue (Y19). However, in contrast to previous observations in S. pombe 6, Xenopus 2,3 and mammalian cells 4,5, dephosphorylation of Y19 is not required for the activation of the CDC28/cyclin kinase. Furthermore, mutation of this tyrosine residue does not affect dependence of mitosis on DNA synthesis nor does it abolish G2 arrest induced by DNA damage. Our data imply that regulated phosphorylation of this tyrosine residue is not the 'universal' means by which the onset of mitosis is determined. We propose that there are other unidentified controls that regulate entry into mitosis.	INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Surana, Uttam/H-1142-2011	Surana, Uttam/0000-0002-4785-6514; Muroff, Ivor/0000-0003-3721-5278; Nasmyth, Kim/0000-0001-7030-4403; Amon, Angelika/0000-0001-9837-0314				COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GAULTIER J, 1991, CELL, V67, P197; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Rubin G M, 1975, Methods Cell Biol, V12, P45; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	23	257	261	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					368	371		10.1038/355368a0	http://dx.doi.org/10.1038/355368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731251				2022-12-28	WOS:A1992HA59100074
J	STORY, RM; WEBER, IT; STEITZ, TA				STORY, RM; WEBER, IT; STEITZ, TA			THE STRUCTURE OF THE ESCHERICHIA-COLI RECA PROTEIN MONOMER AND POLYMER	NATURE			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DUPLEX DNA; CONSTITUTIVE MUTANTS; ELECTRON-MICROSCOPY; FUNCTIONAL REGIONS; SEQUENCE ANALYSIS; BINDING PROTEIN; TRANSFER-RNA; COMPLEXES	The crystal structure of the recA protein from Escherichia coli at 2.3-angstrom resolution reveals a major domain that binds ADP and probably single- and double-stranded DNA. Two smaller subdomains at the N and C termini protrude from the protein and respectively stabilize a 6(1) helical polymer of protein subunits and interpolymer bundles. This polymer structure closely resembles that of recA/DNA filaments determined by electron microscopy. Mutations in recA protein that enhance coprotease, DNA-binding and/or strand-exchange activity can be explained if the interpolymer interactions in the crystal reflect a regulatory mechanism in vivo.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	STORY, RM (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Steitz, Thomas A./C-6559-2009					BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BLANAR MA, 1983, COLD SPRING HARB SYM, V49, P507; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; BRYANT FR, 1986, J BIOL CHEM, V261, P2988; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DEJONG EAM, 1989, J MOL BIOL, V206, P133, DOI 10.1016/0022-2836(89)90529-9; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KAWASHIMA H, 1984, MOL GEN GENET, V193, P288, DOI 10.1007/BF00330682; KIRBY EP, 1967, P NATL ACAD SCI USA, V58, P1903, DOI 10.1073/pnas.58.5.1903; KNIGHT KL, 1984, J BIOL CHEM, V259, P1279; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCKAY DB, 1980, J BIOL CHEM, V255, P6662; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MORAND P, 1977, J BACTERIOL, V131, P572, DOI 10.1128/JB.131.2.572-582.1977; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MUENCH KA, 1991, J BIOL CHEM, V266, P844; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; PUGH BF, 1988, J BIOL CHEM, V263, P76; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SALLES B, 1983, P NATL ACAD SCI-BIOL, V80, P65, DOI 10.1073/pnas.80.1.65; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WILSON DH, 1990, J BIOL CHEM, V265, P7351; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050; ZLOTNICK A, 1989, J MOL BIOL, V206, P133	57	693	710	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					318	325		10.1038/355318a0	http://dx.doi.org/10.1038/355318a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731246				2022-12-28	WOS:A1992HA59100055
J	PALENIK, B; HASELKORN, R				PALENIK, B; HASELKORN, R			MULTIPLE EVOLUTIONARY ORIGINS OF PROCHLOROPHYTES, THE CHLOROPHYLL B-CONTAINING PROKARYOTES	NATURE			English	Article							RNA-POLYMERASE; NUCLEOTIDE-SEQUENCE; GREEN CHLOROPLASTS; CYANOBACTERIA; GENE	PROCHLOROPHYTES are prokaryotes that Carry out oxygenic photosynthesis using chlorophylls a and b, but lack phycobiliproteins as light-harvesting pigments 1. These characteristics distinguish them from cyanobacteria, which contain phycobiliproteins, but no chlorophyll b. Three prochlorophyte genera have been described: Prochloron 1-3, Prochlorothrix 4 and Prochlorococcus 5,6. The prochlorophytes share their pigment characteristics with green plant and euglenoid chloroplasts, which has led to a debate on whether these chloroplasts may have arisen from an endosymbiotic prochlorophyte rather than a cyanobacterium 2,7. Molecular sequence data, including those presented here based on a fragment of the rpoC1 gene encoding a subunit of DNA-dependent RNA polymerase, indicate that the known prochlorophyte lineages do not include the direct ancestor of chloroplasts 8-11. We also show that the prochlorophytes are a highly diverged polyphyletic group. Thus the use of chlorophyll b as a light-harvesting pigment has developed independently several times in evolution. Similar conclusions have been reached in parallel studies using 16S ribosomal RNA sequences 12.			PALENIK, B (corresponding author), UNIV CHICAGO,920 E 58TH ST,CHICAGO,IL 60637, USA.		Palenik, Brian/AAA-1822-2020	Palenik, Brian/0000-0002-3717-9046				BERGSLAND KJ, 1991, J BACTERIOL, V173, P3446, DOI 10.1128/jb.173.11.3446-3455.1991; BORODIN AM, 1988, BIOORG KHIM+, V14, P1179; BURGERWIERSMA T, 1986, NATURE, V320, P262, DOI 10.1038/320262a0; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; CHISHOLM SW, IN PRESS ARCH MIKROB; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; JAYNES JM, 1982, TRENDS BIOCHEM SCI, V7, P22, DOI 10.1016/0968-0004(82)90058-5; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; LEWIN R A, 1975, Phycologia, V14, P153, DOI 10.2216/i0031-8884-14-3-153.1; LEWIN RA, 1976, NATURE, V261, P697, DOI 10.1038/261697b0; LEWIN RA, 1989, PROCHIORON MICROBIAL; MORDEN CW, 1989, NATURE, V339, P400, DOI 10.1038/339400a0; MORDEN CW, 1989, NATURE, V337, P382, DOI 10.1038/337382a0; MORDEN CW, 1991, J MOL EVOL, V32, P379, DOI 10.1007/BF02101278; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1982, NUCLEIC ACIDS RES, V10, P4035, DOI 10.1093/nar/10.13.4035; PUEHLER G, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P4569; SCHNEIDER GJ, 1988, J BACTERIOL, V170, P4136, DOI 10.1128/jb.170.9.4136-4140.1988; SCHNEIDER GJ, 1987, J BIOL CHEM, V262, P14633; Stackebrandt E, 1989, PROCHLORON MICROBIAL, P65; TURNER S, 1989, NATURE, V337, P380, DOI 10.1038/337380a0; URBACH E, 1992, NATURE, V355, P267, DOI 10.1038/355267a0	28	191	204	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					265	267		10.1038/355265a0	http://dx.doi.org/10.1038/355265a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731224				2022-12-28	WOS:A1992GZ69400072
J	GELBER, RH; FUKUDA, K; BYRD, S; MURRAY, LP; SIU, P; TSANG, M; REA, TH				GELBER, RH; FUKUDA, K; BYRD, S; MURRAY, LP; SIU, P; TSANG, M; REA, TH			A CLINICAL-TRIAL OF MINOCYCLINE IN LEPROMATOUS LEPROSY	BRITISH MEDICAL JOURNAL			English	Article									UNIV SO CALIF,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90033	University of Southern California	GELBER, RH (corresponding author), HANSENS DIS RES PROGRAM,SAN FRANCISCO,CA 94115, USA.							GELBER RH, 1987, J INFECT DIS, V156, P236, DOI 10.1093/infdis/156.1.236; GELBER RH, 1991, ANTIMICROB AGENTS CH, V35, P992, DOI 10.1128/AAC.35.5.992; GROSSET JH, 1990, INT J LEPROSY, V58, P281; REES RJW, 1970, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5688.89; SHEPARD CC, 1981, LEPROSY REV, V52, P299	5	49	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					91	92		10.1136/bmj.304.6819.91	http://dx.doi.org/10.1136/bmj.304.6819.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737148	Green Published, Bronze			2022-12-28	WOS:A1992HA17100024
J	RYAN, M				RYAN, M			RUSSIAN REPORT - DOCTORS AND HEALTH-SERVICE REFORM	BRITISH MEDICAL JOURNAL			English	Article											RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							BLIEV Y, 1990, MEDITSINSKAYA G 0923, P2; BORICH I, 1990, MEDITSINSKAYA G 1028, P1; KHUDYAKOVA T, 1991, IZVESTIYA       0611, P3; KUINA N, 1991, MEDITSINSKAYA G 0201, P2; KUZINA N, 1991, MEDITSINSKAYA G 0628, P2; KUZYMENKO M, 1991, MEDITSINSKAYA G 0111, P2; 1990, MEDITSINSKAYA G 1205, P1	7	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					101	103		10.1136/bmj.304.6819.101	http://dx.doi.org/10.1136/bmj.304.6819.101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737108	Bronze, Green Published			2022-12-28	WOS:A1992HA17100029
J	MATSUI, K; BONIFACE, JJ; REAY, PA; SCHILD, H; FAZEKAS DE ST GROTH, B; DAVIS, MM				MATSUI, K; BONIFACE, JJ; REAY, PA; SCHILD, H; FAZEKAS DE ST GROTH, B; DAVIS, MM			LOW AFFINITY INTERACTION OF PEPTIDE-MHC COMPLEXES WITH T-CELL RECEPTORS	SCIENCE			English	Article							PIGEON CYTOCHROME-C; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; POSITIVE SELECTION; ADHESION RECEPTORS; RECOGNITION; SPECIFICITY; PROTEINS; BIOLOGY; IA	The interaction of antigen-specific T cell receptors (TCRs) with their ligands, peptides bound to molecules of the major histocompatibility complex (MHC), is central to most immune responses, yet little is known about its chemical characteristics. The binding to T cells of a labeled monoclonal antibody to the TCR was inhibited by soluble class 11 MHC heterodimers complexed to different peptides. Inhibition was both peptide- and TCR-specific and of low affinity, with a K(D) = 4 x 10(-5) to 6 x 10(-5) M, orders of magnitude weaker than comparable antibody-antigen interactions. This finding is consistent with the scanning nature of T cell recognition and suggests that antigen-independent adhesion precedes TCR engagement.	STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Stanford University	MATSUI, K (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.		de St Groth, Barbara Fazekas/O-3017-2017	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Davis, Mark/0000-0001-6868-657X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19512] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONIFACE J, UNPUB; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CARBONE FR, 1987, J IMMUNOL, V138, P1838; CHANG TW, 1982, J IMMUNOL, V128, P585; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DAVIS M, UNPUB; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ELLIOT EW, UNPUB; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; GOLDSTEIN A, 1987, MOL PHARMACOL, V31, P603; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JACOBS S, 1975, BIOCHEM BIOPH RES CO, V66, P687, DOI 10.1016/0006-291X(75)90564-1; JANEWAY CA, 1989, IMMUNOL REV, V109, P77, DOI 10.1111/j.1600-065X.1989.tb00020.x; JORGENSEN JL, 1991, IN PRESS NATURE; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1, pCH38; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PARHAM P, 1986, HDB EXPT IMMUNOLOGY, V1, pCH14; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PINCUS MR, 1983, P NATL ACAD SCI-BIOL, V80, P3297, DOI 10.1073/pnas.80.11.3297; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REAY PA, UNPUB; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROCK EP, UNPUB; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; Singer A., 1986, PROG IMMUNOL, V6, P60; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; WEISS A, 1984, J IMMUNOL, V133, P123; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	55	348	362	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1788	1791		10.1126/science.1763329	http://dx.doi.org/10.1126/science.1763329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763329				2022-12-28	WOS:A1991GW31600042
J	VARTY, K; VANDORPE, J; STJOHNSTON, JA; CAMPBELL, WB				VARTY, K; VANDORPE, J; STJOHNSTON, JA; CAMPBELL, WB			WHAT HAPPENS TO PATIENTS WITH NONVASCULAR LEG PAIN	BRITISH MEDICAL JOURNAL			English	Article							NEUROGENIC CLAUDICATION; DIFFERENTIATION		ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter	CAMPBELL, WB (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND.							CARTER SA, 1972, NEW ENGL J MED, V287, P749; GOODREAU JJ, 1978, SURGERY, V84, P749; SMIGIEL M, 1985, GERIATRIC CLIN N AM, V1, P373; STANTON PE, 1987, AM SURGEON, V53, P71; TAIT WF, 1985, BRIT J SURG, V72, P315, DOI 10.1002/bjs.1800720425	5	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1516	1516		10.1136/bmj.303.6816.1516	http://dx.doi.org/10.1136/bmj.303.6816.1516			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782493	Bronze, Green Published			2022-12-28	WOS:A1991GV47600026
J	BALARAJAN, R; RALEIGH, VS; YUEN, P; WHEELER, D; MACHIN, D; CARTWRIGHT, R				BALARAJAN, R; RALEIGH, VS; YUEN, P; WHEELER, D; MACHIN, D; CARTWRIGHT, R			HEALTH RISKS ASSOCIATED WITH BATHING IN SEA-WATER	BRITISH MEDICAL JOURNAL			English	Article									PUBL HLTH LAB SERV,GUILDFORD,ENGLAND		BALARAJAN, R (corresponding author), UNIV SURREY,INST PUBL HLTH,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Wheeler, David/0000-0002-4058-7286				EYKIN SJ, 1988, BMJ, V296, P1484; 1990, HLTH RISKS ASS BATHI; 1990, 4TH HOUS COMM ENV CO; 1976, OFFICIAL J EURO 0205	4	48	51	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1444	1445		10.1136/bmj.303.6815.1444	http://dx.doi.org/10.1136/bmj.303.6815.1444			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773151	Bronze, Green Published			2022-12-28	WOS:A1991GU38500026
J	BOCHNER, BS; LICHTENSTEIN, LM				BOCHNER, BS; LICHTENSTEIN, LM			ANAPHYLAXIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXERCISE-INDUCED ANAPHYLAXIS; INFUSED HISTAMINE; MAST-CELLS; IMMUNOTHERAPY; ALLERGY; HYPERSENSITIVITY; MANIFESTATIONS; PROTEOGLYCANS; SENSITIVITY; PENICILLIN		JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University	BOCHNER, BS (corresponding author), JOHNS HOPKINS UNIV,CTR ASTHMA & ALLERGY,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027429, R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07290, AI 27429, AI 08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; BARACH EM, 1984, JAMA-J AM MED ASSOC, V251, P2118, DOI 10.1001/jama.251.16.2118; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; FULCHER DA, 1991, MED J AUSTRALIA, V154, P210, DOI 10.5694/j.1326-5377.1991.tb121038.x; GOLDEN DBK, 1985, ALLERGY, P507; GRAFT DF, 1987, CLIN REV ALLERG, V5, P149; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P511, DOI 10.1016/0091-6749(85)90736-5; GREENBERGER P, 1980, INVEST RADIOL, V15, pS40, DOI 10.1097/00004424-198011001-00011; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P540, DOI 10.1016/0091-6749(84)90391-9; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAMES LP, 1964, NEW ENGL J MED, V270, P97; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Lamson R.W., 1924, JAMA-J AM MED ASSOC, V82, P1091; LICHTENSTEIN LM, 1985, CECIL TXB MED, V2, P1870; LICHTENSTEIN LM, IN PRESS ANN NY ACAD; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; MCGRATH KG, 1984, JAMA-J AM MED ASSOC, V252, P1314, DOI 10.1001/jama.252.10.1314; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; METCALFE DD, 1984, J IMMUNOL, V132, P1943; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; PATTERSON R, 1982, JAMA-J AM MED ASSOC, V248, P2632, DOI 10.1001/jama.248.20.2632; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; SULLIVAN TJ, 1988, CURRENT THERAPY ALLE, V3, P91; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRIGGIANI M, 1990, J IMMUNOL, V144, P4773; WASSERMAN SI, 1988, ALLERGY PRINCIPLES P, V2, P1365; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; WILLIS J, 1982, FDA DRUG B, V12, P17; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65; ZINSSER H, 1923, INFECTION RESISTANCE, P405; 1973, JAMA-J AM MED ASSOC, V224, P613	50	331	342	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1785	1790		10.1056/NEJM199106203242506	http://dx.doi.org/10.1056/NEJM199106203242506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	1789822				2022-12-28	WOS:A1991FR68100006
J	GRISSOM, CK; ROACH, RC; SARNQUIST, FH; HACKETT, PH				GRISSOM, CK; ROACH, RC; SARNQUIST, FH; HACKETT, PH			ACETAZOLAMIDE IN THE TREATMENT OF ACUTE MOUNTAIN-SICKNESS - CLINICAL EFFICACY AND EFFECT ON GAS-EXCHANGE	ANNALS OF INTERNAL MEDICINE			English	Article						ACETAZOLAMIDE; PULMONARY GAS EXCHANGE; ALTITUDE SICKNESS; PULMONARY EDEMA	DEXAMETHASONE	Objective: To determine the efficacy of acetazolamide in the treatment of patients with acute mountain sickness and the effect of the drug on pulmonary gas exchange in acute mountain sickness. Design: A randomized, double-blind, placebo-controlled trial. Setting: The Denali Medical Research Project high-altitude research station (4200 m) on Mt. McKinley, Alaska. Participants: Twelve climbers attempting an ascent of Mt. McKinley (summit, 6150 m) who presented to the medical research station with acute mountain sickness. Intervention: Climbers were randomly assigned to receive acetazolamide, 250 mg orally, or placebo at 0 (baseline) and 8 hours after inclusion in the study. Main Outcome Measures: An assessment of acute mountain sickness using a symptom score and pulmonary gas exchange measurements was done at baseline and at 24 hours. Main Results: After 24 hours, five of six climbers treated with acetazolamide were healthy, whereas all climbers who received placebo still had acute mountain sickness (P = 0.015). Arterial blood gas specimens were obtained from three of the six acetazolamide recipients and all of the placebo recipients. The alveolar to arterial oxygen pressure difference (PA(O2)-Pa(O2) difference) decreased slightly over 24 hours in the acetazolamide group (- 0.8 +/- 1.2 mm Hg) but increased in the placebo group (+ 3.3 +/- 2.3 mm Hg) (P = 0.024). Acetazolamide improved Pa(o2) over 24 hours (+ 2.9 +/- 0.8 mm Hg) when compared with placebo (- 1.3 +/- 2.8 mm Hg) (P = 0.045). Conclusion: In established cases of acute mountain sickness, treatment with acetazolamide relieves symptoms, improves arterial oxygenation, and prevents further impairment of pulmonary gas exchange.	UNIV ALASKA, SCH HLTH PROFESS, DENALI MED RES PROJECT, ANCHORAGE, AK USA	University of Alaska System; University of Alaska Anchorage			Roach, Robert/F-4729-2011	Roach, Robert/0000-0002-7998-8976				ANHOLM JD, 1979, CHEST, V75, P33, DOI 10.1378/chest.75.1.33; BERTHELSEN P, 1986, BRIT J ANAESTH, V58, P512, DOI 10.1093/bja/58.5.512; BRADWELL A R, 1988, Clinical Science (London), V74, p62P; CAIN SM, 1966, J APPL PHYSIOL, V21, P1195, DOI 10.1152/jappl.1966.21.4.1195; HACKETT PH, 1979, AM J MED, V67, P214, DOI 10.1016/0002-9343(79)90393-0; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950; HACKETT PH, 1983, SEMIN RESPIR MED, V5, P132, DOI 10.1055/s-2007-1011443; Hackett PH, 1986, AM ALPINE J, V28, P129; HACKETT PH, 1988, HYPOXIA TOLERABLE LI, P383; HAYNES R C JR, 1990, P1431; JOHNSON TS, 1984, NEW ENGL J MED, V310, P683, DOI 10.1056/NEJM198403153101103; KRONENBERG RS, 1968, AEROSPACE MED, V39, P296; LARSON EB, 1982, JAMA-J AM MED ASSOC, V248, P328, DOI 10.1001/jama.248.3.328; LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; SUTTON JR, 1976, AVIAT SPACE ENVIR MD, V47, P1032; SWENSON ER, 1991, RESP PHYSIOL, V86, P333, DOI 10.1016/0034-5687(91)90104-Q; WASSERMAN K, 1987, PRINCIPLES EXERCISE, P253	19	111	112	2	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					461	465		10.7326/0003-4819-116-6-461	http://dx.doi.org/10.7326/0003-4819-116-6-461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739236				2022-12-28	WOS:A1992HJ59800005
J	BRODERICK, JP; BROTT, T; TOMSICK, T; HUSTER, G; MILLER, R				BRODERICK, JP; BROTT, T; TOMSICK, T; HUSTER, G; MILLER, R			THE RISK OF SUBARACHNOID AND INTRACEREBRAL HEMORRHAGES IN BLACKS AS COMPARED WITH WHITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL INFARCTION; CEREBROVASCULAR-DISEASE; CIGARETTE-SMOKING; STROKE; HYPERTENSION; COMMUNITY; RATES	Background. Stroke is an important cause of death among blacks, and intracerebral and subarachnoid hemorrhages account for nearly half of all early deaths from stroke. The present study investigates whether blacks and whites differ in their risk of having either intracerebral or subarachnoid hemorrhage. Methods. We reviewed the medical records, autopsy reports, and CT scans of all patients suspected of having had an intracerebral or subarachnoid hemorrhage during 1988 among the nearly 1.3 million people in the Greater Cincinnati metropolitan area. Results. There were 221 cases of first spontaneous intracranial hemorrhage among 1,086,462 whites (159 intracerebral and 62 subarachnoid hemorrhages), and 45 cases among 171,718 blacks (27 intracerebral and 18 subarachnoid hemorrhages). Blacks had 2.1 times the risk of subarachnoid hemorrhage of whites (95 percent confidence interval, 1.3 to 3.6) and 1.4 times the risk of intracerebral hemorrhage (95 percent confidence interval, 0.9 to 2.1). In those under the age of 75, the risk of intracerebral hemorrhage among blacks was 2.3 times that of whites (95 percent confidence interval, 1.5 to 3.6), whereas the risk among blacks 75 or older was one fourth that of whites (95 percent confidence interval, 0.1 to 0.8). Deaths within 30 days of intracerebral or subarachnoid hemorrhage accounted for 1.9 years of life lost per 1000 blacks under 65 years of age, as compared with 0.5 year per 1000 whites. Conclusions. Young and middle-aged blacks have a substantially higher risk of subarachnoid or intracerebral hemorrhage than whites of similar age. These types of stroke are important causes of excess mortality among young and middle-aged blacks.	UNIV CINCINNATI,MED CTR,DEPT RADIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	BRODERICK, JP (corresponding author), UNIV CINCINNATI,MED CTR,DEPT NEUROL,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.							ABUZEID HAH, 1977, STROKE, V8, P106, DOI 10.1161/01.STR.8.1.106; [Anonymous], 1989, RACIAL ETHNIC DIFFER; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BONITA R, 1983, STROKE, V14, P342, DOI 10.1161/01.STR.14.3.342; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; BROTT T, 1986, STROKE, V17, P1078, DOI 10.1161/01.STR.17.6.1078; DRURY I, 1984, NEUROLOGY, V34, P653, DOI 10.1212/WNL.34.5.653; FRIDAY G, 1989, NEUROLOGY, V39, P1165, DOI 10.1212/WNL.39.9.1165; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; HOWARD G, 1991, J CLIN EPIDEMIOL, V44, P293, DOI 10.1016/0895-4356(91)90041-7; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEYFITZ N, 1966, HUM BIOL, V38, P309; KLATSKY AL, 1991, STROKE, V22, P299, DOI 10.1161/01.STR.22.3.299; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; OKADA H, 1976, STROKE, V7, P599, DOI 10.1161/01.STR.7.6.599; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; 1986, MMWR S2S, V35, pS1; 1985, HYPERTENSION, V7, P457; 1990, DHHS PHS901232 PUBL	25	327	332	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					733	736		10.1056/NEJM199203123261103	http://dx.doi.org/10.1056/NEJM199203123261103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738378	Bronze			2022-12-28	WOS:A1992HH06400003
J	SIMONDS, RJ; HOLMBERG, SD; HURWITZ, RL; COLEMAN, TR; BOTTENFIELD, S; CONLEY, LJ; KOHLENBERG, SH; CASTRO, KG; DAHAN, BA; SCHABLE, CA; RAYFIELD, MA; ROGERS, MF				SIMONDS, RJ; HOLMBERG, SD; HURWITZ, RL; COLEMAN, TR; BOTTENFIELD, S; CONLEY, LJ; KOHLENBERG, SH; CASTRO, KG; DAHAN, BA; SCHABLE, CA; RAYFIELD, MA; ROGERS, MF			TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM A SERONEGATIVE ORGAN AND TISSUE DONOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY-TRANSPLANT RECIPIENTS; RENAL-TRANSPLANTATION; HIV TRANSMISSION; BLOOD-DONORS; P24 ANTIGEN; INFECTION; ANTIBODY; INACTIVATION; PROTEINS; CULTURE	Background. Since 1985, donors of organs or tissues for transplantation in the United States have been screened for human immunodeficiency virus type 1 (HIV-1), and more than 60,000 organs and 1 million tissues have been transplanted. We describe a case of transmission of HIV-1 by transplantation of organs and tissues procured between the time the donor became infected and the appearance of antibodies. The donor was a 22-year-old man who died 32 hours after a gunshot wound; he had no known risk factors for HIV-1 infection and was seronegative. Methods. We reviewed the processing and distribution of all the transplanted organs and tissues, reviewed the medical histories of the donor and HIV-1 -infected recipients, tested stored donor lymphocytes for HIV-1 by viral culture and the polymerase chain reaction, and tested stored serum samples from four organ recipients for HIV-1 antigen and antibody. Results. HIV-1 was detected in cultured lymphocytes from the donor. Of 58 tissues and organs obtained from the donor, 52 could be accounted for by the hospitals that received them. Of the 48 identified recipients, 41 were tested for HIV-1 antibody. All four recipients of organs and all three recipients of unprocessed fresh-frozen bone were infected with HIV-1. However, 34 recipients of other tissues - 2 receiving corneas, 3 receiving lyophilized soft tissue, 25 receiving ethanol-treated bone, 3 receiving dura mater treated with gamma radiation, and 1 receiving marrow-evacuated, fresh-frozen bone - tested negative for HIV-1 antibody. Despite immunosuppressive chemotherapy, HIV-1 antibody appeared between 26 and 54 days after transplantation in the three organ recipients who survived more than 4 weeks. Conclusions. Although rare, transmission of HIV-1 by seronegative organ and tissue donors can occur. Improvements in the methods used to screen donors for HIV-1, advances in techniques of virus inactivation, prompt reporting of HIV infection in recipients, and accurate accounting of distributed allografts would help to reduce further this already exceedingly low risk.	LIFENET TRANSPLANT SERV,VIRGINIA BEACH,VA; VIRGINIA DEPT HLTH,RICHMOND,VA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA HOSP,RICHMOND,VA 23284; COLORADO DEPT HLTH,DENVER,CO	Virginia Commonwealth University	SIMONDS, RJ (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD,MS E-45,ATLANTA,GA 30333, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; BUCK BE, 1990, CLIN ORTHOP RELAT R, V251, P249; BUSCH MP, 1990, NEW ENGL J MED, V323, P1308, DOI 10.1056/NEJM199011083231904; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CARBONE LG, 1988, AM J KIDNEY DIS, V11, P387, DOI 10.1016/S0272-6386(88)80051-9; CLARKE JA, 1987, LANCET, V1, P983; CONWAY B, 1991, AIDS, V5, P608, DOI 10.1097/00002030-199105000-00029; DUMMER JS, 1989, TRANSPLANTATION, V47, P134, DOI 10.1097/00007890-198901000-00030; ERICE A, 1991, REV INFECT DIS, V13, P537; FEORINO P, 1987, J CLIN MICROBIOL, V25, P2344, DOI 10.1128/JCM.25.12.2344-2346.1987; HILFENHAUS JW, 1990, CANCER DETECT PREV, V14, P369; HORSBURGH CR, 1989, LANCET, V2, P637; JACKSON JB, 1990, ARCH PATHOL LAB MED, V114, P249; KITCHEN AD, 1989, VOX SANG, V56, P223, DOI 10.1111/j.1423-0410.1989.tb02033.x; KUMAR P, 1987, ANN INTERN MED, V106, P244, DOI 10.7326/0003-4819-106-2-244; LAGESTEHR J, 1985, LANCET, V2, P1361; NEUMAYER HH, 1987, TRANSPLANT P, V19, P2169; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; PROMPT CA, 1985, LANCET, V2, P672; QUARTO M, 1989, NEW ENGL J MED, V320, P1754; RUBIN RH, 1988, TRANSPLANT INT, V1, P36; SAMUEL D, 1988, LANCET, V1, P1221; Schirm J., 1988, Serodiagnosis and Immunotherapy in Infectious Disease, V2, P91, DOI 10.1016/0888-0786(88)90041-8; SCHWARZ A, 1987, TRANSPLANTATION, V44, P21, DOI 10.1097/00007890-198707000-00006; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WARD JW, 1989, TRANSPLANTATION, V47, P722, DOI 10.1097/00007890-198904000-00030; WELLS MA, 1986, TRANSFUSION, V26, P210, DOI 10.1046/j.1537-2995.1986.26286152919.x; 1985, MMWR, V34, P1; 1987, MMWR, V36, P306; 1991, FED REGISTER, V56, P43026; 1985, MMWR, V34, P294; 1988, MMOWR, V37, P597; 1988, MMWR, V37, P63; 1988, MMWR, V37, P57	34	446	454	2	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					726	732		10.1056/NEJM199203123261102	http://dx.doi.org/10.1056/NEJM199203123261102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738377	Green Published			2022-12-28	WOS:A1992HH06400002
J	HEALY, B				HEALY, B			HELPING CHILDREN INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							PROBER CG, 1991, PEDIATR INFECT DIS J, V10, P684, DOI 10.1097/00006454-199109000-00012; 1991, JAMA-J AM MED ASSOC, V266, P3439	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1319	1319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740841				2022-12-28	WOS:A1992HG67800004
J	PEPIN, MC; POTHIER, F; BARDEN, N				PEPIN, MC; POTHIER, F; BARDEN, N			IMPAIRED TYPE-II GLUCOCORTICOID-RECEPTOR FUNCTION IN MICE BEARING ANTISENSE RNA TRANSGENE	NATURE			English	Article							OBESE ZUCKER RAT; MESSENGER-RNA; PROTEIN; CELLS; BRAIN; BINDING; ADRENOCORTICOTROPIN; ADRENALECTOMY; INHIBITION; EXPRESSION	GLUCOCORTICOIDS, in conjunction with their cognate receptors, exert negative-feedback effects on the hypothalamus-pituitary-adrenal axis, suppressing adrenal steroid secretions. Two types of corticosteroid receptor, distinguishable by their ability to bind corticosterone, have been identified as classical mineralocorticoid (type I) 1 and glucocorticoid (type II) 2 receptors by cloning their complementary DNAs. The type I receptor controls the basal circadian rhythm of corticosteroid secretion. Both receptor types are involved in negative feedback 3, but the type II receptor may be more important for terminating the stress response as it is the only one to be increased in animals rendered more sensitive to corticosteroid negative-feedback effects 4 . Here we create a transgenic mouse with impaired corticosteroid-receptor function by partially knocking out gene expression with type II glucocorticoid receptor antisense RNA. We use this animal to study the glucocorticoid feedback effect on the hypothalamus-pituitary-adrenal axis.	CHU LAVAL,RES CTR,DEPT PHYSIOL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; CHU LAVAL,DEPT ZOOTECHNIE,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; UNIV LAVAL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA	Laval University; Laval University; Laval University	PEPIN, MC (corresponding author), CHU LAVAL,RES CTR,MOLEC PSYCHOGENET LAB,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL BJ, 1976, ARCH GEN PSYCHIAT, V33, P1039; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FARMER SR, 1983, MOL CELL BIOL, V3, P182, DOI 10.1128/MCB.3.2.182; FLETCHER JM, 1986, BRIT J NUTR, V56, P141, DOI 10.1079/BJN19860094; FREEDMAN MR, 1986, AM J PHYSIOL, V250, pR595, DOI 10.1152/ajpregu.1986.250.4.R595; FUNDER JW, 1987, ANNU REV PHYSIOL, V49, P397; GIGUERE V, 1982, ENDOCRINOLOGY, V110, P1225, DOI 10.1210/endo-110-4-1225; GREDEN JF, 1983, ARCH GEN PSYCHIAT, V40, P493; HOGAN B, 1986, MANIPULATING MOUSE E; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; KATSUKI M, 1988, SCIENCE, V241, P593, DOI 10.1126/science.2456614; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; LANGLEY SC, 1990, BRAIN RES, V533, P268, DOI 10.1016/0006-8993(90)91349-L; LINKOWSKI P, 1985, J CLIN ENDOCR METAB, V61, P429, DOI 10.1210/jcem-61-3-429; MCGARRY TJ, 1986, P NATL ACAD SCI USA, V83, P399, DOI 10.1073/pnas.83.2.399; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; PEIFFER A, 1991, PSYCHONEUROENDOCRINO, V16, P505, DOI 10.1016/0306-4530(91)90034-Q; PEPIN MC, 1989, MOL BRAIN RES, V6, P77, DOI 10.1016/0169-328X(89)90031-4; PEPIN MC, 1991, MOL CELL BIOL, V11, P1647, DOI 10.1128/MCB.11.3.1647; PROVENCHER P, 1990, J STEROID BIOCHEM, V36, P589, DOI 10.1016/0022-4731(90)90177-T; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; SVEC F, 1981, J BIOL CHEM, V256, P5984; TORNELLO S, 1982, NEUROENDOCRINOLOGY, V35, P411, DOI 10.1159/000123429; WHITE BD, 1990, J STEROID BIOCHEM, V36, P681, DOI 10.1016/0022-4731(90)90188-X	30	284	292	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					725	728		10.1038/355725a0	http://dx.doi.org/10.1038/355725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741058				2022-12-28	WOS:A1992HE60400063
J	GALVE, E; ORDI, J; BARQUINERO, J; EVANGELISTA, A; VILARDELL, M; SOLERSOLER, J				GALVE, E; ORDI, J; BARQUINERO, J; EVANGELISTA, A; VILARDELL, M; SOLERSOLER, J			VALVULAR HEART-DISEASE IN THE PRIMARY ANTIPHOSPHOLIPID SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						HEART VALVE DISEASE; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; CARDIOLIPINS; LUPUS ERYTHEMATOSUS, SYSTEMIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; THROMBOCYTOPENIC PURPURA; MITRAL REGURGITATION; ANTICOAGULANT; ASSOCIATION; NECROPSY; PATTERNS; PATIENT	Objective: To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome. Design: Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 21 months. Setting: University-based tertiary medical center. Patients: Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls. Measurements and Main Results: Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valve involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with mitral valve involvement was 7.0 +/- 1.6 mm, compared with 2.7 +/- 0.8 mm in patients with normal valves and 3.2 +/- 0.9 mm in the control group. The mean aortic valve thickness in patients with aortic valve involvement was 3.8 +/- 0.5 mm compared with 1.4 +/- 0.3 mm in patients with normal valves and 1.4 +/- 0.5 mm in the control group. Stenotic lesions were not found. Regurgitation was severe in two patients (one required surgery), moderate in three patients, and mild in three patients. Conclusions: Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome. The lesions are left-sided, causing regurgitation that may be clinically important.			GALVE, E (corresponding author), HOSP GEN UNIV VALL HEBRON, DEPT MED, SERV CARDIOL, PASEO VALL HEBRON S-N, E-08035 BARCELONA, SPAIN.		Barquinero, Jordi/F-6979-2011	Barquinero, Jordi/0000-0002-1677-9851				ANDERSON D, 1987, J RHEUMATOL, V14, P839; ARROYO R A, 1989, Arthritis and Rheumatism, V32, pS73; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BULKLEY BH, 1975, AM J MED, V58, P243, DOI 10.1016/0002-9343(75)90575-6; CANOSO RT, 1987, BRIT J HAEMATOL, V65, P495, DOI 10.1111/j.1365-2141.1987.tb04157.x; CHARTASH EK, 1989, AM J MED, V86, P407, DOI 10.1016/0002-9343(89)90337-9; CONLEY CL, 1952, J CLIN INVEST, V31, P621; DALTON JG, 1985, STROKE, V16, P512, DOI 10.1161/01.STR.16.3.512; DELEZE M, 1988, J RHEUMATOL, V15, P611; EVANGELISTA A, 1989, European Heart Journal, V10, P404; EXNER T, 1978, BRIT J HAEMATOL, V40, P143, DOI 10.1111/j.1365-2141.1978.tb03648.x; FORD PM, 1988, J RHEUMATOL, V15, P597; GALVE E, 1988, NEW ENGL J MED, V319, P817, DOI 10.1056/NEJM198809293191302; GALVE E, 1989, NEW ENGL J MED, V320, P740; HARRIS EN, 1987, BRIT J RHEUMATOL, V26, P324; HARRIS EN, 1985, BRIT J HAEMATOL, V59, P231, DOI 10.1111/j.1365-2141.1985.tb02989.x; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; HUGHES GRV, 1985, CLIN EXP RHEUMATOL, V3, P285; KEANE A, 1987, BRIT J RHEUMATOL, V26, P346; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; KOCHENOUR NK, 1987, OBSTET GYNECOL, V69, P460; KOZLOWSKI CL, 1987, POSTGRAD MED J, V63, P793, DOI 10.1136/pgmj.63.743.793; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MALIA RG, 1988, CLIN EXP IMMUNOL, V73, P456; MURPHY JJ, 1989, BRIT HEART J, V62, P61; NANDA NN, 1989, ATLAS COLOR DOPPLER; NIHOYANNOPOULOS P, 1990, CIRCULATION, V82, P369, DOI 10.1161/01.CIR.82.2.369; OROURKE RA, 1990, CIRCULATION, V82, P636, DOI 10.1161/01.CIR.82.2.636; PONSLLADO G, 1986, AM J CARDIOL, V57, P806, DOI 10.1016/0002-9149(86)90618-1; POPE JM, 1991, AM J MED, V90, P299, DOI 10.1016/0002-9343(91)90569-J; ROUGET JP, 1983, ANN MED INTERNE, V134, P111; SALVARANI C, 1989, CLIN EXP RHEUMATOL, V7, P329; SCHLEIDER MA, 1976, BLOOD, V48, P499; SONTHEIMER RD, 1987, ARCH DERMATOL, V123, P590, DOI 10.1001/archderm.123.5.590; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; THIAGARAJAN P, 1986, BLOOD, V68, P869; TIRRI G, 1990, CLIN EXP RHEMATOL, V8, P215; VAARALA O, 1986, CLIN IMMUNOL IMMUNOP, V41, P8, DOI 10.1016/0090-1229(86)90046-2	38	162	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					293	298		10.7326/0003-4819-116-4-293	http://dx.doi.org/10.7326/0003-4819-116-4-293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733383				2022-12-28	WOS:A1992HD54600004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MORATORIUM ON SILICONE GEL BREAST IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732641				2022-12-28	WOS:A1992HC48400005
J	HOWELL, JBL				HOWELL, JBL			LEADING FOR HEALTH - RESPONSES - REEXAMINING THE FUNDAMENTAL PRINCIPLES OF THE NHS .1.	BRITISH MEDICAL JOURNAL			English	Article											HOWELL, JBL (corresponding author), SOUTHAMPTON GEN HOSP,MED,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; KLEIN R, 1991, BRIT MED J, V302, P1, DOI 10.1136/bmj.302.6767.1; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561; THWAITES B, 1987, NHS END RAINBOW; 1983, REPORT; 1990, CCSC GUIDANCE CLIN D; 1991, TIME            1125, P34; 1991, LEADING HLTH BMA AGE	8	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					297	299		10.1136/bmj.304.6822.297	http://dx.doi.org/10.1136/bmj.304.6822.297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739832	Bronze, Green Published			2022-12-28	WOS:A1992HC70800025
J	PISON, G; AABY, P; KNUDSEN, K				PISON, G; AABY, P; KNUDSEN, K			INCREASED RISK OF DEATH FROM MEASLES IN CHILDREN WITH A SIBLING OF OPPOSITE SEX IN SENEGAL	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRANSMISSION; INFECTION; EXPOSURE; PATTERN; AREA	Objective - To examine whether contracting measles from a sibling of the opposite sex affects mortality. Design - Prospective registration during 15-20 years of all births and deaths, including 243 measles related deaths. Measles infection was not registered; however, as in fatal cases measles was probably contracted from a maternal sibling the risk of dying during measles outbreaks was examined in families with two boys, two girls, or a boy and a girl. Setting - 31 small villages in two rural areas of eastern Senegal. Subjects - 766 children living in families with two children aged under 10 years during outbreaks of measles, 107 (14%) of whom died of measles. Main outcome measure - Deaths from measles, size of village, age and sex of maternal siblings. Results - The interval between outbreaks in the same village was greater than 10 years. The risk of dying of measles was significantly related to age, increasing with the age difference between siblings and decreasing with the size of village. In a multiple logistic regression analysis adjusting for these background factors, children in families with a boy and a girl had a significantly higher mortality than children in families with two boys or two girls (odds ratio = 1.81, 95% confidence interval 1.17 to 2.82). The increase in risk was the same for boys and girls in families with two children one of whom was a boy and one a girl. Conclusion - Cross sexual transmission may be an important determinant of severity of measles infection.	MUSEUM NATL HIST NAT,ANTHROPOL BIOL LAB,F-75231 PARIS 05,FRANCE; STATENS SERUM INST,DEPT EPIDEMIOL,DK-2300 COPENHAGEN,DENMARK; UNIV COPENHAGEN,STAT RES UNIT,DK-1168 COPENHAGEN,DENMARK	Museum National d'Histoire Naturelle (MNHN); Statens Serum Institut; University of Copenhagen				Aaby, Peter/0000-0001-8331-1389				AABY P, 1991, J INFECTION, V22, P287, DOI 10.1016/S0163-4453(05)80014-3; AABY P, 1989, DAN MED BULL, V36, P93; AABY P, 1990, J INFECT DIS, V161, P171, DOI 10.1093/infdis/161.2.171; AABY P, 1991, INT J EPIDEMIOL, V20, P504, DOI 10.1093/ije/20.2.504; AABY P, 1984, REV INFECT DIS, V6, P239; AABY P, 1990, BRIT MED J, V301, P143, DOI 10.1136/bmj.301.6744.143; AABY P, 1986, REV INFECT DIS, V8, P138; AABY P, IN PRESS ANN TROP PA; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BHUIYA A, 1987, SOC SCI MED, V24, P439, DOI 10.1016/0277-9536(87)90217-6; FARGUES P, 1988, DOUZE ANS MORTALITE; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MCGREGOR I A, 1964, West Afr Med J, V13, P251; MONASTIRI H, 1961, Tunis Med, V39, P179; PISON G, 1988, REV INFECT DIS, V10, P468; PISON G, 1985, POP STUD-J DEMOG, V39, P387, DOI 10.1080/0032472031000141586; PISON G, 1982, DYNAMIQUE UNE POPULA	18	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					284	287		10.1136/bmj.304.6822.284	http://dx.doi.org/10.1136/bmj.304.6822.284			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739828	Bronze, Green Published			2022-12-28	WOS:A1992HC70800020
J	[Anonymous]				[Anonymous]			INTERNATIONAL COLLABORATION - A LIFELINE FROM ABROAD	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1992	355	6359					387	387						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734271				2022-12-28	WOS:A1992HB53000020
J	CHANG, TC; KAO, SCS; HUANG, KM				CHANG, TC; KAO, SCS; HUANG, KM			OCTREOTIDE AND GRAVES OPHTHALMOPATHY AND PRETIBIAL MYXEDEMA	BRITISH MEDICAL JOURNAL			English	Article							PATHOGENESIS; SOMATOSTATIN		NATL TAIWAN UNIV HOSP,DEPT OPHTHALMOL,TAIPEI 100,TAIWAN; NATL TAIWAN UNIV HOSP,DEPT RADIOL,TAIPEI 100,TAIWAN	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	CHANG, TC (corresponding author), NATL TAIWAN UNIV HOSP,DEPT INTERNAL MED,TAIPEI 100,TAIWAN.							BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; HANSSON HA, 1986, LANCET, V1, P218; KRISS JP, 1987, ENDOCRIN METAB CLIN, V16, P409, DOI 10.1016/S0889-8529(18)30486-9; TSUZAKI S, 1990, ENDOCRINOLOGY, V126, P3131, DOI 10.1210/endo-126-6-3131	4	69	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					158	158		10.1136/bmj.304.6820.158	http://dx.doi.org/10.1136/bmj.304.6820.158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737161	Green Published, Bronze			2022-12-28	WOS:A1992HA97900022
J	SMITH, DL; JOHNSON, AD				SMITH, DL; JOHNSON, AD			A MOLECULAR MECHANISM FOR COMBINATORIAL CONTROL IN YEAST - MCM1 PROTEIN SETS THE SPACING AND ORIENTATION OF THE HOMEODOMAINS OF AN ALPHA-2 DIMER	CELL			English	Article							REPRESSOR-OPERATOR INTERACTIONS; MATING-TYPE LOCUS; TRANSCRIPTIONAL ACTIVATOR; ANTENNAPEDIA HOMEODOMAIN; DNA; BINDING; IDENTIFICATION; RESOLUTION; COMPLEX; GENES	DNA recognition sequences for dimeric proteins typically contain two types of information. The first is the DNA sequence of each half-site, and the second is the arrangement of these half-sites. We show that dimers of the yeast homeodomain protein alpha-2, although able to read the first type of information, lack the ability to assess the second type. Rather, alpha-2 dimers bind with equal affinity to artificial operators in which the two half-sites are arrayed as inverted repeats, as direct repeats, or as everted (inside-out) repeats. We show that a second protein - MCM1 - sets the exact spacing and orientation of the homeodomains in the alpha-2 dimer so that they accommodate only the geometry of the naturally occurring operators. These experiments show directly how the target specificity of a homeodomain protein is raised by an auxiliary protein, allowing it to distinguish the biologically correct operators from closely related sequences in the cell.			SMITH, DL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1990, ANN REV BIOCH, V59, P933; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Maniatis T., 1982, MOL CLONING; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; Miller J.H., 1972, EXPT MOL GENETICS; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PERSIC O, 1989, CELL, V59, P797; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; Sherman F, 1979, METHODS YEAST GENETI; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLBERGER C, 1991, J MOL BIOL, V217, P11, DOI 10.1016/0022-2836(91)90605-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	155	159	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					133	142		10.1016/0092-8674(92)90212-U	http://dx.doi.org/10.1016/0092-8674(92)90212-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732062				2022-12-28	WOS:A1992GZ58300015
J	WAWER, MJ; SERWADDA, D; MUSGRAVE, SD; KONDELULE, JK; MUSAGARA, M; SEWANKAMBO, NK				WAWER, MJ; SERWADDA, D; MUSGRAVE, SD; KONDELULE, JK; MUSAGARA, M; SEWANKAMBO, NK			DYNAMICS OF SPREAD OF HIV-I INFECTION IN A RURAL DISTRICT OF UGANDA	BRITISH MEDICAL JOURNAL			English	Article							VIRUS-INFECTION; IVORY-COAST; PREVALENCE; POPULATION; TANZANIA; REGION; AIDS	Objective - To define the geographical distribution of HIV infection and the community characteristics associated with HIV prevalence in a rural population of Uganda. Design - Seroprevalence survey and interviews of the population aged 13 years and older in 21 randomly selected clusters. Setting - Rural population of Rakai district, south west Uganda. Subjects - 1292 adults, of whom 594 men and 698 women gave a blood sample and answered the questionnaire. Main outcome measures - HIV status determined by ELISA and western blotting in relation to community characteristics. Results - The weighted seroprevalence of HIV for the district was 12.6% with prevalence by cluster varying from 1.2% to 52.8%. Seroprevalence was highest in main road trading centres (men 26%, women 47%), intermediate in rural trading villages on secondary roads (men 22%, women 29%), and lowest in rural agricultural villages (men 8%, women 9%). For both men and women, multiple regression showed a strong negative association between cluster seroprevalence and the proportion of the population employed in agriculture (beta = -0.677 for men, -0.807 for women). Among women, cluster seroprevalence increased with a higher proportion of the population reporting multiple sex partners (beta = 0.814), external travel (beta = 0.579), and injections (beta = 0.483). Conclusions - Community characteristics, particularly the proportion of the population in agriculture, are associated with HIV prevalence and can be used for targeting interventions. The seroprevalences of HIV suggest spread of infection from main road trading centres, through intermediate trading villages, to rural agricultural villages.	MULAGO HOSP,DEPT MED,KAMPALA,UGANDA; UGANDAN MINIST HLTH,RAKAI PROJECT,ENTEBBE,UGANDA; MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA; MAKERERE UNIV,INST PUBL HLTH,KAMPALA,UGANDA	Mulago National Referral Hospital; Makerere University; Makerere University	WAWER, MJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,NEW YORK,NY 10032, USA.			Sewankambo, Nelson/0000-0001-9362-053X	PHS HHS [R01-A129314-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARSWELL JW, 1989, AIDS, V3, P759, DOI 10.1097/00002030-198911000-00013; CARSWELL JW, 1987, AIDS, V1, P223; Cochran W.G., 2007, SAMPLING TECHNIQUES; DECOCK KM, 1989, LANCET, V2, P408; DELALLA F, 1988, AIDS, V2, P317, DOI 10.1097/00002030-198808000-00013; DENIS F, 1987, LANCET, V1, P408; DOLMANS WMV, 1989, AIDS, V3, P297, DOI 10.1097/00002030-198905000-00008; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; NAAMARA W, 1988, 2ND P INT C AIDS AFR; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PLORDE DS, 1981, BRIT J VENER DIS, V57, P357; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; WILCOX RR, 1980, BR J VENER DIS, V56, P277	16	108	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1303	1306		10.1136/bmj.303.6813.1303	http://dx.doi.org/10.1136/bmj.303.6813.1303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747672	Green Published, Bronze			2022-12-28	WOS:A1991GT01100021
J	EASTON, JA; TURNER, SW				EASTON, JA; TURNER, SW			DETENTION OF BRITISH CITIZENS AS HOSTAGES IN THE GULF - HEALTH, PSYCHOLOGICAL, AND FAMILY CONSEQUENCES	BRITISH MEDICAL JOURNAL			English	Article							POSTTRAUMATIC STRESS DISORDER; SOUTHEAST ASIAN REFUGEES; TORTURE; IMPACT	Objective - To describe the physical, psychological, and family consequences of the detention of British subjects as hostages in Kuwait or Iraq, or both, after the invasion of Kuwait on 2 August 1990 and to investigate the relation between types of trauma experienced and these reactions. Design - Postal questionnaire. Subjects - 381 respondents. Results - Many health, social, and psychological sequelae were identified. Problems with present finance, accommodation, and work are important causes of distress. Many hostages coped well and gained self esteem. Conclusions - A minority of respondents require further support and treatment. Expatriates in risk areas should retain assets in their home country.	MIDDLESEX HOSP,ACAD DEPT PSYCHIAT,LONDON W1N 8AA,ENGLAND	University of London; University College London	EASTON, JA (corresponding author), HARCOURT MED CTR,SALISBURY SP2 7TD,ENGLAND.							DANTO BL, 1990, STRESSORS ADJUSTMENT, P294; DAVIDSON J, 1985, AM J PSYCHIAT, V142, P90; Dyregrov A, 1989, DISASTER MANAGEMENT, V2, P25; EVANS SJW, 1991, BRIT MED J, V302, P302, DOI 10.1136/bmj.302.6772.302; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Goldberg DP., 1972, DETECTION PSYCHIATRI; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Horowitz M. J., 1976, STRESS RESPONSE SYND; KROLL J, 1989, AM J PSYCHIAT, V146, P1592; Labuc S., 1991, HDB MILITARY PSYCHOL, P471; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P1567; NORUSUS MJ, 1988, STATISTICAL PACKAGE; RACHMAN S, 1980, BEHAV RES THER, V18, P51, DOI 10.1016/0005-7967(80)90069-8; RAPHAEL B, 1989, ACTA PSYCHIAT SCAND, V80, P1, DOI 10.1111/j.1600-0447.1989.tb03041.x; SHAW JA, 1990, STRESSORS ADJUSTMENT, P340; TURNER S, 1990, BRIT J PSYCHIAT, V157, P475, DOI 10.1192/bjp.157.4.475; TURNER SW, 1989, DISASTER MANAGEMENT, V2, P31; WILSON J, IN PRESS INT HDB TRA; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC; 1990, AMNESTY INT 1990 REP, P125	21	16	16	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1231	1234		10.1136/bmj.303.6812.1231	http://dx.doi.org/10.1136/bmj.303.6812.1231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747642	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200021
J	HILL, R; WILLIAMS, J; BRITTON, J; TATTERSFIELD, A				HILL, R; WILLIAMS, J; BRITTON, J; TATTERSFIELD, A			CAN MORBIDITY ASSOCIATED WITH UNTREATED ASTHMA IN PRIMARY-SCHOOL CHILDREN BE REDUCED - A CONTROLLED INTERVENTION STUDY	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; WHEEZING ILLNESS; PREVALENCE; HEALTH; ABSENCE; LABEL	Objective - To determine whether an intervention programme based on existing school and community resources can reduce school absence and improve participation in games lessons and sport in children with unrecognised or undertreated asthma. Design - Parallel group controlled intervention study. Setting - 102 primary schools in Nottingham: 49 were randomised to receive the intervention and 53 to be control schools. Subjects - All children aged 5 to 10 years with parent reported absence from school because of wheezing in the previous year and taking no treatment or beta-agonists only. Interventions - Children with asthma were referred to their general practitioner for assessment of symptoms and treatment. Teachers were given education on asthma by the school nurse in 44 of the 49 intervention schools. Main outcome measures - Changes in school absence and missed games and swimming lessons because of wheezing, and schools' policy towards management of asthma in school. Results - Of 17 432 children screened, 451 met the entry criteria-228 in intervention schools and 223 in control schools. 152 (67%) children in intervention schools visited their general practitioner, of whom 39 (26%) were given a new diagnosis of asthma and 58 (38%) had treatment for asthma increased or changed. Over the next academic year mean (SE) parent reported school absence due to wheezing fell significantly, but to a similar extent, in both intervention and control schools (0.82 (0.11) and 1.09 (0.21) weeks respectively). There was little change in school recorded absence or participation in games lessons and swimming lessons in either group. At the end of the study intervention schools were more likely to have improved aspects of management of asthma in school. Conclusion - The intervention resulted in a majority of children being assessed by their general practitioner and improved teachers' understanding and management of asthma, but it did not result in any appreciable reduction in morbidity.			HILL, R (corresponding author), CITY HOSP,RESP MED UNIT,NOTTINGHAM NG5 1PB,ENGLAND.		Britton, John R/G-9705-2011					ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ANDERSON HR, 1981, LANCET, V2, P1030; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; COLVER AF, 1984, ARCH DIS CHILD, V59, P449, DOI 10.1136/adc.59.5.449; COUGHLIN SP, 1988, J ROY COLL GEN PRACT, V38, P253; DENBAK JH, 1986, BRIT MED J, V292, P175, DOI 10.1136/bmj.292.6514.175; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; HILL RA, 1987, ARCH DIS CHILD, V624, P114; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; LEVY M, 1984, BRIT MED J, V289, P1115, DOI 10.1136/bmj.289.6452.1115; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; SPEIGHT ANP, 1978, BRIT MED J, V2, P331, DOI 10.1136/bmj.2.6133.331; STORR J, 1987, BRIT MED J, V295, P251, DOI 10.1136/bmj.295.6592.251; 1983, SPSSX USERS GUIDE, P601; 1986, GENERALISED LINEAR I	20	34	35	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1169	1174		10.1136/bmj.303.6811.1169	http://dx.doi.org/10.1136/bmj.303.6811.1169			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747614	Bronze, Green Published			2022-12-28	WOS:A1991GP48800023
J	MCWILLIAM, LJ; KNOX, F; WILKINSON, N; OOGARAH, P				MCWILLIAM, LJ; KNOX, F; WILKINSON, N; OOGARAH, P			PERFORMANCE OF SKIN BIOPSIES BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							1990 CONTRACT	Objective - To evaluate and appraise skin biopsies performed by general practitioners and compare their performance with that of hospital doctors. Design - Retrospective analysis of histology records. Setting - University hospital. Subjects - Records of 292 skin biopsy specimens obtained by general practitioners and 324 specimens obtained by general and plastic surgeons. Main outcome measures - Clinical and pathological diagnoses and completeness of excision. Results - The number of specimens received from hospital surgeons and general practitioners increased over the study period; the proportion of specimens from general practitioners rose from 17/1268 (1.3%) in 1984 to 201/2387 (8.7%) in 1990. The range of diagnoses was similar among hospital and general practitioner cases, although malignancy was commoner in hospital cases (63/324 (19%) upsilon 14/292 (5%) in general practitioner cases; chi-2 = 28, p < 0.00001). Completeness of excision was less common among general practitioners than hospital surgeons (150/233 (3/15 malignant) upsilon 195/232 (57/63); chi-2 = 22, p < 0.00001). Conclusions - The increase in minor surgery has implications for the staffing and finance of histopathology departments. General practitioners must be given proper training in performing skin biopsies, and all specimens should be sent for examination.			MCWILLIAM, LJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT PATHOL SCI,DIV HISTOPATHOL,MANCHESTER M20 8LR,LANCS,ENGLAND.							BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; BROWN JS, 1986, MINOR SURGERY TEXT A; CHEW C, 1991, BRIT MED J, V302, P1211, DOI 10.1136/bmj.302.6786.1211-b; FRY J, 1990, COLOUR ATLAS MINOR S; Galloway M, 1990, Health Serv J, V100, P1037; GODFREY E, 1990, HLTH TRENDS, V2, P57; JENKINS S, 1990, BRIT MED J, V300, P825, DOI 10.1136/bmj.300.6728.825; PRINGLE M, 1991, BRIT MED J, V302, P830, DOI 10.1136/bmj.302.6780.830; SHARMAN J, 1986, PRACTITIONER, V230, P27; SLATER D, 1990, BRIT MED J, V300, P1074, DOI 10.1136/bmj.300.6731.1074; WALL DW, 1987, FAM PRACT, V4, P322, DOI 10.1093/fampra/4.4.322; WALL DW, 1985, MED ANN 1985, P74; 1990, STATEMENT FEES ALLOW; 1989, GENERAL PRACTICE NAT; 1983, COST EFFECTIVENESS G; 1987, CM249	16	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1177	1179		10.1136/bmj.303.6811.1177	http://dx.doi.org/10.1136/bmj.303.6811.1177			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747616	Bronze, Green Published			2022-12-28	WOS:A1991GP48800026
J	TSUKAMOTO, T; MIURA, S; FUJIKI, Y				TSUKAMOTO, T; MIURA, S; FUJIKI, Y			RESTORATION BY A 35K MEMBRANE-PROTEIN OF PEROXISOME ASSEMBLY IN A PEROXISOME-DEFICIENT MAMMALIAN-CELL MUTANT	NATURE			English	Article							RAT-LIVER PEROXISOMES; ENDOPLASMIC-RETICULUM; ZELLWEGER SYNDROME; CARBOXY TERMINUS; POLYPEPTIDE; ENVELOPE; GENOME	PEROXISOMES are among the intracellular organelles of eukaryotic cells that contain specialized sets of enzymes with specific functions 1. Little is known of membranous components involved in assembly of the intracellular compartments 2-5. We isolated two peroxisome-deficient and mutually complementary, Chinese hamster ovary cell mutants, Z65 and Z24 6, which closely resembled fibroblasts from patients with autosomal recessive, peroxisome-defective disorders such as Zellweger syndrome 1,7. These patients show characteristic dysmorphism, severe hypotonia, psychomotor retardation, and peroxisomal dysfunctions and rarely survive early childhood. Here we report what seems to be the first direct cloning and characterization of a complementary DNA encoding a peroxisomal membrane protein of relative molecular mass 35,000 (M(r) 35K) that restores the biogenesis of peroxisomes and complements the defect of peroxisomal functions in the mutant Z65.	MEIJI INST HLTH SCI,MOLEC CELL BIOL LAB,ODAWARA,KANAGAWA 250,JAPAN									AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERTHET J, 1951, BIOCHEM J, V50, P174, DOI 10.1042/bj0500174; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREITMAN ML, 1982, MOL CELL BIOL, V2, P966, DOI 10.1128/MCB.2.8.966; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORI M, 1979, P NATL ACAD SCI USA, V76, P3719; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SONE T, 1987, J BIOL CHEM, V262, P5878; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	29	223	225	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					77	81		10.1038/350077a0	http://dx.doi.org/10.1038/350077a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1750930				2022-12-28	WOS:A1991FA69300070
J	BARRETT, BJ; PARFREY, PS; VAVASOUR, HM; ODEA, F; KENT, G; STONE, E				BARRETT, BJ; PARFREY, PS; VAVASOUR, HM; ODEA, F; KENT, G; STONE, E			A COMPARISON OF NONIONIC, LOW-OSMOLALITY RADIOCONTRAST AGENTS WITH IONIC, HIGH-OSMOLALITY AGENTS DURING CARDIAC-CATHETERIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIALS; CALCIUM-BINDING ADDITIVES; CONTRAST-MEDIA; VENTRICULAR-FIBRILLATION; CORONARY ANGIOGRAPHY; COMPLICATIONS	Background. Nonionic, low-osmolality radiocontrast agents are used frequently because they are believed to be safer than ionic, high-osmolality agents, but they are also more expensive. We conducted a randomized trial to compare the incidence of adverse events after the administration of ionic, high-osmolality and of nonionic, low-osmolality radiocontrast agents during cardiac angiography. Methods. We compared the need to treat patients for adverse reactions and the frequency and severity of specific hemodynamic, systemic, and symptomatic side effects in two groups of patients randomly assigned to receive either ionic, high-osmolality or nonionic, low-osmolality radiocontrast material, and also in 366 patients who could not be randomized. Results. Treatment for adverse events was required in 213 of 737 patients who received high-osmolality contrast agents (29 percent) but in only 69 of 753 patients who received nonionic agents (9 percent) (95 percent confidence interval for the percent difference, 15.9 to 23.6 percent). Hemodynamic deterioration and symptoms also occurred more often in the high-osmolality group, as did severe or prolonged reactions (2.9 percent, as compared with 0.8 percent in the nonionic group; P = 0.035). The severe reactions were largely confined to patients with severe cardiac disease. Multivariate analysis showed that the presence of severe coronary disease and unstable angina were predictors of clinically important adverse reactions. If all the patients in our randomized trial had been given nonionic contrast material, the incremental cost per procedure would have been $89. Conclusions. Nonionic, low-osmolality contrast material is better tolerated during cardiac angiography than ionic, high-osmolality contrast material. Since cost constraints may prevent the universal use of nonionic contrast material, its selective use in patients with severe cardiac disease could be considered.	MEM UNIV NEWFOUNDLAND,HLTH SCI CTR,DIV NEPHROL,ST JOHNS A1B 3V6,NEWFOUNDLAND,CANADA; MEM UNIV NEWFOUNDLAND,GEN HOSP,DEPT MED,DIV CARDIOL,ST JOHNS A1B 3V6,NEWFOUNDLAND,CANADA	Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba; Memorial University Newfoundland								BARRETT BJ, IN PRESS RADIOLOGY; BARRETT BJ, IN PRESS KIDNEY INT; BARRETT BJ, 1991, ACUTE RENAL FAILURE, P481; BETTMANN MA, 1985, INVEST RADIOL, V20, pS70, DOI 10.1097/00004424-198501002-00017; DAVIDSON CJ, 1990, AM J CARDIOL, V65, P1481, DOI 10.1016/0002-9149(90)91359-E; DEVORE JL, 1987, PROBABILITY STATISTI; DIXON WJ, 1985, BMDP STATISTICAL SOF; FELDMAN RL, 1988, AM J CARDIOL, V61, P1334, DOI 10.1016/0002-9149(88)91179-4; GOEL V, 1989, CAN MED ASSOC J, V140, P389; HIRSHFELD JW, 1990, AM J CARDIOL, V66, P355, DOI 10.1016/0002-9149(90)90849-V; HLATKY MA, 1990, J AM COLL CARDIOL, V16, P871, DOI 10.1016/S0735-1097(10)80335-3; KINNISON ML, 1989, RADIOLOGY, V170, P381, DOI 10.1148/radiology.170.2.2643140; LINTON AL, 1990, NEW ENGL J MED, V323, P1463, DOI 10.1056/NEJM199011223232106; MURDOCK DK, 1985, CATHETER CARDIO DIAG, V11, P153, DOI 10.1002/ccd.1810110206; POWE NR, 1989, RADIOLOGY, V170, P377, DOI 10.1148/radiology.170.2.2911662; ZUKERMAN LS, 1987, J AM COLL CARDIOL, V10, P1249	16	124	124	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					431	436		10.1056/NEJM199202133260702	http://dx.doi.org/10.1056/NEJM199202133260702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732770				2022-12-28	WOS:A1992HD16400002
J	ZENILMAN, JM; ERICKSON, B; FOX, R; REICHART, CA; HOOK, EW				ZENILMAN, JM; ERICKSON, B; FOX, R; REICHART, CA; HOOK, EW			EFFECT OF HIV POSTTEST COUNSELING ON STD INCIDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEXUALLY-TRANSMITTED DISEASES; VIRUS-INFECTION; CLINICS; AIDS; MEN	Objective. - To evaluate the effectiveness of human immunodeficiency virus (HIV) testing and posttest counseling in reducing subsequent high-risk behavior. Methods. - The incidence of sexually transmitted diseases (STDs) in the Baltimore, Md, public STD clinic population after HIV testing and counseling was determined by chart review and was compared in two groups, 868 HIV-seropositive patients and 1104 HIV-seronegative patients, matched by age, sex, and month in which HIV test was conducted. Patients were observed for incident STDs at intervals of 6 through 23 months. Patients with incident STDs were classified hierarchically after being notified of the HIV test result and receiving posttest counseling. Results. - Of HIV-seropositive patients, 615 (71%) returned for their test results and received posttest counseling; 694 HIV-seronegative patients (63%) returned. Of all those who returned for results and posttest counseling, 60 (9.7%) of 615 HIV-seropositive patients and 61 (8.8%) of 694 HIV-seronegative patients were diagnosed at least once with definite STD (syphilis, gonorrhea, or trichomoniasis) (P, not significant). Twenty-four HIV-seropositive patients (3.9%) and 71 HIV-seronegative patients (10.2%) returned with probable STD (nongonococcal urethritis or pelvic inflammatory disease) (P < .001). Nine HIV-seropositive patients (1.5%) and 23 HIV-seronegative patients (3.3%) returned having had an STD-infected sexual partner (P < .03). Age, sexual orientation, and drug use behavior did not predict return with STD. Conclusions. - Both HIV-seropositive and HIV-seronegative patients showed high rates of repeat STDs after posttest counseling, an important public health challenge in creating effective high-risk behavior prevention strategies.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; BALTIMORE CITY DEPT HLTH,BALTIMORE,MD	Johns Hopkins University					NIAID NIH HHS [AI29508, AI27727] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029508, R01AI027727] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; HANDSFIELD HH, 1990, SEX TRANSM DIS, V17, P211, DOI 10.1097/00007435-199010000-00011; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; REICHART CA, 1990, SEX TRANSM DIS, V17, P147, DOI 10.1097/00007435-199007000-00007; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; 1991, HIV AIDS SURVEILLANC, P1; 1989, MMWR SS8, V38, P1	12	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					843	845		10.1001/jama.267.6.843	http://dx.doi.org/10.1001/jama.267.6.843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732658				2022-12-28	WOS:A1992HC48400031
J	TASAYCO, ML; CAREY, J				TASAYCO, ML; CAREY, J			ORDERED SELF-ASSEMBLY OF POLYPEPTIDE FRAGMENTS TO FORM NATIVE-LIKE DIMERIC TRP REPRESSOR	SCIENCE			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; DNA-BINDING; TROPONIN-C; NMR; APOREPRESSOR; RESOLUTION; INTERMEDIATE	Subdomain-size proteolytic fragments of Escherichia coli trp repressor have been produced that assemble in defined order to regenerate fully native dimers. By characterization of the secondary and tertiary structures of isolated and recombined fragments, the structure of assembly intermediates can be correlated with the kinetic folding pathway of the intact repressor deduced from spectroscopic measurement of folding rates. The nativelike structure of these intermediates provides further evidence that protein folding pathways reflect the stabilities of secondary structural units and assemblies found in the native state. The proteolytic method should be generally useful in adding structural detail to spectroscopically determined folding mechanisms.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043558, R29GM043558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARROWSMITH CH, 1991, J AM CHEM SOC, V113, P4020, DOI 10.1021/ja00010a070; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CAREY J, 1989, J BIOL CHEM, V264, P1941; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HYDE EI, 1989, EUR J BIOCHEM, V183, P545, DOI 10.1111/j.1432-1033.1989.tb21083.x; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LESK AM, 1981, P NATL ACAD SCI-BIOL, V78, P4304, DOI 10.1073/pnas.78.7.4304; MMULVEY RS, 1974, BIOCHEMISTRY-US, V13, P782; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Taniuchi H, 1986, Methods Enzymol, V131, P185; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	27	96	96	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					594	597		10.1126/science.1736361	http://dx.doi.org/10.1126/science.1736361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736361				2022-12-28	WOS:A1992HB53100042
J	HARLEY, VR; JACKSON, DI; HEXTALL, PJ; HAWKINS, JR; BERKOVITZ, GD; SOCKANATHAN, S; LOVELLBADGE, R; GOODFELLOW, PN				HARLEY, VR; JACKSON, DI; HEXTALL, PJ; HAWKINS, JR; BERKOVITZ, GD; SOCKANATHAN, S; LOVELLBADGE, R; GOODFELLOW, PN			DNA-BINDING ACTIVITY OF RECOMBINANT SRY FROM NORMAL MALES AND XY FEMALES	SCIENCE			English	Article							TESTIS-DETERMINING FACTOR; SEX-DETERMINING REGION; DETERMINING GENE; PROTEINS; ENCODES; DIFFERENTIATION; EXPRESSION; HOMOLOGY; MUTATION; SEQUENCE	The protein encoded by the human testis determining gene, SRY, contains a high mobility group (HMG) box related to that present in the T cell-specific, DNA-binding protein TCF-1. Recombinant SRY protein was able to bind to the same core sequence AACAAAG recognized by TCF-1 in a sequence dependent manner. In five XY females point mutations were found in the region encoding the HMG box. In four cases DNA binding activity of mutant SRY protein was negligible; in the fifth case DNA binding was reduced. These results imply that the DNA binding activity of SRY is required for sex determination.	IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; JOHNS HOPKINS CHILDREN CTR,DIV PEDIAT ENDOCRINOL,BALTIMORE,MD 21205; NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	Cancer Research UK; Johns Hopkins University; Johns Hopkins Medicine; MRC National Institute for Medical Research			Harley, Vincent/B-8092-2018; Hawkins, Ross/M-7702-2014	Harley, Vincent/0000-0002-2405-1262; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER AP, 1985, J BIOL CHEM, V19, P10613; DELACHAPELLE A, 1987, DEVELOPMENT, V101, P33; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; FERGUSONSMITH MA, 1990, HUM GENET, V84, P198; FORD CE, 1959, LANCET, V1, P711; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, UNPUB; GUELLAEN G, 1984, NATURE, V307, P172, DOI 10.1038/307172a0; HAGGREN W, 1988, MOL CELL BIOL, V8, P1282, DOI 10.1128/MCB.8.3.1282; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS JR, IN PRESS HUM GENET; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Jost A., 1973, Recent Progress Hormone Res, V29, P1; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PENTECOST BT, 1985, NUCLEIC ACIDS RES, V13, P4871, DOI 10.1093/nar/13.13.4871; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; ROTH SY, 1987, NUCLEIC ACIDS RES, V15, P8112, DOI 10.1093/nar/15.19.8112; SINCLAIR AG, UNPUB; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; SUMMERS M, 1987, TEX ASGR EXP STN B, V1555; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VERGNAUD G, 1986, AM J HUM GENET, V38, P172; WATERMAN M L, 1990, New Biologist, V2, P621; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; [No title captured]	44	392	403	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					453	456		10.1126/science.1734522	http://dx.doi.org/10.1126/science.1734522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1734522				2022-12-28	WOS:A1992HA59000037
J	FU, YH; KUHL, DPA; PIZZUTI, A; PIERETTI, M; SUTCLIFFE, JS; RICHARDS, S; VERKERK, AJMH; HOLDEN, JJA; FENWICK, RG; WARREN, ST; OOSTRA, BA; NELSON, DL; CASKEY, CT				FU, YH; KUHL, DPA; PIZZUTI, A; PIERETTI, M; SUTCLIFFE, JS; RICHARDS, S; VERKERK, AJMH; HOLDEN, JJA; FENWICK, RG; WARREN, ST; OOSTRA, BA; NELSON, DL; CASKEY, CT			VARIATION OF THE CGG REPEAT AT THE FRAGILE-X SITE RESULTS IN GENETIC INSTABILITY - RESOLUTION OF THE SHERMAN PARADOX	CELL			English	Article							HUMAN DNA; EXPRESSION	Fragile X syndrome results from mutations in a (CGG)n repeat found in the coding sequence of the FMR-1 gene. Analysis of length variation in this region in normal individuals shows a range of allele sizes varying from a low of 6 to a high of 54 repeats. Premutations showing no phenotypic effect in fragile X families range in size from 52 to over 200 repeats. All alleles with greater than 52 repeats, including those identified in a normal family, are meiotically unstable with a mutation frequency of one, while 75 meioses of alleles of 46 repeats and below have shown no mutation. Premutation alleles are also mitotically unstable as mosaicism is observed. The risk of expansion during oogenesis to the full mutation associated with mental retardation increases with the number of repeats, and this variation in risk accounts for the Sherman paradox.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,ATLANTA,GA 30322; ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS; QUEENS UNIV,DEPT CYTOGENET,KINGSTON K7L 3N6,ONTARIO,CANADA	Emory University; Howard Hughes Medical Institute; Emory University; Howard Hughes Medical Institute; Erasmus University Rotterdam; Queens University - Canada	FU, YH (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,CTR HUMAN GENOME,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Sutcliffe, James S/C-1348-2012; Warren, Stephen T/A-2498-2012	Sutcliffe, James S/0000-0001-5200-6007; Verkerk, Annemieke JMH/0000-0002-7523-3656; PIZZUTI, Antonio/0000-0003-3245-1925	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00038] Funding Source: Medline; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; EDWARDS A, 1991, AM J HUM GENET, V49, P746; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD CD, 1987, GENETICS, V117, P587; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	23	1703	1764	0	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1047	1058		10.1016/0092-8674(91)90283-5	http://dx.doi.org/10.1016/0092-8674(91)90283-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760838				2022-12-28	WOS:A1991GX16400005
J	APPELMAN, CLM; CLAESSEN, JQPJ; TOUWOTTEN, FWMM; HORDIJK, GJ; DEMELKER, RA				APPELMAN, CLM; CLAESSEN, JQPJ; TOUWOTTEN, FWMM; HORDIJK, GJ; DEMELKER, RA			CO-AMOXICLAV IN RECURRENT ACUTE OTITIS-MEDIA - PLACEBO CONTROLLED-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; MYRINGOTOMY; ANTIBIOTICS; CLAVULANATE; PENICILLIN; INFANTS	Objective - To determine the efficacy of coamoxiclav in children aged 6 months to 12 years with recurrent acute otitis media. Design - A randomised double blind placebo controlled clinical trial. Setting - General practice in the Netherlands. Patients - 121 children with recurrent acute otitis media, defined by onset of otalgia and otoscopic signs of middle ear infection within four to 52 weeks after the previous attack. Confirmation of diagnosis and randomisation was done by otolaryngologists. Intervention - Oral co-amoxiclav or placebo in weight related doses for seven days. Main outcome measure - An irregular clinical course defined as the presence of otalgia or a body temperature greater-than-or-equal-to 38-degrees-C, or both, after three days. Results - Eleven (16%; 95% confidence interval 9% to 28%) children had an irregular course in the co-amoxiclav group and 10 (19%; 9% to 31%) in the placebo group (difference not significant). Age, dichotomised at 2 years, was the only significant prognostic factor for irregular course of the disease (odds ratio 5.9; 1.8 to 19.1). Among children aged below 2 years, 28% (4/14) in the co-amoxiclav group and 58% (7/12) in the placebo group had irregular courses. For children 2 years and older these percentages were 13% (7/52) and 7% (3/41). Conclusion - Children with recurrent acute otitis media are at greater risk of an irregular clinical course of the disease than children with a first episode of acute otitis media. Co-amoxiclav has no significant benefit over placebo in treating children over 2 years with acute otitis media.	UNIV UTRECHT, DEPT EAR NOSE & THROAT SURG, 3511 ZC UTRECHT, NETHERLANDS	Utrecht University	APPELMAN, CLM (corresponding author), UNIV UTRECHT, DEPT GEN PRACTICE, 3511 ZC UTRECHT, NETHERLANDS.							BASS JW, 1967, JAMA-J AM MED ASSOC, V202, P137; ENGELHARD D, 1989, LANCET, V2, P141; Feenstra L, 1985, Ned Tijdschr Geneeskd, V129, P532; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; HOWIE VM, 1975, AM J DIS CHILD, V129, P679, DOI 10.1001/archpedi.1975.02120430016006; INGVARSSON L, 1982, ACTA OTO-LARYNGOL, V94, P283, DOI 10.3109/00016488209128915; INGVARSSON L, 1988, RECENT ADV OTITIS ME, P6; KALEIDA PH, 1987, PEDIATR INFECT DIS J, V6, P265, DOI 10.1097/00006454-198703000-00013; KLEIN JO, 1988, RECENT ADV OTITIS ME, P14; LORENTZEN P, 1977, J LARYNGOL OTOL, V91, P331, DOI 10.1017/S0022215100083742; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; PUKANDER J, 1982, ACTA OTO-LARYNGOL, V93, P447, DOI 10.3109/00016488209130903; STICKLER GB, 1967, AM J DIS CHILD, V114, P123, DOI 10.1001/archpedi.1967.02090230053002; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	17	59	59	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1991	303	6815					1450	1452		10.1136/bmj.303.6815.1450	http://dx.doi.org/10.1136/bmj.303.6815.1450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773154	Green Published, Bronze			2022-12-28	WOS:A1991GU38500030
J	REILLY, DT; WOLFE, JHN				REILLY, DT; WOLFE, JHN			ABC OF VASCULAR DISEASES - THE SWOLLEN LEG	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	REILLY, DT (corresponding author), WATFORD DIST GEN HOSP,WATFORD,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1462	1465		10.1136/bmj.303.6815.1462	http://dx.doi.org/10.1136/bmj.303.6815.1462			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773158	Bronze, Green Published			2022-12-28	WOS:A1991GU38500034
J	SCHULTZ, R; READ, AW; STRATON, JAY; STANLEY, FJ; MORICH, P				SCHULTZ, R; READ, AW; STRATON, JAY; STANLEY, FJ; MORICH, P			GENITOURINARY TRACT INFECTIONS IN PREGNANCY AND LOW-BIRTH-WEIGHT - CASE-CONTROL STUDY IN AUSTRALIAN ABORIGINAL WOMEN	BRITISH MEDICAL JOURNAL			English	Article							WESTERN-AUSTRALIA; PRETERM BIRTH; HEALTH; MEMBRANES	Objective - To investigate the association between genital and urinary tract infections in pregnant Aboriginal women and low birth weight. Design - Retrospective case-control study controlling for potential confounding variables. Setting - Western Australia from 1985 to 1987. Subjects - All Aboriginal women (n = 269) who had given birth to singleton infants weighing 2250 g or less (cases), and 269 randomly selected Aboriginal women who had given birth to singleton infants weighing 3000 g or more (controls). Main outcome measures - Proportions of women in case and control groups who had had genital and urinary tract infections; odds ratios for low birth weight when genitourinary tract infection was present; population attributable fraction of low birth weight to genitourinary tract infection. Results - At the time of delivery 51% of women in the case group (109/215) had genitourinary tract infections compared with 13% of controls (35/266). After controlling for potential confounding variables the odds ratio for giving birth to infants weighing 2250 g or less when genitourinary tract infection was present was 4.0 (95% confidence interval 2.3 to 7.0). The proportion of infants with low birth weight attributable to genitourinary tract infection in the whole population of Aboriginal women was 32% (95% confidence interval 17% to 49%). Conclusions - There was a strong association between low birth weight and the presence of genitourinary tract infections in Aboriginal women both during pregnancy and at the time of delivery. A community intervention trial of screening and treatment of genitourinary infections in this population is recommended.	WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,WA 6001,AUSTRALIA	Telethon Kids Institute; University of Western Australia	SCHULTZ, R (corresponding author), UNIV WESTERN AUSTRALIA,DEPT PUBL HLTH,NEDLANDS,WA 6009,AUSTRALIA.							ARTURO ZC, 1989, THESIS U W AUSTR, P127; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BLAND M, 1987, INTRO MED STATISTICS; BOWER C, 1988, REPORT CONGENITAL MA; CHISWICK ML, 1986, BRIT J OBSTET GYNAEC, V93, P1236, DOI 10.1111/j.1471-0528.1986.tb07857.x; CREASY RK, 1980, OBSTET GYNECOL, V55, P692; HILL C, 1987, VALIDATION STUDY W A; HOUSTON S, 1985, MED J AUSTRALIA, V143, pS45; ILLSLEY R, 1963, PERINATAL MORTALITY, P270; KHOURY MJ, 1988, PEDIATRICS, V82, P83; KLIEWER EV, 1989, MED J AUSTRALIA, V151, P493, DOI 10.5694/j.1326-5377.1989.tb128495.x; Lee M L, 1988, J Perinat Neonatal Nurs, V2, P10; LEGER WJ, 1989, AM J PERINAT, V6, P234; MCGREGOR JA, 1988, AM J REPROD IMMUNOL, V16, P123; MOORE D, 1988, PERINATAL STATISTICS; NAEYE RL, 1980, LANCET, V1, P192; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; ROMERO R, 1989, J REPROD MED, V34, P797; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEWARD JF, 1981, MED J AUSTRALIA, V2, P80, DOI 10.5694/j.1326-5377.1981.tb100804.x; THOMSON N, 1984, AUST NZ J MED, V14, P705, DOI 10.1111/j.1445-5994.1984.tb05038.x; THOMSON N, 1985, MED J AUSTRALIA, V143, pS46; THOMSON N, 1983, AUST ABORIG STUD, V1, P10; TOTH M, 1988, OBSTET GYNECOL, V71, P723; Wang E, 1989, EFFECTIVE CARE PREGN, P534; 1989, AM J EPIDEMIOL, V129, P1247; 1985, SAS PROCEDURES GUIDE	28	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1369	1373		10.1136/bmj.303.6814.1369	http://dx.doi.org/10.1136/bmj.303.6814.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760603	Bronze, Green Published			2022-12-28	WOS:A1991GU38400020
J	NICOLAIDES, AN				NICOLAIDES, AN			ABC OF VASCULAR DISEASES - ASSESSMENT OF LEG ISCHEMIA	BRITISH MEDICAL JOURNAL			English	Article											NICOLAIDES, AN (corresponding author), ST MARYS HOSP,VASC SURG,LONDON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1323	1326		10.1136/bmj.303.6813.1323	http://dx.doi.org/10.1136/bmj.303.6813.1323			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747678	Bronze, Green Published			2022-12-28	WOS:A1991GT01100028
J	ANNAS, GJ				ANNAS, GJ			CHANGING THE CONSENT RULES FOR DESERT-STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P61; CURRIE DP, 1990, CONSTITUTION SUPREME, P280; HOWE EG, 1991, HASTINGS CENT REP, V21, P21, DOI 10.2307/3562332; JOHNSON WH, 1953, SCIENCE, V117, P212; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; 1990, FED REGISTER, V55, P52814; 1991, AM J HOSP PHARM, V48, P1525	7	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					770	773		10.1056/NEJM199203123261117	http://dx.doi.org/10.1056/NEJM199203123261117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738394	Green Published			2022-12-28	WOS:A1992HH06400032
J	BRANCATI, FL; MEAD, LA; LEVINE, DM; MARTIN, D; MARGOLIS, S; KLAG, MJ				BRANCATI, FL; MEAD, LA; LEVINE, DM; MARTIN, D; MARGOLIS, S; KLAG, MJ			EARLY PREDICTORS OF CAREER ACHIEVEMENT IN ACADEMIC MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN PHYSICIANS; PERFORMANCE; JOURNALS	Objective. - To identify early personal and scholastic factors that predict academic career choice and long-term career achievement among academic physicians. Design. - A longitudinal cohort study. Participants. - Nine hundred forty-four male physicians who graduated from The Johns Hopkins University School of Medicine, Baltimore, Md, from 1948 through 1964. Outcome Measures. - Career achievement outcomes included attained faculty rank in 1990 and the number of citations (20 to 24 years after graduation) to published work. Results. - Of the 944 physicians, 424 (45%) had chosen academic careers. Scholastic performance and research experience in medical school were independently associated with having chosen an academic career (P < .001). Among academicians, higher attained rank in 1990 was independently associated with the following: (1) membership in Alpha Omega Alpha (relative risk [RR] = 4.94, P = .0001); (2) rank in the top third of the graduating class (RR = 2.68, P = .01); and (3) research experience in medical school (RR = 3.11, P = .0001). These three factors were also independently associated with more citations to participants' published work (P < .05). Conclusion. - These data suggest that scholastic performance and research experience during medical school predict career achievement in academic medicine over 20 years in the future.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218; UNIV FLORIDA,DEPT SURG,GAINESVILLE,FL 32611	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; State University System of Florida; University of Florida					NHLBI NIH HHS [HL07024, HL07180] Funding Source: Medline; NIA NIH HHS [AG01760] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRANCATI FL, 1991, CLIN RES, V39, pA615; EVERED DC, 1987, BRIT MED J, V295, P241, DOI 10.1136/bmj.295.6592.241; GARFIELD E, 1972, SCIENCE, V178, P471, DOI 10.1126/science.178.4060.471; GRAVES PL, 1985, JAMA-J AM MED ASSOC, V254, P781, DOI 10.1001/jama.254.6.781; HEALY B, 1988, NEW ENGL J MED, V319, P1058, DOI 10.1056/NEJM198810203191605; MITCHELL KJ, 1990, ACAD MED, V65, P149, DOI 10.1097/00001888-199003000-00005; MONK MA, 1970, JOHNS HOPKINS MED J, V127, P254; NARINS F, 1976, 70R COMPT HOR PROJ; SHERMAN CR, 1981, BIOMEDICAL INNOVATIO, P123; SMITH R, 1988, BRIT MED J, V296, P920, DOI 10.1136/bmj.296.6626.920; STOSSEL TP, 1990, NEW ENGL J MED, V322, P739, DOI 10.1056/NEJM199003153221106; THIER SO, 1980, CLIN RES, V28, P85; WESTLING.H, 1970, JOHNS HOPKINS MED J, V127, P273; WINGARD JR, 1973, J MED EDUC, V48, P311; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; 1990, J HOPKINS MED ALUMNI; 1976, SCI CITATION INDEX 1; 1981, SCI CITATION INDEX 1; 1990, ABMS COMPENDIUM CERT; 1986, SCI CITATION INDEX 1; 1971, SCI CITATION INDEX 1; 1989, NIH891042 PUBL; 1986, J HOPKINS MED ALUMNI; 1991, SCI WATCH, V1, P8	24	92	93	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1372	1376		10.1001/jama.267.10.1372	http://dx.doi.org/10.1001/jama.267.10.1372			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740860				2022-12-28	WOS:A1992HG67800032
J	FIRLIK, AD				FIRLIK, AD			WHAT WE FAIL TO SEE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1328	1328		10.1001/jama.267.10.1328	http://dx.doi.org/10.1001/jama.267.10.1328			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740845				2022-12-28	WOS:A1992HG67800009
J	BROOKOFF, D; POLOMANO, R				BROOKOFF, D; POLOMANO, R			TREATING SICKLE-CELL PAIN LIKE CANCER PAIN	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE; ANEMIA; CRISIS; ANALGESICS; MANAGEMENT	Objective: To assess the effect of a structured analgesic regimen on hospital use by patients with sickle cell disease. Intervention: Intravenous and oral controlled-release morphine was used instead of intramuscular meperidine and short-acting oral opioids for the treatment of sickle cell pain. Design: Time series in which emergency and admission records for four 6-month periods before and two 6-month periods after the institution of the new analgesic protocol were reviewed. Setting: Inner-city university hospital providing care for adults with sickle cell disease. Patients: All patients (an average of 50) who used the emergency department or the inpatient medical service for treatment of sickle cell crisis during the study periods. Measurements and Main Results: The number of admissions for sickle cell pain decreased by 44%, total inpatient days by 57%, length of hospital stay by 23%, and the number of emergency department visits by 67% after initiation of the morphine protocol. Hospital use remained at these lower levels one year later. Similar declines were seen for a subset of 15 patients who had a history of frequent admissions for sickle cell pain and who used this hospital exclusively and accounted for more than half of the admissions for sickle cell disease. Conclusion: A pain-control program modeled on regimens used to treat chronic cancer pain reduced hospital use by adult patients with sickle cell pain.	HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine								ABBUHL S, 1986, ANN EMERG MED, V15, P433, DOI 10.1016/S0196-0644(86)80183-4; ALAVI JB, 1984, MED CLIN N AM, V68, P545, DOI 10.1016/S0025-7125(16)31115-4; BEAVER WT, 1980, JAMA-J AM MED ASSOC, V244, P2653; BROOKS I, 1989, J FAM PRACTICE, V28, P275; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1986, HOSP PRACT, V21, P173; CHARACHE S, 1981, ANNU REV MED, V32, P195, DOI 10.1146/annurev.me.32.020181.001211; COHEN M, 1981, HOSP PHARM, V16, P296; Conley CL, 1980, BLOOD PURE ELOQUENT, P319; Diggs LW, 1934, SOUTH MED J, V27, P839; FOLEY KM, 1989, CANCER-AM CANCER SOC, V63, P2257, DOI 10.1002/1097-0142(19890601)63:11<2257::AID-CNCR2820631134>3.0.CO;2-6; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FRIEDMAN EW, 1986, ANN EMERG MED, V15, P787, DOI 10.1016/S0196-0644(86)80373-0; GALLOWAY S J, 1988, Journal of Emergency Medicine, V6, P213, DOI 10.1016/0736-4679(88)90329-0; LANDE WM, 1988, BLOOD, V72, P2056; MACEIRARODRIGUE.L, 1985, HOSP PHYSICIAN, V3, P14; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MCGUIRE DB, 1988, INSTRUMENTS CLIN NUR, P333; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; PETERSON CM, 1974, ANN INTERN MED, V81, P152, DOI 10.7326/0003-4819-81-2-152; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POLOMANO R, 1988, J PAIN SYMPTOM MANAG, V3, pS15; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; PORTENOY RK, 1987, MED CLIN N AM, V71, P233, DOI 10.1016/S0025-7125(16)30867-7; Powars D R, 1987, Prog Clin Biol Res, V240, P393; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; RODGERS GP, 1991, PJAMA, V256, P2097; Schechter N L, 1988, J Pain Symptom Manage, V3, P109, DOI 10.1016/0885-3924(88)90169-8; SIRS JA, 1963, LANCET, V1, P971; Taub A., 1982, NARCOTIC ANALGESICS, P199; 1974, JAMA-J AM MED ASSOC, V228, P1125; 1986, CANCER PAIN RELIEF	33	68	68	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					364	368		10.7326/0003-4819-116-5-364	http://dx.doi.org/10.7326/0003-4819-116-5-364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736768				2022-12-28	WOS:A1992HF26800003
J	EMINI, EA; SCHLEIF, WA; NUNBERG, JH; CONLEY, AJ; EDA, Y; TOKIYOSHI, S; PUTNEY, SD; MATSUSHITA, S; COBB, KE; JETT, CM; EICHBERG, JW; MURTHY, KK				EMINI, EA; SCHLEIF, WA; NUNBERG, JH; CONLEY, AJ; EDA, Y; TOKIYOSHI, S; PUTNEY, SD; MATSUSHITA, S; COBB, KE; JETT, CM; EICHBERG, JW; MURTHY, KK			PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY GP120 V3 DOMAIN-SPECIFIC MONOCLONAL-ANTIBODY	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; GLYCOPROTEIN GP120; ACID SEQUENCE; ENVELOPE; EPITOPE; PROTEIN; BINDING; FUSION; CELLS	THE acquired immunodeficiency syndrome (AIDS) is the late-stage clinical manifestation of long-term persistent infection with the human immunodeficiency virus type 1 (HIV-1). Immune responses directed against the virus and against virus-infected cells during the persistent infection fail to mediate resolution of the infection. As a result, a successful AIDS vaccine must elicit an immune state that will prevent the establishment of the persistent infection following introduction of the virus into the host. The third hypervariable (V3) domain of the HIV-1 gp120 envelope glycoprotein is a disulphide-linked closed loop of about 30 amino acids which binds and elicits anti-HIV-1 type-specific virus-neutralizing antibodies 1-7 . The in vitro characteristics of anti-V3 domain antibody suggest that this antibody could by itself prevent HIV-1 infection in vivo 8,9, an idea supported by chimpanzee challenge studies in which protection against the HIV-1 persistent infection seemed to correlate with the presence of anti-V3 domain antibody 10-12. Here we directly demonstrate the protective efficacy of anti-V3 domain antibody in vivo and propose that this antibody is potentially useful as both a pre- and post-exposure prophylactic agent.	CHEMOSEROTHERAPEUT RES INST,KUMAMOTO 86115,JAPAN; REPLIGEN CORP,CAMBRIDGE,MA 02139; KUMAMOTO UNIV,KUMAMOTO 860,JAPAN; SW FDN BIOMED RES,SAN ANTONIO,TX 78284	Kumamoto University; Texas Biomedical Research Institute	EMINI, EA (corresponding author), MERCK SHARP & DOHME LTD,W POINT,PA 19486, USA.		Matsushita, Shuzo/F-5782-2013					BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOUDSMIT J, 1988, AIDS, V2, P157; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KENEALY WR, 1989, AIDS RES HUM RETROV, V5, P173, DOI 10.1089/aid.1989.5.173; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; ROBERTSON GA, 1988, J VIROL METHODS, V20, P195, DOI 10.1016/0166-0934(88)90123-1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988	15	493	526	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					728	730		10.1038/355728a0	http://dx.doi.org/10.1038/355728a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741059				2022-12-28	WOS:A1992HE60400064
J	GOTO, M; RUBENSTEIN, M; WEBER, J; WOODS, K; DRAYNA, D				GOTO, M; RUBENSTEIN, M; WEBER, J; WOODS, K; DRAYNA, D			GENETIC-LINKAGE OF WERNER SYNDROME TO 5 MARKERS ON CHROMOSOME-8	NATURE			English	Article							DNA; POLYMORPHISMS; CELLS	WERNER'S syndrome (WS) is a rare autosomal recessive disease in which the affected individuals display symptoms of premature ageing 1-3. The substantial phenotypic overlap between WS and normal ageing indicates that these two conditions may have pathogenetic mechanisms in common 3-5. The WS mutation has pleiotropic effects, and patients and their cells show many differences compared with normals 5. Despite extensive study of the clinical and biochemical features of this disorder, the primary genetic defect remains unknown. We have undertaken a genetic linkage study in an effort to identify the locus of the primary defect 6. Here we report close genetic linkage of the WS mutation to a group of markers on chromosome 8.	GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT SCI COMP,S SAN FRANCISCO,CA 94080; TOKYO METROPOLITAN OTSUKA HOSP,DEPT RHEUMATOL,TOKYO 170,JAPAN; MARSHFIELD FDN MED RES,MARSHFIELD,WI 54449	Roche Holding; Genentech; Roche Holding; Genentech								AOKI R, 1988, JPN J MED, V77, P125; ARAM H, 1974, CUTIS, V14, P215; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CERIMELE D, 1982, HUM GENET, V62, P25, DOI 10.1007/BF00295600; CHI K, 1988, W JPN J DERMAT, V50, P824; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJISAWA A, 1989, JPN J OPHTHALMOL, V31, P6785; GOTO M, 1978, CLIN CHIM ACTA, V85, P101, DOI 10.1016/0009-8981(78)90227-9; GOTO M, 1981, CLIN GENET, V19, P8; GOTO M, 1987, NEUROCUTANEOUS DIS, P242; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; HAYASHI N, 1985, JPN J ORTHOP, V31, P1871; KITATANI M, 1988, HUM GENET, V78, P94, DOI 10.1007/BF00291244; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MASHIYAMA S, 1988, JPN J NEUROSURG, V16, P75; MATSUMURA T, 1985, ADV EXP MED BIOL, V190, P313; MATSUNAGA I, 1975, JPN J OPHTHALMOL, V69, P743; MORI S, 1988, Japanese Journal of Geriatrics, V25, P486; OKUNO N, 1990, DIABETES, V33, P179; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; SALK D, 1985, WERNERS SYNDROME HUM; SAMANTRAY SK, 1977, AUST NZ J MED, V7, P309, DOI 10.1111/j.1445-5994.1977.tb03695.x; SHINDO Y, 1986, Journal of Dermatology (Tokyo), V13, P396; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; THANNHAUSER SJ, 1945, ANN INTERN MED, V23, P559, DOI 10.7326/0003-4819-23-4-559; THORLEYLAWSON DA, 1977, J EXP MED, V146, P495, DOI 10.1084/jem.146.2.495; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WERNER O, 1904, THESIS U KIEL; YANGFENG TL, 1985, CYTOGENET CELL GENET, V40, P784	33	188	195	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					735	738		10.1038/355735a0	http://dx.doi.org/10.1038/355735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741060				2022-12-28	WOS:A1992HE60400067
J	KETTL, PA				KETTL, PA			THATS POLITICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					798	798						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732643				2022-12-28	WOS:A1992HC48400009
J	SEPKOWITZ, KA; BROWN, AE; TELZAK, EE; GOTTLIEB, S; ARMSTRONG, D				SEPKOWITZ, KA; BROWN, AE; TELZAK, EE; GOTTLIEB, S; ARMSTRONG, D			PNEUMOCYSTIS-CARINII PNEUMONIA AMONG PATIENTS WITHOUT AIDS AT A CANCER HOSPITAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTIOUS COMPLICATIONS; MARROW TRANSPLANTATION; LYMPHOCYTIC-LEUKEMIA; NEOPLASTIC DISEASES; THERAPY; CHILDREN; CHEMOPROPHYLAXIS; CYCLOSPORINE; DIAGNOSIS	Objectives. - To determine the predisposing factors, attack rate by underlying disease, and outcome of Pneumocystis carinii pneumonia among patients without the acquired immunodeficiency syndrome (AIDS) at a cancer center. Data Source. - Twelve-year retrospective review from a tertiary-care cancer center. Study Selection. - One hundred forty patients, constituting 142 cases, with morphologically proved P carinii pneumonia. Data Synthesis. - Hematologic malignancy (47%) (including lymphoma [27%] and leukemia [18%]), solid tumor (31%), or bone marrow transplantation (18%) was the underlying condition in the majority of cases. Twenty-five cases (18%) were diagnosed at autopsy. All but seven patients had previously established predisposing factors for P carinii pneumonia, including corticosteroid use in 87%. The attack rate for hospitalized patients with primary or metastatic brain tumor increased during the 12-year interval. The attack rates for hospitalized patients with hematologic neoplasm or bone marrow transplantation were stable. The overall mortality rate did not change during the period reviewed, Conclusions. - Despite the availability of effective prophylaxis, P carinii pneumonia continues to occur among patients with neoplastic disease. In addition to patients with certain hematologic neoplasms, those with primary or metastatic brain neoplasm who receive corticosteroids are at risk for the development of P carinii pneumonia and should receive P carinii pneumonia prophylaxis.			SEPKOWITZ, KA (corresponding author), CORNELL UNIV,MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER; NIAID NIH HHS [5 UO1 AI27669-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENOUSAN T, 1990, LANCET, P1066; BRAZINSKY JH, 1969, J AMER MED ASSOC, V209, P1527, DOI 10.1001/jama.209.10.1527; BROWNE MJ, 1986, ANN INTERN MED, V104, P338, DOI 10.7326/0003-4819-104-3-338; BURKE BA, 1973, MEDICINE, V52, P23, DOI 10.1097/00005792-197301000-00002; CAPITANI.MA, 1966, AMER J ROENTGENOL RA, V97, P174, DOI 10.2214/ajr.97.1.174; CHAVE JP, 1991, AIDS, V5, P927, DOI 10.1097/00002030-199108000-00002; CHUSID MJ, 1978, PEDIATRICS, V62, P1031; FOSSIECK BE, 1980, CHEST, V78, P721, DOI 10.1378/chest.78.5.721; FRANSON TR, 1987, ARCH SURG-CHICAGO, V122, P1034; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; GIRON JA, 1982, LANCET, V2, P46; GLATT AE, 1990, ARCH INTERN MED, V150, P271, DOI 10.1001/archinte.150.2.271; GOESCH TR, 1991, LANCET, P627; GRYZAN S, 1988, AM REV RESPIR DIS, V137, P1268, DOI 10.1164/ajrccm/137.6.1268; HARDY AM, 1984, J INFECT DIS, V149, P143, DOI 10.1093/infdis/149.2.143; HARDY R, 1987, J NATL MED ASSOC, V79, P1205; HARON E, 1988, LANCET, V2, P904; HENSON JW, 1991, ARCH NEUROL-CHICAGO, V48, P406, DOI 10.1001/archneur.1991.00530160074017; HIGGINS RM, 1989, TRANSPLANTATION, V47, P558, DOI 10.1097/00007890-198903000-00032; HUGHES WT, 1978, JOHNS HOPKINS MED J, V143, P184; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1984, J INFECT DIS, V150, P305, DOI 10.1093/infdis/150.2.305-a; HUGHES WT, 1977, NEW ENGL J MED, V297, P1381, DOI 10.1056/NEJM197712222972505; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1975, CANCER, V36, P2004, DOI 10.1002/cncr.2820360912; HUGHES WT, 1974, AM J DIS CHILD, V128, P44, DOI 10.1001/archpedi.1974.02110260046008; HUGHES WT, 1973, J PEDIATR-US, V82, P404, DOI 10.1016/S0022-3476(73)80113-1; HUGHES WT, 1982, J INFECT DIS, V145, P767, DOI 10.1093/infdis/145.2.767; HUGHES WT, 1987, PNEUMOCYSTIS CARINII; IVADY G, 1967, LANCET, V1, P616; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; KOUIDES PA, 1988, BRIT J HAEMATOL, V70, P383, DOI 10.1111/j.1365-2141.1988.tb02500.x; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KRITZ A, 1991, NEW ENGL J MED, V325, P661; LECLAIR RA, 1969, AM REV RESPIR DIS, V99, P542; LEFF RL, 1990, ANN INTERN MED, V112, P716, DOI 10.7326/0003-4819-112-9-716_1; LUNA MA, 1989, SEMIN DIAGN PATHOL, V6, P262; LUNA MA, 1972, TEX REP BIOL MED, V30, P41; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MASUR H, 1988, ANN INTERN MED, V109, P755, DOI 10.7326/0003-4819-109-9-755; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MILLIGAN DW, 1987, LANCET, V1, P867; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1582, DOI 10.1164/ajrccm/141.6.1582; NATALE RB, 1981, CANCER, V47, P2933, DOI 10.1002/1097-0142(19810615)47:12&lt;2933::AID-CNCR2820471233&gt;3.0.CO;2-G; PERERA DR, 1970, J AMER MED ASSOC, V214, P1074, DOI 10.1001/jama.214.6.1074; PETERS SG, 1987, AM J MED, V82, P73, DOI 10.1016/0002-9343(87)90380-9; RAO CP, 1983, J PEDIATR-US, V103, P410, DOI 10.1016/S0022-3476(83)80415-6; ROSEN P, 1972, AM J MED, V53, P428, DOI 10.1016/0002-9343(72)90138-6; ROSEN PP, 1975, AM J MED, V58, P794, DOI 10.1016/0002-9343(75)90634-8; RUEBUSH TK, 1978, AM J DIS CHILD, V132, P143, DOI 10.1001/archpedi.1978.02120270041009; RUSKIN J, 1967, J AMER MED ASSOC, V202, P1070, DOI 10.1001/jama.202.12.1070; SANTIAGODELPIN EA, 1988, TRANSPLANT P, V20, P462; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SEDAGHATIAN MR, 1972, CANCER-AM CANCER SOC, V29, P772, DOI 10.1002/1097-0142(197203)29:3<772::AID-CNCR2820290333>3.0.CO;2-K; SELIK RM, 1987, AIDS, V1, P175; SINGER C, 1979, AM J MED, V66, P110, DOI 10.1016/0002-9343(79)90490-X; SINGER C, 1975, ANN INTERN MED, V82, P772, DOI 10.7326/0003-4819-82-6-722; TALSETH T, 1988, TRANSPLANT P, V20, P400; VOGEL CL, 1968, ANN INTERN MED, V68, P97, DOI 10.7326/0003-4819-68-1-97; WALLIS PJW, 1989, ANN RHEUM DIS, V48, P247, DOI 10.1136/ard.48.3.247; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WALZER PD, 1977, SCIENCE, V197, P177, DOI 10.1126/science.301657; WALZER PD, 1991, NEW ENGL J MED, V324, P263, DOI 10.1056/NEJM199101243240411; WALZER PD, 1973, J PEDIATR-US, V82, P416, DOI 10.1016/S0022-3476(73)80114-3; WATANABE JM, 1965, J AMER MED ASSOC, V193, P685, DOI 10.1001/jama.1965.03090080047017; WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001	67	233	240	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					832	837		10.1001/jama.267.6.832	http://dx.doi.org/10.1001/jama.267.6.832			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732656				2022-12-28	WOS:A1992HC48400029
J	ASO, T; VASAVADA, HA; KAWAGUCHI, T; GERMINO, FJ; GANGULY, S; KITAJIMA, S; WEISSMAN, SM; YASUKOCHI, Y				ASO, T; VASAVADA, HA; KAWAGUCHI, T; GERMINO, FJ; GANGULY, S; KITAJIMA, S; WEISSMAN, SM; YASUKOCHI, Y			CHARACTERIZATION OF CDNA FOR THE LARGE SUBUNIT OF THE TRANSCRIPTION INITIATION-FACTOR TFIIF	NATURE			English	Article							RNA POLYMERASE-II; ACTIVATOR; SEQUENCES; GENE	AT least six chromatographically resolvable general transcription factors may participate in accurate initiation by RNA polymerase II in HeLa cell-derived systems 1-3. TFIIF (also termed FC, RAP30/74 and beta/gamma) can bind directly to RNA polymerase II in solution 4-6 and decrease the affinity of RNA polymerase II for nonspecific DNA 7. From studies on the kinetics of transcription initiation 1, on the composition of transcription initiation complexes fractionated by acrylamide gel electrophoresis 8, and on template competition experiments 9, TFIIF is known to act at an intermediate stage in initiation complex formation. It acts after TFIID firmly associates with DNA, but coincidentally with or immediately after RNA polymerase II binding to DNA, and before the recruitment of factor TFIIE. TFIIF may 6 or may not 4,5 have DNA helicase activity. The small subunit (RAP30) of TFIIF has been cloned 6 and shows some amino-acid sequence homology to bacterial-sigma-factors. We have partially sequenced the RAP74 protein from purified HeLa cells, cloned its complementary DNA and shown that its translation product can interact with RAP30 in vitro as well as in vivo. The cDNA predicts an amino-acid sequence that lacks obvious DNA or RNA helicase motifs. It has regions rich in charged amino acids, including segments containing a higher content of acidic amino acids than are found in strong transcriptional activators such as VP16 (ref. 10).	YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510; TOKYO MED & DENT UNIV,MED RES INST,DEPT MED,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT MOLEC GENET,BUNKYO KU,TOKYO 113,JAPAN	Yale University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BURTOWSKI S, 1989, CELL, V56, P549; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; FLORES O, 1990, J BIOL CHEM, V265, P5629; GANGULY S, 1989, P NATL ACAD SCI USA, V86, P5247, DOI 10.1073/pnas.86.14.5247; HORIKOSHI M, 1991, NUCLEIC ACIDS RES, V19, P5436, DOI 10.1093/nar/19.19.5436; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KITAJIMA S, 1989, P NATL ACAD SCI USA, V86, P6106, DOI 10.1073/pnas.86.16.6106; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9159; SWAROOP A, 1988, NUCLEIC ACIDS RES, V16, P8739, DOI 10.1093/nar/16.17.8739; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VASAVADA H, IN PRESS P NATN ACAD	19	73	74	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					461	464		10.1038/355461a0	http://dx.doi.org/10.1038/355461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734283				2022-12-28	WOS:A1992HB53000074
J	MEISEL, A; BICKLE, TA; KRUGER, DH; SCHROEDER, C				MEISEL, A; BICKLE, TA; KRUGER, DH; SCHROEDER, C			TYPE-III RESTRICTION ENZYMES NEED 2 INVERSELY ORIENTED RECOGNITION SITES FOR DNA CLEAVAGE	NATURE			English	Article							BACTERIOPHAGE-T7 DNA; ESCHERICHIA-COLI; ENDONUCLEASE	TYPE III restriction/modification enzymes recognize short, non-palindromic sequences that can be methylated on only one strand, with the paradoxical consequence that during replication of what is in effect hemimethylated DNA totally unmodified sites arise 1. Why the unmodified sites are not subject to suicidal restriction was not clear. Here we show that restriction requires two unmodified recognition sites that can be separated by different distances but which must be in inverse orientation. All of the unmodified sites in newly replicated DNA are of course in the same orientation, which explains why they are not restricted. This result may be of relevance to other manifestations of anisotropy in double-stranded DNA, such as genetic imprinting 2.	UNIV BASEL,BIOZENTRUM,DEPT MICROBIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND; HUMBOLDT UNIV BERLIN,SCH MED CHARITE,INST VIROL,O-1040 BERLIN,GERMANY	University of Basel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Meisel, Andreas/0000-0001-7233-5342				BICKLE TA, 1983, NUCLEASES, P85; HADI SM, 1979, J MOL BIOL, V134, P655, DOI 10.1016/0022-2836(79)90372-3; HADI SM, 1983, J MOL BIOL, V165, P19, DOI 10.1016/S0022-2836(83)80240-X; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KUGER DH, 1990, NUCLEIC ACID METHYLA, P113; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; REISER J, 1977, J BIOL CHEM, V252, P451; Sambrook J, 1989, MOL CLONING LABORATO; SCHROEDER C, 1986, GENE, V45, P77, DOI 10.1016/0378-1119(86)90134-4; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1	12	123	127	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					467	469		10.1038/355467a0	http://dx.doi.org/10.1038/355467a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1734285				2022-12-28	WOS:A1992HB53000076
J	DUCHOSAL, MA; EMING, SA; FISCHER, P; LETURCQ, D; BARBAS, CF; MCCONAHEY, PJ; CAOTHIEN, RH; THORNTON, GB; DIXON, FJ; BURTON, DR				DUCHOSAL, MA; EMING, SA; FISCHER, P; LETURCQ, D; BARBAS, CF; MCCONAHEY, PJ; CAOTHIEN, RH; THORNTON, GB; DIXON, FJ; BURTON, DR			IMMUNIZATION OF HU-PBL-SCID MICE AND THE RESCUE OF HUMAN MONOCLONAL FAB FRAGMENTS THROUGH COMBINATORIAL LIBRARIES	NATURE			English	Article							HEPATITIS-B VIRUS; SEVERE COMBINED IMMUNODEFICIENCY; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ANTIBODY-PRODUCTION; LYMPHOCYTES; ANTIGEN; EXPRESSION; GENERATION; MOUSE	ANTIBODIES are usually prepared from recently boosted animals and reflect ongoing immune responses 1-6. In humans, this is restrictive as ethical constraints generally prevent antigen-boosting. Therefore the rich memory compartment of human antibody responses remains largely untapped 7. Severe combined immune deficiency (SCID) mice 8 populated with human cells 9-11 allow the stimulation of human antibody memory without the usual constraints. Here we show how peripheral blood lymphocytes can be stimulated by antigen to produce large secondary responses after transfer to SCID mice. Specific monoclonal human Fab fragments can then be isolated from the mice by repertoire cloning even when the human donor's last contact with antigen was more than 17 years ago.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; UNIV SHEFFIELD, KREBS INST, DEPT MOLEC BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; University of Sheffield	DUCHOSAL, MA (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Thornton, George/0000-0002-8744-4987				BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BURTON DR, 1991, TRENDS BIOTECHNOL, V9, P169, DOI 10.1016/0167-7799(91)90055-M; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CATON AJ, 1991, P NATL ACAD SCI USA, V88, P1590; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Hansen T. H., 1989, Fundamental immunology., P445; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JAMES K, 1987, J IMMUNOL METHODS, V100, P5, DOI 10.1016/0022-1759(87)90170-0; KRAMS SM, 1989, J EXP MED, V170, P1919, DOI 10.1084/jem.170.6.1919; LERNER RA, 1991, P NATL ACAD SCI USA, V88, P9705, DOI 10.1073/pnas.88.21.9705; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425; MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; SEPPALA IJT, 1984, EUR J IMMUNOL, V14, P868, DOI 10.1002/eji.1830140918; STAHL S, 1982, P NATL ACAD SCI-BIOL, V79, P1606, DOI 10.1073/pnas.79.5.1606; TIGHE H, 1990, EUR J IMMUNOL, V20, P1843, DOI 10.1002/eji.1830200832; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; VALENZUELA P, 1979, NATURE, V280, P815, DOI 10.1038/280815a0; WILLIAMSON RA, 1991, BIOCHEM J, V277, P561, DOI 10.1042/bj2770561; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	30	139	212	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					258	262		10.1038/355258a0	http://dx.doi.org/10.1038/355258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1731222				2022-12-28	WOS:A1992GZ69400070
J	MCKAY, K; FOZDARFAROUDI, S; BOWMAN, CE				MCKAY, K; FOZDARFAROUDI, S; BOWMAN, CE			HOW HEAVY THE PATIENT	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,WESTON SUPER MARE,AVON BS23 4TQ,ENGLAND									BOWMAN CE, 1981, LANCET, V1, P1005	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1608	1608		10.1136/bmj.303.6817.1608	http://dx.doi.org/10.1136/bmj.303.6817.1608			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773190	Bronze, Green Published			2022-12-28	WOS:A1991GX95600023
J	LEE, DK; HORIKOSHI, M; ROEDER, RG				LEE, DK; HORIKOSHI, M; ROEDER, RG			INTERACTION OF TFIID IN THE MINOR GROOVE OF THE TATA ELEMENT	CELL			English	Article							RNA POLYMERASE-II; INTEGRATION HOST FACTOR; BOX-BINDING-PROTEIN; B-DNA DODECAMER; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; YEAST; GENE; PROMOTER	TFIID binding in the minor groove of DNA at the TATA element was demonstrated by methylation interference and hydroxyl radical footprinting assays, and by binding studies with thymine analog substituted oligonucleotides. These results provide an explanation for TFIID-dependent DNA bending at the TATA element. TFIID binding shows phosphate contacts with the same residues that were found to be essential for TFIID interactions by methylation and thymine-specific modification interference assays. Based on previous studies implicating residues conserved between the direct repeats in DNA binding, as well as models of prokaryotic DNA binding proteins, these results also suggest a model in which the direct repeats of TFIID form two basic antiparallel beta-ribbon arms that could contact DNA through the minor groove.			LEE, DK (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUN L, 1975, BIOCHEMISTRY-US, V14, P1795, DOI 10.1021/bi00679a036; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	60	150	151	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1241	1250		10.1016/0092-8674(91)90300-N	http://dx.doi.org/10.1016/0092-8674(91)90300-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760848				2022-12-28	WOS:A1991GX16400022
J	BOLGER, PG; STEWARTBROWN, SL; NEWCOMBE, E; STARBUCK, A				BOLGER, PG; STEWARTBROWN, SL; NEWCOMBE, E; STARBUCK, A			VISION SCREENING IN PRESCHOOL-CHILDREN - COMPARISON OF ORTHOPTISTS AND CLINICAL MEDICAL OFFICERS AS PRIMARY SCREENERS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AMBLYOPIA; SERVICE; NEED	Objective - To see if there were differences in referral rates and abnormalities detected from two areas that were operating different preschool vision screening programmes. Design - Cohort study using case notes of referrals. Setting - Community based secondary referral centres in the county of Avon. Patients - 263 referrals from a child population of 7105 in Southmead district, an area that used orthoptists as primary vision screeners; 111 referrals from a child population of 2977 in Weston-super-Mare, an area that used clinical medical officers for screening. Main outcome measures - Amblyopia and squint detection rates, together with false positive referral rates. Results - The amblyopia detection rate in Southmead district was significantly higher than in Weston-super-Mare (11/1000 children v 511000), as was the detection rate of squint (I 1/1000 v 3/1000). However, the false positive referral rate from Southmead was significantly lower than that from Weston-super-Mare (9/1000 v 23/1000). Conclusion - Preschool vision screening using orthoptists as primary screeners offers a more effective method of detecting visual abnormalities than using clinical medical officers.	SOUTHMEAD HLTH AUTHOR, PUBL HLTH MED, BRISTOL, ENGLAND; WORCESTER & DIST HLTH AUTHOR, PUBL HLTH MED, WORCESTER, ENGLAND; BRISTOL EYE HOSP, DEPT ORTHOPT, BRISTOL, ENGLAND	Bristol Eye Hospital								BAIRD G, 1985, BRIT MED J, V291, P583, DOI 10.1136/bmj.291.6495.583; BEUDSELL R, 1989, BRIT ORTHOP J, V46, P7; BIRNBAUM MH, 1977, AM J OPTOM PHYS OPT, V54, P269; BOSANQUET R, 1989, BRIT MED J, V298, P1581, DOI 10.1136/bmj.298.6687.1581; CAMERON JH, 1978, BRIT MED J, V2, P1693, DOI 10.1136/bmj.2.6153.1693; DEVRIES J, 1985, BRIT J OPHTHALMOL, V69, P504, DOI 10.1136/bjo.69.7.504; DHOLAKIA S, 1987, OPHTHAL PHYSL OPT, V7, P469, DOI 10.1111/j.1475-1313.1987.tb00780.x; FRIEDMAN Z, 1980, J PEDIAT OPHTH STRAB, V17, P261; FRIENDLY DS, 1987, PEDIATR CLIN N AM, V34, P1389; GRAHAM PA, 1974, BRIT J OPHTHALMOL, V58, P224, DOI 10.1136/bjo.58.3.224; HALL DMB, 1989, REPORT JOINT WORKING; HALL SM, 1982, BRIT MED J, V285, P1096, DOI 10.1136/bmj.285.6348.1096; IHEDA H, 1975, BRIT ORTHOP J, V32, P2; INGRAM RM, 1989, BMJ-BRIT MED J, V298, P204, DOI 10.1136/bmj.298.6668.204; INGRAM RM, 1979, BRIT J OPHTHALMOL, V63, P236, DOI 10.1136/bjo.63.4.236; INGRAM RM, 1986, BRIT J OPHTHALMOL, V70, P16, DOI 10.1136/bjo.70.1.16; INGRAM RM, 1980, LANCET, V1, P585; JOHNSON A, 1989, BMJ-BRIT MED J, V299, P545, DOI 10.1136/bmj.299.6698.545; MACLELLAN AV, 1979, BRIT MED J, V1, P994, DOI 10.1136/bmj.1.6169.994; SOMERSALO M, 1988, ACTA OPHTHALMOL, V66, P509; STEWARTBROWN SL, 1988, ARCH DIS CHILD, V63, P356, DOI 10.1136/adc.63.4.356; TAYLOR D, 1987, ARCH DIS CHILD, V62, P982, DOI 10.1136/adc.62.10.982; TOMMILA V, 1981, BRIT J OPHTHALMOL, V65, P575, DOI 10.1136/bjo.65.8.575; TONGUE AC, 1987, PEDIATR CLIN N AM, V34, P1425	24	41	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1991	303	6813					1291	1294		10.1136/bmj.303.6813.1291	http://dx.doi.org/10.1136/bmj.303.6813.1291			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747671	Bronze, Green Published			2022-12-28	WOS:A1991GT01100018
J	HIRSH, J				HIRSH, J			DRUG-THERAPY - ORAL ANTICOAGULANT DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GAMMA-CARBOXYGLUTAMIC ACID; CONFORMATION-SPECIFIC ANTIBODIES; RANDOMIZED PROSPECTIVE TRIAL; HEART-VALVE REPLACEMENT; ANTI-COAGULANT THERAPY; PROTEIN-C DEFICIENCY; LONG-TERM TREATMENT; LOW-DOSE HEPARIN; VITAMIN-K; PROTHROMBIN TIME		MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	HIRSH, J (corresponding author), HAMILTON CIVIC HOSP RES CTR, 711 CONCESS ST, HAMILTON L8V 1C3, ONTARIO, CANADA.							ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; ALVING BM, 1985, ARCH INTERN MED, V145, P499, DOI 10.1001/archinte.145.3.499; [Anonymous], 1988, LANCET, V2, P349; BAUER KA, 1985, J CLIN INVEST, V76, P826, DOI 10.1172/JCI112040; BAUER KA, 1987, BLOOD, V70, P343; BECHTOLD H, 1984, THROMB HAEMOSTASIS, V51, P358; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BRECKENRIDGE A, 1974, CLIN PHARMACOL THER, V15, P424; BRECKENRIDGE A, 1978, SEMIN HEMATOL, V15, P19; BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V49, P251; BROWN CH, 1974, NEW ENGL J MED, V291, P265, DOI 10.1056/NEJM197408082910601; CAZENAVE JP, 1973, P SOC EXP BIOL MED, V142, P159; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; CHOONARA IA, 1986, BRIT J CLIN PHARMACO, V21, P271, DOI 10.1111/j.1365-2125.1986.tb05190.x; CHOONARA IA, 1988, BRIT J CLIN PHARMACO, V25, P1; CHURCH WR, 1989, BLOOD, V74, P2418; DALE J, 1980, AM HEART J, V99, P746, DOI 10.1016/0002-8703(80)90625-0; DENBOW CE, 1990, SOUTHERN MED J, V83, P981, DOI 10.1097/00007611-199008000-00033; DEYKIN D, 1970, NEW ENGL J MED, V283, P691, DOI 10.1056/NEJM197009242831307; DEYKIN D, 1970, NEW ENGL J MED, V283, P801, DOI 10.1056/NEJM197010082831508; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FENNERTY A, 1984, BRIT MED J, V288, P1268, DOI 10.1136/bmj.288.6426.1268; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FRIEDMAN PA, 1977, BIOCHIM BIOPHYS ACTA, V494, P271, DOI 10.1016/0005-2795(77)90155-6; FURIE B, 1979, J BIOL CHEM, V254, P9766; FURIE B, 1990, BLOOD, V75, P1753; FURIE B, 1990, BLOOD, V75, P344; GINSBERG JS, 1989, CHEST, V95, pS156, DOI 10.1378/chest.95.2.156S; GOLDBERG RJ, 1985, AM HEART J, V109, P616, DOI 10.1016/0002-8703(85)90581-2; GRAHAM DY, 1986, ANN INTERN MED, V104, P390, DOI 10.7326/0003-4819-104-3-390; GRIMAUDO V, 1989, BRIT MED J, V298, P233, DOI 10.1136/bmj.298.6668.233; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HELLEMANS J, 1963, BRIT J HAEMATOL, V9, P506, DOI 10.1111/j.1365-2141.1963.tb05475.x; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; Hirsh J, 1989, CHEST, V96, P962; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HURSTING M, 1989, BLOOD S, V74, pA256; ITURBEALESSIO I, 1986, NEW ENGL J MED, V315, P1390, DOI 10.1056/NEJM198611273152205; KELLY JG, 1979, CLIN PHARMACOKINET, V4, P1, DOI 10.2165/00003088-197904010-00001; KIRKWOOD TBL, 1983, THROMB HAEMOSTASIS, V49, P238; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOCHWESE.J, 1971, NEW ENGL J MED, V285, P487, DOI 10.1056/NEJM197108262850905; KOCHWESE.J, 1971, NEW ENGL J MED, V285, P547, DOI 10.1056/NEJM197109022851005; KRETSCHMER G, 1988, LANCET, V1, P797; LADER E, 1980, ANN INTERN MED, V93, P373, DOI 10.7326/0003-4819-93-2-373_3; LAGERSTEDT CI, 1985, LANCET, V2, P515; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; LAO TT, 1985, BRIT J OBSTET GYNAEC, V92, P202, DOI 10.1111/j.1471-0528.1985.tb01082.x; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; LEVINE MN, 1989, CHEST, V95, pS26, DOI 10.1378/chest.95.2.26S; LEWIS RJ, 1974, J CLIN INVEST, V53, P1607, DOI 10.1172/JCI107711; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P155; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P148; LOELIGER EA, 1983, NEW ENGL J MED, V308, P1228; LOELIGER EA, 1964, THROMB DIATH HAEMOST, V10, P267; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V54, P515; LORENTZ SM, 1985, CLIN PHARMACY, V4, P332; LUCAS FV, 1987, AM J CLIN PATHOL, V88, P442, DOI 10.1093/ajcp/88.4.442; MALHOTRA OP, 1989, BIOCHEM CELL BIOL, V67, P411, DOI 10.1139/o89-066; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MALHOTRA OP, IN PRESS BIOCHEMISTR; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCKENNA R, 1983, J PEDIATR-US, V103, P325, DOI 10.1016/S0022-3476(83)80378-3; MOK CK, 1985, CIRCULATION, V72, P1059, DOI 10.1161/01.CIR.72.5.1059; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; O'Reilly R A, 1987, Adv Exp Med Biol, V214, P205; OREILLY RA, 1974, CLIN PHARMACOL THER, V16, P348; OREILLY RA, 1987, CLIN PHARMACOL THER, V42, P290, DOI 10.1038/clpt.1987.149; OREILLY RA, 1970, PHARMACOL REV, V22, P35; OREILLY RA, 1980, CLIN PHARMACOL THER, V28, P187, DOI 10.1038/clpt.1980.149; OREILLY RA, 1976, NEW ENGL J MED, V295, P354, DOI 10.1056/NEJM197608122950702; OREILLY RA, 1980, NEW ENGL J MED, V302, P33, DOI 10.1056/NEJM198001033020106; OREILLY RA, 1964, NEW ENGL J MED, V271, P809, DOI 10.1056/NEJM196410152711602; OREILLY RA, 1981, ARCH INTERN MED, V141, P458, DOI 10.1001/archinte.141.4.458; OREILLY RA, 1978, FED PROC, V37, P545; OREILLY RA, 1972, THROMB DIATH HAEMOST, V27, P309; OREILLY RA, 1980, NEW ENGL J MED, V303, P160; OREILLY RA, 1968, ANN NY ACAD SCI, V151, P913, DOI 10.1111/j.1749-6632.1968.tb11950.x; OREILLY RA, 1975, ANN INTERN MED, V83, P506, DOI 10.7326/0003-4819-83-4-506; OREILLY RA, 1976, ANNU REV MED, V27, P245, DOI 10.1146/annurev.me.27.020176.001333; OWENS JC, 1962, NEW ENGL J MED, V266, P76, DOI 10.1056/NEJM196201112660205; PETERSEN P, 1989, LANCET, V1, P175; POLLER L, 1982, BRIT J HAEMATOL, V51, P479, DOI 10.1111/j.1365-2141.1982.tb02805.x; POLLER L, 1989, J CLIN PATHOL, V42, P97, DOI 10.1136/jcp.42.1.97; POLLER L, 1985, BRIT MED J, V290, P1683, DOI 10.1136/bmj.290.6483.1683; POLLER L, 1987, BRIT MED J, V294, P1184, DOI 10.1136/bmj.294.6581.1184; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; POLLER L, 1969, BRIT J HAEMATOL, V16, P31, DOI 10.1111/j.1365-2141.1969.tb00376.x; Poller L., 1987, HEMATOLOGY REV, V1, P225; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; Quick AJ, 1935, J BIOL CHEM, V110, P107; RESNEKOV L, 1989, CHEST, V95, pS52, DOI 10.1378/chest.95.2_Supplement.52S; Richards RK, 1943, SCIENCE, V97, P313, DOI 10.1126/science.97.2518.313; ROOS J, 1980, LANCET, V2, P989; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; SAMAMA M, 1984, THROMB HAEMOSTASIS, V51, P132; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SCHULMAN S, 1989, BRIT J RHEUMATOL, V28, P46; SEVITT S, 1959, LANCET, V2, P981; SHERMAN DG, 1989, CHEST, V95, pS140; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUTCLIFFE F A, 1987, Reviews on Drug Metabolism and Drug Interactions, V5, P225; SUTFIN T, 1989, THER DRUG MONIT, V11, P176, DOI 10.1097/00007691-198903000-00010; SUTTIE JW, 1988, AM J CLIN NUTR, V47, P475, DOI 10.1093/ajcn/47.3.475; TABERNER DA, 1978, BRIT MED J, V1, P272, DOI 10.1136/bmj.1.6108.272; THOMAS P, 1984, BRIT MED J, V288, P191, DOI 10.1136/bmj.288.6412.191; TOON S, 1986, BRIT J CLIN PHARMACO, V21, P245, DOI 10.1111/j.1365-2125.1986.tb05186.x; TOON S, 1986, CLIN PHARMACOL THER, V39, P15, DOI 10.1038/clpt.1986.3; TRIVEDI LS, 1988, ARCH BIOCHEM BIOPHYS, V264, P67, DOI 10.1016/0003-9861(88)90571-1; TURPIE AGG, 1988, LANCET, V1, P1242; UDALL JA, 1965, J AMER MED ASSOC, V194, P127, DOI 10.1001/jama.194.2.127; VERHAGEN H, 1954, ACTA MED SCAND, V148, P453; VIGANO S, 1984, BRIT J HAEMATOL, V57, P213, DOI 10.1111/j.1365-2141.1984.tb02889.x; WEIBERT RT, 1989, CLIN PHARMACY, V8, P210; WEINBERG AC, 1983, J UROLOGY, V130, P352, DOI 10.1016/S0022-5347(17)51147-7; WEITEKAMP MR, 1983, JAMA-J AM MED ASSOC, V249, P69, DOI 10.1001/jama.249.1.69; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730; WHITLON DS, 1978, BIOCHEMISTRY-US, V17, P1371, DOI 10.1021/bi00601a003; WRIGHT IS, 1969, ANN INTERN MED, V71, P823, DOI 10.7326/0003-4819-71-4-823; ZAUBER NP, 1986, ANN INTERN MED, V104, P659, DOI 10.7326/0003-4819-104-5-659; ZUCKER S, 1970, AM J CLIN PATHOL, V53, P348; 1973, JAMA-J AM MED ASSOC, V225, P724; 1969, BMJ, V1, P335	133	528	539	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1865	1875						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	1801769				2022-12-28	WOS:A1991FT58000006
J	KEMPER, CA; MENG, TC; NUSSBAUM, J; CHIU, J; FEIGAL, DF; BARTOK, AE; LEEDOM, JM; TILLES, JG; DERESINSKI, SC; MCCUTCHAN, JA				KEMPER, CA; MENG, TC; NUSSBAUM, J; CHIU, J; FEIGAL, DF; BARTOK, AE; LEEDOM, JM; TILLES, JG; DERESINSKI, SC; MCCUTCHAN, JA			TREATMENT OF MYCOBACTERIUM-AVIUM COMPLEX BACTEREMIA IN AIDS WITH A 4-DRUG ORAL REGIMEN - RIFAMPIN, ETHAMBUTOL, CLOFAZIMINE, AND CIPROFLOXACIN	ANNALS OF INTERNAL MEDICINE			English	Article						MYCOBACTERIUM-AVIUMINTRACELLULARE INFECTION; CIPROFLOXICIN; CLOFAZIMINE; ETHAMBUTOL; RIFAMPIN; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED IMMUNODEFICIENCY SYNDROME; INTRACELLULARE BACTEREMIA; INFECTION; THERAPY; ANSAMYCIN	Objective: To determine the quantitative microbiologic response and the clinical response of patients with Mycobacterium avium complex bacteremia and AIDS to an oral antimycobacterial regimen. Design: A phase II, multicenter clinical trial. Setting: Four university-affiliated medical centers. Patients: Forty-one patients with HIV infection who had at least two consecutive blood cultures positive for M. avium complex and who had not received previous antimycobacterial therapy were enrolled in the study. Thirty-one patients were evaluable with regard to the efficacy of the oral regimen. Interventions: Patients received a combination of orally administered rifampin (600 mg), ethambutol (15 mg/kg body weight), clofazimine (100 mg once daily), and ciprofloxacin (750 mg twice daily) for 12 weeks. Parenterally administered amikacin, 7.5 mg/kg daily for 4 weeks after the first 4 weeks of oral therapy, was used at the discretion of the individual investigator. Measurements: Clinical symptoms, Karnofsky scores, and adverse events were monitored. Colony counts for M. avium complex were determined. Main Results: The mean logarithmic (log) baseline colony count decreased from 2.1 to 0.7 after 4 weeks of oral therapy (P < 0.001). Suppression of bacteremia was sustained throughout therapy. Thirteen patients (42%) became culture negative during therapy. The mean duration of treatment was 9.7 weeks. Nineteen evaluable patients (61 %) completed 12 weeks of therapy. Adverse reactions to one or more agents were common. Conclusions. A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin. Colony counts rose dramatically after therapy was discontinued, suggesting that more prolonged periods of therapy are necessary to eradicate systemic infection.			KEMPER, CA (corresponding author), SANTA CLARA VALLEY MED CTR, DIV INFECT DIS, 751 S BASCOM AVE, ANNEX ROOM 137, SAN JOSE, CA 95128 USA.							AGINS BD, 1989, J INFECT DIS, V159, P784, DOI 10.1093/infdis/159.4.784; BACH MC, 1989, ANN INTERN MED, V110, P169, DOI 10.7326/0003-4819-110-2-169; BENSON C, 1990, 6TH INT C AIDS SAN F; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; GILL VJ, 1985, J CLIN MICROBIOL, V22, P543, DOI 10.1128/JCM.22.4.543-546.1985; HAVLIK JA, 1990, 6TH INT C AIDS SAN F; HORSBURG CR, 1990, 6TH INT C AIDS SAN F; HORSBURGH CR, 1986, ANTIMICROB AGENTS CH, V30, P955, DOI 10.1128/AAC.30.6.955; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; LINDHOLMLEVY PJ, 1988, TUBERCLE, V69, P179, DOI 10.1016/0041-3879(88)90019-0; MASUR H, 1987, J INFECT DIS, V155, P127, DOI 10.1093/infdis/155.1.127; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; TOMIOKA H, 1989, MICROBIOL IMMUNOL, V33, P509, DOI 10.1111/j.1348-0421.1989.tb02000.x; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926; WONG B, 1985, AM J MED, V78, P35, DOI 10.1016/0002-9343(85)90458-9; YOUNG LS, 1988, J INFECT DIS, V157, P863, DOI 10.1093/infdis/157.5.863	19	153	161	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					466	472		10.7326/0003-4819-116-6-466	http://dx.doi.org/10.7326/0003-4819-116-6-466			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739237				2022-12-28	WOS:A1992HJ59800006
J	GREY, MR				GREY, MR			SYPHILIS AND AIDS IN BELLE-GLADE, FLORIDA, 1942 AND 1992	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; HISTORY OF MEDICINE; SEXUALLY TRANSMITTED DISEASES; SYPHILIS; PUBLIC HEALTH		In the 1980s, Belle Glade, Florida, attracted intense medical attention because of its high incidence of the acquired immunodeficiency syndrome (AIDS). Concern about possible mosquito-borne transmission was raised when early epidemiologic surveys showed that no risk factors were identified in 19% of the cases of AIDS. Further research dispelled this hypothesis. Instead, multiple sexual partners, drug use, and poverty strongly correlated with seropositivity for human immunodeficiency virus (HIV) in Belle Glade. In the 1940s, the predominantly poor, black migrant workers of Belle Glade experienced an epidemic of syphilis that also attracted national attention. Researchers for the U.S. Public Health Service (USPHS) and the Department of Agriculture's Farm Security Administration (FSA) concluded that organized prostitution, sexual promiscuity, inadequate access to medical care, and alcohol use promoted near endemic syphilis in pre-World War II Belle Glade. Analogous socioeconomic and behavioral factors contribute to the current AIDS epidemic in Belle Glade. The Belle Glade experience with epidemics illustrates the historical continuities characteristic of public health problems in our society. The syphilis epidemic in Belle Glade in the 1940s foreshadowed the city's current AIDS epidemic and shares with it analogous socioeconomic roots that must be understood in order to stem the current epidemic.			GREY, MR (corresponding author), UNIV CONNECTICUT, HLTH CTR,DEPT MED,DIV GEN INTERNAL MED, OCCUPAT MED PROGRAM, BLDG 12, FARMINGTON, CT 06030 USA.							ANDERSON OL, 1943, AM J SYPHILIS VENERE, V27, P432; BISHOP CE, 1968, RURAL POVERTY US REP, P322; BRANDT AM, 1987, MAGIC BULLET SOCIAL; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CASTRO KG, 1990, NY TIMES        1114, pA10; ETHERIDGE EW, 1972, BUTTERFLY CASTE SOCI, P204; FAVERMAN AE, 1937, REPORT MIGRATORY DEM; GREY MR, 1989, J HIST MED ALL SCI, V44, P320, DOI 10.1093/jhmas/44.3.320; Lieb S, 1988, J Fla Med Assoc, V75, P301; MCWILLIAMS C, 1942, ILL FARES LAND, P243; MINER CE, 1944, COMMUNICATION   0308; MOTT F, 1944, COMMUNICATION   0405; MOTT F, 1944, COMMUNICATION   0202; Mott Frederick D., 1948, RURAL HLTH MED CARE; MURROW ER, 1961, HARVEST SHAME; NEWDORP J, COMMUNICATION; NEWDORP J, 1944, COMMUNICATION   0129; NEWDORP J, 1944, COMMUNICATION   0315; OSLER W, 1917, LANCET          0526, P787; Parran T, 1937, SHADOW LAND SYPHILIS; SANTAYANA G, 1905, LIFE REASON; VONDERLEHR RA, 1937, J SYPHILIS VENEREAL, V21, P32; WEBB JN, 1937, WORKS PROGR ADM DIVI, V7, P2	23	15	15	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					329	334		10.7326/0003-4819-116-4-329	http://dx.doi.org/10.7326/0003-4819-116-4-329			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733390				2022-12-28	WOS:A1992HD54600011
J	RING, EJ; LAKE, JR; ROBERTS, JP; GORDON, RL; LABERGE, JM; READ, AE; STERNECK, MR; ASCHER, NL				RING, EJ; LAKE, JR; ROBERTS, JP; GORDON, RL; LABERGE, JM; READ, AE; STERNECK, MR; ASCHER, NL			USING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS TO CONTROL VARICEAL BLEEDING BEFORE LIVER-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article						PORTOSYSTEMIC SHUNT, SURGICAL; LIVER TRANSPLANTATION; ESOPHAGEAL AND GASTRIC VARICES; HEMORRHAGE, GASTROINTESTINAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT	PORTACAVAL-SHUNT; ENDOSCOPIC SCLEROTHERAPY; HEMORRHAGE; STENTS; MANAGEMENT	Objective: To determine the safety and efficacy of transjugular intrahepatic portosystemic shunts (TIPS) in controlling bleeding from esophageal varices in patients awaiting liver transplantation. Design: Prospective, uncontrolled trial. Setting: University medical center with an active liver transplant program. Patients: Thirteen patients referred for liver transplantation with either active variceal hemorrhage or recurrent variceal hemorrhage despite sclerotherapy; four patients had been previously treated with surgical portosystemic shunts. Intervention: An intrahepatic portosystemic shunt created via a transjugular approach to the hepatic veins using expandable, flexible metallic stents. Measurements: Portal pressures before and after the creation of the shunt, the direction of portal blood flow at differing diameters of the shunts, procedure-related complications, and outcome in terms of survival, liver transplantation, and recurrent variceal bleeding. Main Results: The transjugular intrahepatic portosystemic shunt was placed successfully in 13 patients, and bleeding was controlled acutely in all 13. After the procedure, the mean portal pressure decreased from 34 +/- 8.9 cm H2O to 22.4 +/- 5.4 cm H2O (P < 0.001). No complications were associated with the procedure; however, two patients died of causes unrelated to the procedure. Seven patients subsequently underwent liver transplantation and are doing well, and three patients are being managed conservatively. Bleeding recurred in one patient 102 days after the procedure secondary to shunt occlusion caused by neointimal proliferation. Conclusion: Placement of a transjugular intrahepatic portosystemic shunt is apparently safe and effective therapy for variceal hemorrhage in patients referred for liver transplantation.			RING, EJ (corresponding author), UNIV CALIF SAN FRANCISCO, BOX 0628, SAN FRANCISCO, CA 94143 USA.			Lake, John/0000-0002-4332-0528				CELLO JP, 1984, NEW ENGL J MED, V311, P1589, DOI 10.1056/NEJM198412203112501; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; CRASS RA, 1989, AM J SURG, V157, P476, DOI 10.1016/0002-9610(89)90638-7; DEFRANCHIS R, 1988, NEW ENGL J MED, V319, P983; IWATSUKI S, 1988, SURGERY, V104, P697; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AM J ROENTGENOL, V145, P821, DOI 10.2214/ajr.145.4.821; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; ROBERTS JP, 1991, TRANSPLANTATION, V52, P160, DOI 10.1097/00007890-199107000-00036; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; RYPINS EB, 1990, SURG CLIN N AM, V70, P395; SARFEH IJ, 1986, SURGERY, V100, P52; TURRION VS, 1991, TRANSPLANT P, V23, P1570; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; ZEMEL G, 1991, JAMA-J AM MED ASSOC, V266, P390, DOI 10.1001/jama.266.3.390	17	230	229	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					304	309		10.7326/0003-4819-116-4-304	http://dx.doi.org/10.7326/0003-4819-116-4-304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733385				2022-12-28	WOS:A1992HD54600006
J	BERWICK, DM; ENTHOVEN, A; BUNKER, JP				BERWICK, DM; ENTHOVEN, A; BUNKER, JP			QUALITY MANAGEMENT IN THE NHS - THE DOCTORS ROLE .2.	BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES		STANFORD UNIV,GRAD SCH BUSINESS,STANFORD,CA 94305; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA 02215; KINGS COLL,SCH MED & DENT,CRC,CTR CLIN TRIALS,LONDON SE5 9NU,ENGLAND	Stanford University; University of London; King's College London								BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; Berwick D M, 1990, QRB Qual Rev Bull, V16, P246; Berwick D M, 1991, HMO Pract, V5, P174; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; BUNKER JP, 1977, COSTS RISKS BENEFITS; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MARGOLIS CZ, 1988, SOLVING COMMON PEDIA; SMITH R, 1990, BRIT MED J, V301, P679, DOI 10.1136/bmj.301.6754.679; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; Weinstein MC, 1980, CLIN DECISION ANAL; 1989, CMND555	15	73	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					304	308		10.1136/bmj.304.6822.304	http://dx.doi.org/10.1136/bmj.304.6822.304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739834	Bronze, Green Published			2022-12-28	WOS:A1992HC70800027
J	WITHKA, JM; SWAMINATHAN, S; SRINIVASAN, J; BEVERIDGE, DL; BOLTON, PH				WITHKA, JM; SWAMINATHAN, S; SRINIVASAN, J; BEVERIDGE, DL; BOLTON, PH			TOWARD A DYNAMIC STRUCTURE OF DNA - COMPARISON OF THEORETICAL AND EXPERIMENTAL NOE INTENSITIES	SCIENCE			English	Article							DOUBLE HELIX; MOLECULAR-DYNAMICS; IMINO PROTONS; BASE-PAIR; KINETICS; EXCHANGE; D(CGCGAATTCGCG); SEQUENCE; GEOMETRY	Comparisons of experimental and calculated interproton nuclear Overhauser effect (NOE) buildup curves for duplex d(CGCGAATTCGCG)2 have been made. The calculated NOEs are based on molecular dynamics simulations including counterions and water and on the single-structure canonical A, B, and crystal forms. The calculated NOE effects include consideration of the motions of individual interproton vectors and the anisotropic tumbling of the DNA. The effects due to inclusion of anisotropic tumbling are much larger than those due to the local motion, and both improve the agreement between calculated and experimental results. The predictions based on the dynamical models agree significantly better with experiment than those based on either of the canonical forms or the crystal structure.			WITHKA, JM (corresponding author), WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008271, R37GM037909, R01GM037909] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37909, 1T32 GM-08271] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON PH, 1990, PROG NUCL MAG RES SP, V22, P423, DOI 10.1016/0079-6565(90)80006-4; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DICKERSON RE, 1990, STRUCTURE METHOD, V3; EIMER W, 1990, BIOCHEMISTRY-US, V29, P799, DOI 10.1021/bi00455a030; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; GOCHIN M, 1990, BIOCHEMISTRY-US, V29, P11172, DOI 10.1021/bi00503a004; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; KONING TMG, 1991, BIOCHEMISTRY-US, V30, P3787, DOI 10.1021/bi00229a028; McCammon A. J., 1986, DYNAMICS PROTEINS NU; MOE JG, 1990, NUCLEIC ACIDS RES, V18, P821, DOI 10.1093/nar/18.4.821; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; PARDI A, 1982, BIOCHEMISTRY-US, V21, P6567, DOI 10.1021/bi00268a038; PARDI A, 1982, BIOCHEMISTRY-US, V21, P4686, DOI 10.1021/bi00262a026; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; Saenger W., 1983, PRINCIPLES NUCL ACID; SRINIVASAN J, 1990, BIOPHYS J, V58, P533, DOI 10.1016/S0006-3495(90)82397-3; SWAMINATHAN S, 1991, J AM CHEM SOC, V113, P5027, DOI 10.1021/ja00013a043; Van Gunsteren W F, 1986, Ann N Y Acad Sci, V482, P287; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WITHKA JM, 1991, J AM CHEM SOC, V113, P5041, DOI 10.1021/ja00013a044; WITHKA JM, 1990, J MAGN RESON, V89, P386, DOI 10.1016/0022-2364(90)90246-6; WITHKA JM, 1991, P NATO ADV RES WORKS, P409; WITHKA JM, UNPUB; Wuthrich K., 1986, NMR PROTEINS NUCL AC	27	61	61	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1992	255	5044					597	599		10.1126/science.1736362	http://dx.doi.org/10.1126/science.1736362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB531	1736362				2022-12-28	WOS:A1992HB53100043
J	MORGAN, MJ				MORGAN, MJ			SPATIAL-FILTERING PRECEDES MOTION DETECTION	NATURE			English	Article							RANDOM-DOT PATTERNS; APPARENT MOTION; PERCEPTION; DISPLACEMENT; FREQUENCY; VISION; SYSTEM	WHEN we perceive motion on a television or cinema screen, there must be some process that allows us to track moving objects over time: if not, the result would be a conflicting mass of motion signals in all directions. A possible mechanism, suggested by studies of motion displacement in spatially random patterns, is that low-level motion detectors have a limited spatial range, which ensures that they tend to be stimulated over time by the same object 1-3. This model predicts that the direction of displacement of random patterns cannot be detected reliably above a critical absolute displacement value (D(max)) that is independent of the size or density of elements in the display 1,4,5. It has been inferred that D(max) is a measure of the size of motion detectors in the visual pathway 1,3. Other studies, however, have shown that D(max) increases with element size 6-8, in which case the most likely interpretation is that D(max) depends on the probability of false matches between pattern elements following a displacement. These conflicting accounts are reconciled here by showing that D(max) is indeed determined by the spacing between the elements in the pattern, but only after fine detail has been removed by a physiological prefiltering stage: the filter required to explain the data has a similar size to the receptive field of neurons in the primate magnocellular pathway. The model explains why D(max) can be increased by removing high spatial frequencies from random patterns, and simplifies our view of early motion detection.			MORGAN, MJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PHARMACOL,NEUROSCI LAB,1 GEORGE SQ,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							ANSTIS SM, 1980, PHILOS T ROY SOC B, V290, P153, DOI 10.1098/rstb.1980.0088; BAKER CL, 1982, VISION RES, V22, P1253, DOI 10.1016/0042-6989(82)90137-7; BISCHOF WF, 1990, VISION RES, V30, P1341, DOI 10.1016/0042-6989(90)90008-9; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; BRADDICK OJ, 1980, PHILOS T ROY SOC B, V290, P137, DOI 10.1098/rstb.1980.0087; CAVANAGH P, 1985, PERCEPTION, V14, P151, DOI 10.1068/p140151; CHANG JJ, 1983, VISION RES, V23, P639, DOI 10.1016/0042-6989(83)90070-6; CLEARY R, 1990, VISION RES, V30, P317, DOI 10.1016/0042-6989(90)90046-N; CROOK JM, 1988, J PHYSIOL-LONDON, V396, P205, DOI 10.1113/jphysiol.1988.sp016959; LAPPIN JS, 1976, VISION RES, V16, P161, DOI 10.1016/0042-6989(76)90093-6; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MARR D, 1980, PROC R SOC SER B-BIO, V207, P187, DOI 10.1098/rspb.1980.0020; MORGAN MJ, IN PRESS VISION RES; RODIECK RW, 1965, J NEUROPHYSIOL, V28, P883; SATO T, 1989, VISION RES, V29, P1749, DOI 10.1016/0042-6989(89)90157-0; SATO T, 1990, PERCEPTION, V19, pA7; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5	19	102	102	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					344	346		10.1038/355344a0	http://dx.doi.org/10.1038/355344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1731247				2022-12-28	WOS:A1992HA59100065
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - NOISE - BREAKING THE SILENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY SAMPLE; HEARING-LOSS; SLEEP											ATHERLEY G, 1985, AM J IND MED, V8, P101, DOI 10.1002/ajim.4700080205; BARONE JA, 1987, J OCCUP ENVIRON MED, V29, P741; BASTNIER H, 1975, ENV QUALITY LIFE; BEALES PH, 1965, NOISE HEARING DEAFNE; BICKERDIKE J, 1979, EVALUATION HEARING D; BROADBENT D, 1978, HDB NOISE CONTROL, P1; Burns W., 1970, HEARING NOISE IND, DOI [10.1093/annhyg/14.1.53, DOI 10.1093/ANNHYG/14.1.53]; CARTER NL, 1980, AUDIOLOGY, V19, P86; DAVIS A, 1985, DAMAGE HEARING ARISI; DAVIS AC, 1989, INT J EPIDEMIOL, V18, P911, DOI 10.1093/ije/18.4.911; Fosbroke J., 1831, LANCET, V1, P645; FRERICHS RR, 1980, AM J PUBLIC HEALTH, V70, P357, DOI 10.2105/AJPH.70.4.357; HETU R, 1991, OCCUPATIONAL NOISE I; LANGDON FJ, 1977, J SOUND VIB, V50, P13, DOI 10.1016/0022-460X(77)90548-X; LARGE JB, 1977, ROY SOC HEALTH J, V97, P147, DOI 10.1177/146642407709700404; PHANEUF R, 1990, J OTOLARYNGOL, V19, P31; RAMAZZINI B, 1968, DISEASES WORKERS; ROBINSON DW, 1987, NOISE EXPOSURE HEARI; ROBINSON DW, 1988, TABLES ESTIMATION HE; SMITH A, 1991, NONAUDITORY EFFECTS; STANSFELD SA, 1985, PSYCHOL MED, V15, P243, DOI 10.1017/S0033291700023527; STANSFELD SA, 1988, 5 P INT C NOIS PUBL, V3, P339; SUTER AH, 1991, DORMANT NOISE CONTRO; TARNOPOLSKY A, 1978, PSYCHOL MED, V8, P219, DOI 10.1017/S0033291700014276; TARNOPOLSKY A, 1980, AIRCRAFT NOISE PREVA; THOMPSON SJ, 1983, 4TH P INT C NOIS PUB, V1, P711; VALLET M, 1979, P I ACOUSTICS, V3, P1; VERNET M, 1979, J SOUND VIB, V66, P483, DOI 10.1016/0022-460X(79)90869-1; 1990, NOISE WORK REGULATIO; 1980, ENV HLTH CRITERIA, V12; 1990, NOISE HEARING LOSS C, V8, P1; 1979, 2ND SURVEY AIRCRAFT; 1990, PERSONAL STEREOS CHI; 1988, DIGEST ENV PROTECTIO; 1991, MRC7 PROGR MED RES C; 1990, 1990 DEP ENV NOIS RE	36	26	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1992	304	6819					110	113		10.1136/bmj.304.6819.110	http://dx.doi.org/10.1136/bmj.304.6819.110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737111	Bronze, Green Published			2022-12-28	WOS:A1992HA17100032
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - TRANSPORT - A PUBLIC-HEALTH ISSUE	BRITISH MEDICAL JOURNAL			English	Article																		CLARKE A, 1987, PROBIKE CYCLING POLI; HILLMAN M, 1990, ONE FALSE MOVE STUDY; HILLMAN M, 1990, CYCLING HLTH CITY, P3; HILLMAN M, 1983, ENERGY PERSONAL TRAV, P185; HOLCOMB MC, 1987, TRANSPORTATION DATA; HUGHES P, 1991, TOWN COUNTRY PLANN, V60, P267; LOWE M, 1990, STATE WORLD 1990 WOR; LOWE M D, 1991, P56; MORRIS JN, 1990, BRIT HEART J, V63, P325; NEWMAN P, 1989, CITIES AUTOMOBILE DE; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1986, URBAN TRANSPORT WORL; 1991, HLTH MOVE POLICIES H; 1988, QUALITY STREETS TRAD; 1990, CYCLING HLTH CITY, P20	15	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					48	50						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734996				2022-12-28	WOS:A1992GY90900040
J	SCHULMAN, KA; GLICK, HA; RUBIN, H; EISENBERG, JM				SCHULMAN, KA; GLICK, HA; RUBIN, H; EISENBERG, JM			COST-EFFECTIVENESS OF HA-1A MONOCLONAL-ANTIBODY FOR GRAM-NEGATIVE SEPSIS - ECONOMIC-ASSESSMENT OF A NEW THERAPEUTIC AGENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLONGED MECHANICAL VENTILATION; LINKED IMMUNOSORBENT ASSAYS; MEDICAL INTENSIVE-CARE; SURVIVAL; MORTALITY; DIAGNOSIS; OUTCOMES; CHARGES; BLOOD; VIRUS	Objective. - To assess the cost-effectiveness of the HA-1A monoclonal antibody for the treatment of gram-negative bacteremia. Design. - Cost-effectiveness analysis of a randomized, double-blind, placebo-controlled trial using clinical efficacy data reported in the medical literature. Setting. - Hospitalized patients with sepsis. Patients. - 543 patients with sepsis and suspected gram-negative infection. Patients enrolled in the study met strict criteria for sepsis, including fever or hypothermia (< 35.6-degrees-C or > 38.3-degrees-C), tachycardia (> 90 beats per minute), tachypnea (> 20 breaths per minute), and hypotension or two of six signs of systemic toxicity. Intervention. - HA-1A vs placebo in addition to usual care. Main Outcome Measures. - We determined the range of possible cost-effectiveness ratios for HA-1A therapy, using modeling techniques when clinical or economic variables were unknown. We subjected the model to rigorous sensitivity analysis. We calculated the incremental cost of care and years of life saved for patients with sepsis and modeled two different treatment strategies: treat all patients with sepsis or test and then treat only patients with positive test results. Results. - The cost-effectiveness of therapy based on our two models was $24 100 per year of life saved based on the treat strategy and $14 900 based on the test strategy. In sensitivity analysis the ratios ranged from $5200 to $110 200 per year of life gained. Annual costs of care for these two strategies are $1.3 billion for the test strategy and $2.3 billion for the treat strategy. Conclusion. - Economic assessment of new technologies early in their development can be used to guide their efficient clinical introduction.	UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,GEN INTERNAL MED SECT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,INFECT DIS SECT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	EISENBERG, JM (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT MED,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.							BEIER JC, 1990, J MED ENTOMOL, V27, P377, DOI 10.1093/jmedent/27.3.377; BROOK FRH, 1971, NEW ENGL J MED, V285, P1509; CHASSIN MR, 1982, MED CARE, V20, P165, DOI 10.1097/00005650-198202000-00004; CHIODI F, 1986, J MED VIROL, V18, P149, DOI 10.1002/jmv.1890180207; CULLEN DJ, 1976, NEW ENGL J MED, V294, P982, DOI 10.1056/NEJM197604292941805; DALEY C, 1990, J CLIN MICROBIOL, V28, P1586, DOI 10.1128/JCM.28.7.1586-1590.1990; Donham C S, 1990, Health Care Financ Rev, V11, P169; EISENBERG JM, 1986, JAMA-J AM MED ASSOC, V255, P1584, DOI 10.1001/jama.255.12.1584; EISENBERG JM, 1983, MED DECIS MAKING, V3, P155, DOI 10.1177/0272989X8300300203; FANT WK, 1990, AM J HOSP PHARM S3, V47, P16; FIELD PR, 1988, J CLIN MICROBIOL, V26, P990, DOI 10.1128/JCM.26.5.990-994.1988; FOX JL, 1990, BIO-TECHNOL, V8, P1240; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LINDE A, 1990, J INFECT DIS, V161, P903, DOI 10.1093/infdis/161.5.903; LUDWIGS UG, 1991, J INTERN MED, V229, P117, DOI 10.1111/j.1365-2796.1991.tb00318.x; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; OBAYASHI T, 1990, ADV EXP MED BIOL, V256, P215; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PARNO JR, 1982, CRIT CARE MED, V10, P569, DOI 10.1097/00003246-198209000-00002; PARNO JR, 1984, MED CARE, V22, P167, DOI 10.1097/00005650-198402000-00008; Pessi T T, 1973, Ann Chir Gynaecol Fenn Suppl, V185, P3; ROSOFF JD, 1989, J CLIN MICROBIOL, V27, P1997, DOI 10.1128/JCM.27.9.1997-2002.1989; ROTH RI, 1986, J LAB CLIN MED, V114, P306; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SEARLE JF, 1985, ANN ROY COLL SURG, V67, P187; SPICHER JE, 1987, ARCH INTERN MED, V147, P421, DOI 10.1001/archinte.147.3.421; TANAKA R, 1987, LIVER, V7, P316; TEPLIZKI H, 1907, ISRAEL J MED SCI, V23, P1121; THIBAULT GE, 1980, NEW ENGL J MED, V302, P938, DOI 10.1056/NEJM198004243021703; THONER J, 1987, ACTA ANAESTH SCAND, V31, P693, DOI 10.1111/j.1399-6576.1987.tb02647.x; VANDEVENTER SJH, 1988, LANCET, V1, P605; WEINSTEIN MP, 1991, J CLIN MICROBIOL, V29, P879, DOI 10.1128/JCM.29.5.879-882.1991; YAMAGAMI S, 1990, INT J ARTIF ORGANS, V13, P205, DOI 10.1177/039139889001300403; YOUNG LS, 1985, PRINCIPLES PRACTICE; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1989, LENGTH STAY; 1989, CANCER STATISTICS RE; 1990, MMWR, V39, P31; 1990, STATISTICAL ABSTRACT; 1989, FED REG         0130, V54, P4302	42	81	86	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3466	3471		10.1001/jama.266.24.3466	http://dx.doi.org/10.1001/jama.266.24.3466			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744962				2022-12-28	WOS:A1991GV87800034
J	HSU, MC; SCHUTT, AD; HOLLY, M; SLICE, LW; SHERMAN, MI; RICHMAN, DD; POTASH, MJ; VOLSKY, DJ				HSU, MC; SCHUTT, AD; HOLLY, M; SLICE, LW; SHERMAN, MI; RICHMAN, DD; POTASH, MJ; VOLSKY, DJ			INHIBITION OF HIV REPLICATION IN ACUTE AND CHRONIC INFECTIONS INVITRO BY A TAT ANTAGONIST	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; TRANSCRIPTIONAL REGULATION; QUANTITATIVE-ANALYSIS; ZIDOVUDINE AZT; HTLV-III; SEQUENCE; TYPE-1; PROTEIN	The human immunodeficiency virus-I (HIV-1) trans-activator Tat is an attractive target for the development of antiviral drugs because inhibition of Tat would arrest the virus at an early stage. The drug Ro 5-3335 [7-chloro-S-(2-pyrryl)-3H-1,4-benzodiazepin-2(H)-one], inhibited gene expression by HIV-1 at the level of transcriptional trans-activation by Tat. The compound did not inhibit the basal activity of the promoter. Both Tat and its target sequence TAR were required for the observed inhibitory activity. Ro 5-3335 reduced the amount of cell-associated viral RNA and antigen in acutely, as well as in chronically infected cells in vitro (median inhibition concentration 0.1 to 1 micromolar). Effective inhibition of viral replication was also observed 24 hours after cells were transfected with infectious recombinant HIV-1 DNA. The compound was active against both HIV-1 and HIV-2 and against 3'-azido-3'-deoxythymidine (AZT)-resistant clinical isolates.	UNIV CALIF SAN DIEGO,VET ADM MED CTR,INFECT DIS SECT,SAN DIEGO,CA 92161; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,MOLEC VIROL LAB,NEW YORK,NY 10019	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Columbia University; Mount Sinai St. Luke's; Mount Sinai West	HSU, MC (corresponding author), HOFFMANN LA ROCHE INC,DEPT VIROL,NUTLEY,NJ 07110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397, U01AI027670, R37AI029164, R01AI029164] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27670, AI 29164, AI 27397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CASAREALE D, 1987, VIROLOGY, V156, P40, DOI 10.1016/0042-6822(87)90434-X; CONNELL EV, COMMUNICATION; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; HAEFELY WE, COMMUNICATION; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAYES T, COMMUNICATION; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2551; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; TANNEAU F, 1990, J INFECT DIS, V162, P837, DOI 10.1093/infdis/162.4.837; TOWN C, COMMUNICATION; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOLSKY DJ, 1990, J VIROL METHODS, V28, P257, DOI 10.1016/0166-0934(90)90119-Z	39	228	245	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1799	1802		10.1126/science.1763331	http://dx.doi.org/10.1126/science.1763331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763331				2022-12-28	WOS:A1991GW31600046
J	COLLOPY, BT				COLLOPY, BT			INTERNATIONAL QUALITY ASSURANCE - AUDIT ACTIVITIES IN AUSTRALIA	BRITISH MEDICAL JOURNAL			English	Article											COLLOPY, BT (corresponding author), AUSTRALIAN COUNCIL HEALTHCARE STAND,CARE EVALUAT PROGRAM,7TH FLOOR,154 GIPPS ST,MELBOURNE,VIC 3002,AUSTRALIA.							CASS M, 1990, AUST CLIN REV, V10, P1269; COLLOPY B, 1983, AUST CLIN REV, V10, P6; Collopy B T, 1990, Aust Clin Rev, V10, P141; Collopy B T, 1990, Aust Clin Rev, V10, P83; COLLOPY BT, 1979, MED J AUSTRALIA, V2, P689, DOI 10.5694/j.1326-5377.1979.tb104280.x; LEMBCKE PA, 1956, JAMA-J AM MED ASSOC, V162, P646, DOI 10.1001/jama.1956.72970240010009; Paull J, 1990, Aust Clin Rev, V10, P126; PICKERING E, 1980, AUSTR HLTH REV, V3, P15; RENWICK M, 1989, QUALITY ASSURANCE HO; SMYTH J, 1959, MED J AUSTRALIA, V1, P313	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1523	1525		10.1136/bmj.303.6816.1523	http://dx.doi.org/10.1136/bmj.303.6816.1523			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782496	Green Published, Bronze			2022-12-28	WOS:A1991GV47600029
J	ZHANG, K; PAPAGEORGE, AG; MARTIN, P; VASS, WC; OLAH, Z; POLAKIS, PG; MCCORMICK, F; LOWY, DR				ZHANG, K; PAPAGEORGE, AG; MARTIN, P; VASS, WC; OLAH, Z; POLAKIS, PG; MCCORMICK, F; LOWY, DR			HETEROGENEOUS AMINO-ACIDS IN RAS AND RAP1A SPECIFYING SENSITIVITY TO GAP PROTEINS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; CATALYTIC DOMAIN; EFFECTOR DOMAIN; RAS-P21 GTPASE; P21; IDENTIFICATION; MUTANTS; PURIFICATION; STIMULATION	Guanosine triphosphatase (GTPase) activity of Ras is increased by interaction with Ras-GAP (GTPase-activating protein) or with the GAP-related domain of the type 1 neurofibromatosis protein (NF1-GRD), but Ras is not affected by interaction with cytoplasmic and membrane forms of Rap-GAP; Rap1A, whose effector function can suppress transformation by Ras, is sensitive to both forms of Rap-GAP and resistant to Ras-GAP and NF1-GRD. A series of chimeric proteins composed of portions of Ras and Rap were constructed; some were sensitive to Ras-GAP but resistant to NF1-GRD, and others were sensitive to cytoplasmic Rap-GAP but resistant to membrane Rap-GAP. Sensitivity of chimeras to Ras-GAP and cytoplasmic Rap-GAP was mediated by amino acids that are carboxyl-terminal to the effector region. Residues 61 to 65 of Ras conferred Ras-GAP sensitivity, but a larger number of Rap1A residues were required for sensitivity to cytoplasmic Rap-GAP. Chimeras carrying the Ras effector region that were sensitive only to Ras-GAP or only to cytoplasmic Rap-GAP transformed NIH 3T3 cells poorly. Thus, distinct amino acids of Ras and Rap1A mediate sensitivity to each of the proteins with GAP activity, and transforming potential of Ras and sensitivity of Ras to Ras-GAP are at least partially independent properties.	CETUS CORP,EMERYVILLE,CA 94608		ZHANG, K (corresponding author), NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1990, MOL CARCINOGEN, V3, P185, DOI 10.1002/mc.2940030404; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; Zhang K. Y., UNPUB	43	36	39	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1630	1634		10.1126/science.1749934	http://dx.doi.org/10.1126/science.1749934			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749934				2022-12-28	WOS:A1991GV07300041
J	SMITH, T				SMITH, T			MEDICINE IN EUROPE .2. EUROPEAN HEALTH CHALLENGES	BRITISH MEDICAL JOURNAL			English	Article																			0	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1395	1397		10.1136/bmj.303.6814.1395	http://dx.doi.org/10.1136/bmj.303.6814.1395			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760611	Green Published, Bronze			2022-12-28	WOS:A1991GU38400028
J	SIGURGEIRSSON, B; LINDELOF, B; EKLUND, G				SIGURGEIRSSON, B; LINDELOF, B; EKLUND, G			CONDYLOMATA ACUMINATA AND RISK OF CANCER - AN EPIDEMIOLOGIC-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENITAL WARTS; PAPILLOMAVIRUSES; ROCHESTER; MINN	Objective-To determine whether patients with condylomata acuminata have an increased risk o developing cancer. Design-Prospective cohort study on patients diagnosed as having condylomata acuminata. The number of malignant tumours in the cohort was compared with national incidences obtained from the Swedish Cancer Registry. Setting-Dermatology department of the Karolinska Hospital, Stockholm, Sweden. Subjects-3260 patients (2549 males and 711 females, median (range) age 23 (1-80) years) seen during 1969-84, with a mean follow up of 7.8 years. Main outcome measures-Number of malignant tumours observed in the cohort during the study period and expected number from national incidence. Results-There were 27 malignancies in the study group. There was no significant increase genital cancer in females compared with the national incidence. Only one patient had invasive cervical cancer (relative risk = 1.8; 95% confidence interval 0 to 10.1). Seventeen women had cervical carcinoma in situ (1.5; 0.9 to 2.5) compared with an expected number of 11.5; this increase was not significant. For males 22 cancers were observed at all sites (1.6; 1.0 to 2.5). The number of genitourinary cancers observed in males was almost three times higher than expected (2.6; 1.2 to 5.0). Conclusion-The results indicate that the risk of developing cervical carcinoma in situ or invasive cervical cancer after a genital human papillomavirus infection is less than previously thought. The implications of increase in the genitourinary malignancies in males are uncertain.	KAROLINSKA HOSP, DEPT CANC EPIDEMIOL, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet; Karolinska University Hospital	SIGURGEIRSSON, B (corresponding author), KAROLINSKA HOSP, DEPT DERMATOL, S-10401 STOCKHOLM 60, SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				ADAMI HO, 1989, ACTA ONCOL, V28, P463, DOI 10.3109/02841868909092251; ARMSTRONG B, 1988, LANCET, V1, P756; BAFVERSTEDT B, 1967, ACTA DERM-VENEREOL, V47, P376; BARRETT TJ, 1954, JAMA-J AM MED ASSOC, V154, P333, DOI 10.1001/jama.1954.02940380043010c; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BREHART M, 1984, EMBO J, V3, P1151; BUNNEY MH, 1985, VIRAL WARTS THEIR BI, P22; CHUANG TY, 1984, ARCH DERMATOL, V120, P469, DOI 10.1001/archderm.120.4.469; CHUANG TY, 1984, ARCH DERMATOL, V120, P476, DOI 10.1001/archderm.120.4.476; CHUANG TY, 1987, J AM ACAD DERMATOL, V16, P376, DOI 10.1016/S0190-9622(87)70053-X; DUNN AEG, 1968, J ULTRA MOL STRUCT R, V22, P282, DOI 10.1016/S0022-5320(68)90021-X; GISSMANN L, 1982, INT J CANCER, V29, P143, DOI 10.1002/ijc.2910290205; GISSMANN L, 1986, BANBURY REPORT, V21, P217; Grisson, 1915, DERMATOL WOCHENSCHR, V60, P89; HAUSEN HZ, 1985, PROG MED VIROL, V32, P15; HAUSEN HZ, 1977, CURR TOP MICROBIOL, P1; KAPAUR TR, 1982, INDIAN J DERMATOL, V48, P23; KOVI J, 1974, AM J CLIN PATHOL, V61, P702; LYNCH PJ, 1985, CLIN OBSTET GYNECOL, V28, P142, DOI 10.1097/00003081-198528010-00017; MATTSSON B, 1984, THESIS KAROLINSKA I, P1; MCCANCE DJ, 1988, NATURE, V335, P765, DOI 10.1038/335765a0; MCNICOL PJ, 1990, J CLIN MICROBIOL, V28, P409, DOI 10.1128/JCM.28.3.409-412.1990; ORIEL JD, 1977, SEX TRANSM DIS, V4, P153, DOI 10.1097/00007435-197710000-00009; ORTH G, 1978, B CANCER, V65, P151; RAGOZZINO MW, 1984, MAYO CLIN PROC, V59, P719, DOI 10.1016/S0025-6196(12)62062-X; SHAFEEK MA, 1979, OBSTET GYNECOL, V54, P120, DOI 10.1097/00006250-197907000-00027; SIEGEL A, 1962, AM J SURG, V103, P613, DOI 10.1016/0002-9610(62)90531-7; SIGURGEIRSSON B, IN PRESS COMPUT METH; SYRJANEN KJ, 1983, OBSTET GYNECOL, V62, P617; VONKROGH G, 1982, ACTA DERM-VENEREOL, V62, P1; WALKER PG, 1983, BRIT J VENER DIS, V59, P120; 1961, CANCER INCIDENCE SWE	32	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1991	303	6798					341	344		10.1136/bmj.303.6798.341	http://dx.doi.org/10.1136/bmj.303.6798.341			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1781836	Green Published, Bronze			2022-12-28	WOS:A1991GA60600021
J	POLISH, LB; SHAPIRO, CN; BAUER, F; KLOTZ, P; GINIER, P; ROBERTO, RR; MARGOLIS, HS; ALTER, MJ				POLISH, LB; SHAPIRO, CN; BAUER, F; KLOTZ, P; GINIER, P; ROBERTO, RR; MARGOLIS, HS; ALTER, MJ			NOSOCOMIAL TRANSMISSION OF HEPATITIS-B VIRUS ASSOCIATED WITH THE USE OF A SPRING-LOADED FINGERSTICK DEVICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMON-SOURCE OUTBREAK; HEMODIALYSIS UNIT; ANTIGEN	Background and Methods. From June 1989 through March 1990, 26 patients, of whom 23 had diabetes, contracted acute hepatitis B virus (HBV) infection in a hospital in California. All 26 patients and one HBV carrier (also a diabetic) had been admitted to a single medical ward during the six months before the case patients became infected with HBV. To determine the source of the infection, we conducted a retrospective cohort study of the 72 patients with diabetes who had been admitted to the ward from January through December 1989 and a case-control study comparing the 3 nondiabetic patients who contracted hepatitis with 20 nondiabetic controls. Results. The retrospective cohort study of all the patients with diabetes who were admitted to the ward during 1989 found that those who underwent capillary blood sampling by finger stick with a spring-loaded lancet device were more likely to contract HBV infection than those who did not have finger sticks (attack rate, 42 percent vs. 0 percent; P = 0.08). In addition, a dose-response relation was observed between the number of finger sticks received and the frequency of hepatitis B (P = 0.002). The case-control study found that all 3 of the nondiabetic patients who contracted hepatitis underwent finger-stick blood sampling with the device, as compared with none of the 20 nondiabetic controls (P = 0.0006). A review of nursing procedures indicated that the platform of the device was not routinely changed after each use; this finding suggested that contamination of the platform by HBV-infected blood was the mechanism of percutaneous transmission of HBV. Conclusions. Proper use of finger-stick devices as well as strict adherence to universal precautions to avoid contamination by blood are required to decrease the possibility of transmission of blood-borne pathogens among hospitalized patients.	FRESNO VET AFFAIRS HOSP,FRESNO,CA; CALIF DEPT HLTH & HUMAN SERV,BERKELEY,CA	California Health & Human Services Agency	POLISH, LB (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; BIRNIE GG, 1983, GUT, V24, P171, DOI 10.1136/gut.24.2.171; BOND WW, 1981, LANCET, V1, P550; CANTER J, 1990, ARCH INTERN MED, V150, P1923; CARL M, 1983, DIALYSIS TRANSPLANT, V12, P222; DODD RY, 1973, AM J EPIDEMIOL, V97, P111, DOI 10.1093/oxfordjournals.aje.a121487; DOUVIN C, 1990, NEW ENGL J MED, V322, P57, DOI 10.1056/NEJM199001043220112; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; NATH N, 1985, AM J EPIDEMIOL, V122, P218, DOI 10.1093/oxfordjournals.aje.a114092; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J	11	111	116	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					721	725		10.1056/NEJM199203123261101	http://dx.doi.org/10.1056/NEJM199203123261101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738376	Bronze			2022-12-28	WOS:A1992HH06400001
J	OHRT, CK; MCKINNEY, WP				OHRT, CK; MCKINNEY, WP			ACHIEVING COMPLIANCE WITH INFLUENZA IMMUNIZATION OF MEDICAL HOUSE STAFF AND STUDENTS - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							HOSPITAL PERSONNEL; PHYSICIANS; PREVENTION; VACCINE	Objective. - To determine the optimal method to increase influenza immunization rates of medical house staff and students. Design. - Prospective randomized trial and cross-sectional survey. Study Group. - Four hundred forty-two internal medicine, obstetrics-gynecology, and general surgery residents and junior medical students. Measurements. - The four interventions employed were (1) an educational memorandum outlining vaccine indications sent to all study group members, (2) a personal letter mailed to a random sample of half of the remaining unimmunized persons, (3) a telephone call to half of the unimmunized letter recipients, and (4) vaccine offered directly to the remaining unimmunized persons in clinics and conferences. In addition, a questionnaire was administered to all persons requesting or offered vaccine. Main Results. - During the 3 weeks after the memorandum, 87 (20%) of 442 persons were immunized. Five weeks after the letter, 61 (34%) of persons receiving a letter and 30 (17%) of the no-letter controls (P = .0005) had been immunized. After the telephone call, there was a statistically insignificant trend toward increased compliance. In clinics and conferences, 90% of persons reached were immunized and 10% refused, largely extinguishing the effect of prior interventions. At completion of the study, 275 (62%) of 442 participants were immunized, 29 (7%) refused, and 138 (31%) were not reached. Questionnaire results revealed that only 32% had ever been previously immunized against influenza, yet 70% stated that they had worked despite having influenzalike symptoms. Conclusion. - A high rate of immunization of house staff and medical students can be achieved most effectively by offering vaccine in clinics and conferences. Continued education about influenza immunization is necessary for physicians and medical students.	DALLAS DEPT VET AFFAIRS MED CTR,MED SERV 111,GEN INTERNAL MED SECT,4500 S LANCASTER RD,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DALLAS,TX 75230	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Decker M D, 1990, Infect Dis Clin North Am, V4, P211; GIRASEK DC, 1990, AM J PUBLIC HEALTH, V80, P1272; HAMMOND GW, 1984, CAN MED ASSOC J, V131, P449; KAPILA R, 1977, CHEST, V71, P576, DOI 10.1378/chest.71.5.576; LEWY R, 1988, J OCCUP ENVIRON MED, V30, P822; LEWY R, 1987, J OCCUP ENVIRON MED, V29, P433; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; PACHUCKI CT, 1989, ARCH INTERN MED, V149, P77, DOI 10.1001/archinte.149.1.77; POLAND GA, 1990, ANN INTERN MED, V113, P628, DOI 10.7326/0003-4819-113-8-628; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; VANVORIS LP, 1982, ANN INTERN MED, V96, P153, DOI 10.7326/0003-4819-96-2-153; WEINGARTEN S, 1989, AM J INFECT CONTROL, V17, P202, DOI 10.1016/0196-6553(89)90129-6; 1989, MMWR, V38, P297; 1981, MMWR, V30, P79; 1984, MMWR, V33, P253	15	67	69	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1377	1380		10.1001/jama.267.10.1377	http://dx.doi.org/10.1001/jama.267.10.1377			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740861				2022-12-28	WOS:A1992HG67800033
J	RABKIN, CS; HILGARTNER, MW; HEDBERG, KW; ALEDORT, LM; HATZAKIS, A; EICHINGER, S; EYSTER, ME; WHITE, GC; KESSLER, CM; LEDERMAN, MM; DEMOERLOOSE, P; BRAY, GL; COHEN, AR; ANDES, WA; MANCOJOHNSON, M; SCHRAMM, W; KRONER, BL; BLATTNER, WA; GOEDERT, JJ				RABKIN, CS; HILGARTNER, MW; HEDBERG, KW; ALEDORT, LM; HATZAKIS, A; EICHINGER, S; EYSTER, ME; WHITE, GC; KESSLER, CM; LEDERMAN, MM; DEMOERLOOSE, P; BRAY, GL; COHEN, AR; ANDES, WA; MANCOJOHNSON, M; SCHRAMM, W; KRONER, BL; BLATTNER, WA; GOEDERT, JJ			INCIDENCE OF LYMPHOMAS AND OTHER CANCERS IN HIV-INFECTED AND HIV-UNINFECTED PATIENTS WITH HEMOPHILIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RENAL-TRANSPLANT RECIPIENTS; NON-HODGKIN LYMPHOMA; KAPOSIS-SARCOMA; DISEASE; AIDS; RISK; PAPILLOMAVIRUS	Objective. - To determine the types and rates of cancers occurring in excess in the presence of infection with the human immunodeficiency virus type 1 (HIV-1). Design. - Cohort analytic study of HIV-infected and HIV-uninfected subjects followed for up to 12 years. Setting. - Fifteen hemophilia treatment centers. Patients. - A total of 1701 patients with hemophilia, of whom 1065 (63%) were HIV-1 seropositive. Main Outcome Measures. -Morphologic classification and incidence rates of cancers. Main Results. - The incidence of non-Hodgkin's lymphoma after HIV seroconversion averaged 0.15 case per 100 person-years (95% confidence interval [Cl], 0.08 to 0.25) and rose exponentially with increasing duration of HIV infection. Although the greatest absolute risk of lymphoma was in the oldest age group, the relative increase compared with general population rates was 38-fold in subjects 10 to 39 years old and 12-fold in older subjects (P <.05). The CD4+ T-lymphocyte levels for lymphoma cases were similar to HIV-positive subjects without the acquired immunodeficiency syndrome (AIDS) who had been infected for the same length of time. The incidence of Kaposi's sacroma was increased 200-fold (95% Cl, 20 to 700). The incidence of cancers other than non-Hodgkin's lymphoma and Kaposi's sarcoma were not increased in the HIV-positive subjects (ratio of observed to expected cases, 0.9 [95% Cl, 0.4 to 1.9]). The HIV-negative subjects had no significant increase in cancer incidence. Conclusions. - HIV infection has restricted effects on cancer incidence that are only partly explained by immunosuppression. Paradoxically, improvements in therapy of HIV infection that prolong survival may lead to further increases in HIV-associated lymphoma.	NCI,VIRAL EPIDEMIOL SECT,BETHESDA,MD 20892; CORNELL UNIV,MED CTR,DEPT PEDIAT HEMATOL ONCOL,NEW YORK,NY 10021; CARDEZA FDN HEMOPHILIA CTR,PHILADELPHIA,PA; MT SINAI MED CTR,DEPT HEMATOL,NEW YORK,NY 10029; NATL RETROVIRUS REFERENCE CTR,ATHENS,GREECE; UNIV ATHENS,SCH MED,ATHENS,GREECE; UNIV VIENNA,DEPT INTERNAL MED,A-1010 VIENNA,AUSTRIA; PENN STATE UNIV,MILTON S HERSHEY MED CTR,SCH MED,DIV HEMATOL,HERSHEY,PA 17033; UNIV N CAROLINA,SCH MED,DIV HEMATOL,CHAPEL HILL,NC 27514; GEORGE WASHINGTON UNIV,MED CTR,DIV HEMATOL ONCOL,WASHINGTON,DC 20037; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; UNIV GENEVA,HEMOSTASIS UNIT,CH-1211 GENEVA 4,SWITZERLAND; HOP CANTONAL GENEVA,CH-1211 GENEVA 4,SWITZERLAND; CHILDRENS HOSP,NATL MED CTR,DEPT HEMATOL,WASHINGTON,DC 20010; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA; TULANE UNIV,SCH MED,HEMATOL SECT,NEW ORLEANS,LA 70112; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT HEMATOL,DENVER,CO 80262; UNIV MUNICH,MED CLIN,DIV HEMOSTASIS,W-8000 MUNICH 2,GERMANY; RES TRIANGLE INST,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; Jefferson University; Icahn School of Medicine at Mount Sinai; Athens Medical School; National & Kapodistrian University of Athens; University of Vienna; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; George Washington University; Case Western Reserve University; University of Geneva; University of Geneva; Children's National Health System; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Tulane University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munich; Research Triangle Institute				, M. Elaine Eyster/0000-0001-8248-6793	NCI NIH HHS [N01-CP-95663, N01-CP-85649, N01-CO-74102] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095663, N01CP085649] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BLUMBERG N, 1989, ARCH PATHOL LAB MED, V113, P246; BREEN EC, 1990, J IMMUNOL, V144, P480; Breslow N. E., 1987, STATISTICAL METHODS, VII; DEVESA SS, IN PRESS CANCER RES; FEINGOLD AR, 1990, J ACQ IMMUN DEF SYND, V3, P896; FILIPOVICH AH, 1980, PREV MED, V9, P252, DOI 10.1016/0091-7435(80)90083-3; Freter C E, 1990, J Natl Cancer Inst Monogr, P45; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; HARWOOD AR, 1979, AM J MED, V67, P759, DOI 10.1016/0002-9343(79)90731-9; HOOVER R, 1973, LANCET, V2, P55; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; LIFF JM, 1990, 30TH INT C ANT AG CH; MEEKER TC, 1991, AIDS, V5, P669, DOI 10.1097/00002030-199106000-00005; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; NERI A, 1991, BLOOD, V77, P1092; OVERLY WL, 1987, ANN INTERN MED, V106, P334, DOI 10.7326/0003-4819-106-2-334_1; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RABKIN CS, 1990, LANCET, V336, P248, DOI 10.1016/0140-6736(90)91775-6; RABKIN CS, 1991, AIDS RES HUM RETROV, V7, P223; ROBERT NJ, 1984, ANN INTERN MED, V101, P142, DOI 10.7326/0003-4819-101-1-142_2; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SELIK RM, 1987, AIDS, V1, P175; SERRANO M, 1990, CANCER-AM CANCER SOC, V65, P2248, DOI 10.1002/1097-0142(19900515)65:10<2248::AID-CNCR2820651015>3.0.CO;2-W; TIRELLI U, 1989, ACTA ONCOL, V28, P637, DOI 10.3109/02841868909092284; 1990, NCI NIH902789 PUBL	32	112	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1090	1094		10.1001/jama.267.8.1090	http://dx.doi.org/10.1001/jama.267.8.1090			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735926				2022-12-28	WOS:A1992HE39100024
J	GOLDMAN, RL				GOLDMAN, RL			THE RELIABILITY OF PEER ASSESSMENTS OF QUALITY OF CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							JUDGMENTS; MEDICINE	Objective. - To critically examine the literature regarding the interreviewer reliability of the standard practice of peer assessment of quality of care. Data Sources. - Computerized searches of the English-language literature from 1966 through 1990 using MEDLINE, HEALTHLINE, and SCISEARCH databases were performed to identify studies reporting data on interreviewer agreement of implicit evaluations of patient care episodes. Study Selection. - Seventeen studies were identified. Five studies were excluded from this review because of deficiencies in the methods or lack of data on chance-corrected indexes of agreement. Data Extraction Synthesis. - The degree of agreement beyond chance was compared with accepted standards in the 12 remaining studies. Most of these studies found agreement corrected for chance to be in the range regarded as poor, indicating that physician agreement regarding quality of care is only slightly better than the level expected by chance. Conclusions. - Given the magnitude of the resources devoted to quality assurance and the centrality of peer assessment to these efforts, there is a need for a global reexamination of the peer review process. A number of proposals appear to have potential for improving the peer review process including more objective assessment procedures, multiple reviewers, higher standards for reviewers, elimination of systematic reviewer bias, use of outcome judgments, and adoption of practice guidelines.			GOLDMAN, RL (corresponding author), US DEPT VET AFFAIRS CENT OFF,QUAL MANAGEMENT OFF,810 VERMONT AVE NW,WASHINGTON,DC 20420, USA.							AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BIGBY J, 1987, AM J MED, V83, P1031, DOI 10.1016/0002-9343(87)90938-7; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BROOK RH, 1987, JAMA-J AM MED ASSOC, V258, P3138, DOI 10.1001/jama.258.21.3138; BROOK RH, 1973, US DHEW HRA743100 PU; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CHASSIN MR, 1988, INQUIRY-J HEALTH CAR, V25, P437; DIXON WJ, 1990, BMDP STATISTICAL SOF, V1, P269; DONABEDIAN A, 1985, EXPLORATIONS QUALITY, V3, P194; DONABEDIAN A, 1982, EXPLORATIONS QUALITY, V2, P17; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FINE J, 1971, NEW YORK STATE J MED, V71, P1963; FLIESS JL, 1973, EDUC PSYCHOL MEAS, V33, P613; FRANKL SE, 1991, AM J MED, V90, P667; HARTZ A, 1989, NATIONAL VALIDATION; HASTINGS GE, 1980, AM J PUBLIC HEALTH, V70, P222, DOI 10.2105/AJPH.70.3.222; Horn S D, 1977, J Community Health, V2, P251, DOI 10.1007/BF01325146; HULKA BS, 1979, MED CARE, V17, P1; KLAUKE DN, 1988, INVESTIGATION MORTAL; Krippendorff K., 1970, SOCIOL METHODOL, V2, P139, DOI 10.2307/270787; KROEGER HH, 1965, J AMER MED ASSOC, V193, P371, DOI 10.1001/jama.1965.03090050047013; LUDKE RL, 1990, SDR87003 US DEP VET; MOREHEAD MA, 1964, STUDY QUALITY HOSPIT; OLEARY DS, 1988, JOINT COMMISSION PER, P2; PETERSON OL, 1956, J MED EDUC         2, V31, P1; PHANEUF MC, 1976, NURSING AUDIT SELF R, P35; POSNER KL, 1990, STAT MED, V9, P1103, DOI 10.1002/sim.4780090917; POSNER KL, 1991, ANESTHESIOLOGY S3A, V75, pA1058; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; Revicki D A, 1990, QRB Qual Rev Bull, V16, P404; Richardson F M, 1972, Med Care, V10, P29, DOI 10.1097/00005650-197201000-00004; ROSENFELD LS, 1957, AM J PUBLIC HEALTH N, V47, P856, DOI 10.2105/AJPH.47.7.856; SANAZARO PJ, 1985, MED CARE, V23, P1097, DOI 10.1097/00005650-198509000-00007; Williamson J W, 1991, Qual Assur Util Rev, V6, P8; 1990, 1991 ACCREDITATION M, P220; 1978, QUALITY MED CARE RES; 1988, ANN REPORT C, P219; 1967, NY STATE J MED, V67, P1205	39	188	188	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					958	960		10.1001/jama.267.7.958	http://dx.doi.org/10.1001/jama.267.7.958			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HD155	1734109				2022-12-28	WOS:A1992HD15500030
J	MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C				MARTELL, JV; SEITZ, RS; HARADA, JK; KOBAYASHI, J; SASAKI, VK; WONG, C			HOSPITALIZATION IN AN URBAN HOMELESS POPULATION - THE HONOLULU URBAN HOMELESS PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article						HOMELESS PERSONS; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; COSTS AND COST ANALYSIS; SUBSTANCE ABUSE	MENTAL-HEALTH	Objective: To determine the rate and estimate the cost of hospitalization in a defined urban homeless population. Design: Retrospective chart review. Setting: Kalihi-Palama Health Clinic Health Care for the Homeless Project, Hawaii State Hospital, and seven acute care hospitals in Honolulu, Hawaii. Patients: A total of 1751 homeless clients contacted between 1 December 1988 and 30 November 1990. Measurements and Main Results: A total of 1751 individuals were studied for an aggregate of 871.3 person-years. Five hundred sixty-four hospitalizations were identified: ninety-two to the state psychiatric hospital and 472 to acute care hospitals. The age- and sex-adjusted hospitalization rate for acute care hospitals was 542/1000 person-years (compared with the state rate of 96/1000 person-years). Homeless persons were admitted to acute care hospitals for 4766 days compared with a predicted 640 days. The age- and sex-adjusted rate of admission to the state psychiatric hospital was 105/1000 person-years (compared with the state rate of 0.8/1000 person-years). Homeless persons were admitted to the state psychiatric hospital for 3837 days compared with a predicted 139 days. Conclusions: Homeless individuals in this study were hospitalized in acute care and psychiatric hospitals far more frequently than were members of the general population.	UNIV HAWAII, JOHN A BURNS SCH MED, OFF STUDENT AFFAIRS, HONOLULU, HI 96822 USA	University of Hawaii System								BAHR HM, 1971, PUBLIC OPIN QUART, V35, P374, DOI 10.1086/267922; BASSUK EL, 1984, SCI AM, V251, P40, DOI 10.1038/scientificamerican0784-40; BORLAND A, 1989, HOSP COMMUNITY PSYCH, V40, P369; Bowdler J E, 1989, Nurse Pract, V14, P50; BOWDLER JE, 1989, NURSE PRACTITIONER, V14, P47; BOWDLER JE, 1989, NURSE PRACT, V14, P50; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1972, ANN INTERN MED, V77, P565, DOI 10.7326/0003-4819-77-4-565; BRICKNER PW, 1986, ANN INTERN MED, V104, P405, DOI 10.7326/0003-4819-104-3-405; CHRIST WR, 1989, SOC WORK HEALTH CARE, V14, P33, DOI 10.1300/J010v14n01_03; COHEN CI, 1988, J GERONTOL, V43, pS121, DOI 10.1093/geronj/43.4.S121; FISCHER PJ, 1986, AM J PUBLIC HEALTH, V76, P519, DOI 10.2105/AJPH.76.5.519; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; LAMB HR, 1986, JAMA-J AM MED ASSOC, V256, P498, DOI 10.1001/jama.256.4.498; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P1232, DOI 10.1001/jama.253.9.1232; MARWICK C, 1985, JAMA-J AM MED ASSOC, V253, P3217, DOI 10.1001/jama.253.22.3217; MORRIS W, 1989, WESTERN J MED, V151, P472; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; ROPERS RH, 1987, SOC SCI MED, V24, P669, DOI 10.1016/0277-9536(87)90310-8; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; TORREY EF, 1990, HOSP COMMUNITY PSYCH, V41, P526; WLODARCZYK D, 1988, WESTERN J MED, V148, P717; 1990, DHHS901232 US DEP HL, P184; 1990, HOSPITAL STATISTICS, P62; 1990, STATE HAWAII DATA BO, P37	25	65	65	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					299	303		10.7326/0003-4819-116-4-299	http://dx.doi.org/10.7326/0003-4819-116-4-299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733384				2022-12-28	WOS:A1992HD54600005
J	FRIED, RE; LEVINE, DM; KWITEROVICH, PO; DIAMOND, EL; WILDER, LB; MOY, TF; PEARSON, TA				FRIED, RE; LEVINE, DM; KWITEROVICH, PO; DIAMOND, EL; WILDER, LB; MOY, TF; PEARSON, TA			THE EFFECT OF FILTERED-COFFEE CONSUMPTION ON PLASMA-LIPID LEVELS - RESULTS OF A RANDOMIZED CLINICAL-TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; DIETARY HABITS; CAFFEINE; MEN; TEA; ASSOCIATION; WOMEN; APOLIPOPROTEINS	Objective. - To determine the effect of filtered-coffee consumption on plasma lipoprotein cholesterol levels in healthy men. Design. - Randomized controlled trial with an 8-week washout period followed by an 8-week intervention period during which men were randomly assigned to drink 720 mL/d of caffeinated coffee, 360 mL/d of caffeinated coffee, 720 mL/d of decaffeinated coffee, or no coffee. Setting. - Outpatient clinical research center in a university medical center. Participants. - One hundred healthy male volunteers. Outcome Measure. - Changes in plasma lipoprotein cholesterol levels during the intervention period. Results. - Men who consumed 720 mL of caffeinated coffee daily had mean increases in plasma levels of total cholesterol (0.24 mmol/L, P =.001), low-density lipoprotein cholesterol (0.17 mmol/L, P = .04), and high-density lipoprotein cholesterol (0.08 mmol/L, P =.03). No significant changes in these plasma lipoprotein levels occurred in the other groups. Compared with the group who drank no coffee, the group who drank 720 mL/d of caffeinated coffee had increases in plasma levels of total cholesterol (0.25 mmol/L, P = .02), low-density lipoprotein cholesterol (0.15 mmol/L, P = .17), and high-density lipoprotein cholesterol (0.09 mmol/L, P = .12) after adjustment for changes in diet. Conclusion. - Consumption of 720 mL/d of filtered, caffeinated coffee leads to a statistically significant increase in the plasma level of total cholesterol, which appears to be due to increases of both low-density lipoprotein and high-density lipoprotein cholesterol levels.	JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EPIDEMIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NCRR NIH HHS [RR00722] Funding Source: Medline; NHLBI NIH HHS [T32 HLO7180] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007180] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAB L, 1983, NEW ENGL J MED, V309, P1250; ARNESEN E, 1984, BRIT MED J, V288, P1960, DOI 10.1136/bmj.288.6435.1960; ARO A, 1987, METABOLISM, V36, P1027, DOI 10.1016/0026-0495(87)90021-7; BACHORIK PS, 1984, CLIN CHEM, V30, P839; BAK AAA, 1989, NEW ENGL J MED, V321, P1432, DOI 10.1056/NEJM198911233212103; BJELKE E, 1974, LANCET, V1, P1116; BONAA K, 1988, BRIT MED J, V297, P1103, DOI 10.1136/bmj.297.6656.1103; CURB JD, 1986, AM J EPIDEMIOL, V123, P648, DOI 10.1093/oxfordjournals.aje.a114284; DAVIS BR, 1988, AM J EPIDEMIOL, V128, P124, DOI 10.1093/oxfordjournals.aje.a114935; DAWBER TR, 1974, NEW ENGL J MED, V291, P871, DOI 10.1056/NEJM197410242911703; DENNIS B, 1980, J AM DIET ASSOC, V77, P641; DONAHUE RP, 1987, PREV MED, V16, P796, DOI 10.1016/0091-7435(87)90019-3; FOLSOM AR, 1984, CVD EPIDEMIOL NEWSLE, V35, P53; FORDE OH, 1985, BRIT MED J, V290, P893, DOI 10.1136/bmj.290.6472.893; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GRANT DM, 1983, CLIN PHARMACOL THER, V33, P591, DOI 10.1038/clpt.1983.80; GREEN MS, 1986, J EPIDEMIOL COMMUN H, V40, P324, DOI 10.1136/jech.40.4.324; HAFFNER SM, 1985, AM J EPIDEMIOL, V122, P1; HEYDEN S, 1979, CIRCULATION, V60, P22, DOI 10.1161/01.CIR.60.1.22; HOFMAN A, 1983, NEW ENGL J MED, V309, P1248; JIANG XR, 1986, CLIN CHEM, V32, P930; KARK JD, 1985, BRIT MED J, V291, P699, DOI 10.1136/bmj.291.6497.699; KLATSKY AL, 1985, AM J CARDIOL, V55, P577, DOI 10.1016/0002-9149(85)90250-4; KOVAR MG, 1983, NEW ENGL J MED, V309, P1249; LITTLE JA, 1965, LANCET, V1, P933; LITTLE JA, 1965, LANCET, V1, P732; MATHIAS S, 1985, AM J EPIDEMIOL, V121, P896, DOI 10.1093/oxfordjournals.aje.a114059; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; NICHOLS AB, 1976, JAMA-J AM MED ASSOC, V236, P1948, DOI 10.1001/jama.236.17.1948; PHILLIPS NR, 1981, ARTERIOSCLEROSIS, V1, P13, DOI 10.1161/01.ATV.1.1.13; PIETINEN P, 1988, INT J EPIDEMIOL, V17, P98, DOI 10.1093/ije/17.1.98; PRINEAS RJ, 1980, J CHRON DIS, V33, P67, DOI 10.1016/0021-9681(80)90029-6; ROSMARIN PC, 1990, AM J MED, V88, P349, DOI 10.1016/0002-9343(90)90488-Y; SACKS FM, 1975, NEW ENGL J MED, V292, P1148, DOI 10.1056/NEJM197505292922203; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SCHREIBER GB, 1988, PREV MED, V17, P280, DOI 10.1016/0091-7435(88)90004-7; SHEKELLE RB, 1983, NEW ENGL J MED, V309, P1249; SHIRLOW MJ, 1984, INT J EPIDEMIOL, V13, P422, DOI 10.1093/ije/13.4.422; SNIDERMAN A, 1975, J LIPID RES, V16, P465; SOLVOLL K, 1989, AM J EPIDEMIOL, V129, P1277, DOI 10.1093/oxfordjournals.aje.a115247; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STENSVOLD I, 1989, J CLIN EPIDEMIOL, V42, P877, DOI 10.1016/0895-4356(89)90101-7; SUPERKO HR, 1989, CIRCULATION S2, V80, P86; THELLE DS, 1983, NEW ENGL J MED, V308, P1464; TUOMILEHTO J, 1987, J EPIDEMIOL COMMUN H, V41, P237, DOI 10.1136/jech.41.3.237; VANDUSSELDORP M, 1990, AM J EPIDEMIOL, V132, P33, DOI 10.1093/oxfordjournals.aje.a115640; WILLIAMS PT, 1985, JAMA-J AM MED ASSOC, V253, P1047; WILSON PWF, 1989, ARCH INTERN MED, V149, P1169, DOI 10.1001/archinte.149.5.1169; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q; 1974, DHEW NIH75628 PUBL; 1988, SAS STAT USERS GUIDE; 1984, JAMA-J AM MED ASSOC, V251, P351; 1988, SAS PROCEDURES GUIDE	55	61	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					811	815		10.1001/jama.267.6.811	http://dx.doi.org/10.1001/jama.267.6.811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732652				2022-12-28	WOS:A1992HC48400025
J	SPIEGAL, N; MURPHY, E; KINMONTH, AL; ROSS, F; BAIN, J; COATES, R				SPIEGAL, N; MURPHY, E; KINMONTH, AL; ROSS, F; BAIN, J; COATES, R			MANAGING CHANGE IN GENERAL-PRACTICE - A STEP BY STEP GUIDE	BRITISH MEDICAL JOURNAL			English	Article											SPIEGAL, N (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,FAC MED,DEPT PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,ENGLAND.							[Anonymous], 1985, PASSION EXCELLENCE L; [Anonymous], 1989, CM555; BAIN DJG, 1990, OPTIMISING CARE PATI; Boydell T, 1986, MANAGERS GUIDE SELF; Fisher R., 1982, GETTING YES NEGOTIAT; MOSSKANTER R, 1983, CHANGE MASTERS, P180; PETERS T, 1985, PASSION EXCELLENCE, P213; PETERS TT, 1985, PASSION EXCELLENCE, P252; Plant R., 1987, MANAGING CHANGE MAKI; PLANT R, 1987, MANAGING CHANGE MAKI, P25; ROGERS EM, 1982, DIFFUSION INNOVATION; STEWART R, 1980, DISTRICT ADM NATIONA; Stocking B, 1985, INITIATIVE INERTIA C; TURRILL T, 1986, CHANGE INNOVATION CH; TURRILL T, 1986, CHANGE INNOVATION CH, P24; TURRILL T, 1986, CHANGE INNOVATION CH, P76; 1989, GENERAL PRACTICE NAT; 1985, WHAT SORT DOCTOR; 1986, QUALITY PRACTICE; 1987, CM249	20	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					231	234		10.1136/bmj.304.6821.231	http://dx.doi.org/10.1136/bmj.304.6821.231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1739799	Green Published, Bronze			2022-12-28	WOS:A1992HA98000028
J	GURDON, JB				GURDON, JB			THE GENERATION OF DIVERSITY AND PATTERN IN ANIMAL DEVELOPMENT	CELL			English	Review							PERIPHERAL NERVOUS-SYSTEM; CELL-ADHESION MOLECULES; MESSENGER-RNA; EMBRYONIC INDUCTION; XENOPUS OOCYTES; EMBRYOGENESIS; DROSOPHILA; DIFFERENTIATION; SEGREGATION; ACTIVATION				GURDON, JB (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; Boycott AE, 1923, P R SOC LOND B-CONTA, V95, P207, DOI 10.1098/rspb.1923.0033; BROCKES J, 1991, NATURE, V350, P15, DOI 10.1038/350015a0; BROWN NA, 1990, DEVELOPMENT, V109, P1; COOKE J, 1990, CELL, V60, P891, DOI 10.1016/0092-8674(90)90336-D; Davidson E. H., 1986, GENE ACTIVITY EARLY; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DUPIN E, 1988, P NATL ACAD SCI USA, V85, P5325; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EYALGILADI H, 1969, J EMBRYOL EXP MORPH, V21, P177; GERHART J, 1989, DEVELOPMENT, V107, P37; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; Gruss P, 1991, CURR OPIN GENET DEV, V1, P204, DOI 10.1016/S0959-437X(05)80071-1; GURDON JB, 1989, TRENDS GENET, V5, P51, DOI 10.1016/0168-9525(89)90022-X; GURDON JB, 1987, DEVELOPMENT, V99, P285; GURDON JB, 1986, J CELL SCI S, V4, P287; Hamburger V, 1988, HERITAGE EXPT EMBRYO; Harrison RG, 1910, J EXP ZOOL, V9, P787, DOI 10.1002/jez.1400090405; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; Horstadius S, 1973, EXPT EMBRYOLOGY ECHI; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JEFFERY WR, 1984, DEV BIOL, V103, P482, DOI 10.1016/0012-1606(84)90335-X; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JOHNSON MH, 1986, J EMBRYOL EXP MORPH, V97, P97; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATTHEWS LS, 1991, CELL, V65, P973; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NIJHOUT HF, 1985, ADV INSECT PHYSIOL, V18, P181; Okada T.S, 1991, TRANSDIFFERENTIATION; OTTE AP, 1990, DEVELOPMENT, V110, P461; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SAXEN L, 1989, International Journal of Developmental Biology, V33, P21; SIMPSON P, 1990, DEVELOPMENT, V109, P509; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STJOHNSTON D, 1992, CELL, V68, P201; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; WHITE G, 1782, NATURAL HIST SELBORN; WHITTAKER JR, 1980, J EMBRYOL EXP MORPH, V55, P343; WHITTAKER JR, 1973, P NATL ACAD SCI USA, V70, P2096, DOI 10.1073/pnas.70.7.2096; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	69	237	258	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					185	199		10.1016/0092-8674(92)90465-O	http://dx.doi.org/10.1016/0092-8674(92)90465-O			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733498				2022-12-28	WOS:A1992HB35300003
J	HYNES, RO; LANDER, AD				HYNES, RO; LANDER, AD			CONTACT AND ADHESIVE SPECIFICITIES IN THE ASSOCIATIONS, MIGRATIONS, AND TARGETING OF CELLS AND AXONS	CELL			English	Review							FIBRONECTIN RECEPTOR COMPLEX; NEURAL CREST MIGRATION; IMMUNOGLOBULIN-LIKE DOMAINS; NERVOUS-SYSTEM NEURONS; GROWTH CONE BEHAVIOR; CHICK VISUAL-SYSTEM; N-CADHERIN; MONOCLONAL-ANTIBODY; NEURITE GROWTH; LEUKOCYTE ADHESION		MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	HYNES, RO (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALBELDA SM, 1990, CANCER RES, V50, P6757; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BALSAMO J, 1991, J CELL BIOL, V113, P429, DOI 10.1083/jcb.113.2.429; BALSAMO J, 1990, J BIOL CHEM, V265, P2923; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEGOVAC PC, 1991, J CELL BIOL, V113, P637, DOI 10.1083/jcb.113.3.637; BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1985, NATURE, V315, P408, DOI 10.1038/315409a0; BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BOUCAUT JC, 1984, NATURE, V307, P364, DOI 10.1038/307364a0; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; BRONNERFRASER M, 1986, DEV BIOL, V117, P528, DOI 10.1016/0012-1606(86)90320-9; BRONNERFRASER M, 1988, J CELL BIOL, V106, P1321, DOI 10.1083/jcb.106.4.1321; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; COLE GJ, 1986, J CELL BIOL, V103, P1739, DOI 10.1083/jcb.103.5.1739; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DUBAND JL, 1988, DEVELOPMENT, V103, P325; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERICKSON CA, 1988, DEVELOPMENT, V103, P63; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; ERICKSON HP, 1988, ADV CELL BIOL, V2, P55; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FRASER SE, 1990, J EXP BIOL, V153, P61; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GALLATIN M, 1986, CELL, V44, P673, DOI 10.1016/0092-8674(86)90832-9; GASSER UE, 1990, P NATL ACAD SCI USA, V87, P4543, DOI 10.1073/pnas.87.12.4543; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GRAY GE, 1991, NEURON, V6, P211, DOI 10.1016/0896-6273(91)90357-6; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; GUNDERSEN RW, 1987, DEV BIOL, V121, P423, DOI 10.1016/0012-1606(87)90179-5; GUNDERSEN RW, 1988, J NEUROSCI RES, V21, P298, DOI 10.1002/jnr.490210222; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HARRISSON F, 1989, International Journal of Developmental Biology, V33, P417; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; HYNES MA, 1990, J NEUROSCI, V10, P1004; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Hynes RO, 1990, FIBRONECTINS; HYNES RO, 1991, ORIGINS HUMAN CANCER, P293; HYNES RO, 1992, IN PRESS CELL; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; IVINS JK, 1991, J NEUROSCI, V11, P1597; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KATER SB, 1991, J NEUROSCI, V11, P891; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; Lander AD, 1990, CURR OPIN CELL BIOL, V2, P907, DOI 10.1016/0955-0674(90)90091-R; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; LASKY LA, 1991, IN PRESS INFLAMMATIO; LAWLER J, 1987, SEMIN THROMB HEMOST, V13, P245, DOI 10.1055/s-2007-1003499; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEHMANN S, 1990, P NATL ACAD SCI USA, V87, P6455, DOI 10.1073/pnas.87.16.6455; LEMMON V, 1991, IN PRESS J NEUROSCI; LETOURNEAU PC, 1985, MOL BASES NEURAL DEV, P269; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINDNER J, 1986, P NATL ACAD SCI USA, V83, P4568, DOI 10.1073/pnas.83.12.4568; MACKIE EJ, 1988, DEVELOPMENT, V102, P237; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; MCKENNA MP, 1988, DEV BIOL, V130, P232, DOI 10.1016/0012-1606(88)90429-0; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; Mosher DF, 1989, FIBRONECTIN; MUIR D, 1989, J CELL BIOL, V109, P2353, DOI 10.1083/jcb.109.5.2353; NAPOLITANO EW, 1991, J CELL BIOL, V113, P893, DOI 10.1083/jcb.113.4.893; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; OOHIRA A, 1991, J NEUROSCI, V11, P822; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PATEL NB, 1985, J NEUROSCI RES, V13, P245, DOI 10.1002/jnr.490130117; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PETTWAY Z, 1990, DEV BIOL, V142, P335, DOI 10.1016/0012-1606(90)90354-L; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; ROGERS SL, 1989, DEV NEUROSCI-BASEL, V11, P248, DOI 10.1159/000111904; ROVASIO RA, 1983, J CELL BIOL, V96, P462, DOI 10.1083/jcb.96.2.462; RUNYAN RB, 1986, J CELL BIOL, V102, P432, DOI 10.1083/jcb.102.2.432; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUTISHAUSER U, 1986, TRENDS NEUROSCI, V9, P374, DOI 10.1016/0166-2236(86)90117-7; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1991, J NEUROSCI, V11, P709; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SCOTT LJC, 1990, J NEUROSCI, V10, P346; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STANFIELD BB, 1991, NEURON, V7, P249, DOI 10.1016/0896-6273(91)90263-Y; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; THANOS S, 1984, P NATL ACAD SCI-BIOL, V81, P1906, DOI 10.1073/pnas.81.6.1906; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; THIERY JP, 1989, FIBRONECTIN, P181; Tomaselli K J, 1991, Curr Opin Neurobiol, V1, P364, DOI 10.1016/0959-4388(91)90054-B; TRISLER D, 1987, SCIENCE, V237, P1208, DOI 10.1126/science.3629237; TRISLER GD, 1981, P NATL ACAD SCI-BIOL, V78, P2145, DOI 10.1073/pnas.78.4.2145; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WALTER J, 1987, DEVELOPMENT, V101, P685; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEHRLE B, 1990, DEVELOPMENT, V110, P401; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YIP JW, 1990, J NEUROSCI, V10, P2476; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	208	844	861	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					303	322		10.1016/0092-8674(92)90472-O	http://dx.doi.org/10.1016/0092-8674(92)90472-O			20	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1733501	Green Published			2022-12-28	WOS:A1992HB35300010
J	DESWIET, M; FAYERS, P; SHINEBOURNE, EA				DESWIET, M; FAYERS, P; SHINEBOURNE, EA			BLOOD-PRESSURE IN 1ST 10 YEARS OF LIFE - THE BROMPTON STUDY	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS; CHILDHOOD; AGE	Objectives - To determine the normal range of blood pressure and its pattern of change in the first 10 years of life. To estimate at what age (if any) children consistently appear in one part of the blood pressure distribution and at what age familial correlations in blood pressure become significant. Design - Longitudinal cohort study. Setting - South east England. Subjects - 2088 children of both sexes born consecutively in Farnborough Hospital, Kent, and their parents. Main outcome measure - Blood pressure measured by Doppler ultrasonography and sphygmomanometry. Results - Systolic blood pressure rose from a mean of 88.5 mm Hg at age 6 months to 96-2 mm Hg at 8 years measured with a 8 cm cuff and from 89.1 mm Hg at age 5 years to 94.3 mm Hg at age 10 years measured with a 12 cm cuff. The larger cuff gave blood pressure readings about 6 mm Hg lower. This effect was independent of body weight and arm circumference. Diastolic blood pressure rose from 57.8 mm Hg at 5 years to 61.8 mm Hg at 10 years (12 cm cuff). There was only about 1 mm Hg difference between sexes. Blood pressure was correlated with weight, weight adjusted for height, height, and arm circumference at all ages studied. The correlation coefficient of repeated yearly measurements increased steadily with age from 0.28 at 2 years to 0.59 at 10 years. The correlation coefficients between child's blood pressure and mother's average blood pressure increased from 0.1 at age 1 year to 0.23 at age 10. Conclusions - Blood pressure changes relatively little between the ages of 6 months and 10 years. Yet because of the increasing strength of between occasion and family correlations, children are more consistently occupying a specific part of the blood pressure distribution as they grow older. Studies in children should help determine why some adults have hypertension and others do not.	BROMPTON HOSP,NATL HEART & LUNG INST,DEPT PAEDIAT,LONDON SW3 6LY,ENGLAND	Imperial College London; Royal Brompton Hospital			Fayers, Peter M/A-5999-2010	Fayers, Peter/0000-0003-4778-1513				[Anonymous], 1987, PEDIATRICS, V79, P1; BURKE GL, 1987, PEDIATRICS, V80, P784; CLARKE WR, 1986, AM J EPIDEMIOL, V123, P67, DOI 10.1093/oxfordjournals.aje.a114225; COLE TJ, 1986, ANN HUM BIOL, V13, P433, DOI 10.1080/03014468600008621; de Swiet M, 1984, J Hypertens, V2, P501; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; DESWIET M, 1980, PEDIATRICS, V65, P1028; DESWIET M, 1980, BMJ-BRIT MED J, V280, P1567, DOI 10.1136/bmj.280.6231.1567; DESWIET M, 1975, CLIN SCI MOL MED, V49, P557, DOI 10.1042/cs0490557; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SHEAR CL, 1986, PEDIATRICS, V77, P862; VERSMOLD HT, 1981, PEDIATRICS, V67, P607; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILSON PD, 1988, AM J EPIDEMIOL, V127, P946, DOI 10.1093/oxfordjournals.aje.a114898	15	79	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					23	26		10.1136/bmj.304.6818.23	http://dx.doi.org/10.1136/bmj.304.6818.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY909	1734987	Bronze, Green Published			2022-12-28	WOS:A1992GY90900028
J	LUPTON, D; CHAPMAN, S				LUPTON, D; CHAPMAN, S			DEATH OF A HEART SURGEON - REFLECTIONS ON PRESS ACCOUNTS OF THE MURDER OF CHANG,VICTOR	BRITISH MEDICAL JOURNAL			English	Editorial Material							DISEASE		UNIV SYDNEY,WESTMEAD HOSP,DEPT COMMUNITY MED,WESTMEAD,NSW,AUSTRALIA; MACQUARIE UNIV,SCH BEHAV SCI,CTR APPL SOCIAL RES,N RYDE,NSW 2113,AUSTRALIA	University of Sydney; Macquarie University			Lupton, Deborah A/F-5638-2011; Lupton, Deborah/L-8591-2016	Lupton, Deborah A/0000-0003-2658-4430; Lupton, Deborah/0000-0003-2658-4430				BATES E, 1985, HTLH MACHINE IMPACT; CHAPMAN S, 1979, SOC SCI MED-MED SOC, V13, P751, DOI 10.1016/0271-7123(79)90122-6; Galtung J., 1973, MANUFACTURE NEWS SOC, P62; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HALL J P, 1988, Medical Journal of Australia, V148, P273; HELMAN CG, 1987, SOC SCI MED, V25, P969, DOI 10.1016/0277-9536(87)90001-3; Karpf Anne, 1988, DOCTORING MEDIA REPO, P4; KRANTZLER NJ, 1986, SOC SCI MED, V22, P933, DOI 10.1016/0277-9536(86)90167-X; MCLAUGHLIN J, 1975, J COMMUN, V25, P182, DOI 10.1111/j.1460-2466.1975.tb00623.x; PFUND N, 1981, J COMMUN, V31, P138, DOI 10.1111/j.1460-2466.1981.tb01237.x; Stein H, 1990, AM MED CULTURE; TUROW J, 1986, J COMMUN, V35, P36; Turow Joseph, 1989, PLAYING DOCTOR TELEV; 1988, HEART FACTS REPORT, P13	15	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1583	1586		10.1136/bmj.303.6817.1583	http://dx.doi.org/10.1136/bmj.303.6817.1583			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX956	1773178	Green Published			2022-12-28	WOS:A1991GX95600010
J	MAKIN, AJ; CARTWRIGHT, KAV; BANKS, RA				MAKIN, AJ; CARTWRIGHT, KAV; BANKS, RA			KEEPING THE CAT OUT OF THE BAG - A HAZARD IN CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	BRITISH MEDICAL JOURNAL			English	Article									GLOUCESTER ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND									DADONE C, 1985, PERITON DIALYSIS B, V5, P138; DAMANI NN, 1987, NEPHRON, V45, P160, DOI 10.1159/000184102; DENT VE, 1982, J APPL BACTERIOL, V52, P21, DOI 10.1111/j.1365-2672.1982.tb04368.x; FANNELLI C, 1990, PERITONEAL DIALYSIS, V10, P247; HEATON A, 1986, BRIT MED J, V293, P938, DOI 10.1136/bmj.293.6552.938	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1610	1611		10.1136/bmj.303.6817.1610	http://dx.doi.org/10.1136/bmj.303.6817.1610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773192	Green Published, Bronze			2022-12-28	WOS:A1991GX95600025
J	NERI, A; CHANG, CC; LOMBARDI, L; SALINA, M; CORRADINI, P; MAIOLO, AT; CHAGANTI, RSK; DALLAFAVERA, R				NERI, A; CHANG, CC; LOMBARDI, L; SALINA, M; CORRADINI, P; MAIOLO, AT; CHAGANTI, RSK; DALLAFAVERA, R			B-CELL LYMPHOMA-ASSOCIATED CHROMOSOMAL TRANSLOCATION INVOLVES CANDIDATE ONCOGENE LYT-10, HOMOLOGOUS TO NF-KAPPA-B P50	CELL			English	Article							HEAVY-CHAIN LOCUS; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-MYC ONCOGENE; DISTINCT PATHOGENETIC FORMS; ENHANCER-BINDING-PROTEINS; HUMAN T-CELLS; BURKITT-LYMPHOMA; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; REL ONCOGENE	A B cell lymphoma-associated chromosomal translocation, t(10;14)(q24;q32), juxtaposes the immunoglobulin C-alpha-1 locus to a novel gene, lyt-10. The normal lyt-10 cDNA codes for a 98 kd protein which displays amino-terminal homology with the rel (DNA-binding) domain of the NF-kappa-B-rel family of transcription factors and carboxy-terminal homology with the NF-kappa-B p50 precursor protein, including the putative proteolytic cleavage domain (poly-G) and the ankyrin-like repeat domains. The lyt-10 protein can bind to kappa-B sequences in vitro, although with different specificity from NF-kappa-B p50, and in vitro DNA-binding is activated by removal of the ankyrin domain. Chromosomal translocation generates an lyt-10-C-alpha-1 fusion gene coding for a protein that retains the rel effector domain, lacks the ankyrin regulatory domain, and binds kappa-B sequences in vitro, suggesting its constitutive activation in vivo. Analogous rearrangements of the lyt-10 gene have been found in an additional three cases of lymphoid neoplasia. The lyt-10 gene defines a new subfamily (rel/poly-G/ankyrin) of NF-kappa-B-rel transcription factors with potential for oncogenic activation in human cancer.	COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,INST RIC & CARATTERE SCI,IST SCI MED,SERV EMATOL,I-20122 MILAN,ITALY; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Columbia University; University of Milan; Memorial Sloan Kettering Cancer Center	NERI, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032, USA.		Neri, Antonino/I-9690-2014; Corradini, Paolo/N-7584-2017	Neri, Antonino/0000-0001-9047-5912; Corradini, Paolo/0000-0002-9186-1353; Critelli, Salvatore/0000-0001-7325-0228	NCI NIH HHS [CA-20194, CA-44029, CA-34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775, R01CA044029, P01CA020194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELL REG, V6; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROTHMAN AR, 1990, CANCER RES, V50, P3795; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1991, ORIGINS HUMAN CANCER; DUBE ID, 1986, BLOOD, V67, P1181; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRUMONT RJ, 1988, ONCOGENE RES, V4, P1; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HAKEM R, 1989, J IMMUNOL, V142, P297; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LU D, 1991, ONCOGENE, V6, P1235; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PESCHLE C, 1984, P NATL ACAD SCI-BIOL, V81, P5514, DOI 10.1073/pnas.81.17.5514; RABBITTS TH, 1981, NUCLEIC ACIDS RES, V9, P4509, DOI 10.1093/nar/9.18.4509; RAIMONDI SC, 1988, BLOOD, V72, P1560; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	81	403	407	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1075	1087		10.1016/0092-8674(91)90285-7	http://dx.doi.org/10.1016/0092-8674(91)90285-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760839				2022-12-28	WOS:A1991GX16400007
J	BUCK, J; DERGUINI, F; LEVI, E; NAKANISHI, K; HAMMERLING, U				BUCK, J; DERGUINI, F; LEVI, E; NAKANISHI, K; HAMMERLING, U			INTRACELLULAR SIGNALING BY 14-HYDROXY-4,14-RETRO-RETINOL	SCIENCE			English	Article							RETINOL-BINDING PROTEIN; RECEPTOR; ACID; PURIFICATION	In mammals, retinol is the precursor for retinoids, which affect various aspects of morphogenesis and development. However, B lymphocytes, although retinol-dependent, do not use retinoic acid as mediator. Retinol is metabolized by B lymphocytes and other cell lines to optically active 14-hydroxy-4,14-retro-retinol; it is this compound that mediates the growth control. Thus another second messenger molecule, in addition to retinoic acid and retinal, is derived from retinol.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University	BUCK, J (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT IMMUNOL,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA49933] Funding Source: Medline; NIAID NIH HHS [AI38351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEECHAM AF, 1971, TETRAHEDRON, V27, P5207, DOI 10.1016/S0040-4020(01)90774-4; BEUTEL RH, 1955, J AM CHEM SOC, V77, P5166, DOI 10.1021/ja01624a065; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; BUCK JD, UNPUB; FEX G, 1977, BIOCHIM BIOPHYS ACTA, V493, P410, DOI 10.1016/0005-2795(77)90197-0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONNELLA NC, 1982, J AM CHEM SOC, V104, P3775, DOI 10.1021/ja00377a063; Goodman, 1984, RETINOIDS; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOSSWEIN L, 1976, THESIS U WURZBURG; HEILBRON I, 1958, B SOC CHIM FR, P83; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCLEAN SW, 1982, CLIN CHEM, V28, P693; NATORI S, 1974, NATURAL PRODUCTS CHE, V1, P30; ONG DE, 1978, J BIOL CHEM, V253, P828; OROSHNIK W, 1952, J AM CHEM SOC, V74, P295, DOI 10.1021/ja01122a003; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; SCHWIETER U, 1969, Pure and Applied Chemistry, V20, P365, DOI 10.1351/pac196920040365; STRAUB O, 1971, CAROTENOIDS, P772; VETTER W, 1971, CAROTENOIDS, P204; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230	25	169	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1654	1656		10.1126/science.1749937	http://dx.doi.org/10.1126/science.1749937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749937				2022-12-28	WOS:A1991GV07300048
J	KOCHEN, MM; HASFORD, JC; JAGER, H; ZIPPEL, S; LAGE, M; ROSENDAHL, C; FUESSL, HS; EICHENLAUB, D				KOCHEN, MM; HASFORD, JC; JAGER, H; ZIPPEL, S; LAGE, M; ROSENDAHL, C; FUESSL, HS; EICHENLAUB, D			HOW DO PATIENTS WITH HIV PERCEIVE THEIR GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; AIDS	Objective - To study the perceptions of patients with HIV of their general practitioners in terms of knowledge, abilities, confidence, and satisfaction. Design - Questionnaire survey of inpatients, outpatients, and members of a self help group. Setting - Two city hospitals, three outpatient clinics, and one AIDS self help group in Munich and Berlin, Germany. Subjects - All 402 patients available between 1 September 1988 and 31 May 1989. Main outcome measures - General practitioners' attitudes towards the patients' HIV status; patients' experience of treatment rejection; reception in the general practitioner's office; the doctor's perceived knowledge about HIV and AIDS. Results - 394 of 402 patients consented to interview; 87% were registered with a general practitioner and 91% of those indicated that the doctor was aware of their HIV diagnosis. The overwhelming majority of patients (94%) had a friendly or at least neutral reception in the general practitioner's surgery and only six patients' general practitioner changed his or her behaviour for the worse because of the HIV diagnosis. Two thirds of patients said they would consult first with their primary care doctor for a physical problem, but only 13% would do so for psychological problems. Over a third of the patients did not routinely inform other doctors or medical staff about their HIV status, but there was no significant correlation between this concealment and ever having been rejected by a doctor (7%) or a dentist (12%). Conclusion - Most patients expressed a high degree of satisfaction with their general practitioners in terms of confidential issues, attitudes, knowledge, and management.	UNIV MUNICH,GEN PRACTICE,W-8000 MUNICH 2,GERMANY; UNIV MUNICH,CHILDRENS HOSP,IMMUNE DEFICIENCY CLIN,W-8000 MUNICH 2,GERMANY; UNIV MUNICH,MED POLICLIN,W-8000 MUNICH 2,GERMANY; SCHWABINGER KRANKENHAUS,IMMUNODEFICIENCY CLIN,MUNICH,GERMANY; SCHWABINGER KRANKENHAUS,DEPT MED 4,MUNICH,GERMANY; AIDS HILFE,MUNICH,GERMANY; AUGUSTE VIKTORIA KRANKENHAUS,DEPT MED 2,BERLIN,GERMANY	University of Munich; University of Munich; University of Munich								BHUGRA D, 1989, J ROY SOC MED, V82, P603, DOI 10.1177/014107688908201013; BUCKNALL A, 1986, J ROY COLL GEN PRACT, V36, P491; GALLAGHER M, 1988, J ROY COLL GEN PRACT, V38, P414; GILLON R, 1987, BRIT MED J, V294, P1332, DOI 10.1136/bmj.294.6583.1332; HODGKIN P, 1988, BRIT MED J, V296, P516, DOI 10.1136/bmj.296.6621.516; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; NORTHFELT DW, 1988, ANN INTERN MED, V108, P773; SIBBALD B, 1988, J ROY COLL GEN PRACT, V38, P500; WOFSY CB, 1987, JAMA-J AM MED ASSOC, V257, P2074, DOI 10.1001/jama.257.15.2074; 1990, STATISTICAL YB FEDER, P355; 1988, J R COLL GEN PRACT, V38, P219; 1990, MED J AUSTRALIA, V153, P5	13	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1365	1368		10.1136/bmj.303.6814.1365	http://dx.doi.org/10.1136/bmj.303.6814.1365			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760602	Green Published, Bronze			2022-12-28	WOS:A1991GU38400019
J	DILLNER, L				DILLNER, L			MATERNITY SERVICES - THE SHAPING OF THINGS TO COME	BRITISH MEDICAL JOURNAL			English	Article																		KLEIN R, 1991, BRIT MED J, V302, P1, DOI 10.1136/bmj.302.6767.1	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1198	1200		10.1136/bmj.302.6786.1198	http://dx.doi.org/10.1136/bmj.302.6786.1198			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	1750884	Bronze, Green Published			2022-12-28	WOS:A1991FN04500030
J	NOBLE, J; FRIEDMAN, RH; STARFIELD, B; ASH, A; BLACK, C				NOBLE, J; FRIEDMAN, RH; STARFIELD, B; ASH, A; BLACK, C			CAREER DIFFERENCES BETWEEN PRIMARY CARE AND TRADITIONAL TRAINEES IN INTERNAL-MEDICINE AND PEDIATRICS	ANNALS OF INTERNAL MEDICINE			English	Article						PEDIATRICS; PHYSICIANS, FAMILY; PRIMARY HEALTH CARE; INTERNSHIP AND RESIDENCY	TRAINING-PROGRAMS; RESIDENTS; MANPOWER; TIME	Objective: To assess the relation of Primary Care Residency Training to career choice, board certification, and practice location of internists and pediatricians. Design: Cohort study with up to 8 years of follow-up. Setting: The United States. Participants: The 17 933 residents trained in all internal medicine (13 750) and pediatrics (4183) residency programs between 1977 and 1982 were studied using information from the National Resident Matching Program, the AMA Physician Masterfile, the Area Resource File, and a telephone survey. Measurements: Career choice, board certification, and practice location were studied in relation to five explanatory variables: type of residency (primary care or traditional track), gender, year of medical school graduation, educational orientation of the teaching hospital, and medical school prestige. Main Results: Graduates of primary care residency training programs chose careers in generalist primary care significantly more often than did graduates of traditional tracks in both internal medicine (72% compared with 54%) and pediatrics (88% and 81 %, respectively; P < 0.001 for both values). Board certification rates in internal medicine were statistically higher for graduates of primary care training programs (80%) than for graduates of traditional programs (76%, P = 0.002) but were not statistically significant for both groups of pediatric graduates. Graduates of primary care programs in pediatrics and internal medicine practiced in medically less served communities more often than did graduates of traditional programs. Conclusion: Graduates of primary care residency training programs in internal medicine and pediatrics differ from graduates of traditional residency programs in career choices, board certification rates, and practice locations.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	Boston University; Johns Hopkins University	NOBLE, J (corresponding author), BOSTON CITY HOSP, GEN INTERNAL MED SECT, 818 HARRISON AVE, BOSTON, MA 02118 USA.			Friedman, Robert/0000-0002-9440-2443	NHLBI NIH HHS [HRSA 240-85-0048] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER R, 1985, J MED EDUC, V60, P174; BERGMAN AB, 1975, PEDIATRICS, V55, P109; CALKINS DR, 1986, CLIN RES, V34, pA812; CLEVELAND WW, 1987, PEDIATRICS, V80, P451; COLE JR, 1977, SOC FORCES, V55, P662, DOI 10.2307/2577462; CRAIN LS, 1981, WESTERN J MED, V135, P248; Ernst R. L., 1985, PHYSICIAN LOCATION S; GOLDENBERG DL, 1979, ANN INTERN MED, V91, P271, DOI 10.7326/0003-4819-91-2-271; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; KELLY NL, 1984, INQUIRY-J HEALTH CAR, V21, P276; LEWIS CE, 1986, ANN INTERN MED, V104, P570, DOI 10.7326/0003-4819-104-4-570; MCPHEE SJ, 1987, JAMA-J AM MED ASSOC, V258, P1491, DOI 10.1001/jama.258.11.1491; NOBLE J, 1988, ASSESSMENT DEV SUPPO; PAIVA REA, 1982, J MED EDUC, V57, P666; PROUT DM, 1986, J GEN INTERN MED, V1, P44, DOI 10.1007/BF02596325; QUILL TE, 1987, ARCH INTERN MED, V147, P971, DOI 10.1001/archinte.147.5.971; REITEMEIER RJ, 1978, NEW ENGL J MED, V299, P1308, DOI 10.1056/NEJM197812072992313; Rezler AG, 1985, INTERPERSONAL DIMENS; SCHLEITER MK, 1983, NATIONAL STUDY INTER; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SHELOV SP, 1987, AM J DIS CHILD, V141, P65, DOI 10.1001/archpedi.1987.04460010065025; THIER SO, 1978, NEW ENGL J MED, V299, P1305, DOI 10.1056/NEJM197812072992312; WECHSLER H, 1978, NEW ENGL J MED, V298, P15, DOI 10.1056/NEJM197801052980104; WEIL PA, 1981, ANN INTERN MED, V94, P691, DOI 10.7326/0003-4819-94-5-691; WEIL PA, 1979, NATIONAL STUDY INTER; WITZBURG RA, 1988, J GEN INTERN MED, V3, P48, DOI 10.1007/BF02595756; 1987, JAMA-J AM MED ASSOC, V258, P240	27	40	40	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					482	487		10.7326/0003-4819-116-6-482	http://dx.doi.org/10.7326/0003-4819-116-6-482			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739239				2022-12-28	WOS:A1992HJ59800009
J	MARTINEZ, S; MARR, JJ				MARTINEZ, S; MARR, JJ			ALLOPURINOL IN THE TREATMENT OF AMERICAN CUTANEOUS LEISHMANIASIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VISCERAL LEISHMANIASIS; METABOLISM; DONOVANI; RIBONUCLEOSIDE	Background. Pentavalent antimony, the generally accepted treatment for leishmaniasis, is given parenterally, and it is expensive and not readily available in developing countries. An inexpensive, orally administered compound would be a substantial advance in treatment. Previous studies in vitro have shown synergism between allopurinol and pentavalent antimony in tissue-culture systems. We designed this clinical study to determine whether synergism could be demonstrated in patients. Methods. We performed a randomized, controlled study of the efficacy of allopurinol plus meglumine antimoniate (Glucantime), as compared with meglumine antimoniate alone, in patients with cutaneous leishmaniasis, who were recruited from a village in southeastern Colombia. In addition, those who declined injections were treated with allopurinol alone, and those who declined any treatment were considered controls. All the patients were followed for one year after the completion of treatment. Lesions that healed completely at three months and remained healed during follow-up were considered to be cured. Results. The cure rate for patients treated with meglumine antimoniate was 36 percent; the addition of allopurinol increased the rate to 74 percent (P < 0.001). Treatment with allopurinol alone yielded a cure rate of 80 percent (P < 0.001). There were no cures among the untreated patients. There was no significant difference between the cure rate with allopurinol plus meglumine antimoniate and that with allopurinol alone. No major toxic effects were observed. Conclusions. For the treatment of American cutaneous leishmaniasis, the combination of allopurinol and meglumine antimoniate is significantly more effective than meglumine antimoniate alone, probably because of the efficacy of allopurinol alone, which appears to be as good as the combination.	UNIV CAUCA,FAC HLTH SCI,DEPT MED,POPAYAN,COLOMBIA; GD SEARLE & CO,DIV RES & DEV,SKOKIE,IL 60077; RUSH MED COLL,DEPT MED,DIV INFECT DIS,CHICAGO,IL 60612	Universidad del Cauca; Pfizer; Rush University								BERENS RL, 1980, BIOCHEM PHARMACOL, V29, P2397, DOI 10.1016/0006-2952(80)90275-0; BERMAN JD, 1988, REV INFECT DIS, V10, P560; CHUNGE CN, 1985, T ROY SOC TROP MED H, V79, P715, DOI 10.1016/0035-9203(85)90200-7; JHA TK, 1983, T ROY SOC TROP MED H, V77, P204, DOI 10.1016/0035-9203(83)90071-8; KAGER PA, 1981, T ROY SOC TROP MED H, V75, P556, DOI 10.1016/0035-9203(81)90198-X; LAFON SW, 1985, J BIOL CHEM, V260, P9660; LOOKER DL, 1983, MOL BIOCHEM PARASIT, V9, P15, DOI 10.1016/0166-6851(83)90053-1; MARR JJ, 1982, BIOCHEM PHARMACOL, V31, P143, DOI 10.1016/0006-2952(82)90203-9; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MARR JJ, 1985, HUMAN PARASITIC DIS, V1, P69; MARTINEZ S, 1988, AM J TROP MED HYG, V39, P250, DOI 10.4269/ajtmh.1988.39.250; SAENZ RE, 1989, J INFECT DIS, V160, P153, DOI 10.1093/infdis/160.1.153	12	141	143	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					741	744		10.1056/NEJM199203123261105	http://dx.doi.org/10.1056/NEJM199203123261105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738379				2022-12-28	WOS:A1992HH06400005
J	AXELROD, PI; LORBER, B; VONDERHEID, EC				AXELROD, PI; LORBER, B; VONDERHEID, EC			INFECTIONS COMPLICATING MYCOSIS-FUNGOIDES AND SEZARY-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL-LYMPHOMAS; RAPID PULMONARY DISSEMINATION; MANAGEMENT; REGRESSION; VARICELLA; SURVIVAL; THERAPY	Objective. - To determine, in patients with mycosis fungoides and Sezary syndrome, the incidence of infections, the importance of nosocomial infections, and the epidemiologic factors associated with cutaneous and visceral infections. Design and Setting. - Retrospective inception cohort study at a university medical center referral clinic. Patients. - Three hundred fifty-six patients with mycosis fungoides or Sezary syndrome. Main Outcome Measures. - Incidence rates for specific infections, and multivariate risk ratios for demographic and clinical factors associated with infection. Results. - Cutaneous bacterial infection was most common (17.0 infections per 100 patient-years), followed by cutaneous herpes simplex virus and herpes zoster virus infection (3.8 infections per 100 patient-years), bacteremia (2.1 infections per 100 patient-years), bacterial pneumonia (1.7 infections per 100 patient-years), and urinary tract infection (1.4 infections per 100 patient-years). Twenty-seven percent of herpesvirus infections disseminated on the skin but none disseminated to internal organs. Pneumonia or bacteremia was present in 88% of patients who died of infection. Only three patients had invasive fungal or protozoal infection. Nosocomial infections accounted for 19% of cutaneous bacterial infections, 59% of bacteremias, 62% of pneumonias, and 88% of infections leading to death. By logistic and Cox regression, the presence of extracutaneous involvement with lymphoma was the most important independent risk factor for recurrent bacterial skin infection (risk ratio [RR], 12; 95% confidence interval [Cl], 1.2 to 120), disseminated herpesvirus infection (RR, 28; 95% Cl, 2.7 to 290), bloodstream infection (RR, 5.5; 95% Cl, 1.7 to 18), and death from infection (RR, 15; 95% Cl, 3.6 to 64). Conclusions. - Community-acquired bacterial skin infections are a common cause of morbidity in patients with mycosis fungoides and Sezary syndrome but are usually treated without hospital admission. Bacteremia and pneumonia, which are usually nosocomial, are the major infectious causes of death. Advanced disease stage, independent of corticosteroids and other therapies, is the most important risk factor for both cutaneous and systemic infections.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,INFECT DIS SECT,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ABEL EA, 1985, DERMATOL CLIN, V3, P647, DOI 10.1016/S0733-8635(18)30863-5; ALTERAS I, 1982, MYCOPATHOLOGIA, V80, P83; BLAYLOCK WK, 1966, CANCER-AM CANCER SOC, V19, P233, DOI 10.1002/1097-0142(196602)19:2<233::AID-CNCR2820190215>3.0.CO;2-3; BLOCK JB, 1963, AM J MED, V34, P228, DOI 10.1016/0002-9343(63)90056-1; BRODER S, 1980, SEMIN ONCOL, V7, P310; BUNN PA, 1979, CANCER TREAT REP, V63, P725; Casazza AR, 1966, JAMA-J AM MED ASSOC, V197, P118; CLENDENNING WE, 1965, CANCER RES, V25, P1844; COHEN SR, 1980, CANCER, V46, P2654, DOI 10.1002/1097-0142(19801215)46:12<2654::AID-CNCR2820461220>3.0.CO;2-1; COX DR, 1972, J R STAT SOC B, V34, P187; CYR DP, 1966, ARCH DERMATOL, V94, P558, DOI 10.1001/archderm.94.5.558; EPSTEIN EH, 1972, MEDICINE, V15, P61; FOSTER GH, 1985, CANCER, V56, P1197, DOI 10.1002/1097-0142(19850901)56:5<1197::AID-CNCR2820560538>3.0.CO;2-H; FUKS ZY, 1973, CANCER, V32, P1385, DOI 10.1002/1097-0142(197312)32:6<1385::AID-CNCR2820320617>3.0.CO;2-#; GAHLENSCHULTE S, 1982, Z HAUTKRANKHEITEN, V57, P1757; GALLIN JI, 1974, P NATL ACAD SCI USA, V71, P498, DOI 10.1073/pnas.71.2.498; GOLDGEIER MH, 1981, J AM ACAD DERMATOL, V4, P176, DOI 10.1016/S0190-9622(81)70021-5; GREEN DC, 1969, ANN THORAC SURG, V6, P561; HAYNES HA, 1975, NEW ENGL J MED, V293, P598; JACOBS JB, 1969, RADIOLOGY, V93, P525, DOI 10.1148/93.3.525; KIRKPATRICK CH, 1972, J CLIN INVEST, V51, P2948, DOI 10.1172/JCI107119; LEVI JA, 1975, MEDICINE, V54, P73, DOI 10.1097/00005792-197501000-00004; LUTZNER M, 1975, ANN INTERN MED, V83, P534, DOI 10.7326/0003-4819-83-4-534; MCGEE DL, 1986, AM J EPIDEMIOL, V124, P702, DOI 10.1093/oxfordjournals.aje.a114444; PINKUS H, 1968, ARCH DERMATOL, V98, P323; POSNER LE, 1981, AM J MED, V71, P210, DOI 10.1016/0002-9343(81)90107-8; RAPPAPORT H, 1974, CANCER-AM CANCER SOC, V34, P1198, DOI 10.1002/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO;2-E; RUBIN DL, 1985, CANCER, V56, P649, DOI 10.1002/1097-0142(19850801)56:3<649::AID-CNCR2820560335>3.0.CO;2-#; SCOTT TFM, 1971, DERMATOLOGY GENERAL, P1878; SEGAL RJ, 1978, ARCH DERMATOL, V114, P1067, DOI 10.1001/archderm.114.7.1067; SLEVIN NJ, 1987, BRIT J DERMATOL, V116, P47, DOI 10.1111/j.1365-2133.1987.tb05790.x; STOKAR LM, 1985, CANCER, V56, P2694, DOI 10.1002/1097-0142(19851201)56:11<2694::AID-CNCR2820561129>3.0.CO;2-B; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; Swartz MN, 1990, PRINCIPLES PRACTICES, V3rd, P796; VANSCOTT EJ, 1971, DERMATOLOGY GENERAL, P556; VONDERHEID EC, 1980, ARCH DERMATOL, V116, P408, DOI 10.1001/archderm.116.4.408; VONDERHEID EC, 1980, ARCH DERMATOL, V116, P1018; YOSHIDA T, 1975, J IMMUNOL, V114, P915; YOSHIKAW.TT, 1974, CHEST, V65, P105, DOI 10.1378/chest.65.1.105	39	150	150	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1354	1358		10.1001/jama.267.10.1354	http://dx.doi.org/10.1001/jama.267.10.1354			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740857				2022-12-28	WOS:A1992HG67800028
J	STOECKLE, JD; REISER, SJ				STOECKLE, JD; REISER, SJ			THE CORPORATE ORGANIZATION OF HOSPITAL WORK - BALANCING PROFESSIONAL AND ADMINISTRATIVE RESPONSIBILITIES	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE; PHYSICIANS; DOCTOR	The development of the hospital into a corporation has influenced the care of patients and the work of the professional staff. As a corporate enterprise, the modern hospital has a private agenda aimed at increasing growth and efficiency with an emphasis on technical services, professionals as employees, and patients as customers. These changes have resulted in a decrease in trustee and professional authority and an increase in administrative control. This shift in the control structure has continued in response to the need for accounting and regulation of services and in response to demands for increased growth and efficiency made by an increasingly competitive market environment. Strategies for the reorganization of hospital staff aimed at improving both inpatient and outpatient care are reviewed. The reorganization of the institution and staff, using either a staff group-practice corporation or an administrative staff model, is proposed. Clinicians have new responsibilities for developing collective arrangements for institutional governance, for allocating institutional resources, for providing public accountability regarding the use of these resources, and for defining the missions of care.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX 77225 USA	Harvard University; Harvard Medical School; University of Texas System; University of Texas Health Science Center Houston	STOECKLE, JD (corresponding author), MASSACHUSETTS GEN HOSP, SERV MED, 32 FRUIT ST, BOSTON, MA 02114 USA.							ASTRACHAN JH, 1989, ARCH INTERN MED, V149, P1509, DOI 10.1001/archinte.149.7.1509; BENNETT SJ, 1987, EXECUTIVE CHESS CREA, P93; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BOWDITCH NI, 1872, IST MASSACHUSETTS GE; BRANCH WT, 1991, ANN INTERN MED, V114, P482, DOI 10.7326/0003-4819-114-6-482; CABOT RC, 1920, BOSTON MED SURG J, V182, P287; CLEMENT JP, 1988, HLTH CARE MANAGE REV, V13, P17; CUNNINGHAM L, 1987, INVOLVING PHYSICIANS; DEZELL M, 1989, PHOENIX          DEC, P22; DONABEDIAN A, 1989, MILBANK Q, V67, P233, DOI 10.2307/3350139; FEINGLASS J, 1990, INT J HEALTH SERV, V20, P233, DOI 10.2190/5N2R-MWAN-FWY2-JVHQ; Fox DM., 1988, PHOTOGRAPHING MED IM; FRANKFORD DM, 1989, COLUMBIA LAW REV, V89, P1861, DOI 10.2307/1122788; FRIEDSON E, 1989, MED WORK AM; FRIEDSON E, 1990, JUIMETRICS J     SUM, P431; GOLDFIELD N, 1989, PHYSICIAN LEADERS PA; GOLDSMITH J, 1989, HARVARD BUS REV, V67, P104; GRIFFITH JR, 1987, WELL MANAGED MYSTIQU; GRINER PF, 1988, MED DECIS MAKING, V8, P151, DOI 10.1177/0272989X8800800301; GROSSMAN JH, 1989, PHYSICIANS MANAGERS; HAISIMAIER EF, 1990, ISSUES SCI TECH  SPR, P59; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; KANIGEL R, 1988, J HOPKINS MAGAZI JUN, P17; KINSTON W, 1989, PEOPLE SHOULD ACT IN; KOVNER AR, 1987, HLTH SERVICES MANAGE; KOVNER AR, 1987, REALLY MANAGING WORK; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LAMONTHAVERS RW, 1969, LE MARTIN LABORATORY; Lorch S, 1989, Int J Technol Assess Health Care, V5, P43; LORSCH JW, 1990, PAWNS POTENTATES REA; MACLEOD GK, 1986, JAMA-J AM MED ASSOC, V256, P58, DOI 10.1001/jama.256.1.58; MARCUS SA, 1984, NEW ENGL J MED, V311, P1508, DOI 10.1056/NEJM198412063112310; MARGULIES N, 1982, ORG DEV HLTH CARE OR; MCKINLAY JB, 1988, INT J HEALTH SERV, V18, P191, DOI 10.2190/YEVW-6C44-YCYE-CGEU; MCKINLAY JB, 1985, INT J HEALTH SERV, V15, P161, DOI 10.2190/JBMN-C0W6-9WFQ-Q5A6; MECHANIC D, 1989, AM J PUBLIC HEALTH, V79, P1218, DOI 10.2105/AJPH.79.9.1218; Mechanic D, 1976, GROWTH BUREAUCRATIC; Neuhauser D, 1990, Int J Technol Assess Health Care, V6, P307; PARSONS T, 1951, AM J ORTHOPSYCHIAT, V21, P452, DOI 10.1111/j.1939-0025.1951.tb00003.x; Reiser S., 1978, MED REIGN TECHNOLOGY; Reiser S. J., 1977, ETHICS MED HIST PERS; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; ROGERS DE, 1986, DAEDALUS-US, V115, P1; Rosenberg Charles E., 1987, CARE STRANGERS RISE; SCOTT WR, 1982, HEALTH SERV RES, V17, P213; Sheldon A., 1986, MANAGING DOCTORS; Shortell S., 1990, STRATEGIC CHOICES AM; SHORTELL SM, 1989, FRONT HLTH SERV MANA, V1, P3; SIMON WH, 1990, RECONSTRUCTION   WIN, P18; Starr Paul., 1984, SOCIAL TRANSFORMATIO; STEMMLER EJ, 1985, J MED EDUC, V60, P949; STOECKLE JD, 1969, NEW ENGL J MED, V280, P1385, DOI 10.1056/NEJM196906192802505; STOECKLE JD, 1988, MILBANK Q, V66, P76; STOECKLE JD, 1987, ANN INTERN MED, V107, P250, DOI 10.7326/0003-4819-107-2-250; Strauss AL., 1985, SOCIAL ORG MED WORK; SUZAKI R, 1988, NEW MANUFACTURING CH; WALSH DC, 1987, CORPORATE PHYSICIANS; 1989, ANN REPORT MASSACHUS; 1964, CORPORATION TAKE OVE; 1945, 132 MASS GEN HOSP AN; 1989, HOSPITALS, V63, P26	61	16	16	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					407	413		10.7326/0003-4819-116-5-407	http://dx.doi.org/10.7326/0003-4819-116-5-407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736774				2022-12-28	WOS:A1992HF26800011
J	TINETTI, ME; LIU, WL; GINTER, SF				TINETTI, ME; LIU, WL; GINTER, SF			MECHANICAL RESTRAINT USE AND FALL-RELATED INJURIES AMONG RESIDENTS OF SKILLED NURSING FACILITIES	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL RESTRAINTS; MEDICAL WARDS; BIAS	Objective: To evaluate the association between mechanical restraint use and the occurrence of injurious falls among persons residing in skilled nursing facilities. Design: Prospective observational cohort study. Setting: Twelve skilled nursing facilities in southern Connecticut. Participants: The 397 persons who were mobile and unrestrained at baseline. Measurements: Restraint use was defined both as the number of days restrained and as "never," "intermittently," or "continually" restrained. The primary outcome measure was the occurrence of a serious fall-related injury. Analyses were done on the entire cohort as well as on a subgroup hypothesized as having a high risk for falls. Main Results: During one year of follow-up, 122 subjects (31%) became restrained, 83 intermittently and 39 continually. A serious fall-related injury was experienced by 5% (15 of 275) of unrestrained, compared with 17% (21 of 122) of restrained, subjects (chi-square = 12.478; P < 0.001). Restraint use remained independently associated with serious injury after adjusting for other factors, both in the entire cohort (adjusted odds ratio, 10.2; 95% CI, 2.8 to 36.9) and in the high-risk subgroup (adjusted odds ratio, 6.2; CI, 1.7 to 22.2). Among the 305 subjects who experienced two or fewer falls, the proportion having a serious injury was 15% for restrained subjects compared with 4% for unrestrained subjects (difference in proportions 11%, CI, 4% to 17%), whereas the comparable proportions for the 92 subjects who experienced more than two falls were 20% and 16%, respectively. Results were similar in the high-risk subgroup. Conclusions: Mechanical restraints were associated with continued, and perhaps increased, occurrence of serious fall-related injuries after controlling for other injury risk factors. Study results suggest the need to consider whether restraints provide adequate, if any, protection.			TINETTI, ME (corresponding author), YALE UNIV, SCH MED, DEPT MED, 333 CEDAR ST, POB 3333, NEW HAVEN, CT 06510 USA.							BERLAND B, 1990, J GEN INTERN MED, V5, P480, DOI 10.1007/BF02600874; BLAKESLEE JA, 1988, AM J NURS, V88, P833, DOI 10.2307/3425798; EVANS L, 1987, GERONTOLOGIST, V27, pA272; Evans L K, 1990, Image J Nurs Sch, V22, P124; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; Feist R R, 1978, J Gerontol Nurs, V4, P15; FRENGLEY JD, 1986, J AM GERIATR SOC, V34, P565, DOI 10.1111/j.1532-5415.1986.tb05760.x; GRANEK E, 1987, J AM GERIATR SOC, V35, P503, DOI 10.1111/j.1532-5415.1987.tb01395.x; HORWITZ RI, 1985, ARCH INTERN MED, V145, P909, DOI 10.1001/archinte.145.5.909; HORWITZ RI, 1987, J CHRON DIS, V40, P91, DOI 10.1016/0021-9681(87)90100-7; JENCKS SF, 1991, JAMA-J AM MED ASSOC, V265, P502; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P143; LEWIN T, 1989, NY TIMES        1229, P12; Lewin Tamar, 1989, N Y Times Web, P9; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; MACPHERSON DS, 1990, J AM GERIATR SOC, V38, P516, DOI 10.1111/j.1532-5415.1990.tb02400.x; MION LC, 1989, J AM GERIATR SOC, V37, P949, DOI 10.1111/j.1532-5415.1989.tb07280.x; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; PODGORSKI CA, 1990, GERONTOLOGIST, V30, pA74; POWELL C, 1989, CAN MED ASSOC J, V141, P561; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; Robbins L J, 1986, Clin Geriatr Med, V2, P591; ROBBINS LJ, 1987, J AM GERIATR SOC, V35, P290, DOI 10.1111/j.1532-5415.1987.tb04633.x; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; STIEBELING M, 1990, J AM GERIATR SOC, V38, pA45; STRUMPF NE, 1988, NURS RES, V37, P132; STRUMPF NE, 1989, GERONTOLOGIST, V29, pA221; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1990, J AM GERIATR SOC, V38, P1311, DOI 10.1111/j.1532-5415.1990.tb03453.x; TINETTI ME, 1991, JAMA-J AM MED ASSOC, V265, P468, DOI 10.1001/jama.265.4.468; TINETTI ME, 1987, J AM GERIATR SOC, V35, P644, DOI 10.1111/j.1532-5415.1987.tb04341.x; 1990, SPECIAL COMMITTEE H, V101; 1989, HLTH CARE FINANCING; 1989, FED REG         0202, V54, P5322; 1988, SAS STAT USERS GUIDE	36	172	175	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					369	374		10.7326/0003-4819-116-5-369	http://dx.doi.org/10.7326/0003-4819-116-5-369			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736769				2022-12-28	WOS:A1992HF26800004
J	SAIKKU, P; LEINONEN, M; TENKANEN, L; LINNANMAKI, E; EKMAN, MR; MANNINEN, V; MANTTARI, M; FRICK, MH; HUTTUNEN, JK				SAIKKU, P; LEINONEN, M; TENKANEN, L; LINNANMAKI, E; EKMAN, MR; MANNINEN, V; MANTTARI, M; FRICK, MH; HUTTUNEN, JK			CHRONIC CHLAMYDIA-PNEUMONIAE INFECTION AS A RISK FACTOR FOR CORONARY HEART-DISEASE IN THE HELSINKI HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CHLAMYDIA-PNEUMONIAE; CORONARY DISEASE; LIPOPOLYSACCHARIDES; GEMFIBROZIL; DEATH, SUDDEN; MYOCARDIAL INFARCTION	ACUTE MYOCARDIAL-INFARCTION; LOW-DENSITY LIPOPROTEIN; NECROSIS FACTOR-ALPHA; FOAM CELL-FORMATION; IMMUNE-COMPLEXES; IGA ANTIBODIES; STRAIN TWAR; LIPOPOLYSACCHARIDE; TRACHOMATIS; FINLAND	Objective: To investigate in the prospective Helsinki Heart Study, whether chronic Chlamydia pneumoniae infection, indicated by elevated antibody titers against the pathogen, chlamydial lipopolysaccharide-containing immune complexes, or both, is a risk factor for coronary heart disease. Design and Setting: The Helsinki Heart Study was a randomized, double-blind, 5-year clinical trial to test the efficacy of gemfibrozil in reducing the risk for coronary heart disease. Participants were randomized to receive either gemfibrozil (2046 patients) or placebo (2035 patients). Fatal and nonfatal myocardial infarction and sudden cardiac death were the main study end points. Serum samples were collected at 3-month intervals from all patients. Patients: One hundred forty cardiac events occurred during the follow-up period. Serum samples from 103 case patients obtained 3 to 6 months before a cardiac end point were matched with those from controls for time point, locality, and treatment. Samples were tested for markers of chronic chlamydial infection. Measurements: Immunoglobulin A (IgA) and G (IgG) antibodies to C. pneumoniae were measured using the microimmunofluorescence method. Lipopolysaccharide-containing immune complexes were measured using two antigen-specific enzyme immunoassays, the lipopolysaccharide-capture and immunoglobulin M (IgM)-capture methods. Main Results: Using a conditional logistic regression model, odds ratios for the development of coronary heart disease were 2.7 (95% Cl, 1.1 to 6.5) for elevated IgA titers, 2.1 (Cl, 1.1 to 3.9) for the presence of immune complexes, and 2.9 (Cl, 1.5 to 5.4) for the presence of both factors. If we adjusted for other coronary heart disease risk factors such as age, hypertension, and smoking, the corresponding values would be 2.3 (Cl, 0.9 to 6.2), 1.8 (Cl, 0.9 to 3.6), and 2.6 (Cl, 1.3 to 5.2), respectively. Conclusion: The results suggest that chronic C. pneumoniae infection may be a significant risk factor for the development of coronary heart disease.	NATL PUBL HLTH INST, SF-00300 HELSINKI, FINLAND; UNIV TAMPERE, DEPT PUBL HLTH, SF-33101 TAMPERE, FINLAND	Finland National Institute for Health & Welfare; Tampere University	SAIKKU, P (corresponding author), UNIV HELSINKI, DEPT VIROL, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND.							BLACK CM, 1990, 90 ANN M AM SOC MICR, P80; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BRETT MM, 1990, ARCH DIS CHILD, V65, P259, DOI 10.1136/adc.65.3.259; CHAIM W, 1989, CONTRACEPTION, V40, P59, DOI 10.1016/0010-7824(89)90028-0; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GRANFORS K, 1979, J CLIN MICROBIOL, V9, P336; GRAYSTON JT, 1989, INT J SYST BACTERIOL, V39, P88, DOI 10.1099/00207713-39-1-88; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; GRIFFITH RL, 1988, J EXP MED, V168, P1041, DOI 10.1084/jem.168.3.1041; HOIBY N, 1988, CLIN MICROBIOL NEWSL, V9, P133; HOJBY N, 1986, ANNU REV MICROBIOL, V40, P29; HUTTUNEN JK, 1989, HIGH DENSITY LIPOPRO, P191; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KLEEMOLA M, 1988, J INFECT DIS, V157, P230, DOI 10.1093/infdis/157.2.230; KLIMOV AN, 1985, ATHEROSCLEROSIS, V58, P1, DOI 10.1016/0021-9150(85)90051-6; LAHESMAARANTALA R, 1987, ANN RHEUM DIS, V46, P121, DOI 10.1136/ard.46.2.121; LEINONEN M, 1990, MICROB PATHOGENESIS, V9, P67, DOI 10.1016/0882-4010(90)90042-O; LOPESVIRELLA MF, 1985, CLIN IMMUNOL IMMUNOP, V37, P377, DOI 10.1016/0090-1229(85)90107-2; MANN RA, 1987, FOOT ANKLE, V8, P1; MANNINEN V, 1989, HIGH DENSITY LIPOPRO, P35; Mardh PA, 1989, CHLAMYDIA; MORDHORST CH, 1990, CHLAMYDIAL INFECTION, P418; NURMINEN M, 1985, INFECT IMMUN, V48, P573, DOI 10.1128/IAI.48.2.573-575.1985; PUOLAKKAINEN M, 1989, EPIDEMIOL INFECT, V102, P287, DOI 10.1017/S0950268800029964; PUOLAKKAINEN M, 1990, CHLAMYDIAL INFECTION, P319; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAIKKU P, 1985, J INFECT DIS, V151, P832, DOI 10.1093/infdis/151.5.832; SAROV I, 1988, 1ST P EUR SOC CHLAM, P234; SHEMERAVNI Y, 1990, DHLAMYDIAL INFECTION, P173; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; VANLENTEN BJ, 1986, P NATL ACAD SCI USA, V83, P2704; Wang SP, 1986, CHLAMYDIAL INFECTION, P329; WILLIAMS DM, 1990, INFECT IMMUN, V58, P1572, DOI 10.1128/IAI.58.6.1572-1576.1990; WILLIAMS DM, 1989, INFECT IMMUN, V57, P1351, DOI 10.1128/IAI.57.5.1351-1355.1989	36	689	723	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					273	278		10.7326/0003-4819-116-4-273	http://dx.doi.org/10.7326/0003-4819-116-4-273			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	1733381				2022-12-28	WOS:A1992HD54600001
J	BAUGHMAN, KL				BAUGHMAN, KL			HYPERTROPHIC CARDIOMYOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							LEFT-VENTRICULAR HYPERTROPHY; AMIODARONE; VERAPAMIL; PATTERNS				BAUGHMAN, KL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,CLAYTON HEART CTR,BALTIMORE,MD 21205, USA.							BROCK R, 1957, Guys Hosp Rep, V106, P221; DAVIES LG, 1952, BRIT HEART J, V14, P206; FRANK S, 1968, CIRCULATION, V37, P759, DOI 10.1161/01.CIR.37.5.759; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KALTENBACH M, 1979, BRIT HEART J, V42, P35; MARON BJ, 1984, AM J CARDIOL, V53, P1087, DOI 10.1016/0002-9149(84)90643-X; MARON BJ, 1981, AM J CARDIOL, V48, P252, DOI 10.1016/0002-9149(81)90604-4; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1981, BRIT HEART J, V46, P173; MCKENNA WJ, 1984, AM J CARDIOL, V54, P802, DOI 10.1016/S0002-9149(84)80212-X; Schmincke A, 1907, DEUT MED WOCHENSCHR, V33, P2082, DOI 10.1055/s-0029-1189154; TEARE D, 1985, BRIT HEART J, V20, P1; WAGNER JA, 1989, NEW ENGL J MED, V320, P755, DOI 10.1056/NEJM198903233201202	17	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					846	849						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732659				2022-12-28	WOS:A1992HC48400032
J	CHOW, SA; VINCENT, KA; ELLISON, V; BROWN, PO				CHOW, SA; VINCENT, KA; ELLISON, V; BROWN, PO			REVERSAL OF INTEGRATION AND DNA SPLICING MEDIATED BY INTEGRASE OF HUMAN-IMMUNODEFICIENCY-VIRUS	SCIENCE			English	Article							RETROVIRAL DNA; VIRAL-DNA; PROTEIN; RECOMBINATION; INVITRO; SEQUENCE; INVIVO	In retroviral integration, the viral integration protein (integrase) mediates a concerted DNA cleavage-ligation reaction in which the target DNA is cleaved and the resulting 5' ends of target DNA are joined to the 3' ends of viral DNA. Through an oligonucleotide substrate that mimics the recombination intermediate formed by this initial cleavage-ligation reaction, the purified integrase of human immunodeficiency virus was shown to promote the same reaction in reverse, a process called disintegration. Analysis of a set of structurally related substrates showed that integrase could promote a range of DNA cleavage-ligation reactions. When the viral DNA component of the disintegration substrate was single-stranded, integrase could mediate a DNA splicing reaction analogous to RNA splicing.	STANFORD UNIV,MED CTR,DEPT PEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University					NIAID NIH HHS [AI27205] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027205] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, J VIROL, V64, P5645, DOI 10.1128/JVI.64.11.5645-5648.1990; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHOW SA, UNPUB; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DOTAN I, UNPUB; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; LUTZ CT, 1987, P NATL ACAD SCI USA, V84, P4379, DOI 10.1073/pnas.84.13.4379; Maxam A M, 1980, Methods Enzymol, V65, P499; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; VARMUS H, 1989, MOBILE DNA, P53; VINCENT KA, UNPUB; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	22	379	392	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					723	726		10.1126/science.1738845	http://dx.doi.org/10.1126/science.1738845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738845				2022-12-28	WOS:A1992HC50600040
J	WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT; GOLDING, J				WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT; GOLDING, J			CAN THE FALL IN AVONS SUDDEN INFANT DEATH RATE BE EXPLAINED BY CHANGES IN SLEEPING POSITION	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the impact of changing practice with regard to infant sleeping position on mortality from the sudden infant death syndrome. Design - A population based study of all infants dying suddenly and unexpectedly during February 1990 to July 1991, and two groups of controls; one comprising every 125th baby born to Avon residents and the other comprising pairs of infants matched to each index case for age, neighbourhood, and date of study. Information about sleeping position was collected at home visits soon after the index baby's death or, for the population based controls, on several occasions in the first six months of life. The design was comparable to that of an earlier study of the same population. Setting - County of Avon. Subjects - 35 infants who died suddenly and unexpectedly (32 of the sudden infant death syndrome), 70 matched controls, and 152 population based controls. Results - The prevalence of prone sleeping in the matched controls was much lower than that found in an earlier study in Avon (28% (18/64) 1990-1 v 58% (76/131) 1987-9; p < 0.001) and was comparable with the prevalence in population based controls (29%). This would be expected to lead to a reduction in the incidence of the sudden infant death syndrome to 2.0/1000 live births (95% confidence interval 1.8/1000 to 2.5/1000). The actual mortality fell from 3.5/1000 in 1987.9 to 1.7/1000. Conclusion - The fall in mortality can be almost entirely accounted for by the reduction in prone sleeping, suggesting a causal relation exists between them. Side and supine positions confer protection but the side position is unstable and the infant may roll prone. We therefore recommend supine as the safest sleeping position for babies.	ST MICHAELS HOSP,DEPT CHILD HLTH,BRISTOL BS2 8EG,ENGLAND; INST CHILD HLTH,PAEDIAT & PERINATAL EPIDEMIOL,BRISTOL BS2 8BJ,ENGLAND; BATH UNIT RES PAEDIAT,BATH BA1 3NG,ENGLAND	University of Bristol			Fleming, Peter J/A-9081-2010; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Golding, Jean/0000-0003-2826-3307				BEAL S, 1988, MED J AUSTRALIA, V149, P562, DOI 10.5694/j.1326-5377.1988.tb120774.x; DEJONGE GA, 1989, LANCET, V2, P1149; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; MITCHELL EA, 1991, LANCET, V338, P192, DOI 10.1016/0140-6736(91)90186-S	5	137	137	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					282	283		10.1136/bmj.304.6822.282	http://dx.doi.org/10.1136/bmj.304.6822.282			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739827	Green Published, Bronze			2022-12-28	WOS:A1992HC70800019
J	OCONNOR, M				OCONNOR, M			MEDICINE IN EUROPE .7. EUROPE AND NUTRITION - PROSPECTS FOR PUBLIC-HEALTH	BRITISH MEDICAL JOURNAL			English	Article											OCONNOR, M (corresponding author), CORONARY PREVENT GRP,102 GLOUCESTER PL,LONDON W1H 3DA,ENGLAND.							GARROW JS, 1991, OBESITY OVERWEIGHT; JAMES WPT, 1988, HLTH NUTRITION, P9; LANG T, 1990, FINAL REPORT STUDY D; OCONNOR M, 1992, HLTH ED J, V50; RICHARDS T, 1991, BRIT MED J, V303, P1319, DOI 10.1136/bmj.303.6813.1319; 1991, DIETARY REFERENCE VA; 1991, EUROPEAN CITIZEN SEP; 1991, DEV FUTURE COMMON AG; 1991, FOOD ADVISORY COMMIT; 1991, CMND1523; 1990, NUTRITION BANDING SC	11	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					178	180		10.1136/bmj.304.6820.178	http://dx.doi.org/10.1136/bmj.304.6820.178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA979	1737167	Bronze, Green Published			2022-12-28	WOS:A1992HA97900030
J	TURNBULL, PJ; STIMSON, GV; DOLAN, KA				TURNBULL, PJ; STIMSON, GV; DOLAN, KA			PREVALENCE OF HIV-INFECTION AMONG EX-PRISONERS IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article											TURNBULL, PJ (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,CTR RES DRUGS & HLTH BEHAV,LONDON SW6 1RQ,ENGLAND.		Dolan, Kate/B-1901-2008; Dolan, Kate/G-7859-2017	Dolan, Kate/0000-0002-9848-807X				FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MADEN A, 1991, BRIT MED J, V302, P880, DOI 10.1136/bmj.302.6781.880; MADEN A, 1991, BRIT MED J, V301, P1133; TURNBULL PJ, 1991, PRISONS HIV AIDS RIS	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1992	304	6819					90	91		10.1136/bmj.304.6819.90	http://dx.doi.org/10.1136/bmj.304.6819.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA171	1737147	Bronze, Green Published			2022-12-28	WOS:A1992HA17100023
J	SNYDER, EY; DEITCHER, DL; WALSH, C; ARNOLDALDEA, S; HARTWIEG, EA; CEPKO, CL				SNYDER, EY; DEITCHER, DL; WALSH, C; ARNOLDALDEA, S; HARTWIEG, EA; CEPKO, CL			MULTIPOTENT NEURAL CELL-LINES CAN ENGRAFT AND PARTICIPATE IN DEVELOPMENT OF MOUSE CEREBELLUM	CELL			English	Article							CHICKEN OPTIC TECTUM; CORTICAL-NEURONS; PRECURSOR CELLS; MONOCLONAL-ANTIBODIES; MIGRATION PATTERNS; COMMON PROGENITOR; NERVOUS-SYSTEM; C-MYC; DIFFERENTIATION; CORTEX	Multipotent neural cell lines were generated via retrovirus-mediated v-myc transfer into murine cerebellar progenitor cells. When transplanted back into the cerebellum of newborn mice, these cells integrated into the cerebellum in a nontumorigenic, cytoarchitecturally appropriate manner. Cells from the same clonal line differentiated into neurons or glia in a manner appropriate to their site of engraftment. Engrafted cells, identified by lacZ expression and PCR-mediated detection of a unique sequence arrangement, could be identified in animals up to 22 months postengraftment. Electron microscopic and immunohistochemical analysis demonstrated that some engrafted cells were similar to host neurons and glia. Some transplant-derived neurons received appropriate synapses and formed normal intercellular contacts. These data indicate that generating immortalized cell lines for repair of, or transport of genes into, the CNS may be feasible. Such lines may also provide a model for commitment and differentiation of cerebellar progenitor cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)			Deitcher, David/K-6538-2019	Deitcher, David/0000-0002-8512-8868	NINDS NIH HHS [5-K08-NS01403-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001403] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altman J., 1982, CEREBELLUM NEW VISTA, V47, P8; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARRY DI, 1987, P NATL ACAD SCI USA, V84, P8712, DOI 10.1073/pnas.84.23.8712; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BJORKLUND A, 1982, NATURE, V298, P652, DOI 10.1038/298652a0; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BUZSAKI G, 1988, P NATL ACAD SCI USA, V85, P9327, DOI 10.1073/pnas.85.23.9327; CEPKO C, 1988, NEURON, V1, P345, DOI 10.1016/0896-6273(88)90184-5; CEPKO C, 1989, NEUROMETHODS, V16, P177; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; EVRARD C, 1990, P NATL ACAD SCI USA, V87, P3062, DOI 10.1073/pnas.87.8.3062; FIELDSBERRY SC, 1992, IN PRESS P NATL ACAD; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FREUND TF, 1985, J NEUROSCI, V5, P603; GAGE FH, 1983, SCIENCE, V221, P966, DOI 10.1126/science.6879196; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GELLER HM, 1988, J CELL BIOL, V107, P1977, DOI 10.1083/jcb.107.5.1977; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GRAVEL C, 1987, J NEUROSCI METH, V21, P145, DOI 10.1016/0165-0270(87)90112-9; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEBER SM, 1990, J NEUROSCI, V10, P2451; LUND RD, 1987, ANN NY ACAD SCI, V495, P227, DOI 10.1111/j.1749-6632.1987.tb23678.x; Maniatis T., 1982, MOL CLONING; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OCHMAN H, 1988, GENETICS, V120, P621; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; Palay S. L., 1974, CEREBELLAR CORTEX CY; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; Peters A., 1991, FINE STRUCTURE NERVO; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Schaper A, 1897, SCIENCE, V5, P430; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; SOTELO C, 1986, P NATL ACAD SCI USA, V83, P1135, DOI 10.1073/pnas.83.4.1135; SOTELO C, 1987, NATURE, V327, P421, DOI 10.1038/327421a0; STANFIELD BB, 1985, NATURE, V313, P135, DOI 10.1038/313135a0; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WEINSTEIN DE, 1990, GLIA, V3, P130, DOI 10.1002/glia.440030207; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913	68	735	784	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					33	51		10.1016/0092-8674(92)90204-P	http://dx.doi.org/10.1016/0092-8674(92)90204-P			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1732063				2022-12-28	WOS:A1992GZ58300007
J	BREARLEY, S				BREARLEY, S			MEDICINE IN EUROPE - MEDICAL-EDUCATION .5.	BRITISH MEDICAL JOURNAL			English	Article																		BREARLEY S, 1989, MED EDUC, V23, P339; 1975, OFFICIAL J EUROPEA L, V167, P1; 1983, 2ND REPORT RECOMMEND; 1986, OFFICIAL J EUROPEA L, V267, P26; 1975, OFFICIAL J EUROPEA L, V167, P17; 1986, 3RD REPORT RECOMMEND; 1978, REPORT RECOMMENDATIO	7	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					41	44		10.1136/bmj.304.6818.41	http://dx.doi.org/10.1136/bmj.304.6818.41			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734995	Green Published, Bronze			2022-12-28	WOS:A1992GY90900036
J	MCGIBBEN, L; BALLARD, CG; HANDY, S; SILVEIRA, WR				MCGIBBEN, L; BALLARD, CG; HANDY, S; SILVEIRA, WR			SCHOOL ATTENDANCE AS A FACTOR IN DELIBERATE SELF POISONING BY 12-15 YEAR OLD ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article											MCGIBBEN, L (corresponding author), WALSGRAVE GEN HOSP,DEPT PSYCHIAT,COVENTRY CV2 2DX,ENGLAND.			Ballard, Clive/0000-0003-0022-5632				Christoffel K K, 1988, Pediatr Emerg Care, V4, P32, DOI 10.1097/00006565-198803000-00011; Durkheim E., 1952, SUICIDE; MASTERTON G, 1991, BRIT J PSYCHIAT, V158, P155, DOI 10.1192/bjp.158.2.155; PAPATHOMOPOULOS E, 1989, CAN J PSYCHIAT, V34, P205, DOI 10.1177/070674378903400309	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1992	304	6818					28	28		10.1136/bmj.304.6818.28	http://dx.doi.org/10.1136/bmj.304.6818.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY909	1734990	Bronze, Green Published			2022-12-28	WOS:A1992GY90900031
J	ELDER, AT; JYOTHINAGARAM, SG; PADFIELD, PL; SHAW, TRD				ELDER, AT; JYOTHINAGARAM, SG; PADFIELD, PL; SHAW, TRD			HEMODYNAMIC-RESPONSE IN SOCCER SPECTATORS - IS SCOTTISH FOOTBALL EXCITING	BRITISH MEDICAL JOURNAL			English	Article							ELECTROCARDIOGRAM	Objective - To determine the effect of watching a game of Scottish football on heart rate and blood pressure. Design - Prospective study. Setting - Two Scottish Premier League football grounds. Subjects - 10 healthy men, each a supporter of one of two clubs. Main outcome measures - Systolic and diastolic blood pressure and heart rate at home, while walking, and during the match. Results - Systolic blood pressure and heart rate were significantly higher when the men were watching the match than when they were at home. While they were watching the match, heart rate was maximal immediately after a goal had been scored by the supported team. Conclusion - The emotional stress invoked by Scottish football is associated with significant increases in heart rate and systolic blood pressure.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	ELDER, AT (corresponding author), WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Elder, Andrew/0000-0003-3229-9601				CLARK S, 1991, J HUM HYPERTENSION, V5, P7; NORTHCOTE RJ, 1983, BRIT HEART J, V50, P372; PRINGLE SD, 1989, BRIT MED J, V299, P1575, DOI 10.1136/bmj.299.6715.1575; SCHIFFER F, 1976, AM J CARDIOL, V37, P41, DOI 10.1016/0002-9149(76)90497-5; TAGGART P, 1973, LANCET, V2, P341; TAGGART P, 1969, BMJ-BRIT MED J, V4, P130, DOI 10.1136/bmj.4.5676.130	6	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1609	1610		10.1136/bmj.303.6817.1609	http://dx.doi.org/10.1136/bmj.303.6817.1609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773191	Bronze, Green Published			2022-12-28	WOS:A1991GX95600024
J	DUNDERDALE, HJ; BENSON, FE; PARSONS, CA; SHARPLES, GJ; LLOYD, RG; WEST, SC				DUNDERDALE, HJ; BENSON, FE; PARSONS, CA; SHARPLES, GJ; LLOYD, RG; WEST, SC			FORMATION AND RESOLUTION OF RECOMBINATION INTERMEDIATES BY ESCHERICHIA-COLI RECA AND RUVC PROTEINS	NATURE			English	Article							HOMOLOGOUS DNA-SEQUENCES; ENDONUCLEASE-VII CLEAVES; ESCHERICHIA-COLI; HOLLIDAY STRUCTURES; STRAND EXCHANGE; GENETIC-RECOMBINATION; ENZYMATIC FORMATION; K-12 REVEALS; REPAIR; JUNCTIONS	The recombination of DNA molecules has been reconstituted in vitro using two purified enzymes from Escherichia coli. RecA protein catalyses homologous pairing and strand exchange reactions to form intermediate DNA structures that are acted upon by RuvC. The newly identified RuvC protein resolves the intermediates by specific endonucleolytic cleavage to produce recombinant DNA molecules.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Sharples, Gary/B-8638-2016	Sharples, Gary/0000-0003-2495-0062; Benson, Fiona Elizabeth/0000-0002-3918-7015; West, Stephen/0000-0001-8848-9418	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CONLEY EC, 1989, CELL, V56, P987, DOI 10.1016/0092-8674(89)90632-6; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; EVANS DH, 1988, J MOL BIOL, V201, P69, DOI 10.1016/0022-2836(88)90439-1; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEMPER B, 1981, EUR J BIOCHEM, V115, P133; KEMPER B, 1984, COLD SPRING HARB SYM, V49, P815, DOI 10.1101/SQB.1984.049.01.092; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; Lilley D. M. J., 1990, Nucleic Acids and Molecular Biology, V4, P55; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LUISIDELUCA C, 1989, GENETICS, V122, P269; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MUELLER JE, 1988, P NATL ACAD SCI USA, V85, P9441, DOI 10.1073/pnas.85.24.9441; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1988, CELL, V52, P621, DOI 10.1016/0092-8674(88)90474-6; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5; WEST SC, 1984, CELL, V37, P683, DOI 10.1016/0092-8674(84)90401-X; WEST SC, 1982, MOL GEN GENET, V180, P333	45	220	229	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					506	510		10.1038/354506a0	http://dx.doi.org/10.1038/354506a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1758493				2022-12-28	WOS:A1991GW75100008
J	ZWI, AB; CABRAL, AJR				ZWI, AB; CABRAL, AJR			IDENTIFYING HIGH-RISK SITUATIONS FOR PREVENTING AIDS	BRITISH MEDICAL JOURNAL			English	Article							AFRICA		MINIST HLTH MAPUTO,MAPUTO,MOZAMBIQUE		ZWI, AB (corresponding author), LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON WC1E 7HJ,ENGLAND.		Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				BALDO M, 1991, ACTION AIDS SO AFRIC, P34; BASSETT MT, 1991, INT J HEALTH SERV, V21, P143, DOI 10.2190/N0NJ-FKXB-CT25-PA09; EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; FREUDENBERG N, 1990, INT J HEALTH SERV, V20, P589, DOI 10.2190/W70D-28M1-C62K-K60R; Freudenberg N, 1989, AIDS Educ Prev, V1, P12; FREUDENBERG N, 1981, INT J HLTH ED, V24, P1; Green LW, 1988, HLTH PROMOT, V3, P151; HUNT CW, 1989, J HEALTH SOC BEHAV, V30, P353, DOI 10.2307/2136985; JOCHELSON K, 1991, INT J HEALTH SERV, V21, P157, DOI 10.2190/11UE-L88J-46HN-HR0K; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; McKeown Thomas, 1979, ROLE MED; NABARRO D, 1989, AIDS, V3, pS265, DOI 10.1097/00002030-198901001-00037; PACKARD RM, 1991, SOC SCI MED, V33, P771, DOI 10.1016/0277-9536(91)90376-N; PIOT P, 1988, TROPICAL GEOGRAPHICA, P894; ROSENFIELD PL, 1988, TROPICAL GEOGRAPHICA, P197; SANDERS D, 1991, HEALTH POLICY PLANN, V6, P157, DOI 10.1093/heapol/6.2.157; WILSON D, 1990, SOC SCI MED, V31, P609, DOI 10.1016/0277-9536(90)90097-C; Zwi A., 1990, Health Policy and Planning, V5, P316, DOI 10.1093/heapol/5.4.316; 1986, HLTH PROMOTION, V1, P3	19	53	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1527	1529		10.1136/bmj.303.6816.1527	http://dx.doi.org/10.1136/bmj.303.6816.1527			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782498	Bronze, Green Published			2022-12-28	WOS:A1991GV47600030
J	CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K				CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K			SAFETY OF THROMBOLYSIS IN ASSOCIATION WITH CARDIOPULMONARY-RESUSCITATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN, DEPT MED & THERAPEUT, ABERDEEN AB9 1FX, SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM, DEPT CARDIAC, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; DEBONO D, 1990, PRACTICAL CORONARY T, P28; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; PASTERNAK RC, 1988, HEART DISEASE TXB CA, P1222; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465	5	24	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1991	303	6812					1242	1242		10.1136/bmj.303.6812.1242	http://dx.doi.org/10.1136/bmj.303.6812.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747647	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200026
J	DINNING, G; DOUGHTY, RW; REID, MM; LLOYD, HL				DINNING, G; DOUGHTY, RW; REID, MM; LLOYD, HL			POTASSIUM CONCENTRATIONS IN IRRADIATED BLOOD	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; REG TRANSFUS CTR,NEWCASTLE TYNE NE2 4NQ,ENGLAND	Newcastle University - UK								BUTTON LN, 1981, TRANSFUSION, V21, P419, DOI 10.1046/j.1537-2995.1981.21481275998.x; LEITMAN SF, 1985, TRANSFUSION, V25, P293, DOI 10.1046/j.1537-2995.1985.25485273804.x; RAMIREZ AM, 1987, TRANSFUSION, V27, P444, DOI 10.1046/j.1537-2995.1987.27587320546.x; RIVET C, 1989, TRANSFUSION, V29, P185, DOI 10.1046/j.1537-2995.1989.29289146841.x; 1989, LANCET, V1, P529	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1110	1110		10.1136/bmj.303.6810.1110	http://dx.doi.org/10.1136/bmj.303.6810.1110			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747580	Bronze, Green Published			2022-12-28	WOS:A1991GN20900024
J	MOONEY, G; HEALEY, A				MOONEY, G; HEALEY, A			STRATEGY FULL OF GOOD INTENTIONS	BRITISH MEDICAL JOURNAL			English	Article											MOONEY, G (corresponding author), UNIV ABERDEEN SCH MED,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND.			Healey, Andrew/0000-0003-2013-3161				BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; DONALDSON C, IN PRESS BMJ; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; McGuire A., 1988, EC HLTH CARE INTRO T; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; 1991, CM1523	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1119	1120		10.1136/bmj.303.6810.1119	http://dx.doi.org/10.1136/bmj.303.6810.1119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747582	Bronze, Green Published			2022-12-28	WOS:A1991GN20900028
J	DYKEWICZ, CA; DATO, VM; FISHERHOCH, SP; HOWARTH, MV; PEREZORONOZ, GI; OSTROFF, SM; GARY, H; SCHONBERGER, LB; MCCORMICK, JB				DYKEWICZ, CA; DATO, VM; FISHERHOCH, SP; HOWARTH, MV; PEREZORONOZ, GI; OSTROFF, SM; GARY, H; SCHONBERGER, LB; MCCORMICK, JB			LYMPHOCYTIC CHORIOMENINGITIS OUTBREAK ASSOCIATED WITH NUDE-MICE IN A RESEARCH-INSTITUTE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS-INFECTIONS; SENTINEL MICE; PERSONNEL; HAMSTERS	Objective. - After an employee at a cancer research institute was diagnosed with lymphocytic choriomeningitis, an investigation was performed to determine the extent of lymphocytic choriomeningitis virus (LCMV) infections among the institute's employees and to identify risk factors for infection. Design. - Retrospective cohort study. Setting. - A US cancer research institute. Participants. - Eighty-two of 90 institute employees. Main Outcome Measures. - Serum LCMV antibodies. Results. - Seven workers (9%) with definite LCMV infection (LCMV IgG antibody titer greater-than-or-equal-to 16) and one worker (1%) with probable infection (IgG titer = 8) were identified (10% overall seroprevalence). All infected employees handled animals or animal tissues and were more likely than other animal handlers to have worked with nude mice (Mus musculus) (P < .02). Among the 31 employees who worked with nude mice at the institute, infected workers were more likely to clean the cages of nude mice (P much less than .001), change their bedding (P < .01), and change their water (P < .001). The institute had been injecting nude mice with LCMV-infected tumor cell lines and had recently increased the nude mouse population and the duration of experiments. These changes would have increased the LCMV burden at the facility and were temporally associated with the cluster of LCMV infections in employees. Conclusions. - This LCMV outbreak, the first reported since 1974, is the first associated with nude mice. It illustrates the ongoing hazard LCMV poses in research laboratories. Since the symptoms of LCMV infection can be nonspecific, clinicians should consider this diagnosis in ill patients who report laboratory rodent exposure.	CTR DIS CONTROL,DIV VIRAL & RICKETTSIAL DIS,1600 CLIFTON RD NE,MAILSTOP A32,ATLANTA,GA 30333; CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,TRENTON,NJ	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services			Dykewicz, Clare A/GVU-7495-2022	Dykewicz, Clare A/0000-0003-0533-7721; McCormick, Joseph/0000-0002-5844-8102				ACKERMANN R, 1972, DEUT MED WOCHENSCHR, V97, P1725, DOI 10.1055/s-0028-1107638; ARMSTRONG C, 1940, HARVEY LECT, V36, P39; ARMSTRONG D, 1969, J AMER MED ASSOC, V209, P265, DOI 10.1001/jama.209.2.265; BAUM SG, 1966, NEW ENGL J MED, V7274, P934; BIGGAR RJ, 1975, JAMA-J AM MED ASSOC, V232, P494, DOI 10.1001/jama.232.5.494; BIGGAR RJ, 1976, CANCER RES, V36, P551; BIGGAR RJ, 1977, J AM VET MED ASSOC, V171, P829; BLUMENTHAL W, 1970, ZENTBL BAKTERIOLOG P, V213, P36; BOWEN GS, 1975, AM J EPIDEMIOL, V102, P233, DOI 10.1093/oxfordjournals.aje.a112152; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CHILDS JE, 1991, AM J TROP MED HYG, V44, P117, DOI 10.4269/ajtmh.1991.44.117; CHRISTOFFERSEN PJ, 1976, ACTA PATH MICRO IM C, V84, P520; DEIBEL R, 1975, JAMA-J AM MED ASSOC, V232, P501, DOI 10.1001/jama.232.5.501; DILLEHAY DL, 1990, LAB ANIM SCI, V40, P367; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GREGG MB, 1975, B WORLD HEALTH ORGAN, V52, P549; HINMAN AR, 1975, AM J EPIDEMIOL, V101, P103, DOI 10.1093/oxfordjournals.aje.a112076; HIRSCH MS, 1974, NEW ENGL J MED, V291, P610, DOI 10.1056/NEJM197409192911206; HOTCHIN J, 1971, AM J PATHOL, V64, P747; HOTCHIN J, 1974, SCIENCE, V185, P1173, DOI 10.1126/science.185.4157.1173; Jacoby R. O., 1984, Laboratory animal medicine, P31; JOHNSON KM, 1981, J CLIN MICROBIOL, V14, P527, DOI 10.1128/JCM.14.5.527-529.1981; LAREGINA MC, 1988, LAB ANIM, V17, P40; LEHMANNGRUBE F, 1971, LYMPHOCYTIC CHORIOME, V30, P89; MCCORMICK JB, 1990, VIROLOGY, P1245; MMAIZTEGUI JI, 1990, 8TH INT C VIR BERL; PIKE RM, 1979, ANNU REV MICROBIOL, V33, P41, DOI 10.1146/annurev.mi.33.100179.000353; RICHARDSON JH, 1988, BIOSAFETY MICROBIOLO, P77; SCHEINBERGAS MM, 1981, INFECT IMMUN, V31, P837; Smadel JE, 1942, P SOC EXP BIOL MED, V49, P683; Small J.D., 1984, LAB ANIMAL MED, P709; THIGPEN JE, 1989, LAB ANIM SCI, V39, P324; Traub E, 1936, J EXP MED, V64, P183, DOI 10.1084/jem.64.2.183; Traub E, 1938, J EXP MED, V68, P229, DOI 10.1084/jem.68.2.229; VANZEE BE, 1975, AM J MED, V58, P803, DOI 10.1016/0002-9343(75)90635-X; WARKEL RL, 1973, NEUROLOGY, V23, P198, DOI 10.1212/WNL.23.2.198; 1974, MMWR, V23, P139	37	43	46	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1349	1353						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740856				2022-12-28	WOS:A1992HG67800027
J	KATO, S; TORA, L; YAMAUCHI, J; MASUSHIGE, S; BELLARD, M; CHAMBON, P				KATO, S; TORA, L; YAMAUCHI, J; MASUSHIGE, S; BELLARD, M; CHAMBON, P			A FAR UPSTREAM ESTROGEN RESPONSE ELEMENT OF THE OVALBUMIN GENE CONTAINS SEVERAL HALF-PALINDROMIC 5'-TGACC-3' MOTIFS ACTING SYNERGISTICALLY	CELL			English	Article							RETINOIC ACID RECEPTOR; CHICKEN PROGESTERONE-RECEPTOR; NEGATIVE REGULATORY ELEMENTS; MAMMARY-TUMOR VIRUS; TRANSCRIPTIONAL ACTIVATION; COOPERATIVE BINDING; ENHANCER ELEMENTS; NUCLEAR RECEPTORS; STEROID-HORMONES; THYROID-HORMONE	We have identified an estrogen-responsive enhancer element (DH3 ERE) in the estrogen-induced DNAase I-hypersensitive region III of the chicken ovalbumin gene, which is located approximately 3.3 kb upstream from the mRNA start site and does not contain palindromic ERE. Four TGACC half-palindromic motifs, separated from each other by more than 100 bp, are responsible for conferring estrogen inducibility either to the proximal ovalbumin gene promoter or to heterologous promoters. Thus, widely spaced half-palindromic ERE motifs can act synergistically. Each half-palindromic motif was shown to bind the estrogen receptor (ER) with a low efficiency in vitro. However, two widely spaced half-palindromic motifs bound the ER cooperatively, much more efficiently than expected from binding to isolated half-ERE motifs. The ovalbumin promoter half-palindromic ERE motif located close to the TATA box was required for the activity of the distal DH3 ERE, but could be replaced by the binding sites of other transactivators.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	KATO, S (corresponding author), TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN.		Jansen, Heiko T./A-5770-2008; Tora, Laszlo/E-9999-2018	Jansen, Heiko T./0000-0003-0178-396X; Tora, Laszlo/0000-0001-7398-2250				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUB MP, 1987, EMBO J, V6, P2313, DOI 10.1002/j.1460-2075.1987.tb02506.x; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PALMITER RD, 1977, COLD SPRING HARB SYM, V42, P639, DOI 10.1101/SQB.1978.042.01.066; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4163, DOI 10.1093/nar/15.10.4163; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	59	282	289	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					731	742		10.1016/0092-8674(92)90148-6	http://dx.doi.org/10.1016/0092-8674(92)90148-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739978				2022-12-28	WOS:A1992HF44000013
J	GUSTAFSON, ML; LEE, MM; SCULLY, RE; MONCURE, AC; HIRAKAWA, T; GOODMAN, A; MUNTZ, HG; DONAHOE, PK; MACLAUGHLIN, DT; FULLER, AF				GUSTAFSON, ML; LEE, MM; SCULLY, RE; MONCURE, AC; HIRAKAWA, T; GOODMAN, A; MUNTZ, HG; DONAHOE, PK; MACLAUGHLIN, DT; FULLER, AF			MULLERIAN INHIBITING SUBSTANCE AS A MARKER FOR OVARIAN SEX-CORD TUMOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							GRANULOSA-CELL TUMORS; ANNULAR TUBULES; RADIOIMMUNOASSAY; ESTRADIOL; SERUM; GENE		MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,WARREN 11,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,VINCENT RES LAB,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Lee, Mary/0000-0002-7204-4884	NCI NIH HHS [5 RO1 CA17393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN GH, 1986, CANCER, V57, P1066, DOI 10.1002/1097-0142(19860301)57:5<1066::AID-CNCR2820570534>3.0.CO;2-C; BERNSTEIN JR, 1990, BIOL REPROD, V43, P492, DOI 10.1095/biolreprod43.3.492; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATE RL, 1990, HDB EXPT PHARM PEPTI, V95, P179; COOPER DS, 1979, J CLIN INVEST, V64, P1669, DOI 10.1172/JCI109629; DONAHOE PK, 1977, J SURG RES, V23, P141, DOI 10.1016/0022-4804(77)90202-5; DONAHOE PK, 1987, RECENT PROG HORM RES, V43, P431; FILICORI M, 1984, J CLIN INVEST, V73, P1638, DOI 10.1172/JCI111370; GAGNON S, 1989, MODERN PATHOL, V2, P63; GLOOR E, 1979, VIRCHOWS ARCH A, V384, P185, DOI 10.1007/BF00427255; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; KAYE SB, 1986, GYNECOL ONCOL, V24, P261, DOI 10.1016/0090-8258(86)90035-1; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; LEE MM, 1992, ENDOCRINOLOGY, V130, P847, DOI 10.1210/en.130.2.847; LOMAX CW, 1977, OBSTET GYNECOL, V50, pS39; MACLAUGHLIN DT, 1983, ENDOCRINOLOGY, V113, P141, DOI 10.1210/endo-113-1-141; MATAMALA MF, 1987, INT J GYNECOL PATHOL, V6, P185, DOI 10.1097/00004347-198706000-00010; NAKASHIMA N, 1984, ARCH PATHOL LAB MED, V108, P786; RODGERS KE, 1990, GYNECOL ONCOL, V37, P381, DOI 10.1016/0090-8258(90)90372-R; SCHNEYER AL, 1990, J CLIN ENDOCR METAB, V70, P1208, DOI 10.1210/jcem-70-4-1208; TAKAHASHI M, 1986, MOL CELL ENDOCRINOL, V47, P225, DOI 10.1016/0303-7207(86)90116-4; UENO S, 1989, ENDOCRINOLOGY, V124, P1000, DOI 10.1210/endo-124-2-1000; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5	25	109	115	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					466	471		10.1056/NEJM199202133260707	http://dx.doi.org/10.1056/NEJM199202133260707			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1732773				2022-12-28	WOS:A1992HD16400007
J	REMPEL, DM; HARRISON, RJ; BARNHART, S				REMPEL, DM; HARRISON, RJ; BARNHART, S			WORK-RELATED CUMULATIVE TRAUMA DISORDERS OF THE UPPER EXTREMITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARPAL-TUNNEL SYNDROME; SENSORY LATENCIES; SHOULDER; PREVALENCE; HAND; NECK	Cumulative trauma disorders due to performance of repetitive tasks account for more than 50% of all occupational illnesses in the United States today. Employees affected by these disorders frequently experience substantial pain and functional impairment that may require a change in occupation. For the employer, these injuries result in loss of productivity and increased costs in the form of higher medical expenses and disability payments for injured workers. Successful treatment of work-related repetitive tissue injuries depends on early diagnosis and appropriate therapy. Prevention requires identifying sites and tasks that place employees at risk of injury and supporting efforts to develop safer work environments.	UNIV CALIF SAN FRANCISCO,DIV OCCUPAT MED,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,OCCUPAT MED PROGRAM,SEATTLE,WA 98195	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle			Rempel, David/E-8424-2013					Aguayo AJ, 1975, PERIPHERAL NEUROPATH, P688; AMADIO PC, 1987, J HAND SURG-AM, V12A, P875, DOI 10.1016/S0363-5023(87)80253-8; AREZZO JC, 1980, J OCCUP ENVIRON MED, V22, P461; ARMSTRONG TJ, 1987, J HAND SURG-AM, V12A, P830, DOI 10.1016/S0363-5023(87)80244-7; Armstrong TJ, 1987, CLIN CONCEPTS REGION, P333; BARNHART S, 1987, WESTERN J MED, V147, P37; BECKENBAUGH R, 1986, PHYSICIANS CLIN FINA, V1, P1; BLEECKER ML, 1985, NEUROLOGY, V35, P1599, DOI 10.1212/WNL.35.11.1599; CASTORINA J, 1990, 86008 CAL DEP HLTH S; FALCK B, 1983, SCAND J WORK ENV HEA, V9, P291, DOI 10.5271/sjweh.2408; FEINDEL W, 1958, Can J Surg, V1, P287; FELDMAN RG, 1983, AM J IND MED, V4, P661, DOI 10.1002/ajim.4700040508; FRY HJH, 1988, J ROY SOC MED, V81, P572, DOI 10.1177/014107688808101007; GAINER JV, 1977, SOUTHERN MED J, V70, P325, DOI 10.1097/00007611-197703000-00021; GELBERMAN RH, 1981, J BONE JOINT SURG AM, V63, P380, DOI 10.2106/00004623-198163030-00009; GELLMAN H, 1989, J HAND SURG-AM, V14A, P863, DOI 10.1016/S0363-5023(89)80091-7; GREENBERG L, 1976, WORKERS THEIR TOOLS; HAGBERG M, 1987, BRIT J IND MED, V44, P602; HERBERTS P, 1984, CLIN ORTHOP RELAT R, V191, P166; Hymovich L, 1966, J Occup Med, V8, P573; JOHNSON EW, 1983, ARCH PHYS MED REHAB, V64, P556; JOHNSON EW, 1987, ARCH PHYS MED REHAB, V68, P140; KASDAN ML, 1991, OCCUPATIONAL HAND UP, P412; KASDAN ML, 1987, PLAST RECONSTR SURG, V9, P456; Keyserling W.M., 1991, APPL OCCUP ENV HYG, V6, P353, DOI [10.1080/1047322x.1991.10387896, DOI 10.1080/1047322X.1991.10387896]; KIMURA J, 1979, BRAIN, V102, P619, DOI 10.1093/brain/102.3.619; KUONNKA I, 1987, APPL ERGON, V18, P133; KURPPA K, 1979, SCAND J WORK ENV HEA, V5, P15, DOI 10.5271/sjweh.2676; LUNDBORG G, 1986, J HAND SURG-AM, V11A, P693, DOI 10.1016/S0363-5023(86)80014-4; LUNDSTROM R, 1986, ERGONOMICS, V29, P687, DOI 10.1080/00140138608968303; MAEDA K, 1975, Kurume Medical Journal, V22, P231; MASEAR VR, 1986, J HAND SURG-AM, V11A, P222, DOI 10.1016/S0363-5023(86)80055-7; NEVIASER JS, 1980, ORTHOP CLIN N AM, V11, P327; ONISHI N, 1976, Journal of Human Ergology, V5, P87; Phalen G S, 1972, Clin Orthop Relat Res, V83, P29, DOI 10.1097/00003086-197203000-00007; PHALEN GS, 1970, J AMER MED ASSOC, V212, P1365, DOI 10.1001/jama.212.8.1365; PUTZANDERSON V, 1988, CUMULATIVE TRAUMA DI, P22; ROTO P, 1984, SCAND J WORK ENV HEA, V10, P203, DOI 10.5271/sjweh.2344; SAUTER SL, 1987, APPL ERGON, V18, P183, DOI 10.1016/0003-6870(87)90002-0; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; SILVERSTEIN B, 1988, J OCCUP MED, V30, P151; SILVERSTEIN BA, 1986, BRIT J IND MED, V43, P779; Silverstein BA, 1986, SEMIN OCCUP MED, V1, P213; SIMON WH, 1975, ORTHOP CLIN N AM, V6, P521; SJOGAARD G, 1990, MAR C P OCC DIS UPP; SMITH EM, 1977, ARCH PHYS MED REHAB, V58, P379; STEVENS JC, 1987, MUSCLE NERVE, V10, P99, DOI 10.1002/mus.880100202; SZABO RM, 1989, J HAND SURG-AM, V14A, P624, DOI 10.1016/0363-5023(89)90178-0; SZABO RM, 1987, J HAND SURG-AM, V12A, P880, DOI 10.1016/S0363-5023(87)80254-X; THOMPSON AR, 1951, BRIT J IND MED, V8, P150; TURNER J, 1990, MAR C P OCC DIS UPP; VIIKARIJUNTURA E, 1983, SCAND J WORK ENV HEA, V9, P283, DOI 10.5271/sjweh.2416; WARIS P, 1979, SCAND J WORK ENV H S, V3, P3; WIKER SF, 1989, ERGONOMICS, V32, P211, DOI 10.1080/00140138908966080; YAMAGUCHI DM, 1965, MINN MED, P22; 1990, BUREAU LABOR STATIST; 1990, ERGONOMICS PROGRAM M; 1989, OCCUPATIONAL EXPOSUR; 1989, MMWR, V38, P485	59	236	238	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					838	842		10.1001/jama.267.6.838	http://dx.doi.org/10.1001/jama.267.6.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1732657				2022-12-28	WOS:A1992HC48400030
J	KOCKS, C; GOUIN, E; TABOURET, M; BERCHE, P; OHAYON, H; COSSART, P				KOCKS, C; GOUIN, E; TABOURET, M; BERCHE, P; OHAYON, H; COSSART, P			L-MONOCYTOGENES-INDUCED ACTIN ASSEMBLY REQUIRES THE ACTA GENE-PRODUCT, A SURFACE PROTEIN	CELL			English	Article							CELL-LINE CACO-2; LISTERIA-MONOCYTOGENES; SHIGELLA-FLEXNERI; INTRACELLULAR GROWTH; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; F-ACTIN; SPREAD; IDENTIFICATION; PLASMID	The intracellular pathogenic bacterium L. monocytogenes can spread directly from cell to cell without leaving the cytoplasm. The mechanism of this movement, generated through bacterially induced actin polymerization, is not understood. By analyzing an avirulent Tn917-lac mutant defective for actin polymerization, we have identified a bacterial component involved in this process. The transposon had inserted in actA, the second gene of an operon. Gene disruption of downstream genes and transformation of the mutant strain with actA showed that the actA gene encodes a surface protein necessary for bacterially induced actin assembly. Our results indicate that it is a 610 amino acid protein with an apparent molecular weight of 90 kd.	INST PASTEUR,CENT MICROSCOPIE ELECTR STN,F-75724 PARIS 15,FRANCE; UNIV PARIS 05,MICROBIOL LAB,F-75730 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	KOCKS, C (corresponding author), INST PASTEUR,GENET MOLEC LISTERIA LAB,25 & 28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			TABOURET, Marc/0000-0003-0499-2804				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRYAN J, 1989, J BIOL CHEM, V264, P13873; COSSART P, 1989, MOL BIOL MED, V6, P463; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DERYCKE J, 1989, J CLIN MICROBIOL, V27, P983, DOI 10.1128/JCM.27.5.983-988.1989; DOMANN E, 1991, INFECT IMMUN, V59, P65, DOI 10.1128/IAI.59.1.65-72.1991; FUZI M, 1962, NATURE, V13, P195; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAVELL EA, 1986, INFECT IMMUN, V54, P787, DOI 10.1128/IAI.54.3.787-792.1986; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; KUHN M, 1990, INFECT IMMUN, V58, P3477, DOI 10.1128/IAI.58.11.3477-3486.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; LUCAS RD, 1989, LETT APPL MICROBIOL, V9, P215, DOI 10.1111/j.1472-765X.1989.tb00329.x; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; MENGAUD J, 1991, MOL MICROBIOL, V5, P2273, DOI 10.1111/j.1365-2958.1991.tb02158.x; MENGAUD J, 1989, INFECT IMMUN, V57, P3695, DOI 10.1128/IAI.57.12.3695-3701.1989; MENGAUD J, 1991, INFECT IMMUN, V59, P1043, DOI 10.1128/IAI.59.3.1043-1049.1991; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PAL T, 1989, INFECT IMMUN, V57, P477; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETIT MA, 1990, J BACTERIOL, V172, P6736, DOI 10.1128/jb.172.12.6736-6740.1990; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; RACZ P, 1970, ACTA MICROBIOL HUNG, V17, P221; Sambrook J, 1989, MOL CLONING LABORATO; SHAW JH, 1985, J BACTERIOL, V164, P782, DOI 10.1128/JB.164.2.782-796.1985; SULLIVAN M, 1984, GENE, V29, P24; SUN AN, 1990, INFECT IMMUN, V58, P3770, DOI 10.1128/IAI.58.11.3770-3778.1990; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VICENTE MF, 1985, FEMS MICROBIOL LETT, V30, P77; WEST RR, 1991, J BIOL CHEM, V266, P21886; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	48	655	691	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					521	531		10.1016/0092-8674(92)90188-I	http://dx.doi.org/10.1016/0092-8674(92)90188-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1739966				2022-12-28	WOS:A1992HD39800012
J	GRUNDY, CE; ROBINSON, J; GUTHRIE, KA; GORDON, AG; HAY, DM				GRUNDY, CE; ROBINSON, J; GUTHRIE, KA; GORDON, AG; HAY, DM			ESTABLISHMENT OF PREGNANCY AFTER REMOVAL OF SPERM ANTIBODIES INVITRO	BRITISH MEDICAL JOURNAL			English	Article									PRINCESS ROYAL HOSP,HULL,ENGLAND		GRUNDY, CE (corresponding author), UNIV HULL,DEPT APPL BIOL,HULL HU6 7RX,N HUMBERSIDE,ENGLAND.							BRONSON R, 1984, FERTIL STERIL, V42, P171; CLARKE GN, 1985, AM J REPROD IM MIC, V8, P62; GRUNDY CE, 1991, HUM REPROD, V6, P593, DOI 10.1093/oxfordjournals.humrep.a137385; HAAS GG, 1987, FERTIL STERIL, V47, P295; HAAS GG, 1988, J ANDROL, V9, P190	5	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1992	304	6822					292	293		10.1136/bmj.304.6822.292-a	http://dx.doi.org/10.1136/bmj.304.6822.292-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC708	1739830	Green Published, Bronze			2022-12-28	WOS:A1992HC70800023
J	KUHL, PK; WILLIAMS, KA; LACERDA, F; STEVENS, KN; LINDBLOM, B				KUHL, PK; WILLIAMS, KA; LACERDA, F; STEVENS, KN; LINDBLOM, B			LINGUISTIC EXPERIENCE ALTERS PHONETIC PERCEPTION IN INFANTS BY 6 MONTHS OF AGE	SCIENCE			English	Article							LANGUAGE SPEECH-PERCEPTION; JAPANESE ADULTS; DISCRIMINATION; PROTOTYPES; ENGLISH	Linguistic experience affects phonetic perception. However, the critical period during which experience affects perception and the mechanism responsible for these effects are unknown. This study of 6-month-old infants from two countries, the United States and Sweden, shows that exposure to a specific language in the first half year of life alters infants' phonetic perception.	UNIV STOCKHOLM,INST LINGUIST,S-10691 STOCKHOLM,SWEDEN; MIT,ELECTR RES LAB,CAMBRIDGE,MA 02139; UNIV TEXAS,DEPT LINGUIST,AUSTIN,TX 78712	Stockholm University; Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Austin	KUHL, PK (corresponding author), UNIV WASHINGTON,DEPT SPEECH & HEARING SCI,WJ-10,SEATTLE,WA 98195, USA.			de Lacerda, Francisco/0000-0002-7980-3601	NIDCD NIH HHS [DC 00520] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC000520] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARRERA ME, 1981, CHILD DEV, V52, P714, DOI 10.2307/1129196; Bates E., 1988, 1 WORDS GRAMMAR; BENEDICT H, 1979, J CHILD LANG, V6, P183, DOI 10.1017/S0305000900002245; DECASPER AJ, 1980, SCIENCE, V208, P1174, DOI 10.1126/science.7375928; Eimas P. D., 1987, CATEGORICAL PERCEPTI, P161; GOTO H, 1971, NEUROPSYCHOLOGIA, V9, P317, DOI 10.1016/0028-3932(71)90027-3; GRIESER D, 1989, DEV PSYCHOL, V25, P577, DOI 10.1037/0012-1649.25.4.577; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; MEHLER J, 1988, COGNITION, V29, P143, DOI 10.1016/0010-0277(88)90035-2; MILLER JL, 1989, PERCEPT PSYCHOPHYS, V46, P505, DOI 10.3758/BF03208147; MIYAWAKI K, 1975, PERCEPT PSYCHOPHYS, V18, P331, DOI 10.3758/BF03211209; SAMUEL AG, 1982, PERCEPT PSYCHOPHYS, V31, P307, DOI 10.3758/BF03202653; STRANGE W, 1984, PERCEPT PSYCHOPHYS, V36, P131, DOI 10.3758/BF03202673; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WERKER JF, 1988, DEV PSYCHOL, V24, P672, DOI 10.1037/0012-1649.24.5.672; [No title captured]; [No title captured]; [No title captured], DOI DOI 10.2307/1165788	18	1162	1175	5	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1992	255	5044					606	608		10.1126/science.1736364	http://dx.doi.org/10.1126/science.1736364			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HB531	1736364				2022-12-28	WOS:A1992HB53100046
J	SHAH, A; STANHOPE, R; MATTHEW, D				SHAH, A; STANHOPE, R; MATTHEW, D			LESSON OF THE WEEK - HAZARDS OF PHARMACOLOGICAL TESTS OF GROWTH-HORMONE SECRETION IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							COMA		HOSP SICK CHILDREN,ENDOCRINE UNIT,LONDON WC1N 3JH,ENGLAND; HOSP SICK CHILDREN,GEN INTENS CARE UNITS,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; DARENDELILER F, 1990, J ENDOCRINOL, V125, P311, DOI 10.1677/joe.0.1250311; FRANTZ ID, 1975, J PEDIATR-US, V87, P417, DOI 10.1016/S0022-3476(75)80646-9; FREIDENBERG GR, 1980, NEW ENGL J MED, V303, P863, DOI 10.1056/NEJM198010093031507; HOFFMAN WH, 1983, DIABETOLOGIA, V25, P531; HUGHES IA, 1986, HDB ENDOCRINE TESTS; KELNAR CJH, 1976, BRIT MED J, V1, P751, DOI 10.1136/bmj.1.6012.751; ROSE SR, 1988, NEW ENGL J MED, V319, P201, DOI 10.1056/NEJM198807283190403; SPILIOTIS BE, 1984, JAMA-J AM MED ASSOC, V251, P2223, DOI 10.1001/jama.251.17.2223; TASKER RC, 1990, NEUROPEDIATRICS, V21, P91, DOI 10.1055/s-2008-1071469	10	194	200	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1992	304	6820					173	174		10.1136/bmj.304.6820.173	http://dx.doi.org/10.1136/bmj.304.6820.173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA979	1737165	Green Published, Bronze			2022-12-28	WOS:A1992HA97900028
J	MIAO, VP; COVERT, SF; VANETTEN, HD				MIAO, VP; COVERT, SF; VANETTEN, HD			A FUNGAL GENE FOR ANTIBIOTIC-RESISTANCE ON A DISPENSABLE (B) CHROMOSOME	SCIENCE			English	Article							NECTRIA-HAEMATOCOCCA; PHYTOALEXIN-DETOXIFICATION; ELECTROPHORETIC KARYOTYPE; ASPERGILLUS-NIDULANS; LARGE DNA; PISATIN; PATHOGENICITY; PLANT	A family of cytochrome P-450 (Pda) genes in the pathogenic fungus Nectria haematococca is responsible for the detoxification of the phytoalexin pisatin, an antimicrobial compound produced by garden pea (Pisum sativum L.). The Pda6 gene was mapped by electrophoretic karyotype analysis to a small meiotically unstable chromosome that is dispensable for normal growth. Such traits are typical of B chromosomes. The strains of Nectria studied here have no sequences that are homologous to the Pda family other than Pda6 and therefore demonstrate that unique, functional genes can be found on B chromosomes. Unstable B chromosomes may be one mechanism for generating pathogenic variation in fungi.	UNIV ARIZONA,DEPT PLANT PATHOL,TUCSON,AZ 85721; CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853	University of Arizona; Cornell University	VANETTEN, HD (corresponding author), UNIV ARIZONA,DEPT PLANT PATHOL,TUCSON,AZ 85721, USA.							BRODY H, 1989, P NATL ACAD SCI USA, V86, P6260, DOI 10.1073/pnas.86.16.6260; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Jones RN, 1982, B CHROMOSOMES; KISTLER HC, 1984, J GEN MICROBIOL, V130, P2595; LUCY MC, 1988, PHYSIOL MOL PLANT P, V33, P187, DOI 10.1016/0885-5765(88)90019-7; MACKINTOSH SF, 1989, MOL PLANT MICROBE IN, V2, P354, DOI 10.1094/MPMI-2-354; MATTHEWS DE, 1983, ARCH BIOCHEM BIOPHYS, V224, P494, DOI 10.1016/0003-9861(83)90237-0; MATUO T, 1972, PHYTOPATHOLOGY, V62, P731, DOI 10.1094/Phyto-62-731; MIAO VP, IN PRESS APPL ENV MI; MIAO VPW, 1991, MOL GEN GENET, V226, P214, DOI 10.1007/BF00273606; MILLS D, 1990, MOL PLANT MICROBE IN, V3, P351, DOI 10.1094/MPMI-3-351; ORBACH MJ, 1988, MOL CELL BIOL, V8, P1469, DOI 10.1128/MCB.8.4.1469; Sambrook J., 1989, MOL CLONING; SCHAFER W, 1989, SCIENCE, V246, P247, DOI 10.1126/science.246.4927.247; VANETTEN HD, 1984, PHYSIOL PLANT PATHOL, V25, P149, DOI 10.1016/0048-4059(84)90053-5; VANETTEN HD, 1989, ANNU REV PHYTOPATHOL, V27, P143, DOI 10.1146/annurev.py.27.090189.001043; VANETTEN HD, 1989, NATO ASI SERIES H, V36, P219; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WELTRING KM, 1988, GENE, V68, P335, DOI 10.1016/0378-1119(88)90036-4	19	223	231	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1773	1776		10.1126/science.1763326	http://dx.doi.org/10.1126/science.1763326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763326				2022-12-28	WOS:A1991GW31600037
J	BHOPAL, RS; THOMSON, R				BHOPAL, RS; THOMSON, R			AUDIT IN PERSON - A FORM TO HELP LEARN AND TEACH ABOUT ASSESSING MEDICAL AUDIT PAPERS	BRITISH MEDICAL JOURNAL			English	Article									NO REG HLTH AUTHOR,SERV QUAL & STAND,NEWCASTLE TYNE NE6 4PY,ENGLAND		BHOPAL, RS (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							EASTERBROOK P, 1990, BMJ, V302, P392; FOWKES FGR, 1991, BRIT MED J, V302, P1136, DOI 10.1136/bmj.302.6785.1136; FOWKES FGR, 1986, BRIT MED J, V292, P883, DOI 10.1136/bmj.292.6524.883; HANCOCK BD, 1990, BRIT MED J, V301, P911, DOI 10.1136/bmj.301.6757.911; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; NEVILLE RG, 1987, J ROY COLL GEN PRACT, V37, P496; RUTHERFORD A D, 1987, Journal of the Royal College of Surgeons of Edinburgh, V32, P72; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA	8	12	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1520	1522		10.1136/bmj.303.6816.1520	http://dx.doi.org/10.1136/bmj.303.6816.1520			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782495	Green Published, Bronze			2022-12-28	WOS:A1991GV47600028
J	GODLEE, F				GODLEE, F			HEALTH IMPLICATIONS OF CLIMATIC-CHANGE	BRITISH MEDICAL JOURNAL			English	Editorial Material																		[Anonymous], 1990, POLICYMAKERS SUMMARY; BROWN L, 1989, STATE WORLD 1989 WOR; Brown L.R., 1990, STATE WORLD 1990 WOR; BROWN LR, 1991, STATE WORLD 1991 WOR; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; HANSEN J, 1988, 1ST P N AM C PREP CL, P35; Houghton J.T., 1990, CLIMATE CHANGE IPCC; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MacKenzie J. J., 1988, ILL WINDS AIRBORNE P; MCELROY MB, 1989, B AM ACADEMY ARTS SC, V42, P25; OESCHLI FW, 1970, ENVIRON RES, V3, P277; PEARCE F, 1991, NEW SCI         1122, P20; ROGOT E, 1976, AM J EPIDEMIOL, V103, P565, DOI 10.1093/oxfordjournals.aje.a112261; TITUS JG, 1989, POTENTIAL EFFECTS GL; WARRICK R, 1986, GREENHOUSE EFFECT CL; 1991, POLICY IMPLICATIONS; 1990, WORLD RESOURCES 1990, P14; 1988, 1988 POL OPT C STAT	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1254	1256		10.1136/bmj.303.6812.1254	http://dx.doi.org/10.1136/bmj.303.6812.1254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747652	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200033
J	WHITTY, P; PARKER, C; PRIETORAMOS, F; ALKHARUSI, S				WHITTY, P; PARKER, C; PRIETORAMOS, F; ALKHARUSI, S			COMMUNICATION OF RESULTS OF NECROPSIES IN NORTH-EAST-THAMES REGION	BRITISH MEDICAL JOURNAL			English	Article							AUTOPSY; AUDIT	Objective - To evaluate the adequacy of reporting of results of necropsy to referring clinicians and to general practitioners. Design - Questionnaire survey of referring clinicians and general practitioners of deceased patients in four districts in North East Thames region. Patients were selected by retrospective systematic sampling of 50 or more necropsy reports in each district. Setting - One teaching hospital, one inner London district general hospital, and two outer London district general hospitals. Participants - 70 consultants and 146 general practitioners who were asked about 214 necropsy reports; coroners' reports were excluded. Main outcome measures - Time taken for dispatch of final reports after necropsy, consultants' recognition of the reports, general practitioners' recognition of the reports or of their findings, and consultants' recall of having discussed the findings with relatives. Results - Only two hospitals dispatched final reports including histological findings (mean time to dispatch 144 days and 22 days respectively). 42 (60%) consultants and 83 (57%) general practitioners responded to the survey. The percentage of reports seen by consultants varied from 37% (n = 13) to 87% (n = 36); in all, only 47% (39/83) of general practitioners had been informed of the findings by any method. Consultants could recall having discussed findings with only 42% (47/112) of relatives. Conclusions - Communication of results of necropsies to hospital clinicians, general practitioners, and relatives is currently inadequate in these hospitals. Implications and action - A report of the macroscopic findings should be dispatched immediately after necropsy to clinicians and general practitioners; relatives should routinely be invited to discuss the necroscopic findings. One department has already altered its practice.	LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON UC1E 7AJ,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								BROWN HG, 1983, ARCH PATHOL LAB MED, V108, P446; CARTWRIGHT A, 1973, LIFE DEATH; CARTWRIGHT A, 1982, LIFE DEATH STUDY ELD; CHANA J, 1990, J ROY COLL PHYS LOND, V24, P185; FRIEDERICI HHR, 1988, JAMA-J AM MED ASSOC, V260, P3461, DOI 10.1001/jama.260.23.3461; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; LAISSUE JA, 1986, SCHWEIZ MED WSCHR, V116, P130; NEVILLE RG, 1987, J ROY COLL GEN PRACT, V37, P496; SCHNED AR, 1986, AM J CLIN PATHOL, V86, P133, DOI 10.1093/ajcp/86.2.133; UNDERWOOD JCE, 1989, LANCET, V1, P442; 1990, J CLIN PATHOL, V43, P89; 1991, AUTOPSY AUDIT	12	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1244	1246		10.1136/bmj.303.6812.1244	http://dx.doi.org/10.1136/bmj.303.6812.1244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747649	Green Published, Bronze			2022-12-28	WOS:A1991GQ34200029
J	Baddeley, A				Baddeley, Alan			Working memory	CURRENT BIOLOGY			English	Editorial Material									Univ York, Dept Psychol, York YO10 5DD, N Yorkshire, England	University of York - UK	Baddeley, A (corresponding author), Univ York, Dept Psychol, York YO10 5DD, N Yorkshire, England.	a.baddeley@psych.york.ac.uk						Atkinson R. C., 1968, PSYCHOL LEARNING MOT, V2, P89, DOI [DOI 10.1016/S0079-7421(08)60422-3, 10.1016/S0079-7421(08)60422-3]; Baddeley A, 1998, PSYCHOL REV, V105, P158, DOI 10.1037/0033-295X.105.1.158; Baddeley A., WORKING MEMORY THOUG, DOI [10.1093/acprof:oso/9780198528012.001.0001, DOI 10.1093/ACPROF:OSO/9780198528012.001.0001]; Baddeley AD, 2009, J MEM LANG, V61, P438, DOI 10.1016/j.jml.2009.05.004; BADDELEY AD, 1975, J VERB LEARN VERB BE, V14, P575, DOI 10.1016/S0022-5371(75)80045-4; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barrouillet P, 2007, J EXP PSYCHOL LEARN, V33, P570, DOI 10.1037/0278-7393.33.3.570; Cowan N, 1999, MODELS WORKING MEMOR, P62, DOI [10.1017/CBO9781139174909.006, DOI 10.1017/CBO9781139174909.006]; Cowan Nelson, 2005, WORKING MEMORY CAPAC; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Engle RW, 2004, PSYCHOL LEARN MOTIV, V44, P145; Gathercole S.E., 2006, WORKING MEMORY ED; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; OLTON DS, 1979, AM PSYCHOL, V34, P583, DOI 10.1037/0003-066X.34.7.583; Repovs G, 2006, NEUROSCIENCE, V139, P1, DOI 10.1016/j.neuroscience.2005.12.007; SHALLICE T, 1970, Q J EXP PSYCHOL, V22, P261, DOI 10.1080/00335557043000203; Vallar G, 2006, COGN NEUROPSYCHOL, V23, P135, DOI 10.1080/02643290542000012	18	6222	6493	69	302	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	FEB 23	2010	20	4					R136	R140		10.1016/j.cub.2009.12.014	http://dx.doi.org/10.1016/j.cub.2009.12.014			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	563QT	1736359	Bronze			2022-12-28	WOS:000275149200009
J	HOLDEN, C				HOLDEN, C			ZAGURY IN THE CLEAR	SCIENCE			English	Editorial Material																		1992, SCIENCE, V255, P280	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					680	680						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738839				2022-12-28	WOS:A1992HC50600018
J	HOLDEN, C				HOLDEN, C			DEBUT FOR 425-MILLION-YEAR-OLD FOSSIL	SCIENCE			English	Editorial Material																			0	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					680	680						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738839				2022-12-28	WOS:A1992HC50600019
J	HOLDEN, C				HOLDEN, C			SARIN INDICTED	SCIENCE			English	Editorial Material																		1992, SCIENCE, V255, P391	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					680	680						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738839				2022-12-28	WOS:A1992HC50600020
J	HOLDEN, C				HOLDEN, C			NEURO NERVES CALMED	SCIENCE			English	Editorial Material																		1991, SCIENCE, V254, P643	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					680	681						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1738839				2022-12-28	WOS:A1992HC50600021
